



Annual '10 Meeting

46th Annual Meeting

June 4–8, 2010

Chicago, Illinois

ANNUAL MEETING PROGRAM

Upcoming Meetings

Breast Cancer Symposium

October 1–3, 2010

Suburban Washington, D.C.

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer

October 18–20, 2010

Hollywood, Florida

Gastrointestinal Cancers Symposium

January 20–22, 2011

San Francisco, California

Genitourinary Cancers Symposium

February 17–19, 2011

Orlando, Florida

47th ASCO Annual Meeting

June 3–7, 2011

Chicago, Illinois

Copyright 2010 by the American Society of Clinical Oncology. All programs presented at the 2010 Annual Meeting constitute copyrighted presentations owned by the American Society of Clinical Oncology.

Copyright of the 2010 ASCO Annual Meeting Program is owned by the American Society of Clinical Oncology. ASCO reserves the rights to all recordings or reproductions or presentations at this Annual Meeting and all ASCO educational and scientific meetings. Attendees are encouraged to check the Annual Meeting program materials for information about Annual Meeting-related publications for purchase and additional ASCO online resources at www.asco.org/chicago2010, including the ASCO Virtual Meeting.

CONTENTS

Sessions and Symposia

Scientific Sessions	4
Special Sessions	6
Clinical Science Symposia	6

Annual Meeting Planning Committees

ASCO Officers and Directors	7
The ASCO Cancer Foundation Officers and Directors	7
Cancer Communications News Planning Subcommittee	7
Cancer Education Committee	8
Scientific Program Committee	10

Continuing Medical Education Information

12

Onsite Details

13

ASCO Shuttle Service

16

Policies

18

Awards

Special Awards	19
Merit Awards	20
Advanced Clinical Research Awards	22
Career Development Awards	22
Clinical Trials Participation Awards	23
Community Oncology Research Grants	23
Comparative Effectiveness Research Professorship	23
Improving Cancer Care Grants	23
International Development and Education Awards	24
Long-term International Fellowship	24
State Affiliate Grants	24
Young Investigator Awards	24
Past ACRA/CDA/TRP/YIA Grant Recipients	25

Descriptions of Session Types

27

Annual Meeting Supporters

28

2010 Annual Meeting Program by Track

31

2010 Annual Meeting Program

55

Friday	56
Saturday	80
Sunday	190
Monday	292
Tuesday	416

SESSIONS AND SYMPOSIA

SCIENTIFIC SESSIONS

Breast Cancer

Local-Regional and Adjuvant Therapy Oral Abstract Session	342
Metastatic Oral Abstract Session	435
Local-Regional and Adjuvant Therapy Poster Discussion Session	393
Metastatic Poster Discussion Session	115
Local-Regional and Adjuvant Therapy General Poster Session	146
Metastatic General Poster Session	158

Cancer Prevention/Epidemiology

Oral Abstract Session	228
Poster Discussion Session	396
General Poster Session	87

Central Nervous System Tumors

Oral Abstract Session	181
Poster Discussion Session	118
General Poster Session	197

Developmental Therapeutics

Clinical Pharmacology and Immunotherapy Oral Abstract Session	437
Experimental Therapeutics Oral Abstract Session	129
Clinical Pharmacology and Immunotherapy Poster Discussion Session	121
Experimental Therapeutics Poster Discussion Session	247
Clinical Pharmacology and Immunotherapy General Poster Session	301
Experimental Therapeutics General Poster Session	308

Gastrointestinal Cancer

Colorectal Cancer Oral Abstract Session	229
Noncolorectal Cancer Oral Abstract Session	408
Colorectal Cancer Poster Discussion Session	421
Noncolorectal Cancer Poster Discussion Session	63
Colorectal Cancer General Poster Session	256
Noncolorectal Cancer General Poster Session	267

Genitourinary Cancer

Prostate Cancer Oral Abstract Session	231
Testes, Kidney, and Bladder Cancer Oral Abstract Session	438
Prostate Cancer Poster Discussion Session	335
Nonprostate Cancer Poster Discussion Session	140
General Poster Session	359

Gynecologic Cancer

Oral Abstract Session	233
Poster Discussion Session	250
General Poster Session	169

Head and Neck Cancer

Oral Abstract Session	410
Poster Discussion Session	66
General Poster Session	202

Health Services Research

Oral Abstract Session	344
Poster Discussion Session	124
General Poster Session	369

Leukemia, Myelodysplasia, and Transplantation

Oral Abstract Session	345
Poster Discussion Session	399
General Poster Session	92

Lung Cancer	
Local-Regional and Adjuvant Therapy Oral Abstract Session	179
Metastatic Oral Abstract Session	406
Local-Regional and Adjuvant Therapy Poster Discussion Session	430
Metastatic Poster Discussion Session	338
Local-Regional and Adjuvant Therapy General Poster Session	208
Metastatic General Poster Session	214
Lymphoma and Plasma Cell Disorders	
Lymphoma Oral Abstract Session	131
Myeloma Oral Abstract Session	234
Poster Discussion Session	69
General Poster Session	98
Melanoma/Skin Cancers	
Oral Abstract Session	133
Poster Discussion Session	299
General Poster Session	223
Patient and Survivor Care	
Oral Abstract Session	182
Poster Discussion Session	424
General Poster Session	378
Pediatric Oncology	
Pediatric Oncology I Oral Abstract Session	236
Pediatric Oncology II Oral Abstract Session	347
Poster Discussion Session	253
General Poster Session	277
Sarcoma	
Oral Abstract Session	357
Poster Discussion Session	427
General Poster Session	280
Tumor Biology	
Oral Abstract Session	412
Poster Discussion Session	143
General Poster Session	107
Trials in Progress Poster Session	314

SESSIONS AND SYMPOSIA continued

SPECIAL SESSIONS

Advancing Pain and Palliative Care Globally for Patients with Cancer	433
ASCO–American Cancer Society Award and Lecture	349
ASCO/American Society of Hematology Joint Session	74
ASCO/European CanCer Organisation Joint Session: Personalized Medicine in Locally Advanced Non-small Cell Lung Cancer	387
B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology	287
Cancer Survivors: A Challenge to Health Care Systems Worldwide	293
Designing Clinical Trials for Older Patients: Laboratory Science and Practical Applications	86
Distinguished Achievement Award	79
Forum on Reimbursement	191
From the Cancer Genome to Patients with Cancer: The Next Generation of Innovation— An ASCO/American Association for Cancer Research Joint Session	413
Health Care Reform: Resetting the Clock	176
Highlights of the Day I including Clinical Trials Participation Awards	190
Highlights of the Day II including Partners in Progress Award	292
Highlights of the Day III	416
Imaging Informatics and Optimizing Imaging in Cancer Diagnosis: An ASCO/ Radiological Society of North America Joint Session	440
Maintenance of Certification and Lifelong Learning Workshop	62
Opening Session with Presidential Address, NCI Director’s Address, David A. Karnofsky Memorial Award and Lecture, and The ASCO Cancer Foundation Donor Recognition Awards	127
Pediatric Oncology Award and Lecture	176
Plenary Session including Science of Oncology Award and Lecture	246
Special Recognition Award	79
The Hospital/Physician Relationship: Tensions Arising	354
Training Program Directors’ Special Session—Addressing the Competencies: Professionalism and Practice-based Learning	242

CLINICAL SCIENCE SYMPOSIA

Circulating Tumor Cells in Breast Cancer: Where Are We?	405
Genetic and Molecular Predictors in Genitourinary Malignancies	84
Molecularly Targeted Trials in Lung Cancer	85
Novel Therapies and Approaches for Management of Gynecologic Cancers	352
Novel Therapies for Myeloma	185
Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets	186
Optimizing Care of the Elderly and Underserved	245
PARP Inhibition: DNA Repair as the Target	187
Paths for Clinical Development of PI3K Inhibition	298
Pharmacologic Treatment of Cancer-related Fatigue: Does It Make a Difference?	240
Predictors of Response to Preoperative Therapy: Where Are We?	286
Promising Targeted Therapies for Head and Neck Cancer	353
Signaling in Pediatric Cancer Comes to the Clinic	184
Smoothed/Hedgehog/Gamma Secretase	241
Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life	139
The MEK Pathway	196
Unraveling the Cancer Genome: Clinical Implications of Next-generation Technologies	392

ANNUAL MEETING PLANNING COMMITTEES

2009-2010 ASCO Board of Directors

ASCO Officers

President

Douglas W. Blayney, MD

President-Elect

George W. Sledge, MD

Immediate Past President

Richard L. Schilsky, MD

Treasurer

Clifford Hudis, MD

Chief Executive Officer

Allen S. Lichter, MD

Directors

Dean F. Bajorin, MD

Monica M. Bertagnoli, MD

Eduardo L. Cazap, MD, PhD

Susan L. Cohn, MD

Bruce E. Johnson, MD

Robert M. Langdon Jr., MD

Robert S. Miller, MD

Kathleen I. Pritchard, MD

Deborah Schrag, MD

Lynn M. Schuchter, MD

Sandra M. Swain, MD

Joel E. Tepper, MD

Everett E. Vokes, MD

Peter P. Yu, MD

2010 The ASCO Cancer Foundation Board of Directors

The ASCO Cancer Foundation Officers

Chair

Martin J. Murphy Jr., PhD, DMedSc

Treasurer

W. Charles Penley, MD

Secretary

Richard L. Schilsky, MD

Chief Executive Officer

Allen S. Lichter, MD, Ex-Officio

Directors

Joseph S. Bailes, MD

Lawrence H. Einhorn, MD

John H. Glick, MD

Nora A. Janjan, MD, MPSA, MBA

Thomas A. Marsland, MD

Robert J. Mayer, MD

Sandra M. Swain, MD

Nancy R. Daly, MS, MPH, Ex-Officio

Cancer Communications Committee News Planning Subcommittee

Chair

Nicholas J. Petrelli, MD

Chair-Elect

Mark G. Kris, MD

Immediate Past Chair

Eric P. Winer, MD

Julie R. Brahmer, MD

Lisa Diller, MD

Therese M. Mulvey, MD

Jennifer C. Obel, MD

Lori Pierce, MD

Sonali M. Smith, MD

Robert P. Sticca, MD

Charles R. Thomas Jr., MD

Timothy J. Whelan, BM, BCh, MSc

Nicholas J. Vogelzang, MD

Subcommittee Liaisons

Lynn M. Schuchter, MD, *Board Liaison*

Michelle W. Lau, MD, *Career Development Subcommittee Liaison*

ANNUAL MEETING PLANNING COMMITTEES continued

Cancer Education Committee (CEC)

Kim Allyson Margolin, MD, *Chair*
Charles Blanke, MD, *Chair-Elect*
Maha Hussain, MD, *Immediate Past Chair*
Bruce E. Johnson, MD, *Board Liaison*

CEC Annual Meeting and Thematic Meetings Subcommittee

Breast Cancer Track

Antonio C. Wolff, MD, FACP, *Track Leader*
Jonas Bergh, MD, PhD
Lisa A. Carey, MD
Maura N. Dickler, MD
Jennifer J. Griggs, MD
Barbara Parker, MD
Anna Storniolo, MD
Richard Zellars, MD

Cancer Genetics Track

Angela R. Bradbury, MD, *Track Leader*
Judy Garber, MD, MPH
Steve B. Gruber, MD, PhD
Beth Karlan, MD
Sancy Leachman, MD, PhD

Cancer Prevention/Epidemiology Track

William Nelson, MD, PhD, *Track Leader*
Marie-France Demierre, MD
Gary E. Goodman, MD
Joanne M. Jeter, MD
Melanie Palomares, MD

Central Nervous System Tumors Track

John L. Villano, MD, PhD, *Track Leader*
Timothy Cloughesy, MD
Patrick Wen, MD

Clinical Trials Track

Julie R. Park, MD, *Track Leader*
Steven D. Averbuch, MD
Christopher Booth, MD
Tim Eisen, PhD, FRCP
Patricia LoRusso, DO
Daniel P. Petrylak, MD
David R. Spigel, MD

Developmental Therapeutics Track

Alexander Dimitrios Colevas, MD, *Track Leader*
Merrill Egorin, MD
Timothy Synold, PharmD
James Andrew Zwiebel, MD, FACP

Ethics Track

Eileen Smith, MD, *Track Leader*
Manish Agrawal, MD
Rebecca D. Pentz, PhD
Jeffrey M. Peppercorn, MD, MPH

Gastrointestinal (Colorectal) Cancer Track

Axel Grothey, MD, *Track Leader*
Bruce D. Minsky, MD
Margaret M. Mooney, MD
David Ryan, MD

Gastrointestinal (Noncolorectal) Cancer Track

Mark Krasna, MD, *Track Leader*
Johanna C. Bendell, MD
Cliff Connery, MD
Peter C. Enzinger, MD

Melanie B. Thomas, MD
Christopher Willett, MD

Genitourinary Cancer Track

Celestia S. Higano, MD, *Track Leader*
Primo Lara Jr., MD
Gary R. MacVicar, MD
Edwin M. Posadas, MD
Andrew Stephenson, MD
Mary-Ellen Taplin, MD

Geriatric Oncology Track

Arash Naeim, MD, *Track Leader*
Kathryn A. Bylow, MD
Arti Hurria, MD
Rosemary Yancik, PhD

Gynecologic Cancer Track

S. Diane Yamada, MD, *Track Leader*
David Cohn, MD
Ursula Matulonis, MD

Head and Neck Cancer Track

Maura Gillison, MD, PhD, *Track Leader*
Vassiliki Papadimitrakopoulou, MD
Gregory T. Wolf, MD

Health Services Research Track

Brent Hollenbeck, MD, MS, *Track Leader*
Steven Katz, MD
Elizabeth B. Lamont, MD, MS
Gary H. Lyman, MD
Rinaa S. Punglia, MD

Leukemia, Myelodysplasia, and Transplantation Track

Koen van Besien, MD, *Track Leader*
Hagop Kantarjian, MD
Moshe Talpaz, MD

Lung Cancer Track

Michael Kelley, MD, *Track Leader*
Jeffrey A. Bogart, MD
Julie R. Brahmer, MD
Ramaswamy Govindan, MD
Renato Martins, MD, MPH
Harvey I. Pass, MD

Lymphoma and Plasma Cell Disorders Track

Todd M. Zimmerman, MD, *Track Leader*
Richard F. Ambinder, MD, PhD
Myron Stefan Czuczman, MD
Francine M. Foss, MD
Amrita Krishnan, MD

Melanoma/Skin Cancers Track

Julie R. Lange, MD, *Track Leader*
Thomas Gajewski, MD, PhD
Christopher D. Lao, MD
Gregory K. Pennock, MD
Hensin Tsao, MD, PhD

Patient and Survivor Care Track

Jennifer A. Ligibel, MD, *Track Leader*
Wendy Demark-Wahnefried, PhD, RD

Michelle Joy Naughton, PhD
Julia Rowland, PhD

Pediatric Oncology Track

Susan Lerner Cohn, MD, *Track Leader*
Lisa Diller, MD
Judith Sato, MD
Anne Warwick, MD, MPH

Practice Management and Information Technology Track

John V. Cox, DO, *Track Leader*
Patrick A. Grusenmeyer, ScD, FACHE
Alan Keller, MD
Therese Mulvey, MD
Dee Anna Smith

Professional Development Track

Timothy J. Moynihan, MD, *Track Leader*
Stephen M. Hahn, MD
Anand Karnad, MD
Allison Kurian, MD, MSc
Gregory Masters, MD, FACP
Lidia Schapira, MD

Sarcoma Track

Samuel Singer, MD, *Track Leader*
Warren Chow, MD, FACP
Rashmi Chugh, MD
R. Lor Randall, MD, FACS

Tumor Biology Track

George Coukos, MD, *Track Leader*
Mary Y. Armanios, MD
Kenneth J. Pienta, MD
Josep Taberero, MD

CEC Continuing Medical Education Subcommittee

Laura Fulper Hutchins, MD, *Subcommittee Chair*
Lucille A. Leong, MD, *Subcommittee Chair-Elect*
Charles F. von Gunten, MD, PhD, FACP, *Immediate Past Chair*
J. Thaddeus Beck, MD
David Danforth Jr., MD
Thomas Fahey Jr., MD
Norah Lynn Henry, MD, PhD
Jeffrey Hines, MD
Halle C. F. Moore, MD
Paul Wissel, MD
Judith L. Bader, MD
Phillip C. Hoffman, MD
Catherine E. Klein, MD
Jed D. Wolchok, MD, PhD

CEC Education Products Subcommittee

Jamie H. Von Roenn, MD, *Subcommittee Chair*
Ronald H. Blum, MD, *Subcommittee Chair-Elect*
Michael C. Perry, MD, *Subcommittee Past Chair*
Kathleen W. Beekman, MD
Jan Buckner, MD
Michael Fisch, MD, MPH
Justin D. Floyd, DO
Martee Leigh Hensley, MD, MSc
Tari A. King, MD
Bhoomi Mehrotra, MD
W. Robert Lee, MD, MS, MEd
Charles Loprinzi, MD
Tina M. Maluso-Bolton, MSN, NP
Robert Gary Mennel, MD
Jennifer E. Schwartz, MD, FRCPC
William Small Jr., MD

ANNUAL MEETING PLANNING COMMITTEES continued

Scientific Program Committee

Daniel F. Hayes, MD, *Chair*
Kathy Miller, MD, *Chair-Elect*
Everett E. Vokes, MD, *Immediate Past Chair*
Douglas W. Blayney, MD, *Board Liaison*

Biostatistics Track

Marc E. Buyse, ScD, *Track Leader*
Thomas Braun, PhD
Elizabeth Garrett-Mayer, PhD
Susan Michelle Geyer, PhD
Daniel Heitjan, PhD
Terry Hyslop, PhD
Alexia Iasonos, PhD
Judith Manola, MS
Andre Rogatko, PhD

Breast Cancer—Local-Regional and Adjuvant Therapy Track

Claudine Isaacs, MD, *Track Leader*
Kirby I. Bland, MD
Stephen K. L. Chia, MD
Reshma Jagsi, MD, PhD
Seema A. Khan, MD, FACS, MPH
Rita Nanda, MD
Lisa Yee, MD

Breast Cancer—Metastatic Track

Herve R. Bonnefoi, MD, *Track Leader*
Harold J. Burstein, MD, PhD
Suzanne D. Conzen, MD
Elizabeth Claire Dees, MD
Hope S. Rugo, MD
Anne F. Schott, MD

Cancer Prevention/Epidemiology Track

Eva Szabo, MD, *Track Leader*
Dean Brenner, MD
Frank Sinicrope, MD
Kala Visvanathan, MD, MHS
Marie Wood, MD

Central Nervous System Tumors Track

M. Kelly Nicholas, MD, PhD, *Track Leader*
Eric L. Chang, MD
Louis Nabors, MD
Myrna R. Rosenfeld, MD, PhD

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy Track

Razelle Kurzrock, MD, *Track Leader*
Ivan Borrello, MD
Tyler J. Curiel, MD
Charles G. Drake, MD, PhD
Kenneth A. Foon, MD
Federico Innocenti, MD, PhD
Duncan Ian Jodrell, MD, MSc
Justin Paul Kline, MD

Developmental Therapeutics—Experimental Therapeutics Track

Michael L. Maitland, MD, PhD, *Track Leader*
Tomislav Dragovich, MD, PhD
Paula M. Fracasso, MD, PhD, FACP
Pasi A. Janne, MD, PhD
Patrick Johnston, MD, PhD
Timothy Madden, PharmD
Patrick Schöffski, MD, MPH
Lillian L. Siu, MD

Gastrointestinal (Colorectal) Cancer Track

Howard S. Hochster, MD, *Track Leader*
Tanios S. Bekaii-Saab, MD
Chris R. Garrett, MD
Richard M. Goldberg, MD
Michael J. Hall, MD
Richard Herrmann, MD
John S. Kauh, MD
John Marshall, MD
Wells A. Messersmith, MD
Blasé N. Polite, MD, MPH
Kenneth Tanabe, MD
Robert S. Warren, MD

Gastrointestinal (Noncolorectal) Cancer Track

David Linehan, MD, *Track Leader*
Charles Blanke, MD
Ian Chau, MD
Theodore S. Hong, MD
Milind M. Javle, MD
Jennifer J. Knox, MD
Timothy M. Pawlik, MD, MPH
Alexandria T. Phan, MD
Gauri Varadhachary, MD
Andrea Wang-Gillam, MD, PhD
Colin D. Weekes, MD, PhD

Genitourinary Cancer Track

Michael J. Morris, MD, *Track Leader*
Daniel J. George, MD
James L. Mohler, MD
Joel B. Nelson, MD
George Phillips, MD, MPH
Brian I. Rini, MD
Matthew R. Smith, MD
Ulka N. Vaishampayan, MD
Richard K. Valicenti, MD
David P. Wood, MD

Gynecologic Cancer Track

Amit M. Oza, MD, *Track Leader*
Ronald J. Buckanovich, MD, PhD
Robert L. Coleman, MD
Patricia J. Eifel, MD
Ernst Lengyel, MD, PhD
Claire F. Verschraegen, MD

Head and Neck Cancer Track

Ezra E. W. Cohen, MD, FRCPC, *Track Leader*
Christine H. Chung, MD
Avraham Eisbruch, MD
D. Neil Hayes, MD, MPH
Cherie-Ann Nathan, MD
Andy Trotti, MD

Health Services Research Track

Sharon Hermes Giordano, MD, *Track Leader*
Charles L. Bennett, MD, PhD
Craig Earle, MD
Chris Friese, RN, PhD
Sarah Hawley, PhD
Jeanne Mandelblatt, MD, MPH

Leukemia, Myelodysplasia, and Transplantation Track

Olatoyosi Odenike, MD, *Track Leader*
Harry Erba, MD, PhD
Jeffrey E. Lancet, MD
Jane Liesveld, MD
Guido Marcucci, MD
Susan M. O'Brien, MD

Lung Cancer—Local-Regional and Adjuvant Therapy Track

Corey J. Langer, MD, *Track Leader*
David Harpole Jr., MD
Katherine Pisters, MD
Joseph B. Putnam, MD, FACS
Joseph K. Salama, MD
Antoinette J. Wozniak, MD
Stephen C. Yang, MD

Lung Cancer—Metastatic Track

Martin J. Edelman, MD, *Track Leader*
D. Ross Camidge, MD, PhD
Raffit Hassan, MD
Rebecca Suk Heist, MD
Gregory P. Kalemkerian, MD
Suresh S. Ramalingam, MD
Karen L. Reckamp, MD, MS
Ravi Salgia, MD, PhD

Lymphoma and Plasma Cell Disorders Track

John P. Leonard, MD, *Track Leader*
Nancy Bartlett, MD
Asher A. Chanan-Khan, MD
Kenneth Cohen, MD
Andrzej J. Jakubowiak, MD, PhD

Melanoma/Skin Cancers Track

F. Stephen Hodi, MD, *Track Leader*
David F. McDermott, MD
Antoni Ribas, MD
Michael S. Sabel, MD, FACS

Patient and Survivor Care Track

Teresa Gilewski, MD, *Track Leader*
Janet Lee Abraham, MD
Gretchen Genevieve Kimmick, MD
Barbara A. Murphy, MD
Thomas J. Smith, MD

Pediatric Oncology Track

John Cunningham, MD, *Track Leader*
Peter C. Adamson, MD
Gregory T. Armstrong, MD
Katherine K. Matthay, MD, MSCE

Sarcoma Track

Bruce Brockstein, MD, *Track Leader*
Suzanne George, MD
Raphael E. Pollock, MD, PhD
William D. Tap, MD

Tumor Biology Track

Charles D. Lopez, MD, PhD, *Track Leader*
Michael J. Ellis, PhD, MB
Phillip G. Febbo, MD
Robert A. Kratzke, MD
Sofia Merajver, MD
Anil Potti, MD

CONTINUING MEDICAL EDUCATION INFORMATION

The goal of the 2010 ASCO Annual Meeting is to foster communication among oncology-related subspecialties and the exchange of a wide range of ideas related to cancer. ASCO's objectives are to advance the education of physicians and other professionals caring for patients with cancer, to support the development of clinical cancer researchers, and to facilitate the delivery of high-quality health care to patients with cancer. The 2010 ASCO Annual Meeting is designed to serve the respective interests of the Society's multidisciplinary membership, with education focused on medical, surgical, and radiation oncology.

Needs Statement

With emerging educational and scientific advances, oncology is a field where patient care standards can change very quickly. Due to the high volume of literature and best practices information available, it is important that oncologists and other cancer care providers synthesize and digest the latest evidence-based information applicable to their practice/research setting.

In an effort to meet educational needs based on this rapid exchange of information, ASCO is committed to disseminating the latest scientific findings in oncology and practice-changing advances in cancer prevention, diagnosis, treatment, and survivorship.

Target Audience

The Annual Meeting is designed for U.S. and international physicians and researchers involved in multidisciplinary clinical cancer care including, but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists.

The Annual Meeting can also benefit nurses, pharmacists, physician assistants, and other health care professionals involved in clinical cancer care and cancer research.

Learning Objectives

Upon participation in this activity, attendees will be able to:

- Examine scientific advances that further enhance knowledge of cancer biology and pathogenesis
- Incorporate knowledge gained pertaining to advances in clinical cancer research into innovative management strategies and trial designs to improve patient outcomes
- Review recent and emerging data from key studies in clinical cancer research
- Evaluate the role of new diagnostic techniques and therapeutic approaches as applied to the care and management of people with cancer
- Implement clinical and scientific strategies designed to improve the quality of cancer care, as appropriate
- Effectively communicate with colleagues and with patients regarding advances in clinical oncology science
- Identify and utilize tools for cancer risk assessment and risk reduction based on the best available evidence
- Engage in networking and collaboration among domestic and international oncology specialists and scientists

Continuing Medical Accreditation Statement and Credit Designation

ASCO is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ASCO designates this educational activity for a maximum of 42 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy and Nursing Continuing Education

Due to limited demand and increased accreditation requirements, ASCO will no longer be partnering with Professional Education Services Group to offer specific nursing and pharmacy continuing education credit for 2010 Annual Meeting sessions. All nonphysician attendees are welcome to submit a request for a Certificate of Participation, through the submission of the evaluation form, which may enable nonphysicians to apply their Annual Meeting participation toward re-licensure.

Any questions related to CME may be directed to ASCO Staff at cme@asco.org or 571-483-1403.

New for 2010: Submit Program Evaluation Online, Certificates Available Immediately

All attendees are encouraged to provide feedback to the planning committees to develop future Symposium sessions and document their participation, requesting either a CME Certificate (MD and DO) or a Certificate of Participation that may be used to claim credits toward re-licensure (nonphysicians).

Evaluations will be accepted until July 9, 2010. In an effort to be environmentally friendly, paper evaluations are no longer being accepted. Evaluations must be submitted online at www.asco.org/chicago2010 or www.asco.org/cme. Attendees can access the Internet onsite by using the Internet Stations available throughout the convention center or by taking advantage of the complimentary Wi-Fi access available throughout the public areas.

Proof of Attendance

An official certificate that verifies attendance at the 2010 Annual Meeting is available at www.asco.org/chicago2010.

ONSITE DETAILS

Air Travel Assistance Desk

Attendees who made their air travel arrangements through TravelStore, Inc. can check or change their flight arrangements with a travel agent at the Air Travel Assistance Desk located in ASCO Concierge Services in the North Building, Grand Concourse Lobby.

ASCO Annual Business Meeting and Presentation of ASCO Statesman Awards

ASCO members are encouraged to attend the 2010 ASCO Annual Business Meeting, to be held on Monday, June 7 from 12:00 PM to 1:00 PM at the Hyatt McCormick Place, Regency Ballroom. The Annual Business Meeting will feature the presentation of the Statesman Awards, which honor the meritorious service of Society members for their significant volunteer efforts. Criteria for award selection include at least 20 cumulative years of volunteer service to the Society in elected or appointed positions, such as participation on committees, guideline panels, and task forces, or as an association liaison.

ASCO Headquarters Office

ASCO Headquarters office is located in the North Building, Room N427a.

ASCO on Twitter

ASCO maintains a profile page on the social networking site Twitter. Access attendee information, news, and events in real time leading up to and during the Annual Meeting. Visit ASCO on Twitter and click "Follow". ASCO is tweeting several times a day and using the following hashtags:

- #ASCO10—For attendee information, event reminders, and Meeting-related news and commentary
- #ASCOPress—For breaking news, media alerts, and updates

ASCO TV

The onsite Annual Meeting broadcast network, ASCO TV features important messages from ASCO leadership as well as replays of Highlights of the Day, Plenary, and other sessions of interest. ASCO TV Cafés are located in the South Building, S102 Lobby; North Building, Grand Concourse Lobby; South Building, Oncology Professionals Hall Food Court (Hall A2), and East Building, Hall E Lobby.

Baggage Check

Coat and baggage check services are available for all attendees in the following areas: South Building, Room S104 (near Gate 2); South Building, Level 1, Main Entrance (near Gate 4); North Building, Level 1, Lobby (near Gate 26); and East Building, Level 2, Room E251 (near Registration). There is a charge per item for this service.

Career Fair

The 10th Annual Career Fair offers a convenient way for Meeting attendees to explore available career options with representatives from hospitals, academic institutions, private practices, and leading firms in the field of oncology. Job seekers will learn about new job openings, meet face-to-face with recruiters, and schedule personal interviews in the employers' private interview booth. The Career Fair is located in Exhibits, in the South Building, Level 3, Halls A1-A2. The Career Fair is open Saturday through Sunday from 9:00 AM to 5:00 PM. Career Fair participants must be registered for the Meeting to gain access to the Career Fair.

Career Opportunities and Other Medical Meetings Posting Boards

The Career Opportunities and Other Medical Meetings Posting Boards, located in Exhibits, adjacent to the Career Fair, provides organizations with the opportunity to make readily available to attendees information about job openings or other medical meetings held throughout the year. ASCO staff are available on Friday, June 4 from 7:00 AM to 6:00 PM at any of the Annual Meeting Information Desks throughout McCormick Place to receive authorized postings. Once the Hall opens on Saturday, June 5, ASCO staff are available at the Career Fair registration desk from 9:00 AM to 5:00 PM to receive and approve authorized postings.

Electronic Health Records (EHR) Lab

Attendees can visit the Electronic Health Records (EHR) Lab (Booth #16087 in Exhibits) to learn about EHR technologies appropriate for their practices and gain hands-on experience with the latest EHRs. A special EHR compare challenge will highlight the capacity of the vendor products to provide oncology-specific support. The EHR Lab is open Saturday through Monday from 9:00 AM to 5:00 PM.

ePosters

ePosters allow attendees to view 2010 Annual Meeting poster presentations electronically onsite at the ePoster Station (located in the Oncology Professionals Hall) or the Virtual Meeting Replay Station (located in the North Building, Level 2.5) at anytime throughout the Meeting. New this year, ePosters offer the following benefits:

- View electronic posters before they are available on Virtual Meeting
- Get a more detailed look at the poster using "Pan & Zoom" feature
- E-mail the poster presenter with questions

Exhibitor Directory

The Exhibitor Directory is a list of Annual Meeting exhibitors distributed to all attendees at tote bag pick-up areas. It is also available online at Exhibitor Directory Stations, located at the entrance to the Oncology Professionals Hall. The online Exhibitor Directory offers Meeting attendees the opportunity to view a detailed

ONSITE DETAILS continued

floor plan of Exhibits and to search the list of exhibitors by company name, keyword, category, cancer type, country, or pavilion.

Emergency Response for Visitors

If an alarm sounds in McCormick Place

- Please proceed to the nearest exit
- Instructions will be given over the public announcement system

Evacuation Instructions

- Visitors will be directed over the public announcement system to exit through the closest “Emergency Exit”
- Doors marked as “Stairs” also serve as emergency exits
- In the event of a power failure, all emergency systems will run on emergency power
- Temporary safe areas are available in open parking lots, roadways, and grass areas adjacent to McCormick Place

Faculty Registration and Ready Room

During registration hours, all faculty will check in at the Faculty Registration and Ready Room, located in the North Building, Room N426, to receive their badges and Meeting materials. Additionally, faculty should report to this room to review and submit their presentations, with assistance from ASCO’s audiovisual personnel.

First Aid

Staffed First Aid stations are located in the South Building, Level 2.5 Lobby (near the Business Center) and East Building, Level 1 (near Arie Crown Theater). Both stations are able to accommodate nursing mothers. Check with onsite security personnel or the staff at any ASCO Information Desk for the location of the nearest First Aid station. In addition, directional signage is available throughout the facility.

Internet Stations

Internet Stations, which offer full Internet access, are located throughout McCormick Place. Users can view ASCO.org, print their itinerary from the online Annual Meeting Program, and access ASCO online evaluation and CME credit request forms, as well as check and send e-mail.

Lost and Found

ASCO Lost and Found is located in the South Building, Level 1, Room S101 and is open from 7:00 AM to 6:00 PM Friday through Monday, and from 7:00 AM to 1:00 PM Tuesday.

Oncology Professionals Hall

Located in the South Building, Level 3, Halls A1-A2, the Oncology Professionals Hall (formerly known as the Exhibit Hall) is comprised of Exhibits, General Posters, and a Food Court. Exhibits will highlight the most advanced treatments, products, and services in oncology and will provide attendees the opportunity to meet with representatives from the health care industry, including pharmaceutical companies, scientific publishers, and advocacy groups. Exhibits are open during the following hours:

Saturday, June 5 9:00 AM – 5:00 PM
Sunday, June 6 9:00 AM – 5:00 PM
Monday, June 7 9:00 AM – 5:00 PM

General Posters are located on the far right side of the Oncology Professionals Hall and can be accessed directly from the South Building escalators, by S102. You can also enter General Posters from the Grand Concourse entrance to the Oncology Professionals Hall.

New this year to the Oncology Professionals Hall, ASCO’s Networking & Connection Hub (Booth #10163) offers topic-based discussions for interaction with your peers; demonstrations of networking tools such as mobile applications, smart phones, and e-readers; and sessions introducing ASCO on social networking platforms. The full schedule for each day is available in that day’s edition of *ASCO Daily News*, as well as posted at the booth. “Lunchtime Conversations” each day from 12:00 PM to 1:30 PM provide a unique opportunity for attendees to pick up lunch at the nearby food court and join a conversation with senior members of ASCO’s staff and volunteer leadership.

Passport Program

The ASCO Cancer Foundation is excited to offer the Passport Program for the second year. Passport booklets will be distributed at tote bag pick-up areas and at the Grand Concourse entrance to the Oncology Professionals Hall and in the ASCO Cancer Foundation Donor Lounge (Room S401). Attendees who have their passport stamped by all participating exhibitors will receive an ASCO Cancer Foundation hand sanitizer and the opportunity to win one of the following:

- Complimentary registration to the 2011 Annual Meeting (eight winners)
- Complimentary registration to the 2011 Annual Meeting and hotel accommodations for five nights at a downtown Chicago hotel (two winners)

Winners will be announced following the Annual Meeting.

Podcast

Presentations from the Meeting are also available in the form of audio and video podcasts. Subscribers to the Annual Meeting Podcast enjoy full access to all captured oral presentations and can conveniently listen to the

files on a computer, download them to a portable MP3 player, or burn them to a CD. Video podcasts are optimized for viewing on an MP4 player or iPod. Subscriptions are available to ASCO members for \$80 and to nonmembers for \$100. Attendees who purchased a subscription prior to or at the event can activate their accounts online. Audio and video files will be available for download within 24 hours of the session's completion. Only those who have purchased a subscription will have access to the podcasts. Save up to 80% on Virtual Meeting and Podcast when you purchase with Annual Meeting registration.

Services Available to Meeting Attendees

The following services are available to attendees at McCormick Place:

- Air Travel Assistance Desk: North Building, Grand Concourse Lobby
- Annual Meeting Information Desks: Located throughout McCormick Place
- ASCO Store: North Building, Grand Concourse Lobby and South Building, ASCO Central (Booth #7004)
- ASCO TV: Grand Concourse Lobby; Hall E Lobby; and Oncology Professionals Hall Food Court (Hall A2)
- Baggage Checks: South Building, Room S104; South Building, Level 1, Main Entrance; North Building, Level 1, Lobby; East Building, Level 2, Room E251
- Chicago Information Desk: North Building, Grand Concourse Lobby
- Exhibitor Directory Stations: South Building, Grand Concourse Entrance to Halls A1-A2
- First Aid Stations: South Building, Level 2.5 Lobby near Business Center; East Building, Level 1 near Arie Crown Theater
- Housing Assistance Desk: North Building, Grand Concourse Lobby
- International Assistance Desk: North Building, Grand Concourse Lobby
- Internet Stations: South Building, S101 Lobby; North Building, Grand Concourse Lobby; South Building, Hall A2; East Building, Hall D2 Lobby
- Member Services Desk: North Building, Grand Concourse Lobby; South Building, ASCO Central (Booth #7004); East Building, Hall E, Registration
- Restaurant Reservations Desk: North Building, Grand Concourse Lobby
- Virtual Meeting Replay Station: North Building, Level 2.5
- Virtual Meeting and Podcast Sales and Assistance: North Building, Level 2.5

Shuttle Bus Service

ASCO provides complimentary shuttle transportation June 4-8 between all official ASCO hotels and McCormick Place (except for the Hyatt Regency McCormick Place, which is adjacent to the convention center). Please refer to page 16 for the shuttle bus schedule.

Special Assistance

All of the official ASCO hotels, as well as McCormick Place, comply with the Americans with Disabilities Act. If you require special assistance with housing for the Annual Meeting, please contact the ASCO Housing Center by phone at 888-788-1522 or 703-449-6418.

Tote Bag/Meeting Materials Pick-up

Attendees who have registered and received their badge in advance may bring their tote bag coupon to Registration in Hall E or the other satellite tote bag pick-up locations throughout McCormick Place.

Virtual Meeting

Virtual Meeting helps maximize your participation at the Annual Meeting by allowing you to view or review sessions from your hotel room, home, or office. Virtual Meeting allows viewing of video and slides of all captured educational and scientific sessions from the Annual Meeting within 24 hours of the session's completion.

Experience the Virtual Meeting onsite by visiting the **Virtual Meeting Replay Station**, located in the North Building, Level 2.5 Lobby. The Virtual Meeting Replay Station provides attendees who may have missed an important presentation and opportunity to view and listen to selected sessions from the previous day(s). Access to the Virtual Meeting Replay Station is available to all Meeting attendees free of charge for the duration of the Annual Meeting.

For continued access to the Virtual Meeting after June 8, purchasing "Registration with Virtual Meeting" includes exclusive access to 2010 Annual Meeting content until June 1, 2013, when all sessions become available to the public. Those who registered without purchasing the Virtual Meeting can add the Virtual Meeting until the close of the Meeting by choosing the "Changes and Cancellations" option on the online registration page at www.asco.org/chicago2010. The fee for ASCO member attendees is \$45 and the fee for nonmember attendees is \$75.

Wi-Fi Access

Meeting attendees with wireless capabilities can access the Internet in selected areas of McCormick Place. Full Internet access is available to attendees with a laptop, PDA, or any Internet-capable device. Technical assistance, power supplies, and Ethernet connections to the Internet also are available in the North Building, Level 2.5 in the Wi-Fi Zone.

ASCO SHUTTLE SERVICE

Complimentary shuttle service is provided between McCormick Place and the hotels listed below. **Please be sure to check the ASCO Shuttle sign in your hotel upon arrival for any changes, additional information, frequency of service, and specific departure times for the designated route.**

Hours of Operation

Friday, June 4

Shuttle between hotels and McCormick Place 6:45 AM - 7:00 PM*

Saturday, June 5

Shuttle between hotels and McCormick Place 6:45 AM - 7:00 PM*

Sunday, June 6

Shuttle between hotels and McCormick Place 6:45 AM - 7:00 PM*

Monday, June 7

Shuttle between hotels and McCormick Place 6:45 AM - 7:00 PM*

Tuesday, June 8

Shuttle between hotels and McCormick Place 6:45 AM - 1:30 PM*

*Last shuttle departs McCormick Place at this time. Last shuttle departs hotels approximately 90 minutes prior to this time.

Shuttle service is approximately every 20 minutes. McCormick Place is the transfer point to change routes.

If you have any questions regarding the shuttle, or would like to make a reservation for a wheelchair-accessible ASCO Shuttle, please see the ASCO Shuttle supervisor at McCormick Place during shuttle hours or call KUSHNER & ASSOCIATES at 312-808-2000 during shuttle hours.

Route 1 - Gate 1: South Building, Level 1, near Room S105

One-way travel time is approximately 20-25 minutes.

Hard Rock Hotel
Holiday Inn Chicago Mart Plaza
Hotel 71
Hotel Monaco Chicago
Renaissance Chicago Hotel
Residence Inn Chicago Downtown River North
Springhill Suites by Marriott Chicago Downtown River North
theWit, a Doubletree Hotel
Westin Chicago River North

Route 2 - Gate 1: South Building, Level 1, near Room S105

One-way travel time is approximately 20-25 minutes.

Amalfi Hotel Chicago
Best Western River North Hotel
Comfort Inn and Suites Downtown
Courtyard Chicago Downtown River North
Dana Hotel
Embassy Suites Hotel Chicago Downtown
Hampton Inn and Suites
Hilton Garden Inn Chicago Downtown Magnificent Mile
Homewood Suites by Hilton Chicago Downtown
Hotel Felix
Hotel Palomar
Hotel Sax Chicago
Trump International Hotel & Tower

Route 3 - Gate 2: South Building, Level 1, near Room S103

One-way travel time is approximately 15-20 minutes.

Chicago Marriott Downtown Magnificent Mile
Conrad Chicago
Four Points by Sheraton Chicago Downtown
Hotel Cass, Holiday Inn Express
Hotel InterContinental Chicago
James Hotel, The

Route 4 - Gate 2: South Building, Level 1, near Room S103

One-way travel time is approximately 12-15 minutes.
Sheraton Chicago Hotel and Towers

Route 5 - Gate 2: South Building, Level 1, near Room S103

One-way travel time is approximately 15-20 minutes.
Courtyard by Marriott Magnificent Mile
Doubletree Hotel Chicago Magnificent Mile
Embassy Suites Chicago Downtown - Lakefront
Inn of Chicago
W Chicago Lakeshore

Route 6 - Gate 3: South Building, Level 1, near Room S100

One-way travel time is approximately 20-25 minutes.

Affinia Chicago
Allerton Hotel, The
Avenue Crowne Plaza Hotel Chicago
Fairfield Inn and Suites Chicago
Omni Chicago
Park Hyatt Chicago
Peninsula Chicago, The
Red Roof Inn Chicago Downtown
Wyndham Chicago

Route 7 - Gate 3: South Building, Level 1, near Room S100

One-way travel time is approximately 20-30 minutes.

Drake Hotel, The
Elysian Hotel
Four Seasons Hotel Chicago
Hilton Suites Chicago Magnificent Mile
Millennium Knickerbocker Hotel
Residence Chicago Downtown Magnificent Mile
Ritz-Carlton Chicago, The
Seneca Hotel, The
Sofitel Chicago Water Tower
Sutton Place Hotel, The
Talbot Hotel, The
Tremont Hotel, The
Westin Michigan Avenue Chicago, The

Route 8 - Gate 21: North Building, Level 1, near Room N139

One-way travel time is approximately 20-30 minutes.
Ambassador East Hotel
Hotel Indigo Chicago Gold Coast

Route 9 - Gate 21: North Building, Level 1, near Room N139

One-way travel time is approximately 20-25 minutes.
Hotel Allegro Chicago, A Kimpton Hotel
W Chicago City Center

Route 10 - Gate 26: North Building, Level 1 Escalator Lobby

One-way travel time is approximately 15-20 minutes.
Blackstone - A Renaissance Hotel, The
Hilton Chicago

Route 11 - Gate 26: North Building, Level 1 Escalator Lobby

One-way travel time is approximately 20-25 minutes.
Hampton Majestic
Hotel Burnham Chicago, A Kimpton Hotel
Palmer House Hilton
Silversmith Hotel, The

Route 12 - Gate 26: North Building, Level 1 Escalator Lobby

One-way travel time is approximately 15-20 minutes.
Chicago South Loop Hotel

Route 13 - Gate 31: East Building, Level 2, near Arie Crown Theater Box Office

One-way travel time is approximately 12-15 minutes.
Fairmont Chicago
Hyatt Regency Chicago
Swissotel Chicago

Route 14 - Gate 32: East Building, Level 2, near Arie Crown Theater Box Office

One-way travel time is approximately 20-25 minutes.
Crowne Plaza Chicago Metro
Holiday Inn Hotel & Suites - Chicago Downtown
Hotel Blake
Union League Club of Chicago

Walk to McCormick Place

No shuttle bus service is provided for the Hyatt Regency McCormick Place as it is within walking distance of McCormick Place.

POLICIES

Important Security and Attendee Conduct Information

For security reasons, 2010 ASCO Annual Meeting badges are required for admittance to all events. Badges should be worn and visible at all times. Lost badges should be reported to the Registration staff immediately. The following badge policies are in effect throughout the Meeting:

- 1) 2010 ASCO Annual Meeting badges are the sole property of ASCO.
- 2) Badges are nontransferable.
- 3) False certification of individuals as paid Annual Meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any Annual Meeting event, or any inappropriate or unauthorized conduct will be just cause for repossessing badges of any individuals involved and expelling all parties involved from the Meeting without obligation on the part of ASCO for refund of any fees.

In addition, individuals who are part of the 2010 ASCO Annual Meeting may not engage in any demonstrations or other behavior that ASCO deems to be potentially disruptive to the conduct of the Meeting. Violation of this rule is grounds for immediate dismissal from the Meeting and/or ineligibility for attendance at future Annual Meetings. Any person who is dismissed from the Meeting may request that ASCO review the matter, provided, however, that the individual understands that such dismissal will be effective immediately and will continue until and unless ASCO issues a contrary decision.

Cancellation Statement

ASCO reserves the right to cancel this activity because of unforeseen circumstances. In the event of such cancellation, the full registration fee will be returned to each registrant.

Equal Opportunity Statement

ASCO events and activities are available without regard to race, color, sex, national origin, disability, age, or veteran status as provided by law and in accordance with the Society's respect for personal dignity.

Age Requirement for Attendees

Due to the detailed nature of the programs, no persons under the age of 18 will be admitted into any official ASCO function. This includes, but is not limited to, education and scientific sessions, as well as the Oncology Professionals Hall.

Annual Meeting Policy of Recording (Audio, Video, and Still Photography)

Copyright of the 2010 ASCO Annual Meeting program is owned by the American Society of Clinical Oncology. ASCO reserves the rights to all recordings or reproductions or presentations at this Annual Meeting and all ASCO educational and scientific meetings.

Any photography, filming, taping, recording, or reproduction in any medium, including via the use of tripod-based equipment, of any of the programs and/or posters presented at the 2010 Annual Meeting without the express written consent of the American Society of Clinical Oncology is strictly forbidden. Exception: Non-flash photography and audiotape recording using hand-held equipment, for **strictly personal and noncommercial** use, are permitted **if not disruptive**.

Smoking Prohibition

Smoking is prohibited in all 2010 ASCO Annual Meeting facilities, including public areas and the Oncology Professionals Hall. This policy will be enforced.

Unlabelled Usage Statement

The information presented is that of the contributing faculty and does not necessarily represent the views of the American Society of Clinical Oncology and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.

AWARDS

ASCO 2010 SPECIAL AWARDS

David A. Karnofsky Memorial Award and Lecture

Presented during the Annual Meeting Opening Session, Saturday, June 5, 9:30 AM–12:00 PM
Daniel D. Von Hoff, MD, Translational Genomics Research Institute

Science of Oncology Award and Lecture

Presented during the Plenary Session, Sunday, June 6, 1:00 PM–4:00 PM
Frank McCormick, PhD, FRS, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center

ASCO–American Cancer Society Award and Lecture

Monday, June 7, 9:45 AM–11:00 AM
Joseph V. Simone, MD, University of Florida Shands Cancer Center

Gianni Bonadonna Breast Cancer Award and Lecture

To be presented at the 2010 Breast Cancer Symposium, Suburban Washington, D.C., October 1-3, 2010
Nancy E. Davidson, MD, University of Pittsburgh Cancer Institute

B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Sunday, June 6, 4:45 PM–6:00 PM
Harvey Jay Cohen, MD, Duke University Medical Center

Pediatric Oncology Award and Lecture

Saturday, June 5, 3:00 PM–4:15 PM
Sharon B. Murphy, MD, Institute of Medicine

Distinguished Achievement Award

Presented during a private function on Friday, June 4
Eli Glatstein, MD, University of Pennsylvania School of Medicine

Partners in Progress Award

Presented during the Highlights of the Day II Session, Monday, June 7, 7:30 AM–9:00 AM
Ellen V. Sigal, PhD, Friends of Cancer Research

Special Recognition Award

Presented during a private function on Friday, June 4
Patrick J. Loehrer Sr., MD, Indiana University School of Medicine

ASCO Statesman Awards

Presented during the ASCO Annual Business Meeting on Monday, June 7, 12:00 PM–1:00 PM

Laurence H. Baker, DO
Edward P. Balaban, DO
C. D. Blanke, MD
Howard A. Burris III, MD
John V. Cox, DO
Robert Dreicer, MD
Stephen B. Edge, MD
Alexander M. Eggermont, MD, PhD
Charles M. Haskell, MD
Maha Hussain, MD
Mark G. Kris, MD
Theodore S. Lawrence, MD, PhD
Gary H. Lyman, MD
Gregory A. Masters, MD

Therese M. Mulvey, MD
Olufunmilayo I. Olopade, MBBS
Bruce A. Peterson, MD
William T. Purcell, MD
Derek Raghavan, MD, PhD
Gregory H. Reaman, MD
Mack Roach III, MD
Bruce J. Roth, MD
Mace L. Rothenberg, MD
Charles A. Schiffer, MD
Branimir I. Sikic, MD
Margaret A. Tempero, MD
Linda T. Vahdat, MD
Antonio C. Wolff, MD

AWARDS continued

2010 Merit Awards

Bradley Stuart Beller Merit Award

This special recognition is given to the fellow who submitted the overall highest-ranking abstract as determined by the Scientific Program Committee. This individual receives \$2,000 and is given special recognition during the Opening Ceremony.

Kristin A. Higgins, MD, Duke University Medical Center

Brigid Leventhal Merit Award

In honor of Brigid Leventhal, a physician-pioneer in pediatric research, the Brigid Leventhal Merit Award is presented to the fellow who submitted the highest-ranking abstract in pediatrics as determined by the Program Committee's Pediatrics Subcommittee. This individual is also recognized during the Opening Ceremony and is awarded a \$1500 stipend.

Laura E. Hogan, MD, New York University Langone Medical Center

Merit Award Recipients

One hundred \$1,500 Merit Awards are given annually in recognition of outstanding abstracts submitted to the Scientific Program Committee for the upcoming Annual Meeting. The Merit Award program was established to encourage more fellows to attend the Annual Meeting and to further promote clinical research in young scientists.

The First Author must meet all of the following requirements to be considered for a Merit Award:

- Hold a doctoral degree (including but not limited to MD, DO, PharmD, or PhD) or be a doctoral degree candidate at the time of abstract submission
- Be enrolled in an oncology fellowship training program at the time of abstract submission
- Be working in an oncology laboratory or clinical research setting
- Be the First Author and presenter of the submitted abstract
- Provide a letter of support from his or her Training Program Director indicating eligibility for the award
- Provide a two-page curriculum vitae

Charu Aggarwal, MD, MPH, Fox Chase Cancer Center

Alain P. Algazi, MD, University of California, San Francisco

Eitan Amir, MB, ChB, Princess Margaret Hospital

Valsamo K. Anagnostou, MD, Yale University School of Medicine

Joo Ern Ang, MB, BChir, MA, MRCP, The Royal Marsden NHS Foundation Trust

Fernanda I. Arnaldez, MD, Pediatric Oncology Branch, National Cancer Institute

Mohamad Ayoubi, MD, University of Texas M. D. Anderson Cancer Center

Xavier Badoux, MB, BS, University of Texas M. D. Anderson Cancer Center

Aditya Bardia, MD, MPH, Sidney Kimmel Comprehensive Cancer Center at John Hopkins University

Gregory L. Beatty, MD, PhD, Abramson Cancer Center, University of Pennsylvania

Yanis Bellil, MD, Duke University Medical Center

Stefan H. Boeck, MD, University of Munich

Pierre O. Bohanes, MD, University of Southern California Norris Comprehensive Cancer Center

Linda E. Coate, MD, Princess Margaret Hospital and University of Toronto

Austin J. Combest, PharmD, MBA, University of North Carolina Eshelman School of Pharmacy

Elizabeth A. Comen, MD, Memorial Sloan-Kettering Cancer Center

Sandra P. D'Angelo, MD, Memorial Sloan-Kettering Cancer Center

Jonas A. De Souza, MD, The University of Chicago Medical Center

Andrea Dean, MD, University of Texas M. D. Anderson Cancer Center

Erin R. DeRose, MD, Beth Israel Deaconess Medical Center

Vincent O. Dezentje, MD, Leiden University Medical Center

Neesha C. Dhani, MD, FRCPC, Princess Margaret Hospital

Karel Eechoute, MD, Daniel den Hoed Cancer Center, Erasmus University Medical Center

David J. Gallagher, MD, Memorial Sloan-Kettering Cancer Center

Bernardo Haddock L. Goulart, MD, Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center

Mrinal M. Gounder, MD, Memorial Sloan-Kettering Cancer Center

Christian Grommes, MD, Memorial Sloan-Kettering Cancer Center

Philip G. Hepp, MD, University Dusseldorf

Michaela J. Higgins, MD, Sidney Kimmel Comprehensive Cancer Center at John Hopkins University

Matthias Holdhoff, MD, Johns Hopkins University

Hui Y. Hou, Penn State Hershey Medical Center

Ilaria Iacobucci, Department of Hematology/Oncology Seràgnoli

Antoine Italiano, MD, PhD, Institut Bergonie

Sekwon Jang, MD, University of Minnesota

Filip Janku, MD, PhD, University of Texas M. D. Anderson Cancer Center

Nagesh H. Jayaram, MD, Indiana University School of Medicine

Sao Jiralerspong, MD, PhD, University of Texas M. D. Anderson Cancer Center

Tom John, MBBS, PhD, FRACP, Princess Margaret Hospital
 Richard W. Joseph, MD, University of Texas M. D. Anderson Cancer Center
 Eva J. Kantelhardt, MD, Martin Luther University
 Kiana Keyvanjah, PharmD, Pfizer Inc.
 Eric S. Kim, MD, University of Texas M. D. Anderson Cancer Center
 Jin-Soo Kim, MD, University of Texas M. D. Anderson Cancer Center
 Elizabeth Min Hui Kim, MD, Massachusetts General Hospital
 Jennifer Y. Lai, MD, MPH, British Columbia Cancer Agency
 Hyo Jin Lee MD, PhD, Chungnam National University College of Medicine
 Ho Yun Lee, MD, Samsung Medical Center
 Eric Leung, MD, Princess Margaret Hospital
 Daniel Lewinshstein, MD, BSc, Virginia Mason Medical Center
 Sherene Loi, MD, PhD, Institute Jules Bordet
 Frederik Marme, University Hospital Heidelberg
 Jennifer L. Marti, MD, Memorial Sloan-Kettering Cancer Center
 Diego M. Marzese, IHEM-CCT-CONICET, National University of Cuyo
 Nader N. Massarweh, MD, University of Washington
 Dhaval R. Mehta, MD, University of Pittsburgh Medical Center
 Nicholas Mitsiades, Memorial Sloan-Kettering Cancer Center
 Alexei Morozov, MD, PhD, Memorial Sloan-Kettering Cancer Center
 Patrick G. Morris, MD, Memorial Sloan-Kettering Cancer Center
 Lakshmi Nayak, MD, Memorial Sloan-Kettering Cancer Center
 Joel W. Neal, MD, PhD, Massachusetts General Hospital Cancer Center
 David Olmos, MD, Royal Marsden Hospital/Institute of Cancer Research
 Geoffrey R. Oxnard, MD, Memorial Sloan-Kettering Cancer Center
 Dionysios Papadatos-Pastos, MD, MRCP(UK), Drug Development Unit, Royal Marsden Hospital
 Sameer A. Parikh, MD, University of Texas M. D. Anderson Cancer Center
 Jeong-Yeol Park, University of Ulsan College of Medicine
 Sapna P. Patel, MD, University of Texas M. D. Anderson Cancer Center
 Chad V. Pecoř, MD, University of Texas M. D. Anderson Cancer Center
 Nir Peled, University of Colorado Denver Cancer Center
 Georg Pfeiler, Medical University of Vienna
 Sophie Postel-Vinay, MD, Institut Gustave Roussy
 Brigitte K. Rack, MD, Klinikum der Ludwig-Maximilians-Universität
 Leon Raskin, PhD, University of Michigan
 Ulrich Ronellenfitsch, MD, University Medical Centre Mannheim
 April K. Salama, MD, The University of Chicago
 Rachel B. Salit, MD, Experimental Transplantation and Immunology Branch, National Cancer Institute
 Shahneen K. Sandhu, MD, FRACP, Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
 Jacob G. Scott, MD, H. Lee Moffitt Cancer Center
 Bostjan Seruga, MD, Princess Margaret Hospital
 Shreya K. Shah, MD, University of California, San Francisco
 Manish Sharma, MD, The University of Chicago
 Berta A. Sousa, Sunnybrook Odette Cancer Centre, University of Toronto
 Simona Soverini, Department of Hematology/Oncology Seràgnoli
 Marvaretta M. Stevenson, MD, Duke University Medical Center
 Jennifer M. Suga, MD, University of California, Davis
 Vincent C. Tam, MD, Princess Margaret Hospital
 Daniel S. Tan, BSc, MBBS, MRCP, The Royal Marsden Hospital NHS Foundation Trust
 Juliette Thariat, Anticancer Center, Centre Antoine-Lacassagne
 Warren H. Tseng, MD, University of California, Davis
 Astrid A. van der Veldt, MD, VU University Medical Center
 Carlos E. Vigil, University of Texas M. D. Anderson Cancer Center
 Klaus W. Wagner, MD, PhD, University of Texas M. D. Anderson Cancer Center
 Axel Walther, Wellcome Trust Centre for Human Genetics
 Jiping Wang, MD, PhD, Brigham and Women's Hospital
 David J. Watkins, MBBS, The Royal Marsden Hospital
 Andrew J. Weickhardt, FRACP, MBBS, Ludwig Institute for Cancer Research
 Robert Wesolowski, MD, Cleveland Clinic
 Arvin Yang, MD, PhD, Memorial Sloan-Kettering Cancer Center
 Timothy A. Yap, BSc, MBBS, MRCP, Royal Marsden Hospital
 Benoit You, Princess Margaret Hospital

AWARDS continued

2010 Advanced Clinical Research Award in Breast Cancer

Isabelle Bedrosian, MD, University of Texas M. D. Anderson Cancer Center

This grant was generously supported by The Breast Cancer Research Foundation.

2010 Advanced Clinical Research Award in Colorectal Cancer

Sanjay Goel, MD, MS, Montefiore Medical Center

This grant was generously supported by Genentech BioOncology™.

2010 Advanced Clinical Research Award in Sarcoma

David G. Kirsch, MD, PhD, Duke University Medical Center

This grant was generously supported by the Sarcoma Foundation of America and the Capon Family.

2010 Career Development Awards*

Philippe Armand, MD, PhD, Dana-Farber Cancer Institute

Nilofer Azad, MD, The Johns Hopkins University

Rupal Satish Bhatt, MD, PhD, Beth Israel Deaconess Medical Center

Toni K. Choueiri, MD, Dana-Farber Cancer Institute

Richard D. Carvajal, MD, Memorial Sloan-Kettering Cancer Center

Michael Arywn Davies, MD, PhD, University of Texas M. D. Anderson Cancer Center

Daniel Hamstra, MD, PhD, University of Michigan

Nimish Arun Mohile, MD, University of Rochester

Kimmie Ng, MD, MPH, Dana-Farber Cancer Institute

Shannon Puhalla, MD, University of Pittsburgh

Guilherme Rabinowits, MD, University of Louisville/James Graham Brown Cancer Center

Carlos A. Ramos, MD, Baylor College of Medicine

Neil H. Segal, MD, PhD, Memorial Sloan-Kettering Cancer Center

Zsofia K. Stadler, MD, Memorial Sloan-Kettering Cancer Center

These grants were generously supported by Amgen (2), The ASCO Cancer Foundation, The Breast Cancer Foundation, Celgene Corporation, Genentech BioOncology™ (5), Lilly USA, LLC, Novartis Oncology, sanofi-aventis U.S. (2)

*As of April 22, 2010

2010 Clinical Trials Participation Awards

The purpose of the Clinical Trials Participation Awards is to increase the awareness of and participation in clinical trials among physicians through the recognition of quality, community-based clinical research sites. This award is supported by the Coalition of Cancer Cooperative Groups.

Dean Hematology Oncology
Madison, Wisconsin

Gundersen Lutheran Center for Cancer and Blood Disorders
La Crosse, Wisconsin

New Hanover Radiation Oncology Center (NHROC)
Wilmington, North Carolina

Aurora Advanced Health Care
Wauwatosa, Wisconsin

Saint Francis Medical Center/Cancer Treatment Center
Grand Island, Nebraska

Sanford Hematology and Oncology
Sioux Falls, South Dakota

Sandra and Malcolm Berman Cancer Institute, Greater Baltimore Medical Center
Baltimore, Maryland

Southeastern Medical Oncology Center
Goldsboro, North Carolina

The Virginia Mason Cancer Institute
Seattle, Washington

The West Clinic
Memphis, Tennessee

2010 Community Oncology Research Grants

The Community Oncology Research Grants provide funding to quality, U.S., community-based practices to support efforts to enhance their clinical trials programs. This grant is supported by Astellas USA Foundation.

Kellogg Cancer Centers
Evanston, Illinois

Missouri Baptist Medical Center
St. Louis, Missouri

Saint Francis Medical Center/Cancer Treatment Center
Grand Island, Nebraska

2010 Comparative Effectiveness Research Professorship in Breast Cancer

Patricia A. Ganz, MD, University of California, Los Angeles

This grant was generously supported by The Breast Cancer Research Foundation.

2010 ASCO Cancer Foundation Improving Cancer Care Grants, funded by Susan G. Komen for the Cure®

Patricia Harrigan Hardenbergh, MD, Shaw Regional Cancer Center
Ann Partridge, MD, MPH, Dana-Farber Cancer Institute

AWARDS continued

2010 International Development and Education Awards

The ASCO Cancer Foundation International Development and Education Award (IDEA) provides support for early-career oncologists in developing countries to attend the ASCO Annual Meeting and spend additional time at a cancer center in the United States or Canada. Eligible recipients also receive three years of complimentary ASCO membership, which includes a subscription to the Journal of Clinical Oncology. The awards are designed to provide continuing medical education, assist in career development, and help establish strong relationships between recipients and leading ASCO members who serve as scientific mentors.

Motasem Mohammad Al-Hanaqta, MD	Jordan
Clarissa Seródio da Baldotto, MD	Brazil
Yanin Chávarri Guerra, MD	Mexico
Ganesh Dangal, MD	Nepal
Luiz Henrique de Lima Araújo, MD	Brazil
Senem Demirci, MD	Turkey
Song Dong, PhD	China
Vuong Ngoc Duong, MD	Vietnam
Mustafa S. El-Sherify, MD	Kuwait
Nikhil Suresh Ghadyalpatil, MD, DM	India
Suthinee Ithimakin, MD	Thailand
Mustapha Abubakar Jamda, MBBS, MPH, FMCPH	Nigeria
Nehal Rishi Khanna, MD	India
Haresh Kunhiparambath, MBBS, MD, DNB	India
Iwona A. Lugowska, MD, PhD	Poland
Ilya Pokataev, MD	Russia
Mudasiru Adebayo Salami, MD, MRCS(Glasg.), FWACS	Nigeria
Krishna Sagar Sharma, MD	Nepal
Amelia Janina Szymanowska-Narloch, MD, PhD	Poland
Chanida Vinayanuwattikun, MD	Thailand
Xin-Rong Yang, MD, PhD	China

2010 Long-term International Fellowship

Cesar Giovanni Sanchez Rojel, MD, Washington University in St. Louis

2010 State Affiliate Grants

Alabama Cancer Congress
Kansas Society of Clinical Oncology
Northern New England Clinical Oncology Society
Washington State Medical Oncology Society
West Virginia Oncology Society

2010 Young Investigator Awards*

Aditya Bardia, MD, MPH, The Johns Hopkins University
Daniel Becker, MD, Columbia University Medical Center
Trevor Bivona, MD, PhD, Memorial Sloan-Kettering Cancer Center
Elizabeth Buchbinder, MD, Beth Israel Deaconess Medical Center
Monika Burness, MD, The University of Chicago
Nicole Chau, MD, Princess Margaret Hospital
Lucy Chen, MD, The University of Chicago
Anthony Conley, MD, University of Texas M. D. Anderson Cancer Center
Aimee Crago, MD, PhD, Memorial Sloan-Kettering Cancer Center
Marco Davila, MD, PhD, Memorial Sloan-Kettering Cancer Center
Farshid Dayyani, MD, PhD, University of Texas M. D. Anderson Cancer Center
Christina Derleth, MD, Vanderbilt University Medical Center
Andrew Epstein, MD, Memorial Sloan-Kettering Cancer Center
Felix Feng, MD, University of Michigan
Terence Friedlander, MD, University of California, San Francisco
Ahmad Paiman Ghafoori, MD, Duke University Medical Center
Keerthi Gogineni, MD, University of Pennsylvania

Matthias Holdhoff, MD, PhD, The Johns Hopkins University
 Andrew Caleb Hsieh, MD, University of California, San Francisco
 Gopa Iyer, MD, Memorial Sloan-Kettering Cancer Center
 Richard Joseph, MD, University of Texas M. D. Anderson Cancer Center
 R. Katie Kelley, MD, University of California, San Francisco
 Jenny J. Kim, MD, MSc, The Cleveland Clinic
 Holbrook Edwin Kohrt, MD, Stanford University
 Maxwell M. Krem, MD, PhD, University of Washington/Fred Hutchinson Cancer Center
 Nicole M. Kuderer, MD, MS, Duke University Medical Center
 Christopher Lieu, MD, University of Texas M. D. Anderson Cancer Center
 Frederick L. Locke, MD, The University of Chicago
 Maryam Lustberg, MD, The Ohio State University
 Kami Maddocks, MD, The Ohio State University
 Ana Maria Molina, MD, Memorial Sloan-Kettering Cancer Center
 Janet E. Murphy, MD, Massachusetts General Hospital/Dana-Farber Cancer Institute
 Geoffrey R. Oxnard, MD, Memorial Sloan-Kettering Cancer Center
 Navin Pinto, MD, The University of Chicago
 Ran Reshef, MD, University of Pennsylvania
 Jeffrey Rothman, MD, PhD, Columbia University Medical Center
 William Rule, MD, University of Texas Southwestern Medical Center at Dallas
 Philip Saylor, MD, Massachusetts General Hospital
 Theresa Shao, MD, Columbia University Medical Center
 Rachna Shroff, MD, University of Texas M. D. Anderson Cancer Center
 Grace Suh, MD, University of Texas M. D. Anderson Cancer Center
 Iain Tan, MBBS, MRCP, National Cancer Centre Singapore
 Neeta Kiran Venepalli, MD, Vanderbilt University Medical Center
 Shaveta Vinayak, MD, MS, Stanford University
 Channing Yu, MD, PhD, Dana-Farber Cancer Institute
 Jingsong Zhang, MD, PhD, H. Lee Moffitt Cancer Center

These grants were generously provided by Abbot Oncology, Abraxis BioScience (2), American Association for Cancer Research, Amgen (2), ASCO and The ASCO Cancer Foundation Boards of Directors, The ASCO Cancer Foundation, ASCO Cancer Research Committee, ASCO Clinical Practice Committee, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., The Breast Cancer Research Foundation (2), Bristol-Myers Squibb, Don Shula Foundation, Inc., Celgene Corporation, Eisai, Inc. (2), EMD Serono Inc., Estate of Sandra Syms (2), Ewa Maria Kukrika Fund for Pancreatic Cancer Research, Genentech BioOncoLogy™ (5), Journal of Clinical Oncology, Kidney Cancer Association, Lilly USA, LLC, Merck Oncology, Millennium: The Takeda Oncology Company (2), Novartis Oncology (4), OSI Pharmaceuticals, Inc., Roche (5), sanofi-aventis U.S. (3), Sarcoma Foundation of America, and WWWW Foundation, Inc. (QuadW).

*As of April 22, 2010

Past ACRA/CDA/TRP/YIA Grant Recipients

The recipients listed below submitted an abstract that includes the results of the research funded by their Advanced Clinical Research Award (ACRA), Career Development Award (CDA), Translational Research Professorship (TRP), or Young Investigator Award (YIA). Visit www.ascocancerfoundation.org for recipients' research titles.

Presented Abstracts

These recipients submitted an abstract that was selected to be presented within designated tracks at the Meeting.

2004 CDA	Shabbir M. H. Alibhai, MD, MSc	Abstract #9027
2002 YIA/2006 CDA	Fabrice Andre, MD	Abstract #550
2007 YIA	Tracy A. Balboni, MD, MPH	Abstract #9012
2006 YIA/2009 CDA	Don M. Benson, MD	Abstract #8139
2009 CDA	Jaishri O'Neill Blakeley, MD	Abstract #2012
2008 YIA	Daniel Costin Danila, MD	Abstract #4635
2009 TRP	Merrill J. Egorin, MD	Abstract #2545
2007 ACRA	David H. Gorski, MD, PhD, FACS	Abstract #10619

AWARDS continued

2006 YIA	Paul Haluska, MD, PhD	Abstract #TPS129
2007 CDA	Michael J. Hassett, MD, MPH	Abstract #566
2002 YIA/2005 CDA	Arti Hurria, MD	Abstract #9001
2008 YIA	Danelle Frances James, MD	Abstract #6583
2007 YIA	Sao Jiralerspong, MD, PhD	Abstract #10525
2008 YIA	Richard T. Lee, MD	Abstract #9109
2005 YIA	Nancy U. Lin, MD	Abstract #1154
2009 YIA	Elizabeth Trice Loggers, MD	Abstract #6117
2005 YIA	Sherene Loi, MD, PhD	Abstract #522
2009 YIA	Nicholas Mitsiades, MD, PhD	Abstract #4544
2009 YIA	Alexei Morozov, MD, PhD	Abstract #10637
	Jeffrey M. Peppercorn, MD, MPH	Abstract #6067
2007 CDA	Blase N. Polite, MD, MPH	Abstract #6036
2008 CDA	Daniel Aaron Pollyea, MD	Abstract #TPS280
2009 YIA	Lajos Pusztai, MD, PhD	Abstract #TPS130
2008 ACRA	Noopur S. Raje, MD	Abstract #522
2007 CDA	Giridharan Ramsingh, MD, MBBS	Abstract #8140
2009 YIA	Mandira Ray, MD	Abstract #10501
2009 YIA	Karen L. Reckamp, MD, MS	Abstract #6120
2004 YIA	Diane Lauren Reidy, MD	Abstract #TPS337
2008 YIA	Jia Ruan, MD	Abstract #4163
2005 YIA/2007 CDA	Vered Stearns, MD	Abstract #8091
2004 ACRA	Jennifer S. Temel, MD	Abstract #3097
2005 CDA	Larissa K. F. Temple, MD	Abstract #7509
2005 CDA	Anne S. Tsao, MD	Abstract #3657
2003 YIA/2007 CDA	Apostolia Tsimberidou, MD, PhD	Abstract #7042
2007 CDA	William Nassib William Jr., MD	Abstract #6521
2009 YIA	Alexi A. Wright, MD	Abstract #5548
2009 YIA		Abstract #5085

Publication Abstracts

This recipient submitted an abstract that was selected for online publication at www.asco.org.

This abstract is not scheduled to be presented onsite at the Meeting.

2008 YIA	Loren K. Mell, MD	Abstract #e13570
----------	-------------------	------------------

DESCRIPTIONS OF SESSION TYPES

The 2010 Annual Meeting, developed by the ASCO 2009-2010 Cancer Education Committee and Scientific Program Committee, is made up of the following types of sessions:

Special Sessions

Special Sessions include the following:

- presentation of Special Awards as well as Award Lectures—didactic lectures presented by the recipients of ASCO's Special Awards;
- Highlights of the Day—morning sessions in which experts in the field present key findings, put abstracts into clinical context, and provide an overview of the previous day's Oral Abstract Sessions; and
- sessions recommended by individuals and other oncology-related organizations (and developed in conjunction with ASCO), the Cancer Education Committee, the Scientific Program Committee, and the ASCO Board of Directors as being of particular interest, importance, and relevance to Meeting attendees.

Clinical Science Symposia

Clinical Science Symposia provide a forum for science in oncology, combining didactic lectures on a specific topic with the presentation of abstracts. Experts in the field classify studies on the basis of the strength of the evidence and critically discuss the conclusions in terms of their applicability to clinical practice.

Education Sessions

Education Sessions offer multidisciplinary explorations of focused topics in clinical oncology. Particular care is taken to ensure that these sessions are integrated when appropriate regarding issues such as surgical, radiation, and geriatric oncology; symptom management; health services research; international perspectives; and pathology.

Extended Education Sessions

Extended Education Sessions are part of ASCO's continuing effort to provide in-depth learning experiences on topics that address educational needs in oncology, as determined by the Cancer Education Committee and other ASCO leaders.

Oral Abstract Sessions

Oral Abstract Sessions include didactic presentations of the abstracts determined by the Scientific Program Committee to be of the highest scientific merit. Experts in the field serve as Discussants to place the findings into perspective. The Plenary Session includes the abstracts selected by the Scientific Program Committee as having practice-changing findings.

Poster Discussion Sessions

Poster Discussion Sessions highlight selected abstracts of clinical research in poster format. The posters are grouped by topic and are on display for a specified time, followed by a discussion session in which expert Discussants provide commentary on the research findings.

General Poster Sessions

General Poster Sessions include selected abstracts of clinical research in poster format. The posters are grouped by topic and are on display for a specified time.

Trials in Progress Poster Session

The Trials in Progress Poster Session is a new Annual Meeting session designed to facilitate awareness of open, ongoing clinical trials. This session encourages discussion of new clinical research and the exchange of ideas on clinical trial design. There will be no presentation of trial results.

Ticketed Sessions

Ticketed sessions require additional registration. Each ticketed session has a code that should be entered during the registration process. Early registration is encouraged, as attendance in these sessions is limited.

Meet the Professor Sessions

Meet the Professor Sessions provide open discussion between recognized experts and session attendees, with an opportunity for attendees to obtain answers to specific questions.

Clinical Problems in Oncology Sessions

Clinical Problems in Oncology Sessions combine the use of case-based panel discussion with interactive, keypad technology for audience participation.

2010 ANNUAL MEETING SUPPORTERS*

THE ASCO CANCER FOUNDATION MISSION ENDOWMENT FOUNDING DONORS

Genentech BioOncology™
GlaxoSmithKline Oncology
Novartis Oncology
sanofi-aventis

THE ASCO CANCER FOUNDATION MISSION ENDOWMENT 2009 SUSTAINING DONORS

Millennium: The Takeda Oncology Company
sanofi-aventis

EDUCATIONAL SUPPORT

Amgen

Best of ASCO Meetings
Developmental Therapeutics—Clinical
Pharmacology Track
Gastrointestinal (Colorectal) Cancer Track
Genitourinary Cancer Track
Health Services Research Track
Pediatric Oncology Track

ARIAD Pharmaceuticals, Inc.

Sarcoma Track

Boehringer Ingelheim Pharmaceuticals, Inc.

Best of ASCO Meetings
Lung Cancer Track

Bristol-Myers Squibb

Gastrointestinal (Colorectal) Cancer Track
Head and Neck Cancer Track
Leukemia, Myelodysplasia, and Transplantation
Track
Lymphoma and Plasma Cell Disorders Track

Celgene Corporation

Leukemia, Myelodysplasia, and Transplantation
Track
Lymphoma and Plasma Cell Disorders Track

Centocor Ortho Biotech Inc.

Gynecologic Cancer Track

Dendreon Corporation

Best of ASCO Meeting
Genitourinary Cancer Track

Eisai Inc.

Best of ASCO Meetings
Leukemia, Myelodysplasia, and Transplantation
Track

EMD Serono Inc.

Breast Cancer Track
Central Nervous System Tumors Track
Lung Cancer Track

GE Healthcare

Practice Management and Information Technology
Track

Genentech BioOncology™

Breast Cancer Track
Tumor Biology Track
Gastrointestinal (Colorectal) Cancer Track

Genitourinary Cancer Track
Lymphoma and Plasma Cell Disorders Track
Lung Cancer Track
Professional Development Track

Kidney Cancer Association

Genitourinary Cancer Track

Lilly USA, LLC

Best of ASCO Meetings
Breast Cancer Track
Gynecologic Cancer Track
Gastrointestinal (Colorectal) Cancer Track
Head and Neck Cancer Track
Lung Cancer Track

Merck Oncology

Sarcoma Track

Millennium: The Takeda Oncology Company

Best of ASCO Meetings
Genitourinary Cancer Track
Lymphoma and Plasma Cell Disorders Track

Myriad Genetics Laboratories, Inc.

Cancer Genetics Track

Pfizer Oncology

Best of ASCO Meetings
Genitourinary Cancer Track
Leukemia, Myelodysplasia, and Transplantation
Track
Lung Cancer Track
Lymphoma and Plasma Cell Disorders Track

Purdue Pharma L.P.

Patient and Survivor Care Track

sanofi-aventis U.S.

Best of ASCO Meetings
Breast Cancer Track
Educational Book
Gastrointestinal (Colorectal) Cancer Track
International Track

GENERAL SUPPORT

Abbott Oncology

The ASCO Cancer Foundation Young Investigator
Award

Abraxis BioScience

The ASCO Cancer Foundation Young Investigator
Award (2)

American Cancer Society

The ASCO Cancer Foundation Merit Awards
ASCO–American Cancer Society Award and
Lecture

Amgen

The ASCO Cancer Foundation Career Development
Award (2)
The ASCO Cancer Foundation International
Development and Education Awards
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator
Award (2)
Long-term International Fellowship (LIFE) *in memory*
of Lina Cassol, MD

ARIAD Pharmaceuticals, Inc.

The ASCO Cancer Foundation Advanced Clinical Research Award in Sarcoma Research

ASCO and the ASCO Cancer Foundation Boards of Directors

The ASCO Cancer Foundation Young Investigator Award

ASCO Cancer Research Committee

The ASCO Cancer Foundation Young Investigator Award

ASCO Clinical Practice Committee

The ASCO Cancer Foundation Young Investigator Award

Association of Specialty Professors

B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Astellas USA Foundation

Community Oncology Research Grants

AstraZeneca

The ASCO Cancer Foundation Young Investigator Award

Bayer Healthcare Pharmaceuticals

The ASCO Cancer Foundation General Contribution

Boehringer Ingelheim Pharmaceuticals, Inc.

Abstracts on ASCO.org

Annual Meeting Smartphone Applications

The ASCO Cancer Foundation Young Investigator Award

Bradley Stuart Beller Endowed Fund

Bradley Stuart Beller Special Merit Award

The Breast Cancer Research Foundation

The ASCO Cancer Foundation Advanced Clinical Research Award in Breast Cancer

The ASCO Cancer Foundation Career Development Award in Breast Cancer

The ASCO Cancer Foundation Comparative Effectiveness Research Professorship in Breast Cancer

The ASCO Cancer Foundation Young Investigator Award in Breast Cancer

The ASCO Cancer Foundation Young Investigator Award in Breast Cancer *in honor of Susan Hirschhorn and in memory of her mother*

Bristol-Myers Squibb

Annual Meeting Program (Pocket Program)

The ASCO Cancer Foundation Merit Awards

The ASCO Cancer Foundation Young Investigator Award

Celgene Corporation

The ASCO Cancer Foundation Career Development Award

The ASCO Cancer Foundation Merit Awards

The ASCO Cancer Foundation Young Investigator Award

Patient Advocate Scholarship

Coalition of Cancer Cooperative Groups

The ASCO Cancer Foundation Clinical Trials Participation Award

Dendreon Corporation

ASCO Annual Meeting Proceedings Parts I and II (print versions)

The ASCO Cancer Foundation General Contribution Wi-Fi Zones

Don Shula Foundation, Inc.

The ASCO Cancer Foundation Young Investigator Award in Breast Cancer

Eisai Inc.

The ASCO Cancer Foundation Young Investigator Award (2)

Exhibitor Directory Stations

Patient Advocate Scholarship Program

Preliminary Annual Meeting Program

Wi-Fi Zones

The ASCO Cancer Foundation General Contribution

EMD Serono Inc.

The ASCO Cancer Foundation Young Investigator Award

EMD Serono Inc. and Merck KGaA

The ASCO Cancer Foundation International Development and Education Awards

Internet Stations

Estate of Sandra Syms

The ASCO Cancer Foundation Young Investigator Award in Kidney Cancer Research (2)

Ewa Maria Kukrika Fund for Pancreatic Cancer Research

The ASCO Cancer Foundation Young Investigator Award in Pancreatic Cancer

Genentech BioOncology™

The ASCO Cancer Foundation Advanced Clinical Research Award in Colorectal Cancer

The ASCO Cancer Foundation Advanced Clinical Research Award in Glioma

The ASCO Cancer Foundation Advanced Clinical Research Award in Hematologic Malignancies

The ASCO Cancer Foundation Career Development Award (5)

The ASCO Cancer Foundation Translational Research Professorship

The ASCO Cancer Foundation Young Investigator Award (5)

Associate and Active-Junior Lounge

Program Announcement

Registration and Housing Announcement

Genzyme

The ASCO Cancer Foundation Merit Awards

GlaxoSmithKline Oncology

The ASCO Cancer Foundation Translational Research Professorship

Journal of Clinical Oncology

The ASCO Cancer Foundation Young Investigator Award

Kidney Cancer Association

The ASCO Cancer Foundation Young Investigator Award in Renal Cell Carcinoma

2010 ANNUAL MEETING SUPPORTERS continued

Lilly USA, LLC

The ASCO Cancer Foundation Career Development Award
The ASCO Cancer Foundation General Contribution
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator Award
Patient Advocate Scholarship Program

Merck Oncology

The ASCO Cancer Foundation Young Investigator Award

Millennium: The Takeda Oncology Company

Annual Meeting Smartphone Applications
The ASCO Cancer Foundation General Contribution
The ASCO Cancer Foundation International Development and Education Awards
The ASCO Cancer Foundation Young Investigator Award (2)
Internet Stations
Patient Advocate Scholarship Program
Virtual Meetings

Novartis Oncology

The ASCO Cancer Foundation Career Development Award
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator Award (4)

Onyx Pharmaceuticals, Inc.

The ASCO Cancer Foundation General Contribution

OSI Pharmaceuticals, Inc.

The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator Award

Pfizer Oncology

The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator Award (3)
ASCO Annual Meeting Proceedings Part I (USB) and Part II (CD)

Roche

The ASCO Cancer Foundation International Development and Education Awards
The ASCO Cancer Foundation Young Investigator Award (5)

Virtual Meetings
Wi-Fi Zones

sanofi-aventis U.S.

Abstracts on ASCO.org
Annual Meeting Smartphone Applications
The ASCO Cancer Foundation Career Development Award (2)
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Oncology Trainee Travel Awards
The ASCO Cancer Foundation Young Investigator Award (3)
Virtual Meetings

Sarcoma Foundation of America

The ASCO Cancer Foundation Young Investigator Award in Sarcoma Research

Sarcoma Foundation of America and Capon Family

The ASCO Cancer Foundation Advanced Clinical Research Award in Sarcoma Research

The Susan G. Komen for the Cure®/ASCO Cancer Foundation Collaborative Commitment:

The Susan G. Komen for the Cure/ASCO Cancer Foundation Research Initiative

- *The ASCO Cancer Foundation Improving Cancer Grant, funded by Susan G. Komen for the Cure*

The Susan G. Komen for the Cure/ASCO Quality of Care Initiative

- *The ASCO Breast Cancer Registry Pilot Program, funded by Susan G. Komen for the Cure*
- *The ASCO Diversity in Oncology Initiative, funded by Susan G. Komen for the Cure*
- *The ASCO Study of Collaborative Practice Arrangements, funded by Susan G. Komen for the Cure*
- *The ASCO Study of Geographic Access to Oncology Care, funded by Susan G. Komen for the Cure*

WWW Foundation, Inc. (Quad W) and McHenry and Lisa Tichenor Fund of Communities Foundation of Texas

The ASCO Cancer Foundation Young Investigator Award in Sarcoma *in memory of Willie Tichenor*

*This list reflects commitments as of April 22, 2010.

PROGRAM BY TRACK

The 2010 ASCO Annual Meeting is structured to serve the respective interests of the Society's multidisciplinary membership, with education focused on medical, surgical, and radiation oncology. Again this year, both educational and scientific sessions have been combined to form tracks, or series of focused learning opportunities on disease-specific topics and oncology-related subjects. Because many sessions can be categorized according to more than one track, attendees are encouraged to review the sessions offered in other tracks to ensure that they find all the sessions in their preferred area of interest. Attendees can customize their meeting schedules through the online Meeting Program, available at www.asco.org/chicago2010.

Note: Sessions in which Special Awards are being presented are shaded in gray.

BREAST CANCER

FRIDAY, JUNE 4, 2010

1:00 PM - 2:15 PM Education Session

Bone Therapy in Breast Cancer: Why, When, and What's Next? *E Hall D1*

1:00 PM - 3:15 PM Extended Education Sessions

Advances in Prevention of Major Malignancies *E354b*

Sex and the Survivor *E Arie Crown Theater*

4:30 PM - 5:45 PM Education Session

Molecular Profiling in Breast Cancer: Ten Years Later *E Hall D1*

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Sessions

Cancer Fatigue and Contributing Factors: Recognition and Treatment *E354b*

Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation

E Arie Crown Theater

8:00 AM - 1:00 PM Poster Discussion Session

Breast Cancer—Metastatic *E450b*

2:00 PM - 6:00 PM General Poster Sessions

Breast Cancer—Local-Regional and Adjuvant Therapy *S Hall A2*

Breast Cancer—Metastatic *S Hall A2*

3:00 PM - 4:15 PM Clinical Problems in Oncology

Central Nervous System Metastases: From Local to Systemic Therapy (C05)-TICKETED SESSION

E451a

4:45 PM - 6:00 PM Education Session

Updates in Hormone Receptor-positive, HER2-positive, and Triple-negative Breast Cancer *N Hall B1*

SUNDAY, JUNE 6, 2010

9:45 AM - 11:00 AM Education Session

Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat *S100a*

4:30 PM - 6:00 PM Clinical Science Symposium

Predictors of Response to Preoperative Therapy: Where Are We? *N Hall B1*

4:45 PM - 6:00 PM Education Session

Physical Activity in Cancer Populations: What's New? *E354b*

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Session

Controversies in Adjuvant Systemic Treatment of Early-stage Breast Cancer *N Hall B1*

9:30 AM - 12:30 PM Oral Abstract Session

Breast Cancer—Local-Regional and Adjuvant Therapy *N Hall B1*

PROGRAM BY TRACK

Breast Cancer *continued*

1:15 PM - 2:30 PM Education Session

Controversies in the Management of Metastatic Breast Cancer *E Hall D1*

2:00 PM - 6:00 PM Poster Discussion Session

Breast Cancer—Local-Regional and Adjuvant Therapy *S403*

3:00 PM - 4:30 PM Clinical Science Symposium

Circulating Tumor Cells in Breast Cancer: Where Are We? *N Hall B1*

4:45 PM - 6:00 PM Education Session

Biology and Treatment of Breast Cancer in Survivors of Pediatric Cancer *S504*

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Session

Building Bridges for Successful Breast Cancer Survivorship Care *E354a*

9:30 AM - 12:30 PM Oral Abstract Session

Breast Cancer—Metastatic *E Hall D1*

CANCER GENETICS

FRIDAY, JUNE 4, 2010

4:30 PM - 5:45 PM Education Session

Molecular Profiling in Breast Cancer: Ten Years Later *E Hall D1*

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session

Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation

E Arie Crown Theater

3:00 PM - 4:15 PM Meet the Professor Session

Clinical Management of Hereditary Colorectal Cancer (M03)-TICKETED SESSION *E451b*

4:45 PM - 6:00 PM Education Session

Cutaneous Cancer Syndromes *E353*

SUNDAY, JUNE 6, 2010

11:30 AM - 12:45 PM Education Session

Evaluating the Evidence and Marketing of Pharmacogenomic Tests *E353*

4:45 PM - 6:00 PM Education Session

The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers

Affect Treatment Decisions? *E Hall D1*

MONDAY, JUNE 7, 2010

4:45 PM - 6:00 PM Special Session

From the Cancer Genome to Patients with Cancer: The Next Generation of Innovation—An

ASCO/American Association for Cancer Research Joint Session *S404*

4:45 PM - 6:00 PM Clinical Problems in Oncology

Advances in Hereditary Pancreatic Cancer (C13)-TICKETED SESSION *E451a*

CANCER PREVENTION/EPIDEMIOLOGY

FRIDAY, JUNE 4, 2010

1:00 PM - 3:15 PM Extended Education Session

Advances in Prevention of Major Malignancies *E354b*

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session

Micronutrient Supplementation versus Dietary Modification of Cancer Prevention: Which Is Better?
S100b

8:00 AM - 12:00 PM General Poster Session

Cancer Prevention/Epidemiology *S Hall A2*

1:00 PM - 2:15 PM Meet the Professor Session

Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention (M02)-TICKETED SESSION *E451b*

1:15 PM - 2:30 PM Education Session

The Global Burden of Cancer: The Worldwide Challenge of Cancer Control *S100b*

4:45 PM - 6:00 PM Meet the Professor Session

Aspirin and Nonsteroidal Anti-inflammatory Drugs for Colorectal Cancer Prevention (M04)-TICKETED SESSION *E451b*

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session

The Global Status of HPV Vaccination *S100b*

9:30 AM - 12:30 PM Oral Abstract Session

Cancer Prevention/Epidemiology *S100b*

11:30 AM - 12:45 PM Clinical Problems in Oncology

Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors: What to Do after Adjuvant Therapy? (C09)-TICKETED SESSION *E451a*

4:45 PM - 6:00 PM Education Session

The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers Affect Treatment Decisions? *E Hall D1*

MONDAY, JUNE 7, 2010

9:45 AM - 11:00 AM Clinical Problems in Oncology

Treatment of Barrett's Esophagus to Prevent Esophageal Cancer (C12)-TICKETED SESSION *E451a*

2:00 PM - 6:00 PM Poster Discussion Session

Cancer Prevention/Epidemiology *E450b*

CENTRAL NERVOUS SYSTEM TUMORS

FRIDAY, JUNE 4, 2010

1:00 PM - 2:15 PM Education Session

Neurologic Complications of Cancer Therapies *S100b*

2:45 PM - 4:00 PM Education Session

Geriatric Issues in Neuro-oncology *S100b*

4:30 PM - 5:45 PM Education Session

Improving Clinical Trial Outcome in Neuro-oncology *S100b*

SATURDAY, JUNE 5, 2010

8:00 AM - 1:00 PM Poster Discussion Session

Central Nervous System Tumors *S103*

3:00 PM - 6:00 PM Oral Abstract Session

Central Nervous System Tumors *S100b*

PROGRAM BY TRACK

Central Nervous System Tumors *continued*

SUNDAY, JUNE 6, 2010

8:00 AM - 12:00 PM General Poster Session
Central Nervous System Tumors *S Hall A2*

4:45 PM - 6:00 PM Education Session
Stem Cells in Neuro-oncology *S100b*

MONDAY, JUNE 7, 2010

1:15 PM - 2:30 PM Clinical Problems in Oncology
Nonglial and Heritable Central Nervous System Tumors (C14)-TICKETED SESSION *E451a*

3:00 PM - 4:15 PM Education Session
Caring for the Child with Brain Cancer *S504*

3:00 PM - 4:15 PM Clinical Problems in Oncology
Neuro-oncology for Medical Oncologists (C15)-TICKETED SESSION *E451a*

TUESDAY, JUNE 8, 2010

9:30 AM - 10:45 AM Education Session
Supportive Care for Patients with Non-small Cell Lung Cancer *E353*

CLINICAL TRIALS

FRIDAY, JUNE 4, 2010

1:00 PM - 3:15 PM Extended Education Session
Fundamentals of Clinical Trial Design and Methodology *S100a*

1:00 PM - 3:30 PM Extended Education Session
Grant Writing Workshop I: Basic Grant Writing *S106a*

3:45 PM - 6:00 PM Extended Education Session
Advanced Concepts in Clinical Trial Design and Methodology *S100a*

4:00 PM - 6:00 PM Extended Education Session
Grant Writing Workshop II: Improving Your Grant Writing Skills (Small Group Discussions) *S106a*

4:45 PM - 6:00 PM Clinical Problems in Oncology
Talking with Your Patients about Clinical Trials (C01)-TICKETED SESSION *E451a*

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session
Clinical Trials in Survivorship Populations: Emerging Concepts and Barriers to Application *S100a*

1:15 PM - 2:30 PM Education Sessions
Implementing Clinical Trials: Risks, Benefits, Marketing, and Paying for It All *E353*
Improving Access to Clinical Trials *S100a*

3:00 PM - 4:15 PM Education Sessions
International Collaboration in Clinical Trials: Special Emphasis on Ethics and Regulatory Issues *S100a*

Update on Gastrointestinal Noncolorectal Malignancies: What's New since the 2009 ASCO Annual Meeting? *N Hall B1*

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Session
Impact of Health Literacy on Health Care, Decision Making, and Consent *E353*

8:00 AM - 12:00 PM Trials in Progress Poster Session
Trials in Progress Poster Session *S Hall A2*

9:45 AM - 11:00 AM Education Session

Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction? *E Hall D2*

9:45 AM - 11:00 AM Meet the Professor Session

Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor (M10)-TICKETED SESSION
E451b

9:45 AM - 11:30 AM Education Session

Improving the Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the National Cancer Institute's Clinical Trials and Translational Research Advisory Committee *S100a*

11:30 AM - 12:45 PM Education Session

Are We Asking Too Much? The Challenges of Mandatory Research Biopsies within Clinical Trials
S100b

1:15 PM - 2:30 PM Education Session

NCI Community Cancer Centers Program (NCCCP): A New Paradigm for Clinical Trials in the Community Setting *S404*

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Sessions

Developing Drugs in Special Populations: Organ Dysfunction Studies *E354b*

Selection of Endpoints in Clinical Trials: From Bench to Trials to Practice *S100b*

DEVELOPMENTAL THERAPEUTICS

FRIDAY, JUNE 4, 2010

2:45 PM - 4:00 PM Education Session

Future Treatment Approaches toward Colorectal Cancer: New Therapeutic Pathways, New Targets
E Hall D1

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Sessions

Melanoma Immunotherapy: Current Status, Future Opportunities *S406 (Vista Room)*

The Expanding Role of Antibody-based Therapy in Children, Adolescents, and Young Adults with Cancer *S504*

8:00 AM - 1:00 PM Poster Discussion Session

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy *E450a*

1:00 PM - 4:00 PM Oral Abstract Session

Developmental Therapeutics—Experimental Therapeutics *E Hall D2*

4:30 PM - 6:00 PM Clinical Science Symposium

PARP Inhibition: DNA Repair as the Target *E Arie Crown Theater*

SUNDAY, JUNE 6, 2010

8:00 AM - 9:30 AM Clinical Science Symposium

The MEK Pathway *E354a*

9:45 AM - 11:15 AM Clinical Science Symposium

Smoothened/Hedgehog/Gamma Secretase *E353*

11:30 AM - 12:45 PM Education Session

Evaluating the Evidence and Marketing of Pharmacogenomic Tests *E353*

2:00 PM - 6:00 PM Poster Discussion Session

Developmental Therapeutics—Experimental Therapeutics *E450b*

4:45 PM - 6:00 PM Education Session

New Technology in Cancer Immune Therapy *E353*

PROGRAM BY TRACK

Developmental Therapeutics *continued*

MONDAY, JUNE 7, 2010

8:00 AM - 9:30 AM Clinical Science Symposium

Paths for Clinical Development of PI3K Inhibition *E Arie Crown Theater*

8:00 AM - 12:00 PM General Poster Sessions

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy *S Hall A2*

Developmental Therapeutics—Experimental Therapeutics *S Hall A2*

9:45 AM - 11:00 AM Meet the Professor Session

Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor (M10)-TICKETED SESSION
E451b

11:30 AM - 12:45 PM Education Session

Are We Asking Too Much? The Challenges of Mandatory Research Biopsies within Clinical Trials
S100b

1:15 PM - 2:30 PM Education Sessions

Combined Modalities in Pancreatic Cancer: Should Recent Trials Change Our Practice? *N Hall B1*

Immunoconjugates as Cancer Therapeutics *S100b*

4:45 PM - 6:00 PM Education Session

Oral Chemotherapy: A Hard Pill to Swallow *S406 (Vista Room)*

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Sessions

Developing Drugs in Special Populations: Organ Dysfunction Studies *E354b*

Selection of Endpoints in Clinical Trials: From Bench to Trials to Practice *S100b*

9:30 AM - 12:30 PM Oral Abstract Session

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy *E354a*

9:45 AM - 11:00 AM Education Session

Even Patients with Liver Dysfunction Can Get Chemotherapy! *E354b*

ETHICS

FRIDAY, JUNE 4, 2010

2:45 PM - 4:00 PM Education Session

Creating Teams That Work: Hiring Right, Communication Skills, and Disruptive Personalities *E353*

4:45 PM - 6:00 PM Clinical Problems in Oncology

Talking with Your Patients about Clinical Trials (C01)-TICKETED SESSION *E451a*

SATURDAY, JUNE 5, 2010

3:00 PM - 4:15 PM Special Session

Health Care Reform: Resetting the Clock *E Arie Crown Theater*

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session

Caregiving to Elderly Patients: Clinical, Ethical, and Psychosocial Challenges *S100a*

MONDAY, JUNE 7, 2010

9:45 AM - 11:00 AM Education Session

Family Members and Caretakers: Helping the Family and Helping the Family Help the Patient *E353*

11:30 AM - 12:45 PM Education Session

Are We Asking Too Much? The Challenges of Mandatory Research Biopsies within Clinical Trials
S100b

1:15 PM - 2:30 PM Education Session

Defining Professionalism in Oncology: Current Dilemmas and the Future of the Workforce *E353*

3:00 PM - 4:15 PM Education Session

Navigating Conflicts of Interest in Medicine and Research: Proper Interactions with Industry in a Time of Increasing Scrutiny *S100b*

4:45 PM - 6:00 PM Education Session

Decision-making Capacity: When Should Oncologists Honor Refusals of Treatment by Individuals with Diminished Capacity? *S100b*

GASTROINTESTINAL (COLORECTAL) CANCER

FRIDAY, JUNE 4, 2010

1:00 PM - 3:15 PM Extended Education Session

Sex and the Survivor *E Arie Crown Theater*

2:45 PM - 4:00 PM Education Session

Future Treatment Approaches toward Colorectal Cancer: New Therapeutic Pathways, New Targets *E Hall D1*

SATURDAY, JUNE 5, 2010

1:15 PM - 2:30 PM Education Session

Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions) *E354b*

3:00 PM - 4:15 PM Meet the Professor Session

Clinical Management of Hereditary Colorectal Cancer (M03)-TICKETED SESSION *E451b*

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session

Controversies in the Management of Colorectal Cancer *N Hall B1*

9:30 AM - 12:30 PM Oral Abstract Session

Gastrointestinal (Colorectal) Cancer *E Hall D1*

9:45 AM - 11:00 AM Education Session

Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat *S100a*

11:30 AM - 12:45 PM Clinical Problems in Oncology

Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors: What to Do after Adjuvant Therapy? (C09)-TICKETED SESSION *E451a*

2:00 PM - 6:00 PM General Poster Session

Gastrointestinal (Colorectal) Cancer *S Hall A2*

4:45 PM - 6:00 PM Education Sessions

Aging, Frailty, and Medical Therapy for Colorectal Cancer: Who Should Be Treated and How? *S404*

Physical Activity in Cancer Populations: What's New? *E354b*

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Session

Biomarker-driven Treatment in Stage II Colon Cancer: When to Hold and When to Fold *S100a*

TUESDAY, JUNE 8, 2010

8:00 AM - 12:00 PM Poster Discussion Session

Gastrointestinal (Colorectal) Cancer *S403*

9:45 AM - 11:00 AM Clinical Problems in Oncology

The Best Treatment for Hepatic Metastases: What Is the Evidence? (C18)-TICKETED SESSION *E451a*

PROGRAM BY TRACK

Gastrointestinal (Noncolorectal) Cancer

GASTROINTESTINAL (NONCOLORECTAL) CANCER

FRIDAY, JUNE 4, 2010

2:00 PM - 6:00 PM Poster Discussion Session
Gastrointestinal (Noncolorectal) Cancer E450b

SATURDAY, JUNE 5, 2010

1:15 PM - 2:45 PM Clinical Science Symposium
Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life N Hall B1

3:00 PM - 4:15 PM Education Session
Update on Gastrointestinal Noncolorectal Malignancies: What's New since the 2009 ASCO Annual Meeting? N Hall B1

SUNDAY, JUNE 6, 2010

2:00 PM - 6:00 PM General Poster Session
Gastrointestinal (Noncolorectal) Cancer S Hall A2

4:45 PM - 6:00 PM Education Session
The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers Affect Treatment Decisions? E Hall D1

MONDAY, JUNE 7, 2010

9:45 AM - 11:00 AM Education Session
Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction? E Hall D2

9:45 AM - 11:00 AM Clinical Problems in Oncology
Treatment of Barrett's Esophagus to Prevent Esophageal Cancer (C12)-TICKETED SESSION E451a

1:15 PM - 2:30 PM Education Session
Combined Modalities in Pancreatic Cancer: Should Recent Trials Change Our Practice? N Hall B1

3:00 PM - 6:00 PM Oral Abstract Session
Gastrointestinal (Noncolorectal) Cancer E Hall D1

4:45 PM - 6:00 PM Clinical Problems in Oncology
Advances in Hereditary Pancreatic Cancer (C13)-TICKETED SESSION E451a

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Session
Developing Drugs in Special Populations: Organ Dysfunction Studies E354b

9:45 AM - 11:00 AM Education Session
Even Patients with Liver Dysfunction Can Get Chemotherapy! E354b

9:45 AM - 11:00 AM Clinical Problems in Oncology
The Best Treatment for Hepatic Metastases: What Is the Evidence? (C18)-TICKETED SESSION E451a

11:30 AM - 12:45 PM Clinical Problems in Oncology
Hepatocellular Carcinoma: Is This Patient a Transplant, Resection, or Chemoembolization Candidate? (C19)-TICKETED SESSION E451a

GENERAL ONCOLOGY

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session
Cancer Fatigue and Contributing Factors: Recognition and Treatment E354b

1:15 PM - 2:30 PM Education Sessions

Evolving Standards of Care in Advanced Renal Cell Carcinoma *E Hall D1*

Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions) *E354b*

4:45 PM - 6:00 PM Education Session

Updates in Hormone Receptor-positive, HER2-positive, and Triple-negative Breast Cancer *N Hall B1*

SUNDAY, JUNE 6, 2010

7:30 AM - 9:00 AM Highlights of the Day

Highlights of the Day I including Clinical Trials Participation Awards *E Hall D1*

9:45 AM - 11:00 AM Education Session

Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat *S100a*

1:00 PM - 4:00 PM Plenary Session

Plenary Session including Science of Oncology Award and Lecture *N Hall B1*

MONDAY, JUNE 7, 2010

7:30 AM - 9:00 AM Highlights of the Day

Highlights of the Day II including Partners in Progress Award *E Hall D1*

11:30 AM - 12:45 PM Education Session

Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer *E Arie Crown Theater*

3:00 PM - 4:15 PM Education Session

Maintenance Chemotherapy for Non-small Cell Lung Cancer: Effectiveness and Cost-effectiveness *S404*

TUESDAY, JUNE 8, 2010

7:30 AM - 9:00 AM Highlights of the Day

Highlights of the Day III *E Hall D1*

8:00 AM - 9:15 AM Education Session

Early-stage Non-small Cell Lung Cancer: Staging and Primary Treatment *E353*

9:30 AM - 10:45 AM Education Session

Supportive Care for Patients with Non-small Cell Lung Cancer *E353*

11:30 AM - 12:45 PM Education Session

Management of the Elderly Patient with Cancer *S100b*

GENITOURINARY CANCER

FRIDAY, JUNE 4, 2010

1:00 PM - 3:15 PM Extended Education Session

Advances in Prevention of Major Malignancies *E354b*

SATURDAY, JUNE 5, 2010

8:00 AM - 9:30 AM Clinical Science Symposium

Genetic and Molecular Predictors in Genitourinary Malignancies *E Hall D2*

1:15 PM - 2:30 PM Education Session

Evolving Standards of Care in Advanced Renal Cell Carcinoma *E Hall D1*

2:00 PM - 6:00 PM Poster Discussion Session

Genitourinary (Nonprostate) Cancer *E450a*

PROGRAM BY TRACK Genitourinary Cancer *continued*

SUNDAY, JUNE 6, 2010

9:30 AM - 12:30 PM Oral Abstract Session
Genitourinary (Prostate) Cancer *E Hall D2*

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Session
Toward Optimizing Outcomes in Early-stage Testicular Cancer: How Little or How Much Therapy?
E354b

8:00 AM - 9:15 AM Clinical Problems in Oncology
The Spectrum of Therapeutic Dilemmas in Kidney Cancer: From Early- to Late-stage Disease (C11)-TICKETED SESSION *E451a*

8:00 AM - 1:00 PM Poster Discussion Session
Genitourinary (Prostate) Cancer *E450a*

9:30 AM - 10:45 AM Education Session
Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer *S406 (Vista Room)*

11:30 AM - 12:45 PM Education Session
Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer *E Arie Crown Theater*

1:00 PM - 5:00 PM General Poster Session
Genitourinary Cancer *S Hall A2*

1:15 PM - 2:30 PM Education Session
Exploiting the Endocrine Axis in Prostate Cancer Therapy: Current Status and Future Directions
E Hall D2

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Session
Localized Prostate Cancer: Reducing Mortality and Burden of Therapy *E Arie Crown Theater*

9:30 AM - 12:30 PM Oral Abstract Session
Genitourinary (Testes, Kidney, and Bladder) Cancer *E Arie Crown Theater*

GERIATRIC ONCOLOGY

FRIDAY, JUNE 4, 2010

2:45 PM - 4:00 PM Education Session
Geriatric Issues in Neuro-oncology *S100b*

3:30 PM - 4:45 PM Education Session
Management of Older Patients with Lymphoma and Myeloma *E354b*

SATURDAY, JUNE 5, 2010

8:00 AM - 11:00 AM Special Session
Designing Clinical Trials for Older Patients: Laboratory Science and Practical Applications (Limited Seating Available) *S106a*

1:15 PM - 2:30 PM Education Sessions
Improving Access to Clinical Trials *S100a*

Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions) *E354b*

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session
Caregiving to Elderly Patients: Clinical, Ethical, and Psychosocial Challenges *S100a*

9:45 AM - 11:00 AM Education Session
Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat *S100a*

11:30 AM - 1:00 PM Clinical Science Symposium
Optimizing Care of the Elderly and Underserved S100a

4:45 PM - 6:00 PM Special Session
B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology S100a

4:45 PM - 6:00 PM Education Session
Ageing, Frailty, and Medical Therapy for Colorectal Cancer: Who Should Be Treated and How? S404

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Session
Disparities in Cancer Care S404

9:30 AM - 10:45 AM Education Session
Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer S406 (Vista Room)

11:30 AM - 12:45 PM Education Session
Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer E Arie Crown Theater

1:15 PM - 2:30 PM Education Session
Exploiting the Endocrine Axis in Prostate Cancer Therapy: Current Status and Future Directions E Hall D2

4:45 PM - 6:00 PM Education Session
Decision-making Capacity: When Should Oncologists Honor Refusals of Treatment by Individuals with Diminished Capacity? S100b

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Sessions
Building Bridges for Successful Breast Cancer Survivorship Care E354a
Localized Prostate Cancer: Reducing Mortality and Burden of Therapy E Arie Crown Theater

11:30 AM - 12:45 PM Education Session
Management of the Elderly Patient with Cancer S100b

GYNECOLOGIC CANCER

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session
Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation E Arie Crown Theater

1:15 PM - 2:30 PM Education Session
Future Directions in the Management of Endometrial Cancer E Arie Crown Theater

2:00 PM - 6:00 PM General Poster Session
Gynecologic Cancer S Hall A2

4:45 PM - 6:00 PM Clinical Problems in Oncology
Complex and Recurrent Gynecologic Cancers: What's an Oncologist to Do? (C06)-TICKETED SESSION E451a

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session
HPV Status and Clinical Decision Making for Patients with Oropharynx Cancer E Hall D2

9:30 AM - 12:30 PM Oral Abstract Session
Gynecologic Cancer E Arie Crown Theater

PROGRAM BY TRACK

Gynecologic Cancer *continued*

2:00 PM - 6:00 PM Poster Discussion Session
Gynecologic Cancer E450a

MONDAY, JUNE 7, 2010

9:45 AM - 11:15 AM Clinical Science Symposium
Novel Therapies and Approaches for Management of Gynecologic Cancers E Arie Crown Theater

3:00 PM - 4:15 PM Education Session
Integrated Considerations in the Management of the Patient with Advanced Ovarian Cancer E Arie Crown Theater

HEAD AND NECK CANCER

FRIDAY, JUNE 4, 2010

1:00 PM - 2:15 PM Education Session
Use of Induction Chemotherapy in Clinical Practice S406 (Vista Room)

2:00 PM - 6:00 PM Poster Discussion Session
Head and Neck Cancer S403

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session
HPV Status and Clinical Decision Making for Patients with Oropharynx Cancer E Hall D2

8:00 AM - 12:00 PM General Poster Session
Head and Neck Cancer S Hall A2

9:45 AM - 11:00 AM Clinical Problems in Oncology
Therapeutic Choices for Patients with Intermediate-stage Head and Neck Cancer (C08)-TICKETED SESSION E451a

MONDAY, JUNE 7, 2010

9:45 AM - 11:00 AM Education Session
Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction? E Hall D2

9:45 AM - 11:15 AM Clinical Science Symposium
Promising Targeted Therapies for Head and Neck Cancer E354a

11:30 AM - 12:45 PM Clinical Problems in Oncology
Management of Less Common Head and Neck Cancers (C16)-TICKETED SESSION E451a

3:00 PM - 6:00 PM Oral Abstract Session
Head and Neck Cancer E354b

HEALTH SERVICES RESEARCH

FRIDAY, JUNE 4, 2010

1:00 PM - 3:15 PM Extended Education Sessions
Cancer and Thrombosis: Risk, Prevention, and Treatment E354a
Childhood Cancer Survivorship: Lessons Learned and Future Steps S504

4:30 PM - 5:45 PM Education Session
Electronic Health Records in Oncology: A Requirement for 2014 E353

SATURDAY, JUNE 5, 2010

8:00 AM - 1:00 PM Poster Discussion Session
Health Services Research S403

SUNDAY, JUNE 6, 2010

4:45 PM - 6:00 PM Clinical Problems in Oncology

Incidental Findings on Imaging in the Patient with Cancer: A Prudent Approach to Evaluation and Management (C10)-TICKETED SESSION *E451a*

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Special Session

Cancer Survivors: A Challenge to Health Care Systems Worldwide *S100b*

8:00 AM - 9:15 AM Education Sessions

Disparities in Cancer Care *S404*

Health Disparities in Lung Cancer: Race, Sex, and Genes *E Hall D2*

Impact of Health Literacy on Health Care, Decision Making, and Consent *E353*

9:30 AM - 12:30 PM Oral Abstract Session

Health Services Research *S404*

9:45 AM - 11:30 AM Education Session

Improving the Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the National Cancer Institute's Clinical Trials and Translational Research Advisory Committee *S100a*

11:30 AM - 12:45 PM Education Session

Addressing the Cost of Cancer Care with Patients: Practice-based Strategies for Communicating the "New Bad News" *E353*

1:00 PM - 5:00 PM General Poster Session

Health Services Research *S Hall A2*

3:00 PM - 4:15 PM Education Session

Caring for the Child with Brain Cancer *S504*

4:45 PM - 6:00 PM Education Session

Oral Chemotherapy: A Hard Pill to Swallow *S406 (Vista Room)*

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Sessions

Comparative Effectiveness Research in Oncology: Opportunities and Challenges *S404*

Localized Prostate Cancer: Reducing Mortality and Burden of Therapy *E Arie Crown Theater*

9:30 AM - 10:45 AM Education Session

Closing the Loop: Evidence, Guidelines, Reporting, and Quality *S100a*

11:30 AM - 12:45 PM Education Session

Management of the Elderly Patient with Cancer *S100b*

INTERNATIONAL

SATURDAY, JUNE 5, 2010

1:15 PM - 2:30 PM Education Session

The Global Burden of Cancer: The Worldwide Challenge of Cancer Control *S100b*

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session

The Global Status of HPV Vaccination *S100b*

PROGRAM BY TRACK

International *continued*

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Special Session

Cancer Survivors: A Challenge to Health Care Systems Worldwide *S100b*

8:00 AM - 9:15 AM Education Session

Disparities in Cancer Care *S404*

TUESDAY, JUNE 8, 2010

9:00 AM - 12:00 PM Special Session

Advancing Pain and Palliative Care Globally for Patients with Cancer *S504*

LEUKEMIA, MYELODYSPLASIA, AND TRANSPLANTATION

FRIDAY, JUNE 4, 2010

3:30 PM - 4:45 PM Education Session

Current Challenges for Cellular Therapies *S504*

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session

Curable and Highly Treatable Leukemias: How Do I Optimize Outcome? *E354a*

8:00 AM - 12:00 PM General Poster Session

Leukemia, Myelodysplasia, and Transplantation *S Hall A2*

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Sessions

Allogeneic Transplantation Advances and Controversies *E354b*

Optimal Treatment for Adolescents and Young Adults with Acute Lymphoblastic Leukemia *S504*

4:45 PM - 6:00 PM Education Session

Myelodysplastic Syndromes and Elderly Acute Myeloid Leukemia *E354a*

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Session

Personalizing Therapeutic Approaches to Chronic Lymphocytic Leukemia *E354a*

9:30 AM - 12:30 PM Oral Abstract Session

Leukemia, Myelodysplasia, and Transplantation *E354b*

1:15 PM - 2:30 PM Education Session

The Biology of Leukemia and Myeloproliferative Disorders: Implications for Treatment *E354b*

2:00 PM - 6:00 PM Poster Discussion Session

Leukemia, Myelodysplasia, and Transplantation *E450a*

3:00 PM - 4:15 PM Education Session

Acute Leukemia: Integration of Novel Diagnostic and Therapeutic Measures *E354a*

LUNG CANCER

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session

Cancer Fatigue and Contributing Factors: Recognition and Treatment *E354b*

8:00 AM - 9:30 AM Clinical Science Symposium

Molecularly Targeted Trials in Lung Cancer *E Hall D1*

1:15 PM - 2:30 PM Clinical Problems in Oncology
Improving Outcomes for Patients with Locally Advanced Lung Cancer (C04)-TICKETED SESSION
E451a

3:00 PM - 5:30 PM Oral Abstract Session
Lung Cancer—Local-Regional and Adjuvant Therapy *E Hall D1*

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Meet the Professor Session
Controversies in Stage IIIA Non-small Cell Lung Cancer (M05)-TICKETED SESSION *E451b*

8:00 AM - 12:00 PM General Poster Sessions
Lung Cancer—Local-Regional and Adjuvant Therapy *S Hall A2*
Lung Cancer—Metastatic *S Hall A2*

9:45 AM - 11:00 AM Education Session
Therapy for Patients with Activating Mutations of the Epidermal Growth Factor Receptor *N Hall B1*

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Session
Health Disparities in Lung Cancer: Race, Sex, and Genes *E Hall D2*

8:00 AM - 1:00 PM Poster Discussion Session
Lung Cancer—Metastatic *E450b*

9:45 AM - 11:00 AM Education Session
Seminal Advances in Lung Cancer Research 2010: Translational and Clinical *E Hall D1*

1:15 PM - 2:30 PM Special Session
ASCO/European CanCer Organisation Joint Session: Personalized Medicine in Locally Advanced Non-small Cell Lung Cancer *E Arie Crown Theater*

3:00 PM - 4:15 PM Education Session
Maintenance Chemotherapy for Non-small Cell Lung Cancer: Effectiveness and Cost-effectiveness
S404

3:00 PM - 5:30 PM Oral Abstract Session
Lung Cancer—Metastatic *E Hall D2*

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Session
Early-stage Non-small Cell Lung Cancer: Staging and Primary Treatment *E353*

8:00 AM - 9:15 AM Clinical Problems in Oncology
Debates in Adjuvant Therapy: Chemotherapy versus Observation for Node-negative Non-small Cell Lung Cancer and Radiotherapy versus Observation for Node-positive Non-small Cell Lung Cancer (C17)-TICKETED SESSION *E451a*

8:00 AM - 1:00 PM Poster Discussion Session
Lung Cancer—Local-Regional and Adjuvant Therapy *E450b*

9:30 AM - 10:45 AM Education Session
Supportive Care for Patients with Non-small Cell Lung Cancer *E353*

LYMPHOMA AND PLASMA CELL DISORDERS

FRIDAY, JUNE 4, 2010

2:00 PM - 6:00 PM Poster Discussion Session
Lymphoma and Plasma Cell Disorders *E450a*

3:30 PM - 4:45 PM Education Session
Management of Older Patients with Lymphoma and Myeloma *E354b*

PROGRAM BY TRACK

Lymphoma and Plasma Cell Disorders *continued*

SATURDAY, JUNE 5, 2010

8:00 AM - 12:00 PM General Poster Session
Lymphoma and Plasma Cell Disorders S Hall A2

1:00 PM - 4:00 PM Oral Abstract Session
Lymphoma E354a

4:30 PM - 6:00 PM Clinical Science Symposium
Novel Therapies for Myeloma E354a

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Clinical Problems in Oncology
Immunosuppression in Patients with Lymphoma and Myeloma (C07)-TICKETED SESSION E451a

9:30 AM - 12:30 PM Oral Abstract Session
Myeloma E354b

9:45 AM - 11:00 AM Meet the Professor Session
Nontransplant Options for Mantle Cell Lymphoma (M06)-TICKETED SESSION E451b

11:30 AM - 12:45 PM Education Session
Survivorship in Lymphoma E354a

4:45 PM - 6:00 PM Meet the Professor Session
Cutaneous B-cell Lymphoma (M08)-TICKETED SESSION E451b

MONDAY, JUNE 7, 2010

1:15 PM - 2:30 PM Education Sessions
Complications of Myeloma and Myeloma Therapies E354a

Immunoconjugates as Cancer Therapeutics S100b

Response-based Therapy: A Personalized Approach to Pediatric Hodgkin Lymphoma S504

MELANOMA/SKIN CANCERS

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session
Melanoma Immunotherapy: Current Status, Future Opportunities S406 (Vista Room)

9:45 AM - 11:00 AM Clinical Problems in Oncology
Ocular Melanoma (C03)-TICKETED SESSION E451a

1:00 PM - 2:15 PM Meet the Professor Session
Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention (M02)-TICKETED SESSION E451b

1:00 PM - 4:00 PM Oral Abstract Session
Melanoma/Skin Cancers S406 (Vista Room)

4:30 PM - 6:00 PM Clinical Science Symposium
Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets S406 (Vista Room)

4:45 PM - 6:00 PM Education Session
Cutaneous Cancer Syndromes E353

SUNDAY, JUNE 6, 2010

8:00 AM - 12:00 PM General Poster Session
Melanoma/Skin Cancers S Hall A2

4:45 PM - 6:00 PM Education Session
Nonmelanoma Skin Cancers: New Insights, New Directions S406 (Vista Room)

MONDAY, JUNE 7, 2010

8:00 AM - 12:00 PM Poster Discussion Session
Melanoma/Skin Cancers S403

11:30 AM - 12:45 PM Clinical Problems in Oncology
Management of Less Common Head and Neck Cancers (C16)-TICKETED SESSION E451a

PATIENT AND SURVIVOR CARE

FRIDAY, JUNE 4, 2010

1:00 PM - 2:15 PM Education Session
Neurologic Complications of Cancer Therapies S100b

1:00 PM - 3:15 PM Extended Education Sessions
Cancer and Thrombosis: Risk, Prevention, and Treatment E354a
Sex and the Survivor E Arie Crown Theater

3:30 PM - 4:45 PM Education Session
Update on Patient Safety: Basic Science, Practical Strategies in Oncology Practice, and Discussing Complications E Arie Crown Theater

4:30 PM - 5:45 PM Education Session
Electronic Health Records in Oncology: A Requirement for 2014 E353

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session
Cancer Fatigue and Contributing Factors: Recognition and Treatment E354b

8:00 AM - 9:15 AM Clinical Problems in Oncology
When Onco-cardiology Meets Cardio-oncology: A Global Perspective (C02)-TICKETED SESSION E451a

1:15 PM - 2:30 PM Education Sessions
A Family's Year with Cancer S404
Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions) E354b

3:00 PM - 6:00 PM Oral Abstract Session
Patient and Survivor Care E354b

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session
Caregiving to Elderly Patients: Clinical, Ethical, and Psychosocial Challenges S100a

8:00 AM - 9:15 AM Clinical Problems in Oncology
Immunosuppression in Patients with Lymphoma and Myeloma (C07)-TICKETED SESSION E451a

9:45 AM - 11:15 AM Clinical Science Symposium
Pharmacologic Treatment of Cancer-related Fatigue: Does It Make a Difference? E354a

11:30 AM - 12:45 PM Education Session
Survivorship in Lymphoma E354a

11:30 AM - 12:45 PM Clinical Problems in Oncology
Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors: What to Do after Adjuvant Therapy? (C09)-TICKETED SESSION E451a

11:30 AM - 1:00 PM Clinical Science Symposium
Optimizing Care of the Elderly and Underserved S100a

4:45 PM - 6:00 PM Education Session
Physical Activity in Cancer Populations: What's New? E354b

PROGRAM BY TRACK

Patient and Survivor Care *continued*

4:45 PM - 6:00 PM Clinical Problems in Oncology

Incidental Findings on Imaging in the Patient with Cancer: A Prudent Approach to Evaluation and Management (C10)-TICKETED SESSION *E451a*

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Sessions

Impact of Health Literacy on Health Care, Decision Making, and Consent *E353*

Toward Optimizing Outcomes in Early-stage Testicular Cancer: How Little or How Much Therapy? *E354b*

8:00 AM - 9:15 AM Clinical Problems in Oncology

The Spectrum of Therapeutic Dilemmas in Kidney Cancer: From Early- to Late-stage Disease (C11)-TICKETED SESSION *E451a*

9:30 AM - 10:45 AM Education Session

Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer *S406 (Vista Room)*

9:45 AM - 11:00 AM Education Session

Family Members and Caretakers: Helping the Family and Helping the Family Help the Patient *E353*

11:30 AM - 12:45 PM Education Session

Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer *E Arie Crown Theater*

1:00 PM - 5:00 PM General Poster Session

Patient and Survivor Care *S Hall A2*

1:15 PM - 2:30 PM Education Sessions

Complications of Myeloma and Myeloma Therapies *E354a*

Exploiting the Endocrine Axis in Prostate Cancer Therapy: Current Status and Future Directions *E Hall D2*

4:45 PM - 6:00 PM Education Session

Oral Chemotherapy: A Hard Pill to Swallow *S406 (Vista Room)*

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Sessions

Building Bridges for Successful Breast Cancer Survivorship Care *E354a*

Comparative Effectiveness Research in Oncology: Opportunities and Challenges *S404*

8:00 AM - 12:00 PM Poster Discussion Session

Patient and Survivor Care *E450a*

9:00 AM - 12:00 PM Special Session

Advancing Pain and Palliative Care Globally for Patients with Cancer *S504*

9:30 AM - 10:45 AM Education Sessions

Closing the Loop: Evidence, Guidelines, Reporting, and Quality *S100a*

Supportive Care for Patients with Non-small Cell Lung Cancer *E353*

9:45 AM - 11:00 AM Education Session

Even Patients with Liver Dysfunction Can Get Chemotherapy! *E354b*

9:45 AM - 11:00 AM Clinical Problems in Oncology

The Best Treatment for Hepatic Metastases: What Is the Evidence? (C18)-TICKETED SESSION *E451a*

11:30 AM - 12:45 PM Education Session

Management of the Elderly Patient with Cancer *S100b*

PEDIATRIC ONCOLOGY

FRIDAY, JUNE 4, 2010

1:00 PM - 3:15 PM Extended Education Session

Childhood Cancer Survivorship: Lessons Learned and Future Steps *S504*

3:30 PM - 4:45 PM Education Sessions

Current Challenges for Cellular Therapies *S504*

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session

The Expanding Role of Antibody-based Therapy in Children, Adolescents, and Young Adults with Cancer *S504*

9:45 AM - 11:00 AM Meet the Professor Session

Germ Cell Tumors in Children, Adolescents, and Young Adults (M01)-TICKETED SESSION *E451b*

1:15 PM - 2:30 PM Education Session

New Treatments for Sarcoma in Children, Adolescents, and Young Adults *S504*

3:00 PM - 4:15 PM Special Session

Pediatric Oncology Award and Lecture *S504*

4:30 PM - 5:45 PM Clinical Science Symposium

Signaling in Pediatric Cancer Comes to the Clinic *S504*

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session

Optimal Treatment for Adolescents and Young Adults with Acute Lymphoblastic Leukemia *S504*

9:30 AM - 12:30 PM Oral Abstract Session

Pediatric Oncology I *S504*

11:30 AM - 12:45 PM Education Session

Evaluating the Evidence and Marketing of Pharmacogenomic Tests *E353*

2:00 PM - 6:00 PM Poster Discussion Session

Pediatric Oncology S Hall A2

2:00 PM - 6:00 PM General Poster Session

Pediatric Oncology S Hall A2

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Sessions

The Biology and Treatment of Wilms Tumor *S504*

Translocation-specific Sarcomas: Can Molecular Targets Translate to Therapeutics?
S406 (Vista Room)

9:30 AM - 12:30 PM Oral Abstract Session

Pediatric Oncology II *S504*

1:15 PM - 2:30 PM Education Session

Response-based Therapy: A Personalized Approach to Pediatric Hodgkin Lymphoma *S504*

3:00 PM - 4:15 PM Education Session

Caring for the Child with Brain Cancer *S504*

PROGRAM BY TRACK Pediatric Oncology *continued*

4:45 PM - 6:00 PM Education Sessions

Biology and Treatment of Breast Cancer in Survivors of Pediatric Cancer *S504*

Decision-making Capacity: When Should Oncologists Honor Refusals of Treatment by Individuals with Diminished Capacity? *S100b*

PRACTICE MANAGEMENT AND INFORMATION TECHNOLOGY

FRIDAY, JUNE 4, 2010

1:00 PM - 2:15 PM Education Session

Clinical Practice: The Challenge of Financial Survival *E353*

2:45 PM - 4:00 PM Education Session

Creating Teams That Work: Hiring Right, Communication Skills, and Disruptive Personalities *E353*

4:30 PM - 5:45 PM Education Session

Electronic Health Records in Oncology: A Requirement for 2014 *E353*

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session

How to Use Data to Improve Practice: Nexus of Quality and Efficiency *E353*

1:15 PM - 2:30 PM Education Session

Implementing Clinical Trials: Risks, Benefits, Marketing, and Paying for It All *E353*

3:00 PM - 4:15 PM Special Session

Health Care Reform: Resetting the Clock *E Arie Crown Theater*

3:00 PM - 4:15 PM Education Session

Managing Survivorship in a Community Practice *E353*

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Special Session

Forum on Reimbursement *E Arie Crown Theater*

11:30 AM - 12:45 PM Meet the Professor Session

Electronic/Digital Resources in Oncology: Value versus Distraction (M07)-TICKETED SESSION *E451b*

MONDAY, JUNE 7, 2010

11:30 AM - 12:45 PM Special Session

The Hospital/Physician Relationship: Tensions Arising *E354a*

11:30 AM - 12:45 PM Education Session

Addressing the Cost of Cancer Care with Patients: Practice-based Strategies for Communicating the "New Bad News" *E353*

1:15 PM - 2:30 PM Education Session

NCI Community Cancer Centers Program (NCCCP): A New Paradigm for Clinical Trials in the Community Setting *S404*

TUESDAY, JUNE 8, 2010

9:45 AM - 11:00 AM Special Session

Imaging Informatics and Optimizing Imaging in Cancer Diagnosis: An ASCO/Radiological Society of North America Joint Session *S404*

PROFESSIONAL DEVELOPMENT

FRIDAY, JUNE 4, 2010

1:00 PM - 3:30 PM Extended Education Sessions
Grant Writing Workshop I: Basic Grant Writing *S106a*

On the Shoulders of Giants: Historical Perspective on Drug Development and Renal Cancer *E350*

1:00 PM - 4:00 PM Extended Education Session
Maintenance of Certification and Lifelong Learning Workshop (MOC)-TICKETED SESSION *E451a*

2:45 PM - 4:00 PM Education Session
Creating Teams That Work: Hiring Right, Communication Skills, and Disruptive Personalities *E353*

3:30 PM - 4:45 PM Education Session
Update on Patient Safety: Basic Science, Practical Strategies in Oncology Practice, and Discussing Complications *E Arie Crown Theater*

3:30 PM - 6:00 PM Extended Education Session
Career Choices in Oncology: Options in Academic, Private Practice, Industry, and Government *S404*

4:00 PM - 6:00 PM Extended Education Session
Grant Writing Workshop II: Improving Your Grant Writing Skills (Small Group Discussions) *S106a*

4:45 PM - 6:00 PM Clinical Problems in Oncology
Talking with Your Patients about Clinical Trials (C01)-TICKETED SESSION *E451a*

SATURDAY, JUNE 5, 2010

7:30 AM - 8:00 AM Education Session
How to Navigate the Annual Meeting (Fellows and Junior Faculty Only) *S501*

8:00 AM - 9:15 AM Education Session
How to Use Data to Improve Practice: Nexus of Quality and Efficiency *E353*

1:15 PM - 2:30 PM Education Session
A Family's Year with Cancer *S404*

3:00 PM - 4:15 PM Education Session
Update on Gastrointestinal Noncolorectal Malignancies: What's New since the 2009 ASCO Annual Meeting? *N Hall B1*

SUNDAY, JUNE 6, 2010

10:30 AM - 12:30 PM Special Session
Training Program Directors' Special Session—Addressing the Competencies: Professionalism and Practice-based Learning *S404*

11:30 AM - 12:45 PM Meet the Professor Session
Electronic/Digital Resources in Oncology: Value versus Distraction (M07)-TICKETED SESSION *E451b*

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Meet the Professor Session
Contract Negotiation for Your First Job (M09)-TICKETED SESSION *E451b*

9:45 AM - 11:00 AM Education Session
Family Members and Caretakers: Helping the Family and Helping the Family Help the Patient *E353*

9:45 AM - 11:00 AM Meet the Professor Session
Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor (M10)-TICKETED SESSION *E451b*

11:30 AM - 12:45 PM Education Session
Addressing the Cost of Cancer Care with Patients: Practice-based Strategies for Communicating the "New Bad News" *E353*

PROGRAM BY TRACK

Professional Development *continued*

1:15 PM - 2:30 PM Education Sessions

Controversies in the Management of Metastatic Breast Cancer *E Hall D1*

Defining Professionalism in Oncology: Current Dilemmas and the Future of the Workforce *E353*

NCI Community Cancer Centers Program (NCCCP): A New Paradigm for Clinical Trials in the Community Setting *S404*

3:00 PM - 4:15 PM Education Session

Physician Burnout: How to Survive and Stay Happy in Oncology *E353*

SARCOMA

SATURDAY, JUNE 5, 2010

1:15 PM - 2:30 PM Education Session

New Treatments for Sarcoma in Children, Adolescents, and Young Adults *S504*

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session

Controversies in the Management of Desmoid Tumors *S406 (Vista Room)*

9:45 AM - 11:00 AM Education Session

Creative Approaches to Advanced and Metastatic Sarcoma *S406 (Vista Room)*

11:30 AM - 12:45 PM Education Session

Lessons Learned from Clinical Trials in Gastrointestinal Stromal Tumor *S406 (Vista Room)*

2:00 PM - 6:00 PM General Poster Session

Sarcoma *S Hall A2*

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Session

Translocation-specific Sarcomas: Can Molecular Targets Translate to Therapeutics? *S406 (Vista Room)*

1:00 PM - 4:00 PM Oral Abstract Session

Sarcoma *S406 (Vista Room)*

TUESDAY, JUNE 8, 2010

8:00 AM - 12:00 PM Poster Discussion Session

Sarcoma *S103*

SPECIAL SESSIONS

FRIDAY, JUNE 4, 2010

3:30 PM - 4:45 PM Special Session

ASCO/American Society of Hematology Joint Session *E354a*

7:00 PM - 9:00 PM Special Session
(Presented during a Private Function)

Distinguished Achievement Award

Special Recognition Award

SATURDAY, JUNE 5, 2010

8:00 AM - 11:00 AM Special Session

Designing Clinical Trials for Older Patients: Laboratory Science and Practical Applications (Limited Seating Available) *S106a*

PROGRAM BY TRACK

Special Sessions

9:30 AM - 12:00 PM Special Session

Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award and Lecture, and The ASCO Cancer Foundation Donor Recognition Awards *N Hall B1*

3:00 PM - 4:15 PM Special Session

Health Care Reform: Resetting the Clock *E Arie Crown Theater*

3:00 PM - 4:15 PM Special Session

Pediatric Oncology Award and Lecture *S504*

SUNDAY, JUNE 6, 2010

7:30 AM - 9:00 AM Highlights of the Day

Highlights of the Day I including Clinical Trials Participation Awards *E Hall D1*

8:00 AM - 9:15 AM Special Session

Forum on Reimbursement *E Arie Crown Theater*

10:30 AM - 12:30 PM Special Session

Training Program Directors' Special Session—Addressing the Competencies: Professionalism and Practice-based Learning *S404*

1:00 PM - 4:00 PM Plenary Session

Plenary Session including Science of Oncology Award and Lecture *N Hall B1*

4:45 PM - 6:00 PM Special Session

B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology *S100a*

MONDAY, JUNE 7, 2010

7:30 AM - 9:00 AM Highlights of the Day

Highlights of the Day II including Partners in Progress Award *E Hall D1*

8:00 AM - 9:15 AM Special Session

Cancer Survivors: A Challenge to Health Care Systems Worldwide *S100b*

8:00 AM - 12:00 PM Trials in Progression Poster Session

Trials in Progress Poster Session *S Hall A2*

9:45 AM - 11:00 AM Special Session

ASCO—American Cancer Society Award and Lecture *S100b*

9:45 AM - 11:30 AM Education Session

Improving the Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the National Cancer Institute's Clinical Trials and Translational Research Advisory Committee *S100a*

11:30 AM - 12:45 PM Special Session

The Hospital/Physician Relationship: Tensions Arising *E354a*

12:00 PM - 1:00 PM Special Session

ASCO Annual Business Meeting including Statesman Awards (ASCO Members Only)
Hyatt McCormick Place Regency Ballroom

1:15 PM - 2:30 PM Special Session

ASCO/European CanCER Organisation Joint Session: Personalized Medicine in Locally Advanced Non-small Cell Lung Cancer *E Arie Crown Theater*

PROGRAM BY TRACK

Special Sessions *continued*

4:45 PM - 6:00 PM Special Session

From the Cancer Genome to Patients with Cancer: The Next Generation of Innovation—An ASCO/American Association for Cancer Research Joint Session S404

6:30 PM - 9:30 PM Special Session

Answers to Cancer: Annual Meeting Public Forum Sheraton Chicago Hotel & Towers, Chicago Ballroom 10

TUESDAY, JUNE 8, 2010

7:30 AM - 9:00 AM Highlights of the Day

Highlights of the Day III E Hall D1

9:00 AM - 12:00 PM Special Session

Advancing Pain and Palliative Care Globally for Patients with Cancer S504

9:45 AM - 11:00 AM Special Session

Imaging Informatics and Optimizing Imaging in Cancer Diagnosis: An ASCO/Radiological Society of North America Joint Session S404

TUMOR BIOLOGY

FRIDAY, JUNE 4, 2010

2:45 PM - 4:00 PM Education Session

Application of Epigenetics to Diagnosis and Therapy S406 (Vista Room)

SATURDAY, JUNE 5, 2010

8:00 AM - 12:00 PM General Poster Session

Tumor Biology S Hall A2

2:00 PM - 6:00 PM Poster Discussion Session

Tumor Biology S103

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session

PARP Inhibitors and More in DNA Repair E353

4:45 PM - 6:00 PM Education Sessions

New Technology in Cancer Immune Therapy E353

Stem Cells in Neuro-oncology S100b

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Sessions

Biomarker-driven Treatment in Stage II Colon Cancer: When to Hold and When to Fold S100a

Health Disparities in Lung Cancer: Race, Sex, and Genes E Hall D2

The Biology and Treatment of Wilms Tumor S504

1:15 PM - 2:30 PM Education Session

Immunoconjugates as Cancer Therapeutics S100b

1:15 PM - 2:45 PM Clinical Science Symposium

Unraveling the Cancer Genome: Clinical Implications of Next-generation Technologies S100a

3:00 PM - 6:00 PM Oral Abstract Session

Tumor Biology S100a

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Session

Omics: Toward Personalizing Care S100a

9:45 AM - 11:00 AM Education Session

Angiogenesis: Where Do We Go from Here? S100b

American Society of Clinical Oncology 46th Annual Meeting

Meeting Program

Note: Sessions in which Special Awards are presented
are shaded in gray

Friday, June 4, 2010

**1:00 PM - 2:15 PM
EDUCATION SESSIONS**

Bone Therapy in Breast Cancer: Why, When, and What's Next?

Location: E Hall D1

CME credit: 1.25

Track(s): Breast Cancer

Gabriel N. Hortobagyi, MD, FACP—Chair

University of Texas M. D. Anderson Cancer Center

Systemic Therapy for Bone Metastasis: Past, Present, and Future

Theresa Guise, MD

Indiana University School of Medicine

The Bone Microenvironment and the Potential Antitumor Effects of Bone Therapy

Catherine H. Van Poznak, MD

University of Michigan

Is There a Role for Bisphosphonates in the Adjuvant Setting?

Clinical Practice: The Challenge of Financial Survival

Location: E353

CME credit: 1.25

Track(s): Practice Management and Information Technology

Jeffery C. Ward, MD—Chair

Puget Sound Cancer Centers

The Hospital Refuge: Oasis or Mirage?

Elaine L. Towle, CMPE

Oncology Metrics

The Changing Face of Oncology Practice

William M. Jordan, DO

The Center for Cancer and Blood Disorders

Creating a Product for the Future

Neurologic Complications of Cancer Therapies

Location: S100b

CME credit: 1.25

Track(s): Central Nervous System Tumors; Patient and Survivor Care

Patrick Y. Wen, MD—Chair

Dana-Farber Cancer Institute

Central Nervous System Complications (Including Effects of Targeted Therapies)

David Schiff, MD

University of Virginia Medical Center

Peripheral Neuropathies

Michelle Monje, MD, PhD

Stanford University

Radiation and Chemotherapy Effects on Cognition (Including "Chemo Brain")

Use of Induction Chemotherapy in Clinical Practice

Location: S406 (Vista Room)

CME credit: 1.25

Track(s): Head and Neck Cancer

Everett E. Vokes, MD—Chair

The University of Chicago

Combined Modality Therapy in Perspective

Marshall R. Posner, MD

Dana-Farber Cancer Institute

Induction Chemotherapy and Sequential Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck in Clinical Practice

Jonathan Jay Beitler, MD, MBA, FACP

Emory University Winship Cancer Institute

Radiation Oncology Perspective

Friday, June 4, 2010

**1:00 PM - 3:15 PM
EXTENDED EDUCATION SESSIONS**

Advances in Prevention of Major Malignancies

Location: E354b

CME credit: 2.25

Track(s): Cancer Prevention/Epidemiology; Breast Cancer; Genitourinary Cancer

Victor G. Vogel, MD—Chair

American Cancer Society

Ian Thompson, MD

University of Texas Health Science Center at San Antonio

5-alpha Reductase Inhibitors for Prostate Cancer Prevention

Monica M. Bertagnolli, MD

Brigham and Women's Hospital

Chemoprevention of Colorectal Cancer

Jack Cuzick, PhD

Wolfson Institute of Preventive Medicine

SERMs in the Prevention of Breast Cancer

Cancer and Thrombosis: Risk, Prevention, and Treatment

Location: E354a

CME credit: 2.25

Track(s): Health Services Research; Patient and Survivor Care

Gary H. Lyman, MD, MPH—Chair

Duke Comprehensive Cancer Center

Review of Currently Available Guidelines for the Prevention of Cancer-associated Thrombosis

Alok A. Khorana, MD

University of Rochester

Review of the Incidence and Prevalence of Cancer-associated Thrombosis

Howard A. Liebman, MD

University of Southern California

Risk of Venous Thromboembolism in Patients Receiving Newer Cancer Therapies

Charles W. Francis, MD

University of Rochester

Prevention of Venous Thromboembolism in Hospitalized Medical Patients

Ajay Kumar Kakkar, MD

Thrombosis Research Institute

Prevention of Venous Thromboembolism in Surgical Cancer Patients

Mark Norman Levine, MD

Henderson Research Institute

Prevention of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy

Anna Falanga, MD

Ospedali Riuniti di Bergamo

Current and Future Clinical Trials of Venous Thromboembolism Prophylaxis in Cancer Patients

Craig M. Kessler, MD

Lombardi Comprehensive Cancer Center

*Diagnosis and Initial Treatment of Venous Thromboembolism in Cancer Patients***Agnes Y. Y. Lee, MD, MSc, FRCP(C)**

University of British Columbia

*Special Populations and Extended Anticoagulation of Cancer Patients for the Prevention of Recurrent Venous Thromboembolism***Childhood Cancer Survivorship: Lessons Learned and Future Steps**

Location: S504

CME credit: 2.25

Track(s): Health Services Research; Pediatric Oncology

Kevin C. Oeffinger, MD—Chair

Memorial Sloan-Kettering Cancer Center

Smita Bhatia, MD, MPH

City of Hope National Medical Center

*Current Guidelines for Follow-up of the Survivors of Pediatric Cancers: Current New Areas of Research Including Issues Related to Genetic Susceptibility to Toxicities***Christopher Recklitis, MPH, PhD**

Dana-Farber Cancer Institute

*Long-term Psychosocial Effects Following the Treatment of Pediatric Cancers***Gregory T. Armstrong, MD, MSCE**

St. Jude Children's Research Hospital

*The Childhood Cancer Survivor Study (CCSS)***Leslie L. Robison, PhD**

St. Jude Children's Research Hospital

*The Childhood Cancer Survivor Study (CCSS)***Fundamentals of Clinical Trial Design and Methodology**

Location: S100a

CME credit: 2.25

Track(s): Clinical Trials

Michael Paul Link, MD—Chair

Stanford University School of Medicine

*Overview and Introduction of Speakers***James L. Abbruzzese, MD**

University of Texas M. D. Anderson Cancer Center

*Clinical Trials Issues and Design***Susan G. Hilsenbeck, PhD**

Baylor College of Medicine

*Statistical Principles in Clinical Trials***Steven Joffe, MD, MPH**

Dana-Farber Cancer Institute

*Ethics in Cancer Clinical Trials***Ian Tannock, MD, PhD**

Princess Margaret Hospital

Practical Considerations in Clinical Trial Design

Friday, June 4, 2010

Sex and the Survivor

Location: E Arie Crown Theater

CME credit: 2.25

Track(s): Patient and Survivor Care; Breast Cancer; Gastrointestinal (Colorectal) Cancer

Leslie R. Schover, PhD—Chair

University of Texas M. D. Anderson Cancer Center

Overview of Current Strategies to Prevent and Treat Cancer-related Sexual Dysfunction

Patricia A. Ganz, MD

University of California, Los Angeles Schools of Medicine and Public Health

Preventing and Treating Sexual Dysfunction in Women with Breast Cancer

Stacy Tessler Lindau, MD, MAPP

The University of Chicago

Gynecologic Approach to Women's Cancer-related Sexual Dysfunction

John Mulhall, MD

Memorial Sloan-Kettering Cancer Center

Urologic Treatment of Men's Cancer-related Sexual Dysfunction

Francesco Di Fabio, MD

Southampton University Hospitals NHS Trust, Southampton General Hospital

Sexuality in Survivors of Colorectal Cancer

Michelle Marion Rhodes, PhD

Prairie View A&M University

SPIRIT: Peer Counseling to Promote Reproductive Health in African-American Breast Cancer Survivors

Sharon L. Bober, PhD

Dana-Farber Cancer Institute

Sexual Impact of Being at High Genetic Risk for Cancer

1:00 PM - 3:30 PM EXTENDED EDUCATION SESSIONS

Grant Writing Workshop I: Basic Grant Writing

Location: S106a

CME credit: 2.5

Track(s): Professional Development; Clinical Trials

Mary L. (Nora) Disis, MD—Chair

University of Washington

Grant Writing Pearls

Jonathan S. Wiest, PhD

National Cancer Institute

National Cancer Institute Training and Career Development Grants

Jennifer C. King, PhD

The ASCO Cancer Foundation

The ASCO Cancer Foundation Grants Program

Merrill J. Egorin, MD

University of Pittsburgh Cancer Institute

Choosing a Mentor and Obtaining Letters of Support

Charles M. Rudin, MD, PhD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Developing a Hypothesis and Stating Aims

Donna S. Neuberg, ScD

Dana-Farber Cancer Institute

Statistical Considerations

William G. Blum, MD

The Ohio State University

R21 Grants, Perseverance, and Resubmission

On the Shoulders of Giants: Historical Perspective on Drug Development and Renal Cancer

Location: E350

CME credit: 2.5

Track(s): Professional Development

Lisa A. Carey, MD—Chair

University of North Carolina

Moderator

Manuel Hidalgo, MD, PhD

Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III

Drug Development

Robert John Motzer, MD

Memorial Sloan-Kettering Cancer Center

Renal Cancer

William Kaelin, MD

Dana-Farber Cancer Institute

Breakout Session—Renal Cell Biologist

Vicki Leigh Keedy, MD

Vanderbilt University Medical Center

Breakout Session—Case Study Presenter

Michelle Wan Yee Lau, MD

Beth Israel Deaconess Medical Center

Breakout Session—Case Study Presenter

Friday, June 4, 2010

**1:00 PM - 4:00 PM
EXTENDED EDUCATION SESSION**

**Maintenance of Certification and Lifelong Learning Workshop
(MOC)-TICKETED SESSION**

Location: E451a

CME credit: 0

Track(s): Professional Development

Hyman Bernard Muss, MD—Chair

University of North Carolina at Chapel Hill

MOC Module Presenter

Matthew I. Milowsky, MD

Memorial Sloan-Kettering Cancer Center

MOC Module Presenter

Philip Jay Bierman, MD

University of Nebraska

MOC Module Presenter

2:00 PM - 6:00 PM POSTER DISCUSSION SESSION

Gastrointestinal (Noncolorectal) Cancer

Display Time: 2:00 PM - 6:00 PM

Display Location: E450b

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: E354a

CME credit: 1

Track(s): Gastrointestinal (Noncolorectal) Cancer

Gauri R. Varadhachary, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

Andrea Wang-Gillam, MD, PhD—Co-Chair

Washington University of St. Louis

Discussion

5:00 PM Peter C. Enzinger, MD (Abstracts #4013–4017)
Dana-Farber Cancer Institute

Discussion

5:15 PM Stephen Swisher, MD (Abstracts #4018–4023)
University of Texas M. D. Anderson Cancer Center

Discussion

5:30 PM Jennifer J. Knox, MD, FRCP (Abstracts #4024–4030)
Princess Margaret Hospital

Discussion

5:45 PM Milind M. Javle, MD (Abstracts #4033–4037)
University of Texas M. D. Anderson Cancer Center

Brd. 1 **5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4013)**
S. Al-Batran, N. Homann, J. T. Hartmann, M. H. Moehler, C. Pauligk, S. Probst, V. Rethwisch, N. Prasnikar, J. Stoehlmacher, E. Jaeger

Brd. 2 **Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). (Abstract #4014)**
M. A. Shah, S. Shibata, R. G. Stoller, M. Kemeny, P. S. Ritch, S. S. Krishnamurthi, Y. B. Su, Y. Y. Janjigian, M. Capanu, D. P. Kelsen, MSKCC Gastric Cancer Consortium

Brd. 3 **Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report. (Abstract #4015)**
T. Kishimoto, H. Imamura, F. Uedou, K. Fujitani, S. Iijima, H. Takiuchi, M. Imano, T. Shimokawa, Y. Kurokawa, H. Furukawa

Brd. 5 **Validation of tumoral matrix-metalloproteinase-9 (MMP-9) mRNA expression as a molecular prognostic factor for metastatic gastroesophageal cancer. (Abstract #4017)**
A. Atmaca, K. Steinmetz, C. Pauligk, R. M. Wirtz, N. Homann, R. Hofheinz, C. Petry, H. Altmannsberger, E. Jaeger, S. Al-Batran

Brd. 6 **Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer: Tolerability and feasibility of a phase III study. (Abstract #4018)**
E. Bajetta, I. Floriani, M. Di Bartolomeo, R. Labianca, A. Falcone, A. Santoro, R. Casaretti, E. Pasquini, A. Martoni, C. Carlomagno

- Brd. 7** Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma. (Abstract #4019)
 A. F. Okines, R. Langley, F. H. Cafferty, S. P. Stenning, S. Falk, M. T. Seymour, D. Smith, G. W. Middleton, F. Y. Coxon, D. Cunningham
- Brd. 8** Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma (JCOG0110): Analyses of operative morbidity, operation time, and blood loss. (Abstract #4020)
 T. Sano, M. Sasako, T. Shibata, S. Yamamoto, A. Tsuburaya, A. Nashimoto, S. Ito, M. Kaji, H. Furukawa, N. Fukushima, Japan Clinical Oncology Group
- Brd. 9** Perioperative chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX7) for locally advanced gastric cancer: Final results of a prospective multicenter phase II study (BJSJ-01) with 2 years follow-up. (Abstract #4021)
 J. Ji, A. Wu, Z. Li, Y. Liu, R. Li, Z. Zhang, S. Wang, Y. Ye, F. Li
- Brd. 10** Meta-analysis of preoperative chemotherapy (CTX) versus primary surgery for locoregionally advanced adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus (GE adenocarcinoma). (Abstract #4022)
 U. Ronellenfitsch, M. Schwarzbach, R. Hofheinz, P. Kienle, P. Hohenberger, K. Jensen, M. Kieser, T. E. Slanger, GE Adenocarcinoma Meta-analysis Group
- Brd. 11** Comparison of the 2010 AJCC TNM staging system with a modified lymph node ratio staging system in 7,233 gastric cancer patients. (Abstract #4023)
 J. Wang, P. Dang, P. K. Pandalai, C. P. Raut, U. N. Maduekwe, S. S. Yoon
- Brd. 12** Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial. (Abstract #4024)
 K. Okita, O. Matsui, H. Kumada, K. Tanaka, S. Kaneko, H. Moriwaki, N. Izumi, T. Okusaka, Y. Ohashi, M. Makuuchi, Peretinoin Study Group
- Brd. 13** A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC). (Abstract #4025)
 T. Meyer, M. Roughton, D. Yu, N. Davies, E. Williams, S. P. Pereira, D. Hochhauser, J. O'Beirne, D. Patch, A. K. Burroughs
- Brd. 14** Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): Second interim safety and efficacy analysis. (Abstract #4026)
 Y. Chung, B. Kim, C. Chen, J. Wang, H. CHU, J. Yoon, K. Seetalarom, S. Bae, Y. Chao, C. Li, T. Lee
- Brd. 15** European multicenter evaluation of survival for patients with hepatocellular carcinoma (HCC) treated by radioembolization with ⁹⁰y-labeled resin microspheres. (Abstract #4027)
 B. Sangro, L. Carpanese, R. Cianni, R. Golfieri, D. Gasparini, S. Ezzidin, R. Hoffman, F. Fiore, on behalf of the European Network on Radioembolization Using Y90 Microspheres (ENRY)
- Brd. 16** The impact of antiviral therapy on the outcome of hepatitis B viral (HBV)-related hepatocellular carcinoma (HCC) detected in surveillance program. (Abstract #4028)
 V. W. Wong, F. Mo, G. S. Liem, T. Mok, A. T. Chan, H. L. Chan, W. Yeo, S. L. Chan
- Brd. 17** Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in advanced biliary tract adenocarcinoma. (Abstract #4029)
 M. Kang, J. Lee, T. Kim, S. Lee, D. Park, D. Seo, M. Kim
- Brd. 18** A randomized phase II study of TSU-68 in patients (pts) with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). (Abstract #4030)
 Y. Arai, Y. Inaba, T. Yamamoto, F. Kanai, T. Aramaki, T. Tanaka, K. Yamakado, M. Kudo, S. Kaneko, K. Imanaka

- Brd. 19** **Cox proportional hazard analysis of sunitinib (SU) efficacy across subgroups of patients (pts) with progressive pancreatic neuroendocrine tumors (NET). (Abstract #4031)**
E. Raymond, P. Niccoli, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. W. Valle, S. Patyna, R. C. Chao, D. Lu
- Brd. 20** **The role of octreotide imaging in detecting neuroendocrine tumors (NETs) in 2010: Do we still need it? (Abstract #4032)**
L. Saltz, M. Gollub, D. L. Reidy
- Brd. 21** **A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. (Abstract #4033)**
H. Riess, U. Pelzer, B. Opitz, M. Stauch, P. Reitzig, S. Hahnfeld, L. Müller, J. Stieler, B. Dörken, H. Oettle
- Brd. 22** **ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC). (Abstract #4034)**
J. Berlin, P. J. Catalano, Y. Feng, A. M. Lowy, A. W. Blackstock, P. A. Philip, R. R. McWilliams, J. L. Abbruzzese, A. B. Benson
- Brd. 23** **A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). (Abstract #4035)**
H. L. Kindler, D. A. Richards, J. Stephenson, L. E. Garbo, C. S. Rocha Lima, H. Safran, J. S. Wizek, E. G. Feigal, S. Bray, C. Fuchs
- Brd. 24** **The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET study. (Abstract #4036)**
D. J. Watkins, N. Starling, I. Chau, J. Thomas, J. Webb, J. R. Oates, G. Brown, K. Thomas, D. Cunningham
- Brd. 25** **A multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study. (Abstract #4037)**
Y. Nakai, H. Isayama, T. Sasaki, N. Sasahira, K. Hirano, T. Tsujino, M. Tada, M. Omata, K. Koike, GEMSAP Study Group

Friday, June 4, 2010

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Head and Neck Cancer

Display Time: 2:00 PM - 6:00 PM
Display Location: S403
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: S406 (Vista Room)
CME credit: 1
Track(s): Head and Neck Cancer

Ranee Mehra, MD—Co-Chair

Fox Chase Cancer Center

Cherie-Ann Nathan, MD—Co-Chair

Louisiana State University Medical Center

Discussion

5:00 PM Danny Rischin, MD (Abstracts #5512–5518)
Peter McCallum Cancer Centre

Discussion

5:15 PM Cherie-Ann Nathan, MD (Abstracts #5520–5524)
Louisiana State University Medical Center

Discussion

5:30 PM Anil Chaturvedi, DVM, PhD (Abstracts #5525–5529)
National Cancer Institute

Discussion

5:45 PM Ranee Mehra, MD (Abstracts #5530–5536)
Fox Chase Cancer Center

Brd. 1 Long-term results from TAX324: A phase III trial of sequential therapy comparing TPF to PF in locally advanced (LA) squamous cell cancer of the head and neck (HNC). (Abstract #5512)

J. H. Lorch, M. R. Posner, O. Goloubeva, K. J. Cullen, N. J. Sarlis, R. B. Tishler, R. I. Haddad, TAX 324 Study Group

Brd. 2 Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68–72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303). (Abstract #5513)

H. J. Wanebo, M. S. Ghebremichael, B. Burtness, J. A. Ridge, S. Spencer, F. R. Rosen, M. R. Hancock, K. A. Tolba, A. A. Forastiere

Brd. 3 TPF induction-radioimmunochemotherapy for the treatment of advanced head and neck cancer. (Abstract #5514)

W. Jordan, I. Wildfang, H. Welkoborsky, J. Borghardt, H. Zakaria, S. Fanaei, H. Niebuhr, S. Luft, B. Tschechne

Brd. 4 Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): Mature results with HPV analysis. (Abstract #5515)

R. L. Ferris, D. E. Heron, S. Kim, M. K. Gibson, D. Posluszny, R. R. Seethala, W. E. Gooding, J. T. Johnson, J. R. Grandis, A. Argiris

Brd. 5 Radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma: Ten-year results of the 94–01 GORTEC randomized study. (Abstract #5516)

G. Calais, S. Chapet, Y. Pointreau, E. Bardet, C. Sire, T. Germain

Brd. 6 Need for postradiotherapy neck dissection by tumor site and nodal stage for head and neck cancer. (Abstract #5517)

J. Thariat, A. W. Ahmad, K. Ang, J. Myers, D. I. Rosenthal, B. S. Glisson, W. H. Morrison, R. S. Weber, P. Allen, A. S. Garden

- Brd. 7** **Clinical efficacy and tolerability of continuous course reirradiation with concurrent weekly carboplatin-paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5518)**
A. Marwaha, N. W. Choong, S. Firat, C. J. Schultz, D. Wang, S. J. Wong
- Brd. 9** **Use of XPF expression in tumors and XPF single nucleotide polymorphisms to predict clinical outcome in head and neck cancer. (Abstract #5520)**
A. E. Vaezi, X. Wang, S. C. Buch, D. Farrow, D. T. Weaver, A. D. D'Andrea, R. R. Seethala, M. Romkes, L. J. Niedernhofer, J. R. Grandis
- Brd. 10** **Gene expression profiling of oral preneoplastic lesions (OPL) from a prospective prevention trial. (Abstract #5521)**
P. Saintigny, L. Zhang, A. K. El-Naggar, V. Papadimitrakopoulou, L. Feng, J. Lee, E. S. Kim, W. K. Hong, S. M. Lippman, L. Mao
- Brd. 11** **Comparison of primary site biopsies and transverse surgical sections of squamous cell carcinoma of the head and neck for translational research analysis. (Abstract #5522)**
M. Hambek, S. Mörtel, J. Wagenblast, A. Eckardt, T. Stöver
- Brd. 12** **Association of circulating tumor cells with lymph node metastasis in squamous cell carcinoma of the head and neck region (SCCHN). (Abstract #5523)**
I. Tinhofer, T. Hristozova, R. Kanschak, A. Fusi, V. Budach, U. Keilholz
- Brd. 13** **Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving induction chemotherapy and definitive chemoradiotherapy. (Abstract #5524)**
S. Kim, D. Yoon, Y. Cho, S. Nam, S. Choi, S. Lee, J. Lee, J. Kim, K. Cho
- Brd. 14** **Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival. (Abstract #5525)**
M. R. Posner, J. H. Lorch, O. Goloubeva, M. Tan, L. Schumaker, N. J. Sarlis, R. I. Haddad, K. J. Cullen
- Brd. 15** **A population-based evaluation of incidence trends in oropharynx cancer (OP) focusing on socioeconomic status (SES), sex, and race/ethnicity. (Abstract #5526)**
A. D. Colevas, C. A. Clarke, D. Lichtensztajn, E. T. Chang
- Brd. 16** **Human papillomavirus (HPV) transmission from oropharyngeal cancer patients to sexual partners. (Abstract #5527)**
V. Papadimitrakopoulou, M. Guo, C. Etzel, B. Solomon, E. M. Sturgis, S. M. Lippman, W. K. Hong, A. S. Tsao
- Brd. 17** **Relationship between epidermal growth factor receptor (EGFR) gene copy number, p16 status, and outcome in locally advanced squamous cell carcinoma of the head and neck (LASCCHN). (Abstract #5528)**
B. J. Solomon, R. J. Young, R. Fisher, S. B. Fox, G. A. McArthur, D. Rischin
- Brd. 18** **Plasma human papillomavirus (HPV) DNA as a potential tool for tumor detection and monitoring response in HPV-related oropharyngeal carcinoma (OP). (Abstract #5529)**
H. Cao, S. Kwok, X. Shi, R. Bala, B. Pinsky, A. D. Colevas, N. Pourmand, A. Koong, C. Kong, Q. Le
- Brd. 19** **An open-label, randomized study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study. (Abstract #5530)**
K. G. Babu, L. Viswanath, B. K. Reddy, K. Shenoy, A. Shenoy, T. Naveen, B. Joseph, M. S. Vidyasagar, R. Bonanthaya, C. T. Pasha, P. P. Bapsy, A. S. Aravind, A. Eswaraiah, N. Gupta
- Brd. 20** **Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5531)**
C. Le Tourneau, E. Winquist, S. J. Hotte, S. A. Laurie, D. Soulieres, S. K. Chia, S. Singh, T. Wang, C. Mormont, L. L. Siu

- Brd. 21** **A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). (Abstract #5532)**
A. L. Sabichi, M. S. Kies, B. S. Glisson, C. Lu, L. E. Ginsberg, C. I. Bartos, L. Feng, H. T. Tran, S. M. Lippman, G. R. Blumenschein Jr.
- Brd. 22** **Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results and correlation with TS, MTHFR, and VEGF gene polymorphisms. (Abstract #5533)**
A. Argiris, M. Karamouzis, W. E. Gooding, B. Branstetter, S. Zhong, L. E. Raez, P. Savvides, M. Romkes
- Brd. 23** **Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial. (Abstract #5534)**
R. Mesia, A. Rueda, R. Vera, A. Lozano, J. A. Medina, D. Aguiar Bujanda III, F. Arias de la Vega, G. Triana, M. Guix, R. Lopez
- Brd. 24** **Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: Results of a phase I study. (Abstract #5535)**
N. F. Saba, S. Muller, A. Y. Chen, W. Grist, K. Gibson, S. Nannapaneni, C. S. Yang, F. R. Khuri, Z. G. Chen, D. M. Shin
- Brd. 25** **Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. (Abstract #5536)**
A. S. Lucas, E. E. Cohen, R. B. Cohen, M. K. Krzyzanowska, C. H. Chung, B. A. Murphy, T. Tanvetyanon, J. Gilbert, D. T. Moore, D. N. Hayes

2:00 PM - 6:00 PM POSTER DISCUSSION SESSION

Lymphoma and Plasma Cell Disorders

Display Time: 2:00 PM - 6:00 PM

Display Location: E450a

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: E354b

CME credit: 1

Track(s): Lymphoma and Plasma Cell Disorders

Nancy Bartlett, MD—Co-Chair

Washington University

Robert Z. Orlowski, MD, PhD—Co-Chair

University of Texas M. D. Anderson Cancer Center

Discussion

5:00 PM Giampaolo Merlini, MD, PhD (Abstracts #8022–8026)
University of Pavia
New Developments in Amyloidosis

Discussion

5:15 PM Robert Z. Orlowski, MD, PhD (Abstracts #8027–8032)
University of Texas M. D. Anderson Cancer Center
Personalized Therapy and New Agents in Myeloma

Discussion

5:30 PM Lawrence D. Kaplan, MD (Abstracts #8033–8035)
University of California, San Francisco
Approaches for HIV-associated Lymphoma

Discussion

5:45 PM Nancy Bartlett, MD (Abstracts #8036–8042)
Washington University
Novel Agents in Lymphoma

- Brd. 1** **Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial. (Abstract #8022)**
V. Sanchorawala, V. Bolejack, J. Crowley, A. Hoering, K. T. Finn, S. Fennessey, D. C. Seldin, B. Barlogie
- Brd. 2** **Weekly and twice-weekly bortezomib in AL amyloidosis: Results of a phase II study. (Abstract #8023)**
D. E. Reece, U. Hegenbart, V. Sanchorawala, G. Merlini, J. Blade, K. Liu, C. Enny, H. Van De Velde, A. Cakana, R. Comenzo, VELCADE CAN2007 Study Group
- Brd. 3** **Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis. (Abstract #8024^)**
C. Gasparetto, V. Sanchorawala, R. M. Snyder, J. Matous, H. R. Terebelo, N. Janakiraman, M. Y. Mapara, C. Webb, J. Abrams, J. A. Zonder
- Brd. 4** **A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis. (Abstract #8025)**
A. Dispenzieri, M. A. Gertz, S. R. Hayman, S. Kumar, C. B. Reeder, S. R. Zeldenrust, J. Allred, J. Mikhael, F. Buadi, M. Lacy
- Brd. 5** **Comparison of bortezomib- and lenalidomide-based therapies for the treatment of primary (AL) amyloidosis. (Abstract #8026)**
D. J. Landsburg, E. A. Stadtmauer, S. J. Schuster, P. Mangan, B. Shelly, D. T. Vogl
- Brd. 6** **Outcome with total therapy 3 (TT3) compared to total therapy 2 (TT2): Role of GEP70-defined high-risk disease with trisomy of 1q21 and activation of the proteasome gene *PSMD4*. (Abstract #8027)**
J. D. Shaughnessy, P. Qu, E. Tian, R. Edmondson, B. P. Nair, S. Waheed, Y. Alsayed, F. Van Rhee, J. Haessler, J. Crowley, B. Barlogie

Friday, June 4, 2010

- Brd. 7** **Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy. (Abstract #8028[^])**
D. E. Joshua, J. Bashford, J. Szer, N. Horvath, A. Spencer, M. S. Hertzberg, E. Ashurst, J. Wade, M. C. Copeman, H. M. Prince
- Brd. 8** **Dose-escalation study of carfilzomib (CFZ) + lenalidomide (LEN) + low-dose dexamethasone (Dex) (CRD) in relapsed/refractory multiple myeloma (R/R MM). (Abstract #8029)**
W. Bensinger, M. Wang, R. Z. Orlowski, M. Alsina, T. Martin, S. Singhal, N. Y. Gabrail, M. Vallone, M. Kauffman, R. Niesvizky
- Brd. 9** **Phase Ib study of oral panobinostat (LBH589) + lenalidomide (LEN) + dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Ref and refractory (Ref) multiple myeloma (MM). (Abstract #8030[^])**
M. Mateos, A. Spencer, K. Taylor, S. Lonial, J. De La Rubia, T. Facon, B. Bengoudifa, K. Hazell, P. M. Bourquelot, J. F. San-Miguel
- Brd. 10** **Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM). (Abstract #8031)**
P. G. Richardson, D. M. Weber, C. S. Mitsiades, M. A. Dimopoulos, J. Harousseau, J. Howe, T. Graef, C. Byrne, K. C. Anderson, D. S. Siegel
- Brd. 11** **Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. (Abstract #8032)**
A. K. Mahindra, P. G. Richardson, P. Hari, J. Laubach, I. M. Ghobrial, R. L. Schlossman, E. Weller, N. C. Munshi, K. C. Anderson, N. S. Raju
- Brd. 12** **Incorporation of rituximab and liposomal doxorubicin into CODOX-m/IVAC for HIV-negative and HIV-positive adult patients (pts) with untreated Burkitt's lymphoma (BL): Preliminary results of a multicenter phase II study. (Abstract #8033)**
S. A. Gregory, P. M. Barr, C. Nabhan, A. Nukala, L. Gallot, A. Larsen, M. Z. Moll, S. E. Smith, L. I. Gordon, A. M. Evens
- Brd. 13** **A phase II trial of pegylated doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in patients with newly diagnosed AIDS-associated B-cell non-Hodgkin's lymphoma (ARL): An AIDS Malignancy Consortium Trial (AMC 047). (Abstract #8034)**
A. M. Levine
- Brd. 14** **HIV-associated Hodgkin's lymphoma (HIV-HL): Results of a prospective multicenter trial. (Abstract #8035)**
M. Hentrich, M. Berger, C. Hoffmann, J. M. Siehl, T. Wolf, J. Rockstroh, G. Fätkenheuer, K. Arastéh, F. A. Mosthaf Sr., C. Wyen, German HIV-related Lymphoma Study Group
- Brd. 15** **Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. (Abstract #8036)**
N. H. Fowler, P. McLaughlin, F. B. Hagemeister, L. W. Kwak, M. A. Fanale, S. S. Neelapu, L. Fayad, R. Z. Orlowski, M. Wang, F. Samaniego
- Brd. 16** **Lenalidomide (LEN) in patients with transformed lymphoma: Results from a large international phase II study (NHL-003). (Abstract #8037)**
C. B. Reeder, J. Vose, T. E. Witzig, P. L. Zinzani, R. Buckstein, J. Polikoff, J. Li, D. Pietronigro, A. L. Ervin-Haynes, M. S. Czuczman
- Brd. 17** **Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with non-germinal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R). (Abstract #8038)**
F. J. Hernandez-Ilizaliturri, G. Deeb, P. L. Zinzani, S. A. Pileri, F. Malik, W. R. Macon, T. E. Witzig, A. Goy, M. S. Czuczman
- Brd. 18** **Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602. (Abstract #8039)**
S. M. Smith, N. Bartlett, J. L. Johnson, J. Lister, A. F. Cashen, S. Jung, H. Schöder, K. Egan, B. D. Cheson

- Brd. 19** **Enzastaurin in patients with follicular lymphoma: Results of a phase II study. (Abstract #8040)**
L. Schwartzberg, R. C. Hermann, I. W. Flinn, D. B. Flora, J. Song, O. Hamid, B. K. Lin, M. H. Dreyling
- Brd. 20** **Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma. (Abstract #8041)**
J. L. Vacirca, P. I. Acs, B. J. Shimkus, P. J. Rosen
- Brd. 21** **Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL). (Abstract #8042^)**
M. S. Czuczman, A. Viardot, G. Hess, O. V. Gadeberg, L. M. Pedersen, I. Gupta, T. S. Lin, C. Strange, K. Windfeld, C. A. Russell
- Brd. 22** **Phase II trial of daclizumab in human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL). (Abstract #8043)**
J. L. Berkowitz, J. E. Janik, D. M. Stewart, S. Fioravanti, E. S. Jaffe, T. A. Fleisher, N. Urquhart, G. H. Wharfe, T. A. Waldmann, J. C. Morris
- Brd. 23** **Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study. (Abstract #8044)**
M. Yamaguchi, Y. Kwong, Y. Maeda, C. Hashimoto, W. Kim, C. Suh, R. Hyo, S. Nakamura, K. Oshimi, R. Suzuki, The NK-Cell Tumor Study Group
- Brd. 24** **Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial. (Abstract #8045)**
F. M. Foss, N. N. Sjak-Shie, A. Goy, R. Advani, E. D. Jacobsen
- Brd. 25** **A phase I/II trial of clofarabine in patients with relapsed T-cell or NK-cell lymphomas. (Abstract #8046)**
D. A. Mulford, B. L. Pohlman, P. A. Hamlin, F. Young, E. Pamer, S. M. Horwitz

Friday, June 4, 2010

**2:45 PM - 4:00 PM
EDUCATION SESSIONS**

Application of Epigenetics to Diagnosis and Therapy

Location: S406 (Vista Room)

CME credit: 1.25

Track(s): Tumor Biology

Jean Pierre Issa, MD—Chair

University of Texas M. D. Anderson Cancer Center

Use of Epigenetic Information for Individualized Cancer Care

Gerd P. Pfeifer, PhD

City of Hope

Cancer Epigenetics: Basic Biology

Paul Cairns, PhD

Fox Chase Cancer Center

Can We Use Epigenetics in Early Detection of Cancer?

Creating Teams That Work: Hiring Right, Communication Skills, and Disruptive Personalities

Location: E353

CME credit: 1.25

Track(s): Practice Management and Information Technology; Ethics; Professional Development

John Vernon Cox, DO—Chair

Texas Oncology

Disruptive Behaviors: Is There a Solution?

Gay G. Cox, JD

Lessons from Life: How to Optimize Communication in Multidisciplinary Conferences (Or with Your Teenager)

John McCracken, PhD

University of Texas at Dallas

Behavioral Fit: A Tool for Success in Assimilation of a New Hire

Future Treatment Approaches toward Colorectal Cancer: New Therapeutic Pathways, New Targets

Location: E Hall D1

CME credit: 1.25

Track(s): Gastrointestinal (Colorectal) Cancer; Developmental Therapeutics

Josep Tabernero, MD—Chair

Vall d'Hebron University Hospital

Membrane Receptors as Targets for Therapeutic Approaches in Colorectal Cancer

Wells A. Messersmith, MD

University of Colorado

Intracellular Components of Signal Transduction Pathways as Therapeutic Targets in Colorectal Cancer

Scott Kopetz, MD

University of Texas M. D. Anderson Cancer Center

Small- and Large-molecule Angiogenesis Inhibitors: Excitement and Disappointments

Geriatric Issues in Neuro-oncology

Location: S100b

CME credit: 1.25

Track(s): Central Nervous System Tumor; Geriatric Oncology

Lauren E. Abrey, MD—Chair

Memorial Sloan-Kettering Cancer Center

Geriatric Neuro-oncology: Overview with Lessons from Primary CNS Lymphoma

Glenn S. Bauman, MD

London Regional Cancer Program

Radiotherapy of Brain Tumors in the Elderly: Issues and Controversies

Alba Ariela Brandes, MD

ASL Bologna

Glioblastoma in the Elderly

Friday, June 4, 2010

**3:30 PM - 4:45 PM
SPECIAL SESSION**

ASCO/American Society of Hematology Joint Session

Location: E354a

CME credit: 1.25

Track(s): Special Session

Douglas W. Blayney, MD—Co-Chair

University of Michigan

Hal E. Broxmeyer, PhD—Co-Chair

Indiana University

Mark J. Levis, MD, PhD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Results from a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse

Noopur S. Raje, MD

Massachusetts General Hospital Cancer Center

A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma

Mathias J. Rummel, MD, PhD

University Hospital Giessen

Bendamustine plus Rituximab Is Superior with Respect to Progression-free Survival and CR Rate When Compared to CHOP plus Rituximab as First-line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL

Peter Borchmann, MD

University Hospital of Cologne

Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (GY) Is the New Standard of Care in the Treatment of Patients with Early-stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSH) HD10

3:30 PM - 4:45 PM EDUCATION SESSIONS

Current Challenges for Cellular Therapies

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology; Leukemia, Myelodysplasia, and Transplantation

John M. Cunningham, MBBS—Chair

The University of Chicago Medical Center

When Should Immunablative Therapies Be Considered in the Treatment of Pediatric Cancer?

Laurence Cooper, MD, PhD

University of Texas M. D. Anderson Cancer Center

Adoptive Cellular Therapies Utilizing Gene-modified Lymphocytes

Wing H. Leung, MD, PhD

St. Jude Children's Research Hospital

The Role of NK Cells in Transplant and Nontransplant Scenarios

Management of Older Patients with Lymphoma and Myeloma

Location: E354b

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders; Geriatric Oncology

Vicki A. Morrison, MD—Chair

University of Minnesota

Approaches to Diffuse Large Cell Lymphoma in Very Elderly Patients

Stuart M. Lichtman, MD

Memorial Sloan-Kettering Cancer Center

Using the Geriatric Assessment and Related Strategies in the Practical Management of Lymphoma and Myeloma Patients

Jesús San-Miguel, MD, PhD

Hospital Clinico Universitario

New and Old: New Regimens for Older Multiple Myeloma Patients

Update on Patient Safety: Basic Science, Practical Strategies in Oncology Practice, and Discussing Complications

Location: E Arie Crown Theater

CME credit: 1.25

Track(s): Patient and Survivor Care; Professional Development

James Bagian, MD—Chair

Veterans Health Administration

Saul Weingart, MD, PhD

Dana-Farber Cancer Institute

Glenn D. Steele, MD, PhD

Geisinger Health System

Friday, June 4, 2010

**3:30 PM - 6:00 PM
EXTENDED EDUCATION SESSION**

**Career Choices in Oncology: Options in Academic, Private Practice, Industry,
and Government**

Location: S404

CME credit: 0

Track(s): Professional Development

John E. Pippen, MD, FACP—Chair

Sammons Cancer Center

Hybrid: Academia and Private Practice

Angelo Di Leo, MD, PhD

Sandro Pitigliani Medical Oncology Unit

Career Options in Academia

R. Steven Paulson, MD

Texas Oncology PA

Career Options in Private Practice

Mace L. Rothenberg, MD

Pfizer Oncology

Career Options in Industry

Richard Pazdur, MD

U.S. Food and Drug Administration

Career Options in Government

**3:45 PM - 6:00 PM
EXTENDED EDUCATION SESSION**

Advanced Concepts in Clinical Trial Design and Methodology

Location: S100a

CME credit: 2.25

Track(s): Clinical Trials

Richard Simon, DSc—Chair

National Institutes of Health

New Designs for Phase III Clinical Trials

Mark J. Ratain, MD

The University of Chicago

Innovative Designs: Randomized Phase II Trials

Yu Shyr, PhD

Vanderbilt-Ingram Cancer Center

Advanced Statistical Considerations: Things You Think You Can Do, But . . .

4:00 PM - 6:00 PM
EXTENDED EDUCATION SESSION

Grant Writing Workshop II: Improving Your Grant Writing Skills (Small Group Discussions)

Location: S106a

CME credit: 2

Track(s): Professional Development; Clinical Trials

Bruce E. Johnson, MD—Chair

Dana-Farber Cancer Institute

Alex A. Adjei, MD, PhD

Roswell Park Cancer Institute

William G. Blum, MD

The Ohio State University

Mary L. (Nora) Disis, MD

University of Washington

Merrill J. Egorin, MD

University of Pittsburgh Cancer Institute

Dawn L. Hershman, MD

New York Presbyterian

Jennifer C. King, PhD

The ASCO Cancer Foundation

Donna S. Neuberg, ScD

Dana-Farber Cancer Institute

Charles M. Rudin, MD, PhD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Eric Jay Small, MD

University of California, San Francisco

Friday, June 4, 2010

**4:30 PM - 5:45 PM
EDUCATION SESSIONS**

Electronic Health Records in Oncology: A Requirement for 2014

Location: E353

CME credit: 1.25

Track(s): Practice Management and Information Technology; Health Services Research; Patient and Survivor Care

Peter Paul Yu—Chair

Palo Alto Medical Foundation

Interoperability: Getting the Relevant Information to the Right Place in Real Time

Jonathan B. Perlin, MD, PhD, MSHA, FACP, FACMI

Hospital Corporation of America

So You Want Me to Adopt EHR by 2014?

Lawrence N. Shulman, MD

Dana-Farber Cancer Institute

Getting More out of Your EHR

Improving Clinical Trial Outcome in Neuro-oncology

Location: S100b

CME credit: 1.25

Track(s): Central Nervous System Tumors

Timothy Cloughesy, MD—Chair

University of California, Los Angeles

Optimal Trial Endpoints in the Era of Antiangiogenic Therapies: Lessons Learned from Bevacizumab

Ingo K. Mellinghoff, MD

Memorial Sloan-Kettering Cancer Center

Optimizing the Role of Genotyping for Patient Care and Trial Design

Donald A. Berry, PhD

University of Texas M. D. Anderson Cancer Center

Novel Trial Design in Neuro-oncology

Molecular Profiling in Breast Cancer: Ten Years Later

Location: E Hall D1

CME credit: 1.25

Track(s): Breast Cancer; Cancer Genetics

George W. Sledge, MD—Chair

Indiana University School of Medicine

How to Integrate Molecular Profiling with Standard Pathology in Clinical Practice

Charles M. Perou, PhD

University of North Carolina at Chapel Hill

The Past and The Future of Molecular Profiling

Richard Iggo, MD, PhD

Bergonié Institute

Do Other Clinically Relevant Subtypes Exist?

4:45 PM - 6:00 PM
CLINICAL PROBLEMS IN ONCOLOGY

Talking with Your Patients about Clinical Trials (C01)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Clinical Trials; Ethics; Professional Development

Stephen S. Grubbs, MD—Chair

Medical Oncology Hematology Consultants, PA

Community Perspective

Afshin Dowlati, MD

Case Western Reserve University

Academic Perspective

Mary Lou Smith, JD, MBA

Research Advocacy Network

Patient Advocacy Perspective

7:00 PM - 9:00 PM
SPECIAL SESSION

(Presented during a Private Function)

Distinguished Achievement Award

Eli Glatstein, MD

University of Pennsylvania School of Medicine

Special Recognition Award

Patrick J. Loehrer Sr., MD

Indiana University School of Medicine

Saturday, June 5, 2010

**7:30 AM - 8:00 AM
EDUCATION SESSION**

How to Navigate the Annual Meeting (Fellows and Junior Faculty Only)

Location: S501

Track(s): Professional Development

John E. Phippen, MD, FACP—Chair
Sammons Cancer Center

**8:00 AM - 9:15 AM
EDUCATION SESSIONS**

Cancer Fatigue and Contributing Factors: Recognition and Treatment

Location: E354b

CME credit: 1.25

Track(s): Patient and Survivor Care; Breast Cancer; General Oncology; Lung Cancer

Ann Malone Berger, RN, PhD, AOCN, FAAN—Chair

University of Nebraska Medical Center

Cancer-related Fatigue: Who Gets It and How Long Does It Last?

Eduardo Bruera, MD

University of Texas M. D. Anderson Cancer Center

Do Medications Work to Decrease Cancer-related Fatigue?

Bernadine Cimprich, RN, PhD, CS, FAAN

University of Michigan

Nonpharmacologic Interventions to Decrease Fatigue

SATURDAY

Clinical Trials in Survivorship Populations: Emerging Concepts and Barriers to Application

Location: S100a

CME credit: 1.25

Track(s): Clinical Trials

Melissa M. Hudson, MD—Chair

St. Jude Children's Research Hospital

Promoting Health during and beyond Cancer Therapy

Melinda L. Irwin, PhD, MPH

Yale University

Conducting Clinical Trials of Physical Activity in Cancer Survivors

Janette L. Vardy, MD, PhD

The University of Sydney

Clinical Trials in Cancer Survivors with Chemotherapy-related Cognitive Impairment

Curable and Highly Treatable Leukemias: How Do I Optimize Outcome?

Location: E354a

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation

Moshe Talpaz, MD—Chair

University of Michigan

Therapy for CML: What Is the Best TKI? When? And Beyond?

Bayard L. Powell, MD

Wake Forest University

Update on Acute Promyelocytic Leukemia

Giuseppe Saglio, MD

University of Turin

Monitoring Recommendations: What Defines Resistance?

How to Use Data to Improve Practice: Nexus of Quality and Efficiency

Location: E353

CME credit: 1.25

Track(s): Practice Management and Information Technology; Professional Development

Robert D. Siegel, MD—Chair

The Helen & Harry Gray Cancer Center

Getting More out of QOPI

Peter G. Ellis, MD

University of Pittsburgh Medical Center Cancer Center

Challenge of Reducing Disease-specific Variation in Care

David C. Fryefield, MD

Willamette Valley Cancer Institute

Quality and Efficiency: Continuous Improvement Tools for the Oncology Practice

Saturday, June 5, 2010

Melanoma Immunotherapy: Current Status, Future Opportunities

Location: S406 (Vista Room)

CME credit: 1.25

Track(s): Melanoma/Skin Cancers; Developmental Therapeutics

Patrick Hwu, MD—Chair

University of Texas M. D. Anderson Cancer Center

Adoptive T-cell Transfer

Jedd D. Wolchok, MD, PhD

Memorial Sloan-Kettering Cancer Center

Checkpoint Blockade

Craig L. Slingluff, MD

University of Virginia Health System

Melanoma Vaccines

Micronutrient Supplementation versus Dietary Modification of Cancer Prevention: Which Is Better?

Location: S100b

CME credit: 1.25

Track(s): Cancer Prevention/Epidemiology

Peter Gann, MD, ScD—Chair

University of Illinois at Chicago

Epidemiology versus Clinical Trials as Evidence for Propensity of Dietary Components/Micronutrients to Prevent Cancer

Eric A. Klein, MD

Cleveland Clinic Taussig Cancer Institute

The Use of Antioxidant Micronutrient Supplements for Cancer Prevention: Lessons from SELECT

John A. Milner, PhD

National Cancer Institute

Vitamin D: Should We Be Supplementing to Prevent Cancer?

The Expanding Role of Antibody-based Therapy in Children, Adolescents, and Young Adults with Cancer

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology; Developmental Therapeutics

Alice L. Yu, MD, PhD—Chair

University of California, San Diego

Progress in Treatment of High-risk Neuroblastoma with Immunotherapy

Mitchell S. Cairo, MD

Columbia University

Update on Immunotherapy Strategies in the Treatment of Lymphomas in Children, Adolescents, and Young Adults

Douglas Yee, MD

Masonic Cancer Center, University of Minnesota

The Efficacy of Epitope-specific IGFR1 Antibodies in Therapy of Pediatric, Adolescent, and Young Adult Solid Tumors

Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation

Location: E Arie Crown Theater

CME credit: 1.25

Track(s): Breast Cancer; Cancer Genetics; Gynecologic Cancer

Abram Recht, MD—Chair

Beth Israel Deaconess Medical Center

Radiation Therapy and Hereditary Breast Cancer

Marian B. E. Menke-Pluymers, MD, PhD

Erasmus University Medical Center

Surgical Options for Breast Cancer Patients with a BRCA 1/2 Mutation or a Familial Predisposition

Susan M. Domchek, MD

Abramson Cancer Center

Systemic Therapy in BRCA1 and BRCA2 Mutation Carriers with Breast Cancer

8:00 AM - 9:15 AM

CLINICAL PROBLEMS IN ONCOLOGY

When Onco-cardiology Meets Cardio-oncology: A Global Perspective (C02)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Patient and Survivor Care

Stefan D. Anker, MD, PhD—Chair

Charité Universitätsmedizin Berlin

Cardiac Problems in Oncology Patients beyond Cardiotoxicity: A Road to Cancer Cachexia

Erica L. Mayer, MD

Dana-Farber Cancer Institute

Patterns of Cardiac Toxicity with Novel Therapies and Management Issues

Daniel John Lenihan, MD

Vanderbilt University

Pathophysiology of Cardiotoxicity in Chemotherapy and Targeted Therapy

Saturday, June 5, 2010

8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM

Genetic and Molecular Predictors in Genitourinary Malignancies

Location: E Hall D2

CME credit: 1.5

Track(s): Genitourinary Cancer

Andrew J. Armstrong, MD, ScM—Co-Chair

Duke University Medical Center

Adam Stuart Kibel, MD—Co-Chair

Washington University School of Medicine

8:00 AM Predicting prostate-cancer-specific death: Is it in the cancer? (Abstract #4500)

G. E. Ayala, B. J. Miles, C. T. Freund, R. Li, A. Frolov, M. M. Ittmann, D. Kadmon, P. T. Scardino, T. Wheeler, D. Rowley

8:15 AM Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). (Abstract #4501)

B. I. Rini, M. Zhou, H. Aydin, P. Elson, T. Maddala, D. Knezevic, L. Parodi, R. M. Bukowski, W. F. Novotny, J. W. Cowens

Discussion

8:30 AM To be determined

8:45 AM Evaluation of the genetic component of early-onset prostate cancer. (Abstract #4502)

K. A. Cooney, C. A. Salinas, A. M. Ray, Y. Wang, E. M. Lange, K. A. Zuhlke

9:00 AM Susceptibility loci associated with prostate cancer progression and mortality. (Abstract #4503)

D. J. Gallagher, V. Joseph, A. Cronin, A. J. Vickers, V. E. Reuter, H. I. Scher, J. Eastham, H. Lilja, T. Kirchoff, K. Offit

Discussion

9:15 AM Elaine Ostrander, PhD (Abstracts #4502–4503)

National Human Genome Research Institute

Emerging Evidence for a Genetic Risk of Prostate Cancer

SATURDAY

8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM

Molecularly Targeted Trials in Lung Cancer

Location: E Hall D1
 CME credit: 1.5
 Track(s): Lung Cancer

Marvaretta Miesha Stevenson, MD—Co-Chair

Duke University Medical Center

Heather A. Wakelee, MD—Co-Chair

Stanford University

8:00 AM **Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). (Abstract #7500)**

J. Jassem, C. J. Langer, D. D. Karp, T. Mok, R. J. Benner, S. J. Green, K. Park, S. Novello, J. Strausz, A. Gualberto

Discussion

8:15 AM D. Ross Camidge, MD, PhD (Abstract #7500)

University of Colorado, Denver
IGF1R: Where Do We Go from Here?

8:30 AM **A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC. (Abstract #LBA7501)**

J. Von Pawel, J. H. Harvey, D. R. Spigel, M. Dediu, M. Reck, C. L. Cebotaru, E. Kumm, G. Gallant, N. Fox, D. R. Camidge

Discussion

8:45 AM Bruce E. Johnson, MD (Abstract #LBA7501)

Dana-Farber Cancer Institute
Where Does This TRAIL Lead Us?

9:00 AM **Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). (Abstract #LBA7502)**

J. H. Schiller, W. L. Akerley, W. Brugger, D. Ferrari, E. G. Garmey, D. E. Gerber, S. V. Orlov, R. Ramlau, J. Von Pawel, L. V. Sequist

Discussion

9:15 AM Ravi Salgia, MD, PhD (Abstract #LBA7502)

The University of Chicago
Combinations of Targeted Agents

Saturday, June 5, 2010

**8:00 AM - 11:00 AM
SPECIAL SESSION**

Designing Clinical Trials for Older Patients: Laboratory Science and Practical Applications (Limited Seating Available)

Location: S106a

CME credit: 3 Track(s): Special Session; Geriatric Oncology

Kathryn A. Bylow, MD—Co-Chair
Medical College of Wisconsin

Hyman Bernard Muss, MD—Co-Chair
University of North Carolina at Chapel Hill

Arash Naeim, MD
University of California, Los Angeles
Comparative Effectiveness

Arti Hurria, MD
City of Hope National Medical Center
Defining Frailty

Norman E. Sharpless, MD
University of North Carolina School of Medicine
Biomarkers

William Dale, MD, PhD
The University of Chicago
Decision Making

SATURDAY

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Cancer Prevention/Epidemiology

Location: S Hall A2

Tracks(s): Cancer Prevention/Epidemiology

- Brd. 1A** **High prevalence of *BRCA1/2* germline mutations in female breast cancer patients with triple-negative phenotype (TNBC) and family history. (Abstract #1534)**
C. Saura, G. Sánchez-Ollé, N. Bosch, N. Gadea, M. Masas, A. Tenes, S. Gutierrez-Enríquez, O. Díez, J. Baselga, J. Balmaña
- Brd. 1B** **Prospective screening for Lynch syndrome (LS) in a cohort of colorectal cancer (CRC) surgical patients in a community hospital. (Abstract #1535)**
P. R. Duncan, J. T. Lin, R. Feddersen
- Brd. 1C** **Effect of *BRCA1* gene and estrogen-receptor α on regulation of serum estradiol levels in women with breast cancer. (Abstract #1536)**
J. Kim, S. Lee, K. H. Oktay
- Brd. 1D** **Association of death receptor 4 variant (*Glu228Ala*) with ovarian cancer risk in *BRCA1*-mutation carriers. (Abstract #1537)**
M. G. Dick, B. Versmold, C. Engel, C. Sutter, R. K. Schmutzler, German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC)
- Brd. 1E** **Breast cancer gene expression profile in young women who are noncarriers of *BRCA1/2* mutations with and without familial history. (Abstract #1538)**
D. M. Carraro, C. A. Moreira-Filho, P. L. Ramos, B. C. Lisboa, H. Brentani, M. W. Achatz, M. A. Koike Folgueira, M. H. Katayama, M. Brentani
- Brd. 1F** **Publication bias in translational research and number of polymorphisms analyzed in genetic association studies. (Abstract #1539)**
L. Tsali, A. Valachis, C. Neophytou, N. P. Polyzos, S. Drachtidí, L. Tsilidou, E. E. Skamagouli, V. Paparoupa, D. Mauri
- Brd. 1G** ***MUTYH* gene mutations in Spanish individuals with multiple colorectal adenomas without *APC* gene mutation. (Abstract #1540)**
A. I. Ferrer, M. Strunk, R. Andres, A. Ferrandez, A. Alonso, M. Fernandez, A. Tres, J. Godino
- Brd. 1H** **Association between *XRCC1* gene haplotype tagging single nucleotide polymorphisms and non-small cell lung cancer in Korean patients. (Abstract #1541)**
G. Lee, I. Kim, D. Kim, S. Kim, H. Kim, J. Kang, S. Oh
- Brd. 2A** **Mutation position in *BRCA*-associated breast cancers. (Abstract #1542)**
F. Meric-Bernstam, A. Gutierrez-Barrera, J. K. Litton, L. Mellor-Crummey, K. Ready, A. M. Gonzalez-Angulo, K. H. Lu, G. N. Hortobagyi, B. Arun
- Brd. 2B** **Association of *HER2* 655 ile→Val polymorphism with pathological response to neoadjuvant chemotherapy and trastuzumab in breast cancer. (Abstract #1543)**
A. M. Astorga
- Brd. 2C** **Is lobular breast cancer mainly inherited from the father? (Abstract #1544)**
H. L. Olsson, C. Ellberg
- Brd. 2D** **Gene expression profiles in non-small cell lung cancers (NSCLCs) and in corresponding healthy lung tissues in smokers versus nonsmokers. (Abstract #1545)**
A. Szymanowska-Narloch, M. Skrzypski, M. Taron, H. Dienemann, W. Rzyman, M. Jarzab, T. Muley, E. Jassem, R. Rosell, J. Jassem
- Brd. 2E** **Pilot program of fast-track germline genetic analyses as part of integrated breast, ovarian, or gastrointestinal personalized cancer care program. (Abstract #1546)**
O. Caron, B. Bressac-de-Paillerets, D. Malka, A. Remenieras, C. Bourcier, C. Uzan, M. Spielmann, M. Blayau, T. Frébourg, S. Delaloge

- Brd. 2F** Disparities in referral by risk profile for genetic counseling of high-risk individuals: A disease-specific analysis of mutation frequencies of 1,193 patients presenting for presumptive hereditary breast ovarian cancer (HBOC) or colorectal cancer syndromes (CCS). (Abstract #1547)
I. Shapira, R. J. Gralla, K. S. Sultan, V. S. John, C. E. Devoe, J. T. D'Olimpio, H. Raftopoulos, L. Donahue, V. Vinciguerra, S. Cohen
- Brd. 2G** Characterization of a major colon cancer susceptibility locus (Ccs3) on mouse chromosome 3. (Abstract #1548)
C. Meunier, J. Cai, A. Fortin, T. Kwan, J. Marquis, C. Turbide, L. Van Der Kraak, S. Jothy, N. Beauchemin, P. Gros
- Brd. 2H** Analysis of plasma proteome from BRCA1/BRCA2 mutation carriers as modifier risk factor of breast cancer. (Abstract #1549)
A. Custodio, P. Pérez-Segura, J. Zamorano, A. López-Farré, E. Olivera, J. Puente, E. Diaz-Rubio
- Brd. 3A** A unique community-based family cancer registry. (Abstract #1550)
N. Y. Gabrail, C. L. Smith, J. Fox
- Brd. 3B** Promoter methylation of p16^{INK4A}, RASSF1A, and RAR2b genes in tumor DNA from patients with breast cancer (BC) in correlation with clinical recurrence. (Abstract #1551)
S. Voyatzki, K. Desiris, D. A. Paikos, E. Stergiou, G. Geromichalos, K. Pazaitou, A. Kiziridou, P. Stravoravdi, G. Simbilidis
- Brd. 3C** Type II diabetes and breast cancer. (Abstract #1552)
K. D. Erickson, J. P. Pierce, R. E. Patterson, T. R. Reid, L. Natarajan, S. Flatt, B. A. Parker, D. Heath
- Brd. 3D** Does dietary estrogen intake from meat relate to the incidence of hormone-dependent cancers? (Abstract #1553)
Y. Handa, H. Fujita, Y. Watanabe, S. Honma, M. Kaneuchi, H. Minakami, R. Kishi
- Brd. 3E** A multi-analyte serum test for the early diagnosis of non-small cell lung cancer. (Abstract #1554)
M. S. Vercillo, E. C. Farlow, J. Coon, S. Basu, A. W. Kim, P. Faber, P. Bonomi, M. J. Liptay, J. A. Borgia
- Brd. 3F** Lung cancer risk and polymorphisms in UGT1A6. (Abstract #1555)
L. Kua, R. A. Soo, A. Khoo, S. Lee, T. Chin, P. Chong, D. Nur, R. C. Soong, B. C. Goh, W. Yong
- Brd. 3G** Breast density and calculated breast cancer risk. (Abstract #1556)
F. B. Khan, F. Kingsley, K. Dittus, B. L. Sussman, M. E. Wood
- Brd. 3H** Method of detection of DCIS to predict HER2 overexpression. (Abstract #1557)
S. Schradling, E. Wardelmann, W. Kuhn, H. H. Schild, C. K. Kuhl
- Brd. 4C** The accuracy of the HPV-associated diseases risk assessment inventory for detecting cervical dysplasias in medically underserved women in the United States. (Abstract #1560)
M. S. Cyrus-David, W. Wang, G. Siddiqui
- Brd. 4D** Economic value of disability adjusted life years lost to cancers: 2008. (Abstract #1561)
R. M. John, H. Ross
- Brd. 4E** The association between the use of statin and breast cancer recurrence. (Abstract #1562)
Y. Chae, M. E. Valsecchi, J. Kim, A. M. Desai, W. J. Tester
- Brd. 4F** A prospective study of combined colon and endometrial cancer screening in women with Lynch syndrome: A novel patient-centered approach. (Abstract #1563)
M. Huang, C. C. Sun, S. Boyd-Rogers, J. K. Burzawa, A. Milbourne, E. Keeler, R. Yzquierdo, P. M. Lynch, S. K. Peterson, K. H. Lu

- Brd. 4G** **Factors influencing long-term altered quality of life, sexual functioning, and menopausal symptoms after prophylactic bilateral salpingo-oophorectomy (PBSO) among high-risk women (wm). (Abstract #1564)**
C. Touboul, C. Uzan, J. Ichante, O. Caron, A. Dunant, S. Dauchy, S. Gouy, P. Morice, M. Spielmann, S. Delaloge
- Brd. 4H** **Influence of thiozolidinediones (TZD) exposure on the progression of oral leukoplakia (L) and erythroplakia (E) to the development of head and neck cancer (HNC). (Abstract #1565)**
A. Kunthur, E. Siegel, R. Govindarajan
- Brd. 5B** **High-precision tissue acquisition in the evaluation of breast microcalcifications. (Abstract #1567)**
J. Janssens, R. Harries, S. Lawson
- Brd. 5C** **Barriers to colorectal cancer screening among African American population. (Abstract #1568)**
Z. M. Bo, V. Ghevariya, M. Ahluwalia, K. Veerabhadrapappa, G. M. Villani, S. Anand
- Brd. 5D** **Determinants of low cell yield in random fine needle aspiration (rFNA) procedures of the breast in healthy women unselected by risk. (Abstract #1569)**
S. A. Khan, S. Sukumar, N. Khouri, L. K. Jacobs, A. Eiring, D. Ivancic, C. Shehata, C. M. Zalles, R. T. Chatterton, V. Stearns
- Brd. 5E** **Knowledge of cancer risk factors. (Abstract #1570)**
K. M. Gil, S. Yeropoli, B. Fish, L. Schnegg, J. L. Savitski
- Brd. 5F** **Mammography utilization in women age 40 to 49: The French EDIFICE survey. (Abstract #1571)**
F. Eisinger, X. B. Pivot, J. Blay, Y. Coscas, J. Viguier, A. Calazel Benque, C. Roussel, J. F. Morere
- Brd. 5G** **Young age at first live birth and long duration of breast feeding: Are they universally accepted protective factors against breast cancer? A case control study of the Cancer Research Group in Pakistan. (Abstract #1572)**
M. Masood, S. Ahmed, S. Kanwal, H. Masood, K. Ahmad, A. Mahmood, M. Faheem, N. Akbar, M. Hafeez
- Brd. 5H** **Do Asian breast cancer patients younger than age 40 have more aggressive biologic characteristics than their western counterparts? A comparison between Shanghai and Vienna. (Abstract #1573)**
M. M. Tea, L. Fan, Z. Shao, C. F. Singer
- Brd. 6A** **Fecundity after childhood cancer: A nationwide, population-based study. (Abstract #1574)**
M. Cvancarova, M. R. Forman, S. D. Fossa
- Brd. 6B** **Trends in incidence and location of colorectal cancer in the colonoscopy era. (Abstract #1575)**
D. Pulte, S. B. Chalasani, H. Brenner
- Brd. 6C** **Predictors of independent living status in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #1576)**
A. Kunin-Batson, N. Kadan-Lottick, L. Zhu, V. Bordes, D. K. Srivastava, L. K. Zeltzer, L. L. Robison, K. R. Krull
- Brd. 6D** **Differing age patterns in chronic myeloid leukemia by racial ethnic group. (Abstract #1577)**
A. M. Mendizabal, W. F. Anderson, P. Garcia-Gonzalez, P. H. Levine
- Brd. 6E** **Characterization of 25-OH vitamin D (Vit D) and factors associated with obesity in patients with high-risk breast cancer (BC): NCIC CTG MA.21. (Abstract #1578)**
E. V. Tsvetkova, J. W. Chapman, T. D. Baetz, M. J. Burnell, K. A. Gelmon, N. Pu, P. O'Brien, L. E. Shepherd, P. J. Goodwin
- Brd. 6F** **Risk of metachronous contralateral testicular germ cell tumor (met-TGCT) among 7,248 Norwegian patients (1953–2007). (Abstract #1579)**
K. E. Andreassen, T. Grotmol, M. Cvancarova, T. B. Johannesen, S. D. Fossa

Saturday, June 5, 2010

- Brd. 6G** **The effect of age on delay in diagnosis and stage of breast cancer. (Abstract #1580)**
A. H. Partridge, M. E. Hughes, Y. Wong, S. B. Edge, R. L. Theriault, D. W. Blayney, J. C. Niland, E. P. Winer, J. C. Weeks, R. M. Tamimi
- Brd. 6H** **Innate immunity-related sequence variants as predictors of breast cancer risk among women of African descent. (Abstract #1581)**
K. S. Kimbro, G. M. Oprea, B. G. Burns, T. T. VanCleave, W. Tang, M. Bouzyk, L. R. Kidd
- Brd. 7A** **Is tumor size important in HER2-positive breast cancer? (Abstract #1582)**
C. Parise, K. Bauer, V. Caggiano
- Brd. 7B** **Incidence of early-onset multiple myeloma among families with endometrial carcinoma. (Abstract #1583)**
A. R. Sama, W. Gonsalves, X. Fang, H. T. Lynch, S. Thome
- Brd. 7C** **Breast cancer and high-risk diagnosis in core biopsies stratified by ethnicity. (Abstract #1584)**
E. Kim, J. Sharko, B. Drohan, C. Roche, M. Specht, M. Gadd, B. L. Smith, K. S. Hughes
- Brd. 7D** **Epidemiologic risk factors associated with breast cancer subtypes. (Abstract #1585)**
A. Bambhroliya, M. Bondy, P. Thompson, A. Sahin, J. L. Murray, R. Zhou, K. Sexton, A. M. Brewster
- Brd. 7E** **The influence of ER on small HER2-positive invasive breast cancers. (Abstract #1586)**
V. Caggiano, C. Parise, K. Bauer
- Brd. 7F** **Frequency of L858R and D746–750 EGFR mutations in 411 Caucasian patients with non-small cell lung cancer measured by mutation-specific antibodies. (Abstract #1587)**
A. T. Dimou, K. N. Syrigos, S. Agarwal, L. Lozovatsky, V. Zolota, V. K. Anagnostou, D. Rimm
- Brd. 7G** **A significant dietary change after breast cancer diagnosis: Early results of a United Kingdom prospective multicenter study. (Abstract #1588)**
L. S. Velentzis, J. V. Woodside, M. M. Cantwell, A. J. Leathem, M. R. Keshtgar
- Brd. 7H** **Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study. (Abstract #1589)**
C. Murphy, D. Mallam, S. Stein, S. Patil, J. Howard, N. T. Sklarin, M. Gemignani, C. Hudis, A. D. Seidman
- Brd. 8A** **Mortality for non-AIDS-defining cancers among people with AIDS. (Abstract #1590)**
A. Zucchetto, B. Suligoj, A. De Paoli, S. Pennazza, M. Spina, S. Bruzzone, G. Rezza, U. Tirelli, L. Dal Maso, D. Serraino
- Brd. 8B** **Clinical and pathologic characteristics of Hispanic breast cancer patients in a tertiary care safety net hospital. (Abstract #1591)**
T. M. Lee, L. A. Stead, M. M. Loch, J. L. Westrup, M. Hernandez-Perez, J. C. Lee, A. de las Morenas, T. P. Ahern, C. L. Rosenberg
- Brd. 8C** **Patterns of antidepressant use among women initiating tamoxifen therapy for the treatment of breast cancer in Ontario, Canada. (Abstract #1592)**
C. M. Kelly, T. Gomes, M. Duong-Hua, K. I. Pritchard, L. F. Paszat, D. N. Juurlink
- Brd. 8D** **Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter? (Abstract #1593)**
S. Muhsen, M. Morrogh, A. P. Andrade, R. Sakr, W. Paik, M. Morrow, T. A. King
- Brd. 8E** **Longitudinal self-reported and serum-based assessment of tobacco or nicotine use in head and neck cancer patients during definitive radiotherapy or chemoradiotherapy. (Abstract #1594)**
M. R. Kudrimotij, S. M. Arnold, J. Valentino, M. Randall, G. W. Warren

- Brd. 8F** **Survival among never and ever smokers with lung cancer in the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study. (Abstract #1595)**
C. Clément-Duchêne, X. Xu, S. L. Gomez, E. T. Chang, D. W. West, H. A. Wakelee, M. K. Gould
- Brd. 8G** **Characteristics and behavior of invasive breast cancer developed despite prior oophorectomy. (Abstract #1596)**
J. R. Nitzkorski, F. Zhu, V. Siripurapu, R. A. Burger, C. S. Denlinger, E. R. Sigurdson, G. M. Freedman, R. J. Bleicher
- Brd. 8H** **Incidental finding of pulmonary nodule on CT pulmonary angiogram (CTPA) in view of current surveillance recommendations: Is any lung cancer screening protocol applicable? (Abstract #1597)**
O. C. Enrizo, T. Baykaner, M. J. Janicek
- Brd. 9A** **Prevalence of anal squamous intraepithelial lesions in HIV-positive and HIV-negative men who have sex with men in Thailand. (Abstract #1598)**
T. Chalermchai, A. H. Li, J. Ananworanich, N. Teeratakulpisarn, W. Sathainthammawit, C. Pakam, S. Chaithongwongwatthana, C. Shikuma, P. Phanuphak, N. Phanuphak
- Brd. 9B** **Evaluation of machine learning versus Cox regression in identification of factors predicting recurrence following resection of non-small cell lung cancer. (Abstract #1599)**
J. K. Blayney, C. M. Grills, P. V. Jithesh, I. I. Wistuba, M. Jacobson, K. J. O'Byrne, K. M. Kerr, G. Scagliotti, R. J. Holt, D. A. Fennell
- Brd. 9C** **Recurrence pattern in early-stage breast cancer in a minority cohort. (Abstract #1600)**
S. B. Sreenivasappa, B. Ciobanu, S. Sandhu, F. Feitosa, J. Samuel
- Brd. 9D** **Influence of market access conditions on utilization of innovative drugs in Europe: The cases of trastuzumab and cetuximab. (Abstract #1601)**
J. Misset, M. Toumi, L. Krukowski, M. Lamure, S. Aballea
- Brd. 9E** **Molecular profiles of breast cancer in Ilorin, Nigeria. (Abstract #1602)**
K. A. Adeniji, D. Huo, A. Khramtsov, C. Zhang, O. I. Olopade
- Brd. 9F** **Colon cancer disparities: A SEER-based analysis of epidemiologic data on Asian and Pakistani immigrants in the United States. (Abstract #1603)**
R. N. Rahman, A. M. Hossain, J. Abraham
- Brd. 9G** **Analysis of the geographical distribution of cancer in Israel. (Abstract #1604)**
A. Zick, Y. Rottenberg, M. Barchana, M. Shirav-Schwartz, T. Peretz
- Brd. 9H** **Mammography-detected breast cancer among 40–49-year-old patients at a community-based cancer center: 1990–2008. (Abstract #1605)**
J. A. Malmgren, M. K. Atwood, H. G. Kaplan
- Brd. 10A** **Thymic malignancies (TM) in the United States: A population-based study of incidence and survival trends. (Abstract #1606)**
M. A. Gubens, C. Clément-Duchêne, H. A. Wakelee
- Brd. 10B** **Comorbidities of the underserved and minority patient with cancer presenting to a public safety-net hospital: A deterrent for clinical trial participation? (Abstract #1607)**
S. N. Wolff, Z. Brifkani, P. Millner, K. Palka, D. Wujcik
- Brd. 10C** **Characteristics of adult osteosarcoma patients: Results from an ongoing postmarketing drug safety surveillance study. (Abstract #1608)**
K. D. Midkiff, A. Gilsenan, Y. Wu, D. Masica, E. Andrews

Saturday, June 5, 2010

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Leukemia, Myelodysplasia, and Transplantation

Location: S Hall A2

Tracks(s): Leukemia, Myelodysplasia, and Transplantation

- Brd. 11B** Thymic renewal and antileukemic effect in adults after haploidentical transplantation and suicide gene therapy. (Abstract #6534)
C. Bordignon, L. Vago, G. Oliveira, D. Ghio, M. Lupo Stanghellini, J. Peccatori, A. Bondanza, A. Lambiase, F. Ciceri, C. Bonini
- Brd. 11F** First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: Interim analysis of MPD-RC 101 protocol. (Abstract #6535)
D. Rondelli, M. W. Boyer, L. M. Isola, T. Shore, A. Bacigalupo, R. B. Klisovic, R. Marchioli, J. D. Goldberg, R. Hoffman, L. R. Silverman, Myeloproliferative Disorders Research Consortium
- Brd. 11G** EPOCH-FR: A novel salvage regimen for patients with lymphoid malignancies being considered for reduced-intensity allogeneic hematopoietic stem cell transplantation. (Abstract #6536)
R. B. Salit, D. H. Fowler, W. H. Wilson, S. Z. Pavletic, K. Dunleavy, F. Hakim, S. M. Steinberg, J. Odom, K. Bryant, M. R. Bishop
- Brd. 11H** A prospective feasibility study of clofarabine (CLO) cyto-reduction prior to allogeneic stem cell transplant (HCT) conditioning for refractory leukemia and MDS. (Abstract #6537)
F. L. Locke, A. S. Artz, L. A. Godley, O. Odenike, R. A. Larson, K. Van Besien, W. Stock
- Brd. 12A** ⁹⁰Y-ibritumomab tiuxetan followed by reduced-intensity conditioning (RIC) and allogeneic stem-cell transplantation (SCT) in patients with high-risk relapsed, refractory, or transformed follicular lymphoma (FL). (Abstract #6538)
K. Abou-Nassar, K. Stevenson, J. H. Antin, A. Freedman
- Brd. 12B** Treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapsing after allogeneic hematopoietic cell transplantation (HCT). (Abstract #6539)
A. Chiattonne, B. Andersson, Q. Bashir, D. Landau, G. Rondon, Y. Nieto, G. Al Atrash, S. Giralt, R. E. Champlin, M. De Lima
- Brd. 12F** Single-nucleotide polymorphism analysis of candidate genes in chronic GVHD. (Abstract #6540)
W. B. Clark, K. D. Brown-Gentry, F. G. Schuening, D. C. Crawford, M. H. Jagasia
- Brd. 12G** Pharmacokinetics and assessment of renal toxicity of a clofarabine (Clo), melphalan (Mel), and alemtuzumab (Alm) conditioning regimen. (Abstract #6541)
K. Van Besien, J. P. Kline, M. Hardj, L. A. Godley, R. A. Larson, V. H. Nguyen, O. Odenike, W. Stock, S. Horowitz, A. S. Artz
- Brd. 12H** Is there a relationship between glucocorticoid (GC) dose and performance on functional outcome measures? (Abstract #6542)
J. S. Scheetz, C. A. Brown, N. V. Paddison, G. S. Morris, K. Shin
- Brd. 13A** Phase I dose-escalation trial of high-dose melphalan (M) with palifermin (P) for cytoprotection followed by autologous stem cell transplantation (ASCT) for myeloma (MM) patients with normal renal function (NRF). (Abstract #6543)
M. H. Abidi, N. Tajeja, Z. S. Al-Kadhimi, J. Abrams, S. Cronin, M. Ventimiglia, L. J. Ayash, L. G. Lum, V. Ratanatharathorn, J. P. Uberti
- Brd. 13B** CD26 expression in donor stem cell harvest and its correlation with engraftment in human haematopoietic stem cell transplantation: Potential predictor of early engraftment. (Abstract #6544)
K. Prabhash, N. Khattry, V. Alai, A. Joshi, A. V. Bakshi, S. Kannan, P. Sastry, P. M. Parikh, J. Kode

- Brd. 13C Results of new cases of APL treatment by arsenic trioxide and long-term follow-up: Is it time for using arsenic trioxide in first-line treatment? (Abstract #6545)**
A. Ghavamzadeh, K. Alimoghaddam, S. Ghaffari, S. Rostami, M. Jahani, M. Iravani, S. Mousavi, M. Jalili, N. Alizadeh, A. Khodabandeh, Hematology, Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences
- Brd. 13D Use of deep whole transcriptome sequencing in Philadelphia-positive acute lymphoblastic leukemia (ALL) to identify novel mutated genes and aberrant gene expression and alternative splicing profiles associated with disease progression. (Abstract #6546)**
I. Iacobucci, A. Ferrarini, M. Sazzini, A. Lonetti, E. Giacomelli, L. Xumerle, A. Ferrari, C. Papayannidis, M. Delledonne, G. Martinelli
- Brd. 13E The relationship of cigarette smoking to invasive fungal disease (IFD) in acute myeloid leukemia (AML) patients undergoing induction chemotherapy (IC). (Abstract #6547)**
M. G. Mansour, A. Z. Fu, E. A. Copelan, M. E. Kalaycio, A. S. Advani, Y. Saunthararajah, R. M. Sobeks, M. A. Sekeres
- Brd. 13F Dynamic of morphologic and molecular remission in patients (pts) with APL treated with frontline ATRA and arsenic trioxide (ATO). (Abstract #6548)**
M. Ayoubi, H. Kantarjian, J. E. Cortes, S. Faderl, G. Garcia-Manero, S. Wen, J. Fiorentino, X. Huang, R. Luthra, F. Ravandi Kashani
- Brd. 13G Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rGel in patients (pts) with advanced myeloid malignancies. (Abstract #6549)**
A. Dean, M. Talpaz, H. Kantarjian, S. Faderl, E. Jabbour, F. Ravandi Kashani, S. M. O'Brien, M. Rosenblum, J. E. Cortes
- Brd. 13H Correlation of *RASGRP1/APTX* ratio with clinical response and survival in AML patients treated with tipifarnib-bortezomib combination. (Abstract #6550)**
G. Martinelli, S. Paolini, C. Papayannidis, E. Ottaviani, S. Parisi, I. Iacobucci, A. Curti, D. Cilloni, G. Saglio, A. Candoni, M. Baccarani
- Brd. 14A Analysis of survival of older patients with frontline AML treated with clofarabine with or without low-dose cytarabine or intermediate-dose cytarabine: A matched cohort comparison. (Abstract #6551)**
S. Faderl, F. Ravandi Kashani, G. Borthakur, T. M. Kadia, E. Jabbour, G. Garcia-Manero, M. Brandt, S. Pierce, H. Kantarjian
- Brd. 14B Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML). (Abstract #6552)**
G. Borthakur, E. Jabbour, X. Wang, J. E. Cortes, F. Ravandi Kashani, T. M. Kadia, J. Bass, M. Brandt, H. Kantarjian
- Brd. 14C Association of lymphocytosis following treatment with dasatinib with response and outcome. (Abstract #6553)**
C. A. Schiffer, J. E. Cortes, G. Saglio, P. Le Coutre, E. Bahceci, D. Dejardin, N. P. Shah
- Brd. 14D Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients. (Abstract #6554)**
S. Soverini, S. Angelini, M. Barnett, M. Thornquist, E. Turrini, G. Rosti, P. Hrelia, T. Kalebic, M. Baccarani, G. Martinelli
- Brd. 14E Decitabine therapy in patients with AML or MDS and chromosome 5, 7, or 8 abnormalities. (Abstract #6555)**
S. R. Mohan, M. A. Sekeres, Y. Saunthararajah, J. P. Maciejewski

- Brd. 14F** Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd. (Abstract #6556)
T. P. Hughes, P. D. le Coutre, R. E. Clark, G. Saglio, R. A. Larson, Q. Yin, E. Demirhan, A. Hoenekopp, A. Hochhaus, H. Kantarjian
- Brd. 14G** Long-term outcomes of responders in a randomized, controlled phase II trial of aptamer AS1411 in AML. (Abstract #6557)
D. Rizzieri, K. Stockerl-Goldstein, A. Wei, R. H. Herzig, F. Erlandsson, R. K. Stuart
- Brd. 14H** A clinico-genomic model of performance status in acute myeloid leukemia. (Abstract #6558)
A. Rao, C. Acharya, H. J. Cohen, D. Rizzieri, A. Potti
- Brd. 15A** Obesity, a risk factor for acute myeloid leukemia? Roswell Park Cancer Institute weighs in on the obesity debate. (Abstract #6559)
H. J. Lee
- Brd. 15B** Patient and disease characteristics of women with acute myelogenous leukemia (AML) and a history of breast cancer (BC). (Abstract #6560)
R. R. Yehia, D. Rangachari, K. A. Reiss, A. Blackford, A. Bardia, H. Carraway, V. Stearns, R. J. Arceci, J. E. Karp
- Brd. 15C** Hypocellular acute myeloid leukemia: Better or worse prognosis. (Abstract #6561)
A. Al-Kali, S. N. Konoplev, E. Lin, T. M. Kadia, S. Faderl, F. Ravandi Kashani, M. Ayoubi, M. Brandt, H. Kantarjian, G. Borthakur
- Brd. 15D** The role of FLT3 in sole trisomy 8 acute myeloid leukemia. (Abstract #6562)
A. W. Block, A. E. Groman, G. E. Wilding, L. Ford, S. N. Sait, G. Deeb, P. Starostik, E. S. Wang, J. E. Thompson, M. Wetzler
- Brd. 15E** The importance of imatinib dose intensity in imatinib plus combination chemotherapy in newly diagnosed Ph+ ALL. (Abstract #6563)
S. Lim, K. Lee, Y. Joo, W. Lee, S. Yoon, S. Sohn, S. Bae, M. Hyun, H. Kim, H. Eom, The Korean Society of Hematology, Adult ALL Working Party
- Brd. 15F** Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS). (Abstract #6564)
D. A. Macdonald, S. E. Assouline, J. Brandwein, S. Kamel-Reid, E. A. Eisenhauer, S. Couban, A. Foo, B. Leber
- Brd. 15G** Survival outcomes after initial infused therapy for elderly chronic lymphocytic leukemia (CLL) patients. (Abstract #6565)
M. Danese, R. Griffiths, M. Gleeson, S. Satram-Hoang, K. B. Knopf, J. Mikhael, C. M. Reyes
- Brd. 15H** Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). (Abstract #6566)
Y. Chen, H. Kantarjian, G. Garcia-Manero, Z. Estrov, M. Konopleva, E. Jabbour, T. M. Kadia, B. Williams, S. George, G. Borthakur
- Brd. 16A** BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. (Abstract #6567)
D. Kim, G. Saglio, G. Martinelli, Y. Shou, A. M. Stein, R. C. Woodman, H. Kantarjian, T. P. Hughes, J. P. Radich, A. Hochhaus
- Brd. 16B** Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies. (Abstract #6568)
J. H. Lipton, M. Wetzler, F. Nicolini, M. Bacarani, M. R. Baer, T. Masszi, D. Cram, A. Benichou, N. Nanda, J. E. Cortes
- Brd. 16C** Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy. (Abstract #6569)
G. Saglio, J. E. Cortes, C. A. Schiffer, P. le Coutre, E. Jabbour, E. Bahceci, A. Lambert, N. P. Shah

- Brd. 16D Race and overall survival in acute myeloid leukemia. (Abstract #6570)**
J. M. Bierenbaum, Y. Ning, M. Tidwell, I. Gojo, M. R. Baer
- Brd. 16E Prognostic factors associated with progression of myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) in patients (pts) treated with decitabine. (Abstract #6571)**
A. Fullmer, G. Borthakur, T. M. Kadia, G. Garcia-Manero, E. Jabbour
- Brd. 16F CPX-351 IN AML after failed induction with cytarabine and daunorubicin. (Abstract #6572)**
J. E. Lancet, E. J. Feldman, J. E. Cortes, D. Hogge, M. S. Tallman, T. Kovacovics, A. C. Louie
- Brd. 16G Incidence of unconventional infections (UC) in patients with acute myelogenous leukemia (AML) treated with clofarabine (CLO)-containing induction therapy. (Abstract #6573)**
R. Knoebel, A. R. McQuary, E. Estey, P. S. Becker
- Brd. 16H Activity of azacitidine in chronic myelomonocytic leukemia. (Abstract #6574)**
R. B. Costa
- Brd. 17A BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia. (Abstract #6575)**
A. H. Teitelbaum, H. J. Henk, V. Bollar
- Brd. 17B Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN- γ) treatment. (Abstract #6576)**
J. D. Burton, R. Stein, A. Chandra, S. Chen, N. Mishra, T. Shah, D. M. Goldenberg
- Brd. 17C Central nervous system disease and acute myeloid leukemia or chronic myeloid leukemia: Cytogenetic profile. (Abstract #6577)**
F. Shihadeh, V. K. Reed, A. Mazloom, J. Phan, H. Kantarjian, S. Faderl, B. S. Dabaja
- Brd. 17D A phase III randomized, double-blind, placebo controlled trial of North American (NA) ginseng (*Panax quinquefolium*) extract (CVT-E002) in patients with chronic lymphocytic leukemia: Effect on respiratory infection and antibiotic use. (Abstract #6578)**
K. P. High, L. D. Case, R. D. Siegel, J. Metzner-Sidurski, J. C. Krauss, B. Chinnasami, G. H. Sanders, S. Rousey, G. J. Lesser, E. G. Shaw
- Brd. 17E Epidemiology, risk factors, and outcomes of invasive fungal infection in adults with acute myelogenous leukemia undergoing intensive induction chemotherapy. (Abstract #6579)**
K. Lu, D. Neofytos, A. Blackford, A. H. Seung, J. E. Karp
- Brd. 17F Family history (FH) of women with breast cancer (BC) and acute myelogenous leukemia (AML). (Abstract #6580)**
K. A. Reiss, R. R. Yehia, D. Rangachari, A. Blackford, H. Carraway, V. Stearns, R. J. Arceci, J. E. Karp
- Brd. 17G Serum interleukin-6, cardiovascular disease, and mortality in chronic lymphocytic leukemia. (Abstract #6581)**
D. E. Dawe, J. Yoon, S. Gibson, J. B. Johnston
- Brd. 17H Treatment-related AML and AML evolving from MDS: Similar outcomes following treatment with amonafide plus cytarabine. (Abstract #6582)**
M. A. Sekeres, S. L. Allen, S. R. Mohan, A. S. Lundberg, H. P. Erba
- Brd. 18A Lenalidomide and rituximab for the initial treatment of chronic lymphocytic leukemia: Report of an ongoing study. (Abstract #6583)**
D. F. James, J. R. Brown, L. Werner, W. G. Wierda, K. R. Rai, J. Gould, J. E. Castro, L. Rassenti, D. S. Neuberg, T. J. Kipps
- Brd. 18B Four routinely recorded parameters define four distinct prognostic groups in AML. (Abstract #6584)**
J. R. Novotny, H. Nueckel, A. Aisenbrey, U. Dührsen

- Brd. 18C** **United States (US) practices for chronic myelogenous leukemia (CML) management compared to other countries: A worldwide observational registry. (Abstract #6585)**
R. C. Hermann, C. B. Miller, R. Catchatourian, D. Snyder, D. Williams, M. Juma, J. E. Cortes
- Brd. 18D** **Effect of the presence of P-glycoprotein (MDR1) on the ability of AML patients to achieve complete remission: Results of a meta-analysis of the literature. (Abstract #6586)**
J. Marie, A. S. Lundberg, A. Ajami
- Brd. 18E** **Safety and efficacy of HiDAC induction in de novo AML patients age 60 and older. (Abstract #6587)**
M. L. Arellano, L. Pan, L. Lima, M. Tighiouart, L. T. Heffner, A. A. Langston, M. McLemore, J. Neely, E. F. Winton, H. J. Khoury
- Brd. 18F** **Early intensification of imatinib treatment based on precise definition of accelerated phase in patients with chronic myeloid leukemia: Population-based analysis. (Abstract #6588)**
K. Foryciarz, T. Sacha, Z. Salamanczuk, M. Jakobczyk, S. Czekalska, M. Zawada, M. Szostek, I. Florek, A. B. Skotnicki
- Brd. 18G** **High-dose of daunorubicin as induction treatment for adults with newly diagnosed Philadelphia-negative acute lymphoblastic leukemia. (Abstract #6589)**
S. Lee, Y. Joo, K. Lee, K. Kim, J. Ahn, S. Sohn, H. Kim, Y. Choi, J. Park, G. Lee, Korean Society of Hematology, Adult ALL Working Party
- Brd. 18H** **Prevalence of familial malignancy in a prospectively screened cohort of patients with leukemia. (Abstract #6590)**
A. Prasad, D. Liu, M. Rasul, N. Ahmed, K. Seiter
- Brd. 19A** **Detection of combinations of cytogenetic abnormalities in chronic lymphocytic leukemia (CLL) by fluorescent in situ hybridization (FISH) probes. (Abstract #6591)**
M. T. Schweizer, Y. Zhang, R. Kunnavakkam, T. Karrison, M. M. Le Beau, R. A. Larson
- Brd. 19B** **Molecular characterization of normal karyotype acute myeloid leukemia in Korean patients. (Abstract #6592)**
Y. Choi, J. Lee, D. Kim, J. Ahn, S. Lim, S. Kim, E. Hur, M. Seol, K. Lee
- Brd. 19C** **Reactivation of latent viral hepatitis infection in patients of chronic myeloid leukemia treated with imatinib mesylate: Experience from a tertiary cancer center in India. (Abstract #6593)**
V. Ostwal, N. Ghadyalpatil, K. Prabhash, H. Menon, R. Nair, M. Sengar, V. Noronha, S. Biswas, B. Bhosale, S. Banavali
- Brd. 19D** **Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. (Abstract #6594)**
N. Ghadyalpatil, K. Prabhash, H. Menon, R. Nair, S. Banavali, V. Noronha, V. Wabale, R. Singh, G. Goyal, V. Ostwal
- Brd. 19E** **Flow cytometric bead assay of BCR-ABL fusion proteins in leukemia patients: An Indian experience. (Abstract #6595)**
R. Pandey
- Brd. 19F** **Meta-analysis of cord blood transplantations for indication of leukemia from private umbilical cord blood banks from 1993–2009. (Abstract #6596)**
N. Gottschalk, E. F. Lampeter, V. R. Jacobs
- Brd. 19G** **Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs). (Abstract #6597)**
S. Gaballa, A. Al-Kali, H. Kantarjian, E. Jabbour, A. Quintas-Cardama, M. Ayoubi, G. Borthakur, S. M. O'Brien, J. E. Cortes
- Brd. 19H** **Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality. (Abstract #6598)**
P. Fenaux, A. Giagounidis, D. L. Selleslag, O. Beyne-Rauzy, M. Mittelman, P. Muus, R. D. Knight, T. Fu, E. Hellstrom-Lindberg, The MDS-004 Len del(5q) Study Group

- Brd. 20A** **JAK2 V617F mutation positives in the general population. (Abstract #6599)**
S. E. Bojesen, C. Nielsen, H. Birgens, B. G. Nordestgaard, L. Kjaer, H. Hasselbalch
- Brd. 20B** **Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes (MDS). (Abstract #6600)**
E. Kim, F. Pan, S. Peng, R. Fleurence
- Brd. 20C** **Hematologic outcomes of MDS treatment with hypomethylating agents in community practice. (Abstract #6601)**
R. Bordoni, B. A. Feinberg, J. W. Gilmore, S. Haislip, E. Kim, J. Jackson, E. Farrelly, D. Buchner
- Brd. 20D** **Increased of overall survival (OS) and malignancies (K) during tyrosine kinase inhibitors (TKI) in a real life cohort of patients (pts) with a chronic myeloid leukemia (CML). (Abstract #6602)**
M. Gourin, P. Turlure, N. Gachard, S. Girault, M. Touati, J. Abraham, C. Philippon, J. Feuillard, D. Bordessoule
- Brd. 20E** **Eltrombopag effect on the engraftment efficiency of human hematopoietic stem cells in a NOD/SCID xenotransplant model. (Abstract #6603)**
Y. Chen, Y. Tsai, R. Hu, J. Pietrusz, O. Hyrien, K. L. Dawson, C. L. Erickson-Miller, J. Liesveld, H. Sun
- Brd. 20F** **Nonsteroidal anti-inflammatory drugs (NSAIDs) or EP4 receptor antagonism enhances hematopoietic stem and progenitor cell (HSPC) mobilization and facilitates faster hematopoietic recovery after myeloablation. (Abstract #6604)**
J. Hoggatt, P. Singh, A. Hoggatt, J. M. Speth, L. M. Pelus
- Brd. 20G** **Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS). (Abstract #6605)**
N. Pemmaraju, H. Kantarjian, S. Faderl, G. Garcia-Manero, T. M. Kadia, G. Borthakur, J. E. Cortes, F. Ravandi Kashani
- Brd. 20H** **Gene methylation and cytogenetic abnormalities in patients (pts) with higher-risk myelodysplastic syndromes. (Abstract #6606)**
G. J. Mufti, J. G. Herman, S. Gore, J. F. Seymour, V. Santini, A. M. Hagemeyer, B. Skikne, K. J. MacBeth, L. M. Lucy, C. L. Beach
- Brd. 21A** **Phase II study of the histone deacetylase (HDAC) inhibitor belinostat for the treatment of myelodysplastic syndrome (MDS). (Abstract #6607)**
A. F. Cashen, M. Juckett, A. Jumonville, M. R. Litzow, P. J. Flynn, J. R. Eckardt, B. LaPlant, K. M. Laumann, C. Erlichman, J. F. DiPersio
- Brd. 21B** **Identification of genes with different methylation profiles between RAEB and RCMD in myelodysplastic syndrome. (Abstract #6608)**
S. Lee, H. Kwon, S. Kim, S. Oh, K. Kwon, J. H. Lee, Y. Lee, D. Seo, J. Han, H. Kim
- Brd. 21C** **Effect of phosphoinositide-phospholipase c beta1 monoallelic deletion in low-risk MDS patients treated with darbepoetin. (Abstract #6609)**
P. Spadaro, V. Pitini, C. Arrigo, M. Ingemi
- Brd. 21D** **In vitro activation of CMV-specific T-cell response using CyaA toxoids delivering peptide antigenic epitopes derived from pp65 protein. (Abstract #6610)**
J. Jelinek, I. Adkins, P. Sebo, J. Michalek
- Brd. 21E** **Myelodysplastic syndrome (MDS) patients at a VA medical center: Comorbidity and survival. (Abstract #6611)**
K. Kim, T. Kalwar, M. Barry, S. Srinivas, V. T. Chang, K. Toomey, M. L. Gonzalez, L. Duque, M. McPherson, B. Kasimis
- Brd. 21F** **A prospective multicenter observational study for decitabine treatment in Korean patients with myelodysplastic syndrome. (Abstract #6612)**
J. Lee, J. Jang, K. Lee, C. Jung, J. Park, S. Yoon, Y. Joo, Y. Kim, S. Park, Y. Min

Saturday, June 5, 2010

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Lymphoma and Plasma Cell Disorders

Location: S Hall A2

Tracks(s): Lymphoma and Plasma Cell Disorders

- Brd. 22A Romidepsin activity in all three disease compartments (skin, blood, lymph nodes) in patients with cutaneous T-cell lymphoma (CTCL). (Abstract #8047)**
E. Kim, A. Rook, Y. Kim, M. Demierre, A. Lerner, M. Duvic, T. Robak, J. Becker, W. McCulloch, S. Whittaker
- Brd. 22B Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. (Abstract #8048)**
B. Pro, G. F. Perini, L. Feng, J. E. Romaguera, M. A. Rodriguez, P. McLaughlin, F. B. Hagemeister, L. Fayad, T. M. Kadia
- Brd. 22C Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial—A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (Abstract #8049)**
B. Joly, A. Plonquet, M. Grare, M. Delfau-Larue, R. Delarue, A. Delmer, O. Casasnovas, C. Gisselbrecht, P. Gaulard, C. Haioun
- Brd. 22D Transcriptome adaptation caused by vorinostat/bexarotene combination therapy in advanced cutaneous T-cell lymphoma. (Abstract #8050)**
M. B. Karpova, D. Gunz, M. J. Okoniewski, A. Cozzio, K. Schad, K. Baumann Conzett, R. Dummer
- Brd. 22E Prognosis and treatment of patients with peripheral T-cell lymphoma: The M. D. Anderson Cancer Center experience. (Abstract #8051)**
J. V. Pozadzides, G. Perini, M. Hess, J. E. Romaguera, F. B. Hagemeister, P. McLaughlin, L. Fayad, I. F. Khouri, C. Hosing, B. Pro
- Brd. 22F Assessment of combination treatment with gemcitabine, cisplatin, and methylprednisolone (Gem-P) in the management of non-Hodgkin T-cell lymphoma. (Abstract #8052)**
K. Yim, I. Chau, A. Horwich, C. Dearden, G. Morgan, A. Wotherspoon, A. Attygalle, B. Sharma, D. Cunningham
- Brd. 22G Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous T-cell lymphoma (CTCL). (Abstract #8053)**
D. J. Straus, M. Duvic, S. M. Horwitz, K. B. Hymes, A. Goy, F. J. Hernandez-Illizaliturri, T. Feldman, B. Wegner, P. Myskowski
- Brd. 22H Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival. (Abstract #8054)**
A. R. Shustov, B. Pro, S. M. Horwitz, E. D. Jacobsen, A. Boyd, S. M. Fruchtman, O. O'Connor
- Brd. 23A Duration of response in three phase III studies of denileukin diftitox in cutaneous T-cell lymphoma (CTCL). (Abstract #8055)**
M. Duvic, H. M. Prince
- Brd. 23B T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant. (Abstract #8056)**
F. Montanari, G. Bhagat, J. M. Zain, V. E. Seshan, C. S. Magid Diefenbach, S. Clark-Garvey, E. McCormick, M. Crook, M. Conroy, O. O'Connor
- Brd. 23C ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A 10-year follow-up study. (Abstract #8057)**
N. Batty, F. B. Hagemeister, J. E. Romaguera, M. A. Rodriguez, P. McLaughlin, F. Samaniego, A. Copeland, B. S. Dabaja, A. Younes

- Brd. 23D** Does a negative post-therapy PET obviate the need for any further follow-up imaging in patients with nonbulky early-stage Hodgkin's lymphoma (HL)? (Abstract #8058)
A. Gallamini, A. Biggi, S. Chauvie, A. Bianchi, S. Conti, F. Fiore, R. Sorasio, J. Vose, D. L. Thomas, M. E. Juweid
- Brd. 23E** Clinically significant delayed cardiac morbidity following ABVD chemotherapy for Hodgkin lymphoma: A population-based study. (Abstract #8059)
D. C. Hodgson, M. Pintilie, L. Yun, R. Tsang, E. Yu, J. Sussman, R. M. Meyer
- Brd. 23F** Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT. (Abstract #8060)
C. Martinez, C. Canals, E. Alessandrino, D. Karakasis, G. Leone, M. Trneny, J. Snowden, J. Apperley, N. Milpied, A. Sureda, on behalf of the Lymphoma Working Party of the EBMT
- Brd. 23G** Correlation of FDG-PET results after one cycle and after two cycles of chemotherapy in Hodgkin lymphoma. (Abstract #8061)
M. Hutchings, L. Kostakoglu, A. Loft, M. Coleman, L. Specht
- Brd. 23H** Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series. (Abstract #8062)
N. Bartlett, L. E. Grove, D. A. Kennedy, E. L. Sievers, A. Forero-Torres
- Brd. 24A** Body mass index (BMI) and obesity as a predictor of clinical outcome in patients with Hodgkin's lymphoma treated with AVBD. (Abstract #8063)
R. Patil, F. J. Hernandez-Ilizaliturri, A. Elefante, M. S. Czuczman
- Brd. 24B** Results of the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL). (Abstract #8064)
M. Pfreundschuh, V. Poeschel, S. Zeynalova, A. Viardot, M. Haenel, U. Keller, M. Reiser, N. Murawski, M. Loeffler, J. Schubert
- Brd. 24C** Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL). (Abstract #8065)
K. A. Pierz, S. Gu, M. E. Lewis, S. Hsu, C. Falandry, G. A. Salles, M. F. Fey, G. Martinelli, F. Hitz, M. E. Ghielmini
- Brd. 24D** Phase II study of short course CHOP-rituximab followed by 90-y ibritumomab tiuxetan as first-line treatment for follicular lymphoma: Extended follow-up and predictors of relapse. (Abstract #8066)
D. R. Mehta, R. C. Jankowitz, D. E. Lenzner, S. R. Land, S. A. Jacobs
- Brd. 24E** Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL). (Abstract #8067)
T. Feldman, A. R. Mato, T. Zielonka, A. Masood, S. Goldberg, S. D. Rowley, M. Donato, D. S. Siegel, A. Pecora, A. Goy
- Brd. 24F** CD137 stimulation of natural killer cells to enhance the antilymphoma activity of rituximab. (Abstract #8068)
H. E. Kohrt, R. Houot, M. Goldstein, K. Weiskopf, L. Chen, T. Tedder, R. Levy
- Brd. 24G** Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (Abstract #8069)
C. Haioun, F. Morschhauser, E. Jourdan, J. Karsenti, G. Hess, U. Diehrsen, S. Kravchenko, G. van Hal, M. Hahka-Kemppinen

- Brd. 24H Correlation of the intra-tumor phospholipid-related signatures determined noninvasively by phosphorus and hydrogen MR spectroscopy: An approach to increase the sensitivity and applicability of the technique to predict therapeutic outcome in non-Hodgkin's lymphoma. (Abstract #8070)**
F. Arias-Mendoza, F. Howe, J. R. Griffiths, J. D. Glickson, O. O'Connor, J. A. Koutcher, M. O. Leach, A. Heerschap, T. R. Brown, The Cooperative Group of MR Applications in Cancer
- Brd. 25A Duration of remission using I-131 tositumomab in patients with B-cell lymphoma relapsing after autologous stem cell transplant. (Abstract #8071)**
D. D. Shepard, J. Estes, K. A. Griffith, M. S. Kaminski
- Brd. 25B Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement, clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M. D. Anderson Cancer Center. (Abstract #8072)**
G. F. Perini, J. E. Romaguera, M. A. Rodriguez, B. Pro, A. Younes, N. H. Fowler, F. B. Hagemeister, F. Samaniego, L. W. Kwak, L. Fayad
- Brd. 25F Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma (FL) treated with radiotherapy. (Abstract #8073)**
P. Bains, A. J. Al-Tourah, B. A. Campbell, T. Pickles, R. D. Gascoyne, J. M. Connors, K. J. Savage
- Brd. 25G Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factors in 40 consecutive Asian patients. (Abstract #8074)**
W. D. Tai, H. P. Phoon, S. Tan, Y. Koo, R. H. Quek, M. Tao, S. Lim
- Brd. 25H Immunochemotherapy with rituximab in combination with fludarabine and epirubicine as first-line treatment in patients with chronic lymphocytic leukemia. (Abstract #8075)**
K. U. Chow, S. Kim-Wanner, S. Hermann, L. Wunderle, H. J. Cordes, L. Bergmann Sr.
- Brd. 26A Effect of CpG oligodeoxynucleotides on the growth of aggressive human B-cell lymphomas. (Abstract #8076)**
R. E. Yamada, D. J. Betting, M. Ahdoot, J. Timmerman
- Brd. 26B Clinical characteristics of non-Hodgkin's lymphoma (NHL) in Vietnam era (V) and non-Vietnam era veterans (Non V). (Abstract #8077)**
S. Srinivas, K. Kim, T. Kalwar, M. Barry, V. T. Chang, M. Bryan, M. L. Gonzalez, J. Cogswell, M. Cholankeril, B. Kasimis
- Brd. 26F Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). (Abstract #8078)**
G. E. Manoukian, F. B. Hagemeister, P. McLaughlin, L. Fayad, F. Samaniego, A. Goy, J. E. Romaguera, B. Pro, F. Cabanillas, M. A. Rodriguez
- Brd. 26G Comparison of contrast-enhanced CT, PET/CT, PET, and low-dose non-contrast enhanced CT imaging of diffuse large B-cell (DLBCL), follicular (FL), small lymphocytic/CLL (CLL/SLL), and marginal zone lymphomas (MZL). (Abstract #8079)**
E. A. Chong, D. A. Torigian, A. Alavi, J. Svoboda, S. Nasta, L. H. Downs, S. J. Schuster
- Brd. 26H Association of serum B7-H1 level and lymphopenia in diffuse large B-cell non-Hodgkin lymphoma. (Abstract #8080)**
R. A. Wilcox, X. Frigola Baro, L. F. Porrata, E. D. Kwon, M. J. Maurer, I. N. Micallef, T. E. Witzig, S. M. Ansell
- Brd. 27A High-dose sequential chemotherapy and rituximab (R-HDS) supported by autologous stem cell transplantation (ASCT) in patients (pts) with systemic B-cell lymphoma with CNS involvement (SCNSL) at diagnosis or relapse: Interim analysis of feasibility and activity of a phase II trial. (Abstract #8081)**
A. Assanelli, K. Patti, S. Cortelazzo, L. Rigacci, L. Devizzi, M. Foppoli, A. Mulé, F. Ciceri, C. Tarella, A. J. Ferreri, on behalf of the Intergruppo Italiano Linfomi

SATURDAY

- Brd. 27B** **Quality of life in 269 poor-risk diffuse large B-cell lymphoma patients treated with rituximab versus observation after front-line auto transplantation: The GELA LNH98-3 randomized trial. (Abstract #8082)**
 N. Mounier, N. Heutte, C. Haioun, P. Feugier, B. Coiffier, H. Tilly, C. Ferme, J. Gabarre, F. Morchhauser, C. Gisselbrecht
- Brd. 27C** **Clinicopathological differences between EBV-positive and EBV-negative diffuse large B-cell lymphoma. (Abstract #8083)**
 B. E. Beltran, D. Morales, A. Capellino, R. Miranda, J. Castillo
- Brd. 27D** **Maintenance rituximab versus observation after R-CHOP or R-EPOCH in patients with untreated poor-prognosis diffuse large B-cell lymphoma and grade III follicular lymphoma. (Abstract #8084)**
 Y. J. Li, Z. J. Xia, S. Li, X. Q. Chen, Y. Xia, F. Xu, Z. H. Wang
- Brd. 27E** **Changes in regulatory T-cells in responding and non-responding patients with indolent B-cell or mantle cell lymphomas during treatment with lenalidomide, dexamethasone, and rituximab. (Abstract #8085)**
 N. Agui, L. Leinbach, E. A. Chong, T. Ahmadi, J. Svoboda, A. Gordon, L. H. Downs, S. Nasta, S. J. Schuster
- Brd. 27F** **Phase II study of MGCD0103 in patients with relapsed follicular lymphoma (FL): Study reinitiation and update of clinical efficacy and safety. (Abstract #8086)**
 R. E. Martell, A. Younes, S. E. Assouline, D. Rizzieri, S. Fox, M. A. Drouin, J. Wilhelm, M. Mehran, J. M. Besterman, R. H. Van Der Jagt
- Brd. 27G** **Effect of YM155, a potent survivin suppressant, on the antitumor effect of rituximab in diffuse large B-cell lymphoma (DLBCL) xenograft models: FLT-/FDG-PET imaging studies. (Abstract #8087)**
 K. Mitsuoka, S. Miyoshi, A. Kita, K. Yamanaka, M. Nakata, Y. Murakami, A. Noda, M. Jitsuoka, H. Fushiki, S. Nishimura
- Brd. 27H** **Hypogammaglobulinemia in pts receiving rituximab immunotherapy and the impact of rituximab maintenance. (Abstract #8088)**
 C. Casulo, J. Maragulia, A. D. Zelenetz, Lymphoma Service, Department of Medicine
- Brd. 28A** **Clinical relevance of a positive result in cerebrospinal fluid (CSF) by flow cytometry (FCM) in patients with diffuse large B-cell lymphoma (DLBCL). (Abstract #8089)**
 R. Alvarez, J. Dupuis, A. Plonquet, C. Christov, C. Copie-Bergman, I. Gaillard, T. EL Gnaoui, K. Belhadj, F. Hemery, C. Haioun
- Brd. 28B** **Correlation of tumoricidal activity of lenalidomide against hematologic tumor cells with cyclin D1/D2 expression and effect on tumor-suppressor gene upregulation. (Abstract #8090)**
 L. Zhang, J. Kosek, P. Schafer, J. B. Bartlett
- Brd. 28C** **Participation of elderly patients with lymphoma and myeloma in clinical trials of novel agents. (Abstract #8091)**
 J. Ruan, T. M. Mark, J. Allan, J. Morrison, A. Koirala, P. Martin, M. Coleman, M. Lachs, R. Niesvizky, J. P. Leonard
- Brd. 28D** **The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC). (Abstract #8092)**
 A. R. Mato, T. Zielonka, T. Feldman, P. Bhattacharyya, C. Bejot, N. George, S. Stives, S. Goldberg, A. Pecora, A. Goy
- Brd. 28E** **Effect of inactivation of argininosuccinate synthetase on sensitivity of lymphomas to caspase-dependent apoptosis following treatment with arginine deiminase. (Abstract #8093)**
 P. W. Szlosarek, B. Delage, C. O'Riain, E. Hatzimichael, T. Crook, M. Calaminici, J. G. Gribben, N. Lemoine, T. A. Lister, J. Fitzgibbon

Saturday, June 5, 2010

- Brd. 28F** Efficacy of combination of rituximab (R), obatoclox (O), and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL). (Abstract #8094)
W. Riaz, F. J. Hernandez-Ilizaliturri, C. Mavis, P. Tsai, M. S. Czuczman
- Brd. 28G** Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma. (Abstract #8095)
M. J. Barth, F. J. Hernandez-Ilizaliturri, C. Mavis, P. Tsai, J. F. Gibbs, M. S. Czuczman
- Brd. 28H** Rituximab-related (R-R) reactivation of hepatitis B virus (HBV) in lymphoma: Analysis of FDA safety reports and a systematic literature review with meta-analysis. (Abstract #8096)
A. M. Evens, B. Chiu, Y. Su, M. Dai, B. Jovanovic, B. Fintel, D. Ganger, T. Chen, S. Lin, C. Kuo
- Brd. 29A** Late phase II study of amrubicin in previously untreated patients with non-Hodgkin's lymphoma (NHL). (Abstract #8097)
J. Suzumiya, K. Suzuki, N. Uike, F. Kawano, T. Takeo, S. Okamura, C. Sakai, M. Mori, K. Tamura, Amrubicin LYM Study Group
- Brd. 29B** Effect of a rituximab-based regimen on the incidence of CNS relapse in patients with diffuse large B-cell lymphoma. (Abstract #8098)
M. Mahrous, R. Buckstein, E. Piliotis, M. C. Cheung, N. L. Berinstein
- Brd. 29C** Cladribine plus rituximab for the initial treatment of mantle cell lymphoma. (Abstract #8099)
T. Pindyck, S. E. Spurgeon, C. Y. Okada, E. E. Epler
- Brd. 30A** Use of maintenance rituximab (R) in the United States following R-based induction for follicular lymphoma (FL). (Abstract #8100)
C. Flowers, M. Taylor, J. Hirata, H. Dillon, A. D. Zelenetz, J. D. Hainsworth, J. R. Cerhan, E. S. Rogers, J. W. Friedberg, B. K. Link
- Brd. 30B** Prognostic value of the absolute lymphocyte count reduction in patients with diffuse large B-cell lymphoma treated with R-CHOP. (Abstract #8101)
S. Kim, B. Kang, Y. Chae, J. Kim, Y. Kim, S. Sohn
- Brd. 30C** 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus FLIPI as a predictor of therapy response in follicular lymphoma (FL) patients. (Abstract #8102)
D. M. Lamonica, T. Hahn, D. Drumsta, M. Achakzai, M. S. Czuczman, F. J. Hernandez-Ilizaliturri
- Brd. 31A** Maximum standardized uptake (SUVmax) on initial ¹⁸F-FDG-PET/CT as prognostic value in patients with diffuse large B-cell lymphoma. (Abstract #8103)
B. Kwon, Y. Choi, Y. Soel, M. Song, S. Kim, H. Shin, J. Chung, G. Cho
- Brd. 31B** Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL). (Abstract #8104)
D. Belada, J. Mayer, M. S. Czuczman, I. W. Flinn, B. Durbin-Johnson, G. L. Bray
- Brd. 31C** Radioimmunotherapy for consolidation and relapse therapy for aggressive B-cell non-Hodgkin lymphoma: Retrospective analysis of the International RIT-Network. (Abstract #8105)
K. Hohloch, C. Windemuth-Kiesselbach, M. Lorsbach, P. L. Zinzani, L. Trümper
- Brd. 32A** A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis. (Abstract #8106)
V. A. Morrison, J. L. Johnson, S. Jung, J. P. Leonard, B. D. Cheson

- Brd. 32B Association of maintenance rituximab with clinical outcome in rituximab-naïve patients with Waldenström's macroglobulinemia (WM) who respond to a rituximab-containing regimen. (Abstract #8107)**
L. I. Ioakimidis, C. A. Hanzis, R. J. Manning, C. J. Patterson, J. D. Soumerai, Z. R. Hunter, P. S. Brodsky, P. S. Sheehy, B. Turnbull, S. P. Treon
- Brd. 32C Association of CR/VGPR with progression-free survival in rituximab-naïve WM patients undergoing rituximab-based therapy, as predicted by polymorphisms in FcγRIIIA-158. (Abstract #8108)**
Z. R. Hunter, G. Yang, L. I. Ioakimidis, C. A. Hanzis, R. J. Manning, C. J. Patterson, P. S. Sheehy, P. Gong, L. Xu, S. P. Treon
- Brd. 33A Long-term follow-up of patients with lymphoplasmacytic lymphoma (Waldenström's macroglobulinemia) who were treated with alemtuzumab. (Abstract #8109)**
J. D. Soumerai, Z. R. Hunter, M. Boxer, B. S. Kahl, L. I. Ioakimidis, C. J. Patterson, S. P. Treon
- Brd. 33B Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenström's macroglobulinemia, and effect on miRNA expression. (Abstract #8110)**
D. W. McMillin, Z. R. Hunter, J. Delmore, P. Smith, A. Birner, P. G. Richardson, K. C. Anderson, S. P. Treon, C. S. Mitsiades
- Brd. 33C Association of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, with MGUS and multiple myeloma in different ethnic groups. (Abstract #8111)**
S. Grass, S. Iida, A. Wikowicz, N. Fadle, A. Inagaki, K. Preuss, M. Ziepert, R. Ueda, M. Pfreundschuh
- Brd. 34A Activity of the CD20-directed monoclonal antibody GA101 relative to rituximab in Waldenström's macroglobulinemia (WM), and applicability to patients expressing FcγRIIIA-158 F/F. (Abstract #8112)**
G. Yang, P. Gong, L. Xu, Z. R. Hunter, Y. Zhou, X. Liu, Y. Cao, B. Ciccarelli, C. J. Patterson, S. P. Treon
- Brd. 34B Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma. (Abstract #8113)**
H. Avet-Loiseau, P. Moreau, C. Mathiot, C. Charbonnel, T. Facon, M. Attal, C. Hulin, G. Marit, S. Minvielle, J. Harousseau, Intergroupe Francophone du Myélome
- Brd. 34C Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenström's macroglobulinemia (WM). (Abstract #8114)**
S. P. Treon, C. A. Hanzis, L. I. Ioakimidis, C. J. Patterson, Z. R. Hunter, P. S. Brodsky, P. S. Sheehy, R. J. Manning
- Brd. 35A Racial disparities in incidence and survival among 37,977 blacks and whites with multiple myeloma. (Abstract #8115)**
A. J. Waxman, P. Mink, S. Devesa, W. F. Anderson, B. M. Weiss, S. Kristinsson, K. McGlynn, O. Landgren
- Brd. 35B Primary plasma cell leukemia (PCL): Clinical and laboratory presentation and clinical outcome with total therapy (TT) protocols. (Abstract #8116)**
B. P. Nair, N. Petty, S. Waheed, A. Hoering, F. Van Rhee, E. J. Anaissie, R. Lorschbach, C. Bailey, B. Barlogie
- Brd. 35C Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications. (Abstract #8117)**
C. J. Heuck, J. Mehta, N. Pulliam, R. Meagher, L. Zhou, E. Vickrey, E. Voigt, J. Greally, A. Verma, S. Singhal
- Brd. 35D BIK (Bcl2-Interacting Killer) CpG methylation status as a potential predictive biomarker of relapsed/refractory multiple myeloma disease. (Abstract #8118)**
E. Hatzimichael, A. Dasoula, G. Dranitsaris, A. Vassou, A. Papoudou-Bai, J. Stebbing, K. Bourantas, T. Crook

- Brd. 35E** **Cure fractions (CF) modeled from event-free survival and complete response duration plots in total therapy (TT) trials for newly diagnosed multiple myeloma (MM). (Abstract #8119)**
 J. Crowley, J. D. Shaughnessy, V. Bolejack, E. J. Anaissie, F. Van Rhee, B. Barlogie
- Brd. 35F** **Genomic evolution in total therapy 2 (TT2) and total therapy 3 (TT3) for newly diagnosed multiple myeloma (MM): Comparison of baseline (BL) and relapse (REL) gene expression profiling (GEP) signatures. (Abstract #8120)**
 A. Hoering, J. D. Shaughnessy, J. Haessler, R. Sexton, F. Van Rhee, Y. Alsayed, S. Waheed, B. P. Nair, J. Crowley, B. Barlogie
- Brd. 35G** **Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T), and bortezomib (V). (Abstract #8121)**
 F. Van Rhee, B. Barlogie, J. Szymonifka, E. J. Anaissie, B. P. Nair, S. Waheed, Y. Alsayed, N. Petty, J. D. Shaughnessy, A. Hoering, J. Crowley
- Brd. 35H** **Gene expression profiling (GEP) in multiple myeloma (MM): Distinguishing relapses with high-risk transformation from those with sustained low risk. (Abstract #8122)**
 J. Sawyer, J. D. Shaughnessy, J. Haessler, A. Hoering, B. Barlogie
- Brd. 36A** **Metaphase cytogenetic abnormalities (M-CA) in multiple myeloma (MM): Examining number of M-CA for survival in total therapy protocols (TT1, TT2, TT3). (Abstract #8123)**
 J. Haessler, B. P. Nair, J. Sawyer, A. Hoering, J. D. Shaughnessy, B. Barlogie
- Brd. 36B** **Expression of erythropoietin receptors by plasma cells from patients with multiple myeloma express: Potential relevance to pharmacological use of erythropoietin. (Abstract #8124)**
 P. S. Becker, C. P. Miller, B. L. Wood, S. Chien, W. Bensinger, F. Shahjani, C. A. Blau
- Brd. 36C** **Treatment patterns and outcome among patients with multiple myeloma relapsing and/or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study. (Abstract #8125)**
 S. Kumar, J. Crowley, S. K. Klein, J. J. Lahuerta, J. Lee, P. Moreau, G. Morgan, P. G. Richardson, D. S. Siegel, B. G. Durie, on behalf of the International Myeloma Working Group (IMWG)
- Brd. 36D** **Gene expression profiling (GEP) analysis of CD138-purified plasma cells (PC) obtained from MRI-defined focal lesions (FL) under CT guidance: Applying the 70 gene risk model and comparison with data generated on random samples (RS) from multiple myeloma (MM) treated with total therapy 2, 3, 4, and 5 (TT2, TT3, TT4 and TT5). (Abstract #8126)**
 Y. Qiang, R. van Hemert, T. Brown, J. D. Shaughnessy, F. Van Rhee, A. Hoering, B. Barlogie
- Brd. 36E** **Retrospective analysis of multiple myeloma survival outcomes in veterans: Focus on racial differences, age, and novel therapies. (Abstract #8127)**
 D. I. Da Graca, S. Yellapragada, Z. Yasin, C. E. Arce-Lara
- Brd. 36F** **Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency. (Abstract #8128)**
 A. Z. Badros, R. Vij, T. Martin, J. A. Zonder, A. F. Wong, T. Woo, K. Boussina, Z. Wang, R. Niesvizky
- Brd. 36G** **Bortezomib and high-dose melphalan as conditioning regimen before transplantation for de novo multiple myeloma patients: Updated data of the IFM phase II study. (Abstract #8129)**
 M. Roussel, P. Moreau, A. Huynh, J. Mary, D. Caillot, C. Hullin, C. Mathiot, H. Avet-Loiseau, J. Harousseau, M. Attal, IFM

SATURDAY

- Brd. 36H** **MP versus MPT for previously untreated elderly patients with multiple myeloma: A meta-analysis of 1,682 individual patient data from six randomized clinical trials. (Abstract #8130)**
A. Waage, A. P. Palumbo, P. Fayers, M. Beksac, C. Hulin, J. Mary, S. Brinthen, P. Sonneveld, P. Wijermans, T. Facon, NMSG, GIMEMA, TMSG, HOVON, IFM, European Myeloma Network
- Brd. 37A** **A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM). (Abstract #8131)**
M. L. Khan, C. B. Reeder, S. Kumar, M. Lacy, D. E. Reece, K. M. Laumann, J. Mikhael, R. Fonseca, V. Rajkumar, A. K. Stewart
- Brd. 37B** **Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM). (Abstract #8132)**
J. J. Shah, A. D. Cohen, J. A. Zonder, J. L. Kaufman, S. M. Burt, B. B. Freeman, S. Rush, A. M. Ptaszynski, R. Z. Orlowski, S. Lonial
- Brd. 37C** **Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM). (Abstract #8133^)**
S. Jagannath, D. S. Siegel, R. Hajek, M. A. Dimopoulos, S. Yoon, S. Lonial, T. Graef, L. Lupinacci, D. Reiser, K. C. Anderson
- Brd. 37D** **A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM). (Abstract #8134)**
J. R. Berenson, O. Yellin, C. Chen, R. Patel, A. Bessudo, R. V. Boccia, H. Yang, V. Gupta, J. Hilger, R. A. Swift
- Brd. 37E** **Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI). (Abstract #8135)**
J. L. Wolf, R. Vij, S. Lonial, M. Wang, S. Jagannath, S. Singhal, M. H. Le, C. Kirk, S. Arastu-Kapur, D. S. Siegel, The Multiple Myeloma Research Consortium
- Brd. 37F** **The Arkansas experience with autotransplantation (AT) for older patients (OP, age > 65) with multiple myeloma (MM). (Abstract #8136)**
E. J. Anaissie, M. Graziutti, J. Szymonifka, B. P. Nair, F. Van Rhee, Y. Alsayed, S. Waheed, A. Hoering, B. Barlogie
- Brd. 37G** **Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: Final results of a phase I study. (Abstract #8137)**
A. Guenther, P. Baumann, R. Burger, W. Klapper, R. Schmidmaier, M. Gramatzki
- Brd. 37H** **Predicting 10+ year survivors in total therapy 1 (TT1) for multiple myeloma (MM). (Abstract #8138)**
S. Waheed, Y. Alsayed, R. Sexton, A. Hoering, B. Barlogie
- Brd. 38A** **A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma. (Abstract #8139)**
D. M. Benson, S. Padmanabhan, C. C. Hofmeister, C. E. Bakan, R. Abonour, A. Suvannasankha, Y. A. Efebera, P. J. Squiban, M. A. Caligiuri, S. Farag
- Brd. 38B** **Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma. (Abstract #8140)**
N. S. Rajee, N. C. Munshi, A. K. Mahindra, S. Pozzi, P. G. Richardson, J. Laubach, I. M. Ghobrial, R. L. Schlossman, K. C. Anderson
- Brd. 38C** **Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor. (Abstract #8141)**
S. Z. Usmani, R. D. Bona, G. Chiosis, Z. Li
- Brd. 38D** **Is low-dose cyclophosphamide (Cy) plus G-CSF (G) mobilization as effective as plerixafor plus G in multiple myeloma (MM) patients (pts) who are candidates for tandem autologous transplants (autoT)? (Abstract #8142)**
C. Karanes, A. Daxis, S. Wang, A. Y. Krishnan, F. Sahebi, L. Popplewell, P. M. Parker, S. J. Forman, J. Palmer, G. Somlo

- Brd. 38E** **A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. (Abstract #8143)**
A. Spencer, P. Walker, P. Asvadi, M. Wong, D. Campbell, K. Reed, M. C. Copeman, G. Nichol, L. J. Cohen, R. Dunn
- Brd. 38F** **An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve an unconfirmed stringent complete remission. (Abstract #8144)**
T. M. Mark, A. Koirala, R. N. Pearse, F. Zafar, D. Jayabalan, J. P. Leonard, M. Coleman, R. Niesvizky
- Brd. 38G** **Single/tandem autologous hematopoietic progenitor cell transplantation in high-risk de novo multiple myeloma patients: A retrospective analysis. (Abstract #8145)**
M. V. Martino, R. Fedele, G. Console, G. Irrera, G. Messina, C. Stelitano, M. Brugiattelli, C. Musolino, S. Molica, P. Iacopino
- Brd. 38H** **Does the magnitude of response to initial induction therapy impact plans for immediate autologous stem cell transplant (ASCT) consolidation in the transplant-eligible patient with a new diagnosis of multiple myeloma (MM)? (Abstract #8146)**
J. Willey, K. E. Lemke, M. E. Williams, M. R. Green, S. Lonial
- Brd. 39A** **Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies. (Abstract #8147)**
P. Lee, A. F. Wong, H. A. Burris III, K. Papadopoulos, E. A. Sausville, P. J. Rosen, D. S. Mendelson, J. R. Infante, A. Patnaik, M. S. Gordon
- Brd. 39B** **Use of combined FDG-PET and laboratory data for predicting relapse in multiple myeloma. (Abstract #8148)**
B. M. Elliott, S. Peti, D. Lee, K. Osman, L. M. Isola, E. Scigliano, L. Kostakoglu
- Brd. 39F** **Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma. (Abstract #8149)**
M. Veeraputhiran, Z. Singh, B. Barlogie, M. Cottler-Fox
- Brd. 39G** **Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging. (Abstract #8150)**
K. Belhadj, C. Lin, A. Luciani, T. EL Gnaoui, I. Gaillard, J. Dupuis, F. Kuhnowski, M. Bedoui, A. Rahmouni, C. Haioun
- Brd. 39H** **Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (The BoMeR trial): Impact on response and time to progression. (Abstract #8151)**
S. J. Harrison, H. Quach, J. Dean, A. Milner, M. C. Copeman, H. M. Prince

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Tumor Biology

Location: S Hall A2

Tracks(s): Tumor Biology

- Brd. 40A** **EGFR mutations in men and cigarette smokers with lung adenocarcinoma. (Abstract #10538)**
M. Pietanza, S. P. D'Angelo, M. L. Johnson, P. K. Paik, G. J. Riely, V. A. Miller, M. F. Zakowski, V. W. Rusch, M. Ladanyi, M. G. Kris
- Brd. 40B** **Molecular types and prognostic markers PA/PAI-1 for 2,497 early breast cancer patients in the multicenter, randomized NNBC 3-Europe trial. (Abstract #10539)**
E. J. Kantelhardt, C. Thomssen, M. Vetter, C. Meisner, M. Schmidt, P. Martin, F. Sweep, G. Von Minckwitz, M. Schmitt, N. Harbeck, on behalf of the NNBC 3-Europe Study Group
- Brd. 40F** **Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial. (Abstract #10540)**
J. D. Hainsworth, D. R. Spigel, M. S. Rubin, R. V. Boccia, E. P. Fox, I. Firdaus, M. G. Erlander, C. Schnabel, F. A. Greco
- Brd. 40G** **Effect of IKK ϵ knock-down on prostate cancer xenograft growth. (Abstract #10541)**
B. Péant, Y. Huon, K. Leclerc-Desaulniers, N. Delvoye, M. Latour, A. Mes-Masson, F. Saad
- Brd. 40H** **Immunohistochemistry detection of epidermal growth factor receptor (EGFR) exons 19 and 21 mutations in non-small cell lung cancer (NSCLC) using novel mutation specific antibodies. (Abstract #10542)**
Y. Kato, N. Peled, K. Yoshida, M. W. Wynes, M. Pardo, C. J. Mascaux, M. Tsuboi, T. Ohira, N. Ikeda, F. R. Hirsch
- Brd. 41A** **Analysis of the methylation profile of 49 cancer-related regions in human breast cancer. (Abstract #10543)**
D. M. Marzese, F. Gago, J. I. Orozco, O. M. Tello, M. Roqué, L. M. Vargas-Roig
- Brd. 41B** **Prospective multicentric trial evaluating prognostic and predictive value of circulating tumor cells in first-line chemotherapy metastatic breast patients. (Abstract #10544)**
J. Pierga, T. D. Bachelot, F. Bidard, S. Delalogue, E. Brain, M. Campone, B. Asselain, C. Mathiot
- Brd. 41C** **Effect of kinesins on taxane resistance. (Abstract #10545)**
R. Wesolowski, M. Orloff, E. Downs-Kelly, G. T. Budd, G. R. Stark, S. De, R. R. Tubbs, J. P. Crowe, C. Eng
- Brd. 41D** **Impact of high-risk classification by FISH on overall survival in myeloma: An Eastern Cooperative Oncology Group (ECOG) study E4A03. (Abstract #10546)**
S. J. Jacobus, S. A. Van Wier, G. J. Ahmann, K. J. Henderson, N. S. Callander, M. E. Williams, D. S. Siegel, P. R. Greipp, S. V. Rajkumar, R. Fonseca
- Brd. 41E** **Early operable primary breast cancer in elderly (≥ 70 years) women: Are they biologically different from their younger counterparts? (Abstract #10547)**
K. Cheung, B. M. Syed, A. R. Green, D. A. Morgan, I. O. Ellis
- Brd. 41F** **Can cetuximab specific IgE antibodies predict cetuximab-induced anaphylaxis? (Abstract #10548)**
B. Dupont, D. Mariotte, M. Galais, K. Bouhier, B. Le Mauff, J. Reimund, R. Gervais
- Brd. 41G** **Determining true HER2 status in breast cancers with polysomy using alternative chromosome 17 reference genes: Implications for trastuzumab therapy. (Abstract #10549)**
A. M. Gown, C. C. Tse, L. C. Goldstein, P. L. Kandalaft, H. C. Hwang

- Brd. 41H Identification of DNA methylation changes in esophageal cancer before/after chemoradiation therapy using a MCA-microarray and bisulfate pyrosequencing. (Abstract #10550)**
T. Tsuda, Y. Watanabe, M. Hirakawa, K. Hosoya, N. Izawa, H. Inaba, N. Matsumoto, M. Toyota, F. Itoh
- Brd. 42A Prediction of response to neoadjuvant therapy in breast cancer using plasma and tumor proteomic analyses. (Abstract #10551)**
C. Desauw, L. Hornez, J. Bonnetterre, M. Baranzelli, M. Chauvet, E. Blot, A. Hollebecque, C. Fournier, A. Leroy, J. Peyrat
- Brd. 42B Value of quantitative DNA fingerprinting in classification of second breast tumors and association with outcome. (Abstract #10552)**
B. L. Schlechter, P. S. Larson, Q. Yang, R. Klett, K. Armstrong, A. de las Morenas, C. L. Rosenberg
- Brd. 42C CpG-b oligodeoxynucleotides potently activate human NK cells and sensitize chronic lymphocytic leukemia cells to NK cell-mediated killing. (Abstract #10553)**
V. Bachanova, X. Liang, A. S. Chan, A. J. Peterson, L. Y. Chen, P. T. Robertson, A. Panoskaltis-Mortari, B. R. Blazar, J. S. Miller, W. Chen
- Brd. 42D Use of a combination of 5-fluorouracil pathway genes to predict treatment outcome of S-1 monotherapy in advanced gastric cancer. (Abstract #10554)**
G. Kim, H. Jeung, S. Y. Rha, J. K. Roh, S. Noh, H. C. Chung
- Brd. 42E Use of CD8 and Foxp3 immune infiltrates after neoadjuvant chemotherapy to predict survival in HER2-overexpressing breast cancer patients. (Abstract #10555)**
F. Ghiringhelli, B. P. Coudert, L. Arnould, P. Fumoleau, S. Ladoire
- Brd. 42F Efficient detection of EGFR alterations in lung adenocarcinomas. (Abstract #10556)**
M. G. Denis, S. Theoleyre, C. Chaplais, H. Gourdet, S. Caulet-Maugendre, H. Le Ho, R. Corre, H. Lena, C. Sagan, J. Bennouna
- Brd. 42G Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood as a predictor of response to gefitinib. (Abstract #10557)**
J. Wu, H. Bai, G. Zhu, J. Xu, W. Jiang, L. Lin, C. Xue, L. Zhang
- Brd. 42H Biomarkers of early operable primary breast cancer in elderly (≥ 70 years) women (EPC) and their correlation with breast cancer-specific survival (BCSS). (Abstract #10558)**
B. M. Syed, A. R. Green, E. C. Paish, D. A. Morgan, I. O. Ellis, K. Cheung
- Brd. 43A Clinical significance of ^{18}F -alpha-methyl tyrosine PET as a potential surrogate marker of LAT1 expression for predicting prognosis of non-small cell lung cancer. (Abstract #10559)**
N. Oriuchi, K. Kaira, K. Shimizu, H. Tominaga, H. Hanaoka, Y. Arisaka, T. Higuchi, T. Naoe, K. Endo
- Brd. 43B Correlation of expression of circadian genes with liver metastasis and outcomes in colorectal cancer. (Abstract #10560)**
T. Oshima, C. Kunisaki, T. Sato, S. Fujii, N. Yamamoto, M. Shiozawa, M. Akaike, Y. Rino, M. Masuda, T. Imada
- Brd. 43C Epigenetic silencing of Dab-2 in head and neck cancer. (Abstract #10561)**
C. Lo Nigro, L. Lattanzio, D. Vivenza, M. C. Merlano, T. Crook, G. Inman, M. Gasco
- Brd. 43D The single-nucleotide polymorphism A>G rs397768 in APC gene as a new biomarker of response to chemotherapy in advanced colorectal cancer. (Abstract #10562)**
J. Villa Guzman, R. Zarate, V. Boni, A. Gomez, J. De la Haba, E. Bandres, J. Garcia-Foncillas, E. Aranda

- Brd. 43E Biomarkers of treatment benefit in a randomized phase II study of bevacizumab in combination with carboplatin and paclitaxel in metastatic melanoma patients (BEAM). (Abstract #10563)**
P. Hegde, B. Xing, S. O'Day, K. B. Kim, M. Schmidt, S. J. Scherer, H. Nguyen, A. C. Peterson, P. Cheverton, D. S. Chen
- Brd. 43F Use of peripheral blood mRNA signatures to distinguish colorectal cancer patients from colonoscopy-negative patients. (Abstract #10564)**
Y. Xu, S. Ni, Q. Xu, F. Liu, F. Wu, X. Ye, X. Meng, B. Mougin, X. Du, S. Cai
- Brd. 43H Application of kinase activity profiles to predict response to erlotinib in a neoadjuvant setting in early stage non-small cell lung cancer (NSCLC). (Abstract #10566)**
R. Hilhorst, E. Schaaake, R. van Pel, P. Nederlof, L. Houkes, R. de Wijn, R. Ruijtenbeek, M. van den Heuvel, P. Baas, H. M. Klomp
- Brd. 44A Prognostic value of serum protein biomarkers in patients with epithelial ovarian cancer. (Abstract #10567)**
M. Wang, S. Bush, S. A. Ghamande, J. She
- Brd. 44B Relationship of expression level of CD133 with tumor angiogenesis and prognosis of hepatocellular carcinoma after liver transplantation. (Abstract #10568)**
Y. Xu, J. Fan
- Brd. 44C Lung cancer autoantibody signature as indicator of early disease. (Abstract #10569)**
T. V. Pedchenko, R. Mernaugh, D. Pareh, P. P. Massion
- Brd. 44D Evaluation of the prognostic value of UBE2C mRNA levels in early breast cancer. (Abstract #10570)**
D. Psyrrì, R. Kronenwett, E. Timotheadou, R. M. Wirtz, A. Onyenadum, G. E. Pentheroudakis, C. A. Papadimitriou, E. Razis, T. Economopoulos, G. Fountzilas
- Brd. 44E Use of T-cell proliferation to predict survival and recurrence in patients with resected colorectal liver metastases. (Abstract #10571)**
A. V. Maker, H. Ito, Q. Mo, L. Qin, R. P. DeMatteo, L. H. Blumgart, Y. Fong, S. K. Maithel, W. R. Jarnagin, M. I. D'Angelica
- Brd. 44F Biomarker profiles and changes from baseline in trastuzumab (T) refractory HER2-positive inflammatory breast cancer (IBC) that predict decreases in tumor burden from lapatinib (L) monotherapy. (Abstract #10572)**
S. R. Johnston, C. Swanton, S. H. Stein, Y. Liu, R. C. Gagnon, M. E. Trudeau, B. Kaufman, A. Martin, V. M. Salazar
- Brd. 44G Markers of anaerobic glycolysis as predictive factor in neoadjuvant chemoradiotherapy of rectal cancer. (Abstract #10573)**
D. Sun, B. Shim, J. Jung, K. Lee, H. Kim, S. Hong, S. Kim, H. Cho
- Brd. 44H SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC). (Abstract #10574)**
D. A. Yardley, B. R. Daniel, R. C. Inhorn, E. R. Vazquez, V. N. Trieu, K. Motamed, L. Hwang, H. S. Rugo, N. Desai
- Brd. 45A Gene expression differences in current versus former smokers lung squamous preneoplasia. (Abstract #10575)**
C. J. Mascoux, C. D. Coldren, B. Haibe-Kains, G. Anthoine, A. Haller, V. Ninane, A. Burny, J. P. Sculier, F. R. Hirsch
- Brd. 45B Molecular profiling of pulmonary pleomorphic carcinoma: Implications for targeted treatment of a rare lung malignancy. (Abstract #10576)**
Y. Kim, S. Lee, Y. Choi, J. Park, J. Lee, Y. Park, J. Ahn, K. Park, M. Ahn
- Brd. 45C Role of the type III TGF- β receptor in mediating immunosuppression during breast cancer progression. (Abstract #10577)**
B. A. Hanks, J. D. Lee, M. Morse, T. M. Clay, H. K. Lyerly, G. C. Blobe

Saturday, June 5, 2010

- Brd. 45D** Use of circulating and tumor-infiltrating myelomonocytic cells to predict survival in human malignant pleural mesothelioma (MPM). (Abstract #10578)
B. Burt, T. Tilleman, R. Bueno, D. Sugarbaker
- Brd. 45E** Impact of a gene expression-based tissue of origin test on diagnosis and recommendations for first-line chemotherapy. (Abstract #10579)
M. Laourí, J. S. Nystrom, M. Halks-Miller, W. D. Henner
- Brd. 45F** Circulating exosomes may provide a more sensitive platform to monitor disease progression compared to circulating tumor cells. (Abstract #10580)
T. L. Pawlowski, D. Spetzler, T. Tinder, J. Kimbrough, T. Deng, J. Kim, P. Ellis, A. Tyrell, P. Kennedy, C. Kuslich
- Brd. 45G** Use of peripheral blood mRNA signature to distinguish patients with breast cancer from benign breast disease and nonconclusive mammography. (Abstract #10581)
B. Yang, Q. Xu, F. Wu, F. Liu, X. Ye, X. Meng, B. Mougín, G. Liu, S. Zhimin, J. Wu
- Brd. 45H** Predictive value of the Theros Breast Cancer Index (TBCI) for distant recurrence and overall survival (OS) in comparison to Adjuvant! Online and clinicopathologic characteristics in women with lymph node (LN)-negative, ER-positive breast cancer (BCa). (Abstract #10582)
R. C. Jankowitz, M. Chivukula, X. Ma, M. G. Erlander, L. L. Mock, L. S. Mazur, H. Li, R. Salunga, S. Sereika, A. Brufsky
- Brd. 46A** MST1R, a receptor tyrosine kinase expressed in malignant pleural mesothelioma. (Abstract #10583)
D. Easty, S. G. Gray, A. Soltermann, D. Nonaka, D. A. Fennell, I. Opitz, H. I. Pass, L. Mutti, D. M. O'Donnell, K. J. O'Byrne
- Brd. 46B** Protein expression (PE) and increased IGF1R gene copy number (GCN) in small cell lung cancer (SCLC). (Abstract #10584)
A. Badzio, M. W. Wynes, R. Dziadziuszko, D. Merrick, M. Pardo, S. Singh, A. Kowalczyk, W. Rzyman, J. Jassem, F. R. Hirsch
- Brd. 46C** Evaluation of macrophage inflammatory protein-3 alpha (MIP-3a) as a serum marker for prognosis of colorectal cancer. (Abstract #10585)
T. Iwata, K. Tanaka, Y. Inoue, Y. Toiyama, J. Hiro, S. Saigusa, Y. Mohri, C. Miki, T. Tabata, M. Kusunoki
- Brd. 46D** Feasibility of a prospective host cell reactivation assay (HCRA) in non-small cell lung cancer (NSCLC) patients. (Abstract #10586)
P. Mendez, M. Taron, T. Moran, E. Carcereny, V. Quiroga, P. Grassi, M. A. Fernandez, P. Gomez, J. Sanchez, R. Rosell
- Brd. 46E** D-dimer levels and prediction of overall survival in cancer patients. (Abstract #10587)
C. Ay, D. Dunkler, R. Vormittag, P. Quehenberger, R. Pirker, O. Wagner, C. Zielinski, I. Pabinger
- Brd. 46F** The prognostic relevance of CXC-chemokines in stage II and III colorectal cancer (CRC) tissue and inflammatory infiltrate. (Abstract #10588)
O. Oladipo, S. Conlon, T. O'Grady, C. Purcell, C. Wilson, P. Maxwell, M. Stevenson, E. Kay, R. H. Wilson, D. J. Waugh
- Brd. 46G** Relations of circadian clocks genes with endocrine, proliferation, differentiation, and P53 mutation status in human locally invasive primary breast cancer. (Abstract #10589)
I. Iurisci, F. Valet, S. Giacchetti, S. Delalogue, E. Brain, J. Pierga, H. de Thé, B. Sigal-Zafrani, M. E. Marty, F. Levi
- Brd. 46H** Race and the influence of p53 as a marker of prognosis in women of lower SES with breast cancer. (Abstract #10590)
K. A. Dookeran, J. J. Dignam, K. Ferrer, M. Sekosan, E. K. Radeke, T. E. Lad, N. Holloway, W. J. McCaskill-Stevens, S. J. Gehlert

- Brd. 47A Primary resistances to EGFR inhibitors (EGFRi) in HPV-positive and -negative oropharyngeal squamous cell carcinoma (OSCC). (Abstract #10591)**
 F. Perrone, B. Cortelazzi, M. Orsenigo, G. Jocollè, E. Tarantino, S. Brich, P. Bossi, L. Locati, L. F. Licitra, S. Pilotti
- Brd. 47B Implication of the alternative NF-kappa B pathway in prostate cancer progression. (Abstract #10592)**
 I. Labouba, S. Mehairi, M. Latour, A. Mes-Masson, F. Saad
- Brd. 47C Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB). (Abstract #10593)**
 E. G. Lipsitz, V. Nguyen, H. Zhao, J. Ecsedy, J. M. Maris, P. C. Adamson, Y. P. Mosse
- Brd. 47D Use of protein pathway activation mapping of NSCLC to identify distinct molecular subtypes and a prognostic signature for aggressive node-negative tumors. (Abstract #10594)**
 A. Zupa, G. Improta, J. Deng, M. Aieta, P. Musto, L. A. Liotta, C. Belluco, E. Mammano, J. D. Wulfschlegel, E. Petricoin III
- Brd. 47E Nuclear expression of aryl hydrocarbon receptor and prognosis for non-small lung cancer. (Abstract #10595)**
 H. Chang
- Brd. 47F Preclinical in vivo evaluation of a novel treatment strategy combining a Wee1 inhibitor with radiotherapy. (Abstract #10596)**
 K. Mason, J. Pickett, C. Ware, H. Hirai, P. Strack, S. D. Shumway, K. Ang, T. A. Buchholz, L. Milas, C. A. Buser
- Brd. 47G Antagonists of growth hormone-releasing hormone potentiate radiation response in prostate cancer. (Abstract #10597)**
 M. Abdel-Wahab, A. Schally, F. Rick, L. Szalontay, J. Varga, Y. Shi, M. Zarandi, A. Pollack
- Brd. 47H Clinico-pathologic features of lung cancer with EML4-ALK translocation. (Abstract #10598)**
 T. Mitsudomi, K. Suda, K. Tomizawa, Y. Yatabe
- Brd. 48A Evaluation of ADAM28 as a serological and histochemical marker for non-small cell lung cancers. (Abstract #10599)**
 H. Kuroda, M. Shimoda, M. Kawamura, H. Nomori, Y. Okada
- Brd. 48B Effect of plasma SPARC on outcome in cancer models. (Abstract #10600)**
 N. Desai, M. Piacente, X. Liu, O. D'Cruz, L. Hwang, X. Lin, S. Ran, S. Markovic, K. Motamed, V. N. Trieu
- Brd. 48C Evaluation of the hedgehog pathway as a therapeutic target for preventing the progress to invasive-stage from noninvasive-stage breast cancer. (Abstract #10601)**
 M. Sozaki, M. Kubo, M. Kai, C. Kameda, H. Tanaka, H. Onishi, M. Nakamura, M. Tanaka, M. Katano
- Brd. 48D Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment. (Abstract #10602)**
 N. Normanno, M. Gallo, L. Lamura, A. De Luca
- Brd. 48E Clinical relevance of the detection of tumor cells in the bone marrow of patients before lung cancer surgery. (Abstract #10603)**
 R. Nakahara, M. Anraku, A. Ui, N. Oohata, H. Matsuguma, S. Igarashi, K. Yokoi
- Brd. 48F Molecular markers for epithelial-mesenchymal transition (EMT) and tumor aggressiveness in breast carcinoma. (Abstract #10604)**
 S. Sethi, F. H. Sarkar, Q. Ahmed, S. Bandyopadhyay, Z. A. Nahleh, W. Sakr, A. Munkarah, R. Ali-Fehmi

- Brd. 48G Risk partitioning model shows need to address time dependence of breast cancer recurrence. (Abstract #10605)**
L. Esserman, B. Chu, R. Chung, E. Ozanne, C. Yau, P. Tsing, F. L. Baehner, A. N. Tutt, D. H. Moore, C. Benz
- Brd. 48H Role and prognostic value of placenta growth factor (PIGF) in colorectal carcinomas. (Abstract #10606)**
M. Baek, S. Bae, S. Cho, D. Jeong, C. Kim
- Brd. 49A Evaluation of gene expression signatures induced by stromal factors as a predictor of survival in breast cancer. (Abstract #10607)**
I. Luehr, A. Klein, H. Pospisil, C. Standfuss, T. Kunze, F. Hilpert, C. Mundhenke, W. Jonat, M. Bauer
- Brd. 49B BRCA1 expression evaluated by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in operable breast cancer. (Abstract #10608)**
P. Potemski, E. Pluciennik, A. K. Bednarek, R. Kusinska, S. Debska, R. Kubiak, R. M. Kordek
- Brd. 49C Gene set comparison analyses of gene expression signatures for the acquired chemotherapy resistance. (Abstract #10609)**
H. K. Kim, I. J. Choi, C. G. Kim, J. E. Green
- Brd. 49D Activation of the PI3K pathway and prognostic information in epithelial ovarian cancer. (Abstract #10610)**
D. D. Handolias, P. Chan, W. Phillips, S. B. Fox, R. Pearson, S. Sawyer, I. Campbell, R. Salemi, G. A. McArthur, Australian Ovarian Cancer Study Group
- Brd. 49E Inhibitor of differentiation-1 (Id1): A novel prognostic and predictive factor in lung adenocarcinoma (AC). (Abstract #10611)**
I. Gil-Bazo, M. Ponz-Sarvisé, M. J. Pajares, M. D. Lozano, J. Agorreta, J. Garcia-Foncillas, C. Behrens, I. I. Wistuba, L. M. Montuenga, A. Calvo
- Brd. 49F Comparison of folate derivate levels in mucosa and tumor tissue in the course of antifolate treatment with pemetrexed. (Abstract #10612)**
B. Gustavsson, E. Odin, G. Kurlberg, T. Swartling, G. Carlsson, H. Björkqvist, P. Kålebo, M. Holmqvist, A. Thareau Vaury, C. Stoffregen
- Brd. 49G Involvement of angiogenesis genes in pathologic response of advanced ovarian carcinoma. (Abstract #10613)**
M. Mendiola, J. Barriuso, A. Redondo, I. Sánchez-Navarro, A. Mariño-Enriquez, R. Madero, P. Zamora, J. De-Santiago, E. Espinosa, D. Hardisson
- Brd. 49H Tumor characteristics and patient outcomes in ductal compared with lobular carcinoma. (Abstract #10614)**
S. Nour, M. Mokri, H. Afshin Alavi, S. Shariat Torbaghan, M. Atri, K. Visvanathan
- Brd. 50A Substratification of 70-gene high-risk breast cancers with a validated 80-gene molecular subtyping profile. (Abstract #10615)**
F. de Snoo, B. Chan, P. Roepman, R. A. Bender, A. Glas
- Brd. 50B Prognostic significance of immunoglobulin kappa C in node-negative breast cancer is both conserved across and independent from molecular subtypes. (Abstract #10616)**
M. Schmidt, I. Petry, D. Boehm, A. Lebrecht, H. Koelbl, M. Gehrmann, J. G. Hengstler
- Brd. 50C C-src: A potential target for the treatment of triple-negative breast cancer. (Abstract #10617)**
S. Walsh, D. Tryfonopoulos, C. Quinn, L. Flanagan, A. Pierce, E. McDermott, D. Evoy, N. O'Donovan, J. Crown, M. J. Duffy
- Brd. 50D Cancers involving the lung mediate human marrow cell phenotype change. (Abstract #10618)**
P. J. Quesenberry, J. Aliotta, M. Del Tatto, M. Dooner, G. A. Colvin
- Brd. 50E Metabotropic glutamate receptor-1: A new molecular target for the therapy of triple-negative breast cancer. (Abstract #10619)**
D. H. Gorski, C. L. Speyer, J. Smith, M. L. Banda, J. S. Goydos

- Brd. 50F** **Use of protein pathway mapping of brain metastasis from breast and lung cancer patients to identify new therapeutic targets: A seed/soil study. (Abstract #10620)**
G. Improta, A. Zupa, J. Deng, H. Fillmore, M. Aieta, P. Musto, W. Broaddus, L. A. Liotta, J. D. Wulfkuhle, E. Petricoin III
- Brd. 50G** **Triple-negative breast cancers: Biomarkers and outcomes. (Abstract #10621)**
L. Malorni, P. B. Shetty, S. G. Hilsenbeck, M. F. Rimawi, R. M. Elledge, C. De Angelis, C. K. Osborne, S. De Placido, G. Arpino
- Brd. 50H** **Effect of matrix metalloproteinase-2 on the ability of human dendritic cells to prime inflammatory T_H2 cells via an IL-12 and OX40L dependent pathway. (Abstract #10622)**
E. Godefroy
- Brd. 51A** **Plasma levels of VEGF-A and VEGFR-2 in advanced NSCLC. (Abstract #10623)**
E. Sanmartin, E. Jantus, A. Blasco, R. Sirera, C. Caballero, S. Gallach, R. M. Bremnes, N. del Pozo, A. Berrocal, C. Camps
- Brd. 51B** **Use of quantum dots-based immunofluorescence nanotechnology for quantitative HER2 and ER detection in breast cancer tissue array to identify correlations in HER2-overexpressed and ER-positive breast cancer. (Abstract #10624)**
C. Chen, Y. Li, J. Peng, H. S. Xia, Y. P. Gong, D. W. Pang
- Brd. 51C** **Effect of calcyclin-binding protein on proliferation and tumorigenicity of pancreatic cancer. (Abstract #10625)**
X. Chen
- Brd. 51D** **Toll-like receptor (TLR) 7 and TLR8 expression in CD133+ cells in colorectal cancer and role for inflammation-induced TLRs in tumorigenesis and tumor progression. (Abstract #10626)**
M. Gasser, M. Grimm, M. Kim, A. Rosenwald, C. T. Germer, A. Waaga-Gasser
- Brd. 51E** **Detection of aberrant *SHP-1* promoter methylation, an implication in advanced non-small cell lung cancer. (Abstract #10627)**
C. Vinayanuwattikun, V. Sriuranpong, A. Mutirangura
- Brd. 51F** **Neuropilin-2 and epithelial to mesenchymal transition in colorectal cancer cells. (Abstract #10628)**
C. Grandclement, R. Bedel, B. Kantelip, A. Bouard, V. Mougey, M. Klagsbrun, C. Ferrand, P. Tiberghien, X. B. Pivot, C. Borg
- Brd. 51G** **EMMPRIN up-regulates VEGFR-2 through HIF-2alpha mediated mechanism: Consequences on angiogenesis and tumor progression. (Abstract #10629)**
F. Bougatef, S. Menashi, C. Quemener, B. Naimi, M. Podgorniak, C. Dosquet, F. M. Calvo, C. Lebbé, S. Mourah
- Brd. 51H** **Evaluation of the combined expression of chemokine SDF-1 α and its receptor CXCR4 as a marker for prognosis in gastric cancer. (Abstract #10630)**
H. Lee, Y. Oh, H. Kim, S. Jin, H. Yun, D. Jo, S. F. Kim
- Brd. 52A** **Evaluation of CYP24A1 mRNA expression as a prognostic marker and predictor of calcitriol activity in lung adenocarcinoma. (Abstract #10631)**
N. Ramnath, A. N. King, G. Chen, L. Zhao, R. U. Simpson, D. E. Brenner, P. J. Christensen, D. G. Beer
- Brd. 52B** **Integrated genomics-based discovery of new oncoproteins as a biomarker and a molecular target for lung cancer. (Abstract #10632)**
Y. Daigo, A. Takano, Y. Nakamura
- Brd. 52C** **Interim analysis of CALGB 150607: A pilot project to study the expression of MET and P53 in resected lung adenocarcinoma specimens. (Abstract #10633)**
A. K. Salama, H. Pang, R. A. Kratzke, W. G. Richards, E. E. Vokes, R. Salgia

- Brd. 52D DNA repair biomarker alterations in breast cancer relevant to adjuvant chemotherapy treatment decisions. (Abstract #10634)**
K. M. Sprott, X. Wang, W. Pierceall, J. Kutok, T. Heikkinen, P. Heikkila, J. Bartek, D. T. Weaver, C. Blomqvist, H. Nevanlinna
- Brd. 52E MicroRNAs as a potential prognostic factor in gastric cancer. (Abstract #10635)**
O. Purim, M. Hoshen, G. Marshak, Y. Kundel, S. Morgenstern, M. Halpern, R. Aharonov, Y. Niv, M. Kushnir, B. Brenner
- Brd. 52F Use of immunohistochemical profiling of node-negative breast carcinomas for prediction of metastatic risk. (Abstract #10636)**
C. Charpin, S. Giusiano, V. Secq, X. Carcopino, L. Andrac, M. Lavaut, C. Allasia, P. Bonnier, S. Garcia, J. Iovanna
- Brd. 52G Direct visualization of circulating sarcoma cells by whole-blood fluorescence in situ hybridization. (Abstract #10637)**
A. Morozov, M. Leversha, M. Keohan, D. R. D'Adamo, G. K. Schwartz, P. A. Meyers, R. G. Maki, M. A. Moore
- Brd. 52H Circulating tumor cells: Multimarker gene profile for tailoring chemotherapeutical response in adeno carcinomas. (Abstract #10638)**
N. Fersis, I. Kubisch, D. Ernst, A. de Albuquerque, S. Kaul, G. Stamminger, U. Stoelzel, A. Teubner
- Brd. 53A MMP-7 serum levels as predictor or prognostic of cetuximab benefit in the treatment of advanced colorectal cancer: Results from a HCB-05 prospective trial. (Abstract #10639)**
G. Carrera, X. Garcia-Albeniz, V. Alonso-Espinaco, C. Pericay, V. Alonso, M. P. Escudero, C. Fernandez-Martos, R. Gallego, S. Castellvi-Bel, J. Maurel
- Brd. 53B HIF-1 α and EGFR as prognostic factors for therapy response and 1-year locoregional recurrence not for distant metastasis and 2-year OS in unresectable stage IIIA NSCLC treated with combined chemoradiotherapy. (Abstract #10640)**
Y. Yang, J. Yu, L. Xing, X. Sun, M. Hu, D. Mu, A. Han
- Brd. 53F Correlations of mRNA expression levels of genes in the targeted pathways and Kras mutation status in patients with colorectal cancer. (Abstract #10641)**
D. Yang, W. Zhang, T. Winder, P. O. Bohanes, Y. Ning, K. D. Danenberg, A. B. El-Khoueiry, P. M. Wilson, M. J. Labonte, H. Lenz
- Brd. 53G Prediction of survival in early-stage non-small cell lung cancer based on kinase activity profiles. (Abstract #10642)**
R. Ruijtenbeek, V. Thijssen, R. van Suylen, L. Houkes, R. de Wijn, R. Hilhorst, A. C. Dingemans
- Brd. 53H Analysis of the prognostic role of regulatory T-lymphocyte-associated marker expression in resectable NSCLC. (Abstract #10643)**
M. Usó, R. Sirera, A. Blasco, E. Jantus, E. Palomares, C. Caballero, R. M. Bremnes, J. Galbis, R. Guijarro, C. Camps
- Brd. 54A Role of antiapoptotic STAT3 and BCL-2 signaling in promoting lung tumor cells to survive against combined MET-/EGFR-targeted inhibitors. (Abstract #10644)**
P. C. Ma, W. Fan, Z. Tang, S. Hafez-Khayyata, C. A. Flask, H. B. Koon, Case Western Reserve University
- Brd. 54B Pregnancy-associated breast cancer: Characterization and potential chemoprevention with anti-inflammatory treatment. (Abstract #10645)**
V. F. Borges, T. Lyons, J. O'Brien, S. Jindal, P. J. Schedin
- Brd. 54F Correlation of PITX2 gene expression and invasive potential of breast cancer cells. (Abstract #10646)**
R. Aft, S. Pillai, N. Dasgupta, T. Fleming, M. Watson
- Brd. 54G Correlation of the Oncotype DX recurrence score with a composite index comprised of ER, PR, HER2, and breast tumor grade. (Abstract #10647)**
J. Geradts, S. M. Bean, R. C. Bentley, W. Barry

8:00 AM - 1:00 PM POSTER DISCUSSION SESSION

Breast Cancer—Metastatic

Display Time: 8:00 AM - 12:00 PM

Display Location: E450b

Discussion Time: 12:00 PM - 1:00 PM

Discussion Location: E Hall D1

CME credit: 1

Track(s): Breast Cancer

Anne F. Schott, MD—Co-Chair

University of Michigan

Hope S. Rugo, MD—Co-Chair

University of California, San Francisco

Discussion

12:00 PM David A. Cameron, MD (Abstracts #1012–1016)
Edinburgh University

Discussion

12:15 PM Lisa A. Carey, MD (Abstracts #1017–1021, 1031)
University of North Carolina at Chapel Hill

Discussion

12:30 PM Catherine H. Van Poznak, MD (Abstracts #1022–1026)
University of Michigan

Discussion

12:45 PM Nancy U. Lin, MD (Abstracts #1027–1030)
Dana-Farber Cancer Institute

- Brd. 1** **A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). (Abstract #1012)**
K. Miller, L. Gianni, F. Andre, V. Dieras, R. L. Mahtani, N. Harbeck, J. E. Huang, T. Shih, Y. Choi, H. A. Burris III
- Brd. 2** **Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial. (Abstract #1013^)**
F. Dalenc, M. Campone, P. Hupperets, R. O'Regan, C. Manlius, L. Vittori, P. Mukhopadhyay, C. Massacesi, T. Sahnoud, F. Andre
- Brd. 3** **Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer. (Abstract #1014)**
P. H. Morrow, G. M. Wulf, D. J. Booser, J. A. Moore, P. R. Flores, I. E. Krop, E. P. Winer, G. N. Hortobagyi, D. Yu, F. J. Esteva
- Brd. 4** **Correlation of cyclin D1, A870G, polymorphism, and clinical outcome in patients with HER2-positive, metastatic breast cancer treated with lapatinib plus capecitabine. (Abstract #1015)**
M. J. Labonte, D. Yang, W. Zhang, P. M. Wilson, R. D. Ladner, T. Winder, P. O. Bohanes, Y. Ning, H. Lenz
- Brd. 5** **Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy. (Abstract #1016)**
P. LoRusso, I. E. Krop, H. A. Burris III, S. J. Vukelja, K. Miller, M. Zheng, Y. Chu, M. Lu, L. C. Amler, H. S. Rugo

- Brd. 7** Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial. (Abstract #1018)
R. A. Dent, G. J. Lindeman, M. Clemons, H. Wildiers, A. Chan, N. J. McCarthy, C. F. Singer, E. S. Lowe, K. Kemsley, J. Carmichael
- Brd. 8** A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. (Abstract #1019)
S. J. Isakoff, B. Overmoyer, N. M. Tung, R. S. Gelman, V. L. Giranda, K. M. Bernhardt, K. R. Habin, L. W. Ellisen, E. P. Winer, P. E. Goss
- Brd. 9** Activity of taxane chemotherapy for metastatic breast cancer (MBC) in BRCA1 and BRCA2 mutation carriers compared to sporadic BC patients. (Abstract #1020)
C. Seynaeve, A. Jager, M. Hoening, C. H. Van Deurzen, M. Bontenbal, J. Blom, M. Collee, A. Ouweland van den, M. Kriege
- Brd. 10** Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). (Abstract #1021)
A. Brufsky, R. R. Rivera, S. A. Hurvitz, I. N. Bondarenko, V. Smirnov, V. Valero, H. S. Rugo, R. Swamy, H. Mu, E. A. Perez
- Brd. 11** A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study. (Abstract #1022)
E. Jäger, S. Al-Batran, S. Saupe, M. Schmidt, R. Kreienberg, L. Müller, B. J. Otremba, M. Warm, D. Waldenmaier, N. Harbeck
- Brd. 12** Impact of first-line chemotherapy duration in metastatic breast cancer: A systematic review. (Abstract #1023)
A. Gennari, M. Sormani, O. Nanni, M. Stockler, N. Wilcken, M. Puntoni, D. Amadori, A. De Censi, P. Bruzzi
- Brd. 13** Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial. (Abstract #1024)
A. Stopeck, L. Fallowfield, D. Patrick, C. S. Cleeland, R. H. De Boer, G. G. Steger, Y. Qian, Q. Jiang, R. D. Dansey, K. Chung
- Brd. 14** Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: Results from a randomized phase III trial. (Abstract #1025)
L. Fallowfield, D. Patrick, J. Body, A. Lipton, K. S. Tonkin, Y. Qian, Q. Jiang, R. D. Dansey, K. Chung
- Brd. 15** Ibandronate in the treatment of patients (pts) with breast cancer (BC) with metastatic bone disease (MBD): Final results of a large-scale noninterventional study (NIS). (Abstract #1026)
I. J. Diehl, T. Hesse, C. A. Lerchenmuller, M. Schmidt
- Brd. 16** The prognostic contribution of intrinsic breast cancer subtype, race, and age among patients with brain metastases. (Abstract #1027)
C. K. Anders, A. M. Deal, C. Khorram, H. Meng, E. Burrows, C. Livasy, K. Fritchie, M. G. Ewend, C. M. Perou, L. A. Carey
- Brd. 17** A graded prognostic assessment (GPA) for women with breast cancer and brain metastases. (Abstract #1028)
P. W. Sperduto, Z. Xu, P. Sneed, X. Luo, D. Roberge, A. K. Bhatt, A. W. Jensen, H. A. Shih, J. Kirkpatrick, L. E. Gaspar, Graded Prognostic Assessment (GPA) Work Group
- Brd. 18** Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. (Abstract #1029)
A. Niwinska, M. Murawska, K. Pogoda

- Brd. 19** **Correlation between quantitative HER2 protein level and the risk of brain metastasis (BM) in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy. (Abstract #1030)**
R. Duchnowska, B. Szostakiewicz, T. Jankowski, B. Arlukowicz-Czartoryska, P. J. Wysocki, W. Huang, M. P. Bates, J. Weidler, M. Haddad, J. Jassem
- Brd. 20** **Male breast cancer in Veterans Affairs population: Retrospective analysis of VACCR database. (Abstract #1031)**
S. Subbiah, T. Tashi, W. Gonsalves, M. Kalaiah, N. Didwaniya, R. Thota, S. Kanuri, P. Townley, I. Aldoss, P. T. Silberstein

Saturday, June 5, 2010

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Central Nervous System Tumors

Display Time: 8:00 AM - 12:00 PM

Display Location: S103

Discussion Time: 12:00 PM - 1:00 PM

Discussion Location: S100b

CME credit: 1

Track(s): Central Nervous System Tumors

David Peereboom, MD—Co-Chair

Cleveland Clinic

Deric M. Park, MD—Co-Chair

University of Pittsburgh Cancer Institute

Discussion

12:00 PM John L. Villano, MD, PhD (Abstracts #2009–2012)
The University of Chicago

Discussion

12:15 PM Martin Kelly Nicholas, MD, PhD (Abstracts #2013–2017)
The University of Chicago

Discussion

12:25 PM Michael Prados, MD (Abstracts #2018–2023)
University of California, San Francisco

Discussion

12:40 PM Kurt A. Jaeckle, MD (Abstracts #2024–2029)
Mayo Clinic Florida

Discussion

12:50 PM Eric L. Chang, MD (Abstracts #2030–2032)
University of Texas M. D. Anderson Cancer Center

Brd. 1 **ANG1005: Results of a phase I study in patients with recurrent malignant glioma. (Abstract #2009)**

J. Drappatz, A. J. Brenner, S. Rosenfeld, M. D. Groves, T. Mikkelsen, D. Schiff, J. Sarantopoulos, E. Wong, P. Y. Wen, J. Castaigne

Brd. 2 **Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study. (Abstract #2010)**

K. Fink, T. Mikkelsen, L. B. Nabors, P. Ravin, S. R. Plotkin, D. Schiff, C. Hicking, M. Picard, D. A. Reardon

Brd. 3 **Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM). (Abstract #2011)**

D. Schiff, D. A. Reardon, S. Kesari, T. Mikkelsen, J. F. De Groot, L. Fichtel, T. E. Coyle, E. Wong, C. Eaton, B. Silver

Brd. 4 **Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma. (Abstract #2012)**

J. O. Blakeley, X. Ye, S. A. Grossman, T. Mikkelsen, M. R. Rosenfeld, C. R. Bradley, A. F. Eichler, L. B. Nabors, S. Desideri, J. G. Supko, The Adult Brain Tumor Consortium

Brd. 5 **Iatrogenic immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide: A NABTT CNS Consortium study. (Abstract #2013)**

S. A. Grossman, X. Ye, G. J. Lesser, A. E. Sloan, C. Carson, S. Piantadosi

Brd. 6 **Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM). (Abstract #2014)**

R. Lai, L. D. Recht, D. A. Reardon, N. Paleologos, M. D. Groves, M. R. Rosenfeld, S. Meech, T. A. Davis, D. Pavlov, J. H. Sampson

- Brd. 7** **The efficacy of interferon- β and temozolomide combination therapy for newly diagnosed primary glioblastoma: Multicenter study. (Abstract #2015)**
K. Motomura, A. Natsume, M. Fujii, M. Ito, H. Namba, T. Abe, Y. Nakasu, R. Watanabe, K. Wakai, T. Wakabayashi
- Brd. 8** **Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D. (Abstract #2016)**
J. N. Sarkaria, E. Galanis, M. P. Gustafson, A. B. Dietz, W. Wu, P. D. Brown, J. H. Uhm, C. Giannini, K. A. Jaeckle, J. C. Buckner
- Brd. 9** **Testosterone levels in men undergoing treatment for malignant gliomas. (Abstract #2017)**
M. Holdhoff, X. Ye, L. Blair, S. A. Grossman, J. O. Blakeley
- Brd. 10** **NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. (Abstract #2018)**
E. Galanis, K. A. Jaeckle, S. Anderson, T. J. Kaufmann, J. H. Uhm, C. Giannini, S. Kumar, D. W. Northfelt, P. J. Flynn, J. C. Buckner
- Brd. 11** **Heterogeneity of response to bevacizumab in multifocal and multicentric glioblastomas. (Abstract #2019)**
S. S. Ong, V. K. Puduvalli
- Brd. 12** **Change in pattern of relapse in newly diagnosed high-grade glioma following bevacizumab therapy. (Abstract #2020)**
M. L. Gruber, S. Kunnakkat, P. Medabalmi, D. B. Gruber, J. Golfinos, E. Parker, A. Narayana
- Brd. 13** **Radiographic patterns of relapse in glioblastoma. (Abstract #2021)**
M. C. Chamberlain
- Brd. 14** **Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenic drugs? (Abstract #2022)**
E. Franceschi, A. A. Brandes, A. Tosoni, A. Bacci, L. Morandi, F. Spagnoli, R. Degli Esposti, S. Bartolini, R. Poggi, M. Ermani
- Brd. 15** **Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). (Abstract #2023)**
J. J. Vredenburgh, A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick, J. E. Herndon, J. Marcello, L. Bailey, S. Threatt, H. S. Friedman
- Brd. 16** **Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab. (Abstract #2024)**
J. Wu, M. R. Gilbert, J. F. De Groot, W. A. Yung, V. K. Puduvalli
- Brd. 17** **Deletion of NFKBIA in malignant gliomas. (Abstract #2025)**
M. Bredel, A. Yadav, J. Renfrow, D. Scholtens, C. Bredel, J. Chandler, A. Scheck, K. D. Aldape, A. Chakravarti, G. Harsh
- Brd. 18** **Use of perfusion MR imaging for differentiation between tumor progression and pseudo-progression in recurrent glioblastoma multiforme. (Abstract #2026)**
C. Heidemans-Hazelaar, A. Y. Verbeek, H. M. Oosterkamp Sr., B. Van der Kallen, C. J. Vecht
- Brd. 19** **Prognostic impact of stem cell marker CD133 in 61 glioblastoma patients treated with concomitant chemoradiation: A prospective study. (Abstract #2027)**
P. Metellus, I. Nanni-Metellus, C. Delfino, C. Colin, B. Coulbaly, F. Fina, O. L. Chinot, D. Figarella-Branger, L. Ouafik
- Brd. 20** **CD133 expression in glioblastoma recurring after radiation therapy. (Abstract #2028)**
T. Cenci, R. Pallini, M. Martini, L. R. Vitiani, N. Montano, F. Pierconti, R. De Maria, L. Larocca

- Brd. 21** **Prognostic value and analytical performance (reproducibility) of Ki67 index in anaplastic oligodendroglial tumors: A translational study of the EORTC Brain Tumor Group. (Abstract #2029)**
M. Preusser, R. Hoeflberger, A. Woehrer, M. Kouwenhoven, M. Kros, A. Idbaih, A. A. Brandes, H. Heinzl, T. Gorlia, M. J. Van Den Bent
- Brd. 22** **Stereotactic radiosurgery: A new paradigm for melanoma and renal cell carcinoma spine metastases. (Abstract #2030)**
A. Thiagaragan, Y. Yamada, D. M. Lovelock, B. W. Cox, M. J. Zelefsky, M. Bilsky
- Brd. 23** **Chemotherapy (CT) alone for epidural spinal cord compression (ESCC) from germ cell tumors (GCT). (Abstract #2031)**
C. Grommes, G. J. Bosl, L. M. DeAngelis
- Brd. 24** **Immunomagnetic platform technology (IMPT) for the diagnosis of leptomeningeal metastasis in solid tumors (LMST). (Abstract #2032)**
L. Nayak, M. Fleisher, R. Gonzalez-Espinoza, A. S. Reiner, K. Panageas, O. Lin, C. Liu, L. M. DeAngelis, A. M. Omuro

8:00 AM - 1:00 PM POSTER DISCUSSION SESSION

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy

Display Time: 8:00 AM - 12:00 PM

Display Location: E450a

Discussion Time: 12:00 PM - 1:00 PM

Discussion Location: E354b

CME credit: 1

Track(s): Developmental Therapeutics

Razelle Kurzrock, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

Lesley Seymour, MD, PhD—Co-Chair

Queen's University

Discussion

12:00 PM David J. Stewart, MD (Abstracts #2515–2520)
University of Texas M. D. Anderson Cancer Center

Discussion

12:15 PM Ravi Salgia, MD, PhD (Abstracts #2521–2525)
The University of Chicago

Discussion

12:30 PM Lesley Seymour, MD, PhD (Abstracts #2526–2531)
Queen's University

Discussion

12:45 PM Razelle Kurzrock, MD (Abstracts #2532–2538)
University of Texas M. D. Anderson Cancer Center

- Brd. 1** **Phase I trials of novel molecularly targeted therapies: Should we pay more attention to toxicities occurring after cycle 1? (Abstract #2515)**
S. Postel-Vinay, C. A. Gomez-Roca, L. R. Molife, B. Anghan, J. Soria, S. B. Kaye, X. Paoletti
- Brd. 2** **Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience. (Abstract #2516)**
D. Papadatos-Pastos, M. Blanco-Codesido, C. P. Carden, R. S. Fehrmann, L. Trani, L. R. Molife, A. Brunetto, S. K. Sandhu, C. Massard, U. Banerji
- Brd. 3** **An international pooled analysis identifying predictive factors associated with toxicities in phase I trials (Delphi). (Abstract #2517)**
C. A. Gomez-Roca, C. Baey, D. Olmos, A. Berens, E. Bigger, P. LoRusso, M. L. Rothenberg, S. B. Kaye, J. Pignon, J. Soria
- Brd. 4** **Multi-institutional prognostic factor analysis of patients (pts) enrolled in phase I (Ph I) oncology trials: Can pts selection be improved? (Abstract #2518)**
D. Olmos, on behalf of the European Drug Development Network (EDDN)
- Brd. 5** **Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience. (Abstract #2519)**
S. M. Alam, R. S. Fehrmann, D. Olmos, K. Shah, M. Puglisi, D. Sarker, A. Brunetto, S. Postel-Vinay, R. D. Baird, L. R. Molife
- Brd. 6** **VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints. (Abstract #2520)**
M. Sharma, T. Karrison, M. L. Maitland, W. M. Stadler, M. J. Ratain
- Brd. 7** **The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population). (Abstract #2521)**
M. Jäger, A. Schoberth, M. Hennig, A. Burges, M. Heiss, P. Wimberger, B. Schmalfeldt, H. Lindhofer

- Brd. 8** Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti-EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC). (Abstract #2522)
B. Markman, C. Gomez-Roca, A. Cervantes-Ruiperez, J. Delord, L. Paz Ares, J. Soria, J. Corral, S. Hollingsworth, L. Manenti, J. Taberero
- Brd. 9** Radioimmunotherapy (RIT) with ¹³¹I-L19SIP in solid cancers (SC) and lymphoproliferative diseases: Final results of the first human trial. (Abstract #2523)
G. Del Conte, P. A. Erba, A. Fasolo, C. Chiesa, C. Grana, H. Menssen, D. Neri, G. Mariani, E. Bombardieri, L. Gianni
- Brd. 10** First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. (Abstract #2524)
L. S. Rosen, D. S. Mendelson, R. B. Cohen, M. S. Gordon, J. W. Goldman, I. K. Bear, B. Byrnes, R. Perea, S. L. Schoenfeld, A. Gollerkeri
- Brd. 11** Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. (Abstract #2525)
A. Patnaik, G. J. Weiss, K. Papadopoulos, R. Tibes, A. W. Tolcher, F. C. Payumo, M. M. Cotreau, J. Jac, R. Isaacs, R. K. Ramanathan
- Brd. 12** Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies. (Abstract #2526)
M. J. Pishvaian, I. Cotarla, A. J. Wagner, J. F. Deeken, A. R. He, J. J. Hwang, G. D. Demetri, A. Halim, C. Copigneaux, J. Marshall
- Brd. 13** Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium trial. (Abstract #2527)
T. W. Synold, D. D. Tsao-Wei, D. I. Quinn, S. G. Groshen, A. Aparicio, P. Twardowski, W. M. Stadler, D. R. Gandara, P. Lara Jr., E. M. Newman, California Cancer Consortium with Pittsburgh
- Brd. 14** AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies. (Abstract #2528)
T. A. Samuel, C. Sessa, C. Britten, K. S. Milligan, M. M. Mita, U. Banerji, T. J. Pluard, P. Stiegler, C. Quadt, G. Shapiro
- Brd. 15** A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. (Abstract #2529)
J. W. Goldman, R. N. Raju, G. A. Gordon, V. M. Vukovic, R. Bradley, L. S. Rosen
- Brd. 16** Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. (Abstract #2530)
C. P. Carden, E. S. Kim, R. L. Jones, S. M. Alam, F. M. Johnson, A. W. Stephens, S. Poondru, R. Gedrich, S. M. Lippman, S. B. Kaye
- Brd. 17** Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. (Abstract #2531)
T. Evans, C. R. Lindsay, E. Chan, B. Tait, S. A. Michael, S. Day, A. W. Stephens, A. Franke, S. Poondru, I. Puzanov
- Brd. 18** Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy. (Abstract #2532)
J. L. Rubenstein, C. Kadoch, V. S. Wong, W. Hyun, C. Lowell
- Brd. 19** A phase I study of celecoxib (C) and patupilone (EPO906) in patients (pts) with metastatic colorectal cancer (mCRC). (Abstract #2533)
S. Iqbal, A. B. El-Khoueiry, D. Yang, S. Cole, W. Boswell, J. Shriki, Y. Ning, R. D. Agafitei, X. Menendez, H. Lenz

- Brd. 20** **A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P). (Abstract #2534^)**
M. M. Abu-Khalaf, S. N. Gettinger, V. N. Trieu, H. A. Deshpande, M. DiGiovanna, M. Azodi, N. Desai, W. K. Kelly, P. E. Schwartz, L. Harris
- Brd. 21** **A phase I study of gemcitabine, capecitabine, and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies. (Abstract #2535)**
S. Nallapareddy, S. G. Eckhardt, C. L. O'Bryant, S. Eppers, S. Diab, M. A. Kane, C. D. Weekes, J. L. Spratlin, W. A. Messersmith, S. Leong
- Brd. 22** **A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors. (Abstract #2536)**
C. A. Townsley, L. L. Siu, M. San Pedro-Salcedo, L. Liu, H. A. Wakelee
- Brd. 23** **Targeted cancer therapies: FDA approval overview. (Abstract #2537)**
P. Cortazar, P. Keegan, R. L. Justice, J. R. Johnson, R. Pazdur
- Brd. 24** **Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors. (Abstract #2538)**
J. S. Kauh, R. D. Harvey, D. H. Lawson, T. K. Owonikoko, M. Tighiouart, S. S. Ramalingam, D. M. Shin, C. M. Lewis, B. F. El-Rayes, F. R. Khuri

Saturday, June 5, 2010

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Health Services Research

Display Time: 8:00 AM - 12:00 PM
Display Location: S403
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: S504
CME credit: 1
Track(s): Health Services Research

Elissa Ozanne, PhD—Co-Chair
Massachusetts General Hospital

Benjamin D. Smith, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center

Discussion

12:00 PM Elena B. Elkin, PhD (Abstracts #6009–6015)
Memorial Sloan-Kettering Cancer Center
Role of Cost and Comparative Effectiveness Research in Guiding Health Policy

Discussion

12:15 PM Jennifer Malin, MD (Abstracts #6016–6020)
Veterans Affairs Greater Los Angeles
Oncology Guidelines: Adherence and Appraisal

Discussion

12:30 PM Stephen B. Edge, MD (Abstracts #6021–6027)
Roswell Park Cancer Institute
Patterns of Cancer Care

Discussion

12:45 PM Benjamin Djulbegovic, MD, PhD (Abstracts #6028–6033)
University of South Florida
Clinical Trials and Decision Making

Brd. 1 **Burden of illness estimates of metastatic breast cancer (MBC) in the United States. (Abstract #6009)**

S. Sorenson, A. Benedict, D. A. Yardley, M. Martin, K. B. Knopf, F. Pan, J. Goh, C. Giorgetti, C. Chen

Brd. 2 **Adjuvant endocrine monotherapy with tamoxifen or aromatase inhibitors for postmenopausal women with breast cancer: What is the economic impact of CYP 2D6 testing? (Abstract #6010)**

T. Younis, D. Rayson, C. Skedgel

Brd. 3 **Comparative effectiveness of screening, surgery, and chemoprevention among BRCA1/2 mutation carriers. (Abstract #6011)**

V. R. Grann, P. R. Patel, J. S. Jacobson, E. Warner, D. F. Heitjan, M. Ashby-Thompson, D. L. Hershman, A. I. Neugut

Brd. 4 **Therapeutic options for low-risk prostate cancer: A cost-effectiveness analysis. (Abstract #6012)**

J. H. Hayes, D. A. Ollendorf, M. J. Barry, S. D. Pearson, P. M. McMahon

Brd. 5 **Year one evaluation of regional pay for quality (P4Q) oncology program. (Abstract #6013)**

J. A. Scott, W. Wong, T. Olson, B. V. Fortner

Brd. 6 **Conflicts of interest in economic analyses presented at the American Society of Clinical Oncology Annual Meeting. (Abstract #6014)**

S. Jang, Y. Chae, N. S. Majhail

Brd. 7 **Does increasing insurance improve outcomes for U.S. cancer patients? (Abstract #6015)**

J. K. Smith, J. E. Carroll, S. Ng, S. A. Shah, T. P. McDade, J. F. Tseng

SATURDAY

- Brd. 8** **Surgeon influence on patient appraisal of ASCO breast cancer quality indicators. (Abstract #6016)**
S. T. Hawley, A. S. Hamilton, J. Graff, S. J. Katz
- Brd. 9** **The impact of audit and feedback on nodal harvest in colorectal cancer (CRC). (Abstract #6017)**
G. A. Porter, R. Urquhart, J. Bu, P. Johnson, E. Grunfeld
- Brd. 10** **Quality of care in non-small cell lung cancer (NSCLC): Findings from the Florida Initiative for Quality Cancer Care (FIQCC). (Abstract #6018)**
T. Tanvetyanon, M. Corman, W. J. Fulp, J. Lee, P. B. Jacobsen, FIQCC Consortium Members
- Brd. 11** **Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma: Evaluating community guideline adherence. (Abstract #6019)**
N. N. Massarweh, J. O. Park, R. S. Yeung, J. Bruix, R. B. Etzioni, R. G. Symons, L. Baldwin, D. R. Flum
- Brd. 12** **Scientific evidence underlying National Comprehensive Cancer Network Clinical Practice Guidelines. (Abstract #6020)**
T. K. Poonacha, R. S. Go
- Brd. 13** **End-of-life care for elderly patients with advanced lung cancer in the United States and Ontario. (Abstract #6021)**
K. Yabroff, J. Warren, L. C. Barbera, K. Bremner, J. Hoch, M. Barrett, J. Luo, M. Krahn
- Brd. 14** **Impact of care at NCI-designated Comprehensive Cancer Centers (NCICCCs) on racial differences in prostate cancer-specific survival. (Abstract #6022)**
C. Sun, S. Kurian, G. T. Washington, K. Nielsen-Menicucci, L. E. Crocitto, T. G. Wilson, L. Laddaran, W. Landier, S. Smith, S. Bhatia
- Brd. 15** **Trends in prostatectomy: Centralization, robotics, and access to care. (Abstract #6023)**
K. B. Stitzenberg, Y. Wong, M. E. Nielsen, R. Uzzo
- Brd. 16** **PSA surveillance in men with localized prostate cancer. (Abstract #6024)**
D. N. Yeboa, K. Liao, T. Guzzo, N. B. Haas, J. P. Christodouleas, N. Vapiwala, R. Sunderland, N. Mitra, K. Armstrong, J. E. Bekelman
- Brd. 17** **Restoration of medical oncology services at Charity Hospital in New Orleans after Hurricane Katrina: A 2-year experience of the Louisiana State University Health Sciences Center (LSUHSC). (Abstract #6025)**
B. C. Boulmay, R. E. Harmon, T. L. Lin, J. T. Cole
- Brd. 18** **Appropriateness of cardiovascular (CV) care in cancer survivors (CS). (Abstract #6026)**
W. Y. Cheung, M. L. McBride, R. Levin, S. Setoguchi
- Brd. 19** **Estimation of the U.S. rate of neutropenic complications for cancer hospital discharges. (Abstract #6027)**
M. Dickson, C. M. Kozma, R. Barron, V. M. Chia, J. C. Legg, J. Malin
- Brd. 20** **Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs). (Abstract #6028)**
B. Seruga, L. Sterling, L. Wang, I. Tannock
- Brd. 21** **A compendium of unpublished phase III clinical trials in oncology: Characteristics and impact on clinical practice. (Abstract #6029)**
V. C. Tam, I. Tannock, J. Rauw, M. K. Krzyzanowska
- Brd. 22** **The assessment of cost and other barriers to patient clinical trial participation in the community setting. (Abstract #6030)**
D. Weckstein, C. Thomas, I. F. Emery, B. F. Shea, A. Fleury, M. White, E. Chase, S. Frazier, C. Robinson, C. Pilar

Saturday, June 5, 2010

- Brd. 23** **Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials. (Abstract #6031)**
B. You, H. K. Gan, G. R. Pond, E. X. Chen
- Brd. 24** **Influence of nonclinical patient factors on decisions to recommend breast cancer adjuvant chemotherapy. (Abstract #6032)**
T. M. Pini, S. T. Hawley, S. J. Katz, J. Graff, A. S. Hamilton, J. J. Griggs
- Brd. 25** **Factors associated with decision making for use of adjuvant chemotherapy (AT) in referred patients (pts) with resected high-risk colon cancer (CC). (Abstract #6033)**
D. Ksienski, S. Gill

9:30 AM - 12:00 PM
SPECIAL SESSION

**Opening Session with Presidential Address, NCI Director's Address,
David A. Karnofsky Memorial Award and Lecture, and The ASCO Cancer
Foundation Donor Recognition Awards**

Location: N Hall B1

CME credit: 1.5

Track(s): Special Session

Daniel D. Van Hoff, MD—Karnofsky Award Recipient

Translational Genomics Research Institute

The Last Twelve Weeks

9:45 AM - 11:00 AM
MEET THE PROFESSOR SESSION

**Germ Cell Tumors in Children, Adolescents, and Young Adults
(M01)-TICKETED SESSION**

Location: E451b

CME credit: 1.25

Track(s): Pediatric Oncology

A. Lindsay Frazier, MD

Dana-Farber Cancer Institute

Saturday, June 5, 2010

9:45 AM - 11:00 AM

CLINICAL PROBLEMS IN ONCOLOGY

Ocular Melanoma (C03)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Melanoma/Skin Cancers

J. William Harbour, MD—Chair

Washington University School of Medicine

Background and Treatment of Primary Ocular Melanoma

James F. Pingpank Jr., MD, FACS

University of Pittsburgh Medical Center

Regional Therapy for Ocular Melanoma

Takami Sato, MD, PhD

Jefferson Medical College

Systemic Therapy for Metastatic Ocular Melanoma

1:00 PM - 2:15 PM

MEET THE PROFESSOR SESSION

**Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention
(M02)-TICKETED SESSION**

Location: E451b

CME credit: 1.25

Track(s): Cancer Prevention/Epidemiology; Melanoma/Skin Cancers

Aleksandar Sekulic, MD, PhD

Mayo Clinic

1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION

Developmental Therapeutics—Experimental Therapeutics

Location: E Hall D2

CME credit: 3

Track(s): Developmental Therapeutics

Michael L. Maitland, MD, PhD—Co-Chair

The University of Chicago

Richard H. Wilson, MD—Co-Chair

Queen's University Belfast

- 1:00 PM** **First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. (Abstract #3006)**
 D. S. Tan, H. Dumez, D. Olmos, S. K. Sandhu, A. Hoeben, A. W. Stephens, S. Poondru, R. Gedrich, S. B. Kaye, P. Schoffski
- 1:15 PM** **Dual inhibition of IGFR and mTOR pathways. (Abstract #3007)**
 A. Naing, P. LoRusso, S. Gupta, R. S. Benjamin, E. Rohren, H. X. Chen, L. Doyle, D. A. Berry, H. M. Amin, R. Kurzrock
- 1:30 PM** **A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotuzumab (DALO) in patients (pts) with advanced solid tumors. (Abstract #3008)**
 S. Di Cosimo, J. C. Bendell, A. Cervantes-Ruiperez, D. Roda, L. Prudkin, M. N. Stein, A. Leighton-Swayze, Y. Song, S. Ebbinghaus, J. Baselga
- 1:45 PM** **First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. (Abstract #3009)**
 T. A. Yap, A. Patnaik, I. Fearen, D. Olmos, K. Papadopoulos, N. Tunariu, D. Sullivan, L. Yan, J. S. De Bono, A. W. Tolcher
- Discussion**
- 2:00 PM** Manuel Hidalgo, MD, PhD (Abstracts #3006–3009)
 Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III
Drugging the IGF1R/Akt/mTOR Signaling Network
- 2:15 PM** **Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors. (Abstract #3010)**
 E. C. Dees, J. R. Infante, H. A. Burris, I. A. Asatsurov, T. Stinchcombe, H. Liu, K. Galvin, K. Venkatakrishnan, H. J. Fingert, R. B. Cohen
- 2:30 PM** **A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors. (Abstract #3011)**
 K. B. Moss, M. E. Scheulen, A. Frost, D. Scharr, H. Richly, B. Nokay, K. Lee, J. Hilbert, F. Fleischer, O. Fietz
- 2:45 PM** **Phase I first-in-human study of the centromere-associated protein E (CENP-E) inhibitor GSK923295 in patients with advanced solid tumors (study CPE107602). (Abstract #3012)**
 K. D. Holen, E. I. Heath, W. R. Schelman, L. C. Kirby, B. M. Johnson, J. D. Botbyl, J. E. Grilley-Olson, T. A. Lampkin, V. M. Chung

Saturday, June 5, 2010

Discussion

- 3:00 PM** Johann Sebastian De Bono, MD, PhD (Abstracts #3010–3012)
Drug Development Unit, The Royal Marsden NHS Foundation Trust and The
Institute of Cancer Research
Novel Agents and Targets in Mitosis
- 3:15 PM** **Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer. (Abstract #3013)**
D. S. Mendelson, M. S. Gordon, L. S. Rosen, H. Hurwitz, M. K. Wong, B. J. Adams,
D. Alvarez, B. K. Seon, C. P. Theuer, B. R. Leigh
- 3:30 PM** **A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors. (Abstract #3014)**
C. D. Weekes, P. Hegde, Y. Xin, R. Yu, H. Xiang, M. Beeram, L. Gore,
R. K. Brachmann, A. Patnaik

Discussion

- 3:45 PM** To be determined

1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION

Lymphoma

Location: E354a

CME credit: 3

Track(s): Lymphoma and Plasma Cell Disorders

Kenneth Stuart Cohen, MD—Co-Chair

The University of Chicago

John Leonard, MD—Co-Chair

Weill Cornell Medical College

1:00 PM Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. (Abstract #8004)

G. A. Salles, J. F. Seymour, P. Feugier, F. Offner, A. Lopez-Guillermo, R. Bouabdallah, L. M. Pedersen, P. Brice, D. Belada, L. Xerri

1:15 PM Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. (Abstract #8005)

R. Pettengell, N. Schmitz, C. Gisselbrecht, D. Caballero, P. Colombat, E. Conde, B. Metzner, J. A. Walewski, C. Geisler, A. Goldstone, European Group for Blood and Marrow Transplantation

Discussion

1:30 PM Richard I. Fisher, MD (Abstracts #8004–8005)

University of Rochester Medical Center

Role of Maintenance Therapy in Follicular Lymphoma

1:45 PM Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD. (Abstract #8006)

F. Fiore, K. Patti, S. Viviani, A. Rossi, F. Di Raimondo, M. Cantonetti, T. Feldman, A. Biggi, S. Barrington, A. Gallamini

2:00 PM Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT). (Abstract #8007)

A. Sureda, A. Engert, P. J. Browett, J. A. Radford, G. E. Verhoef, R. Ramchandren, N. Myke, A. Shen, C. Le Corre, A. Younes

Discussion

2:15 PM Ralph M. Meyer, MD (Abstracts #8006–8007)

Canadian Cancer Society Clinical Trials Group

Improving Outcomes in Hodgkin Lymphoma

2:30 PM Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial. (Abstract #8008)

E. Thiel, A. Korfel, P. Martus, L. Kanz, F. Griesinger, M. Rauch, L. Fischer, T. Pietsch, M. Bamberg, M. Weller

2:45 PM Limited-stage diffuse large B-cell lymphoma (DLBCL) treated with abbreviated systemic therapy and consolidation radiotherapy: Involved field radiotherapy (IFRT) versus involved nodal radiotherapy (INRT≤5cm). (Abstract #8009)

B. A. Campbell, J. M. Connors, R. D. Gascoyne, T. Pickles, W. J. Morris, L. H. Sehn

Saturday, June 5, 2010

Discussion

- 3:00 PM** Joachim Yahalom, MD (Abstracts #8008–8009)
Memorial Sloan-Kettering Cancer Center
What Is the Role of Radiation in Large Cell Lymphoma?
- 3:15 PM** **A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma. (Abstract #8010)**
F. Kuhnowski, C. Thieblemont, F. Jardin, F. Broussais-Guillemot, M. Meignan, J. Cabecadas, P. Gaulard, H. Tilly, C. Oprea, C. Haioun
- 3:30 PM** **Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for high-dose therapy (HDT): A GELA study. (Abstract #8011)**
T. EL Gnaoui, H. Tilly, N. Mounier, C. Gisselbrecht, C. Sebban, O. Casasnovas, R. Delarue, T. Petrella, D. Canioni, C. Haioun
- 3:45 PM** **Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. (Abstract #8012)**
R. Advani, J. P. Sharman, S. M. Smith, D. A. Pollyea, T. E. Boyd, B. W. Grant, K. S. Kolibaba, J. J. Buggy, A. Hamdy, N. H. Fowler

SATURDAY

1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION

Melanoma/Skin Cancers

Location: S406 (Vista Room)

CME credit: 3

Track(s): Melanoma/Skin Cancers

Tim Eisen, PhD, FRCP—Co-Chair

University of Cambridge/Cancer Research UK

Thomas Gajewski, MD, PhD—Co-Chair

The University of Chicago

- 1:00 PM E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. (Abstract #8504)**

D. H. Lawson, S. J. Lee, A. A. Tarhini, K. A. Margolin, M. S. Ernstoff, J. M. Kirkwood

- 1:15 PM Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961. (Abstract #8505)**

A. M. Eggermont, S. Suci, P. Rutkowski, J. Marsden, A. Testori, P. Corrie, S. Aamdal, P. A. Ascierto, P. Patel, A. Spatz, EORTC Melanoma Group

- 1:30 PM Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial. (Abstract #LBA8506)**

J. J. Grob, T. Jouary, B. Dreno, R. Gutzmer, A. Hauschild, M. T. Leccia, M. Landthaler, J. Asselineau, C. Garbe, H. E. Pehamberger

Discussion

- 1:45 PM** Michael S. Sabel, MD, FACS (Abstracts #8504–LBA8506)
University of Michigan

- 2:00 PM Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM). (Abstract #8507)**

T. M. Petrella, R. Tozer, K. Belanger, K. J. Savage, R. Wong, S. Kamel-Reid, V. Tron, B. Chen, N. N. Hunder, E. A. Eisenhauer

- 2:15 PM First report of a randomized phase II trial of multi-epitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells in patients with metastatic melanoma: An Eastern Cooperative Oncology Group study (E1602). (Abstract #8508)**

C. L. Slingluff, S. J. Lee, K. A. Chianese-Bullock, W. C. Olson, L. H. Butterfield, P. D. Leming, J. M. Kirkwood

- 2:30 PM Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma. (Abstract #8509)**

F. S. Hodi, S. O'Day, D. F. McDermott, J. B. Haanen, C. Robert, X. Zhu, M. J. Yellin, R. A. Ibrahim, A. Hoos, J. D. Wolchok

Saturday, June 5, 2010

Discussion

2:45 PM Antoni Ribas, MD (Abstracts #8507–8509)
University of California, Los Angeles

3:00 PM **Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: Final results of a phase II multicenter study. (Abstract #8510)**
E. Maubec, P. Petrow, P. Duvillard, C. Laouenan, X. Duval, L. Lacroix, M. Bagot, S. J. Faivre, F. Mentre, M. Avril

3:15 PM **Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. (Abstract #8511)**
K. T. Flaherty, S. J. Lee, L. M. Schuchter, L. E. Flaherty, J. J. Wright, P. D. Leming, J. M. Kirkwood

3:30 PM **A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. (Abstract #LBA8512)**
J. F. Pingpank, M. S. Hughes, H. R. Alexander, M. B. Faries, J. S. Zager, R. Royal, E. D. Whitman, C. W. Nutting, G. P. Siskin, S. S. Agarwala

Discussion

3:45 PM Dirk Schadendorf, MD (Abstracts #8510–LBA8512)
University Hospital Essen

SATURDAY

1:15 PM - 2:30 PM
EDUCATION SESSIONS

A Family's Year with Cancer

Location: S404

CME credit: 1.25

Track(s): Professional Development; Patient and Survivor Care

Lidia Schapira, MD—Chair

Massachusetts General Hospital

The Impact of Cancer on Families

David Treadway, PhD

Kate Treadway, MD

Harvard Medical School

Evolving Standards of Care in Advanced Renal Cell Carcinoma

Location: E Hall D1

CME credit: 1.25

Track(s): Genitourinary Cancer; General Oncology

Primo Lara Jr., MD—Chair

University of California, Davis

Toward Individualizing Therapy in Advanced Renal Cell Cancer

Christopher W. Ryan, MD

Oregon Health & Science University

Systemic Therapies in Advanced Renal Cell Cancer: Current Status

Eric Jonasch, MD

University of Texas M. D. Anderson Cancer Center

Integration of Nephrectomy in Advanced Renal Cell Cancer Management

Future Directions in the Management of Endometrial Cancer

Location: E Arie Crown Theater

CME credit: 1.25

Track(s): Gynecologic Cancer

David E. Cohn, MD—Chair

The Ohio State University

Surgically Staging of Endometrial Cancer: The Controversy Continues

Carien Creutzberg, MD, PhD

Leiden University Medical Center

Optimizing Adjuvant Therapy in the Treatment of Early-stage Endometrial Cancer Patients

Gini F. Fleming, MD

The University of Chicago

Incorporating Novel Biologic Therapies into Endometrial Cancer Treatment

Saturday, June 5, 2010

Implementing Clinical Trials: Risks, Benefits, Marketing, and Paying for It All

Location: E353

CME credit: 1.25

Track(s): Practice Management and Information Technology; Clinical Trials

Robin Zon, MD, FACP—Chair

Michiana Hematology-Oncology

Structuring/Marketing a Program for Success

Gary Irvin Cohen, MD

Greater Baltimore Medical Center

The Critical Role of Creating a Research Team

Dee Anna Smith

Sarah Cannon Research Institute

Negotiating a Contract: Knowing Cost to Effectively Budget for Pharma Trials

Improving Access to Clinical Trials

Location: S100a

CME credit: 1.25

Track(s): Clinical Trials; Geriatric Oncology

Derek Raghavan, MD, PhD—Chair

Cleveland Clinic

Overcoming Barriers to Access to Cancer Care and Cancer Trial Enrollment in Minority Populations

J. Phillip Kuebler, MD, PhD

Columbus Oncology Associates

Overcoming Barriers to Clinical Trials: Increasing Accrual through Partnership with Community Oncologists

Hyman Bernard Muss, MD

University of North Carolina at Chapel Hill

Overcoming Barriers to Clinical Trial Accrual in the Elderly Population and Patients with Comorbidities

SATURDAY

Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions)

Location: E354b

CME credit: 1.25

Track(s): Gastrointestinal (Colorectal) Cancer; General Oncology; Geriatric Oncology; Patient and Survivor Care

This session will offer enhanced audience participation through the use of web and mobile technologies. At any time during the session, attendees can send questions to faculty via text (SMS), e-mail, or Twitter. Floor microphones will also be available.

Howard S. Hochster, MD—Chair

New York University

Management of Oxaliplatin-induced Neurotoxicity

Bruce D. Minsky, MD

The University of Chicago

Managing and Reducing Side Effects of Pelvic Radiation

Mario E. Lacouture, MD

Northwestern University

Dermatologic Toxicities of Targeted Therapy in Colorectal Cancer

New Treatments for Sarcoma in Children, Adolescents, and Young Adults

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology; Sarcoma

Stephen X. Skapek, MD—Chair

The University of Chicago

Treatment of Childhood, Adolescent, and Young Adult Sarcoma: Where Do We Go from Here?

R. Lor Randall, MD, FACS

University of Utah

Optimal Approaches for Achieving Local Control in Children, Adolescents, and Young Adults with Sarcoma

Douglas S. Hawkins, MD

Seattle Children's Hospital and Regional Medical Center

Optimal Strategies for Controlling Metastatic Disease in Children, Adolescents, and Young Adults with Sarcoma

The Global Burden of Cancer: The Worldwide Challenge of Cancer Control

Location: S100b

CME credit: 1.25

Track(s): Cancer Prevention/Epidemiology; International

Max D. Parkin, MD—Chair

Cancer Research UK

Causes of Preventable Cancer in the World: From Tobacco to Tanning Boxes (The Expanding List of IARC Class I Carcinogens)

Prabhat Jha, MD, DPhil

University of Toronto

Tobacco as a Cause of Worldwide Cancer Mortality

Mei Hwei Chang, MD

National Taiwan University Hospital

Prevention of Hepatocellular Carcinoma via Universal Vaccination against Hepatitis B

Saturday, June 5, 2010

1:15 PM - 2:30 PM

CLINICAL PROBLEMS IN ONCOLOGY

**Improving Outcomes for Patients with Locally Advanced Lung Cancer (C04)-
TICKETED SESSION**

Location: E451a

CME credit: 1.25

Track(s): Lung Cancer

Julie R. Brahmer, MD—Chair

The Johns Hopkins University

*Systemic Therapy for Locally Advanced NSCLC including the Role of Treatment Post
Chemoradiotherapy*

Douglas E. Wood, MD

University of Washington

Surgical Management of Locally Advanced Lung Cancer

Jeffrey Bogart, MD

SUNY Upstate Medical University

Stage III NSCLC: Does Better Technology Equal Better Treatment?

SATURDAY

1:15 PM - 2:45 PM
CLINICAL SCIENCE SYMPOSIUM

Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life

Location: N Hall B1

CME credit: 1.5

Track(s): Gastrointestinal (Noncolorectal) Cancer

David Linehan, MD—Co-Chair

Washington University School of Medicine

Colin D. Weekes, MD, PhD—Co-Chair

University of Colorado Cancer Center

- 1:15 PM Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). (Abstract #4000)**
P. Niccoli, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. W. Valle, S. Patyna, D. Lu, R. C. Chao, E. Raymond
- 1:30 PM A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). (Abstract #4001)**
A. T. Phan, J. C. Yao, D. R. Fogelman, K. R. Hess, C. S. Ng, S. A. Bullock, P. Malinowski, E. Regan, M. Kulke
- 1:45 PM Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. (Abstract #4002)**
J. C. Yao, A. T. Phan, D. Fogleman, C. S. Ng, C. B. Jacobs, C. D. Dagohoy, C. Leary, K. R. Hess
- Discussion**
- 2:00 PM** Kjell E. Oberg, MD, PhD (Abstracts #4000–4002)
 Uppsala University
- 2:15 PM Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. (Abstract #4003)**
A. Vinik, Y. Bang, J. Raoul, J. W. Valle, P. Metrakos, D. Hörsch, B. Korytowsky, R. Mundayat, R. C. Chao, E. Raymond
- Discussion**
- 2:30 PM** Ian Chau, MD (Abstract #4003)
 Royal Marsden Hospital

Saturday, June 5, 2010

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Genitourinary (Nonprostate) Cancer

Display Time: 2:00 PM - 6:00 PM

Display Location: E450a

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: E Hall D2

CME credit: 1

Track(s): Genitourinary Cancer

Leonard Joseph Appleman, MD, PhD—Co-Chair

University of Pittsburgh Medical Center

George Philips, MD, MBBS, MPH—Co-Chair

University of Vermont

Discussion

5:00 PM Daniel J. George, MD (Abstracts #4520–4526)
Duke University Medical Center
Prediction and Prognosis in Renal Cell Carcinoma

Discussion

5:15 PM Ulka N. Vaishampayan, MD (Abstracts #4527–4530)
Wayne State University
Trial Design and Drug Development in Renal Cell Carcinoma

Discussion

5:25 PM Mary Gospodarowicz, MD (Abstracts #4531–4538)
Princess Margaret Hospital
Germ Cell Tumors: Is Radiation Under- or Overused?

Discussion

5:40 PM Matthew I. Milowsky, MD (Abstracts #4539–4541)
Memorial Sloan-Kettering Cancer Center
Is There a Role for Targeted Therapy in Advanced Urothelial Cancer?

Discussion

5:50 PM Seth P. Lerner, MD (Abstracts #4542–4543)
Baylor College of Medicine
New Therapies in Non-muscle-invasive Urothelial Cancer

Brd. 1 **Association of germline genetic markers in *IL8*, *HIF1A*, *VEGFA*, and *VEGFR2* with treatment response to pazopanib in renal cell carcinoma. (Abstract #4520)**

H. A. Ball, C. Xu, C. N. Sternberg, N. Bing, D. Rajagopalan, C. F. Spraggs, V. E. Mooser, R. G. Amado, L. R. Cardon, L. Pandite

Brd. 2 **Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib. (Abstract #4521)**

K. Eechoute, A. A. van der Veldt, H. Gelderblom, J. A. Gietema, H. Guchelaar, N. Van Erp, E. Boven, J. B. Haanen, R. Mathijssen, J. A. Wessels

Brd. 3 **Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients. (Abstract #4522)**

H. T. Tran, Y. Liu, Y. Lin, A. Martin, K. L. Baker, H. A. Fritsche, A. J. Zurita, L. Pandite, J. Heymach, VEG102616 Investigators, Patients, and Team

Brd. 4 **A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study. (Abstract #4523)**

D. Y. Heng, W. Xie, G. A. Bjarnason, U. N. Vaishampayan, F. Donskov, L. Wood, J. J. Knox, M. Tan, B. I. Rini, T. K. Choueiri

- Brd. 5** **The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration. (Abstract #4524)**
T. K. Choueiri, W. Xie, C. K. Kollmannsberger, B. I. Rini, D. F. McDermott, J. J. Knox, D. Y. Heng
- Brd. 6** **Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). (Abstract #4525)**
S. Halabi, B. I. Rini, W. M. Stadler, E. J. Small
- Brd. 7** **Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage, radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in advanced renal cell carcinoma. (Abstract #4526)**
K. M. Krajewski, D. Y. Heng, I. Pedrosa, N. H. Ramaiya, J. P. Jagannathan, A. D. Van Den Abbeele, M. B. Atkins, D. F. McDermott, F. A. Schutz, T. K. Choueiri
- Brd. 8** **Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure. (Abstract #4527)**
N. M. Tannir, Y. Wong, C. K. Kollmannsberger, M. S. Ernstoff, D. J. Perry, L. J. Appleman, E. M. Posadas, J. Qian, J. L. Ricker, D. Michaelson
- Brd. 9** **A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). (Abstract #4528^)**
C. W. Ryan, B. D. Curti, D. I. Quinn, J. M. Strother, Z. Chen, E. Roberson, T. M. Beer, D. Nauman
- Brd. 10** **Results of a randomized phase II study investigating multi-peptide vaccination with IMA901 in advanced renal cell carcinoma (RCC). (Abstract #4529)**
C. Reinhardt, R. Zdrojowy, C. Szczylik, T. Ciuleanu, W. Brugger, R. Oberneder, A. Kirner, S. Walter, H. Singh, A. Stenzl
- Brd. 12** **Results from SWENOTECA V: A population-based protocol for seminomatous testicular cancer. (Abstract #4531)**
T. Tandstad, R. Småland, O. H. Klepp, E. Cavallin-Stahl, U. Stierner, A. Laurell, P. Flodgren, O. Dahl, G. Cohn-Cedermark
- Brd. 13** **Risk-adapted management of stage I seminoma: Results of the third Spanish Germ Cell Cancer Group study. (Abstract #4532)**
J. Aparicio, L. Robert, X. Garcia del Muro, J. Guma, A. Sanchez, M. Margeli, M. Domenech, R. Bastus, J. P. Maroto, J. R. Germa-Lluch, Spanish Germ Cell Cancer Group
- Brd. 14** **Cardiovascular risk in long-term testicular cancer survivors. (Abstract #4533)**
H. S. Haugnes, T. Wethal, N. Aass, O. Dahl, O. H. Klepp, C. Langberg, T. Wilsgaard, R. M. Bremnes, S. D. Fossa
- Brd. 15** **Total treatment burden in stage I seminoma patients. (Abstract #4534)**
E. Leung, P. W. Chung, T. Panzarella, M. A. Jewett, J. Sweet, M. O'Malley, M. K. Gospodarowicz, M. J. Moore, J. F. Sturgeon, P. R. Warde
- Brd. 16** **Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study. (Abstract #4535)**
P. W. Chung, G. Daugaard, S. Tyldesley, T. Panzarella, C. K. Kollmannsberger, M. K. Gospodarowicz, P. R. Warde
- Brd. 17** **Evolution of management of testicular seminoma: Population-based outcomes with decreased utilization of active therapies. (Abstract #4536)**
C. R. Nichols, S. Tyldesley, C. J. Moore, K. N. Chi, N. Murray, S. Daneshmand, P. C. Black, B. M. Hayes-Lattin, C. K. Kollmannsberger
- Brd. 18** **Risk of secondary malignancy in patients with testicular cancer who have received radiation therapy. (Abstract #4537)**
D. Lewinshtein, C. R. Porter
- Brd. 19** **Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy. (Abstract #4538)**
A. Horwich, S. D. Fossa, S. P. Stenning, J. M. Bliss, E. Hall

Saturday, June 5, 2010

- Brd. 20** Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)—Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial. (Abstract #4539)
D. I. Quinn, A. Aparicio, D. D. Tsao-Wei, S. G. Groshen, T. B. Dorff, T. W. Synold, W. M. Stadler, D. R. Gandara, P. Lara Jr., E. M. Newman, California Cancer Consortium
- Brd. 21** First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit. (Abstract #4540)
J. Bellmunt, J. L. Gonzalez-Larriba, J. P. Maroto, J. Carles, D. E. Castellano, B. Mellado, E. Gallardo, J. L. Perez-Gracia, X. Villanueva Sr., J. Albanell
- Brd. 22** Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). (Abstract #4541)
N. M. Hahn, W. M. Stadler, R. Zon, D. M. Waterhouse, J. Picus, S. R. Nattam, C. S. Johnson, S. M. Perkins, M. J. Waddell, C. Sweeney
- Brd. 23** Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer. (Abstract #4542)
L. J. Barlow, M. A. Laudano, M. J. Mann, M. Desai, D. P. Petrylak, M. C. Benson, J. M. McKiernan
- Brd. 24** Single preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle-invasive bladder cancer: A prospective randomized trial. (Abstract #4543)
S. M. Di Stasi, C. Verri, G. Capelli, M. Brausi, G. Leprini, M. Casilio, G. Zampa

2:00 PM - 6:00 PM POSTER DISCUSSION SESSION

Tumor Biology

Display Time: 2:00 PM - 6:00 PM

Display Location: S103

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: S100a

CME credit: 1

Track(s): Tumor Biology

Charles D. Lopez, MD, PhD—Co-Chair

Oregon Health & Science University

Vered Stearns, MD—Co-Chair

The Johns Hopkins University

Discussion

5:00 PM Richard Simon, DSc (Abstracts #10513–10517)
National Institutes of Health

Discussion

5:15 PM Gerold Bepler, MD, PhD (Abstracts #10518–10521)
H. Lee Moffitt Cancer Center & Research Institute

Discussion

5:30 PM David Paul Carbone, MD, PhD (Abstracts #10522–10530)
Vanderbilt University Medical Center

Discussion

5:45 PM Robert Arthur Kratzke, MD (Abstracts #10531–10537)
University of Minnesota

- Brd. 1** **Utilization of genomic signatures for chemotherapy response in prospective clinical studies. (Abstract #10513)**
W. Barry, C. Acharya, M. B. Datto, H. K. Dressman, P. K. Marcom, N. Ready, G. S. Ginsburg, A. Potti, J. R. Nevins
- Brd. 2** **Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer. (Abstract #10514)**
S. Darb-Esfahani, R. Kronenwett, G. Von Minckwitz, S. Kuemmel, J. Budczies, A. Rody, M. Gehrmann, C. Denkert, A. Du Bois, S. Loibl
- Brd. 3** **Gene expression in serial biopsies in locally advanced breast cancer patients who failed to respond to neoadjuvant chemotherapy. (Abstract #10515)**
M. M. Magbanua, S. E. Davis, J. Crothers, E. Sosa, C. M. Haqq, L. van't Veer, L. Esserman
- Brd. 4** **Response prediction to neoadjuvant chemotherapy: Comparison between pretherapeutic gene expression profiles and in vitro chemosensitivity assay. (Abstract #10516)**
C. F. Singer, F. Klingmüller, C. Staudigl, A. Fink-Retter, D. Gschwantler-Kaulich, G. Pfeiler, A. C. Dressler, C. Sartori, M. Bilban
- Brd. 5** **Correlation of engraftment, mutation status, and response to chemotherapy in primary tumor xenograft models of NSCLC. (Abstract #10517)**
T. John, D. Kohler, N. Yanagawa, M. Pintilie, M. Li, D. Panchal, N. Pham, S. Der, F. A. Shepherd, M. S. Tsao
- Brd. 6** **Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis. (Abstract #10518)**
C. E. Almasi, I. J. Christensen, G. Høyer-Hansen, K. Danø, H. Pappot, H. Dienemann, T. Muley

- Brd. 7** **Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies. (Abstract #10519)**
C. Bernaards, P. Hegde, D. Chen, E. Holmgren, M. Zheng, A. M. Jubb, H. Koeppe, S. J. Scherer, D. S. Chen
- Brd. 8** **Value of a serum proteomic signature in the non-invasive evaluation of lung nodules. (Abstract #10520)**
C. V. Pecot, X. Zhang, R. Rajanbabu, M. Li, J. R. Jett, E. Grogan, D. P. Carbone, Y. Shyr, P. P. Massion
- Brd. 9** **Use of a nanoparticle-based artificial olfactory system, NaNose, to distinguish malignant from benign pulmonary nodules. (Abstract #10521)**
N. Peled, M. Hakim, H. Haick, P. A. Bunn, Y. E. Miller, T. C. Kennedy, J. D. Mitchell, M. J. Weyant, F. R. Hirsch
- Brd. 10** **Association of TS and ERCC1 mRNA expressions with overall survival in patients enrolled in CONFIRM 1 and 2. (Abstract #10522)**
P. P. Grimminger, M. Shi, J. C. Barrett, D. E. Lebowitz, K. D. Danenberg, C. L. Vigen, D. Yang, J. Brabender, P. V. Danenberg, H. Lenz
- Brd. 11** **Prognostic value of the microtubule stability index (MTSI), defined by the quantitative ratio of MAP-tau to stathmin expression, for outcome in breast cancer. (Abstract #10523)**
M. T. Baquero, J. A. Hanna, S. Agarwal, E. J. Killiam, R. L. Camp, L. N. Harris, D. L. Rimm
- Brd. 12** **Association of GRP78 gene polymorphism rs391957 with tumor recurrence in gastric and colon cancer patients. (Abstract #10524)**
P. O. Bohanes, T. Winder, D. G. Power, D. Yang, W. Zhang, Y. Ning, G. Lurje, L. H. Tang, M. A. Shah, H. Lenz
- Brd. 13** **Correlation of Snail expression and survival in patients with early-stage triple-negative breast cancer (TNBC). (Abstract #10525)**
S. Jiralerspong, S. Liu, S. L. Palla, G. B. Mills, M. Hung, G. N. Hortobagyi, A. M. Gonzalez-Angulo
- Brd. 14** **MicroRNA deregulation in peripheral nerve sheath tumor progression. (Abstract #10526)**
N. Presneau, M. Eskandarpour, B. Idowu, D. Halai, E. Coulter, S. Henderson, R. Tirabosco, A. M. Flanagan
- Brd. 15** **Chemobiological screening for identification of molecular targets for thymic epithelial cancers. (Abstract #10527)**
O. D. Cano, Y. Polar, Y. Liu, M. Ivan, K. Fearn, J. Ding, S. S. Badve, G. W. Sledge, P. J. Loehrer, A. A. Cardoso
- Brd. 16** **Molecular classification of non-small cell lung cancer using a four protein quantitative assay. (Abstract #10528)**
V. K. Anagnostou, T. Botsis, E. Killiam, V. Zolota, D. Dougenis, L. Tanoue, F. C. Detterbeck, K. N. Syrigos, G. Bepler, D. Rimm
- Brd. 17** **KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy. (Abstract #10529)**
K. D. Danenberg, P. P. Grimminger, P. C. Mack, P. V. Danenberg, J. Cooc, C. Stephens, S. K. Reddy, T. Li, D. R. Gandara
- Brd. 18** **Prognostic implications of mutations in the epidermal growth factor receptor (EGFR) and KRAS among never-smokers with adenocarcinoma of the lung. (Abstract #10530)**
P. K. Paik, M. L. Johnson, S. P. D'Angelo, C. Sima, Y. Y. Janjigian, G. J. Riely, M. G. Kris
- Brd. 19** **Comprehensive analysis of expression patterns of insulin-like growth factor and Src pathway in patients with non-small cell lung cancer: Two large, independent series of tissue microarray. (Abstract #10531)**
J. Kim, E. S. Kim, D. Liu, J. Lee, L. Solis, P. Yuan, C. Behrens, W. K. Hong, I. I. Wistuba, H. Lee

SATURDAY

- Brd. 20** **Immunohistochemical screening of ALK lung cancer with biopsy specimens of advanced lung cancer. (Abstract #10532)**
K. Kudo, K. Takeuchi, H. Tanaka, N. Yanagitani, A. Horiike, F. Ohyanagi, N. Motoi, Y. Ishikawa, T. Horai, M. Nishio
- Brd. 21** **ALK gene rearrangements in unselected Caucasians with non-small cell lung carcinoma (NSCLC). (Abstract #10533)**
M. Varella-Garcia, Y. Cho, X. Lu, A. E. Barón, L. Terracciano, D. R. Camidge, P. A. Bunn, W. A. Franklin, F. Cappuzzo, R. C. Doebele
- Brd. 22** **A Japanese nationwide network for the diagnosis of EML4-ALK-positive lung cancer: A joint study of ALCAS and NEJ004. (Abstract #10534)**
M. Soda, A. Inoue, K. Isobe, H. Miyazawa, T. Tanaka, K. Takeuchi, Y. Ishikawa, K. Kobayashi, K. Hagiwara, H. Mano
- Brd. 23** **A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue. (Abstract #10535)**
P. V. Danenberg, C. Stephens, J. Cooc, D. R. Gandara, P. C. Mack, P. P. Grimminger, K. D. Danenberg
- Brd. 24** **Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis. (Abstract #10536)**
V. Rimkunas, K. Crosby, M. Kelly, M. Silver, K. Hincman, R. Polakiewicz, D. Li, X. Zhou, H. Haack
- Brd. 25** **ALK chromosomal alterations in colon cancer patients. (Abstract #10537)**
C. Montagut, A. B. Galvan, M. Gallen, M. Salido, F. Sole, F. G. Rojo, E. Arriola, A. Rovira, J. Bellmunt, J. Albanell

Saturday, June 5, 2010

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Breast Cancer—Local-Regional and Adjuvant Therapy

Location: S Hall A2

Tracks(s): Breast Cancer

- Brd. 1A** **DEVA: Randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node-positive postmenopausal early breast cancer (EBC) patients. (Abstract #536)**
R. C. Coombes, J. M. Bliss, M. Espie, F. Erdkamp, J. J. Wals, A. Tres, R. E. Coleman, J. Reise, D. Cooper, P. Hupperets
- Brd. 1B** **Long-term results from the neoadjuvant Geparduo trial: A randomized, multicenter, open phase III study comparing a dose-intensified 8-week schedule of doxorubicin hydrochloride and docetaxel (ADoc) with a sequential 24-week schedule of doxorubicin hydrochloride/ cyclophosphamide followed by docetaxel (AC-Doc) regimen as preoperative therapy (NACT) in patients (pts) with operable breast cancer (BC). (Abstract #537)**
M. Kaufmann, W. Eiermann, M. Schuette, J. Hilfrich, J. U. Blohmer, B. Gerber, S. D. Costa, S. Loibl, V. Nekljudova, G. Von Minckwitz, German Breast Group
- Brd. 1C** **An epidemiologic study of the effect of adjuvant radiotherapy on 2D tumor characteristics and prognosis of contralateral breast cancer (CBC). (Abstract #538)**
M. E. Sandberg, M. Hartman, S. Eloranta, A. Ploner, P. Hall, K. Czene
- Brd. 1D** **The use of Ki67 to predict benefit from adjuvant tamoxifen in node-negative, estrogen receptor-positive patients. (Abstract #539)**
R. Yerushalmi, R. Woods, K. A. Gelmon, C. Speers, P. Ravdin
- Brd. 1E** **Gene signatures as predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel (nab-P) and carboplatin +/- trastuzumab in patients (pts) with stage II-III and inflammatory breast cancer (IBC). (Abstract #540)**
G. Somlo, P. H. Frankel, L. Vora, S. Lau, T. H. Luu, L. Kruper, J. Yim, Y. Yen, F. de Snoo, R. A. Bender
- Brd. 1F** **Obesity and disease-free survival in patients with nodal-positive early-stage breast cancer: The ADEBAR trial. (Abstract #541)**
P. G. Hepp, B. K. Rack, K. Annecke, A. Wischnik, W. Simon, N. Harbeck, H. L. Sommer, K. Friese, M. Kiechle, W. Janni, SUCCESS Study Group
- Brd. 1G** **Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial. (Abstract #542)**
M. N. Pollak, J. W. Chapman, K. I. Pritchard, J. E. Krook, H. S. Dhaliwal, T. A. Vandenberg, T. J. Whelan, S. E. O'Reilly, C. F. Wilson, L. E. Shepherd
- Brd. 1H** **Predictive value of CD24 ala/val polymorphism for pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. (Abstract #543)**
F. Marme, W. Werft, A. Benner, B. Burwinkel, H. Sinn, C. Sohn, P. Lichter, M. Hahn, P. Altevogt, A. Schneeweiss
- Brd. 2A** **Prospective randomized trial comparing postoperative adjuvant concurrent versus sequential hormonal and different radiation fractionation schedule in breast cancer patients. (Abstract #544)**
M. S. Barsoum, M. M. El Mongi, E. M. Khalil, H. E. Eisa, I. M. Hamed, G. A. Attia
- Brd. 2B** **Predictive value of a gene signature evaluated in multiple chemotherapy regimens for breast cancer. (Abstract #545)**
M. Fournier, K. Martin

- Brd. 2C Breast conservation (BCT) for DCIS: A prospective study of how MRI impacts management (MGMT). (Abstract #546)**
J. L. Marti, J. I. Goldberg, S. Patil, V. V. Barbashina, D. D. Giri, S. Brennan, C. Lee, C. Vallejo, E. A. Morris, K. J. Van Zee
- Brd. 2D Trastuzumab versus observation in women with early breast cancer and CK-19 mRNA-positive circulating tumor cells (CTCs): A pilot randomized phase II study. (Abstract #547)**
V. Georgoulas, V. Bozionelou, S. Agelaki, M. Perraki, S. Apostolaki, G. Kallergi, K. Kalbakis, N. E. Androulakis, A. Xyrfas, D. Mavroudis
- Brd. 2E The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis. (Abstract #548)**
R. H. Alvarez, G. Bianchini, L. Hsu, M. Cristofanilli, F. J. Esteva, L. Pusztai, A. Buzdar, G. N. Hortobagyi, V. Valero
- Brd. 2F Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms. (Abstract #549)**
I. E. Krop, L. Flores, D. P. Tuck, P. D. Ryan, A. H. Partridge, D. Morganstern, J. Najita, K. Iezon-Geyda, E. P. Winer, L. Harris
- Brd. 2G Use of myxovirus resistance 1 (MX1) expression to predict efficacy of anthracyclines-based chemotherapy: Biomarker studies from neoadjuvant and adjuvant trials. (Abstract #550)**
F. Andre, M. Delorenzi, A. Goubar, M. Lacroix, C. Desmedt, V. Scott, C. Sotiriou, M. Mathieu, S. Delaloge, L. Pusztai
- Brd. 2H Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. (Abstract #551)**
M. Basik, A. Aguilar-Mahecha, J. W. Chapman, K. Jahan, S. Hassan, L. Han, C. F. Wilson, K. I. Pritchard, L. E. Shepherd, M. N. Pollak
- Brd. 3A Final analysis of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment (NST) in early breast cancer (EBC): Japan Clinical Oncology Group Trial (JCOG0306). (Abstract #552)**
H. Mukai, T. Watanabe, M. Mitsumori, H. Tsuda, S. Nakamura, N. Masuda, N. Yamamoto, T. Shibata, A. Sato, K. Aogi
- Brd. 3B Preoperative diagnosis of sentinel lymph node (SLN) metastasis using 3D CT lymphography (CTLG): A new technology for sentinel node navigation. (Abstract #553)**
M. Nakagawa, M. Morimoto, T. Nagao, Y. Nakagawa Sr., A. Tangoku
- Brd. 3C Report of toxicities from the multicenter, randomized NNBC 3-Europe trial: 6xFEC versus 3xFEC-3xDoc for high-risk node-negative breast cancer patients. (Abstract #554)**
C. Thomssen, E. J. Kantelhardt, K. Plueckhahn, C. Veyret, D. Augustin, V. Hanf, D. Paepke, C. Meisner, G. Von Minckwitz, N. Harbeck, on behalf of the NNBC-3 Europe Study Group
- Brd. 3D The role of beta-blockers and ACE inhibitors in the prevention of trastuzumab-related cardiotoxicity. (Abstract #555)**
J. Munoz, J. Sheqwarra, B. Arango, H. Y. Ali, R. Loutfi, D. W. Weaver
- Brd. 3E Predictive response factors (PRF) in an open, nonrandomized, phase II study of a combination of bevacizumab (BZ) and sequential chemotherapy as preoperative treatment in patients with operable HER2-negative breast cancer (BC). (Abstract #556)**
P. Sanchez Rovira, J. De la Haba, M. Fernández-Navarro, M. Seguí, A. Llombart-Cussac, A. Anton, E. Alba, E. Aranda

- Brd. 3F** **Comparison of 21-gene recurrence score (RS) in African-American (AA) and Caucasian (C) patients with hormone receptor (HR)-positive early-stage breast cancer. (Abstract #557)**
K. M. Davis, A. B. Zelnak, S. Murali, D. Senior-Crosby, S. Gabram-Mendola, G. W. Carlson, W. C. Wood, C. Wang, T. M. Styblo, R. O'Regan
- Brd. 3G** **Effect of dose-dependent interaction between tamoxifen and antidepressants on patient adherence in breast cancer patients. (Abstract #558)**
F. W. Frueh, J. Tinnirello, M. Khalid, N. J. Markward, M. Subar, R. E. Aubert, R. S. Epstein
- Brd. 3H** **BACH: A randomized phase II trial of doxorubicin-cyclophosphamide (AC) versus pegylated liposomal doxorubicin (PLD)-cyclophosphamide-trastuzumab (CCH) followed by paclitaxel-trastuzumab (TH) as adjuvant therapy for HER2-positive breast cancer (BC)—Cardiac safety analysis. (Abstract #559)**
D. Rayson, T. Suter, S. van der Vegt, A. Lluch, J. Van Den Bosch, G. Lopez-Vivanco, A. M. Van Gent, H. Wildiers, L. Provencher, D. Richel
- Brd. 4A** **Gene signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial. (Abstract #560)**
S. M. Hadad, J. A. Dewar, E. Elseedawy, L. Jordan, C. Purdie, S. E. Bray, A. M. Thompson
- Brd. 4B** **Evaluation of the 70-gene prognosis MammaPrint signature for the prediction of prognosis of breast cancer independently from histologic grade. (Abstract #561)**
M. Knauer, E. J. Rutgers, S. Mook, J. Wesseling, L. J. van 't Veer
- Brd. 4C** **Obesity, patient characteristics, and TIMP-1: Effects on non-bone RFS in NCIC CTG MA.14. (Abstract #562)**
J. W. Chapman, S. M. Ali, A. Lipton, K. Leitzel, K. I. Pritchard, L. Han, W. P. Carney, C. F. Wilson, L. E. Shepherd, M. N. Pollak
- Brd. 4D** **Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. (Abstract #563)**
H. Kolesnikov-Gauthier, L. Vanlemmens, M. Baranzelli, P. Carpentier, S. Habbas, P. Vennin, V. Servent, C. Fournier, J. Bonnetterre
- Brd. 4E** **Comparison of first-course PET scan against fourth-course MRI for early detection of poor responders to neoadjuvant chemotherapy (NAC) for breast cancer (BC). (Abstract #564)**
M. Cotto, J. Toro, V. Carlo, R. Vaquer, O. A. Pavia, M. Bruno, E. Rivera, M. M. Echenique, V. Negron, F. Cabanillas
- Brd. 4F** **Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E. (Abstract #565)**
C. Bueno Hume, A. Moreno-Aspitia, D. W. Hillman, A. T. Perez, B. Chen, R. B. Jenkins, A. C. Dueck, D. B. Johnson, R. L. Carolla, E. A. Perez
- Brd. 4G** **Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy. (Abstract #566)**
M. J. Hassett, J. C. Niland, M. E. Hughes, R. L. Theriault, D. W. Blayney, Y. Wong, C. Hudis, P. K. Marcom, C. Laronga, J. C. Weeks
- Brd. 4H** **Five-year results of preoperative concurrent paclitaxel with radiation in locally advanced breast cancer (LABC). (Abstract #567)**
S. Formenti, S. Adams, A. B. Chakravarthy, S. C. Lymberis, D. V. Spicer, J. A. Bauer, M. Volm, D. Roses, J. D. Goldberg, J. A. Pietenpol

SATURDAY

- Brd. 5A** **Prospective study of wide local excision and endocrine therapy without radiotherapy (WORTH) for node-negative, estrogen receptor-positive early breast cancer with negative histologic margins (WORTH trial, Protocol 1): Five-year interim results. (Abstract #568)**
R. Nishimura, S. Ohsumi, H. Inaji, Y. Ohashi, K. Suemasu, N. Masuda, S. Akashi-Tanaka, S. Murakami, T. Ikeda, T. Nishi, Japanese Breast Conserving Treatment Study Group
- Brd. 5B** **Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer. (Abstract #569)**
C. Swanton, N. Juul, J. M. Larkin, A. Eklund, Q. Li, C. Desmedt, C. Sotiriou, L. Pusztai, Z. Szallasi
- Brd. 5C** **Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: An objective assessment of patients from a randomized controlled trial. (Abstract #570)**
M. R. Keshtgar, N. R. Williams, T. Corica, C. Saunders, D. J. Joseph, on behalf of the TARGIT Trialists' Group
- Brd. 5D** **Cardiovascular safety of adjuvant bevacizumab for breast cancer. (Abstract #571)**
E. L. Mayer, A. Nohria, K. Miller, H. S. Rugo, L. A. Carey, N. Ryabin, R. S. Gelman, E. P. Winer, H. J. Burstein
- Brd. 5E** **Association of gene copy number alterations in formalin-fixed, paraffin-embedded tumors with prognostic molecular and pathologic tumor subtypes in early-stage breast cancer. (Abstract #572)**
J. L. Murray, P. Thompson, M. Tuna, A. M. Brewster, K. Do, M. E. Edgerton, A. Sahin, G. B. Mills, S. Tsachavidis, M. Bondy
- Brd. 5F** **Primary endocrine therapy for early operable primary breast cancer in elderly women: Survival analysis of a large series from a single institution. (Abstract #573)**
W. Al-Khyatt, B. M. Syed, D. A. Morgan, A. R. Green, I. O. Ellis, K. Cheung
- Brd. 5G** **Do socioeconomic factors and insurance explain racial/ethnic disparities in receipt of recommended breast cancer care? (Abstract #574)**
R. A. Freedman, K. S. Virgo, Y. He, A. Pavluck, E. P. Winer, E. M. Ward, N. L. Keating
- Brd. 5H** **Chemotherapy (CT) versus tamoxifen (T) versus chemotherapy plus tamoxifen (CTT) in patients with node-positive (N+), estrogen receptor-positive (ER+) breast cancer (bca): Very late results of an Italian multicentric trial. (Abstract #575)**
F. Boccardo, P. Guglielmini, A. Marasco, A. Rubagotti
- Brd. 6A** **Randomized phase II trial of preoperative lapatinib versus placebo in HER2-positive breast cancer. (Abstract #576)**
A. De Censi, M. Puntoni, G. Pruneri, A. Guerrieri-Gonzaga, M. Cazzaniga, H. A. Johansson, O. Pala, G. Pagani, M. Marrè Brunenghi, B. Bonanni
- Brd. 6B** **Decision analysis: Excision alone versus excision plus radiation therapy for ductal carcinoma in situ. (Abstract #577)**
R. S. Punglia, J. S. Wong, H. J. Burstein, J. C. Weeks
- Brd. 6C** **Effect of early discontinuation and nonadherence to adjuvant hormone therapy on mortality in women with breast cancer. (Abstract #578)**
D. L. Hershman, T. H. Shao, L. Kushi, D. Buono, W. Tsai, L. Fehrenbacher, A. I. Neugut
- Brd. 6D** **Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for early-stage breast cancer (ESBC). (Abstract #579)**
M. E. Melisko, S. Greenberg, M. N. Dickler, M. M. Moasser, J. H. Scott, A. N. DeLuca, D. H. Moore, C. Hudis, J. W. Park, H. S. Rugo

- Brd. 6E Outcomes differences in tumors < 1 cm by age and breast cancer subtype. (Abstract #580)**
J. K. Litton, H. Chen, E. A. Mittendorf, F. Meric-Bernstam, M. Chavez-Mac Gregor, W. A. Woodward, A. Sahin, R. L. Theriault, G. N. Hortobagyi, A. M. Gonzalez-Angulo
- Brd. 6F Adjuvant chemotherapy and lymph node irradiation in breast cancer patients with axillary lymph node micrometastases or isolated tumor cells. (Abstract #581)**
M. Gardner, D. Stevens, S. Zilberman, S. Villette, F. Lerebours, P. Moisson, B. De La Lande, R. Le Scodan, J. Guinebretiere, A. Labib
- Brd. 6G Poly(ADP-ribose) polymerase-1 (PARP-1) expression in patients treated with breast-conserving surgery and radiation therapy (BCS+RT). (Abstract #582)**
J. Goswami, S. Goyal, H. Wu, M. S. Moran, B. G. Haffty
- Brd. 6H Cause-specific and all-cause mortality of HER2-positive, node-negative, T1a and T1b breast cancers. (Abstract #583)**
H. K. Chew, M. Brown
- Brd. 7A Comorbidities' impact on survival after treatment for early breast cancer. (Abstract #584)**
L. H. Land, S. O. Dalton, M. Jensen, M. Ewertz
- Brd. 7B MDR1/ABCB1 single nucleotide polymorphism (SNP) as a possible prognostic factor in breast cancer patients receiving docetaxel and doxorubicin neoadjuvant chemotherapy. (Abstract #585)**
H. Kim, B. Keam, S. Im, H. Ham, S. Han, D. Oh, W. Han, T. Kim, D. Noh, Y. Bang
- Brd. 7C Correlation between quantitative HER2 protein level and pathologic complete response (pCR) in HER2-positive (+) breast cancer patients (pts) treated with neoadjuvant (NEO) dose-dense (dd) chemotherapy plus trastuzumab. (Abstract #586)**
J. Hurley, C. Welsh, A. C. Fort, J. Weidler, A. Paquet, W. Huang, Y. Lie, S. Gupta, M. P. Bates, M. D. Pegram
- Brd. 7D Do older patients with T1a lesions require sentinel lymph node biopsy? (Abstract #587)**
M. W. O'Malley, K. A. Griffith, M. S. Sabel, L. A. Newman, T. M. Breslin, A. E. Chang, V. M. Cimmino, C. G. Kleer, K. M. Diehl
- Brd. 7E Use of sequential FDG-PET/CT to guide extent of axillary lymph node dissection in breast cancer receiving neoadjuvant chemotherapy. (Abstract #588)**
B. Keam, S. Im, Y. Koh, S. Han, D. Oh, K. Kang, T. Kim, I. Park, D. Noh, Y. Bang
- Brd. 7F Predictors of pathologic response and correlation with long-term outcomes in a trial of neoadjuvant concurrent paclitaxel radiation in locally advanced breast cancer (LABC). (Abstract #589)**
S. Adams, S. C. Lymeris, A. B. Chakravarthy, D. V. Spicer, T. Hochman, M. Donach, J. D. Goldberg, R. Schneider, J. A. Pietenpol, S. Formenti
- Brd. 7G The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. (Abstract #590)**
R. C. Leonard, D. Adamson, R. Anderson, R. Ballinger, G. Bertelli, R. E. Coleman, L. Fallowfield, M. McLinden, J. Mansi, G. Thomas
- Brd. 7H Obesity and tumor characteristics in nodal-positive early-stage breast cancer: Results of the German ADEBAR study. (Abstract #591)**
U. Andergassen, B. K. Rack, K. Annecke, H. Forstbauer, F. Ruhland, N. Harbeck, H. L. Sommer, K. Friese, W. Janni, M. Kiechle
- Brd. 8A Use of prolyl 3-hydroxylases (P3H) to predict endocrine sensitivity in primary breast cancer. (Abstract #592)**
P. Schmid, C. Fleischmann, M. Wischnewsky, N. Syed, R. Shah, P. Quinlan, L. Tooth, S. Kuemmel, A. M. Thompson, T. Crook

- Brd. 8B** **Is the difference in reexcision rate of various margin assessment methods due solely to difference in volume excised? (Abstract #593)**
 C. K. Culpepper, J. I. Goldberg, L. Choi, E. Brogi, L. Sclafani, T. A. King, A. S. Heerdt, A. S. Reiner, S. Patil, K. J. Van Zee
- Brd. 8C** **Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041). (Abstract #594)**
 A. Buzdar, V. Suman, F. Meric-Bernstam, J. C. Boughey, A. M. Leitch, G. W. Unzeitig, M. J. Ellis, M. Ewer, K. Hunt
- Brd. 8D** **A prospective study to evaluate the role of 2-[¹⁸F] fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET), breast magnetic resonance imaging (MRI), and breast ultrasonography in monitoring tumor responses in patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy. (Abstract #595)**
 S. D. Mukherjee, K. Dhamanaskar, R. Tozer, N. Hodgson, M. MacGillivray, C. Gu, K. Cline, L. Elavathil, J. Julian, K. Y. Gulenchyn
- Brd. 8E** **Guideline adherence rates of chemotherapy treatment for breast cancer patients treated in U.S. community oncology practices. (Abstract #596)**
 K. A. Bergstrom, Z. Wang, I. Aksamit, L. Tuscher, T. Lam, B. S. Tom, C. G. Baker, K. B. Whitlock, Z. Ansari-Jaberi, M. Mayo
- Brd. 8F** **The prognostic impact of age in patients with triple-negative breast cancer. (Abstract #597)**
 C. Liedtke, O. Gluz, L. Kiesel, G. N. Hortobagyi, L. Pusztai, A. M. Gonzalez-Angulo
- Brd. 8G** **Utility of the vulnerable elders survey for predicting sixth-month functional decline among older patients with newly diagnosed breast cancer. (Abstract #598)**
 C. Owusu, M. D. Schluchter, S. M. Koroukian, P. Bakaki, N. A. Berger
- Brd. 8H** **Weight change during adjuvant chemotherapy regimens for breast cancer. (Abstract #599)**
 R. M. Speck, A. DeMichele
- Brd. 9A** **Use of PET to assess tumor metabolism and blood flow by tumor subtype in locally advanced breast cancer. (Abstract #600)**
 S. K. Montgomery, B. F. Kurland, L. K. Dunwald, R. K. Doot, R. B. Livingston, K. H. Allison, E. K. Schubert, D. A. Mankoff, J. M. Specht, UW/Seattle Cancer Care Alliance Breast Medical Oncology
- Brd. 9B** **Activity of ixabepilone and PARP inhibitors in triple-negative breast cancer (TNBC) based on gene expression. (Abstract #601)**
 C. E. Horak, G. Alexe, J. Baselga, L. T. Vahdat, V. Valero, G. Xing, P. Mukhopadhyay, D. M. Opatt, J. Sparano
- Brd. 9C** **Evidence for change in prognostic stratification of breast tumor subtypes. (Abstract #602)**
 S. S. Dawood, A. Buzdar, T. A. Buchholz, G. N. Hortobagyi, A. M. Gonzalez-Angulo
- Brd. 9D** **Is short interval mammogram necessary after breast-conservation surgery and radiation treatment in breast cancer patients? (Abstract #603)**
 R. V. Hymas, D. K. Gaffney, B. T. Parkinson, T. Belnap, W. T. Sause
- Brd. 9E** **Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). (Abstract #604)**
 E. Mrozek, M. B. Lustberg, M. V. Knopp, D. G. Spigos, X. Yang, L. A. Houton, B. Ramaswamy, R. M. Layman, S. P. Pivoski, D. M. Agnese

- Brd. 9F** What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study. (Abstract #605)
B. K. Bennett, D. Goldstein, F. M. Boyle, P. L. De Souza, N. Wilcken, M. Friedlander, I. Hickie, E. Scott, N. Rogers, A. R. Lloyd
- Brd. 9G** HER2 testing: A health economics perspective on alternative test strategies. (Abstract #606)
J. A. Lee, M. F. Press
- Brd. 9H** Residual cancer burden (RCB) in breast cancer patients treated with taxane- and anthracycline-based neoadjuvant chemotherapy: The effect of race. (Abstract #607)
M. Chavez-Mac Gregor, R. Hubbard, F. Meric-Bernstam, S. S. Shinde, J. K. Litton, W. A. Woodward, V. Valero, G. N. Hortobagyi, W. F. Symmans, A. M. Gonzalez-Angulo
- Brd. 10A** Expression of forkhead-box protein A1 (FOXA1) as a significant prognostic and predictive marker for ER-positive breast cancer. (Abstract #608)
E. Tokunaga, Y. Hisamatsu, S. Okada, N. Yamashita, Y. Nakashima, H. Saeki, Y. Emi, M. Morita, Y. Kakeji, Y. Maehara
- Brd. 10B** The influence of mammoplasty in axillary lymphatic drainage patterns and sentinel lymph node detection. (Abstract #609)
C. Bouteille, C. Soler, A. Steiner, B. Geissler, E. Gremillet
- Brd. 10C** Effect of neoadjuvant alternating taxane- and anthracycline-based dose-dense regimen for operable breast cancer on prognosis in triple-negative tumors with a complete histological response. (Abstract #610)
J. Medioni, C. Huchon, M. le Frere-Belda, H. Hoffman, A. Bats, D. Eme, J. Andrieu, S. Oudard, E. Levy, F. Lecuru
- Brd. 10D** Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer. (Abstract #611)
R. L. Jones, F. G. Rojo, R. A'Hern, N. Villena, J. Corominas, S. Servitja, A. Rovira, J. S. Reis-Filho, M. Dowsett, J. Albanell
- Brd. 10E** Breast cancer patients access to screening, radiotherapy, and cancer drugs in 18 European, Asian, and Latin American countries. (Abstract #612)
N. E. Wilking, J. Bergh, B. Jönsson, F. Kasteng
- Brd. 10F** The impact of the radiotherapy boost in ductal carcinoma in situ. (Abstract #613)
P. Wong, C. Lambert, R. V. Agnihotram, M. David, M. Duclos, C. Maietta, E. Pietracupa, C. R. Freeman
- Brd. 10G** Cost-effectiveness of adjuvant systemic therapy in early-stage breast cancer patients with isolated tumor cells or micrometastases in regional lymph nodes. (Abstract #614)
M. De Boer, E. M. Adang, K. C. Van Dycke, J. A. Van Dijck, G. F. Borm, C. H. Van Deurzen, P. J. Van Diest, P. Bult, A. T. Donders, V. C. Tjan-Heijnen
- Brd. 10H** Use of adjuvant trastuzumab with chemotherapy in women with small, node-negative, HER2-positive breast cancers. (Abstract #615)
H. L. McArthur, K. Mahoney, P. G. Morris, S. Patil, L. M. Jacks, J. Howard, L. Norton, C. Hudis
- Brd. 11A** Substituting doxorubicin with nonpegylated liposomal doxorubicin (NPLD) in adjuvant/primary chemotherapy for early breast cancer, impact in cardiac function: A pilot study. (Abstract #616)
N. Davidson, A. Chalkidou, D. Houghton
- Brd. 11B** Positron emission tomography (PET) and estrogen receptor (ER) ligand in patients with invasive breast cancer. (Abstract #617)
M. Gemignani, S. Patil, E. Brogi, S. M. Larson, M. Morrow, N. Pandit-Taskar
- Brd. 11F** Notch and Jak/STAT signaling pathways in breast carcinoma of luminal and basal/triple-negative immunophenotypes. (Abstract #618)
E. Adrover, L. Sanchez-Tejada, G. Peiro, D. Giner, E. Lerma, F. I. Aranda, F. J. Gutierrez-Aviño

- Brd. 11G Germline single nucleotide polymorphisms (SNPs) in XRCC3, XRCC1, and XPD, and survival outcomes after adjuvant chemotherapy (CT) in early breast cancer (EBC) patients (pts). (Abstract #619)**
E. Castro, V. Reguero, A. Garcia, R. Leno, S. Ciria, L. Mezquita, E. Sanchez, C. A. Rodriguez, R. Gonzalez, J. J. Cruz
- Brd. 11H Neoadjuvant chemotherapy (NCT) in operable HR-positive and TN breast cancer (BC): A randomized study comparing standard schedule to response-adapted sequence. (Abstract #620)**
C. Jouannaud, J. Charpentier, I. Van Praagh-Doreau, J. Eymard, X. Durando, P. J. Chollet, E. Brabencova, J. Nabholtz, H. Cure, F. Penault-Llorca
- Brd. 12A Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. (Abstract #621)**
V. Guarneri, M. Chavez-Mac Gregor, L. Hsu, W. F. Symmans, J. K. Litton, E. A. Mittendorf, P. F. Conte, G. N. Hortobagyi, A. M. Gonzalez-Angulo
- Brd. 12B Meta-analysis on the impact of post-mastectomy radiotherapy on breast reconstruction outcome. (Abstract #622)**
M. J. Barry, M. R. Kell
- Brd. 12F Correlation of 18FDG PET-CT with SPET-CT lymphoscintigraphy to guide surgical management of the axilla in patients with T2 or T3 breast cancer. (Abstract #623)**
C. Soler, E. Gremillet, C. Bouteille, A. Steiner, B. Geissler
- Brd. 12G Early operable primary breast cancer in elderly (age 70 and older) women (EPC): Changing pattern of management and clinical outcome over 36 years. (Abstract #624)**
S. J. Johnston, B. M. Syed, L. Winterbottom, H. Kennedy, D. A. Morgan, K. Cheung
- Brd. 12H High pathologic complete response (pCR) in HER2-positive breast cancer to novel nonanthracycline neoadjuvant chemotherapy. (Abstract #625)**
A. B. Zelnak, B. Leyland-Jones, S. Gabram-Mendola, T. M. Styblo, M. Rizzo, W. C. Wood, J. Srinivasiah, W. S. Jonas, F. M. Schnell, R. O'Regan
- Brd. 13A Aromatase inhibitor and tamoxifen's impact on breast cancer recurrence among survivors in a large HMO. (Abstract #626)**
R. Haque, J. E. Schottinger, A. H. Fisher, J. M. Shi, C. C. Avila, A. Guo, S. Zelt, V. P. Quinn
- Brd. 13B Correlation of levels of serum 25-hydroxyvitamin D (25-OHD) and lymph node positivity in operable breast cancer: A Turkish Oncology Group study. (Abstract #627)**
M. K. Altundag, F. Icli, S. Aksoy, O. B. Oksuzoglu, Y. Y. Ozisik, H. Onur, G. Utkan, N. Zengin, N. Alkis, B. Yalcin
- Brd. 13C Role of progesterone receptor status (PR) as predictive factor of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patients. (Abstract #628)**
J. M. Perez-Garcia, C. Saura, E. Muñoz, D. Moreno-Fernandez, P. Gomez, M. Vidal, S. Di Cosimo, J. Cortes, J. Baselga, M. Bellet
- Brd. 13D A phase I/II study of increasing doses of epirubicin (E) and docetaxel (D) plus pegfilgrastim (Pegf) for locally advanced (LABC) or inflammatory breast cancer (IBC): NCIC CTG MA.22. (Abstract #629)**
M. E. Trudeau, M. J. Clemons, R. A. Dent, H. J. Kahn, A. M. Parissenti, J. W. Chapman, P. O'Brien, R. A. Jong, K. I. Pritchard, L. E. Shepherd
- Brd. 13E Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials. (Abstract #630)**
J. B. Huober, S. Gelber, B. Thürlimann, M. M. Regan, K. N. Price, A. Goldhirsch, A. S. Coates, G. Viale, C. Oehlschlegel
- Brd. 13F Trends in the use of implantable partial breast radiation therapy for early-stage breast cancer in the United States. (Abstract #631)**
A. M. Abbott, E. B. Habermann, T. M. Tuttle

- Brd. 13G Clinical relevance of TNM staging system according to breast cancer (BC) subtypes. (Abstract #632)**
Y. Park, S. Lee, J. Kong, E. Cho, Y. Choi, J. Lee, S. Nam, J. Yang, J. Ahn, Y. Im
- Brd. 13H Can tumor biomarkers predict response to neoadjuvant anthracycline/taxane chemotherapy in LABC? (Abstract #633)**
J. F. Hilton, J. I. Weberpals, I. Lorimer, M. Nabavi, F. Kanji, S. Hopkins, S. Robertson, M. Daneshmand, S. Verma
- Brd. 14A Prognostic value of CD44s in the NCI randomized trial on breast conservation with 25-year follow-up. (Abstract #634)**
T. D. Dan, D. Ly, S. M. Hewitt, B. P. Soule, A. S. Nowacki, J. Gillespie, D. N. Danforth, J. B. Mitchell, K. A. Camphausen, N. L. Simone
- Brd. 14B Predictive role of [18F]FDG-PET early evaluation in patients (pts) undergoing preoperative chemotherapy (PCT) for breast cancer (BC). (Abstract #635)**
A. Martoni, C. Zamagni, S. Quercia, M. Rosati, N. Cacciari, A. Bernardi, M. Castellucci, D. Santini, M. Taffurelli
- Brd. 14C The expression patterns of STAT-3, phosphorylated STAT-3, P38 MAP-kinase, and phosphorylated P38 MAP-kinase in triple-negative breast cancers and their prognostic significance. (Abstract #636)**
E. Yaman, I. I. Gonul, S. Buyukberber, U. Coskun, D. Yamac, A. Sevinc, F. Dane, A. Uner, B. Ozturk, A. O. Kaya
- Brd. 14D Use of trastuzumab associated with cisplatin and vinorelbine followed by docetaxel as a neoadjuvant regimen for patients with HER2-positive breast cancer. (Abstract #637)**
G. Carillio, R. Aiello, A. Mazzola, M. Ali', G. Scandurra, E. Taibi, M. Chiarenza, G. Fallica, F. Caruso, M. Caruso, Humanitas Centro Catanese di Oncologia
- Brd. 14E Twenty-year results of alternating radiotherapy and chemotherapy in nonmetastatic inflammatory breast cancer. (Abstract #638)**
E. Lima Pessoa, A. Dunant, S. Heymann, S. Delalogue, M. Spielmann, C. Uzan, M. Mathieu, R. Arriagada, H. Marsiglia, C. Bourgier
- Brd. 14F Early therapeutic intervention based on blood tumor markers (TMs) in patients with primary breast cancer (PBC). (Abstract #639)**
J. F. Robertson, J. Mathew, P. Prinsloo, A. Agrawal, E. Gutteridge, E. Merenah, K. Cheung
- Brd. 14G Independent comparison of three mathematical models for predicting the risk of additional nodal metastases after positive sentinel lymph node biopsy in early breast cancer. (Abstract #640)**
Y. Moghaddam, M. Falzon, L. Fulford, N. R. Williams, M. R. Keshtgar
- Brd. 14H Composite and component expression score correlations in ER-positive breast cancer. (Abstract #641)**
A. M. Wang, C. Santini, U. Vogt, R. Lagier, D. Kemming, C. Rowland, S. Kwok, S. Broder, J. Sninsky, B. Brandt
- Brd. 15A Comparison of a novel molecular assay with touch imprint and permanent histology of sentinel lymph nodes in early-stage breast cancer. (Abstract #642)**
S. Saha, S. Sirop, B. Chakravarty, D. Wiese, M. Soni, A. Singla, E. Quiachon, W. Liu, A. Ahsan, J. Badin
- Brd. 15B Low adherence to long-term adjuvant endocrine therapy in breast cancer women age 40 or younger. (Abstract #643)**
D. Rey-Herlin, A. D. Bouhnik, S. Cortaredona, V. Seror, M. K. Bendiane, Y. Odadia, P. Viens
- Brd. 15C Effect of preoperative concomitant chemoradiotherapy in chemotherapy-refractory breast cancer on feasibility of curative surgery and pathologic tumor response. (Abstract #644)**
I. Ghorbel, S. Heymann, S. Delalogue, A. Belaid, F. Azoury, C. Mazouni, C. Balleyguier, P. Vielh, H. Marsiglia, C. Bourgier

- Brd. 15D Dose-dense chemotherapy in nonmetastatic breast cancer patients: A systematic review and meta-analysis. (Abstract #645)**
L. F. Bonilla, I. Ben-Aharon, L. Vidal, A. Gafter-Gvili, L. Leibovici, S. M. Stemmer
- Brd. 15E MicroRNA expression to classify breast cancer and predict relapse. (Abstract #646)**
J. De La Cruz, V. Scott, C. Richon, P. Dessen, S. Delalogue, M. Mathieu, A. Goubar, S. Vagner, V. Lazar, F. Andre
- Brd. 15F Influence of primary systemic therapy on minimal residual disease in primary breast cancer. (Abstract #647)**
B. Aktas, H. Neubauer, O. Hoffmann, S. Becker, S. Kümmel, D. Wallwiener, R. Kimmig, E. Solomayer, S. Kasimir-Bauer, T. N. Fehm
- Brd. 15G Neoadjuvant chemotherapy (NCT) in 466 patients for operable breast cancer: Predictive factors for pathological response. (Abstract #648)**
C. Abrial, X. Durando, E. Thivat, E. Planchat, I. Raoelfils, M. Mouret-Reynier, P. Gimbergues, I. Van Praagh-Doreau, P. J. Chollet, F. Penault-Llorca
- Brd. 15H Indocyanine green fluorescence imaging system for sentinel lymph node biopsy in early breast cancer patients. (Abstract #649)**
H. Abe, T. Umeda, T. Mori, M. Tanaka, Y. Kawai, H. Cho, Y. Kubota, Y. Kurumi, T. Tani
- Brd. 16A Management and outcome of HER2-positive breast cancer treated with and without adjuvant trastuzumab: The Imperial College London experience. (Abstract #650)**
D. Shah, O. Gojis, J. Krell, R. Ahmad, P. Riddle, R. C. Coombes, R. C. Leonard, K. Fox, S. J. Cleator, C. Palmieri
- Brd. 16B Long-term results of a phase II trial of preoperative concurrent radiochemotherapy for breast cancers. (Abstract #651)**
M. A. Bollet, L. Belin, V. Dieras, F. Thibault, F. Reyat, F. Campana, Y. M. Kirova, J. Pierga, B. Sigal-Zafrani, A. Fourquet
- Brd. 16C Phase II study of the combination of gemcitabine plus carboplatin as neoadjuvant treatment in locally advanced breast cancer. (Abstract #652)**
V. Srimuninimit, S. Ithimakin, C. Akewanlop, A. Ratanawichitrasin, V. Veerasan, S. Rojananin, P. Prasartong-osoht
- Brd. 16D Clinicopathologic, molecular subtype, and survival prognostic features in premenopausal breast cancer patients by age at diagnosis. (Abstract #653)**
C. Vallejos Sologuren, H. L. Gomez, J. E. Abugattas, M. J. Marcelo, F. F. Doimi, S. P. Neciosup, J. F. Suazo, J. A. Pinto, R. G. Velarde, V. E. Carlos
- Brd. 16E Outcome of patients with nonmetastatic breast cancer receiving nitrogen-containing bisphosphonates: A comparative analysis from the Metropolitan Detroit Cancer Surveillance System (MDCSS). (Abstract #654)**
Z. A. Nahleh, J. Abrams, A. Bhargava, K. Nirmal, J. J. Graff
- Brd. 16F Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: Therapeutic versus preemptive use of lamivudine. (Abstract #655)**
B. Sohn, J. Ahn, K. Jung, G. Gong, S. Ahn, S. Kim
- Brd. 16G Updated survival-based analysis using inverse probability of censoring weighted analysis (IPCW) to estimate the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer. (Abstract #656)**
J. Karnon, S. Kaura
- Brd. 16H Breast carcinoma with amplified HER2: A gene expression signature specific for trastuzumab resistance and poor prognosis. (Abstract #657)**
T. Khoury, K. Kanehira, D. Wang, F. O. Ademuyiwa, W. Mojica, J. Conroy, N. Nowak, S. Liu

- Brd. 17A** **An advanced computerized decision support technology to support breast multidisciplinary meetings. (Abstract #658)**
V. Patkar, D. Acosta, T. Davidson, A. Jones, J. Fox, M. R. Keshtgar
- Brd. 17B** **Effect of trastuzumab on antibody-dependent cellular cytotoxicity (ADCC) in HER2 nonamplified (non-amp) breast cancer (BC) cells. (Abstract #659)**
D. M. Collins, N. O'Donovan, J. Dean, A. E. Hogan, J. Ballot, D. McDonnell, A. O'Meara, J. Crown
- Brd. 17C** **The influence of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in stage I-II estrogen receptor-positive breast cancer: Experience at a single center with a uniform treatment policy. (Abstract #660)**
D. B. Geffen, S. Abu-Ghanem, N. Sion-Vardy, R. Braunstein, M. Tokar, S. Ariad, B. Delgado, M. Bayme, M. Koretz
- Brd. 17D** **Prognostic relationship of SATB1 gene expression and estrogen receptor status in breast cancer cells. (Abstract #661)**
L. Mavrova, T. Karn, L. Hanker, E. Ruckhäberle, V. Mueller, U. Holtrich, M. Kaufmann, A. Rody
- Brd. 17E** **Differential response from neoadjuvant chemotherapy across breast cancer subtypes. (Abstract #662)**
H. Jinno, S. Matsuda, T. Hayashida, M. Takahashi, M. Sakata, T. Ikeda, M. Mukai, Y. Kitagawa
- Brd. 17F** **Local effects of tamoxifen versus aromatase inhibitors (AI) on breast tissue: A longitudinal dynamic contrast enhanced (DCE) breast MRI cohort study. (Abstract #663)**
C. K. Kuhl, S. Schradang, W. Kuhn, H. H. Schild
- Brd. 17G** **Microscopic disease after neoadjuvant therapy in inflammatory breast cancer. (Abstract #664)**
A. Lodhi, K. Mosalpuria, S. Krishnamurthy, S. Jackson, C. Hall, E. Andreopoulou, B. Singh, V. Valero, A. Lucci
- Brd. 17H** **Efficacy of capecitabine (C)-based therapy in patients with first-line metastatic breast cancer (MBC) previously treated with adjuvant anthracyclines and taxanes. (Abstract #665)**
F. Siedentopf, W. Schoenegg, M. Kaufmann, M. Debled, N. J. Robert
- Brd. 18A** **Timing of genetic testing relative to breast cancer surgery. (Abstract #666)**
J. R. Trosman, C. B. Weldon, W. J. Gradishar, J. C. Schink
- Brd. 18B** **Assessment of concomitant versus sequential aromatase inhibitor with radiotherapy for postmenopausal women with early-stage breast cancer. (Abstract #667)**
N. M. Abd El-Bary, T. Hashem
- Brd. 18C** **HER2-positive early breast cancers: What proportion are receiving adjuvant trastuzumab therapy? A multicenter audit. (Abstract #668)**
S. Marla, J. Cardale, D. J. Dodwell, A. Skene, O. Gojis, C. Palmieri, P. Abram, S. Cleator, A. Bowman, J. C. Doughty
- Brd. 18D** **The effects of Oncotype DX recurrence scores on chemotherapy receipt in a multi-institutional breast cancer cohort. (Abstract #669)**
F. O. Ademuyiwa, A. Miller, S. B. Edge, M. A. Thorat, G. W. Sledge, S. S. Badve
- Brd. 18E** **A multicenter study to determine the optimum duration of neoadjuvant letrozole on tumor regression to permit breast-conserving surgery: Final analyses. (Abstract #670)**
R. Carpenter, J. C. Doughty, C. Cordiner, N. Moss, A. Gandhi, C. Wilson, C. Andrews, G. Gui, A. Skene
- Brd. 18F** **Nasal septum perforations: A side effect of the association of bevacizumab and taxanes in patients with breast cancer? (Abstract #671)**
A. Mailliez, C. Baldini, V. Servent, Y. Mallet, S. Dewas, J. Bonneterre

- Brd. 18G** **Observational GHEA study: Adjuvant trastuzumab treatment of HER2-positive breast carcinomas in the Italian clinical setting compared to HERA trial. (Abstract #672)**
M. Campiglio, E. Tagliabue, A. Balsari, R. Bufalino, E. Ferri, S. Ménard
- Brd. 18H** **Association between c-myc amplification and other biologic features and prognosis in primary breast cancer. (Abstract #673)**
E. Pietri, L. Medri, S. Bravaccini, E. Scarpi, A. Rocca, R. Maltoni, L. Ceconetto, S. Sarti, T. Ibrahim, D. Amadori
- Brd. 19A** **Indocyanine green (ICG) fluorescence imaging versus radioactive colloid for sentinel lymph node identification in patients with breast cancer. (Abstract #674)**
N. Tagaya, M. Tsumuraya, A. Nakagawa, Y. Iwasaki, H. Kato, K. Kubota
- Brd. 19B** **Predictive factors of ductal spreading in preoperative breast cancer patients. (Abstract #675)**
K. Hisamatsu, W. Takiyama, T. Mimura, J. Taomoto, Y. Sugiyama, S. Saeki, H. Mukaida, N. Hirabayashi, M. Kaneko, T. Ono
- Brd. 19C** **Lymphatic and vascular invasion patterns in triple-negative breast cancer. (Abstract #676)**
S. Yaman, B. Gumuskaya, C. Ozkan, S. Aksoy, G. Guler, M. K. Altundag
- Brd. 19D** **Progesteron receptor status as a predictor of progression-free survival and overall survival in patients with early breast cancer. (Abstract #677)**
T. Latiano, C. D'Addetta, R. Murgo, A. Piano, M. Morritti, V. Valori, L. Lombardi, P. Parrella, M. Copetti, E. Maiello
- Brd. 19E** **Comparative evaluation of two methods of chemotherapy dose calculation according to body surface area and body mass index in obese females with breast cancer. (Abstract #678)**
T. Refaat, S. Abdelmoneim, Y. Rostom
- Brd. 19F** **The effect of aspirin therapy on circulating vascular endothelial growth factor (VEGF) levels in tamoxifen-treated women. (Abstract #679)**
C. E. Holmes, J. Jasielec, J. E. Levis, J. Skelly, H. B. Muss
- Brd. 19G** **Long-term outcome of phase II study of biweekly dose-dense AC followed by weekly paclitaxel and carboplatin and trastuzumab (TC +/- H) based on HER2 status in large and inflammatory breast cancer (BC). (Abstract #680)**
R. S. Mehta, T. Schubbert, D. Jackson
- Brd. 19H** **A multicenter phase II study of primary systemic therapy epirubicin/cyclophosphamide followed by docetaxel plus concurrent trastuzumab for HER2-positive advanced breast cancer. (Abstract #681)**
T. Saeki, K. Aogi, S. Nakamura, M. Kashiwaba, N. Sato, N. Masuda, Y. Rai, S. Ohno, K. Miyakoda, T. Ikeda
- Brd. 20B** **Pathologic response rate for high-risk operable breast cancer after TNCF semi-intensive neoadjuvant chemotherapy: Updated data with long-term results. (Abstract #683)**
X. Durando, H. Cure, C. Abrial, E. Goldschmidt, F. Penault-Llorca, I. Van Praagh-Doreau, C. Pomel, D. Machover, P. J. Chollet, M. Mouret-Reynier
- Brd. 20C** **First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting. (Abstract #684)**
S. K. Gruschkus, J. F. Doan, C. Chen, M. T. Forsyth, D. Lalla, M. Shing
- Brd. 20D** **Phase IB study of primary chemotherapy with paclitaxel, gemcitabine, and sunitinib in patients with HER2-negative stage II/III breast cancer. (Abstract #685)**
K. S. Lee, I. Park, J. Ro, H. S. Kang, S. W. Kim, S. Lee, S. Y. Jung, Y. Kwon

Saturday, June 5, 2010

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Breast Cancer—Metastatic

Location: S Hall A2

Tracks(s): Breast Cancer

- Brd. 21A** **Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guideline (GL) drug therapy recommendations for metastatic breast cancer: An analysis from the commercial managed care claims database PharMetrics (PM). (Abstract #1032)**
E. M. Lepisto, K. Tangirala, J. L. Vandergrift, J. S. McClure, D. L. McNally, C. D. Mullins, B. S. Seal
- Brd. 21B** **Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy. (Abstract #1033)**
M. Giuliano, A. Giordano, L. Hsu, B. C. Handy, N. T. Ueno, E. Andreopoulou, R. H. Alvarez, V. Valero, G. N. Hortobagyi, M. Cristofanilli
- Brd. 21C** **Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer. (Abstract #1034)**
M. Arnedos, S. Drury, M. Afentakis, M. Hills, J. Salter, I. E. Smith, M. Dowsett
- Brd. 21D** **Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET+LAP) versus anastrozole plus trastuzumab (ANA+TZ) as first-line treatment for postmenopausal women with HER2+ and HR+ metastatic breast cancer (MBC) from the U.K. National Health Service (NHS) perspective. (Abstract #1035)**
V. Hastings, T. E. Delea, M. Amonkar, K. Lykopoulos, J. Diaz, S. R. Johnston
- Brd. 21E** **Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy. (Abstract #1036)**
S. S. Badve, L. Li, M. A. Thorat, R. C. Gagnon, C. E. Ellis, J. O'Shaughnessy, K. L. Blackwell, J. Baselga, G. W. Sledge
- Brd. 21F** **Early detection of recurrent breast cancer using metabolite profiling. (Abstract #1037)**
V. Asiago, L. Alvarado, N. Shanaiah, N. Gowda, K. Owusu-Sarfo, R. Ballas, D. Raftery
- Brd. 21G** **A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC). (Abstract #1038)**
K. L. Tedesco, J. L. Blum, A. Goncalves, J. Lubinski, N. Ben-Baruch, C. R. Osborne, P. Lardelli, J. C. Tercero, F. A. Holmes, S. Delalogue
- Brd. 21H** **Use of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patterns in triple-negative compared to receptor-positive cancers. (Abstract #1039)**
L. Santarpià, A. M. Gonzalez-Angulo, Y. Qi, K. Stemke-Hale, B. Wang, D. J. Booser, G. N. Hortobagyi, W. F. Symmans, A. Di Leo, L. Pusztai
- Brd. 22A** **Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results. (Abstract #1040)**
H. S. Rugo, M. Campone, D. Amadori, A. M. Wardley, D. Aldrighetti, P. F. Conte, D. Liu, B. Mudenda, M. B. McHenry, X. B. Pivot
- Brd. 22B** **Maintenance with everolimus (RAD001) and trastuzumab (T) after discontinuation of chemotherapy in patients (pts) with heavily pretreated HER2-positive metastatic breast cancer (MBC): Pooled data of extension cohorts of phase Ib/II studies. (Abstract #1041[^])**
G. H. Jerusalem, A. Fasolo, C. Massacesi, M. Balaisius, C. Manlius, T. Sahmoud, F. Andre, L. Gianni

SATURDAY

- Brd. 22C Phase II study of bavixumab plus docetaxel in locally advanced or metastatic breast cancer. (Abstract #1042)**
D. Tabagari, G. Nemsadze, M. Janjalia, M. Jincharadze, J. Shan
- Brd. 22D Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis. (Abstract #1043)**
V. Calvo, N. Ramirez, C. Saura, M. Vidal, A. Velasco, A. Llombart-Cussac, H. Cortes-Funes, D. Miles, J. Baselga, J. Cortes
- Brd. 22E Use of fresh assessment of tumor-initiating cells in pleural fluid of breast cancer patients to predict overall survival. (Abstract #1044)**
W. A. Woodward, E. N. Cohen, H. Gao, L. Li, C. Jimenez, S. Krishnamurthy, S. L. Tucker, M. Cristofanilli, T. A. Buchholz, J. M. Reuben
- Brd. 22F Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): Metaregression analysis of randomized trials (RCT). (Abstract #1045)**
F. Cuppone, E. Bria, I. Sperduti, V. Vaccaro, C. Nisticò, P. Carlini, M. Milella, A. Fabi, D. Giannarelli, F. Cognetti
- Brd. 22G Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+ metastatic breast cancer. (Abstract #1046)**
F. J. Esteva, S. Franco, M. K. Hagan, A. Brewster, W. Williams, A. M. Florance, K. Koch, S. J. Turner, M. Ridderheim, A. T. Perez
- Brd. 22H High-throughput technologies to personalize medical treatment in patients with metastatic breast cancer. (Abstract #1047)**
R. Wolp-Diniz, J. De La Cruz, V. Scott, C. Richon, M. Campone, T. D. Bachelot, F. Dalenc, V. Lazar, J. Soria, F. Andre
- Brd. 23A Biomarkers as potential predictors of response to treatment with motesanib or bevacizumab in combination with paclitaxel (P) in patients (pts) with locally recurrent or advanced metastatic breast cancer (MBC). (Abstract #1048^)**
S. D. Patterson, M. T. Davis, J. R. Mackey, M. Martin, Y. Hei, M. B. Bass
- Brd. 23B Open-label, multicenter, phase Ib, dose-escalation study of oral lapatinib (L) in combination with docetaxel (D) and trastuzumab (T) in untreated HER2-overexpressing (HER+) metastatic breast cancer (MBC). (Abstract #1049)**
V. Dieras, M. J. Kennedy, P. Tresca, M. E. Marty, H. Burris, M. DeSilvio, N. O'Donovan, M. Lau, M. Ridderheim, J. Crown
- Brd. 23C Use of serum uPA change to predict PFS and overall survival in first-line trastuzumab-treated breast cancer. (Abstract #1050)**
H. Y. Hou, U. Anyanwu, N. Jamshidi, K. Leitzel, S. M. Ali, W. Köstler, E. Fuchs, P. Hamer, W. P. Carney, A. Lipton
- Brd. 23D Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048). (Abstract #1051)**
V. Valero, L. D. Bosserman, D. A. Yardley, H. H. Roche, E. Thomas, L. T. Vahdat, P. Mukhopadhyay, D. M. Opatt, R. A. Peck, J. Sparano
- Brd. 23E Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy. (Abstract #1052)**
A. M. Wardley, R. Stein, J. McCaffrey, J. Crown, Z. Malik, D. Rea, P. J. Barrett-Lee, G. T. Lee
- Brd. 23F Association of receptor activator of NF-kb (RANK) expression with bone metastasis in breast carcinomas. (Abstract #1053)**
D. Santini, B. Vincenzi, A. Russo, C. Ortega, C. Porta, S. Galluzzo, N. M. La Verde, C. Caroti, R. Addeo, G. Tonini

Saturday, June 5, 2010

- Brd. 23G** **A double-blind, randomized, prospective, phase II trial of capecitabine (Cap) plus enzastaurin (Enz) versus cap plus placebo in patients (pts) with advanced breast cancer (BrCa) and prior anthracycline and taxane treatment. (Abstract #1054)**
M. Clemons, K. A. Gelmon, J. Lynch, M. L. Kotliar, A. Joy, J. P. Jordaan, L. L. Han, J. M. Blair, N. A. Iscoe
- Brd. 23H** **Correlations between efficacy and early changes in biomarkers in a metastatic breast cancer (mBC) clinical trial with sunitinib malate. (Abstract #1055)**
K. Keyvanjah, W. Carley, Oncology Business Unit, Pfizer Global Research and Development
- Brd. 24A** **Candidate predictive biomarkers of cetuximab benefit in triple-negative breast cancer. (Abstract #1056)**
S. Khambata-Ford, J. O'Shaughnessy, D. Brickman, J. D. Jensen, L. Asmar, C. E. Horak
- Brd. 24B** **Risk of renal failure associated with IV bisphosphonate use in patients with metastatic breast cancer. (Abstract #1057)**
W. J. Langeberg, K. Chung, M. J. Lage
- Brd. 24C** **Age-specific trends of survival in metastatic breast cancer: Data from a population-based cancer registry in Stockholm, Sweden. (Abstract #1058)**
T. Foukakis, T. Fornander, T. Lekberg, H. Hellborg, J. Adolfsson, J. Bergh, on behalf of the Stockholm Breast Cancer Study Group
- Brd. 24D** **Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer. (Abstract #1059)**
A. Fabi, A. Di Benedetto, R. Merola, G. Metro, M. Mottolese, P. Papaldo, G. Ferretti, P. Vici, I. Sperduti, F. Cognetti
- Brd. 24E** **Safety and efficacy of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast. (Abstract #1060)**
P. Fedele, L. Orlando, P. Schiavone, P. Rizzo, N. Calvani, M. D'Amico, A. Marino, F. Sponziello, A. Nacci e S. Cinieri
- Brd. 24F** **Long-term effect of fulvestrant on signaling elements in breast cancer. (Abstract #1061)**
A. Agrawal, J. F. Robertson, E. Gutteridge, I. O. Ellis, K. Cheung, R. I. Nicholson, S. Kyme, J. M. Gee
- Brd. 24G** **Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results. (Abstract #1062)**
M. Jain, N. Raizada, R. Kuttan, J. Shan, R. Digumarti
- Brd. 24H** **Risk factors for central nervous system (CNS) metastases in patients with stage I-III breast cancer. (Abstract #1063)**
S. P. Neciosup, H. L. Gomez, W. R. Cruz, F. F. Doimi, J. A. Pinto, J. M. Cotrina, J. F. Suazo, V. E. Carlos, L. Mauricio, C. Vallejos Sologuren
- Brd. 25A** **Impact of CNS metastases on treatment and survival in patients receiving trastuzumab for metastatic breast cancer (MBC). (Abstract #1064)**
R. Griffiths, K. Lindquist, D. Lalla, J. F. Doan, M. G. Brammer, M. Danese
- Brd. 25B** **BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies. (Abstract #1065)**
M. H. Schuler, M. M. Uttenreuther-Fischer, M. J. Piccart-Gebhart, N. Harbeck, on behalf of the study group and trial team
- Brd. 25F** **Pertuzumab and trastuzumab: Exploratory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer. (Abstract #1066)**
J. Cortes, J. Baselga, P. Fumoleau, K. A. Gelmon, G. Ross, V. McNally, G. V. Bianchi, M. Venturi, H. Paul, L. Gianni

- Brd. 25G Phase III study of sunitinib (SU) in combination with metronomic dosing of cyclophosphamide (C) and methotrexate (M) in patients (pts) with metastatic breast cancer (MBC). (Abstract #1067)**
 A. J. Chien, J. Aicardi, M. E. Melisko, A. Goga, M. M. Moasser, J. W. Park, P. N. Munster, H. S. Rugo
- Brd. 25H Free methylated DNA in association of clinical signs and circulating blood tumor cells in patients with breast cancer. (Abstract #1068)**
 C. Matuschek, E. Boelke, W. Budach, H. Prissack, H. Taskin, M. Peiper, M. Rezaei, H. Bojar
- Brd. 26A Survival benefit of neck dissection for patients with breast cancer with supraclavicular lymph node metastasis. (Abstract #1069)**
 S. Chen
- Brd. 26B Incorporation of a comprehensive geriatric assessment (CGA) into a randomized phase III trial for metastatic breast cancer (MBC): The PELICAN study. (Abstract #1070)**
 M. De Wit, F. Honecker, U. Wedding, D. Waldenmaier, J. Dorn, M. Warm, S. Al-Batran, M. Schmidt, R. Kreienberg, N. Harbeck
- Brd. 26F The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer. (Abstract #1071)**
 T. Kim, H. Lee, S. Han, D. Oh, S. Im, Y. Bang
- Brd. 26G Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy. (Abstract #1072)**
 K. Gunzer, H. de Mont-Serrat, M. M. Uttenreuther-Fischer, J. Misset, on behalf of study group and trial team
- Brd. 26H Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC). (Abstract #1073)**
 W. J. Gradishar, F. Dalenc, V. G. Kaklamani, F. Costa, T. P. Sahoo, J. Segalla, D. Lokanatha, H. Pinczowski, V. Raina, J. Baselga
- Brd. 27A A phase II study of medroxyprogesterone acetate (MPA) in patients (pts) with hormone receptor-negative (HR-) metastatic breast cancer (MBC): Translational Breast Cancer Research Consortium trial 007. (Abstract #1074)**
 L. G. Vaughn, L. Li, L. Nabell, H. S. Rugo, L. A. Carey, G. G. Kimmick, P. S. Steeg, K. Miller
- Brd. 27B Breast cancer metastasis gene signature: The search for the holy grail. (Abstract #1075)**
 R. E. Ellsworth, L. A. Field, B. Love, J. L. Kane, J. A. Hooke, C. D. Shriver
- Brd. 27C Effect of the novel oncomir MiR-301 on tumor proliferation and invasion in human breast cancer. (Abstract #1076)**
 W. Shi, K. Gerster, N. Alajez, J. Tsang, L. Waldron, M. Pintilie, A. Hui, D. R. McCready, A. W. Fyles, N. Miller, F. F. Liu
- Brd. 27D Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months. (Abstract #1077)**
 L. B. Petruzelka, V. Ganju, D. Becquart, P. F. Conte, N. Tubiana-Mathieu, M. J. Gil Gil, M. Morand, N. Vaissiere, G. Villanova, A. Chan
- Brd. 27E Genetic signature of breast cancer with lymphangitic spread to the chest wall: Results from a randomized phase II study combining bevacizumab with oral vinorelbine plus capecitabine (BEVIX). (Abstract #1078)**
 G. Curigliano, M. Alkalay, M. A. Locatelli, L. Fumagalli, S. Giudici, F. Bertolini, V. Galimberti, G. Viale, F. Nole, A. Goldhirsch

- Brd. 27F** Primary tumor tissue levels of TIMP-1 and outcome following chemotherapy with docetaxel monotherapy or docetaxel in combination with gemcitabine in patients with locally advanced or metastatic breast cancer. (Abstract #1079)
C. L. Jørgensen, E. Balslev, K. D. Bjerre, A. Bartels, S. Møller, B. Ejlersen, N. Brønner, D. L. Nielsen
- Brd. 27G** Treatment and outcome of metastatic HER2-positive breast cancer relapsing post adjuvant trastuzumab exposure. (Abstract #1080)
J. Krell, C. R. James, D. Shah, P. Riddle, R. Ahmad, K. Hogben, R. C. Coombes, P. Madden, S. Cleator, C. Palmieri
- Brd. 27H** Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. (Abstract #1081)
H. Iwata, K. Aogi, N. Masuda, H. Mukai, M. Yoshida, Y. Rai, K. Taguchi, Y. Sasaki, S. Takashima
- Brd. 28A** Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: A monoinstitutional experience. (Abstract #1082)
S. Spazzapan, D. Crivellari, S. Tumolo V, A. Russo
- Brd. 28B** Management of hand-foot skin reaction (HFSR)/hand-foot syndrome (HFS) in SOLTI-0701: A double-blind, randomized phase IIb study comparing sorafenib (SOR) versus placebo (PL) in combination with capecitabine (CAP) in patients (pts) with advanced breast cancer (BC). (Abstract #1083)
P. Gomez, H. H. Roche, F. Costa, J. Segalla, H. Pinczowski, S. Cabral Filho, E. Ciruelos, B. M. Van Eyll, J. Baselga
- Brd. 28C** Do experts agree on how to assess disease progression (DP) and progression-free survival (PFS) in phase III trials? A survey with experts in breast cancer research. (Abstract #1084)
E. D. Saad, A. Katz, L. Pusztai, P. M. Hoff, M. E. Buyse
- Brd. 28D** Interim safety data on the ZICE trial: A randomized phase III, open-label, multicenter, parallel group clinical trial to evaluate and compare the efficacy, safety profile, and tolerability of oral ibandronate versus intravenous zoledronate in the treatment of patients with breast cancer with bone metastases. (Abstract #1085)
P. J. Barrett-Lee, N. Murray, J. Abraham, A. Casbard, H. Clements, T. S. Maughan, G. Griffiths, ZICE Trial Management Group
- Brd. 28E** Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC). (Abstract #1086)
T. A. Traina, J. A. Sparano, J. Caravelli, S. Patil, A. Abbruzzi, R. Hawke, J. Bromberg, J. Nonemaker, L. Norton, C. Hudis
- Brd. 28F** ^{18}F -fluoro-17 β -estradiol (FES)-PET to detect ER-positive tumor lesions in patients with breast cancer with a diagnostic dilemma. (Abstract #1087)
M. van Kruchten, A. W. Glaudemans, E. F. De Vries, C. P. Schroder, E. De Vries, G. Hospers
- Brd. 28G** HER2, p95HER2, and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive, trastuzumab-refractory metastatic breast cancer. (Abstract #1088)
S. Han, J. Ro, A. Paquet, W. Huang, J. Weidler, K. S. Lee, I. Park, D. Oh, S. Im, T. Kim
- Brd. 28H** Combination with zoledronic acid (ZA) and sunitinib (SU) to reduce severity of osteolytic lesions in bone metastases. (Abstract #1089)
C. Schem, D. O. Bauerschlag, A. Lorenzen, S. Tiwari, H. Kalthoff, C. C. Glueer, W. Jonat
- Brd. 29A** Efficacy and safety of oral vinorelbine (NVBO) in first- or second-line metastatic breast cancer (MBC). (Abstract #1090)
I. Blancas, S. Morales, N. Diaz, A. Barnadas, M. L. Gonzalez, S. del Barco, M. H. Lopez de Ceballos, F. J. Perez, A. Lombart-Cussac

- Brd. 29B Risk of gastrointestinal perforation in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis. (Abstract #1091)**
N. Ramirez Merino, V. Calvo, M. Vidal, M. Bellet, J. Perez, A. Llombart-Cussac, H. Cortes-Funes, D. Miles, J. Baselga, J. Cortes
- Brd. 29C Characteristics of triple-negative metastatic breast cancer among older adults: A population-based analysis. (Abstract #1092)**
I. H. Zuckerman, E. Onukwugha, J. F. Gardner, D. L. McNally, B. S. Seal, C. D. Mullins
- Brd. 30A Phase Ib study of sorafenib and vinorelbine as first-line treatment in patients with metastatic breast cancer. (Abstract #1093)**
C. Ferrario, H. Charamis, S. Oyewole-Eletu, C. L. Mihalciou, A. Langleben, W. H. Miller, R. Aloyz, L. C. Panasci
- Brd. 30B Circulating tumor cells (CTCs) and association with survival in molecular subtypes (MST) of metastatic breast cancer (MBC). (Abstract #1094)**
M. Graham, N. Fleming, A. Pinto, E. Dropkin
- Brd. 30C Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE). (Abstract #1095)**
M. N. Saleh, J. C. Bendell, A. Rose, P. Siegel, L. L. Hart, S. Sirpal, S. F. Jones, E. Crowley, R. Simantov, L. T. Vahdat
- Brd. 31A Kinetic analysis of breast tumor decay and growth following ixabepilone plus capecitabine (IXA + CAP) versus capecitabine alone (CAP) to discern whether the superiority of the combination is a result of slower growth, enhanced tumor cell kill, or both. (Abstract #1096)**
A. T. Fojo, W. D. Stein, J. Wilkerson, S. E. Bates
- Brd. 31B A phase II cross-over study of docetaxel versus vinorelbine in anthracycline-resistant, advanced breast cancer. (Abstract #1097)**
C. C. Alifrangis, D. Shipway, O. Gojjs, M. Emson, D. Mackie, R. C. Coombes, C. Palmieri
- Brd. 31C Fulvestrant (F) as first-line palliative treatment for hormone-receptor (HR)-positive metastatic breast cancer. (Abstract #1098)**
R. Bartsch, C. Wenzel, R. Ziebermayr, Z. Bago-Horvath, U. Pluschnig, P. C. Dubsy, M. Rudas, M. Gnant, C. Zielinski, G. G. Steger
- Brd. 32A Analysis of truncated HER2 expression and activation in breast cancer. (Abstract #1099)**
S. Singh, X. Liu, T. Lee, R. Kirkland, A. Kuller, L. Ohrmund, F. Lin, M. Hanna, P. Kim, B. Ybarrondo
- Brd. 32B Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Preliminary results report of a phase II trial. (Abstract #1100)**
Z. Wang, X. Hu, L. Chen, J. Wang, H. Wang, L. Wang, G. Liu, Z. Hu, J. Wu, S. Zhimin
- Brd. 32C Prediction of response in advanced breast cancer (ABC) patients who received trastuzumab-paclitaxel (TP): HER2 FISH ratio, expression of class III beta tubulin (bTubIII), and immunoglobulin G fragment C receptor (FCGR) polymorphisms. (Abstract #1101)**
J. Ahn, M. Jung, J. Koo, Y. Moon, B. Park, S. Kim, S. Park, S. Hong, J. Kim, J. Sohn
- Brd. 33A Serum-transforming growth factor- α (TGF- α) and response to lapatinib plus capecitabine in HER2-positive (HER2+) metastatic breast cancer (MBC). (Abstract #1102)**
J. Rhee, S. Han, Y. Cha, H. Kim, D. Oh, S. Im, J. Ro, Y. Im, Y. Bang, T. Kim
- Brd. 33B Effect of surgical treatment of primary tumor on outcome in stage IV breast cancer. (Abstract #1103)**
M. R. Bower, R. Brown, C. Scoggins, K. M. McMasters, A. B. Chagpar

- Brd. 33C** **Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guidelines (GL) for imaging work-up of patients with metastatic breast cancer: An analysis from the commercial managed care claims PharMetrics (PM) and SEER/Medicare (SM) databases. (Abstract #1104)**
D. L. McNally, B. S. Seal, J. L. Vandergrift, C. D. Mullins, E. M. Lepisto, J. S. McClure, M. Tangirala
- Brd. 34A** **Serum markers to monitor response to zoledronic acid in patients with bone metastases from breast cancer. (Abstract #1105)**
L. Mercatali, T. Ibrahim, E. Sacanna, R. Ricci, E. Scarpi, F. Fabbri, P. Serra, C. Tison, D. Amadori
- Brd. 34B** **Correlation of serum leptin level and waist-to-hip ratio (WHR) with overall survival of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AIs). (Abstract #1106)**
M. Artac, H. S. Bozcuk, A. Kiyici, O. O. Eren, M. C. Boruban, M. Ozdogan
- Brd. 34C** **Quality-of-life outcomes of patients with breast cancer in an integrative cancer treatment setting. (Abstract #1107)**
E. D. Staren, D. Gupta, D. P. Braun
- Brd. 35A** **Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+ metastatic breast cancer patients: A single-center experience. (Abstract #1108)**
P. Papaldo, G. Metro, A. Felici, M. Russillo, D. Pellegrini, A. Fabi, G. Ferretti, M. Introna, F. Cognetti
- Brd. 35B** **Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). (Abstract #1109)**
E. P. Hamilton, G. G. Kimmick, N. Desai, S. Singh, J. O. Hopkins, P. K. Marcom, V. Chadaram, R. Welch, V. N. Trieu, K. L. Blackwell
- Brd. 35C** **Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences. (Abstract #1110)**
R. Mukhtar, A. Moore, O. Nseyo, A. Au, F. L. Baehner, D. H. Moore, M. Campbell, L. Esserman
- Brd. 35D** **Taiwanese patients with breast cancer with brain metastasis (BM) enrolled in the Lapatinib Expanded Access Program (LEAP). (Abstract #1111)**
C. Huang, S. Chen, M. Liu, D. Yeh, M. Hou, T. Chang, R. K. Hsieh, T. Chao, C. J. Tai, C. Tsao
- Brd. 35E** **Low cardiotoxicity of nonpegylated liposomal doxorubicin (NPLD) in patients (pts) with metastatic breast cancer (MBC) previously exposed to 360 mg/m² of doxorubicin (D). (Abstract #1112)**
E. Muñoz, J. M. Perez-Garcia, C. Saura, M. Vidal, G. Sanchez-Olle, M. Bellet, P. Gomez, S. Di Cosimo, J. Baselga, J. Cortes
- Brd. 35F** **Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T). (Abstract #1113)**
V. Freixinos, G. Sánchez-Ollé, L. De Mattos-Arruda, S. Di Cosimo, C. Saura, P. Gomez, J. M. Perez-Garcia, J. Cortes, J. Baselga, M. Bellet
- Brd. 35G** **A regional subgroup analysis of a multinational, double-blind, randomized, placebo-controlled, phase IIb study evaluating sorafenib (SOR) with paclitaxel (PAC) in patients (pts) with advanced breast cancer (BC). (Abstract #1114)**
T. P. Sahoo, V. G. Kaklamani, D. Lokanatha, V. Raina, S. Bondarde, M. Jain, L. S. Schwartzberg, W. J. Gradishar
- Brd. 35H** **A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib. (Abstract #1115)**
N. W. Peacock, S. F. Jones, D. A. Yardley, J. C. Bendell, J. R. Infante, P. B. Murphy, H. A. Burris III

SATURDAY

- Brd. 36A** **A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC). (Abstract #1116)**
D. Mavroudis, I. Boukovinas, C. Christophyllakis, N. Xenidis, P. Papakotoulas, N. A. Malamos, S. Kakolyris, A. Polyzos, V. Georgoulas
- Brd. 36B** **Comparison of hormone receptor and HER2 status in resected brain metastases and primary breast cancer. (Abstract #1117)**
Z. Tomasevic, Z. Milovanovic, Z. M. Tomasevic, M. Skender, G. Pupic, Z. Kovac, D. Grujicic
- Brd. 36C** **Gemcitabine plus cisplatin in pretreated metastatic breast cancer. (Abstract #1118)**
G. L. Moura
- Brd. 36D** **Cardiac safety of nonpegylated liposomal doxorubicin in patients with advanced breast cancer treated with myocet plus vinorelbine or myocet plus cyclophosphamide in a randomized phase II trial. (Abstract #1119)**
V. Lorusso, G. A. De Giorgi, M. Ciccamese, V. E. Chiuri, F. Giotta, R. Bordonaro, E. Maiello, S. Pisconti, S. Cinieri, G. Colucci
- Brd. 36E** **Underuse of anthracyclines in women with HER2-positive advanced breast cancer. (Abstract #1120)**
V. Rossi, F. Nole, S. Redana, M. Donadio, R. Martinello, E. Verri, G. Valabrega, M. Cossu Rocca, M. Aglietta, F. Montemurro
- Brd. 36F** **Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC). (Abstract #1121)**
N. Masuda, K. Aogi, S. Ohno, H. Iwata, M. Kashiwaba, Y. Fujiwara, Y. Ito, T. Ueno, N. Saijo, S. Takashima
- Brd. 36G** **Lack of differences in nephrotoxicity of intravenous bisphosphonates in metastatic breast cancer. (Abstract #1122)**
D. W. Luedders, M. K. Bohlmann, J. Steinhoff, A. Hornemann, K. Diedrich, M. Thill
- Brd. 36H** **Pathological characteristics and prognosis of a cohort of 74 patients (pts) with breast cancer (BC) with neoplastic meningitis (NM). (Abstract #1123)**
N. Kotecki, E. Le Rhun, M. Baranzelli, M. Faivre-Pierret, F. Zairi, F. Dubois, P. Devos, J. Bonnetterre
- Brd. 37A** **Predictive factors for the severity of congestive heart failure after an epirubicin-based treatment for metastatic breast cancer. (Abstract #1124)**
M. Ryberg, D. L. Nielsen, M. T. Jensen, G. Nielsen, P. K. Andersen
- Brd. 37B** **Gemcitabine plus cisplatin in patients with heavily pretreated advanced breast cancer with brain metastases. (Abstract #1125)**
V. A. Gorbunova, M. B. Bychkov, D. R. Naskhletashvili, G. E. Chmutin, V. B. Karahan, V. A. Alosin, E. A. Moskvina, Department of Neurooncology, Department of Chemotherapy
- Brd. 37C** **Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial. (Abstract #1126)**
I. Lang, M. J. Inbar, R. Greil, G. G. Steger, S. Beslija, Z. Kahan, A. E. Eniu, Z. Zvirbule, D. E. Sirbu, C. Zielinski
- Brd. 37D** **An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update. (Abstract #1127)**
C. B. Brezden, G. Cantin, J. Younus, L. C. Panasci, P. Klimo, K. E. Laing, N. Raymond, W. Lam, M. E. Trudeau, A. Robidoux
- Brd. 37E** **Safety and efficacy of metronomic nonpegylated liposomal doxorubicin in heavily pretreated advanced breast cancer. (Abstract #1128)**
L. Manso

- Brd. 37F Concomitant gemcitabine, cisplatin, anastrozole, and zoledronic acid in HER2-negative metastatic breast cancer in postmenopausal women. (Abstract #1129)**
S. Ahmed, A. W. Goraya, M. Hafeez, H. Khan
- Brd. 37G Impact of BMI on clinical outcome of HER2-positive breast cancer. (Abstract #1130)**
V. Parolin, E. Fiorio, A. Mercanti, M. Riolfi, G. L. Cetto, E. Surmacz, A. Molino
- Brd. 37H Recurrence and survival after pulmonary metastasis in triple-negative breast cancer. (Abstract #1131)**
V. K. Gadiyaram, S. Kurian, J. Abraham, B. Ducatman, H. Hazard, G. Hobbs, L. Vona-Davis
- Brd. 38A Factors associated with the choice of taxane monotherapy or combination in the management of advanced breast cancer: Results of an international observational study. (Abstract #1132)**
C. Camci, E. Firoiu, M. Gumus, F. Hurtado de Mendoza, M. A. Chavez-Zamudio, N. Davidson, M. Brychta, M. Donadio, V. Soldatenkova, K. A. Benhadji
- Brd. 38B Vinorelbine metronomic plus bevacizumab as salvage therapy for patients with metastatic breast cancer (MBC): A multicenter phase II study. (Abstract #1133)**
E. S. Saloustros, K. Kalbakis, N. K. Vardakis, A. Kalykaki, G. Milaki, M. Rovithi, S. Agelaki, Z. Saridaki, V. Georgoulis, D. Mavroudis
- Brd. 38C Changes in cancer tissue induced by treatment with bevacizumab in metastatic breast cancer. (Abstract #1134)**
G. Kesisis, P. Touplicki, E. Yiannaki, F. Paulidou, F. Ziouti, M. Koumpanaki, I. Boukovinas, L. Kontovinis, A. H. Kortsaris, K. Papazisis
- Brd. 38D Selective internal radiation therapy (SIRT) for treatment of patients with breast cancer with metastatic liver disease. (Abstract #1135)**
M. Michl, R. T. Hoffmann, R. Laubender, A. Haug, P. Bartenstein, H. Stemmler, T. Helmberger, S. Stintzing, V. Heinemann, T. F. Jakobs
- Brd. 38E After HERA trial: Safety and activity of trastuzumab plus chemotherapy as first-line therapy for patients with breast cancer previously treated with trastuzumab in adjuvant setting—A single-institution experience. (Abstract #1136)**
G. Scandurra, E. Taibi, R. A. Aiello, M. Chiarenza, A. Mazzola, M. V. Sano, E. Miano, G. Fallica, M. Caruso
- Brd. 38F Prospective evaluation of megestrol acetate after aromatase inhibitor failure in advanced endocrine responsive breast cancer: Preliminary results. (Abstract #1137)**
J. Bines, R. Dienstmann, O. Metzger, A. C. Gonçalves, W. M. Claudino, M. F. Costa, R. M. Obadia, I. Á. Small
- Brd. 38G Biweekly liposomal pegylated doxorubicin in elderly women with advanced breast cancer: A prospective multicenter trial focusing on tolerability and cardiotoxicity. (Abstract #1138)**
U. Basso, A. Roma, C. Falci, A. Brunello, P. Fiduccia, L. Vamvakas, A. Bononi, M. Gusella, A. Banzato, S. Monfardini
- Brd. 38H Capecitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC). (Abstract #1139)**
A. Chan, D. Yamamoto, R. Bell
- Brd. 39A CD4 levels as a prognostic marker for metastatic breast cancer. (Abstract #1140)**
H. J. Boyle, O. Tredan, S. Chabaud, A. Bajard, D. Perol, T. D. Bachelot
- Brd. 39B Long-term progression-free survival (PFS) in patients with metastatic breast cancer (BC) treated with tandem autologous followed by allogeneic stem cell transplantation (SCT). (Abstract #1141)**
C. Becker, H. Al-Ali, D. Langanke, F. Hoffmann, U. von Gruenhagen, D. Niederwieser

- Brd. 39F Midkine in the plasma as a novel breast cancer marker. (Abstract #1142)**
Y. Yamamoto, M. Ibusuki, H. Fujimori, K. Ota, Y. Ando, H. Iwase
- Brd. 39G Multicentric, observational, transversal study to describe the clinical profile of patients with metastatic breast cancer (MBC) treated with first-line bevacizumab (TRANSBREAST): Preliminary results. (Abstract #1143)**
M. Guirado-Risueño, G. Perez Manga, J. Rifa, R. M. Perez Carrion, M. García López, A. Velasco, A. Oltra Ferrando, E. Barrajon, G. Lopez-Vivanco, M. Munoz-Mateu
- Brd. 39H Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer. (Abstract #1144)**
M. Kiechle, N. S. Simstich, U. R. Schwarz-Boeger, S. Paepke
- Brd. 40A Lapatinib plus capecitabine in highly pretreated HER2-positive metastatic breast cancer: A single-institution experience. (Abstract #1145)**
D. Crivellari, S. Spazzapan, M. Magri, S. Frustaci, R. Talamini, D. Lombardi, E. Torrasi, S. Scalone, G. Miolo, A. Veronesi
- Brd. 40B Trastuzumab (T) treatment beyond progression in metastatic breast cancer (MBC): Patterns of care in Swiss clinical practice. (Abstract #1146)**
B. Thurlimann, C. Rochlitz, S. P. Aebi, U. Güth, R. von Moos, A. Müller, L. U. Von Rohr, M. Baumann, J. B. Huober
- Brd. 40F Increased mean corpuscular volume of erythrocytes with capecitabine treatment in metastatic breast cancer patients: A marker of clinical benefit? (Abstract #1147)**
S. Aksoy, C. Arslan, M. Kurt, O. Dizdar, D. Sener Dede, E. Dogan, I. H. Gullu, Y. Y. Ozisik, M. K. Altundag, N. Guler
- Brd. 40G Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC): Interim safety analysis. (Abstract #1148)**
R. Borson, W. G. Harker, J. E. Reeves, J. Bromund, L. Zhao, D. F. Tai, D. A. Yardley
- Brd. 40H Comparison of dual-probe CISH with FISH in the determination of HER2/chromosome 17 for patients with breast cancer in China. (Abstract #1149)**
G. Ren, Y. Bai, M. Han, B. Wang
- Brd. 41A HER2 as a prognostic factor in metastatic breast cancer treated with taxanes. (Abstract #1150)**
E. Parkes, S. M. McKenna, J. J. McAleer, J. Clarke, A. J. Clayton, C. R. James
- Brd. 41B Comparative morphometric analysis of breast-circulating tumor cells and their corresponding solid tumor cytology: A case study. (Abstract #1151)**
E. D. Schram, A. Kolatkar, C. Yoshioka, R. Scuderi, D. Lazar, M. Malchiodi, M. Luttgren, X. Yang, K. Bethel, P. Kuhn, Kuhn Laboratory
- Brd. 41C Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methothrexate, and daily prednisone (DalCMP) as therapy for metastatic breast cancer (MBC). (Abstract #1152)**
B. A. Sousa, R. A. Buckman, M. Clemons, S. F. Dent, N. S. Wong, R. Kerbel, D. J. Sutherland, U. Emmenegger, S. Gardner, K. I. Pritchard
- Brd. 41D Prospective evaluation of serum tissue inhibitor of metalloproteinase-1 (TIMP-1) and carbonic anhydrase IX (CAIX) in correlation to circulating tumor cells in patients with metastatic breast cancer. (Abstract #1153)**
T. N. Fehm, B. K. Rack, W. Janni, P. A. Fasching, J. Zeitz, E. Solomayer, B. Aktas, S. Kasimir-Bauer, K. Pantel, V. Mueller, on behalf of the DETECT Study Group
- Brd. 41E Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer. (Abstract #1154)**
N. U. Lin, N. Ramakrishna, W. J. Younger, A. M. Storniolo, S. E. Come, R. S. Gelman, E. Eisenberg, E. P. Winer

Saturday, June 5, 2010

- Brd. 41F Outcome of patients (pts) with brain metastases (BMs) from HER2-positive breast cancer (BC) treated with lapatinib plus capecitabine (LC). (Abstract #1155)**
G. Metro, J. Foglietta, L. Stocchi, M. Russillo, P. Papaldo, L. Crino, D. Giannarelli, F. Cognetti, A. Fabi, S. Gori
- Brd. 41G Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study. (Abstract #1156)**
M. N. Fornier, P. G. Morris, A. Abbruzzi, G. D'Andrea, T. Gilewski, J. Bromberg, C. T. Dang, M. N. Dickler, L. Norton, C. Hudis
- Brd. 41H Clinical characteristics, univariate, and multivariate Cox model analysis of long-term (> 3 years) survivors of stage IV metastatic breast cancer treated on phase II or III North Central Cancer Treatment Group (NCCTG) trials. (Abstract #1157)**
T. A. Patel, H. Liu, D. W. Hillman, A. C. Dueck, J. N. Ingle, V. Roy, T. J. Hobday, D. W. Northfelt, E. A. Perez, North Central Cancer Treatment Group

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Gynecologic Cancer

Location: S Hall A2

Tracks(s): Gynecologic Cancer

- Brd. 45A** **Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer. (Abstract #5034)**
 J. T. Symanowski, A. H. Maurer, R. W. Naumann, N. P. Shah, D. Morgenstern, R. A. Messmann
- Brd. 45B** **Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. (Abstract #5035)**
 G. Emons, S. Tomov, P. Harter, J. Sehouli, P. Wimberger, A. Staehle, L. C. Hanker, F. Hilpert, P. Dall, C. Gruendker, AGO Study Group
- Brd. 45C** **Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial. (Abstract #5036)**
 P. Sabbatini, J. S. Berek, A. Casado, K. Cwiertka, T. Pinter, A. Pluzanska, G. Scambia, E. Pujade-Lauraine, J. B. Vermorken, J. Pfisterer
- Brd. 45D** **Tolerability and pharmacokinetics of intraperitoneal carboplatin and paclitaxel with intravenous bevacizumab. (Abstract #5037)**
 C. N. Krasner, M. Seiden, M. Roche, M. A. Morgan, U. Matulonis, J. Wolf, C. Drescher, R. D. Alvarez, D. K. Armstrong, J. G. Supko
- Brd. 45E** **A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia. (Abstract #5038)**
 R. Correa, H. Mackay, H. W. Hirte, R. Morgan, S. Welch, G. F. Fleming, L. Wang, C. Blattler, S. P. Ivy, A. M. Oza
- Brd. 45F** **Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with ovarian cancer: Results from a phase II study. (Abstract #5039)**
 R. Chekerov, A. Reinthaller, D. Reimer, T. Reimer, L. Angleitner-Boubenizek, M. Halfen, H. Lindhofer, I. Braicu, G. Oskay-Özcelik, J. Sehouli
- Brd. 45G** **The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin. (Abstract #5040)**
 M. De Tursi, E. Salvatorelli, C. Carella, N. Bianco, R. Massari, R. Sacco, P. Menna, G. Minotti, S. Iacobelli
- Brd. 45H** **Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC). (Abstract #5041)**
 J. Ang, T. A. Yap, P. Fong, C. P. Carden, D. S. Tan, J. Hanwell, J. Carmichael, J. S. De Bono, M. E. Gore, S. B. Kaye
- Brd. 46A** **Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: Population pharmacokinetic/pharmacodynamic (PK/PD) modeling to facilitate phase III dose selection. (Abstract #5042)**
 J. Lu, E. Rasmussen, L. Navale, M. Kuchimanchi, E. Hurh, B. Y. Karlan, I. B. Vergote, D. E. Stepan, D. M. Weinreich, Y. Sun
- Brd. 46B** **Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations. (Abstract #5043)**
 T. Safra, L. Borgato, M. Nicoletto, L. Rolnitzky, J. Curtin, R. Geva, S. Peles, T. Grenader, A. Gabizon, F. Muggia

- Brd. 46C Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial. (Abstract #5044)**
M. Brundage, M. Gropp, F. Mefti, K. Mann, B. Lund, V. GebSKI, G. Wolfram, N. Reed, S. Pignata, A. Ferrero
- Brd. 46D Safety and tolerability of a novel IL-12 gene therapeutic administered in combination with carboplatin/docetaxel in patients with recurrent ovarian cancer. (Abstract #5045)**
K. Anwar, M. N. Barnes, F. J. Kelly, C. Chu, K. Cutter, J. Fewell, R. D. Alvarez
- Brd. 46E Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG). (Abstract #5046)**
B. J. Monk, M. Sill, J. L. Walker, P. Hanjani, R. P. Edwards, J. Rotmensch, K. De Geest, A. J. Bonebrake
- Brd. 46F Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer: Update of Japan Clinical Oncology Group (JCOG) Protocol 0102. (Abstract #5047)**
N. Katsumata, H. Yoshikawa, H. Kobayashi, T. Saito, K. Kuzuya, T. Mizunoe, M. Hiura, T. Kasamatsu, T. Shibata, T. Kamura
- Brd. 46G Prognostic role of lymph node status in primary advanced ovarian cancer after complete resection or residual disease less than 1 cm: Results of a meta-analysis of the AGO-OVAR meta-database. (Abstract #5048)**
P. Harter, A. Reuss, J. Pfisterer, E. Pujade-Lauraine, I. L. Ray-Coquard, A. Du Bois
- Brd. 46H Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer. (Abstract #5049)**
R. M. Wenham, J. W. Leach, S. A. Scudder, B. R. Amin, C. H. Pippitt, A. N. Gordon, N. Nanayakkara, E. Hurh, D. E. Stepan, R. J. Schilder
- Brd. 47A Phase Ib study of RAD001 (R) with pegylated-liposomal doxorubicin (PLD) in patients with advanced solid tumors. (Abstract #5050)**
A. Perotti, C. Sessa, N. Colombo, G. Del Conte, A. Delmonte, T. Diena, M. Lapresa, G. Parma, L. Viganò, L. Gianni
- Brd. 47B Intraperitoneal mitoxantrone in the treatment of recurrent ascites from progressive epithelial ovarian cancer. (Abstract #5051)**
M. Marinaccio, E. Mele, E. De Marino, R. Catacchio, C. Pellegrino, F. Sozzi, S. Schonauer
- Brd. 47C The impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: A retrospective Japan clear cell carcinoma study. (Abstract #5052)**
M. Takano, T. Sugiyama, N. Yaegashi, S. Sagae, K. Kuzuya, Y. Udagawa, H. Tsuda, M. Suzuki, T. Goto, Y. Kikuchi, Japan Clear Cell Carcinoma Study Group
- Brd. 47D How does ¹⁸F-FDG PET-CT scan affect clinical judgment and change treatment decisions in patients with epithelial ovarian cancer? (Abstract #5053)**
F. Selcukbiricik, M. Ozguroglu, M. A. Ozturk, N. Ozgur, H. Turna, D. Tural, M. Hallac, F. Demirkiran, M. Arvas, N. M. Mandel
- Brd. 47E Laparoscopic hysterectomy versus abdominal hysterectomy in early-stage endometrial cancer. (Abstract #5054)**
M. J. Mourits, C. J. Bijen, K. M. Vermeulen, A. G. Zee, G. de Bock
- Brd. 47F ERCC1 status in patients with locally advanced cervical cancer treated with RT or CRT: A multicenter clinicopathologic analysis. (Abstract #5055)**
C. M. Doll, A. W. Fyles, C. Aquino-Parsons, M. Pintilie, A. Klimowicz, S. Petrillo, M. Milosevic, S. P. Lees-Miller, B. A. Clarke, A. M. Magliocco
- Brd. 47G The combination of [¹⁸F]fluorodeoxy-glucose and 16alpha-[¹⁸F]fluoro-17beta-estradiol positron emission tomography for identifying leiomyosarcoma in uterine smooth muscle tumors. (Abstract #5056)**
Y. Yoshida, T. Kurokawa, Y. Sawamura, A. Shinagawa, F. Kotsuji

- Brd. 47H Low-grade serous primary peritoneal carcinoma. (Abstract #5057)**
D. M. Gershenson, C. C. Sun, A. Malpica, M. Deavers, D. C. Bodurka, K. M. Schmeler
- Brd. 48A Significance of the hedgehog (Hh) pathway in ovarian cancer xenograft growth. (Abstract #5058)**
B. R. Rueda, C. McCann, W. B. Growdon, R. Foster, M. D. Curley, R. W. Ross, J. Proctor, J. MacDougall
- Brd. 48B A phase I dose escalation study of AGS-8M4 (ASP6183), an anti-AGS-8 fully human antibody, in advanced ovarian cancer. (Abstract #5059)**
D. K. Armstrong, T. J. Herzog, L. M. Reyno, M. Vincent, L. Jackson, P. Sabbatini
- Brd. 48C Trabectedin (Tr) as single agent in relapsed ovarian cancer (ROC) patients (pts) with a platinum-free interval (PFI) of 6 to 12 months. (Abstract #5060)**
J. del Campo, T. Ciuleanu, C. Sessa, A. M. Westermann, A. Roszak, S. Chan, T. Hogberg, P. Zintl, Y. C. Park, C. N. Krasner
- Brd. 48D A novel proteomics biomarker panel as a diagnostic tool for patients with ovarian cancer. (Abstract #5061)**
C. K. Hogdall, E. Fung, I. J. Christensen, L. Nedergaard, S. A. Engelholm, A. L. Petri, S. Risum, L. Lundvall, A. T. Pedersen, E. V. Høgdall
- Brd. 48E New aspects in the treatment of cervical cancer complicated by pregnancy: Laparoscopic nodal evaluation before oncologic treatment delay. (Abstract #5062)**
G. Favero, V. Chiantera, A. Oleszczuk, V. Galotta, H. Hertel, J. Herrmann, C. Köhler, A. Schneider
- Brd. 48F Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: Single or combination chemotherapy? (Abstract #5063)**
G. Adams, J. M. Zekri, H. Wong, J. A. Green
- Brd. 48G Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC). (Abstract #5064)**
F. Muggia, T. Safra, L. Borgato, A. Gandhi, G. Mancinc, A. Gabizon, L. Liebes
- Brd. 48H Preclinical evaluation of PARP inhibition as a treatment for endometrioid endometrial carcinomas. (Abstract #5065)**
K. J. Dedes, D. Wetterskog, A. M. Mendes-Pereira, R. Vatcheva, R. Natrajan, M. B. Lambros, C. J. Lord, A. Ashworth, J. S. Reis-Filho
- Brd. 49A Development of a gene expression-based test for the detection of endometrial cancer in uterine aspirates. (Abstract #5066)**
E. Rosell, C. Pérez, A. Ortega, C. Nieto, A. Doll, A. Gil, J. Ponce, M. Abal, J. Reventós, T. Maes
- Brd. 49B Concurrent weekly cisplatin versus gemcitabine with radiation in advanced carcinoma cervix: A study on 120 patients. (Abstract #5067)**
D. R. Samanta, S. N. Senapati, L. Pattanayak, A. Mohanty, S. K. Giri
- Brd. 49D Prognostic role of dendritic cells and T lymphocytes in the clinical outcomes of stage III ovarian cancer. (Abstract #5069)**
W. Ding, M. J. Maurer, K. Kalli, L. Murphy, L. C. Hartmann, K. L. Knutson, A. C. Clayton
- Brd. 49E The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. (Abstract #5070)**
N. Vasudev, I. Trigonis, D. A. Cairns, G. Hall, D. Jackson, T. Perren

- Brd. 49F Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A planned 200-pt interim safety analysis of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG Intergroup Study (HECTOR). (Abstract #5071)**
W. Meier, W. Lichtenegger, C. Marth, A. J. Gonzalez-Martin, P. Harter, O. Tome, P. Wimberger, C. Kurzeder, G. Oskay-Özcelik, J. Sehouli, NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG Intergroup
- Brd. 49G Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. (Abstract #5072)**
L. Helpman, R. Kupets, R. S. Saad, M. A. Khalifa, N. Ismiil, Z. Ghorab, V. Dube, S. Nofech-Mozes
- Brd. 49H Characteristics and outcomes of pharmaceutical versus nonpharmaceutical affiliated phase III clinical trials on targeted agents for cancer therapy. (Abstract #5073)**
K. Fuh, T. Nguyen, S. M. Ueda, J. Shin, J. Tan, B. J. Monk, K. Osann, D. S. Kapp, J. K. Chan
- Brd. 50A Activity of dual PI3K/mTOR inhibitor, NVP-BE2235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines. (Abstract #5074)**
K. Shoji, K. Oda, S. Nakagawa, Y. Ikeda, H. Kuramoto, M. Nishida, K. Kawana, T. Yano, S. Kozuma, Y. Taketani
- Brd. 50B The association between quality of life and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group study. (Abstract #5075)**
V. E. Von Gruenigen, H. Q. Huang, K. M. Gil, H. E. Frasure, D. K. Armstrong, L. B. Wenzel
- Brd. 50C Immunohistochemical expression of ER and PR and outcomes in patients with newly diagnosed uterine leiomyosarcoma. (Abstract #5076)**
M. M. Leitao, M. L. Hensley, R. R. Barakat, R. O’Cearbhaill, R. A. Soslow
- Brd. 50D CA125 response to bevacizumab in recurrent ovarian cancer. (Abstract #5077)**
R. E. O’Cearbhaill, Q. Zhou, A. Iasonos, J. P. Diaz, W. P. Tew, M. L. Hensley, C. O’Flaherty, C. Aghajanian, D. R. Spriggs, P. Sabbatini
- Brd. 50E Angiogenesis-related gene profile to predict outcome to multimodal therapy in advanced ovarian carcinoma. (Abstract #5078)**
J. Barriuso, M. Mendiola, A. Redondo, I. Sánchez-Navarro, A. Mariño-Enriquez, J. A. Fresno-Vara, E. Perez, A. Hernandez, E. Espinosa, D. Hardisson
- Brd. 50F Expression of tumor-associated antigen C-terminal binding protein-2 in epithelial ovarian tumors and effect on response to HDAC inhibitors in vitro. (Abstract #5079)**
L. M. Barroilhet, J. Yang, K. Hasselblatt, W. Welch, R. S. Berkowitz, S. Ng
- Brd. 50G The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer: Results from the CALYPSO study. (Abstract #5080)**
R. J. Simes, C. K. Lee, M. R. Mirza, P. Sauthier, A. Georgopoulos, I. B. Vergote, G. Ferrandina, N. Donadello, B. Schmalfeldt, R. Delva
- Brd. 50H Clinical trials of WT1 peptide vaccine to gynecologic malignancies that are resistant to conventional therapies. (Abstract #5081)**
T. Miyatake, T. Enomoto, Y. Oka, S. Nishida, A. Tsuboi, T. Shirakata, S. Morita, J. Sakamoto, H. Sugiyama, T. Kimura
- Brd. 51A Time to platinum resistance (TTPR) as a novel surrogate end-point for trials in ovarian cancer. (Abstract #5082)**
I. Pokataev, A. Tryakin, D. Kanagavel, A. Tjulandina, M. Stenina, M. Fedyanin, S. Tjulandin

- Brd. 51B Sequential angiogenic blockade for the treatment of recurrent ovarian cancer. (Abstract #5083)**
U. Matulonis, L. Pereira, H. Lee, S. M. Campos, J. Liu, J. Lee, C. Whalen, T. Atkinson, M. Hill, S. T. Berlin
- Brd. 51C Interval from neoadjuvant chemotherapy to interval debulking surgery in advanced ovarian cancer: Is this a prognostic indicator? (Abstract #5084)**
R. Hariprasad, L. Kumar, A. Mookerjee, V. Radhakrishnan, S. Kumar, S. Mathur, S. Thulkar
- Brd. 51D Associations between age and quality of life in advanced ovarian cancer. (Abstract #5085)**
A. A. Wright, L. Pereira, M. E. Nilsson, C. Gibson, S. M. Campos, M. Roche, S. T. Berlin, C. N. Krasner, R. T. Penson, U. Matulonis
- Brd. 51E Effects of treatment by temsirolimus on patients with clear cell carcinoma of the ovary. (Abstract #5086)**
Y. Kikuchi, K. Kudoh, M. Takano, R. Kikuchi, T. Kita, Y. Hamada, S. Nagao, K. Fujiwara, T. Shiozawa, D. Aoki
- Brd. 51F Regulation of proliferation in endometrial carcinoma cell line by the epidermal growth factor receptor and estrogen receptor beta. (Abstract #5087)**
J. H. Farley, M. Clark, T. J. Wu
- Brd. 51G Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. (Abstract #5088)**
J. Dorn, T. Schuster, A. Gkazepis, M. Kiechle, E. P. Diamandis, A. Harlozinska, V. Magdolen, M. Schmitt
- Brd. 51H Interleukin-6 as a therapeutic target in advanced ovarian cancer. (Abstract #5089)**
J. I. Coward, H. Kulbe, D. Leader, M. Quigley, R. Thompson, A. Leinster, J. Nemeth, J. Vermeulen, I. McNeish, F. Balkwill
- Brd. 52A Relative conditional survival in 41,476 patients with ovarian cancer. (Abstract #5090)**
R. Ware, L. Baldwin, B. Huang, T. Tucker, S. Goodrich, I. Podzielinski, C. P. DeSimone, F. Ueland, J. Vannagell, L. G. Seamon
- Brd. 52B Fertility-sparing management with progestin for young women with early-stage endometrial cancer and complex hyperplasia with atypia. (Abstract #5091)**
J. Park, H. Roh, W. Joo, H. You, D. Kim, J. Kim, Y. Kim, J. Nam
- Brd. 52C Oxaliplatin plus continuous infusion topotecan: An ongoing phase II study for recurrent ovarian cancer—A New York Cancer Consortium study (#N01-CM62204). (Abstract #5092)**
S. Stein, H. S. Hochster, F. Muggia, S. V. Blank, J. P. Curtin, I. Shapira, G. L. Goldberg, A. Tiersten
- Brd. 52D Combination therapy with paclitaxel, carboplatin, and megestrol acetate for advanced-stage and recurrent endometrial carcinoma: A phase II study. (Abstract #5093)**
K. S. Bevis, L. C. Kilgore, R. D. Alvarez, J. M. Straughn, C. A. Leath
- Brd. 52E Rapid, durable restoration of malignant ascites-derived antigen presenting cell immunogenicity by toll-like receptor agonists. (Abstract #5094)**
S. Jean, S. F. Adams, A. Facciabene, X. Peng, G. Coukos
- Brd. 52F Vaginal cuff brachytherapy combined with carboplatin and paclitaxel as adjuvant therapy for high-intermediate-risk patients with endometrial carcinoma. (Abstract #5095)**
L. M. Landrum, R. S. Mannel, K. N. Moore, J. L. Walker, E. J. Syzek, R. E. Zuna, D. S. McMeekin

- Brd. 52G** Prognosis and prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). (Abstract #5096)
C. Uzan, M. Koskas, S. Gouy, P. Pautier, C. Lhomme, C. Baileysguier, C. Haie-Meder, P. Duvillard, P. Morice
- Brd. 52H** Sexual activity and functioning in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. (Abstract #5097)
T. M. Michelsen, A. A. Dahl, C. Trope, A. Dørum
- Brd. 53A** The efficacy and toxicity of belotecan (CKD-602) combined with platinum in patients with recurrent epithelial ovarian cancer. (Abstract #5098)
Y. Kim, S. Lee, S. Kim, D. Kim, J. Kim, J. Nam, Y. T. Kim
- Brd. 53B** Proliferation and lymphangiogenesis markers, and risk of lymph-nodal metastasis in early cervical cancer. (Abstract #5099)
S. Bogliolo, A. Buenerd, P. Mathevet, F. Lecuru
- Brd. 53F** Prognostic impact of primary surgical outcome on survival after recurrence in patients with advanced ovarian cancer: Analysis of prospective randomized phase III trials. (Abstract #5100)
S. Mahner, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, J. Pfisterer, A. Du Bois
- Brd. 53G** Relationship between ERCC1 C8092A and Mad1 G558A polymorphism with disease progression, and survival in patients with advanced epithelial ovarian cancer treated with induction chemotherapy with carboplatine paclitaxel (PC). (Abstract #5101)
L. H. Montalvo, F. M. Vasquez, D. G. Rincon, C. C. Hernandez, M. S. Andrade, P. F. Martinez, C. D. Romero
- Brd. 53H** Interrelated bowel symptoms to fecal incontinence among gynecologic cancer survivors. (Abstract #5102)
G. Dunberger
- Brd. 54A** Inactivation of O⁶-methylguanine-DNA methyltransferase (MGMT) by promoter hypermethylation: A key factor of epithelial ovarian carcinogenesis in specific histologic types. (Abstract #5103)
H. Roh, W. Joo, S. Lee, H. Yoo
- Brd. 54B** Neoadjuvant chemotherapy in second trimester pregnant patients with cervical cancer: First study on in vivo concentrations of cisplatin in fetal and maternal compartments. (Abstract #5104)
S. Marnitz, A. H. Schmittl, K. Hasenbein, G. Favero, A. Schneider, C. Köhler
- Brd. 54F** Development of a nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer based on the CALYPSO trial. (Abstract #5105)
C. K. Lee, E. Guardiola, T. Hogberg, M. Friedlander, J. Bentley, U. Denison, I. B. Vergote, C. Pisano, G. Parma, P. Wimberger
- Brd. 54G** What do primary and recurrent ovarian cancer patients (OC) expect from their doctors? Final results of a German survey in 608 patients. (Abstract #5106)
G. Oskay-Özcelik, S. Neubert, K. Münstedt, C. Liebrich, L. C. Hanker, R. Lorenz, P. Wimberger, S. Mahner, H. Hindenburg, J. Sehouli
- Brd. 54H** A phase I study of the infectivity enhanced CRAAd Ad5-Δ24RGD for recurrent gynecologic cancer. (Abstract #5107)
D. T. Curiel, M. Preuss, M. Wang, K. J. Kimball, M. N. Barnes, W. Wan, G. Siegal, R. Harris, R. Aurigemma, R. D. Alvarez
- Brd. 55A** A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer: HOG GYN-111. (Abstract #5108)
D. Matei, R. Ramasubbaiah, J. Schilder, S. M. Perkins, C. Whalen, T. Breen, C. S. Johnson, M. Callahan, T. Jones, G. Sutton
- Brd. 55B** Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for advanced ovarian cancer. (Abstract #5109)
E. J. Tanner, F. Dao, O. Zivanovic, S. M. Kehoe, D. R. Black, J. A. Konner, R. R. Barakat, S. M. Lichtman, D. A. Levine

- Brd. 55C Prognostic relevance of resection margin distance for loco-regional control in vulvar cancer. (Abstract #5110)**
L. Woelber, C. Eulenburg, M. Hager, M. Choschzick, J. Schwarz, J. Dowaji, F. Giesecking, M. Ihnen, F. Jaenicke, S. Mahner
- Brd. 55D Predictive value of circulating tumor cells for response to therapy in women with recurrent epithelial ovarian cancer. (Abstract #5111)**
D. Kindelberger, K. Daniels, E. Kantoff, T. Atkinson, J. Liu, S. M. Campos, S. T. Berlin, E. Cibas, U. Matulonis
- Brd. 55E Can we increase response rate (RR) and overall survival (OS) by individualizing chemotherapy in ovarian cancer (OC): The role of a new chemotherapy (CT) induced apoptosis assay. (Abstract #5112)**
E. M. Salom, M. Penalver, H. D. Homesley, C. A. Presant, J. Rutledge, M. O. Burrell, A. P. Garrett, A. Hallquist, M. Perree
- Brd. 55F Ten-year relative survival for ovarian cancer. (Abstract #5113)**
L. Baldwin, R. Ware, B. Huang, T. Tucker, S. Goodrich, I. Podzielinski, C. P. DeSimone, J. Vannagell, F. Ueland, L. G. Seamon
- Brd. 55G Intraperitoneal chemotherapy: Who, what, when, and how in diverse academic settings. (Abstract #5114)**
L. R. Boyd, A. Novetsky, T. L. Pua, B. Pothuri, J. P. Curtin, R. C. Wallach, S. V. Blank
- Brd. 55H A cross sectional study on intestinal and bladder symptoms in gynecologic malignancies. (Abstract #5115)**
K. Pushpalatha, P. K. Julka, J. B. Sharma, K. Sunesh Kumar, K. K. Roy, D. Sharma, L. Kumar
- Brd. 56A Efficacy of lower dose of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer resistant to platinum-based therapy. (Abstract #5116)**
V. Michalaki, S. Gennatas, C. G. Gennatas
- Brd. 56B Chemoradiation followed by adjuvant hysterectomy for the treatment of stage IB-2 cervical cancer: 10-year experience. (Abstract #5117)**
G. E. Bigsby, R. W. Holloway, S. Ahmad, M. D. Sombeck, G. Ebra, N. J. Finkler
- Brd. 56C The impact of age on first-line chemotherapy treatment of epithelial ovarian cancer and primary peritoneal carcinoma. (Abstract #5118)**
E. Larbi, T. K. Madhuri, S. Essapen, A. Michael
- Brd. 56D Clinical significance of selected angiogenesis and lymphangiogenesis modulators and markers in ovarian cancer patients. (Abstract #5119)**
D. Klasa-Mazurkiewicz, T. Milczek, M. Jarzab, J. Narkiewicz, B. Lipińska, D. Wydra
- Brd. 56E Excision repair cross-complementation group 1 (ERCC1) expression as a predictor for response of neoadjuvant chemotherapy for locally advanced uterine cervix cancer. (Abstract #5120)**
S. Jeon, S. Hong, E. Jeon, M. Jang, H. Won, S. Park, M. Lee, J. Byun, J. Kang, Y. Hong
- Brd. 56F Tolerability of long-term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC). (Abstract #5121)**
I. Romero, N. Colombo, S. B. Kaye, J. Arranz, A. Roszak, D. M. Provencher, P. Santabarbara, E. Bayever, E. Almorin, F. Muggia
- Brd. 56G The correlation of cone biopsy with findings at radical hysterectomy and the need for adjuvant radiation therapy. (Abstract #5122)**
T. P. Boren, D. L. Richardson, S. M. Kehoe, D. S. Miller Sr.
- Brd. 56H Cisplatin (C) and ifosfamide (I) chemotherapy with vaginal cuff brachytherapy (VCBT) for treatment of uterine carcinosarcoma. (Abstract #5123)**
H. Wang, K. Y. Lin, M. Merl, S. A. Higgins, D. Silasi, A. Santin, M. Azodi, T. Rutherford, P. E. Schwartz, M. M. Abu-Khalaf

Saturday, June 5, 2010

**3:00 PM - 4:15 PM
SPECIAL SESSION**

Health Care Reform: Resetting the Clock

Location: E Arie Crown Theater

CME credit: 1.25

Track(s): Practice Management and Information Technology; Ethics; Special Session

Joseph S. Bailes, MD—Chair

Texas Oncology

J. James Rohack, MD

American Medical Association

SATURDAY

**3:00 PM - 4:15 PM
SPECIAL SESSION**

Pediatric Oncology Award and Lecture

Location: S504

CME credit: 1.25

Track(s): Special Session; Pediatric Cancer

Sharon B. Murphy, MD

Institute of Medicine

Pediatric Oncology: A Model Rapid Learning Health Care System (RLHS)

3:00 PM - 4:15 PM
EDUCATION SESSIONS

International Collaboration in Clinical Trials: Special Emphasis on Ethics and Regulatory Issues

Location: S100a

CME credit: 1.25

Track(s): Clinical Trials

Robert Leo Comis, MD—Chair

Coalition of Cancer Cooperative Groups

Overview of International Collaboration in Cancer Clinical Trials

Denis A. Lacombe, MD

European Organisation for Research and Treatment of Cancer

European Perspective on International Collaborative Clinical Trials

Edward Lloyd Trimble, MD

National Cancer Institute

Review of National Cancer Institute Symposium on Implementation of International Collaborative Clinical Trials in Cancer Therapies

Managing Survivorship in a Community Practice

Location: E353

CME credit: 1.25

Track(s): Practice Management and Information Technology

Marina Z. Khitrik-Palchuk, MD—Chair

Commonwealth Hematology-Oncology

From the Ground Up: Use of Nonphysician Providers in Survivorship Care

Barbara A. Parker, MD

University of California, San Diego

Defining Survivorship: What Are the Pieces?

Scott D. Siegel, PhD

Helen F. Graham Cancer Center

Facilitation of a Survivorship Program with the Local Cancer Center

Update on Gastrointestinal Noncolorectal Malignancies: What's New since the 2009 ASCO Annual Meeting?

Location: N Hall B1

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer; Clinical Trials; Professional Development

Mark Krasna, MD—Chair

St. Joseph Medical Center

Review of the Results of Surgical Trials including Neoadjuvant and Adjuvant Therapy in Upper Gastrointestinal Malignancies over the Past Year

Albert C. Lockhart, MD

Washington University School of Medicine

Progress in the Treatment of Esophageal and Gastric Cancers: What's New since the 2009 ASCO Annual Meeting?

Anthony B. El-Khoueiry, MD

University of Southern California

Hepatobiliary and Pancreatic Cancers since the 2009 ASCO Annual Meeting: Steady Steps Forward and a Long Way to Go

Saturday, June 5, 2010

3:00 PM - 4:15 PM
MEET THE PROFESSOR SESSION

Clinical Management of Hereditary Colorectal Cancer (M03)-TICKETED SESSION

Location: E451b

CME credit: 1.25

Track(s): Cancer Genetics; Gastrointestinal (Colorectal) Cancer

Randall Burt, MD

University of Utah

3:00 PM - 4:15 PM
CLINICAL PROBLEMS IN ONCOLOGY

Central Nervous System Metastases: From Local to Systemic Therapy (C05)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Breast Cancer

Matthew G. Ewend, MD—Chair

University of North Carolina at Chapel Hill

The Integration of Surgery and Radiation Therapy in the Management of Central Nervous System Metastasis in Breast Cancer

Nancy U. Lin, MD

Dana-Farber Cancer Institute

Systemic Treatment Options and Opportunities in Breast Cancer Patients with Central Nervous System Metastases

Michael J. Glantz, MD

Penn State Hershey Medical Center

To Protect and Defend: Novel Treatment and Prevention Options for Patients with Metastatic Breast Cancer and Leptomeningeal Disease

3:00 PM - 5:30 PM
ORAL ABSTRACT SESSION

Lung Cancer—Local-Regional and Adjuvant Therapy

Location: E Hall D1

CME credit: 2.5

Track(s): Lung Cancer

Katherine Pisters, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

Joe B. Putnam, MD—Co-Chair

Vanderbilt University Medical Center

3:00 PM A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER study. (Abstract #7000)

K. G. Tournoy, C. A. Dooms, R. C. Rintoul, P. Deleyn, A. G. Nicholson, E. Deschepper, O. Dekkers, K. F. Rabe, J. P. Van Meerbeeck, J. T. Annema

Discussion

3:15 PM Steven M. Keller, MD (Abstract #7000)

Montefiore Medical Center

Invasive Mediastinal Staging: Necessary and Often Overlooked

3:30 PM Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. (Abstract #7002^)

T. Ciuleanu, M. Samarzija, Y. Demidchik, V. Beliakouski, M. Rancic, D. L. Bentsion, S. V. Orlov, B. A. Schaeffler, R. L. De Jager, H. B. Breit

Discussion

3:45 PM Bonnie S. Glisson, MD (Abstracts #7001–7002^)

University of Texas M. D. Anderson Cancer Center

Small Cell Lung Carcinoma: New Approaches for an Orphan Illness

4:00 PM Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer. (Abstract #7003)

V. Westeel, B. J. Milleron, E. A. Quoix, M. Puyraveau, D. Moro-Sibilot, D. Braun, B. Lebeau, E. Lemarié, D. Debievre, A. G. Depierre, on behalf of the Intergroupe Francophone de Cancerologie Thoracique (IFCT)

4:15 PM A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC). (Abstract #CRA7004)

D. D. Karp, S. J. Lee, G. L. Shaw Wright, D. H. Johnson, M. R. Johnston, G. E. Goodman, G. H. Clamon, G. S. Okawara, R. Marks, J. C. Ruckdeschel, MDACC Thoracic Chemoprevention Research Group

4:30 PM A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-III A non-small cell lung cancer (NSCLC): NCIC CTG BR.19 (Abstract #LBA7005)

G. D. Goss, I. Lorimer, M. S. Tsao, C. J. O'Callaghan, K. Ding, G. A. Masters, P. Roberts, J. R. Jett, M. J. Edelman, F. A. Shepherd

Discussion

4:45 PM David Harpole, MD (Abstracts #7003–LBA7005)

Duke University Medical Center

Evolution of Multimodality Therapy in Early-stage NSCLC

Saturday, June 5, 2010

5:00 PM **A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC). (Abstract #LBA7007)**

P. Fidas, T. A. Ciuleanu, O. Gladkov, G. M. Manikhas, I. N. Bondarenko,
A. Pluzanska, R. Ramlau, T. J. Lynch

Discussion

5:15 PM Julie R. Brahmer, MD (Abstract #LBA7007)

The Johns Hopkins University

Novel Therapeutics in Non-small Cell Lung Cancer

SATURDAY

3:00 PM - 6:00 PM ORAL ABSTRACT SESSION

Central Nervous System Tumors

Location: S100b

CME credit: 3

Track(s): Central Nervous System Tumors

John Frederick De Groot, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

Myrna Rachel Rosenfeld, MD, PhD—Co-Chair

University of Pennsylvania

- 3:00 PM NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). (Abstract #LBA2001)**

W. Wick, C. Engel, S. E. Combs, G. Nikkhah, J. Steinbach, R. Kortmann, M. Simon, C. Wille, G. Reifenberger, M. Weller

- 3:15 PM Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). (Abstract #LBA2002)**

A. Malmstrom, B. H. Grønberg, R. Stupp, C. Marosi, D. Frappaz, H. P. Schultz, M. U. Abacioglu, S. Kinhult, R. Henriksson

Discussion

- 3:30 PM** Stuart Grossman, MD (Abstracts #LBA2001–LBA2002)
The Johns Hopkins University

- 3:45 PM Efficacy of tailored treatment for high- and low-risk medulloblastoma in adults: A large prospective phase II trial. (Abstract #2003)**
A. A. Brandes, E. Franceschi, A. Tosoni, G. Frezza, R. Agati, A. Maestri, C. Ghimenton, V. Mazzocchi, L. Scopece, M. Ermani

- 4:00 PM Everolimus for subependymal giant-cell astrocytomas (SEGAs) in tuberous sclerosis (TS). (Abstract #2004)**
D. N. Franz, D. A. Krueger, M. M. Care, K. Holland-Bouley, K. Agricola, C. Tudor, P. Mangeshkar, A. W. Byars, T. Sahmoud

- 4:15 PM Phase II study of preirradiation chemotherapy for CNS germ cell malignancies: Long-term complications. (Abstract #2005)**
S. I. Robinson, J. C. Buckner, C. Raffel, J. E. Hammack, B. W. Scheithauer, W. Wu, E. G. Shaw

Discussion

- 4:30 PM** To be determined

- 4:45 PM Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). (Abstract #2006)**
P. Y. Wen, M. Prados, D. Schiff, D. A. Reardon, T. Cloughesy, T. Mikkelsen, T. Batchelor, J. Drappatz, M. C. Chamberlain, J. F. De Groot

- 5:00 PM A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma. (Abstract #LBA2007)**
R. Stupp, A. Kanner, H. Engelhard, V. Heidecke, S. Tallibert, F. S. Lieberman, V. Dbalý, E. D. Kirson, Y. Palti, P. H. Gutin

- 5:15 PM Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. (Abstract #2008)**
T. Cloughesy, J. J. Vredenburgh, B. Day, A. Das, H. S. Friedman, for the BRAIN Investigators

Discussion

- 5:30 PM** Alba Ariela Brandes, MD (Abstracts #2006–2008)
ASL Bologna

Saturday, June 5, 2010

3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Patient and Survivor Care

Location: E354b

CME credit: 3

Track(s): Patient and Survivor Care

Teresa Gilewski, MD—Co-Chair

Memorial Sloan-Kettering Cancer Center

Barbara A. Murphy, MD—Co-Chair

Vanderbilt University Medical Center

3:00 PM Hepatitis B screening and positivity prior to chemotherapy. (Abstract #9008)

J. Hwang, M. Fisch, H. Zhang, M. A. Kallen, M. Routbort, L. Lal, J. Vierling,
M. Suarez-Almazor

3:15 PM Prevalence of hepatitis B surface antigen and hepatitis B core antibody in a population initiating immunosuppressive therapy. (Abstract #9009)

E. Ludwig, R. B. Mendelsohn, Y. Taur, M. Kamboj, S. Nagula, K. Sepkowitz,
A. D. Zelenetz

Discussion

3:30 PM Sandra L. Wong, MD, MS (Abstracts #9008–9009)

University of Michigan Health Systems

3:45 PM Yield from risk-based screening in adults treated for cancer in childhood. (Abstract #9010)

M. M. Hudson, V. G. Nolan, K. K. Ness, G. T. Armstrong, D. M. Green, K. R. Krull,
S. L. Spunt, M. Metzger, D. K. Srivastava, L. L. Robison

4:00 PM Executive functions in aging adult survivors of childhood leukemia. (Abstract #9011)

K. R. Krull, N. Jain, Z. Pan, K. Shine, D. K. Srivastava, D. Stewart, C. Jones,
L. L. Robison, M. M. Hudson

4:15 PM Contrasting effects of religious/spiritual support from religious communities versus medical teams on advanced cancer patient end-of-life care. (Abstract #9012)

T. A. Balboni, M. E. Paulk, M. J. Balboni, A. C. Phelps, T. Vanderweele,
A. A. Wright, S. Block, H. G. Prigerson

Discussion

4:30 PM Betty R. Ferrell, RN, PhD, FAAN (Abstracts #9010–9012)

City of Hope

4:45 PM Effect of YOCAS yoga on sleep, fatigue, and quality of life: A URCC CCOP randomized, controlled clinical trial among 410 cancer survivors. (Abstract #9013)

K. M. Mustian, O. Palesh, L. Sprod, L. J. Peppone, C. E. Heckler, J. S. Yates,
P. S. Reddy, M. Melnik, J. K. Giguere, G. R. Morrow

5:00 PM Prevention of pegfilgrastim-induced bone pain (PIP): A URCC CCOP randomized, double-blind, placebo-controlled trial of 510 cancer patients. (Abstract #9014)

J. J. Kirshner, C. E. Heckler, S. R. Dakhil, J. O. Hopkins, C. Coles, G. R. Morrow

5:15 PM A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases. (Abstract #9015)

A. Lipton, A. Stopeck, R. von Moos, D. H. Henry, G. E. Richardson,
G. I. Rodriguez, H. P. Bourgeois, C. Ke, S. June, R. D. Dansey

SATURDAY

- 5:30 PM** **Efficacy and safety of fentanyl pectin nasal spray versus immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain. (Abstract #9016^)**
M. T. Fallon, A. Davies, A. Gatti, E. A. Lux, M. Watling, R. Galvez, Fentanyl Nasal Spray Study 044 Investigators Group

Discussion

- 5:45 PM** Teresa Gilewski, MD (Abstracts #9013–9016^)
Memorial Sloan-Kettering Cancer Center

Saturday, June 5, 2010

4:30 PM - 5:45 PM
CLINICAL SCIENCE SYMPOSIUM

Signaling in Pediatric Cancer Comes to the Clinic

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology

Julia Lynne Glade Bender, MD—Chair

Columbia University

4:30 PM Lexatumumab: Results of a phase I trial in pediatric patients with advanced solid tumors. (Abstract #9500)

M. S. Merchant, A. J. Chou, A. Price, J. I. Geller, M. Tsokos, C. Graham, A. Charles, P. A. Meyers, C. Mackall

4:45 PM A phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medulloblastoma: A Pediatric Brain Tumor Consortium study (PBTC 25). (Abstract #CRA9501)

A. J. Gajjar, C. F. Stewart, D. W. Ellison, T. Curran, P. Phillips, S. Goldman, R. Packer, L. E. Kun, J. M. Boyett, R. J. Gilbertson

5:00 PM A phase I trial of MK-0752 in children with recurrent or refractory CNS malignancies: A Pediatric Brain Tumor Consortium study. (Abstract #9502)

M. Fouladi, J. Olson, C. F. Stewart, M. Kocak, A. J. Gajjar, T. Demuth, S. Goldman, L. E. Kun, J. M. Boyett, R. J. Gilbertson

Discussion

5:15 PM Richard Greg Gorlick, MD (Abstracts #9500–9502)

The Children's Hospital

Signaling comes to the Clinic

SATURDAY

4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM

Novel Therapies for Myeloma

Location: E354a

CME credit: 1.5

Track(s): Lymphoma and Plasma Cell Disorders

Asher Alban Akmal Chanan-Khan, MD—Co-Chair

Roswell Park Cancer Institute

Shaji Kumar, MD—Co-Chair

Mayo Clinic

- 4:30 PM Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM). (Abstract #8000)**
R. Vij, D. S. Siegel, J. L. Kaufman, A. J. Jakubowiak, A. K. Stewart, S. Jagannath, V. Kukreti, M. H. Le, M. K. Bennett, M. Wang, The Multiple Myeloma Research Consortium (MMRC)
- 4:45 PM Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). (Abstract #8001)**
J. F. San-Miguel, O. Sezer, D. S. Siegel, A. Guenther, J. Blade, I. W. Prosser, B. Bengoudifa, M. Klebsattel, P. M. Bourquelot, K. C. Anderson

Discussion

- 5:00 PM** Paul Gerard Guy Richardson, MD (Abstracts #8000–8001)
 Dana-Farber Cancer Institute
Novel Proteasome and HDAC Inhibitors in Myeloma
- 5:15 PM Activity of pomalidomide plus dexamethasone (Pom/dex) in dual lenalidomide/bortezomib refractory multiple myeloma (MM). (Abstract #8002)**
M. Lacy, M. A. Gertz, S. R. Hayman, A. Dispenzieri, S. Kumar, J. Mikhael, A. K. Stewart, J. Allred, S. J. Mandrekar, S. V. Rajkumar
- 5:30 PM Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study. (Abstract #8003)**
A. J. Jakubowiak, D. M. Benson Jr., W. Bensinger, D. S. Siegel, T. M. Zimmerman, A. Mohrbacher, P. G. Richardson, D. Afar, A. K. Singhal, K. C. Anderson, Multiple Myeloma Research Consortium

Discussion

- 5:45 PM** Sagar Lonial, MD (Abstracts #8002–8003)
 Winship Cancer Institute at Emory University
New Immunomodulatory Agents and Antibodies in Myeloma

Saturday, June 5, 2010

4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM

Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets

Location: S406 (Vista Room)

CME credit: 1.5

Track(s): Melanoma/Skin Cancers

Kevin B. Kim, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

David B. Solit, MD—Co-Chair

Memorial Sloan-Kettering Cancer Center

4:30 PM Clinical outcome and pathologic features associated with NRAS mutation in cutaneous melanoma. (Abstract #8500)

B. A. Devitt, W. Liu, R. Salemi, R. Wolfe, J. Kelly, A. Dobrovic, G. A. McArthur

4:45 PM Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. (Abstract #8501)

S. P. Patel, A. J. Lazar, S. Mahoney, C. Vaughn, N. Gonzalez,
N. E. Papadopoulos, P. Liu, J. R. Infante, P. LoRusso, K. B. Kim

Discussion

5:00 PM Neal Rosen, MD, PhD (Abstracts #8500–8501)
Memorial Sloan-Kettering Cancer Center

5:15 PM Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group trial S0438. (Abstract #8502)

K. A. Margolin, J. Moon, L. E. Flaherty, C. D. Lao, W. L. Akerley, J. A. Sosman,
J. M. Kirkwood, V. K. Sondak, Southwest Oncology Group

5:30 PM Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. (Abstract #8503)

R. Kefford, H. Arkenau, M. P. Brown, M. Millward, J. R. Infante, G. V. Long,
D. Ouellet, M. Curtis, P. F. Lebowitz, G. S. Falchook

Discussion

5:45 PM Grant A. McArthur, PhD (Abstracts #8502–8503)
Peter MacCallum Cancer Centre

4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM

PARP Inhibition: DNA Repair as the Target

Location: E Arie Crown Theater

CME credit: 1.5

Track(s): Developmental Therapeutics

Patrick Johnston, MD, PhD—Co-Chair

Queen's University Belfast

Eunice Lee Kwak, MD, PhD—Co-Chair

Massachusetts General Hospital

Discussion

4:30 PM Alan Hilary Calvert, MD

Cancer Research Unit

PARP as a Therapeutic Target

4:45 PM **Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide. (Abstract #3000)**

A. R. Tan, D. Gibbon, M. N. Stein, R. A. Moss, V. Karantza, H. Lin, M. Gounder, A. P. Chen, M. J. Egorin, R. S. DiPaola

5:00 PM **First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. (Abstract #3001)**

S. K. Sandhu, R. M. Wenham, G. Wilding, M. McFadden, L. Sun, C. Toniatti, M. Stroh, C. L. Carpenter, J. S. De Bono, W. R. Schelman

5:15 PM **Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. (Abstract #3002)**

K. A. Gelmon, H. W. Hirte, A. Robidoux, K. S. Tonkin, M. Tischkowitz, K. Swenerton, D. Huntsman, J. Carmichael, E. Macpherson, A. M. Oza

Discussion

5:30 PM James H. Doroshow, MD (Abstracts #3000–3002)

National Cancer Institute

State of Development for PARP Inhibition

Saturday, June 5, 2010

4:45 PM - 6:00 PM
EDUCATION SESSIONS

Cutaneous Cancer Syndromes

Location: E353

CME credit: 1.25

Track(s): Cancer Genetics; Melanoma/Skin Cancers

Sancy Ann Leachman, MD—Chair

University of Utah

Overview of Cutaneous Cancer Syndromes

Hensin Tsao, MD

Massachusetts General Hospital

Melanoma Genetics and Risk Assessment

Stephen B. Gruber, MD, PhD

University of Michigan

Advances in Cowden's Syndrome

Updates in Hormone Receptor-positive, HER2-positive, and Triple-negative Breast Cancer

Location: N Hall B1

CME credit: 1.25

Track(s): Breast Cancer; General Oncology

Lisa A. Carey, MD—Chair

University of North Carolina at Chapel Hill

What's New in HER2-positive Breast Cancer?

Mitchell Dowsett, PhD

Royal Marsden Hospital

What's New in Hormone Receptor-positive Breast Cancer?

Olufunmilayo I. Olopade, MBBS, FACP

The University of Chicago

What's New in Triple-negative Breast Cancer?

4:45 PM - 6:00 PM
MEET THE PROFESSOR SESSION

Aspirin and Nonsteroidal Anti-inflammatory Drugs for Colorectal Cancer Prevention (M04)-TICKETED SESSION

Location: E451b

CME credit: 1.25

Track(s): Cancer Prevention/Epidemiology

John A. Baron, MD

Dartmouth Medical School

4:45 PM - 6:00 PM
CLINICAL PROBLEMS IN ONCOLOGY

Complex and Recurrent Gynecologic Cancers: What's an Oncologist to Do? (C06)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Gynecologic Cancer

Seiko Diane Yamada, MD—Chair

The University of Chicago

Recurrent Germ Cell Tumor of the Ovary

Martee Leigh Hensley, MD, MSc

Memorial Sloan-Kettering Cancer Center

Management of Recurrent Leiomyosarcoma of the Uterus

John H. Farley, MD

Uniformed Services University of the Health Sciences

Management of Recurrent Low-grade Serous Ovarian Carcinoma

Sunday, June 6, 2010

**7:30 AM - 9:00 AM
HIGHLIGHTS OF THE DAY**

Highlights of the Day I including Clinical Trials Participation Awards

Location: E Hall D1

CME credit: 1.5

Track(s): Special Session; General Oncology

Everett E. Vokes, MD—Co-Chair

The University of Chicago

Douglas W. Blayney, MD—Co-Chair

University of Michigan

7:30 AM

Clinical Trials Participation Awards

7:45 AM

Bruce D. Cheson, MD

Georgetown University Hospital

Lymphoma and Plasma Cell Disorders

8:00 AM

Alan B. Sandler, MD

Oregon Health & Science University

Lung Cancer—Local-Regional and Adjuvant Therapy

8:15 AM

Gretchen Genevieve Kimmick, MD

Duke University Medical Center

Patient and Survivor Care

8:30 AM

F. Stephen Hodi, MD

Dana-Farber Cancer Institute

Melanoma/Skin Cancers

8:45 AM

Question and Answer

8:00 AM - 9:15 AM
SPECIAL SESSION

Forum on Reimbursement

Location: E Arie Crown Theater

CME credit: 1.25

Track(s): Practice Management and Information Technology; Special Session

Joseph S. Bailes, MD—Co-Chair

Texas Oncology

Steven Stranne, MD, JD—Co-Chair

Bryan Cave LLP

Sunday, June 6, 2010

8:00 AM - 9:15 AM
EDUCATION SESSIONS

Allogeneic Transplantation Advances and Controversies

Location: E354b

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation

Koen van Besien, MD—Chair

The University of Chicago

Advances in Alternative Donor Transplant

Parameswaran Hari, MD, MRCP, MS

Medical College of Wisconsin

Reduced Intensity, Myeloablative, and Transplant Lite: What's in a Name?

Marcos J. G. De Lima, MD

University of Texas M. D. Anderson Cancer Center

Transplant for Acute Myeloid Leukemia: Who Should be Transplanted in CR1?

Caregiving to Elderly Patients: Clinical, Ethical, and Psychosocial Challenges

Location: S100a

CME credit: 1.25

Track(s): Geriatric Oncology; Ethics; Patient and Survivor Care

Antonella Surbone, MD, PhD, FACP—Chair

New York University

Ethical and Social Implications of Caregiving to Elderly Cancer Patients

Lea Baider, PhD

Hadassah University Hospital

Beyond the Possible: Appraising the Needs of Elderly Cancer Patients' Caregivers

Lodovico Balducci, MD

H. Lee Moffitt Cancer Center & Research Institute

The Spirituality of the Home Caregiver

Controversies in the Management of Colorectal Cancer

Location: N Hall B1

CME credit: 1.25

Track(s): Gastrointestinal (Colorectal) Cancer

Axel Grothey, MD—Chair

Mayo Clinic Rochester

Is There an Optimal Treatment Strategy for Advanced Colorectal Cancer?

David L. Bartlett, MD

University of Pittsburgh Medical Center

Treatment of Colorectal Cancer with Peritoneal Carcinomatosis: Knife, Drugs, or Both?

Claus Roedel, MD

University of Erlangen

Neoadjuvant Therapy of Rectal Cancer: How Can We Make It Better?

Controversies in the Management of Desmoid Tumors

Location: S406 (Vista Room)

CME credit: 1.25

Track(s): Sarcoma

Murray F. Brennan, MD—Chair

Memorial Sloan-Kettering Cancer Center

Local Management of Desmoid Tumors

Sylvie Bonvalot, MD, PhD

Institut Gustave Roussy

Nonoperative Management of Desmoids with or without Systemic Therapy

Alexander Lazar, MD, PhD

University of Texas M. D. Anderson Cancer Center

Molecular Markers of Desmoid Recurrence

HPV Status and Clinical Decision Making for Patients with Oropharynx Cancer

Location: E Hall D2

CME credit: 1.25

Track(s): Head and Neck Cancer; Gynecologic Cancer

Maura L. Gillison, MD, PhD—Chair

The Ohio State University

Clinical Implications of Human Papillomavirus Etiology of Head and Neck Cancers: An Update

Andy Trotti, MD

University Medical Service Association

The Development of Prospective HPV-specific Head and Neck Cancer Clinical Trials

Lisa F. Licitra, MD

Istituto Nazionale Tumori

Biological Correlates of HPV Tumor Status

Optimal Treatment for Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology; Leukemia, Myelodysplasia, and Transplantation

Stephen Hunger, MD—Chair

The Children's Hospital

Converging Approaches to Treating Childhood, Adolescent, and Young Adult ALL

Charles Grenfell Mullighan, MBBS, MSc, MD

St. Jude Children's Research Hospital

New Insights into the Biological Basis of ALL

Ching-Hon Pui, MD

St. Jude Children's Research Hospital

Treatment Options for High-risk Pediatric and Adolescent ALL

Sunday, June 6, 2010

PARP Inhibitors and More in DNA Repair

Location: E353

CME credit: 1.25

Track(s): Tumor Biology

Nicola J. Curtin, PhD—Chair

Newcastle University

PARP Inhibitors' Function and Opportunities for Combination Therapy

James M. Ford, MD

Stanford University Medical Center

DNA Repair: Nuts and Bolts

Thomas Helleday, PhD

University of Oxford

DNA Repair Defect in BRCA Mutant Cells: A New Therapeutic Road

The Global Status of HPV Vaccination

Location: S100b

CME credit: 1.25

Track(s): Cancer Prevention/Epidemiology; International

Patti Gravitt, MS, PhD—Chair

The Johns Hopkins University

HPV Vaccines for the Developing World: Review and New Approaches to Broaden HPV Coverage and Reduce Vaccination Costs

Laura A. Koutsky, PhD, MSPH

University of Washington

Long-term Efficacy of Prophylactic Monovalent HPV Vaccines in Developing Countries

Mark A. Kane, MD, MPH

World Health Organization

Barriers to the Introduction of HPV Vaccines into the Developing World: Should Boys be Vaccinated?

8:00 AM - 9:15 AM
MEET THE PROFESSOR SESSION

Controversies in Stage IIIA Non-small Cell Lung Cancer (M05)-TICKETED SESSION

Location: E451b

CME credit: 1.25

Track(s): Lung Cancer

Renato Martins, MD, MPH

University of Washington

Controversies in Stage IIIA NSCLC

8:00 AM - 9:15 AM
CLINICAL PROBLEMS IN ONCOLOGY

Immunosuppression in Patients with Lymphoma and Myeloma (C07)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders; Patient and Survivor Care

Francine M. Foss, MD—Chair

Yale University Cancer Center

Impact of T-cell Directed Therapies on Immunocompetence

Myron Stefan Czuczman, MD

Roswell Park Cancer Institute

Prolonged B-cell Suppression from Anti-CD20 Therapies: What Are the Risks?

John Zaia, MD

City of Hope

Prevention, Surveillance, and Management of Viral Reactivation in the Setting of Immunosuppressive Therapies for Lymphoma and Myeloma

Sunday, June 6, 2010

8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM

The MEK Pathway

Location: E354a

CME credit: 1.5

Track(s): Developmental Therapeutics

Alex A. Adjei, MD, PhD—Chair

Roswell Park Cancer Institute

Discussion

8:00 AM David B. Solit, MD
Memorial Sloan-Kettering Cancer Center
Introduction

8:15 AM **Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. (Abstract #2503)**
J. R. Infante, L. A. Fecher, S. Nallapareddy, M. S. Gordon, K. T. Flaherty, D. S. Cox, D. J. DeMarini, S. R. Morris, H. A. Burris, W. A. Messersmith

8:30 AM **First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors. (Abstract #2504)**
J. Delord, N. Houede, A. Awada, A. Taamma, S. J. Faivre, T. Besse-Hammer, A. Italiano, C. Vignaud, M. Donica, E. Raymond

8:45 AM **Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors. (Abstract #2505)**
M. J. Borad, C. E. Akerele, R. K. Ramanathan, D. W. Northfelt, L. Reyderman, D. Verbel, K. Feit, D. D. Von Hoff, R. Tibes

Discussion

9:00 AM Patricia LoRusso, DO (Abstracts #2503–2505)
Karmanos Cancer Institute
Closing

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Central Nervous System Tumors

Location: S Hall A2

Tracks(s): Central Nervous System Tumors

- Brd. 1A Predictive impact of *IDH1* or *IDH2* mutations on outcome and response to temozolomide in low-grade gliomas. (Abstract #2033)**
 C. Houillier, X. Wang, G. Kaloshi, K. Mokhtari, J. Laffaire, B. Boisselier, A. Idbaih, K. Hoang-Xuan, M. Sanson, J. Delattre
- Brd. 1B Prognostic factors for glioblastoma (GBM) in individuals age 70 and older: A study of 446 patients from two tertiary centers. (Abstract #2034)**
 J. G. Scott, S. T. Chao, J. H. Suh, A. Cooper, A. S. Reiner, L. Nayak, K. Panageas, L. E. Abrey, F. M. Iwamoto
- Brd. 1C Prognostic and predictive markers in recurrent high-grade glioma (HGG): Results from the BR12 randomized trial. (Abstract #2035)**
 M. Brada, V. P. Collins, K. Ichimura, L. C. Thompson, R. Gabe, S. P. Stenning, BR12 Collaborators
- Brd. 1D Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). (Abstract #2036)**
 A. M. Omuro, K. Beal, S. Karimi, T. A. Chan, K. Panageas, L. Nayak, B. Seko, L. M. DeAngelis, L. E. Abrey, P. H. Gutin
- Brd. 1E Acute neurological toxicity (NT) and long-term outcomes in high-grade glioma RTOG trials. (Abstract #2037)**
 Y. R. Lawrence, M. Wang, A. Dicker, D. W. Andrews, W. J. Curran, J. M. Michalski, L. Souhami, W. A. Yung, M. P. Mehta
- Brd. 1F Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG). (Abstract #2038)**
 A. Brickhouse, J. J. Vredenburgh, S. Gururangan, D. A. Reardon, A. Desjardins, K. Peters, J. E. Herndon, J. Norfleet, J. Marcello, H. S. Friedman
- Brd. 1G Open-label, dose confirmation, and dosimetry study of interstitial ¹³¹I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM): Final results. (Abstract #2039)**
 W. R. Shapiro, K. Judy, S. J. Patel, R. A. Lustig, K. Spicer, S. Shen, J. Lai, J. Shan
- Brd. 1H Methotrexate (M) area under the curve (AUC) and creatinine clearance (CrCl) as prognostic factors in primary central nervous system lymphoma (PCNSL). (Abstract #2040)**
 P. G. Morris, L. E. Abrey, A. S. Reiner, K. Panageas, B. Seko, L. M. DeAngelis, A. M. Omuro
- Brd. 2A Quality-of-life concordance between patients with malignant gliomas (MG) and their caregivers. (Abstract #2041)**
 D. Jacobs, S. A. Grimm, A. Rademaker, L. Rice, J. Chandler, K. Muro, M. H. Marymont, I. B. Helenowski, L. I. Wagner, J. J. Raizer
- Brd. 2B 18F-FET-PET hypermetabolic brain lesions: A correlation study to MRI and histopathologic findings. (Abstract #2042)**
 A. Muigg, M. Nowosielski, J. Schwetz, T. Gotwald, D. Putzer, H. Maier, G. Stockhammer, M. Hutterer
- Brd. 2C Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients. (Abstract #2043)**
 J. Bartolomeo, A. D. Norden, J. Drappatz, A. S. Ciampa, L. M. Doherty, D. C. LaFrankie, E. C. Quant, R. Beroukhim, P. Y. Wen

- Brd. 2D Interim analysis of the randomized PATSGO trial evaluating the prolongation of adjuvant temozolomide in newly diagnosed glioblastoma patients. (Abstract #2044)**
J. Baurain, T. Boterberg, D. Devriendt, F. Hammouch, G. Cosnard, N. Whenham, P. M. Clement, C. Mitine, L. Renard
- Brd. 2E Long-term survival from the initial trial of bevacizumab and irinotecan. (Abstract #2045)**
A. Desjardins, J. J. Vredenburgh, D. A. Reardon, J. E. Herndon, J. Marcello, K. Peters, S. Gururangan, S. Sathornsumetee, J. N. Rich, H. S. Friedman
- Brd. 2F Secondary hematologic malignancies associated with temozolomide (TMZ) in patients with glioma. (Abstract #2046)**
H. Momota, Y. Narita, Y. Miyakita, S. Shibui
- Brd. 2G Influence of vascular endothelial growth factor (VEGF) single nucleotide polymorphisms (SNPs) on prognosis of glioblastoma (GB) patients. (Abstract #2047)**
C. Linassier, M. Ohresser, L. Karayan-Tapon, B. Narciso, M. Wager, M. Marson, L. Moise, B. Malivoir, H. Watier, P. Francois
- Brd. 2H Radiotherapy with or without temozolomide in elderly glioblastoma patients: Treatment results and prognostic factors. (Abstract #2048)**
A. Dirier, M. U. Abacioglu, S. Okkan, Y. Pak, Y. Yukselen Guney, G. Aksu, S. Soyuer, O. B. Oksuzoglu, A. D. Meydan, S. B. Zincircioglu, Turkish Oncology Group-CNS Working Party
- Brd. 3A A mesenchymal/stem cell predictor of survival of patients with malignant gliomas. (Abstract #2049)**
E. P. Sulman, M. Guerrero, T. Mikkelsen, V. Bonato, H. S. Phillips, M. S. Berger, P. Collins, B. Broom, K. Do, K. D. Aldape
- Brd. 3B Phase II and pharmacogenomics study of enzastaurin plus temozolomide and radiation in patients with GBM. (Abstract #2050)**
N. A. Butowski, K. Lamborn, M. C. Polley, J. L. Clarke, A. Nicole, M. Page, S. Nicol, D. Thornton, S. M. Chang, M. Prados
- Brd. 3C Use of functional protein pathway activation mapping in glioblastoma samples to differentiate long-term from short-term survivors along with pathway-driven molecular subgroups. (Abstract #2051)**
C. Mueller, H. Fillmore, W. Broadus, J. C. Watson, R. H. Lipsky, M. Cremona, J. Deng, L. A. Liotta, J. D. Wulfschuhle, E. Petricoin III
- Brd. 3D Expression of endoglin CD105 and nestin to assess neoangiogenesis in peritumor tissue of glioblastoma. (Abstract #2052)**
G. Sica, G. Lama, C. Anile, M. Geloso, G. La Torre, P. De Bonis, G. Maira, L. Lauriola, M. Jhanwar-Uniyal, A. Mangiola
- Brd. 3E MGMT promoter methylation and IDH1 mutation as prognostic markers for a favorable clinical outcome in patients with glioblastoma multiforme. (Abstract #2053)**
A. Wozniak, E. Van Mieghem, H. Ardon, S. De Vleeschouwer, J. Menten, R. Sciot, F. Van Calenbergh, S. Van Gool, M. Debiec-Rychter, P. M. Clement
- Brd. 3F Pseudoprogression after treatment with the TGF-beta 2 inhibitor trabedersen in high-grade glioma patients. (Abstract #2054)**
U. Bogdahn, G. Stockhammer, A. K. Mahapatra, N. K. Venkataramana, V. E. Oliushine, V. E. Parfenov, I. E. Poverennova, P. Jachimczak, H. Heinrichs, K. Schlingensiepen, AP 12009 Glioma Study Group
- Brd. 3G Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results. (Abstract #2055)**
S. Sathornsumetee, A. Desjardins, J. J. Vredenburgh, R. E. McLendon, J. Marcello, J. E. Herndon, J. Norfleet, S. Gururangan, H. S. Friedman, D. A. Reardon
- Brd. 3H Current status of phase III anti-EGF-receptor antibody (OSAG-101) for newly diagnosed glioblastoma. (Abstract #2056)**
M. Westphal, C. Senft, C. Braun, T. Pietsch, M. Warmuth, F. Bach, O. Heese

- Brd. 4A** **Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. (Abstract #2057)**
T. Walbert, M. R. Gilbert, M. D. Groves, V. K. Puduvalli, W. A. Yung, C. A. Conrad, G. C. Bobustuc, H. Colman, B. N. Bekele, V. A. Levin Sr.
- Brd. 4B** **Whole-brain radiotherapy with concurrent fixed-dose daily temozolomide for brain metastases treatment: A randomized phase II trial. (Abstract #2058)**
C. Gamboa-Vignolle, O. G. Arrieta Rodriguez, T. Ferrari-Carballo
- Brd. 4C** **Use of bevacizumab to facilitate up-front chemoradiation in poor-risk patients with glioblastoma multiforme by improving neurologic function. (Abstract #2059)**
R. M. Green, E. A. Woysner, L. Nghiemphu, A. Lai, T. Cloughesy
- Brd. 4D** **Imatinib mesylate plus hydroxyurea for adults with recurrent/progressive low-grade glioma: Final phase II study results. (Abstract #2060)**
K. Peters, A. Desjardins, J. J. Vredenburg, B. Dryman, S. Gururangan, H. S. Friedman, D. A. Reardon
- Brd. 4E** **Evaluation of three stratification systems predicting recurrence and prognosis in patients with brain metastases after tumor removal and whole-brain irradiation. (Abstract #2061)**
V. Lee, K. N. Hung, D. T. Chua, D. L. Kwong, T. W. Leung, G. K. Au
- Brd. 4F** **Determinants of therapeutic resistance in glioblastomas: Lessons learned from RTOG 0211 and beyond. (Abstract #2062)**
A. Chakravarti, M. Wang, H. Robins, A. Guha, W. J. Curran, D. Brachman, A. K. Choucair, M. Dolled-Filhart, T. Lautenschlaeger, M. P. Mehta
- Brd. 4G** **Use of FLAIR MRI in determining glioblastoma response to cediranib. (Abstract #2063)**
E. R. Gerstner, Q. Chen, T. Batchelor, A. G. Sorensen
- Brd. 4H** **Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignant gliomas: A matched-pair study. (Abstract #2064)**
M. Platten, N. Dörner, S. Hofer, N. Schäfer, D. Schemmer, M. Weller, M. Bendszus, W. Wick, A. Wick
- Brd. 5A** **Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV). (Abstract #2065)**
M. Khasraw, L. E. Abrey, A. B. Lassman, A. Hormigo, C. Nolan, I. T. Gavrilovic, I. K. Mellingerhoff, A. S. Reiner, L. M. DeAngelis, A. M. Omuro
- Brd. 5B** **A prospective study of surgery plus biodegradable carmustine wafers for local control and neurocognitive function in 39 patients with one to three brain metastases: Preliminary results. (Abstract #2066^)**
S. Brem, C. A. Meyers, M. Booth-Jones, S. Jain, M. G. Ewend
- Brd. 5C** **Levels of circulating endothelial cells in relapsing glioblastoma patients responding to bevacizumab. (Abstract #2067)**
M. Eoli, A. Calleri, L. Cuppini, P. Mancuso, E. Prodi, S. Pellegatta, C. L. Solero, M. Bruzzone, F. Bertolini, G. Finocchiaro
- Brd. 5D** **A prospective trial on the efficacy of a multiparametric imaging biomarker for early identification of GBM patients resistant to first-line therapy. (Abstract #2068)**
C. J. Galbán, T. L. Chenevert, C. R. Meyer, C. Tsien, T. S. Lawrence, L. Junck, P. C. Sundgren, T. D. Johnson, A. Rehemtulla, B. D. Ross
- Brd. 5E** **Phase I/IIa trial of autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. (Abstract #2069)**
Y. Muragaki, T. Maruyama, H. Iseki, K. Tsuboi, A. Matsumura, T. Yamamoto, M. Matsutani, K. Karasawa, Y. Nakazato, T. Ohno

- Brd. 5F Temozolomide and radiation therapy in elderly patients affected by glioblastomas: A pooled analyses of three prospective phase II trials. (Abstract #2070)**
A. Fiorentino, S. Chiesa, P. De Bonis, S. Manfrida, G. R. D'Agostino, A. Mangiola, A. G. Morganti, V. Frascino, C. Anile, M. Balducci
- Brd. 5G High-dose radiation therapy using photons and carbon ion radiotherapy in patients with atypical and anaplastic meningiomas: Relevance of neuropathologic classification and therapeutic impact of a boost using of carbon ion radiotherapy. (Abstract #2071)**
S. E. Combs, A. von Deimling, J. Debus, D. Schulz-Ertner, C. Hartmann
- Brd. 5H Phase II trial of combined temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. (Abstract #2072)**
S. Ananda, A. K. Nowak, L. Cher, A. J. Dowling, C. Brown, R. J. Simes, M. Rosenthal
- Brd. 6A Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas. (Abstract #2073)**
J. Kirkpatrick, J. J. Vredenburgh, D. A. Reardon, A. Desjardins, K. Peters, S. Gururangan, J. E. Herndon, J. Marcello, S. Woodring, H. S. Friedman
- Brd. 6B Prospective validation of the new graded prognostic assessment scale for brain metastases: A multicenter study. (Abstract #2074)**
S. Villa, D. C. Weber, C. Moretones, A. Manes, P. Puyalto, P. Cuadras, J. Bruna, E. Verger, F. Graus, C. Balana
- Brd. 6C Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM). (Abstract #2075)**
K. C. Shih, D. R. Spigel, H. A. Burris III, R. H. Brown, G. C. Shepard, J. D. Hainsworth
- Brd. 6D MGMT promoter methylation status and DNA mismatch repair genes in paired primary and recurrent glioblastoma: A translational study of the German Glioma Network. (Abstract #2076)**
J. Tonn, J. Felsberg, N. Thon, S. Eigenbrod, M. Westphal, G. Schackert, M. Loeffler, F. Kreth, M. Weller, G. Reifenberger, German Glioma Network
- Brd. 6E Preoperative blood parameters as biomarkers for high-grade gliomas. (Abstract #2077)**
M. Rosenthal, K. M. Field, P. Gibbs, T. Wohlers, K. Drummond
- Brd. 6F Longitudinal analysis of physiologic MRI parameters in patients with newly diagnosed glioblastoma multiforme to predict outcome. (Abstract #2078)**
Y. Li, J. M. Lupo, M. C. Polley, J. C. Crane, W. Bian, S. Cha, S. M. Chang, S. J. Nelson
- Brd. 6G Characterization of pseudoprogression in patients with glioblastoma: Is histology the gold standard? (Abstract #2079)**
I. Melguizo, J. Bruner, N. Guha-Thakurta, K. R. Hess, V. K. Puduvalli
- Brd. 6H Quality of life in patients with pure and mixed anaplastic oligodendroglioma treated with dose-intense temozolomide: A phase II multicenter study. (Abstract #2080)**
N. Hashemi Sadraei, M. S. Ahluwalia, C. Brewer, D. Schiff, P. G. Fisher, M. C. Chamberlain, S. Panullo, H. B. Newton, P. Elson, D. Peereboom
- Brd. 7A Accuracy of a modeling algorithm to optimize perfusion MRI detection of glioma recurrence. (Abstract #2081)**
L. S. Hu, L. C. Baxter, D. S. Pinnaduwage, T. Jensen, A. C. Dueck, J. M. Eschbacher, J. E. Heiserman, J. P. Karis, J. Debbins, K. M. Schmainda
- Brd. 7B Preclinical evaluation of bafetinib for treatment of glioblastoma multiforme. (Abstract #2082)**
V. Velcheti, B. Peterson, D. Levitt, O. Prakash

- Brd. 7C** Phase III study of vandetanib for patients with recurrent malignant gliomas. (Abstract #2083)
K. A. McNicol, T. N. Kreisl, F. M. Iwamoto, J. Sul, H. A. Fine
- Brd. 7D** Correlation of cognitive symptoms with cognitive performance among brain cancer patients after radiation therapy. (Abstract #2084)
S. R. Rapp, L. D. Case, M. E. Loghin, C. A. Meyers, T. J. Saphner, B. G. Sleckman, V. W. Stieber, J. N. Atkins, J. K. Giguere, E. G. Shaw
- Brd. 7E** A new gene expression-based diagnostic test to predict prognosis of gliomas for the support of histopathologic diagnosis. (Abstract #2085)
K. Kato, M. Shirahata, S. Kawarazaki, R. Matoba, J. Takahashi
- Brd. 7F** Circulating endothelial cells, microparticles, and markers of inflammation and coagulation in glioblastoma patients before and after protracted temozolomide and radiotherapy. (Abstract #2086)
G. Reynes, V. Martinez-Sales, V. Vila, T. Fleitas, M. Martin, E. Reganon
- Brd. 7G** Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent malignant glioma (MG). (Abstract #2087)
A. Benouaich-Amiel, E. Mazza, C. Massard, P. Gaviani, F. Fiorentini, A. Scaburri, M. A. Pacciarini, E. Calvo
- Brd. 8A** CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma. (Abstract #2089)
S. Gururangan, J. J. Vredenburgh, A. Desjardins, K. Peters, J. E. Herndon, R. E. McLendon, D. Janney, H. S. Friedman, D. A. Reardon
- Brd. 8B** Assessment of diffusion parameters in scans prior to progression in GBM patients following antiangiogenic therapy. (Abstract #2090)
L. Jalilian, E. Essock-Burns, S. Cha, S. M. Chang, N. A. Butowski, S. J. Nelson
- Brd. 8C** Study of quality of life in brain tumor patients treated with three-dimensional conformal radiotherapy. (Abstract #2091)
V. S. Vankamamidi, V. R. Sunkavalli, K. J. Naidu, M. Malik, S. Pamidighantam
- Brd. 8D** Using a prospective comprehensive database to define features that impact the outcome of patients with glioblastoma multiforme. (Abstract #2092)
K. M. Field, M. Rosenthal, S. Kosmider, P. Gibbs, K. Drummond
- Brd. 8E** Comparison of intratumoral loading of Flt3L/TK-recruited dendritic cells and systemic vaccination with tumor-lysate loaded dendritic cells in the stringent syngeneic CNS1 rat glioma model: Effect of temozolomide on anti-glioma immunity. (Abstract #2093)
P. R. Lowenstein, Y. Mineharu, G. King, M. Candolfi, W. Xiong, H. Assi, K. Yagiz, K. Kroeger, S. Bannykh, M. Castro
- Brd. 8F** A phase II trial of TLN-4601 in patients with glioblastoma multiforme (GBM) at first progression. (Abstract #2094)
W. P. Mason, K. Belanger, G. A. Nicholas, I. Vallieres, D. Mathieu, A. Desjardins, P. Kavan, A. M. Omuro, D. Raymond
- Brd. 8G** A clinical study investigating MPC-6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme. (Abstract #2095)
K. F. Grossmann, J. H. Ward, W. L. Akerley, M. J. Glantz, J. F. De Groot, R. Aiken, J. J. Olson, Y. Matsuoka, M. K. Yu, R. L. Jensen
- Brd. 9A** Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107). (Abstract #2097)
S. Phuphanich, J. Rudnick, M. Mazer, H. Q. Wang, N. Serrano, J. Richardson, C. Wheeler, M. Singh, K. Black, J. Yu
- Brd. 9B** New therapeutic approach for brain tumors: Intranasal administration of Ras inhibitor perillyl alcohol. (Abstract #2098)
C. O. Fonseca

Sunday, June 6, 2010

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Head and Neck Cancer

Location: S Hall A2

Tracks(s): Head and Neck Cancer

- Brd. 10A** Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303). (Abstract #5537)
A. M. Egloff, J. Lee, A. E. Vaezi, C. J. Langer, A. A. Forastiere, H. Quon, B. Burtness, J. R. Grandis, Department of Pathology, University of Pittsburgh
- Brd. 10B** Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA. (Abstract #5538)
E. Pectasides, G. Fountzilias, P. Kountourakis, P. Gouveris, C. Sasaki, D. Duffey, D. Rimm, B. Burtness, D. Psyrri
- Brd. 10C** Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. (Abstract #5539)
R. Mehra, K. Q. Cai, F. Zhu, J. Weaver, N. Nicolaou, R. B. Cohen, M. Lango, J. A. Ridge, A. K. Godwin, B. Burtness
- Brd. 10D** ERCC1 protein, mRNA expression, and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma (HNSCC) patients treated with surgery and adjuvant cisplatin-based chemoradiation (CRT). (Abstract #5540)
G. Castro, F. S. Pasini, S. A. Siqueira, A. R. Ferraz, R. C. Villar, I. M. Snitcovsky, M. H. Federico
- Brd. 10E** Expression and prognostic significance of X-ray crosscomplementation group 1 (XRCC1) in head and neck squamous cell carcinoma patients undergoing concurrent chemoradiation. (Abstract #5541)
M. Ang, N. Zhao, M. Hayward, M. Patel, X. Yin, M. D. Wilkerson, W. K. Funkhouser Jr., K. Fritchie, A. Olshan, D. N. Hayes
- Brd. 10F** Use of angiopoietin-1 expression in squamous cell carcinoma of the head and neck to predict disease-free survival. (Abstract #5542)
M. Dhiwakar, J. P. Malone, P. A. Kay, K. T. Robbins, S. Ran
- Brd. 10G** Correlation of expression of haptoglobin and recurrence in head and neck squamous cell cancer. (Abstract #5543)
Y. Su, C. Lee, S. Hong, H. Lin, S. Li, C. Yu, Y. Tung
- Brd. 10H** Outcomes in HPV-associated oropharyngeal squamous cell carcinoma after postoperative or definitive nonsurgical therapy. (Abstract #5544)
C. R. Spencer, H. Gay, B. H. Haughey, B. Nussenbaum, D. Adkins, D. I. Kuperman, I. El Naqa, J. S. Lewis Jr., V. Auethavekiat, W. L. Thorstad
- Brd. 11A** Detection of antibodies to the HPV16 proteome in head and neck cancer patient sera. (Abstract #5545)
K. S. Anderson, J. Wong, M. R. Posner, A. B. Riemer, J. H. Lorch, R. I. Haddad, J. Bryan, M. Mclean, K. Kelsey
- Brd. 11B** Prognosis of HPV-positive squamous cell carcinoma of tonsil-expressing high level of p16 and low level of EGFR. (Abstract #5546)
H. Won, D. Sun, S. Chun, E. Jeon, M. Chang, C. Jung, B. Shim, M. Lee, J. Kang, J. Kim
- Brd. 11F** Use of T-cell infiltrate to predict long-term survival following local therapy in tongue cancer patients. (Abstract #5547)
J. Kim, S. Kim, J. Choi, B. Shin, S. Yoon, J. Seo, S. W. Shin, Y. H. Kim, J. S. Kim, K. Park

- Brd. 11G** Prognostic value of biomarkers in tissue microarrays (TMAs) of squamous cell carcinomas of the oral tongue (SCCOT). (Abstract #5548)
W. N. William Junior, M. Nunez, X. Gu, R. W. Jacobs, A. M. Litvak, C. R. Pickering, J. Lee, A. K. El-Naggar, B. S. Glisson, J. Myers
- Brd. 11H** Evaluation of ALDH1-A1 as a biomarker for metastasis of head and neck cancer. (Abstract #5549)
Z. G. Chen, S. Nannapaneni, S. Muller, N. F. Saba, M. Tighiouart, L. Pan, D. M. Shin
- Brd. 12A** The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss. (Abstract #5550)
G. Fountzilas, E. Pectasides, P. Kountourakis, P. Gouveris, C. Sasaki, D. Duffey, D. G. Pectasides, D. Rimm, B. Burtness, D. Psyrri
- Brd. 12B** Expression of drug-resistance-related proteins in nasopharyngeal cancer (NPC) patients treated with cisplatin-based concurrent chemoradiotherapy. (Abstract #5551)
Y. Hwang, H. Lee, J. Jeong, S. Kang, M. Ahn, J. Han, J. Kim, C. Kim, J. Choi
- Brd. 12F** Association of high Gli1 expression with poor survival in head and neck cancer patients treated with radiation therapy (RTOG 9003). (Abstract #5552)
C. H. Chung, J. Dignam, M. E. Hammond, A. M. Magliocco, R. Jordan, A. Trotti, S. Spencer, J. S. Cooper, Q. Le, K. Ang
- Brd. 12G** Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). (Abstract #5553)
J. Ley, D. Adkins, D. I. Kuperman, B. A. Siegel, F. Dehdashti, F. Wippold, K. Trinkaus, J. Subramanian, T. Rachocki
- Brd. 12H** A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). (Abstract #5554)
D. G. Pfister, S. Haque, H. Stambuk, D. M. Lisa, R. Shen, D. Carlson, M. G. Fury
- Brd. 13A** A phase II trial of biweekly gemcitabine and paclitaxel (GEMTAX) combination in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group study. (Abstract #5555)
K. E. Bickel, F. P. Worden, J. Moon, O. Kucuk, R. H. Wheeler, J. Clark, G. T. Wolf, S. Urba
- Brd. 13B** A phase II study of GW786034 (pazopanib) in Asian patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma. (Abstract #5556)
W. T. Lim, C. Thng, C. K. Toh, B. Chowbay, B. C. Goh, S. Leong, S. P. Ivy, Q. Ng, D. S. Tan, E. Tan
- Brd. 13C** Efficacy of combining targeted therapies cetuximab and dasatinib for resistant salivary gland carcinomas in vitro. (Abstract #5557)
A. Brohl, K. Steadman, B. Kallakury, J. F. Deeken
- Brd. 13D** Combined hedgehog and epidermal growth factor receptor (EGFR) inhibition in a direct patient tumor model (DPTM) of head and neck squamous cell cancer (HNSCC). (Abstract #5558)
S. Keysar, R. Anderson, S. Takimoto, A. Tan, I. Deyneko, K. McGovern, R. W. Ross, J. Song, A. Jimeno
- Brd. 13E** Activity of novel RET inhibitors against RET genotypes associated with medullary thyroid cancer. (Abstract #5559)
A. W. Gramza, J. Patterson, J. Peters, M. Kaufman, S. Wise, D. Flynn
- Brd. 13F** Mature results of a phase I trial of bortezomib, cisplatin, and radiotherapy for advanced or recurrent head and neck cancer. (Abstract #5560)
R. S. Axelrod, P. H. Ahn, G. J. Kubicek, P. R. Anne, D. Cognetti, A. Dicker, M. Machtay

Sunday, June 6, 2010

- Brd. 13G Phase I trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. (Abstract #5561)**
J. Kao, S. H. Packer, M. Teng, V. Gupta, K. Misiukiewicz, E. M. Genden
- Brd. 13H HN5: A phase I/II study of erlotinib as adjuvant therapy in patients treated by chemoradiation therapy (CRT) for locally advanced SCCHN. (Abstract #5562)**
D. Soulieres, B. Fortin, E. Winquist, D. Charpentier, E. Harnett, W. Walsh, W. Parulekar
- Brd. 14A The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC): Preliminary toxicity report. (Abstract #5563)**
R. I. Haddad, R. B. Tishler, D. Adkins, F. R. Khuri, J. Clark, J. H. Lorch, L. J. Wirth, N. J. Sarlis, Z. Jaffa, M. R. Posner, The Paradigm Study Group
- Brd. 14B Interim safety analysis of a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC). (Abstract #5564)**
B. A. Van Tine, J. Ley, B. Nussenbaum, W. L. Thorstad, H. Gay, T. Rachocki, J. Subramanian, D. I. Kuperman, D. Adkins
- Brd. 14C Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck. (Abstract #5565)**
M. Gupta, V. Madholia, N. Gupta, K. T. Bhowmik
- Brd. 14D Hyperfractionated radiation therapy and concurrent chemotherapy for advanced head and neck cancer. (Abstract #5566)**
K. A. AL Saleh, R. Safwat, A. Bedair, A. AL Basmy
- Brd. 14E Concurrent chemoradiation in stage II laryngeal carcinomas. (Abstract #5567)**
R. Rajendranath, A. Surendranath, A. Vasanthan
- Brd. 14F Network meta-analysis (MA) of taxane-based neoadjuvant chemotherapy (NCT) for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). (Abstract #5568)**
J. McGhie, E. Winquist
- Brd. 14G Induction chemotherapy with carboplatin and paclitaxel followed by radiotherapy and concurrent weekly carboplatin plus paclitaxel in locally advanced nasopharyngeal carcinoma in a nonendemic population. (Abstract #5569)**
G. Numico, M. Airoidi, P. Gabriele, A. Gabriele, M. Garzaro, L. Raimondo, F. Pedani, F. Beatrice, G. Pecorari, C. Giordano
- Brd. 14H Phase II study of synchronous chemoradiotherapy with capecitabine in patients with locally advanced squamous cell carcinoma of the head and neck. (Abstract #5570)**
A. Jegannathan, K. Mais, A. Sykes, L. Lee, B. Yap, A. Birzgalis, J. Homer, D. Ryder, N. Slevin
- Brd. 15A Organ preservation using carboplatin, capecitabine, docetaxel, and radiotherapy in head and neck cancer: A phase II study. (Abstract #5571)**
D. F. Saragiotto, F. C. Maluf, L. G. Brandão, F. F. de Arruda, F. Costa, J. Luis, S. S. Arap, P. Michaluart Jr., S. C. Martins
- Brd. 15B Prediction of outcome of TPF with or without cetuximab induction chemotherapy in head and neck squamous cell carcinoma (HNSCC) using the FLAVINO assay. (Abstract #5572)**
A. Dietz, A. Boehm, A. Reiche, G. Mueller, P. Kruber, U. Keilholz, D. Niederwieser, G. Wichmann
- Brd. 15C The persistence of symptom burden after radiation treatment for head and neck cancer (HNC). (Abstract #5573)**
D. I. Rosenthal, T. R. Mendoza, G. B. Gunn, X. S. Wang, A. C. Hessel, A. S. Garden, W. H. Morrison, C. S. Cleeland

- Brd. 15D** **Oncologically endoscopic nasopharyngectomy for T1/T2a and selected T2b/T3 nasopharyngeal malignancies with nasopharynx resurfaced with posterior pedicle nasal mucoperiosteum flap. (Abstract #5574)**
M. Chen
- Brd. 15E** **A comparison between surgery plus radiotherapy and exclusive chemoradiation therapy regimes in oral and oropharyngeal cancer: Long-term functional and psychological impact. (Abstract #5575)**
M. Airoidi, M. Garzaro, L. Raimondo, G. Pecorari, C. Giordano
- Brd. 15F** **Chemotherapy-enhanced accelerated radiotherapy for intermediate-volume hypopharyngeal cancer. (Abstract #5576)**
M. Kawashima, R. Hayashi, M. Tahara, T. Ogino
- Brd. 15G** **An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): Preliminary report. (Abstract #5577)**
T. Lu, C. Zhao, C. Chen, L. Gao, J. Lang, J. Pan, C. Hu, F. Jin, R. Wang, C. Xie
- Brd. 15H** **Competing mortality in advanced head and neck cancer: A population-based study. (Abstract #5578)**
B. S. Rose, S. K. Nath, S. Lu, L. K. Mell
- Brd. 16A** **Functional outcomes after cisplatin (C)-based concurrent chemoradiation (CCRT) in patients (pts) with human papillomavirus (HPV)-related squamous cell carcinoma of the oropharynx (SCCOP). (Abstract #5579)**
C. P. Rodriguez, D. J. Adelstein, L. A. Rybicki, J. P. Saxton, J. Scharpf, B. Burkey, B. J. Wood, P. D. Knott, A. P. Hoschar, D. I. Ives
- Brd. 16B** **Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): Preliminary toxicity results. (Abstract #5580)**
D. N. Hayes, L. E. Raez, A. K. Sharma, M. A. Papagikos, F. Yunus, U. Parvathaneni, K. D. Eaton, N. Futran, S. G. Wallace, R. Martins
- Brd. 16C** **Toxicity and one-year tumor control with induction chemotherapy and bioradiotherapy for locally advanced unresectable head and neck cancer. (Abstract #5581)**
C. Mercke, H. Haugen, G. Adell, F. Costa-Svedman, J. Nyman, G. Wickart-Johansson, H. Sjödin
- Brd. 16D** **Long-term treatment outcome of nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT). (Abstract #5582)**
M. K. Kam, S. Leung, K. Yu, A. D. King, R. M. Chau, K. Cheung, B. Ma, E. P. Hui, A. T. Ahuja, A. T. Chan
- Brd. 16E** **Postoperative adjuvant chemoradiotherapy versus radiotherapy alone for head and neck squamous cell carcinoma: A meta-analysis evaluating the role of chemotherapy schedules. (Abstract #5583)**
G. A. Viani, S. L. Afonso, L. A. Ramos, V. Afonso, E. Stefano
- Brd. 16F** **Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): First overview of complete data set. (Abstract #5584)**
P. M. Harari, A. Y. Chen, W. J. Curran Jr., A. S. Garden, B. A. Murphy, S. J. Wong, L. A. Bellm, M. Schwartz, C. Schneider, K. Ang
- Brd. 16G** **Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Findings related to the oropharynx. (Abstract #5585)**
S. J. Wong, A. Y. Chen, W. J. Curran Jr., A. S. Garden, P. M. Harari, B. A. Murphy, L. A. Bellm, M. Schwartz, K. Ang
- Brd. 16H** **Phase I trial of combination sorafenib and tipifarnib: The experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). (Abstract #5586)**
M. E. Cabanillas, R. Kurzrock, S. I. Sherman, A. M. Tsimberidou, S. Waguespack, A. Naing, N. Busaidy, R. Gagel, J. J. Wright, D. S. Hong

Sunday, June 6, 2010

- Brd. 17A** **A phase II study of VEGF trap (afibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma. (Abstract #5587)**
E. J. Sherman, A. L. Ho, S. Haque, R. A. Ghossein, D. M. Lisa, H. Schöder, M. S. Baum, A. R. Shaha, R. M. Tuttle, D. G. Pfister
- Brd. 17B** **Epidemiology, treatment outcome, and survival of anaplastic thyroid cancer (ATC) in the United States: A period prevalence SEER database study 1973–2006. (Abstract #5588)**
A. M. Hossain, R. N. Rahman, G. Nagaiah, R. Altaha, S. C. Remick
- Brd. 17C** **Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. (Abstract #5589)**
R. D. Harvey, J. S. Kauh, S. S. Ramalingam, C. M. Lewis, Z. Chen, S. Lonial, I. C. Blount, D. M. Shin, F. R. Khuri, T. K. Owonikoko
- Brd. 17D** **Sorafenib in patients (pts) with advanced thyroid carcinoma (TC): A compassionate use program. (Abstract #5590)**
J. Capdevila, L. Iglesias, I. Halperin, A. Segura, M. Vaz, J. Corral, J. J. Grau, G. Obiols, R. Hitt, J. Taberner
- Brd. 17E** **Intensity-modulated radiation therapy combined with concurrent and adjuvant chemotherapy in anaplastic thyroid carcinoma: A single-institution study. (Abstract #5591)**
K. C. Bible, J. R. Molina, J. C. Kasperbauer, R. V. Lloyd, B. McIver, J. C. Morris III, I. D. Hay, V. Suman, R. C. Smalridge, R. L. Foote
- Brd. 17F** **Use of cystatin C as a biomarker for glomerular filtration rate in patients with head and neck cancer receiving cisplatin-based chemotherapy. (Abstract #5592)**
E. Boelke, G. Schieren, W. Budach, C. Matuschek, M. Peiper, S. Gripp, G. Steinbach, M. Pelzer, C. Antke, D. Hermsen
- Brd. 17G** **Effects of aprepitant use in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with high-dose cisplatin and radiation (RT). (Abstract #5593)**
M. Ong, J. Martin, L. Sax, D. S. Ernst, E. Winquist
- Brd. 17H** **Prognostic significance of epithelitis by concurrent cetuximab and radiotherapy (RT) for locally advanced head and neck squamous cell carcinoma (HNSCC) patients (Pts). (Abstract #5594)**
J. J. Grau, A. Tagliapietra, E. Verger, M. Caballero, C. Muñoz, L. Alos
- Brd. 18A** **Economic burden of resected squamous cell carcinoma of the head and neck (SCCHN) in a U.S.-managed care population. (Abstract #5595)**
B. Chastek, M. Amonkar, N. Samant
- Brd. 18B** **Survival from head and neck cancers based on socioeconomic status in Asians. (Abstract #5596)**
K. P. Chu, S. J. Shema, S. Wu, S. L. Gomez, E. T. Chang, Q. Le
- Brd. 18C** **Stress and depression in head and neck cancer patients by primary surgery versus primary radiotherapy treatment modality. (Abstract #5597)**
C. A. Jensen, J. J. Hu, L. D. Case, J. D. Browne, J. Gilbert, J. Metzner-Sidurski, E. Franzmann, B. Frizzell, C. Schneider, E. G. Shaw
- Brd. 18D** **Comparison of quality of lives between voice-rehabilitated and nonrehabilitated laryngectomees in a developing world community. (Abstract #5598)**
B. T. Varghese, A. Mathew, P. Sebastian
- Brd. 18E** **Do the treatment outcome priorities of head and neck cancer patients change after undergoing radiation treatment? (Abstract #5599)**
H. Badr, D. I. Rosenthal, K. Milbury, A. S. Garden, S. J. Frank, G. B. Gunn, C. S. Cleeland, E. R. Gritz

- Brd. 18F The relationship of presenting symptom burden and survival in patients with head and neck cancer (HNC). (Abstract #5600)**
G. B. Gunn, T. R. Mendoza, X. S. Wang, A. S. Garden, J. S. Lewin, W. H. Morrison, S. J. Frank, M. S. Chambers, C. S. Cleeland, D. I. Rosenthal
- Brd. 18G Routine versus clinically indicated post-treatment surveillance in head and neck cancer. (Abstract #5601)**
N. M. Iyengar, J. K. Salama, K. Stenson, D. J. Haraf, E. A. Blair, E. E. Vokes, E. E. Cohen

Sunday, June 6, 2010

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Lung Cancer—Local-Regional and Adjuvant Therapy

Location: S Hall A2

Tracks(s): Lung Cancer

- Brd. 19A Prognostic impact of the cytoskeleton regulatory protein hMena in resected node-negative non-small cell lung cancer (NSCLC): A clinical-biological risk stratification model. (Abstract #7027)**
E. Bria, M. Mottolese, I. Sperduti, P. Visca, B. Antoniani, F. Facciolo, F. Di Modugno, F. Cognetti, P. Nisticò, M. Milella
- Brd. 19B Prognostic value of three microRNA expression profiles in early-stage squamous cell lung cancer (SqCLC). (Abstract #7028)**
M. T. Skrzypski, A. Szymanowska, E. Jassem, P. Czapiewski, R. Rzepko, W. Biernat, R. Pawowski, W. Rzyman, J. Jassem
- Brd. 19C VDAC1 and prognosis in surgically resected non-small cell lung cancer. (Abstract #7029)**
C. M. Grills, K. J. O'Byrne, K. Gately, D. A. Fennell
- Brd. 19D Cost-effectiveness of an autoantibody test (AABT) as an aid to diagnosis of lung cancer. (Abstract #7030)**
D. Weycker, J. R. Jett, F. C. Detterbeck, D. L. Miller, A. Khuu, T. C. Kennedy, P. Boyle, J. F. Robertson, G. Hamilton-Fairley, J. Edelsberg, AABT Health Economic Group
- Brd. 19E Use of telomere length in peripheral leukocytes to predict risk of recurrence in patients with early-stage non-small cell lung cancer after curative resection. (Abstract #7031)**
E. S. Kim, A. A. Vaporciyan, J. Xing, M. Huang, M. R. Spitz, S. M. Lippman, J. Gu, J. A. Roth, X. Wu
- Brd. 19F Use of serum autoantibodies to identify early-stage lung cancer. (Abstract #7032)**
L. Peek, S. Lam, G. Healey, H. A. Fritsche, C. Chapman, A. Murray, P. Maddison, J. F. Robertson, W. Wood
- Brd. 19G Demographics of populations at high risk of lung cancer and results of the Early CDT-Lung test. (Abstract #7033)**
J. Mathew, G. Healey, W. Jewell, A. Murray, C. Chapman, L. Peek, A. Barnes, W. Wood, J. F. Robertson, P. Boyle
- Brd. 19H Postoperative survivin expression in stage III non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemoradiation. (Abstract #7034)**
M. J. Fidler, S. Basu, K. A. Kaiser-Walters, E. Hadziahmetovic, M. Batus, D. Steker, J. Coon, P. Bonomi
- Brd. 20A Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor. (Abstract #7035)**
H. Lee, K. Lee, M. Ahn, H. Hwang, J. Lee, K. Park, T. Kim, C. Yi, M. Chung
- Brd. 20B Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). (Abstract #7036)**
A. K. Nowak, M. Millward, R. J. Francis, A. Hasani, A. A. van der Schaaf, T. Seguard, A. W. Musk, M. J. Byrne
- Brd. 20C CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). (Abstract #7037)**
A. Dudek, H. Pang, R. A. Kratzke, G. A. Otterson, E. E. Vokes, H. L. Kindler, Cancer and Leukemia Group B.
- Brd. 20D A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using ¹⁸F-FDG-PET. (Abstract #7038)**
S. Irshad, S. Popat, R. N. Shah, S. Burbridge, R. Lal, L. Lang-Lazdunski, Z. Viney, P. Marsden, S. Barrington, J. F. Spicer

- Brd. 20E** **A new prognostic score in patients with malignant pleural mesothelioma. (Abstract #7039)**
G. Selvaggi, A. Billè, M. Gisabella, L. Righi, L. Errico, P. Borasio, F. Ardisson
- Brd. 20F** **A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM). (Abstract #7040)**
N. M. La Verde, A. Bramati, M. Cinquini, M. Tiseo, E. Collovà, G. Michetti, M. Lo Dico, A. Follador, M. C. Garassino, P. Zucali, on behalf of Orion Group
- Brd. 20G** **Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM). (Abstract #7041)**
E. Lorenzi, L. Gianoncelli, P. Zucali, G. Ceresoli, F. De Vincenzo, M. Simonelli, C. Ripa, L. Giordano, A. Santoro
- Brd. 20H** **Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma. (Abstract #7042)**
A. S. Tsao, I. I. Wistuba, R. J. Mehran, J. Gil, M. Nunez, J. Lee, H. Lin, S. M. Lippman, W. K. Hong
- Brd. 21A** **A multimodality treatment for malignant pleural mesothelioma patients with or without lymph node metastases. (Abstract #7043)**
K. A. Cengel, A. Fernandes, R. Mick, D. Smith, M. Culligan, J. Stevenson, D. Serman, E. Glatstein, S. M. Hahn, J. S. Friedberg
- Brd. 21B** **Phase II trial of consolidation chest radiotherapy for extensive-stage small cell lung cancer. (Abstract #7044)**
D. Yee, C. A. Butts, Q. S. Chu, D. W. Fenton, A. Joy, T. J. Reiman, M. Smylie, W. Roa
- Brd. 21C** **Pretreatment positron emission tomography (PET) scan standardized uptake value (SUV) as a prognostic variable for overall survival in limited-stage small cell lung cancer (L-SCLC). (Abstract #7045)**
D. R. Gomez, G. W. Gladish, X. Wei, P. Allen, J. D. Cox, M. O'Reilly, J. J. Erasmus, F. V. Fossella, R. Komaki
- Brd. 21D** **A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC). (Abstract #7046)**
C. M. Rudin, M. R. Oliveira, E. B. Garon, P. Bonomi, D. R. Camidge, C. Nolan, T. Busman, A. Krivoshik, R. Humerickhouse, L. Gandhi
- Brd. 21E** **Should large cell neuroendocrine carcinoma of the lung (LNEC) be classified and treated as a small cell lung cancer (SCLC) or with other large cell carcinomas (OLC)? (Abstract #7047)**
M. M. DeCamp, J. M. Varlotto, J. C. Flickinger, E. Schaefer, A. Recht
- Brd. 21F** **Sabarubicin (SABA) in combination with cisplatin (DDP): Maximum tolerated dose (MTD) evaluation (phase I step) followed by a phase II step in patients (pts) with small cell lung cancer-extensive disease (SCLC-ED). (Abstract #7048)**
O. A. Cornely, J. Wolf, K. M. Josten, T. Mueller, H. A. Duerk, W. Neumeister, M. Sebastian, C. Simonelli, A. Capriati, M. Karthaus, for the SABA with DDP Working Group
- Brd. 21G** **Phase II study of irinotecan and carboplatin followed by maintenance sunitinib in the first-line treatment of extensive-stage small cell lung cancer. (Abstract #7049)**
E. T. Lubiner, D. R. Spigel, F. A. Greco, M. S. Rubin, D. Shipley, D. S. Thompson, J. F. Eakle, R. H. Brown, H. A. Burris III, J. D. Hainsworth
- Brd. 21H** **Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC). (Abstract #7050)**
J. Heymach, B. S. Glisson, R. C. Doebele, C. Huang, D. R. Gandara, S. Le Scouiller, M. A. Marotti, D. R. Camidge

- Brd. 22A Long-acting somatostatin analogues survival differences in limited- and extensive-disease SCLC patients. (Abstract #7051)**
K. Zarogoulidis, E. Eleftheriadou, G. Gerasimou, P. Zarogoulidis, I. Sapardanis, T. Kontakiotis, G. Galaktidou, A. Gotzamani-Psarrakou, N. Karatzas
- Brd. 22B Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC). (Abstract #7052)**
M. O'Brien, J. Jassem, P. Lorigan, L. Bosquée, E. Marshall, F. Bustin, J. Stigt, A. C. Dingemans, B. Hasan, J. P. Van Meerbeeck
- Brd. 22C Retrospective study of irinotecan plus cisplatin induction followed by concurrent thoracic irradiation with irinotecan plus cisplatin chemotherapy for limited-disease small cell lung cancer. (Abstract #7053)**
J. Jeong, J. Sung, H. Pyo, K. Cho, H. Kim, J. Han, T. Yun, G. Lee, J. Lee
- Brd. 22D A phase II trial of combination chemotherapy with topotecan and amrubicin in small cell lung cancer (SCLC). (Abstract #7054)**
N. Nogami, K. Kiura, N. Takigawa, S. Harita, K. Chikamori, T. Shibayama, M. Tabata, K. Hotta, T. Shinkai, M. Tanimoto
- Brd. 22E Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC). (Abstract #7055)**
D. M. Waterhouse, S. K. Morgan, D. R. Spigel, S. Shankar, B. Dharan, D. E. Foose, K. Bhatt
- Brd. 22F Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results. (Abstract #7056)**
N. Ready, F. Dunphy, H. Pang, R. Heinze, J. Crawford, E. E. Vokes
- Brd. 22G Phase II study of amrubicin and carboplatin in patients with the refractory or relapsed small cell lung cancer (SCLC). (Abstract #7057)**
T. Hirose, T. Shirai, S. Kusumoto, T. Sugiyama, T. Yamaoka, K. Okuda, T. Ohmori, T. Ohnishi, M. Adachi A. Hermes
- Brd. 23A Five-year follow-up of preoperative chemotherapy (Cx) of docetaxel with or without cisplatin for clinical (c-) stage IB/II non-small cell lung cancer (NSCLC): Report of a Japan Clinical Oncology Group study (JCOG0204). (Abstract #7059)**
H. Kunitoh, M. Tsuboi, H. Asamura, H. Tada, K. Nagai, T. Mitsudomi, T. Koike, T. Shibata, N. Saijo, Japan Clinical Oncology Group
- Brd. 23B Evaluation of neoadjuvant “window of opportunity” trials with targeted therapy in patients with surgically resectable non-small cell lung cancer. (Abstract #7060)**
B. M. Stiles, F. Mirza, Y. Chiu, J. L. Port, P. C. Lee, S. Paul, N. K. Altorki
- Brd. 23C Does induction chemoradiation effect perioperative mortality and overall survival in patients undergoing pneumonectomy for non-small cell lung cancer? (Abstract #7061)**
J. Oxenberg, T. Li, B. Egleston, M. Goldberg, W. J. Scott
- Brd. 23D Multicenter phase II study evaluating docetaxel, CDDP, and cetuximab as induction regimen prior to surgery in chemotherapy-naïve patients with NSCLC stage IB-IIIa (INN06-study): Preliminary results. (Abstract #7062)**
W. Hilbe, G. Pall, T. Schmid, B. Forstner, A. Zabernigg, H. Jamnig, A. Gaechter, M. Freund, D. Kandler, E. Woell, Tyrolean Lung Cancer Study Group
- Brd. 23E Docetaxel plus cisplatin versus vinorelbine plus cisplatin as adjuvant chemotherapy in stage IB-IIIa non-small cell lung cancer: Preliminary result of phase II pilot trial CHL001/TAX622. (Abstract #7063)**
D. Chu, G. Wu, B. Han, X. Song, G. Chen, C. Zhou, Q. Wang, S. Wu, Y. Wang, W. Zi-Ping

- Brd. 23F Multimodal management of locally advanced (N2) non-small cell lung cancer (NSCLC): Is there a role for surgical resection? A single institution experience. (Abstract #7064)**
J. Bosch-Barrera, C. García-Franco, F. Guillen, M. Moreno-Jiménez, J. M. López-Picazo, A. Gurrpide, J. L. Perez-Gracia, J. Aristu, J. Garcia-Foncillas, I. Gil-Bazo
- Brd. 23G The impact of PET imaging on outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation: A subset analysis of HOG LUN 01–24/USO-023. (Abstract #7065)**
N. H. Jayaram, M. A. Neubauer, C. S. Johnson, T. Breen, C. E. Williams, N. H. Hanna
- Brd. 23H Role of surgery in patients with stage IIIA non-small cell lung cancer (NSCLC): Lessons learned from a tertiary referral cancer center experience. (Abstract #7066)**
C. Aggarwal, B. Egleston, L. Li, H. Borghaei, R. Mehra, N. Somaiah, A. Turaka, W. J. Scott, C. J. Langer, G. R. Simon
- Brd. 24A Influence of surgical interventions on survival in patients with stage IIIB non-small cell lung cancer (NSCLC): The Fox Chase Cancer Center (FCCC) experience. (Abstract #7067)**
W. J. Scott, C. Aggarwal, A. Lebenthal, B. Egleston, H. Borghaei, R. Mehra, N. Somaiah, A. Turaka, G. R. Simon
- Brd. 24B Surgeon-determined variability in quality of surgical resection of lung cancer. (Abstract #7068)**
R. A. Ramirez, A. Farooq, J. W. Allen, A. Berry, T. O'Brien, H. Cole, R. U. Osarogiagbon
- Brd. 24C Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer. (Abstract #7069)**
A. Recht, J. M. Varlotto, L. N. Medford-Davis, E. Schaefer, J. C. Flickinger, M. M. DeCamp
- Brd. 24D Review of mediastinal lymph node examination (mLNE) in a lung cancer resection (LCR) cohort. (Abstract #7070)**
R. U. Osarogiagbon, J. W. Allen, A. Farooq, T. O'Brien, J. T. Wu
- Brd. 24E Accuracy of endobronchial ultrasound-directed transbronchial needle aspiration (EBUS-TBNA) for mediastinal staging in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #7071)**
M. G. Tupayachi, P. J. Hosein, D. M. Nguyen, R. T. Thurer, M. T. Garcia, L. E. Raez, E. Donna
- Brd. 24F Does the revised TNM staging system for lung cancer better estimate actuarial rates of local/regional recurrence after surgery? (Abstract #7072)**
J. M. Pepeck, J. P. Chino, M. W. Onaitis, L. B. Marks, N. Ready, J. Crawford, T. A. D'Amico, J. L. Hubbs, C. R. Kelsey
- Brd. 24G Solitary pulmonary nodules (SPNs): Outcome of 6-year follow-up by a VA multidisciplinary lung cancer group. (Abstract #7073)**
H. B. Niell, J. P. Griffin, H. Cole, J. Salazar, D. Weiman, J. A. Kaufman, M. Zaman, E. V. Thompson, N. Appling
- Brd. 24H Examination of the influence that lymphatic and venous involvement gives consequence of stage I non-small cell lung cancer in new TNM classification. (Abstract #7074)**
K. Kojima, N. Fujiwara, H. Arai
- Brd. 25A Racial disparities on the use of invasive and noninvasive staging in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #7075)**
J. M. Suga, D. V. Nguyen, S. M. Mohammed, M. Brown, R. F. Calhoun, K. Y. Yoneda, D. R. Gandara, P. Lara Jr.
- Brd. 25B Survival of non-small cell lung cancer (NSCLC) patients in a randomized trial as predicted by the FDG-PET standardized uptake value (SUV). (Abstract #7076)**
K. Y. Gulenchyn, T. Farncombe, D. E. Maziak, G. E. Darling, A. A. Driedger, A. Hendler, C. Marriott, F. Raymond, L. Ehrlich, M. N. Levine

- Brd. 25F** Use of PET-measured response in involved mediastinal lymph nodes to predict overall survival (OS) in non-small cell lung cancer (NSCLC) patients treated with induction therapy (IT) and surgery. (Abstract #7077)
S. Barnett, G. Plourde, J. Zheng, M. Pietanza, T. J. Akhurst, R. J. Downey, M. G. Kris, R. Shen, V. W. Rusch, B. J. Park
- Brd. 25G** A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation. (Abstract #7078)
J. W. Neal, N. A. Pennell, B. W. Goodgame, M. Lanuti, R. S. Heist, A. T. Shaw, J. S. Temel, P. A. Janne, C. G. Azzoli, L. V. Sequist
- Brd. 25H** Health-related quality of life (HRQOL) after stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC). (Abstract #7079)
S. Senan, C. Gundy, C. J. Haasbeek, B. J. Slotman, N. K. Aaronson, F. J. Lagerwaard
- Brd. 26A** Stereotactic radiosurgery for stage I NSCLC in medically inoperable patients: A prospective multicenter study. (Abstract #7080)
A. Pennathur, R. I. Whyte, A. Zajac, D. G. Brachman, W. E. Gooding, N. A. Christie, H. C. Urschel, B. W. Loo, D. E. Heron, J. D. Luketich, the Multicenter Stereotactic Radiosurgery Investigators for the Treatment of Lung Cancer
- Brd. 26B** Photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways more than 1.0 cm in diameter. (Abstract #7081)
J. Usuda, N. Ikeda, H. Kato, T. Ohira
- Brd. 26F** Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update. (Abstract #7082)
H. Choy, L. S. Schwartzberg, S. R. Dakhil, E. B. Garon, J. K. Choksi, R. Govindan, G. Peng, A. G. Koustenis, J. Treat, C. K. Obasaju
- Brd. 26G** Randomized phase II trial of tegafur-uracil (UFT) and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small cell lung cancer: NJLCG 0601. (Abstract #7083)
M. Maemondo, S. Sugawara, T. Ishida, A. Inoue, K. Usui, O. Ishimoto, N. Matsubara, M. Tachihara, Y. Saijo, T. Nukiwa, North Japan Lung Cancer Study Group
- Brd. 26H** Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402. (Abstract #7084)
Y. Ohe, Y. Nishiwaki, A. Yokoyama, M. Kawahara, K. Takeda, T. Shibata, T. Tamura, N. Saijo, M. Fukuoka
- Brd. 27A** N0321: A phase I study of bortezomib, paclitaxel, carboplatin (CBDCA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC). (Abstract #7085)
S. E. Schild, J. R. Molina, G. K. Dy, K. M. Rowland, J. N. Sarkaria, S. P. Thomas, D. W. Northfelt, J. W. Kugler, N. R. Foster, A. A. Adjei
- Brd. 27B** A phase I dose-escalation study using three-dimensional conformal radiotherapy with concurrent cisplatin and S-1 in patients with stage III non-small cell lung cancer. (Abstract #7086)
T. Kozuka, H. Harada, M. Nishio, H. Murakami, F. Ohyanagi, S. Ishikura, A. Horiike, J. Eba, T. Nishimura, N. Yamamoto
- Brd. 27C** A phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage IIIA/b non-small cell lung cancer (NSCLC). (Abstract #7087)
A. M. Brade, A. Bezjak, R. M. MacRae, S. A. Laurie, L. Wang, S. Capobianco, F. A. Shepherd

- Brd. 27D** **Vinorelbine and cisplatin concurrently combined with thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: A long-term safety and efficacy report. (Abstract #7088)**
H. Horinouchi, I. Sekine, M. Sumi, K. Noda, Y. Nishiwaki, K. Mori, T. Tamura
- Brd. 27E** **Can we predict 2-year survival for radical radiation dosing schedules in advanced non-small cell lung cancer through a meta-analysis based predictive model? (Abstract #7089)**
W. Sharieff
- Brd. 27F** **Docetaxel (D) and cisplatin (C) induction chemotherapy followed by concurrent thoracic radiotherapy (TRT) and biweekly D and C for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study. (Abstract #7090)**
J. Casal, S. Varela, U. Anido, M. Lázaro, J. L. Firvida, S. Vazquez-Estevez, M. Villanueva, M. Amenedo, M. Caeiro, A. Gomez
- Brd. 27G** **A Galician Lung Cancer Group phase II study: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC). (Abstract #7091)**
S. Vazquez, J. Firvida, M. Lázaro, F. J. Barón, G. Alonso-Jaudenes Curbera, M. Amenedo, L. Santomé, F. J. Afonso, J. V. Cardona, J. Casal
- Brd. 27H** **Concomitant pemetrexed/carboplatin chemotherapy and 3D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy for locally advanced non-small cell lung cancer: Preliminary results of a phase II study. (Abstract #7092)**
S. Ma, Y. Xu, Y. Ji, X. Sun, J. Cheng, X. Du, Y. Zheng, G. Qiu
- Brd. 28A** **Cisplatin (CDDP) and oral vinorelbine (NVBO) concomitantly with radiotherapy (RT) after induction chemotherapy (CT) in locally advanced (LA) non-small cell lung cancer (NSCLC) treatment: Clinical experience in five institutions in Spain. (Abstract #7093)**
J. Remon, I. Diaz Padilla, J. Andrade, A. Gasco, J. M. Jurado, F. J. Perez, M. P. Lianes
- Brd. 28B** **Outcomes of patients with stage III (clinical N2) NSCLC: A VACCR analysis. (Abstract #7094)**
A. Ganti, W. Gonsalves, I. Aldoss, F. R. Loberiza Jr.
- Brd. 28C** **Retrospective review of all patients with thymoma treated over the last 33 years at the Royal Marsden Hospital. (Abstract #7095)**
C. Benson, R. S. Kristeleit, S. Ashley, S. Dolly, C. Mikropoulos, M. O'Brien, S. Popat
- Brd. 28D** **Volumetric analysis of advanced thymic malignancies. (Abstract #7096)**
J. Force, A. Rajan, E. Dombi, S. M. Steinberg, G. Giaccone
- Brd. 28E** **Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions. (Abstract #7097)**
P. Yang, J. Ebbert, L. Chhatwani, J. A. Wampfler, S. Stoddard, F. Zhang, M. de Andrade, M. Aubry
- Brd. 28F** **Baseline results of lung cancer screening program for family lung cancer risk with low-dose spiral CT in Taiwan. (Abstract #7098)**
C. Wang, Y. Tsai, Y. Cheung, H. Ko, Y. Ni, P. Feng, Y. Chen, P. Yang, G. Chang

Sunday, June 6, 2010

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Lung Cancer—Metastatic

Location: S Hall A2
Tracks(s): Lung Cancer

- Brd. 31A** A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non-small cell lung cancer (NSCLC) in fit elderly patients selected with a comprehensive geriatric assessment (CGA): Groupe Français de Pneumocancerologie (GFPC)*0504 (Abstract #7536)
H. Le Caer, F. Barlesi, R. Corre, H. Jullian, S. Bota, L. Falchero, A. Vergnenegre, C. Dujon, J. Y. Delhoume, C. Chouaid
- Brd. 31B** Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). (Abstract #7537)
T. Mok, D. R. Spigel, K. Park, M. A. Socinski, S. Y. Tung, D. Kim, G. Borzillo, H. Zhang, J. P. O'Connell, P. A. Janne
- Brd. 31C** EGFR and *ABCG2* polymorphisms as prognostic and predictive markers in the NCIC CTG BR.21 trial of single-agent erlotinib in advanced non-small cell lung cancer (NSCLC). (Abstract #7538)
G. Liu, D. Cheng, A. Le Maitre, N. Liu, Z. Chen, L. Seymour, K. Ding, F. A. Shepherd, M. S. Tsao
- Brd. 32A** Clinical impact of amphiregulin expression in EGFR wild-type non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. (Abstract #7539)
M. Chang, J. Lee, C. Jung, Y. Park, J. Ahn, K. Park, M. Ahn
- Brd. 32B** Biomarker analyses from a phase I study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #7540)
E. Felip, M. Ranson, S. Cedres, M. Brewster, V. McNally, M. Venturi, A. Passiukov, G. Ross, D. Galdermans
- Brd. 32C** Association of *KRAS* and *EGFR* mutations with survival in patients with advanced lung adenocarcinoma. (Abstract #7541)
M. L. Johnson, C. Sima, P. K. Paik, Y. Y. Janjigian, W. Pao, M. G. Kris, M. Ladanyi, G. J. Riely
- Brd. 33A** EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer. (Abstract #7542)
A. F. Eichler, K. T. Kahle, D. L. Wang, V. A. Joshi, J. A. Engelman, L. V. Sequist
- Brd. 33B** Rates of CNS progression in patients with advanced NSCLC harboring somatic EGFR mutations and treated with gefitinib or erlotinib. (Abstract #7543)
S. Heon, B. Y. Yeap, G. J. Britt, M. S. Rabin, D. M. Jackman, B. E. Johnson
- Brd. 33C** Clinicopathologic differences between lung cancer with EGFR gene major (exon 19 deletions and exon 21 L858R) and other minor mutations. (Abstract #7544)
Y. Yamane, K. Goto, H. Kenmotsu, Y. Ohe, H. Ohmatsu, S. Niho, K. Yoh, G. Ishii, K. Nagai, Y. Nishiwaki
- Brd. 34A** The usefulness of ¹⁸F-fluorothymidine (FLT) and ¹⁸F-FDG PET for early prediction of response to erlotinib therapy in patients with advanced non-small cell lung cancer. (Abstract #7545)
C. Choi, K. Shin, D. Lee, S. Oh, J. Kim, D. Moon, C. Suh, J. Ryu, S. Kim

- Brd. 34B Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastasized non-small cell lung cancer (NSCLC): results of the nonrandomized phase II study TaxErb. (Abstract #7546)**
J. R. Fischer, F. Griesinger, T. Fink, E. Buchholz, T. Salm, A. Marseille, M. Wolf
- Brd. 34C A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7547)**
B. Cho, S. Kim, D. S. Heo, S. Kang, H. Kim, D. Lee, D. Kim, M. Jung, J. Choi, J. Kim
- Brd. 35A Patient selection for cetuximab in NSCLC: A systematic review of candidate predictive biomarkers. (Abstract #7548)**
C. Harbison, C. Stroh, T. J. Lynch, D. R. Gandara, K. J. O'Byrne, R. Pirker, S. Maier, I. Celik, M. R. Weber, S. Khambata-Ford
- Brd. 35B Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR in-frame deletions of exon 19 according to the size of the deletion. (Abstract #7549)**
M. Taron, C. Queralt, C. Mayo, I. de Aguirre, A. Gasco, A. Insa, R. Palmero, C. Camps, J. Sanchez, R. Rosell
- Brd. 35C Association of epithelial mesenchymal transition (EMT) markers and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib. (Abstract #7550)**
N. B. Shah, M. J. Fidler, K. K. Walters, E. Braun, S. Basu, H. Harasty, J. Coon, M. Pool, T. A. Hensing, P. D. Bonomi
- Brd. 35D Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. (Abstract #7551)**
J. Ahn, S. Kim, M. Ahn, J. Lee, J. Uhm, J. Sun, K. Park, Y. Park
- Brd. 35E The association between *PTEN* expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib. (Abstract #7552)**
T. A. Hensing, M. J. Fidler, F. Wong, A. Polish, W. Watkin, S. Basu, K. A. Kaiser-Walters, M. Pool, J. Coon, P. Bonomi
- Brd. 35F Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy. (Abstract #7553)**
R. Karmali, M. J. Fidler, I. Cela, G. Olmsted, O. Rouhi, S. Basu, K. K. Walters, J. Coon, P. Bonomi, J. A. Borgia
- Brd. 35G SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). (Abstract #7554)**
B. A. Waltman, D. Dias-Santagata, A. K. Cosper, M. Mino-Kenudson, D. R. Borger, P. Fidiias, A. T. Shaw, A. J. Iafrate, J. A. Engelman, L. V. Sequist
- Brd. 35H Expression of MET, IGF-1R, IL-6/gp130, and AXL in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations. (Abstract #7555)**
C. Costa, A. Gimenez Capitan, C. Mayo, S. Simonetti, M. Majem, D. Isla, S. Benlloch, M. Taron, J. Sanchez, R. Rosell
- Brd. 36A First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab: Efficacy by histology. (Abstract #7556)**
K. J. O'Byrne, J. Von Pawel, I. Vynnychenko, P. Zatloukal, F. De Marinis, W. E. Eberhardt, L. G. Paz-Ares, K. Schumacher, U. Gatzemeier, R. Pirker
- Brd. 36B Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. (Abstract #7557)**
G. J. Riely, Y. Y. Janjigian, C. G. Azzoli, M. Pietanza, L. M. Krug, N. A. Rizvi, M. G. Kris, V. A. Miller, W. Pao, M. S. Ginsberg

Sunday, June 6, 2010

- Brd. 36C Association of gender and passive smoking with epidermal growth factor receptor mutations in never-smokers with non-small cell lung cancer: A prospective study based on detailed passive smoking questionnaire. (Abstract #7558)**
T. Kawaguchi, M. Ando, A. Kubo, M. Takada, S. Atagi, K. Okishio, K. Asami, A. Matsumura, K. Tsujino, H. Sasaki
- Brd. 36D A phase II study of gefitinib versus vinorelbine or gemcitabine in chemotherapy-naïve elderly patients with advanced non-small cell lung cancer based on epidermal growth factor receptor mutation status. (Abstract #7559)**
S. Fujita, N. Katakami, K. Masago, H. Yoshioka, K. Tomii, T. Kaneda, M. Hirabayashi, T. Morizane, T. Mio
- Brd. 36E Assessment of epidermal growth factor receptor (EGFR) and K-ras mutation status in cytologic stained smears of non-small cell lung cancer (NSCLC) patients. (Abstract #7560)**
M. D. Lozano, A. Gurrpide, J. I. Echeveste, A. Del Barrio, J. L. Perez-Gracia, L. M. Seijo, J. Zulueta, J. M. López-Picazo, I. Gil-Bazo, S. Martin-Algarra
- Brd. 36F First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study). (Abstract #7561)**
Y. Minegishi, M. Maemondo, S. Okinaga, N. Morikawa, A. Inoue, K. Kobayashi, M. Harada, K. Hagiwara, T. Nukiwa, A. Gemma
- Brd. 36G Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA mutations. (Abstract #7562)**
V. Ludovini, F. Bianconi, L. Pistola, R. Chiari, F. R. Tofanetti, A. Siggillino, E. Baldelli, R. Colella, M. G. Mamelì, L. Crinò
- Brd. 36H Predictive value of serum HGF for treatment response to EGFR tyrosine kinase inhibitor in patients with lung adenocarcinoma. (Abstract #7563)**
K. Kasahara, T. Arai, K. Sakai, A. Sakai, T. Sone, M. Nishio, T. Ohira, N. Ikeda, T. Yamanaka, K. Nishio
- Brd. 37A Effect of tumor-specific KRAS mutational status on impact of anti-EGFR therapy in non-small cell lung cancer (NSCLC). (Abstract #7564)**
M. C. Garassino, M. Marabese, M. Brogginì, C. Lauricella, I. Floriani, O. Martelli, S. Marsoni, G. Gherardi, G. Farina, A. Scanni, TAILOR Study Group
- Brd. 37B Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): A randomized phase II study of the German Thoracic Oncology Working Group. (Abstract #7565)**
M. Reck, J. Von Pawel, J. R. Fischer, C. Kortsik, S. Bohnet, M. von Eiff, W. Koester, M. Thomas, P. Schnabel, K. M. Deppermann, German Thoracic Oncology Working Group
- Brd. 37C Comparison of adverse events of erlotinib with those of gefitinib in Japanese patients with NSCLC. (Abstract #7566)**
T. Suzumura, S. Kudoh, T. Kimura, K. Umekawa, H. Tanaka, S. Mitsuoka, N. Yoshimura, K. Hirata
- Brd. 37D Changes in FDG- and FLT-PET imaging in patients with non-small cell lung cancer (NSCLC) following treatment with erlotinib (E). (Abstract #7567)**
L. R. Mileskin, B. G. Hughes, P. Mitchell, V. Charu, B. J. Gitlitz, D. Macfarlane, W. Yu, A. Pirzkall, R. Hicks, B. M. Fine
- Brd. 37E Plans of American medical oncologists (AMO) to order molecular testing before starting first-line therapy for patients with stage IV non-small cell lung cancer (NSCLC). (Abstract #7568)**
M. R. Green, A. J. Wozniak, J. Willey, K. E. Lemke, H. J. West
- Brd. 37F Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC. (Abstract #7569)**
M. A. Villalona-Calero, T. Stinchcombe, M. A. Phelps, S. L. Starrett, A. C. Papp, A. M. Ghany, W. J. Hicks, G. A. Otterson, M. A. Socinski, W. Zhao

- Brd. 37G Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies (mAbs) for screening EGFR mutations in non-small cell lung cancer (NSCLC) patients (p). (Abstract #7570)**
 S. Simonetti, M. A. Molina, C. Mayo, J. Bertran-Alamillo, T. Moran, S. Benlloch, S. Ramon y Cajal, I. I. Wistuba, M. Taron, R. Rosell
- Brd. 37H The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002. (Abstract #7571)**
 A. Inoue, M. Maemondo, K. Kobayashi, S. Oizumi, H. Isoke, A. Gemma, Y. Saijo, K. Hagiwara, S. Morita, T. Nukiwa
- Brd. 38A Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. (Abstract #7572)**
 W. Yeo, G. J. Riely, B. Yeap, M. W. Lau, J. Warner, K. A. Bodio, M. G. Kris, W. Pao, S. Kobayashi, D. B. Costa
- Brd. 38B Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer. (Abstract #7573)**
 A. Horiike, N. Yamamoto, H. Tanaka, N. Yanagitani, K. Kudo, F. Ohyanagi, T. Naito, H. Murakami, T. Horai, M. Nishio
- Brd. 38C A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China. (Abstract #7574)**
 Q. Zhao, J. Zhou, J. Shentu, N. Xu, F. Tan
- Brd. 38D Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL). (Abstract #7575)**
 C. Zhou, Y. Wu, G. Chen, J. Feng, X. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou, S. Ren
- Brd. 38E Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC). (Abstract #7576)**
 T. Stinchcombe, D. S. Bradford, C. B. Lee, D. T. Moore, K. M. Bakri, M. A. Taylor, J. M. Crane, G. Schwartz, T. A. Hensing, M. A. Socinski
- Brd. 38F First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small cell lung cancer patients. (Abstract #7577)**
 C. Lie, M. Lin, T. Chao, J. Wang, H. Chang
- Brd. 38G Efficacy and safety of bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer (NSCLC). (Abstract #7578)**
 D. Tassinari, F. Drudi, F. Carloni, S. Nicoletti, C. Possenti, C. Santelmo, L. Lazzari
- Brd. 38H Comparison of response rate of advanced non-small lung cancer patients to liposomal cisplatin versus cisplatin both combined with paclitaxel: A phase III trial. (Abstract #7579)**
 G. Stathopoulos, D. Antoniou, J. Dimitroulis, J. Stathopoulos, K. Marosis, P. Michalopoulou
- Brd. 39A Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7580)**
 R. Govindan, C. Zergebel, K. Saito, J. H. Schiller
- Brd. 39B Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results. (Abstract #7581)**
 S. Novello, C. Camps, F. Grossi, J. Mazieres, L. E. Abrey, J. Vernejoux, A. D. Thall, T. Usari, R. C. Chao, G. Scagliotti
- Brd. 39F Systemic gene therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer. (Abstract #7582)**
 C. Lu, D. J. Stewart, L. Ji, R. Ramesh, G. Jayachandran, J. J. Erasmus, J. Lee, N. S. Templeton, J. D. McMannis, J. A. Roth

Sunday, June 6, 2010

- Brd. 39G** **BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC). (Abstract #7583)**
L. Faoro, J. D. Hainsworth, D. A. Karlin, J. E. Huang, L. Fang, F. A. Scappaticci
- Brd. 39H** **A randomized phase III study of cisplatin and docetaxel with or without irinotecan in pts with advanced non-small cell lung cancer: Okayama Lung Cancer Study Group OLCSG 0403. (Abstract #7584)**
K. Kiura, M. Tabata, N. Takigawa, S. Kuyama, Y. Segawa, H. Kamei, T. Shibayama, K. Hotta, K. Matsuo, M. Tanimoto
- Brd. 40A** **Phase I study of regorafenib (BAY 73–4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC). (Abstract #7585)**
M. S. Kies, G. R. Blumenschein Jr., O. Christensen, T. Lin, A. W. Tolcher
- Brd. 40B** **Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin (CDDP) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7586)**
T. Seto, Y. Ichinose, N. Yamamoto, K. Kaira, S. Negoro, T. Hida, K. Takeda, N. Masuda, S. Yokota, M. Fukuoka
- Brd. 40F** **Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial. (Abstract #7587)**
E. B. Garon, F. F. Kabbinavar, J. A. Neidhart, J. D. Neidhart, N. Y. Gabrail, M. R. Oliveira, S. P. Lu, J. Balkissoon
- Brd. 40G** **A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAB) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). (Abstract #7588)**
D. R. Camidge, M. S. Ballas, S. Dubey, M. Haigentz, P. J. Rosen, J. F. Spicer, H. J. West, G. D. Shah, H. Youssoufian, A. C. Mita
- Brd. 40H** **Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results. (Abstract #7589)**
R. Digumarti, A. V. Suresh, G. S. Bhattacharyya, L. Dasappa, J. Shan
- Brd. 41A** **Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results. (Abstract #7590)**
R. A. Soo, G. D. Goss, R. Salgia, B. Besse, D. R. Gandara, N. H. Hanna, J. L. Ricker, J. Qian, D. M. Carlson, E. Tan
- Brd. 41B** **First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smk) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial. (Abstract #7591)**
J. Liang, M. Ahn, J. Kang, Q. Xiu, Y. Chen, C. Yang, N. Scheuer, C. Linn, M. Orlando
- Brd. 41C** **Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC). (Abstract #7592)**
A. C. Mita, R. S. Heist, O. Aren, P. N. Mainwaring, L. Bazhenova, S. M. Gadgeel, R. H. Blum, J. Polikoff, J. Biswas, M. A. Spear
- Brd. 41D** **A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. (Abstract #7593)**
D. R. Spigel, F. A. Greco, D. Shipley, T. J. Ervin, E. T. Lubiner, J. D. Peyton, E. K. Barnes, D. S. Thompson, H. A. Burris III, J. D. Hainsworth

- Brd. 41E Phase II study of dasatinib in patients with advanced non-small cell lung cancer. (Abstract #7594)**
 F. M. Johnson, B. N. Bekele, L. Feng, I. I. Wistuba, X. Tang, H. T. Tran, J. J. Erasmus, L. Hwang, N. Takebe, D. J. Stewart
- Brd. 41F Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with measurable asymptomatic inoperable brain metastases (BM): A multicenter phase II trial (GFPC 07-01). (Abstract #7595)**
 G. Robinet, F. Barlesi, R. Gervais, H. Lena, J. Hureauux, H. Berard, D. Paillotin, S. Bota, I. Monnet, A. Chajara
- Brd. 41G PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). (Abstract #7596)**
 A. Campbell, K. L. Reckamp, D. R. Camidge, G. Giaccone, S. M. Gadgeel, F. R. Khuri, J. A. Engelman, L. J. Denis, J. P. O'Connell, P. A. Janne
- Brd. 41H Phase III study comparing vinorelbine/gemcitabine with vinorelbine/carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial. (Abstract #7597)**
 Ø. Fløtten, R. M. Bremnes, B. H. Grønberg, S. Sundstrøm, T. Amundsen, H. Rolke, U. Aasebø, K. Hornslien, T. Wentzel-Larsen, C. von Plessen, Norwegian Lung Cancer Study Group
- Brd. 42A Results of phase IV clinical trial of combining endostar with chemotherapy for treatment of advanced non-small cell lung cancer (NSCLC). (Abstract #7598)**
 J. Wang, Y. Sun, S. Qin, Endostar Phase IV Study Group
- Brd. 42B PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study. (Abstract #7599)**
 K. Park, D. S. Heo, B. Cho, D. Kim, M. Ahn, S. Lee, R. D. Millham, A. Campbell, H. Zhang, J. Kim
- Brd. 42C A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC. (Abstract #7600)**
 G. M. Blumenthal, M. S. Ballas, W. Bernstein, B. K. Shamloo, H. Root, C. Helsabeck, G. Chun, W. D. Figg, G. Giaccone, P. A. Dennis, The Thoracic Oncology Group in the Medical Oncology Branch
- Brd. 42D Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer. (Abstract #7601)**
 D. Shipley, D. R. Spigel, H. A. Burris III, D. M. Waterhouse, C. D. Webb, V. Gian, L. L. Hart, F. A. Greco, J. D. Hainsworth
- Brd. 42E A nonrandomized, multicenter, phase II study of S-1 with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7602)**
 D. V. Jones, C. Zergebel, K. Saito, A. Sandler
- Brd. 42F A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). (Abstract #7603)**
 G. K. Dy, S. J. Mandrekar, G. D. Nelson, H. J. Ross, R. H. Ansari, A. P. Lyss, P. J. Stella, S. E. Schild, J. R. Molina, A. A. Adjei, North Central Cancer Treatment Group
- Brd. 42G Final results of a phase II trial of S-1 with biweekly docetaxel for non-small cell lung cancer previously treated with platinum-based chemotherapy (NJLCG0701). (Abstract #7604)**
 O. Ishimoto, T. Sakakibara, M. Maemondo, N. Morikawa, K. Okudera, K. Usui, T. Suzuki, A. Inoue, T. Nukiwa, S. Sugawara, North Japan Lung Cancer Group

- Brd. 42H Docetaxel (D) plus gemcitabine (G) compared with G in elderly patients with advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized phase III Hellenic Oncology Research Group trial. (Abstract #7605)**
A. Karampeazis, L. Vamvakas, A. G. Pallis, C. Christophyllakis, N. K. Kentepozidis, V. Chandrinou, A. Polyzos, A. Athanasiadis, G. Milaki, V. Georgoulas
- Brd. 43A Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer. (Abstract #7606)**
A. T. Shaw, B. Yeap, D. B. Costa, B. J. Solomon, E. L. Kwak, A. T. Nguyen, K. Bergethon, J. A. Engelman, A. J. Iafrate
- Brd. 43B Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: Subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501. (Abstract #7607)**
W. Zhang, J. Lee, J. H. Schiller, D. P. Carbone, C. H. Chung, H. Lenz
- Brd. 43D Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. (Abstract #7609)**
R. S. Herbst, G. R. Blumenschein Jr., E. S. Kim, J. Lee, A. S. Tsao, C. M. Alden, S. Liu, D. J. Stewart, I. I. Wistuba, W. K. Hong
- Brd. 43E EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. (Abstract #7610)**
G. Altavilla, M. Santaripa, C. Arrigo, M. Rizzo, G. Galletti, G. Marabello, A. Gnani, V. Pitini
- Brd. 43F Molecular profiling of smoking-related non-small cell lung cancer (NSCLC) phenotypes. (Abstract #7611)**
J. H. Strickler, W. Mostertz, M. Stevenson, J. Crawford, N. Ready, W. Barry, A. Potti
- Brd. 43G In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC). (Abstract #7612)**
R. S. Heist, G. D. Duda, D. Sahani, N. A. Pennell, J. W. Neal, M. Ancukiewicz, J. A. Engelman, T. J. Lynch, R. K. Jain
- Brd. 43H Eicosanoids in non-small cell lung cancer (NSCLC). (Abstract #7613)**
D. H. Johnson, L. Horn, Z. Zhao, G. Milne, J. Morrow, A. Sandler, Y. Shyr, D. P. Carbone
- Brd. 44A Serum VEGF and COX-2/SLOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. (Abstract #7614)**
M. J. Edelman, L. Hodgson, X. F. Wang, R. Christenson, E. E. Vokes, R. A. Kratzke
- Brd. 44B Correlation of pharmacogenetic markers with docetaxel-based chemotherapy resistance in patients with advanced/metastatic non-small cell lung cancer. (Abstract #7615)**
C. Papadaki, E. Tsaroucha, L. Kaklamanis, D. Mavroudis, E. Lagoudaki, M. Trypaki, E. Tsakalaki, V. Georgoulas, I. Souglaklos
- Brd. 44C Correlation of genetic polymorphisms in folate metabolic pathway genes with clinical outcomes in pemetrexed-treated advanced NSCLC patients. (Abstract #7616)**
J. Kim, J. Yun, J. Kong, S. Lee, S. Kim, J. Lee, J. Ahn, K. Park, M. Ahn
- Brd. 44D Phase II trial of personalized chemotherapy in stage IV NSCLC: Clinical application of functional profiling in first-line therapy. (Abstract #7617)**
R. A. Nagourney, J. B. Blitzer, E. A. Deo, R. Nandan, R. Shuman, T. Asciuto, D. McConnell, M. Paulsen, S. S. Evans
- Brd. 44E Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS). (Abstract #7618)**
A. J. Wozniak, J. Garst, M. Jahanzeb, M. P. Kosty, R. Vidaver, S. Beatty, S. Teng, E. D. Flick, A. Sing, T. J. Lynch, for the ARIES Investigators

- Brd. 44F Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS). (Abstract #7619)**
P. Kumar, N. A. Fischbach, J. R. Brahmer, D. R. Spigel, S. Beatty, S. Teng, E. D. Flick, A. Sing, T. J. Lynch, ARIES Investigators
- Brd. 44G Expression of sonic hedgehog and its receptor patched in non-small cell lung cancer. (Abstract #7620)**
O. Rouhi, K. A. Kaiser-Walters, D. Escarzaga, D. Steker, S. Basu, M. J. Liptay, P. Gattuso, P. D. Bonomi, J. Coon, J. A. Borgia
- Brd. 44H DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma (NSLA). (Abstract #7621)**
J. Han, K. Yoon, Y. Lee, G. Lee, S. Yoon, K. Hwang, T. Yun, H. Kim, J. Lee
- Brd. 45A Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial. (Abstract #7622)**
J. R. Rigas, M. Schuster, S. V. Orlov, B. Milovanovic, K. Prabhash, J. T. Smith, and the ALD518 Study Group
- Brd. 45B Time trend in treatment-related deaths of patients with advanced non-small cell lung cancer enrolled into phase III trials of systemic treatment. (Abstract #7623)**
Y. Fujiwara, K. Hotta, M. Di Maio, K. Kiura, N. Takigawa, M. Tabata, M. Tanimoto
- Brd. 45C Progression-free survival (PFS) and overall survival (OS) in phase III trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC). (Abstract #7624)**
K. Hotta, K. Kiura, N. Takigawa, M. Tabata, Y. Fujiwara, M. Tanimoto
- Brd. 45D Comparison of efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis. (Abstract #7625)**
G. Des Guetz, B. Uzzan, P. Nicolas, C. Kader, G. Perret, G. Sebbane, J. F. Morere
- Brd. 45E Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S). (Abstract #7626)**
R. J. Kelly, J. Force, A. Rajan, C. Keen, B. Turkbey, L. Cao, M. Raffeld, S. M. Steinberg, J. J. Wright, G. Giaccone
- Brd. 45F Genomic polymorphisms of drug metabolisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with gemcitabine (GEM) or taxanes. (Abstract #7627)**
L. Zhang, C. Zhou
- Brd. 45G Randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer. (Abstract #7628)**
S. Nagel, A. Groeschel, M. Sebastian, S. Andreas, T. Mueller, F. Schneller, S. Guetz, M. I. Leschinger, H. Buettner, M. Reck
- Brd. 45H Impact of the algorithm for declaring exact progression date on progression-free survival (PFS) estimates in advanced lung cancer clinical trials. (Abstract #7629)**
S. J. Mandrekar, S. L. Hillman, K. Allen-Ziegler, A. Jatoi, J. R. Jett, S. E. Schild, A. A. Adjei
- Brd. 46A Circulating tumor cells (CTC) in small cell lung cancer (SCLC), a promising prognostic factor. (Abstract #7630)**
T. J. Hiltermann, J. Liesker, H. Schouwink, J. Kaajan, H. M. Boezen, H. Tissing, A. Tibbe, L. W. Terstappen, H. J. Groen

Sunday, June 6, 2010

- Brd. 46B ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial. (Abstract #7631)**
M. Schuster, J. R. Rigas, S. V. Orlov, B. Milovanovic, K. Prabhash, J. T. Smith, and the ALD518 Study Group
- Brd. 46C HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome. (Abstract #7632)**
S. Pakkala, Z. Chen, D. Rimland, T. K. Owonikoko, C. Gunthel, J. C. Brandes, N. F. Saba, W. J. Curran Jr., F. R. Khuri, S. S. Ramalingam
- Brd. 46D Survival impact of newly approved therapeutic agents in patients with advanced non-small cell lung cancer (NSCLC): A SEER-Medicare database analysis. (Abstract #7633)**
T. K. Owonikoko, S. S. Ramalingam, M. Behera, J. C. Brandes, N. F. Saba, C. Bhimani, S. Harichand-Herd, D. M. Shin, F. R. Khuri, C. Ragin
- Brd. 46E First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project. (Abstract #7634)**
J. L. Vandergrift, R. Mamet, C. Zornosa, M. E. Reid, M. S. Rabin, D. S. Ettinger, G. P. Kalemkerian, G. A. Otterson, J. C. Niland, K. Pisters, NCCN Oncology Outcomes Database Non-Small Cell Lung Cancer Disease Specific Executive Committee
- Brd. 46F Brain metastases (mets) in lung cancer patients (pts): Analysis of the Detroit Surveillance, Epidemiology and End Results (SEER) data. (Abstract #7635)**
S. M. Gadgeel, R. Goveas, F. Vigneau, W. Quarshie, M. Islam, A. Schwartz, A. J. Wozniak, M. Cote
- Brd. 46G Prognostic impact of malignant pleural effusion in patients with stage M1b non-small cell lung cancer. (Abstract #7636)**
D. Morgensztern, S. N. Waqar, D. I. Kuperman, B. W. Goodgame, K. Trinkaus, R. Govindan
- Brd. 46H Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. (Abstract #7637)**
N. R. Foster, Y. Qi, Q. Shi, J. E. Krook, J. W. Kugler, J. R. Jett, J. R. Molina, S. E. Schild, A. A. Adjei, S. J. Mandrekar
- Brd. 47A Ethnic difference in toxicity in non-small cell lung cancer patients treated with chemotherapy: A systematic review on phase II and III clinical trials. (Abstract #7638)**
Y. Hasegawa, T. Kawaguchi, A. Kubo, M. Ando, J. Shiraishi, S. Isa, T. Tsuji, K. Tsujino, K. Nakagawa, M. Takada
- Brd. 47B Improving the accuracy of FNA lung biopsies in a community hospital. (Abstract #7639)**
A. Higgins, A. R. Calvo, R. Pelstring

SUNDAY

**8:00 AM - 12:00 PM
GENERAL POSTER SESSION**

Melanoma/Skin Cancers

Location: S Hall A2

Tracks(s): Melanoma/Skin Cancers

- Brd. 48A Phase I/II study of the combination of decitabine (DAC) and temozolomide (TMZ) in patients (pts) with metastatic melanoma (MM). (Abstract #8533)**
H. A. Tawbi, J. H. Beumer, A. A. Tarhini, S. J. Moschos, M. J. Egorin, S. C. Buch, Y. Lin, J. M. Kirkwood
- Brd. 48B Chemoablation of metastatic melanoma with rose bengal (PV-10). (Abstract #8534)**
S. S. Agarwala, J. F. Thompson, B. M. Smithers, M. I. Ross, B. J. Coventry, D. R. Minor, C. R. Scoggins, E. A. Wachter
- Brd. 48C A phase I trial of intra-lymph node administration of a novel immunotherapeutic regimen (MKC1106-MT) in patients with advanced melanoma. (Abstract #8535)**
J. S. Weber, A. Ribas, A. Bot, M. Obrocea, B. Chmielowski, D. Rosario, Z. Qiu, B. Comin-Anduix
- Brd. 48D Dacarbazine (DTIC) plus bevacizumab (B) combination therapy in chemotherapy (CTh)-naive advanced melanoma (MM) patients (pts): A phase II study. (Abstract #8536)**
A. di Pietro, P. Ferrucci, E. Munzone, M. Mosconi, S. Gandini, C. Pari, F. Cataldo, F. Verrecchia, F. Nole, A. Testori
- Brd. 48E Plitidepsin (APL) alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM). (Abstract #8537)**
E. R. Plummer, P. Lorigan, L. Hayward, J. Jassem, L. Demidov, V. Moiseyenko, V. Soriano, E. Chmielowska, R. Prados, S. Szyldergemajn
- Brd. 48F Evaluation of FOXP3 microsatellite polymorphisms in high-risk melanoma patients receiving adjuvant interferon. (Abstract #8538)**
H. Gogas, E. Wang, A. Monaco, L. Uccellini, C. S. Floudas, Y. Metaxas, U. Dafni, G. Fountzilas, M. Spyropoulou-Vlachou, F. Marincola
- Brd. 48G Screening tools for interferon-related cognitive decline in melanoma patients. (Abstract #8539)**
D. Combs, A. Baker, S. Jordan, S. S. Morgan, L. Pestana, A. Herring, J. M. Jeter, E. Hersh, L. D. Cranmer
- Brd. 48H The impact of multiple primary cutaneous melanomas on survival of 2,942 patients with metastatic melanoma. (Abstract #8540)**
R. Murali, P. T. Brown, R. Kefford, J. F. Thompson, M. B. Atkins, G. V. Long
- Brd. 49A A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma. (Abstract #8541)**
J. M. Kirkwood, R. Gonzalez, D. S. Reintgen, P. R. Clingan, R. R. McWilliams, R. L. Ilaria, D. P. de Alwis, A. Zimmermann, M. P. Brown, M. Millward
- Brd. 49B Prognostic factors for survival after first recurrence of melanoma. (Abstract #8542)**
T. Tu, M. W. Ma, S. Monni, A. E. Rose, D. Polsky, R. S. Berman, R. L. Shapiro, A. C. Pavlick, M. Mazumdar, I. Osman, Interdisciplinary Melanoma Cooperative Group
- Brd. 49C Correlation of polymorphic variants into the susceptibility of CDKN2 locus with melanoma outcome. (Abstract #8543)**
G. Palmieri, M. Casula, M. Budroni, A. Cossu, F. Tanda, P. A. Ascierto, S. Canzanella, G. Palomba, M. Colombino, A. Muggiano, Italian Melanoma Intergroup

Sunday, June 6, 2010

- Brd. 49D Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma. (Abstract #8544)**
P. A. Prieto, J. C. Yang, R. M. Sherry, M. S. Hughes, U. S. Kammula, D. E. White, C. L. Levy, S. A. Rosenberg, G. Q. Phan
- Brd. 49E Sunitinib therapy for metastatic melanomas with KIT aberrations. (Abstract #8545)**
D. R. Minor, S. O'Day, M. Kashani-Sabet, A. Daud, Z. Salman, B. Bastian
- Brd. 49F Preclinical analyses of a new gamma-secretase inhibitor targeting notch signaling in melanoma. (Abstract #8546)**
L. Poliseno, C. T. Huynh, M. F. Segura, R. Medicherla, S. Menendez, A. E. Rose, A. C. Pavlick, J. Boylan, I. Osman, E. Hernando
- Brd. 49G Clinical outcome following therapeutic vaccination with autologous mRNA electroporated dendritic cell (DC) vaccines in patients with advanced melanoma. (Abstract #8547)**
S. Wilgenhof, A. M. Van Nuffel, D. Benteyn, J. Corthals, C. Heirman, L. Pierret, A. De Coninck, A. Bonehill, K. Thielemans, B. Neyns
- Brd. 49H Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma. (Abstract #8548)**
G. V. Long, A. M. Menzies, A. Nagrial, L. Haydu, A. L. Hamilton, G. Mann, T. M. Hughes, J. F. Thompson, R. A. Scolyer, R. Kefford
- Brd. 50A A predictive model to determine the likelihood of positive sentinel lymph node biopsy in thin melanomas. (Abstract #8549)**
S. S. Venna, S. Thummala, M. Nosrati, S. P. Leong, J. R. Miller III, R. Sagebiel, M. Kashani-Sabet
- Brd. 50B Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS update. (Abstract #8550^)**
V. M. Vukovic, A. Hauschild, A. M. Eggermont, S. O'Day
- Brd. 50C Correlation of stem cell marker nestin expression on circulating melanoma cells with extension of disease and survival. (Abstract #8551)**
A. Fusi, U. Reichelt, A. Busse, S. Ochsenreither, A. Rietz, M. Maisel, U. Keilholz
- Brd. 50D Phase I/II trial of association of sorafenib in combination with temozolomide in patients with metastatic melanoma: Looking for predictive markers of efficacy. (Abstract #8552)**
C. Robert, N. Chaput, N. Lassau, A. Auperin, S. Koscielny, E. Hollville, V. Lazar, L. Lacroix, J. Soria, C. Mateus
- Brd. 50E The use of integrative genomics to define molecular signatures of melanoma histologic subtypes. (Abstract #8553)**
A. E. Rose, L. Poliseno, A. Pearlman, J. Wang, H. Ostrer, F. Darvishian, R. L. Shapiro, A. C. Pavlick, E. Hernando, I. Osman
- Brd. 50F Preclinical analysis of targeting miR-182 against melanoma liver metastasis. (Abstract #8554)**
C. T. Huynh, M. F. Segura, S. Menendez, F. Darvishian, E. G. Marcusson, E. Hernando
- Brd. 50G Tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemotherapy-naive stage IV melanoma patients. (Abstract #8555)**
B. Weide, T. K. Eigentler, A. Romanini, F. G. De Braud, L. Giovannoni, D. Neri, H. Menssen, C. Garbe
- Brd. 50H Patterns of recurrence in 208 patients with Merkel cell carcinoma. (Abstract #8556)**
T. L. Bowles, M. I. Ross, M. S. Kies, V. Prieto, J. Myers, J. N. Cormier, P. F. Mansfield, J. E. Lee, J. E. Gershenwald

- Brd. 51A Relation between baseline LDH and tumor burden in advanced melanoma in two phase III trials of oblimersen-dacarbazine (OBL-DTIC) versus DTIC. (Abstract #8557)**
C. Lebbé, J. J. Grob, A. Y. Bedikian, C. Garbe, C. Robert, L. Itri, J. Wu, S. S. Agarwala, A. M. Eggermont
- Brd. 51B MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab (SAKK 50/07). (Abstract #8558)**
A. F. Ochsenbein, P. Schraml, D. Mihic, M. Simcock, R. Dummer, O. Michielin, B. Seifert, M. R. Schlaeppli, H. Moch, R. von Moos, SAKK
- Brd. 51C Induction of apoptosis in human melanoma by the BRAF inhibitor PLX4720: The key to therapeutic success? (Abstract #8559)**
P. Hersey, X. Zhang, C. Jiang
- Brd. 51D Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma. (Abstract #8560)**
J. Lutzky, D. H. Lawson, Y. Enriquez-Nunez, D. Gabrilovich
- Brd. 51E Oblimersen 1-hour IV infusion in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma. (Abstract #8561)**
P. A. Ott, K. M. Madden, R. Kannan, H. Yee, S. Mendoza, B. Dubose, L. Liebes, A. C. Pavlick
- Brd. 51F Phase II study of the src family kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. (Abstract #8562)**
T. Gajewski, Y. Zha, J. Clark
- Brd. 51G The impact of physician specialty on quality of melanoma care. (Abstract #8563)**
J. N. Cormier, Y. T. Shih, Y. Xu, I. Pan, R. L. Askew, M. I. Ross, J. E. Gershenwald, J. E. Lee, R. Royal, Y. Xing
- Brd. 51H Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma. (Abstract #8564)**
L. Si, M. Han, Z. H. Chi, C. L. Cui, X. N. Sheng, S. M. Li, Y. Kong, J. Guo
- Brd. 52A CD20-immunotargeting of malignant melanoma. (Abstract #8565)**
S. N. Wagner, R. Somasundaram, A. Pinc, P. A. Van Belle, C. Wagner, M. Hoermann, G. Karanikas, G. Stingl, D. Elder, M. Herlyn
- Brd. 52B Enhancing DNA repair in the skin: A pilot study of low-dose chloroquine and ultraviolet light. (Abstract #8566)**
H. E. Kanavy, M. A. Warycha, H. Hamilton, A. Souza, I. Osman, L. Chiriboga, H. Yee, N. Soter, B. Strober, D. Polsky
- Brd. 52C Changes in regional immunity and metastasis in melanoma. (Abstract #8567)**
A. S. Mansfield, T. Grotz, J. W. Jakub, T. Flotte, L. Erickson, S. Markovic
- Brd. 52D Effect of TLR4 engagement on TLR3-induced proinflammatory signaling in dendritic cells through IL-10, STAT3, and p38-dependent pathways and on antimelanoma CD8+ T-cell priming. (Abstract #8568)**
D. Bogunovic, O. Manches, A. Yewdall, I. Marie, D. E. Levy, N. Bhardwaj
- Brd. 52E Interleukin-2-induced fever in relation to objective tumor response and survival in patients with metastatic melanoma. (Abstract #8569)**
M. Ellegaard, L. Bastholt, A. Jakobsen, F. Donskov, H. Schmidt
- Brd. 52F Identification of tyrosinase polymorphisms for use in melanoma risk assessment. (Abstract #8570)**
E. Pervolaraki, I. Lobach, I. Belitskaya-Levy, H. Ostrer, J. D. Goldberg, D. Polsky, R. L. Shapiro, R. S. Berman, I. Osman, P. Manga
- Brd. 52G Hair depigmentation as an indicator of durable response to CTLA-4 therapy. (Abstract #8571)**
A. C. Pavlick, P. A. Ott, R. Kannan, K. M. Madden, C. Sorlie, C. Escano, J. Escalon, E. Hernando-Monge, I. Osman, N. Bhardwaj

Sunday, June 6, 2010

- Brd. 52H** N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM). (Abstract #8572)
R. S. Dronca, D. G. Perez, J. Allred, W. J. Maples, E. T. Creagan, B. A. Pockaj, J. S. Kaur, T. D. Moore, B. T. Marchello, S. Markovic
- Brd. 53A** Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone. (Abstract #8573)
A. Y. Bedikian, C. Lebbé, C. Robert, S. S. Agarwala, J. Wu, C. Garbe, J. J. Grob
- Brd. 53B** Effect of a novel cross-talk mechanism on the RAF/MEK/ERK and PI3K/AKT/mTOR pathways in melanoma: Role of ERK-mediated suppression of PTEN expression. (Abstract #8574)
L. Ciuffreda, C. Di Sanza, M. Desideri, M. Ricciardi, U. Cesta Incani, A. Tafuri, F. Cognetti, G. Zupi, D. Del Bufalo, M. Milella
- Brd. 53F** In vivo metabolic activity and transcriptional profiling in melanoma (MM) patients during sorafenib and dacarbazine (DTIC) treatment. (Abstract #8575)
M. J. Barysch, M. B. Karpova, H. Steinert, D. Widmer, C. Burger, M. J. Okoniewski, K. Hoek, N. Maradan, R. Dummer
- Brd. 53G** Role of lymph node ultrasonography (US) in the follow-up of melanoma patients to detect nodal recurrence after sentinel lymph node biopsy (SNLB): A prospective cohort study. (Abstract #8576)
P. Saiag, C. Lebbé, N. Basset Seguin, P. Wolkenstein, N. Dupin, V. Descamps, S. Aractingi, P. Aegerter, S. Chagnon
- Brd. 53H** Final results of a pilot study using sunitinib malate in patients with stage IV uveal melanoma. (Abstract #8577)
L. A. Tijani, M. Luadadio, M. J. Mastrangelo, T. Sato
- Brd. 54A** Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with *nab*-paclitaxel and carboplatin: A translational study of NCCTG trial N057E. (Abstract #8578)
S. Markovic, V. Suman, V. N. Trieu, X. Liu, W. Yeh, L. Hwang, T. Treece, K. Motamed, P. Pramanik, N. Desai
- Brd. 54B** Management of cutaneous metastases by electrochemotherapy. (Abstract #8579)
J. Gehl, L. W. Matthiessen, A. Humphreys, G. Kessell, T. Muir
- Brd. 54F** Immunomodulatory gene expression at the fetomaternal interface and in melanoma: Tolerance meets inflammation. (Abstract #8580)
S. G. Holtan, D. J. Creedon, A. A. Leontovich, S. Markovic
- Brd. 54G** Diagnostic imaging modalities for the surveillance of melanoma patients: A meta-analysis. (Abstract #8581)
Y. Xing, Y. Bronstein, M. I. Ross, R. L. Askew, J. E. Lee, J. E. Gershenwald, R. Royal, J. N. Cormier
- Brd. 54H** Relationship between dose, exposure, and antitumoral activity of sorafenib in melanoma. (Abstract #8582)
N. Pécuchet, M. Avril, D. Kerob, B. Billemonet, B. Blanchet, P. Herait, I. Gorin, M. Viguier, C. Lebbé, F. Goldwasser
- Brd. 55A** Patterns of disease spread in metastatic mucosal melanoma. (Abstract #8583)
K. N. O'Regan, N. H. Ramaiya, J. P. Jagannathan, P. Dipiro, A. D. Van Den Abbeele, F. S. Hodi
- Brd. 55B** Targeting SRC kinase (SRC) in melanoma cells. (Abstract #8584)
A. J. Eustace, T. Mahgoub, S. Kennedy, J. Crown, A. Larkin, D. Tryfonopoulos, L. O'Driscoll, M. Clynes, N. O'Donovan
- Brd. 55C** Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07). (Abstract #8585)
G. Fuerstenberger, E. Boneberg, M. Simcock, R. Dummer, S. M. Goldinger, O. Michielin, B. Seifert, A. F. Ochsenein, M. R. Schlaeppli, R. von Moos

- Brd. 55D A phase II clinical trial of a novel combinatorial antitumor immunotherapy for patients with high-risk resected stage III and metastatic melanoma. (Abstract #8586)**
A. I. Riker, L. C. Alsfeld, M. Harrison, D. Foxworth, Q. Lee, G. R. Rossi, L. Tennant, W. J. Ramsey, N. N. Vahanian, C. J. Link
- Brd. 55E Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy. (Abstract #8587)**
 M. Krogh, I. J. Christensen, M. Bouwhuis, J. S. Johansen, H. Schmidt, J. Hansson, S. Aamdal, A. Testori, A. M. Eggermont, L. Bastholt, The Nordic Melanoma Group and EORTC Melanoma Group
- Brd. 55F Interleukin-10 as a prognostic factor in patients treated with autologous melanoma cell vaccine. (Abstract #8588)**
A. Mahipal, D. Berd, I. Chervoneva, M. Terai, M. J. Mastrangelo, T. Sato
- Brd. 55G Electrochemotherapy with bleomycin: A local treatment with possible systemic implication. (Abstract #8589)**
A. Testori, F. Verrecchia, J. Soteldo, G. Spadola, C. Martinoli, S. Gandini, C. Passoni, F. Cataldo, A. Di Pietro, P. Ferrucci
- Brd. 55H Dual mechanistic function of MDSC subsets in melanoma resistance. (Abstract #8590)**
E. C. Borden, J. Ko Smith, P. A. Rayman, B. Jacobs, J. Ireland, D. Lindner, J. Finke
- Brd. 56A Immunohistochemical expression of Dicer in melanoma. (Abstract #8591)**
C. Capalbo, F. Passarelli, Z. di Rocco, A. Scoppola, P. Marchetti
- Brd. 56B PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial. (Abstract #8592)**
M. E. Lacouture, G. A. McArthur, P. B. Chapman, A. Ribas, K. T. Flaherty, R. J. Lee, K. B. Nolop, K. B. Kim, M. Duvic, J. A. Sosman, Dermatology Working Group
- Brd. 56D Utility of 3-year torso CT and head imaging in asymptomatic patients with high-risk melanoma. (Abstract #8594)**
E. R. DeRose, A. Pleet, V. J. Seery, M. Lee, S. Renzi, R. J. Sullivan, M. B. Atkins
- Brd. 56E Comparison of classification systems in melanoma sentinel nodes: An analysis of 697 patients from a single center. (Abstract #8595)**
R. Gutzmer, F. Schenck, I. Satzger
- Brd. 56F Prognostic relevance of increased detection of lymphovascular invasion in primary melanoma using D2-40 and CD34 compared to routine histology. (Abstract #8596)**
F. Darvishian, A. E. Rose, P. J. Christos, T. Tu, R. L. Shapiro, R. S. Berman, A. C. Pavlick, H. Kamino, M. Mazumdar, I. Osman
- Brd. 56G Effect of mutational status on response, PFS, or OS after treatment with IL-2 for metastatic melanoma. (Abstract #8597)**
R. W. Joseph, R. J. Sullivan, D. Panka, G. Manoukian, A. Percy, R. Harrell, R. L. Bassett Jr., M. B. Atkins, P. Hwu, M. A. Davies

Sunday, June 6, 2010

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Cancer Prevention/Epidemiology

Location: S100b

CME credit: 3

Track(s): Cancer Prevention/Epidemiology

Frank Sinicrope, MD—Co-Chair

Mayo Clinic

Eva Szabo, MD—Co-Chair

National Cancer Institute

9:30 AM Lynch syndrome *TACSTD1* family with predominant colorectal cancer. (Abstract #1500)

H. T. Lynch, S. N. Thibodeau, C. Snyder, J. F. Lynch, J. M. Davies, C. R. Boland, P. M. Lynch, D. Riegert-Johnson

9:45 AM Association of Lynch syndrome and risk of invasive cervical cancer. (Abstract #1501)

Y. C. Antill, J. Dowty, A. Win, T. Thompson, N. M. Lindor, S. Gallinger, I. Winship, M. A. Jenkins

Discussion

10:00 AM Stephen B. Gruber, MD, PhD (Abstracts #1500–1501)
University of Michigan

10:15 AM Long-term survival among 298 Hodgkin lymphoma (HL) patients who develop breast cancer (BC): A population-based study. (Abstract #1502)

M. T. Milano, H. Li, M. H. Gail, L. S. Constine, L. B. Travis

10:30 AM Diabetes, obesity, and survival in a large cohort of early-stage breast cancer patients. (Abstract #1503)

S. H. Giordano, S. Jiralerspong, A. Lopez, L. Feng, E. S. Kim, A. M. Gonzalez-Angulo, G. N. Hortobagyi

10:45 AM Genetic variants in the telomere maintenance pathway as predictors of second primary tumors and recurrence of early-stage head and neck cancer. (Abstract #1504)

J. Y. Chang, S. M. Lippman, J. Lee, M. Huang, X. Wu

Discussion

11:00 AM To be determined

11:15 AM A short-term biomarker modulation prevention study of simvastatin in women at increased risk for breast cancer. (Abstract #1505)

M. J. Higgins, T. M. Prowell, A. Blackford, S. Slater, P. Argani, H. Green, N. Khouri, R. Blumenthal, J. E. Garber, V. Stearns

11:30 AM Characterizing benign breast disease in women at high risk for breast cancer. (Abstract #1506)

S. A. Israel, H. Nassar, A. L. Gross, L. K. Jacobs, D. K. Armstrong, K. Visvanathan

11:45 AM Breast cancer outcome and estrogen plus progestin use in postmenopausal women. (Abstract #1507)

R. T. Chlebowski, G. L. Anderson, M. Gass, D. S. Lane, A. K. Aragaki, L. H. Kuller, J. E. Manson, M. . Stefanick, J. Ockene, R. L. Prentice, for the Women's Health Initiative Investigators To be determined

Discussion

12:00 PM Powel H. Brown, MD, PhD (Abstracts #1505–1507)
University of Texas M. D. Anderson Cancer Center

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Gastrointestinal (Colorectal) Cancer

Location: E Hall D1

CME credit: 3

Track(s): Gastrointestinal (Colorectal) Cancer

Tanios S. Bekaii-Saab, MD—Co-Chair

The Ohio State University Medical Center

Chris R. Garrett, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

- 9:30 AM** Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]). (Abstract #3501)
J. Taberero, E. Aranda, A. Gomez, B. Massuti, J. Sastre, A. Abad, M. Valladares, F. Rivera, M. Safont, E. Diaz-Rubio
- 9:45 AM** Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial. (Abstract #3502)
T. S. Maughan, R. Adams, C. G. Smith, M. T. Seymour, R. H. Wilson, A. M. Meade, D. Fisher, A. Madi, J. Cheadle, R. S. Kaplan, MRC COIN Trial Investigators
- 10:00 AM** Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM). (Abstract #3526)
T. Ruers, C. J. Punt, F. van Coevorden, I. Borel Rinkes, J. A. Ledermann, G. J. Poston, W. Bechstein, M. Lentz, M. Mauer, B. Nordlinger
- Discussion**
- 10:15 AM** Alan Paul Venook, MD (Abstracts #3501, 3502, 3526)
 University of California, San Francisco
- 10:30 AM** Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. (Abstract #3503)
M. J. O'Connell, I. C. Lavery, R. G. Gray, P. Quirke, D. J. Kerr, M. Lopatin, G. A. Yothers, M. Lee, K. Clark-Langone, N. Wolmark
- 10:45 AM** Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer (CC): Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. (Abstract #3504)
A. Roth, D. Klingbiel, P. Yan, R. Fiocca, M. Delorenzi, R. Labianca, D. Cunningham, E. Van Cutsem, F. Bosman, S. Tejpar
- 11:00 AM** Mutant KRAS and BRAF gene expression profiles in colorectal cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. (Abstract #3505)
S. Tejpar, V. Popovici, M. Delorenzi, E. Budinska, H. Estrella, M. Mao, P. Yan, S. Weinrich, E. Van Cutsem, A. Roth
- 11:15 AM** Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. (Abstract #3506)
C. Bokemeyer, C. Kohne, P. Rougier, C. Stroh, M. Schlichting, E. Van Cutsem

Sunday, June 6, 2010

Discussion

11:30 AM Charles Fuchs, MD (Abstracts #3503–3506)
Dana-Farber Cancer Institute

11:45 AM **Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. (Abstract #CRA3507)**
S. R. Alberts, D. J. Sargent, T. C. Smyrk, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. N. Thibodeau, S. Nair

12:00 PM **Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. (Abstract #3508)**
R. M. Goldberg, D. J. Sargent, S. N. Thibodeau, M. R. Mahoney, A. F. Shields, E. Chan, S. Gill, M. S. Kahlenberg, S. Nair, S. R. Alberts

Discussion

12:15 PM Louis M. Weiner, MD (Abstracts #CRA3507–3508)
Georgetown University Medical Center

**9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION**

Genitourinary (Prostate) Cancer

Location: E Hall D2

CME credit: 3

Track(s): Genitourinary Cancer

Dana E. Rathkopf, MD—Co-Chair

Memorial Sloan-Kettering Cancer Center

Evan Y. Yu, MD—Co-Chair

University of Washington

9:30 AM Intergroup randomized phase III study of androgen deprivation therapy (ADT) + radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94–0110; NCT00002633). (Abstract #CRA4504)

P. R. Warde, M. D. Mason, M. R. Sydes, M. K. Gospodarowicz, G. P. Swanson, P. Kirkbride, E. Kostashuk, J. Hetherington, K. Ding, W. Parulekar, NCIC CTG PR.3/MRC PRO7/SWOG JPR3 Investigators

9:45 AM Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer. (Abstract #4505)

N. Mottet, M. Peneau, J. Mazon, V. Molinie, P. Richaud

10:00 AM Surgical outcomes and implications for cure in active surveillance patients who undergo delayed radical prostatectomy. (Abstract #4506)

B. J. Trock, Z. Feng, P. Landis, J. I. Epstein, B. Carter

Discussion

10:15 AM Anthony V. D'Amico, MD, PhD (Abstracts #4504–4506)

Dana-Farber Cancer Institute

Early Prostate Cancer: How Much Therapy Is Too Much?

10:30 PM A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. (Abstract #LBA4507)

K. Fizazi, M. A. Carducci, M. R. Smith, R. Damião, J. E. Brown, L. Karsh, P. Milecki, H. Wang, R. D. Dansey, C. D. Goessl

Discussion

10:45 AM Robert E. Coleman, MD, MBBS (Abstract #LBA4507)

Weston Park Hospital

The Role of RANKL in Castration-resistant Prostate Cancer

11:00 AM Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). (Abstract #4508^)

J. S. De Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. H. Machiels, L. Shen, P. Matthews, A. O. Sartor, for the TROPIC Investigators

11:15 AM Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial. (Abstract #4509)

H. I. Scher, K. N. Chi, R. De Wit, W. R. Berry, P. Albers, B. Henick, P. Venner, A. Heidenreich, L. Chu, G. Heller

Sunday, June 6, 2010

Discussion

- 11:30 AM** Ian Tannock, MD, PhD (Abstracts #4508~4509)
Princess Margaret Hospital
Chemotherapy for Castration-resistant Prostate Cancer: Looking beyond Docetaxel and Mitoxantrone
- 11:45 AM** **A randomized, multicenter, international phase II study of tasquinimod in chemotherapy-naïve patients with metastatic castrate-resistant prostate cancer (CRPC). (Abstract #4510)**
R. Pili, M. Haggman, W. M. Stadler, J. R. Gingrich, V. J. Assikis, A. Björk, G. Forsberg, M. A. Carducci, A. J. Armstrong
- 12:00 PM** **A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. (Abstract #LBA4511)**
W. K. Kelly, S. Halabi, M. A. Carducci, D. J. George, J. F. Mahoney, W. M. Stadler, M. J. Morris, P. W. Kantoff, J. P. Monk III, E. J. Small, Cancer and Leukemia Group B

Discussion

- 12:15 PM** William L. Dahut, MD (Abstracts #4510–LBA4511)
National Cancer Institute
Angiogenic Targeting in Castration-resistant Prostate Cancer

SUNDAY

**9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION**

Gynecologic Cancer

Location: E Arie Crown Theater

CME credit: 3

Track(s): Gynecologic Cancer

Ernst Lengyel, MD, PhD—Co-Chair

The University of Chicago

Amit M. Oza, BSc, MBBS, MD, FRCPC, FRCP—Co-Chair

Princess Margaret Hospital

9:30 AM A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). (Abstract #5003)

K. H. Lu, S. Skates, T. B. Bevers, W. Newland, R. G. Moore, L. Leeds, S. Harris, O. W. Adayinka, H. A. Fritsche, R. C. Bast

Discussion

9:45 AM Usha Menon, MD (Abstract #5003)

University College London

High-risk Ovarian Cancer Screening: Is It Useful?

10:00 AM A gene expression profile of BRCAness that correlates with responsiveness to platinum and PARP inhibitors. (Abstract #5004)

P. Konstantinopoulos, D. Spentzos, B. Karlan, T. Taniguchi, E. Fountzilias, N. Francoeur, D. A. Levine, S. A. Cannistra

Discussion

10:15 AM Elise C. Kohn, MD (Abstract #5004)

National Cancer Institute

Relevance of BRCAness in Selecting Therapy?

10:30 AM Randomized phase III adjuvant study in high-risk cervical cancer: Simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A NOGGO-AGO-Intergroup study. (Abstract #5005)

J. Sehouli, J. U. Blohmer, S. Kuemmel, I. B. Runnebaum, W. Hartmann, R. Richter, A. Belau, H. Leber, M. Kaufmann, W. Lichtenegger, NOGGO

10:45 AM RTOG 0417: A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. (Abstract #5006)

T. E. Scheffer, J. Moughan, J. S. Kwon, K. Stuhr, M. Rotman, B. P. Yaremko, W. Small Jr., D. K. Gaffney

Discussion

11:00 AM Patricia J. Eifel, MD (Abstracts #5005–5006)

University of Texas M. D. Anderson Cancer Center

The Next Step in Chemoradiation for Cervical Cancer

11:15 AM Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer. (Abstract #5013)

I. B. Vergote, J. P. Michá, C. H. Pippitt Jr., G. G. Rao, D. L. Spitz, N. Reed, G. G. Dark, A. Garcia, D. J. Maslyar, G. J. Rustin

Discussion

11:30 AM Claire F. Verschraegen, MD (Abstract #5013)

University of New Mexico

Chemotherapy of the Future in Platinum-resistant Disease

11:45 AM Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report. (Abstract #LBA5008)

M. G. Teneriello, A. N. Gordon, P. Lim, M. Janicek

Discussion

12:00 PM Ronald J. Buckanovich, MD (Abstract #LBA5008)

University of Michigan

Maintenance and Consolidation in Ovarian Cancer

Sunday, June 6, 2010

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Myeloma

Location: E354b

CME credit: 3

Track(s): Lymphoma and Plasma Cell Disorders

Andrzej J. Jakubowiak, MD, PhD—Co-Chair

University of Michigan

Todd M. Zimmerman, MD—Co-Chair

The University of Chicago

9:30 AM Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients. (Abstract #8013)

M. Boccadoro, S. Bringhen, G. Gaidano, R. Ria, M. Offidani, F. Patriarca, C. Nozzoli, P. Musto, M. Petrucci, A. P. Palumbo, Italian Multiple Myeloma Network, GIMEMA

9:45 AM Comparison of reduced-dose bortezomib plus thalidomide and dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007–02 study. (Abstract #8014)

P. Moreau, T. Facon, M. Attal, C. Doyen, C. Hulin, G. Marit, L. Garderet, M. Tiab, H. Avet-Loiseau, J. Harousseau

Discussion

10:00 AM Ruben Niesvizky, MD (Abstracts #8013–8014)
New York Presbyterian Hospital-Cornell Campus
Sorting through the Options for Initial Therapy of Myeloma

10:15 AM A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m²) and autologous transplantation (MEL200) in newly diagnosed myeloma patients. (Abstract #8015)

A. P. Palumbo, F. Cavallo, F. Di Raimondo, D. Ben Yehuda, P. Omedè, V. Montefusco, F. Rossini, I. Hardan, T. Caravita, M. Boccadoro

10:30 AM Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase III study. (Abstract #8016)

K. C. Anderson, E. Weller, S. Lonial, A. J. Jakubowiak, S. Jagannath, N. S. Raje, D. Avigan, R. D. Knight, D. Esseltine, P. G. Richardson

Discussion

10:45 AM Jean L. Harousseau, MD (Abstracts #8015–8016)
Rene Gauducheau Cancer Center
What Is the Role of Transplant for Myeloma in the Era of Novel Agents?

11:00 AM Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. (Abstract #8017)

P. L. McCarthy, K. Owzar, K. C. Anderson, C. C. Hofmeister, H. Hassoun, D. D. Hurd, E. A. Stadtmauer, S. Giralt, V. Hars, C. A. Linker, for CALGB, ECOG, and BMT-CTN

11:15 AM Lenalidomide maintenance after transplantation for myeloma. (Abstract #8018)

M. Attal, C. Cristini, G. Marit, D. Caillot, T. Facon, C. Hulin, P. Moreau, C. Mathiot, H. Avet-Loiseau, J. L. Harousseau, Intergroupe Francophone du Myelome

Discussion

- 11:30 AM** Sergio Giralt, MD (Abstracts #8017–8018)
University of Texas M. D. Anderson Cancer Center
Post-transplant Maintenance Therapies
- 11:45 AM** **Defining the prognostic variables in gene expression profiling (GEP)-defined high-risk multiple myeloma (MM): Distinguishing early failures (EF) from sustained control (SC). (Abstract #8019)**
B. Barlogie, J. D. Shaughnessy, J. Haessler, A. Hoering, F. Van Rhee,
E. J. Anaissie, J. Crowley
- 12:00 PM** **Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study. (Abstract #8020)**
S. Lonial, R. Vij, J. Harousseau, T. Facon, P. Moreau, X. Leleu, C. Westland,
A. K. Singhal, S. Jagannath, Multiple Myeloma Research Consortium
- 12:15 PM** **Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX Study. (Abstract #8021)**
G. Morgan, F. Davies, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy,
M. Drayson, R. G. Owen, G. H. Jackson, J. A. Child

Sunday, June 6, 2010

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Pediatric Oncology I

Location: S504

CME credit: 3

Track(s): Pediatric Oncology

Steven G. DuBois, MD—Co-Chair

University of California, San Francisco

Kenan Onel, MD, PhD—Co-Chair

The University of Chicago

9:30 AM Early results from Children's Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). (Abstract #9503)

B. Weigel, E. Lyden, J. R. Anderson, A. Galster, C. A. Arndt, J. Michalski, D. S. Hawkins, W. H. Meyer

9:45 AM Second-look operation with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG). (Abstract #9504)

D. A. Rodeberg, M. D. Wharam, E. Lyden, J. A. Stoner, K. L. Brown, S. L. Wolden, C. N. Paidas, S. S. Donaldson, D. S. Hawkins, C. A. Arndt

10:00 AM Prognostic factors of localized extremity rhabdomyosarcomas: The results of a pooled analysis from U.S. and European cooperative groups. (Abstract #9505)

O. Oberlin, A. Rey, K. L. Brown, G. Bisogno, E. Koscielniak, M. Stevens, D. S. Hawkins, W. H. Meyer, T. H. La, J. R. Anderson

10:15 AM Nonmetastatic osteosarcoma of the extremity: Neoadjuvant chemotherapy with methotrexate (MTX), cisplatin (CDP), doxorubicin (ADM) with or without ifosfamide (IFO)—A randomized trial of the Italian Sarcoma Group (ISG/OS-1). (Abstract #9506)

S. Ferrari, G. Cefalo, A. Tamburini, A. Comandone, F. Fagioli, P. G. Casali, G. Bisogno, M. Mercuri, P. Picci, G. Bacci

Discussion

10:30 AM Holcombe E. Grier, MD (Abstracts #9503–9506)

Dana-Farber Cancer Institute

Pediatric Sarcomas: Where to Now?

10:45 AM A phase II trial of proton radiotherapy for medulloblastoma: Preliminary results. (Abstract #CRA9507)

T. I. Yock, B. Y. Yeap, D. Ebb, S. M. MacDonald, M. B. Pulsifer, K. C. Marcus, N. Tarbell

11:00 AM Neurocognitive outcomes after proton radiation for pediatric brain tumors. (Abstract #9508)

M. B. Pulsifer, I. Delgado, N. Tarbell, K. Kuhlthau, S. M. MacDonald, T. I. Yock

Discussion

11:15 AM Joel E. Tepper, MD

University of North Carolina

Pediatric Proton Radiotherapy

11:30 AM Cytogenetic and early-response characteristics of adolescents and young adults with acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study. (Abstract #9509)

E. A. Raetz, M. Devidas, A. J. Carroll, N. A. Heerema, M. J. Borowitz, B. L. Wood, J. M. Gastier-Foster, C. L. Willman, M. L. Loh, E. C. Larsen, COG ALL Committee

- 11:45 AM** **Dose-intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Study C9710. (Abstract #9510)**
J. H. Feusner, J. Gregory, B. K. Moser, V. Hars, C. L. Willman, B. L. Powell, R. A. Larson
- 12:00 PM** **Advanced-stage anaplastic large-cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine: A report from the Children's Oncology Group. (Abstract #9511)**
J. M. Kravaka, S. S. Weitzman, L. Smith, J. C. Lynch, M. Chang, M. Kinney, S. L. Perkins, J. H. Laver, T. G. Gross, H. J. Weinstein, Children's Oncology Group

Discussion

- 12:15 PM** James B. Nachman, MD (Abstracts #9509–9511)
The University of Chicago
Bridging the Gap in Leukemia

Sunday, June 6, 2010

9:45 AM - 11:00 AM
EDUCATION SESSIONS

Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat

Location: S100a

CME credit: 1.25

Track(s): Geriatric Oncology; Breast Cancer; Gastrointestinal (Colorectal) Cancer; General Oncology

Peter Ravdin, MD—Chair

University of Texas Health Science Center at San Antonio

Benefits of Adjuvant Therapy

Supriya Gupta Mohile, MD, MS

University of Rochester Medical Center

Estimating Life Expectancy and Benefit from Adjuvant Therapy Based on Comorbidity

Arash Naeim, MD

University of California, Los Angeles

The Importance of Shared Decision Making Regarding Adjuvant Therapy

Creative Approaches to Advanced and Metastatic Sarcoma

Location: S406 (Vista Room)

CME credit: 1.25

Track(s): Sarcoma

Brian O'Sullivan, MD—Chair

Princess Margaret Hospital

Role of Radiation for Treatment of Advanced/Metastatic Sarcoma

Raja Michael Flores, MD

Memorial Sloan-Kettering Cancer Center

Management of Sarcoma Patients with Lung Metastasis: Minimally Invasive/Nonresection Approaches

William D. Tap, MD

University of California, Los Angeles

Novel Systemic Approaches for the Management of Advanced/Metastatic Sarcoma

Therapy for Patients with Activating Mutations of the Epidermal Growth Factor Receptor

Location: N Hall B1

CME credit: 1.25

Track(s): Lung Cancer

William Pao, MD, PhD—Chair

Vanderbilt-Ingram Cancer Center

Mechanisms of Resistance to EGFR Inhibitors

Tony Mok, MD

The Chinese University of Hong Kong

Testing for EGFR in Untreated Patients: Implications for Treatment

David Michael Jackman, MD

Dana-Farber Cancer Institute

Therapy after Progression in First Line for Patients with Activating Mutation of the EGFR

9:45 AM - 11:00 AM
MEET THE PROFESSOR SESSION

Nontransplant Options for Mantle Cell Lymphoma (M06)-TICKETED SESSION

Location: E451b

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders

John Leonard, MD
Weill Cornell Medical College

9:45 AM - 11:00 AM
CLINICAL PROBLEMS IN ONCOLOGY

Therapeutic Choices for Patients with Intermediate-stage Head and Neck Cancer (C08)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Head and Neck Cancer

Merrill S. Kies, MD—Chair
University of Texas M. D. Anderson Cancer Center
Management Strategies for Intermediate Larynx Cancer

Christopher Nutting, MD
Royal Marsden Hospital
Radiation Therapy for the Early-stage Patient

Ted Teknos, MD
The Ohio State University
Multidisciplinary Treatment of Intermediate-stage Oral Cavity Cancer

Sunday, June 6, 2010

9:45 AM - 11:15 AM
CLINICAL SCIENCE SYMPOSIUM

Pharmacologic Treatment of Cancer-related Fatigue: Does It Make a Difference?

Location: E354a

CME credit: 1.5

Track(s): Patient and Survivor Care

Barbara A. Murphy, MD—Co-Chair

Vanderbilt University Medical Center

Thomas J. Smith, MD—Co-Chair

Virginia Commonwealth University

9:45 AM Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7. (Abstract #9004)

D. L. Barton, A. R. Moraska, A. Sood, J. A. Sloan, J. J. Suh, P. C. Griffin, D. B. Johnson, A. A. Ali, P. T. Silberstein, C. L. Loprinzi

10:00 AM Factors associated with response to methylphenidate in advanced cancer patients with cancer-related fatigue. (Abstract #9005)

S. Yennurajalingam, J. L. Palmer, Z. Li, E. Bruera

Discussion

10:15 AM Charles S. Cleeland, MD (Abstracts #9004–9005)
University of Texas M. D. Anderson Cancer Center

10:30 AM A randomized double-blind placebo-controlled study of oral coenzyme Q10 to relieve self-reported cancer treatment-related fatigue in newly diagnosed breast cancer patients. (Abstract #9006)

G. J. Lesser, L. D. Case, N. Stark, S. K. Williford, J. K. Giguere, A. Garino, M. J. Naughton, M. Vitolins, M. Lively, E. G. Shaw, Comprehensive Cancer Center of Wake Forest University CCOP Research Base

10:45 AM Effect of guarana (*Paullinia cupana*) on fatigue in breast cancer patients undergoing systemic chemotherapy. (Abstract #9007)

M. P. Campos, R. Riechelmann, L. C. Martins, B. J. Hassan, F. B. Casa, A. Del Giglio

Discussion

11:00 AM Thomas J. Smith, MD (Abstracts #9006–9007)
Virginia Commonwealth University

9:45 AM - 11:15 AM
CLINICAL SCIENCE SYMPOSIUM

Smoothened/Hedgehog/Gamma Secretase

Location: E353

CME credit: 1.5

Track(s): Developmental Therapeutics

S. Gail Eckhardt, MD—Chair

University of Colorado Cancer Center

Discussion

9:45 AM Patricia LoRusso, DO
Karmanos Cancer Institute
Introduction

10:00 AM **A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. (Abstract #2500)**
J. Rodon Ahnert, J. Baselga, H. A. Tawbi, Y. Shou, C. Granvil, J. Dey, M. M. Mita, A. L. Thomas, D. D. Amakye, A. C. Mita

10:15 AM **A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. (Abstract #2501)**
L. L. Siu, K. Papadopoulos, S. R. Alberts, R. Kirchoff-Ross, B. Vakkalagadda, L. Lang, C. M. Ahlers, K. L. Bennett, J. M. Van Tornout

10:30 AM **A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors. (Abstract #2502)**
A. W. Tolcher, S. M. Mikulski, W. A. Messersmith, E. L. Kwak, D. Gibbon, J. Boylan, Z. X. Xu, M. DeMario, J. J. Wheeler

Discussion

10:45 AM Charles M. Rudin, MD, PhD (Abstracts #2500–2502)
Sidney Kimmel Cancer Center at Johns Hopkins
Closing Remarks

Sunday, June 6, 2010

**10:30 AM - 12:30 PM
SPECIAL SESSION**

**Training Program Directors' Special Session—Addressing the Competencies:
Professionalism and Practice-based Learning**

Location: S404

CME credit: 2

Track(s): Special Session

Michael P. Kosty, MD—Chair

Scripps Clinic

QOPI for Fellows Overview

Jill Gilbert, MD

Vanderbilt University Medical Center

Program Directors' Experiences with QOPI for Fellows

Laurie Jean Lyckholm, MD

Virginia Commonwealth University

Program Directors' Experiences with QOPI for Fellows

Timothy Jerome Moynihan, MD

Mayo Clinic

Professionalism

SUNDAY

11:30 AM - 12:45 PM
EDUCATION SESSIONS

Evaluating the Evidence and Marketing of Pharmacogenomic Tests

Location: E353

CME credit: 1.25

Track(s): Cancer Genetics; Developmental Therapeutics; Pediatric Oncology

Howard L. McLeod, PharmD—Chair

University of North Carolina at Chapel Hill

Overview of Pharmacogenomics: History, Development, and Role in FDA Labeling

Matthew P. Goetz, MD

Mayo Clinic

CYP2D6 Testing and Tamoxifen

Michael L. Maitland, MD, PhD

The University of Chicago

Clinical Cases in Pharmacogenomics

Lessons Learned from Clinical Trials in Gastrointestinal Stromal Tumor

Location: S406 (Vista Room)

CME credit: 1.25

Track(s): Sarcoma

Jean-Yves Blay, MD, PhD—Chair

University Claude Bernard

Combination Therapy with Established and Novel Targeted Agents to Improve Outcomes in Patients with Advanced GIST

Ronald P. DeMatteo, MD

Memorial Sloan-Kettering Cancer Center

The Role of Adjuvant Imatinib after Resection of Localized Primary GIST: An Update on the Z9001 Trial—Optimal Duration of Therapy

Michael C. Heinrich, MD

Oregon Health & Science University

Dosing the Unusual Patient with Non-exon 9/11 GIST

Survivorship in Lymphoma

Location: E354a

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders; Patient and Survivor Care

David J. Straus, MD—Chair

Memorial Sloan-Kettering Cancer Center

Long-term Toxicities of Lymphoma Therapy

Rebecca L. Elstrom, MD

Weill Cornell Medical College

Imaging in Lymphoma Patients: Who, When, How, and How Long?

Jennifer Mills, MSW, MPH

New York University School of Social Work

Psychosocial Issues of Lymphoma Survivors: Cured but Not Healed?

Sunday, June 6, 2010

**11:30 AM - 12:45 PM
MEET THE PROFESSOR SESSION**

**Electronic/Digital Resources in Oncology: Value versus Distraction (M07)-
TICKETED SESSION**

Location: E451b

CME credit: 1.25

Track(s): Practice Management and Information Technology; Professional Development

Robert Stephen Miller, MD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

**11:30 AM - 12:45 PM
CLINICAL PROBLEMS IN ONCOLOGY**

**Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors:
What to Do after Adjuvant Therapy? (C09)-TICKETED SESSION**

Location: E451a

CME credit: 1.25

Track(s): Gastrointestinal (Colorectal) Cancer; Cancer Prevention/Epidemiology; Patient and Survivor Care

Jeffrey A. Meyerhardt, MD, MPH—Chair

Dana-Farber Cancer Institute

Beyond Standard Surgery and Chemotherapy to Lower the Risk of Tumor Recurrence in Patients with Resected Colorectal Cancer

David P. Ryan, MD

Massachusetts General Hospital

Pharmacologic Interventions to Lower the Risk of Tumor Recurrence in Patients with Resected Colorectal Cancer

11:30 AM - 1:00 PM
CLINICAL SCIENCE SYMPOSIUM

Optimizing Care of the Elderly and Underserved

Location: S100a

CME credit: 1.5

Track(s): Patient and Survivor Care; Geriatric Oncology

Gretchen Genevieve Kimmick, MD—Co-Chair

Duke University Medical Center

Jennifer A. Ligibel, MD—Co-Chair

Dana-Farber Cancer Institute

11:30 AM The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: Design and validation. (Abstract #9000)

M. Extermann, I. Boler, R. Reich, G. H. Lyman, R. H. Brown, J. DeFelice, R. M. Levine, E. T. Lubiner, P. Reyes, F. J. Schreiber III

11:45 AM Predicting chemotherapy toxicity in older adults with cancer: A prospective 500-patient multicenter study. (Abstract #9001)

A. Hurria, K. Togawa, S. G. Mohile, C. Owusu, H. D. Klepin, C. Gross, S. M. Lichtman, V. Katheria, S. Klapper, W. P. Tew, on behalf of the Cancer and Aging Research Group

Discussion

12:00 PM Hyman Bernard Muss, MD (Abstracts #9000–9001)
University of North Carolina at Chapel Hill

12:15 PM Racial differences in receipt of guideline-recommended treatment in men with low-, intermediate-, and high-risk prostate cancer (CaP): A population-based study. (Abstract #9002)

R. C. Chen, J. Bainbridge, W. R. Carpenter, Z. A. Wang, M. E. Nielsen, J. Darter, P. A. Godley

12:30 PM Factors contributing to high symptom burden during chemotherapy for advanced lung cancer: The risk of being underserved. (Abstract #9003)

C. S. Cleeland, T. R. Mendoza, G. R. Palos, C. Lu, L. A. Nazario, G. R. Lynch, G. M. Mobley, X. S. Wang

Discussion

12:45 PM Cathy Bradley, PhD (Abstracts #9002–9003)
Virginia Commonwealth University

Sunday, June 6, 2010

1:00 PM - 4:00 PM
PLENARY SESSION

Plenary Session including Science of Oncology Award and Lecture

Location: N Hall B1

CME credit: 3

Track(s): Special Session; General Oncology

Douglas W. Blayney, MD—Co-Chair

University of Michigan

Daniel F. Hayes, MD—Co-Chair

University of Michigan Medical Center

1:00 PM Frank McCormick, PhD—Science of Oncology Award Recipient
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
Success and Failure on the Ras Pathway

1:45 PM Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. (Abstract #LBA1)
R. A. Burger, M. F. Brady, M. A. Bookman, J. L. Walker, H. D. Homesley, J. Fowler, B. J. Monk, B. E. Greer, M. Boente, S. X. Liang

Discussion

2:00 PM Elisabeth A. Eisenhauer, MD (Abstract #LBA1)
NCIC Clinical Trials Group

2:15 PM Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). (Abstract #2)
E. A. Quoix, J. Oster, V. Westeel, E. Pichon, G. Zalcman, L. Baudrin, A. Lavole, J. Dauba, M. Lebitasy, B. J. Milleron, on behalf of IFCT

2:30 PM Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC). (Abstract #3)
Y. Bang, E. L. Kwak, A. T. Shaw, D. R. Camidge, A. J. Iafrate, R. G. Maki, B. J. Solomon, S. I. Ou, R. Salgia, J. W. Clark

Discussion

2:45 PM Martin J. Edelman, MD (Abstracts #2–3)
University of Maryland Greenebaum Cancer Center

3:05 PM A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. (Abstract #4)
S. O'Day, F. S. Hodi, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, X. Zhu, M. J. Yellin, A. Hoos, W. J. Urba

Discussion

3:20 PM Vernon K. Sondak, MD (Abstract #4)
H. Lee Moffitt Cancer Center & Research Institute
Ipilimumab: The Light at the End of the Tunnel?

SUNDAY

**2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION**

Developmental Therapeutics—Experimental Therapeutics

Display Time: 2:00 PM - 6:00 PM

Display Location: E450b

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: E Hall D2

CME credit: 1

Track(s): Developmental Therapeutics

Patrick Schoffski, MD, MPH—Co-Chair

Catholic University Leuven

Ross A. Soo, MD—Co-Chair

National University Health System

Discussion

5:00 PM Tomislav Dragovich, MD, PhD (Abstracts #3015–3018)
Arizona Cancer Center
Combinations Involving Erlotinib

Discussion

5:15 PM David Flockhart, MD, PhD (Abstracts #3019–3022)
Indiana University School of Medicine
Improving Therapeutic Index with Diverse Methods of Modern Clinical Pharmacology

Discussion

5:30 PM Elizabeth A. Eisenhauer, MD (Abstracts #3023–3027)
NCIC Clinical Trials Group
Design of Early-development Combination Trials

Discussion

5:45 PM Jan H. M. Schellens, MD, PhD (Abstracts #3028–3033)
Netherlands Cancer Institute
Applying PK/PD Principles to Development of Anticancer Agents

Brd. 1 **A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. (Abstract #3015)**
R. B. Cohen, P. A. Janne, J. A. Engelman, P. Martinez, Y. Nishida, S. Gendreau, B. Wu, E. Felip

Brd. 2 **Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. (Abstract #3016)**
V. M. Macaulay, M. R. Middleton, S. G. Eckhardt, R. A. Juergens, A. W. Stephens, S. Poondru, S. P. McCarthy, S. M. Gadgeel

Brd. 3 **A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #3017)**
H. A. Wakelee, S. N. Gettinger, J. A. Engelman, P. A. Janne, H. J. West, D. S. Subramaniam, J. W. Leach, M. B. Wax, Y. Yaron, P. Lara Jr.

Brd. 4 **Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors. (Abstract #3018)**
I. Puzanov, J. Sarantopoulos, J. Gilbert, D. Mahalingam, L. I. Chap, H. Deng, M. Zhu, I. McCaffery, G. R. Friberg, L. S. Rosen

Brd. 5 **Association of the hemochromatosis (HFE) gene with pazopanib-induced transaminase elevations in renal cell carcinoma. (Abstract #3019)**
C. Xu, B. H. Reck, V. L. Goodman, Z. Xue, L. Huang, C. F. Spraggs, V. E. Mooser, L. R. Cardon, L. Pandite

- Brd. 6** **Effect of coadministration of statins on neutropenia in a phase I genotype-directed dose-escalation study of irinotecan. (Abstract #3020)**
F. Innocenti, T. Karrison, J. Ramirez, L. A. Janisch, W. Zhang, K. Wu, M. J. Ratain
- Brd. 7** **Inherited genetic variation in *EPHA5*, *FGD4*, and *NRDG1* and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101. (Abstract #3021)**
D. L. Kroetz, R. M. Baldwin, K. Owzar, C. Jiang, H. Zembutsu, M. Kubo, Y. Nakamura, L. N. Shulman, M. J. Ratain, Cancer and Leukemia Group B
- Brd. 8** **Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase I clinical trial. (Abstract #3022)**
A. Ribas, L. Kalinoski, J. D. Heidel, J. Peterkin, D. B. Seligson, J. E. Zuckerman, C. Choi, Y. Yen, M. E. Davis, A. W. Tolcher
- Brd. 9** **Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors. (Abstract #3023)**
P. Tresca, D. Tosi, L. van Doorn, H. Fontaine, A. V. Gaast, C. Veyrat-Follet, C. Oprea, V. Dieras, F. Eskens
- Brd. 10** **A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors. (Abstract #3024)**
A. A. Adjei, J. A. Sosman, G. K. Dy, W. Ma, G. J. Fetterly, D. Skupien, J. A. Means, R. Savage, F. Chai, I. Puzanov
- Brd. 11** **Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer. (Abstract #3025)**
R. C. Newton, E. C. Bradley, R. S. Levy, D. Doval, S. Bondarde, T. P. Sahoo, D. Lokanatha, P. K. Julka, R. Nagarkar, S. M. Friedman
- Brd. 12** **Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs). (Abstract #3026)**
E. Calvo, W. Ma, A. W. Tolcher, M. Hidalgo, J. Soria, R. Bahleda, A. Gualberto, L. J. Denis, R. D. Millham, A. A. Adjei
- Brd. 13** **A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors. (Abstract #3027)**
G. Giaccone, A. Rajan, R. J. Kelly, M. Gutierrez, S. Kummar, M. Yancey, J. J. Ji, Y. Zhang, R. E. Parchment, J. H. Doroshow
- Brd. 14** **Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors. (Abstract #3028)**
N. C. Dhani, H. A. Burris III, L. L. Siu, D. R. Camidge, L. R. Mileskin, H. Xu, K. J. Pierce, N. R. Fahey, H. J. Fingert, S. M. Shreeve
- Brd. 15** **Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data. (Abstract #3029)**
G. J. Fetterly, T. A. Puchalski, C. H. Takimoto, D. E. Mager, S. Seetharam, T. McIntosh, J. S. De Bono, A. W. Tolcher, H. M. Davis, H. Zhou
- Brd. 16** **A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. (Abstract #3030)**
I. Brana, P. LoRusso, J. Baselga, E. I. Heath, A. Patnaik, S. Gendreau, A. Laird, K. Papadopoulos

- Brd. 17** **Pharmacokinetic (PK) and pharmacodynamic (PD) results from two phase I studies of the investigational selective Aurora A kinase (AAK) inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors. (Abstract #3031)**
A. Cervantes-Ruiperez, H. A. Burris III, R. B. Cohen, E. C. Dees, J. R. Infante, H. J. Fingert, V. Shinde, K. Venkatakrishnan, A. Chakravarty, J. Tabernero
- Brd. 18** **Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110 δ isoform, in patients with relapsed or refractory hematologic malignancies. (Abstract #3032)**
R. R. Furman, J. C. Byrd, I. W. Flinn, S. E. Coutre, D. M. Benson Jr., J. R. Brown, B. S. Kahl, N. D. Wagner-Johnston, N. A. Giese, A. S. Yu
- Brd. 19** **Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase (TK) inhibitor, in a phase I study. (Abstract #3033)**
G. Liu, P. LoRusso, E. I. Heath, J. Y. Bruce, A. M. Traynor, M. Pilat, A. Breazna, M. Tortorici, D. R. Shalinsky, A. D. Ricart

Sunday, June 6, 2010

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Gynecologic Cancer

Display Time: 2:00 PM - 6:00 PM
Display Location: E450a
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: E Arie Crown Theater
CME credit: 1
Track(s): Gynecologic Cancer

Claire F. Verschraegen, MD—Co-Chair

University of New Mexico

Seiko Diane Yamada, MD—Co-Chair

The University of Chicago

Discussion

5:00 PM Carol Aghajanian, MD (Abstracts #5009–5015)
Memorial Sloan-Kettering Cancer Center
Old Wines in New Bottles

Discussion

5:15 PM Michael J. Birrer, MD, PhD (Abstracts #5016–5023)
Harvard Medical School, Massachusetts General Hospital
Biomarkers in Ovarian Cancer: Ready for Prime Time?

Discussion

5:30 PM Angeles Alvarez Secord, MD (Abstracts #5024–5029)
Duke University Medical Center
What's New in Endometrial Cancer?

Discussion

5:45 PM Martin Stockler, MBBS, FRACP, MHS (Abstracts #5030–LBA5033)
NHMRC Clinical Trials Centre, University of Sydney
Mining Phase III Studies: Gold or Quicksilver?

Brd. 1 **A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. (Abstract #5009)**
T. D. Tillmanns, M. P. Lowe, L. S. Schwartzberg, M. S. Walker, E. J. Stepanski

Brd. 2 **A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study. (Abstract #5010)**
R. L. Coleman, W. Brady, D. S. McMeekin, P. G. Rose, J. T. Soper, S. S. Lentz, J. S. Hoffman, M. S. Shahin

Brd. 3 **A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer. (Abstract #5011)**
B. B. Benigno, M. O. Burrell, P. Daugherty, P. Hernandez

Brd. 4 **Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study. (Abstract #5012)**
A. Poveda, S. Tjulandin, B. Kong, M. Roy, S. Chan, E. Filipczyk-Cisarz, H. Hagberg, C. Lebedinsky, T. V. Parekh, B. J. Monk

Brd. 5 **PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. (Abstract #LBA5012b)**
R. W. Naumann, J. T. Symanowski, S. A. Ghamande, N. Y. Gabrail, L. Gilbert, M. G. Teneriello, G. Sutton, C. Lovejoy, R. A. Messmann

- Brd. 6** Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC). (Abstract #5014)
E. Gallerani, J. Delord, P. Schoffski, I. B. Vergote, V. N. Trillet-Lenoir, M. Maur, M. G. Jannuzzo, A. Petroccione, G. Locatelli, D. Lorusso
- Brd. 7** Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: A phase II study. (Abstract #5015)
R. W. Holloway, M. Roche, L. DeMars, J. A. Williams Jr., A. Enke, A. Klein, R. G. Linke, C. N. Krasner
- Brd. 8** A KRAS variant as a biomarker of ovarian cancer risk. (Abstract #5016)
J. B. Weidhaas
- Brd. 9** Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): Genotype and survival. (Abstract #5017)
V. Engelstaedter, M. C. Cristea, J. E. Garber, S. L. Neuhausen, P. H. Frankel, S. Sand, L. Steele, U. Matulonis, J. Liu, J. Weitzel
- Brd. 10** Breast cancer protein expression as a prognostic marker in sporadic epithelial ovarian cancer (EOC): An NCIC CTG OV.16 correlative study. (Abstract #5018)
J. I. Weberpals, D. Tu, J. Squire, S. Islam, S. Amin, L. Pelletier, A. O'Brien, P. Hoskins, E. A. Eisenhauer
- Brd. 11** Impact of BRCA1 gene alterations on tumor characteristics and clinical outcome in ovarian cancer (OC) patients. (Abstract #5019)
D. Dimitrova, E. I. Braicu, R. Richter, R. Chekerov, G. Oskay-Ozcelik, K. Pietzner, A. Parashkevova, W. Lichtenegger, S. Olek, J. Sehoul, Tumor Bank Ovarian Cancer Network
- Brd. 12** Use of microarray-based comparative genomic hybridization analysis to identify prognostic subgroups of ovarian clear cell carcinomas. (Abstract #5020)
D. S. Tan, M. Iravani, M. B. Lambros, A. Mackay, C. Gourley, A. Williams, W. G. McCluggage, A. Ashworth, S. B. Kaye, J. S. Reis-Filho
- Brd. 13** A gene expression algorithm for the prediction of platinum sensitivity in ovarian cancer. (Abstract #5021)
J. S. Ferriss, Y. Kim, D. Theodorescu, L. R. Duska, J. Lee
- Brd. 14** Use of HE4 expression in plasma to predict operative outcome in patients with ovarian cancer (OC). (Abstract #5022)
E. I. Braicu, R. Zeillinger, I. B. Vergote, S. Mahner, A. G. Zeimet, I. Cadron, D. Castillo-Tong, R. Chekerov, B. Brandt, J. Sehoul
- Brd. 16** Performance of PREMM_{1,2,6}, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. (Abstract #5024)
R. C. Mercado, H. Hampel, R. Mopala, F. Kastrinos, E. W. Steyerberg, J. Balmaña, D. E. Cohn, F. J. Backes, A. De La Chapelle, S. Syngal, Colon Cancer Family Registry (CCFR)
- Brd. 17** Impact of microsatellite instability in overall survival of women with endometrial cancer. (Abstract #5025)
J. C. Rocha, C. B. Chaves, V. P. Leite, F. C. Moreira, D. M. Ramalho
- Brd. 18** Evaluation of insulin resistance among endometrial cancer patients. (Abstract #5026)
J. K. Burzawa, K. M. Schmeler, M. W. Bevers, T. B. Pustilnik, J. Brown, M. L. Anderson, L. M. Ramondetta, D. Urbauer, G. Tortolero-Luna, K. H. Lu
- Brd. 19** Influence of radiation modality and nodal dissection on survival in high-risk early-stage endometrial cancer. (Abstract #5027)
J. P. Chino, E. Jones, A. Berchuck, L. Havrilesky
- Brd. 20** Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer. (Abstract #5028)
K. Narayan, D. Rischin, M. Quinn, J. C. Goh, R. Cheuk, A. Obermair, D. Bernshaw, B. McClure, A. Milner, L. R. Mileskin

Sunday, June 6, 2010

- Brd. 21** **A phase II trial of radiotherapy sandwiched between carboplatin and docetaxel for stage III, IV, and recurrent endometrial cancer. (Abstract #5029)**
M. A. Geller, J. Ivy, R. Ghebre, L. S. Downs, P. L. Judson, L. F. Carson, A. L. Jonson, K. Dusenbery, M. Boente, P. Argenta
- Brd. 22** **Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182). (Abstract #5030)**
W. P. Tew, J. Java, D. Chi, A. Menzin, J. L. Lovecchio, M. A. Bookman, S. M. Lichtman
- Brd. 23** **Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial. (Abstract #5031)**
J. Kurtz, F. Hilpert, A. Dorum, A. Veillard, L. Elit, M. Buck, E. Petru, N. Reed, G. Scambia, N. Varsellona
- Brd. 24** **Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer. (Abstract #5032)**
D. R. Spriggs, A. Iasonos, P. Sabbatini, R. E. O’Cearbhaill, H. T. Thaler
- Brd. 25** **Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial. (Abstract #LBA5033)**
S. Pignata, G. Scambia, A. Savarese, R. Sorio, E. Breda, F. Legge, V. Gebbia, P. Musso, C. Gallo, F. Perrone, on behalf of MITO Group

SUNDAY

**2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION**

Pediatric Oncology

Display Time: 2:00 PM - 6:00 PM
 Display Location: S Hall A2
 Discussion Time: 5:00 PM - 6:00 PM
 Discussion Location: S504
CME credit: 1
 Track(s): Pediatric Oncology

Rochelle Bagatell, MD—Co-Chair

Children's Hospital of Philadelphia

Maryam Fouladi, MD—Co-Chair

Cincinnati Children's Hospital Medical Center

Discussion

5:00 PM Stephen Hunger, MD (Abstracts #9521–9528)
 The Children's Hospital
Next Generation Biomarkers in Leukemia

Discussion

5:20 PM Frank M. Balis, MD (Abstracts #9529–9538)
 Children's Hospital of Philadelphia
New Agents or Combinations in Pediatric Cancer

Discussion

5:40 PM Mark W. Kieran, MD, PhD (Abstracts #9539–9542)
 Dana-Farber Cancer Institute
Advances in CNS Therapy

Brd. 39A High throughput transcriptome sequencing of pediatric relapsed acute lymphoblastic leukemia (ALL). (Abstract #9521)
 L. E. Hogan, C. Mason, J. Meyer, J. Wang, Z. Tang, S. Brown, D. J. Morrison, S. Hunger, E. A. Raetz, W. L. Carroll

Brd. 39B Association of a genetic variant in the *ABCC2* gene with high methotrexate plasma concentrations in pediatric malignancies. (Abstract #9522)
 M. M. Hagleitner, M. J. Coenen, M. Schrauwen, S. H. Vermeulen, E. S. de Bont, P. Hoogerbrugge, D. M. Te Loo

Brd. 39F Biomarkers in the prediction of vincristine metabolism and neuropathy in pediatric acute lymphoblastic leukemia patients. (Abstract #9523)
 A. S. Lehmann, A. Egbelakin, S. K. Quinney, L. Li, J. L. Renbarger

Brd. 39G ABC drug transporter gene expression in neuroblastoma. (Abstract #9524)
 S. Cialfi, H. P. McDowell, P. Altavista, R. Boldrini, S. Bosco, A. Clerico, A. Jenkner, G. Kokai, B. Pizer, C. Dominici

Brd. 39H Use of loss of function RNA interference screen to evaluate TNK-2 as a factor involved in rhabdomyosarcoma cell growth. (Abstract #9525)
 F. I. Arnaldez, C. L. Yeung, P. J. Grohar, L. J. Helman

Brd. 40A Genetic variants in *MDR1* and *CYP3A5* and vincristine toxicity in children with acute lymphoblastic leukemia. (Abstract #9526)
 D. M. Te Loo, M. M. Hagleitner, R. van Schie, I. M. van der Sluis, M. J. Coenen, P. Hoogerbrugge

Brd. 40B Use of immunoglobulin heavy chain primer pools to assess minimal residual disease/persistent disease (MRD/PD) in children and adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL): A Children's Oncology Group report. (Abstract #9527)
 B. Shiramizu, S. Goldman, I. Kusao, M. Agsalda, J. C. Lynch, L. Harrison, T. G. Gross, W. Sanger, S. L. Perkins, M. S. Cairo, Children's Oncology Group

SUNDAY

- Brd. 40F** Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in pediatric acute lymphoblastic leukemia assessed by nanoparticle-capture mass spectrometry. (Abstract #9528)
E. Petricoin, M. M. Ross, W. Zhou, D. Tamburro, A. Luchini, L. A. Liotta, R. E. Scully, T. L. Miller, S. E. Sallan, S. E. Lipshultz
- Brd. 40G** A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of Aurora A kinase: A Children's Oncology Group Phase I Consortium study. (Abstract #9529)
Y. P. Mosse, E. G. Lipsitz, J. M. Maris, B. Weigel, P. C. Adamson, M. Ingle, C. H. Ahern, S. Blaney
- Brd. 40H** A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children's Oncology Group Phase I Consortium study. (Abstract #9530)
J. R. Park, D. S. Hawkins, M. Ingle, S. C. Borinstein, J. L. Glade Bender, D. Yamashiro, S. Baruchel, A. P. Chen, P. C. Adamson, S. Blaney
- Brd. 41A** A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors. (Abstract #9531)
L. Gore, T. M. Trippett, H. M. Katzenstein, J. L. Boklan, A. Narendaren, A. Smith, M. Macy, N. Narasimhan, C. D. Turner, M. L. Nieder
- Brd. 41B** Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium study. (Abstract #9532)
J. E. Minturn, J. Villablanca, G. A. Yanik, J. R. Park, S. G. Groshen, E. T. Hellriegel, D. Bensen-Kennedy, K. K. Matthay, G. M. Brodeur, J. M. Maris
- Brd. 41C** Phase II window of irinotecan + carboplatin in newly diagnosed patients with rhabdomyosarcoma: Results of Memorial Sloan-Kettering Cancer Center (MSKCC) Protocol IRB 03-099. (Abstract #9533)
L. H. Wexler, S. L. Wolden, S. J. Abramson, A. Price, S. Karimi, M. P. La Quaglia, A. J. Chou, P. R. Merola, P. A. Meyers
- Brd. 41D** Cisplatin plus pirarubicin chemotherapy and combination ifomide, etoposide, pirarubicin, and carboplatin chemotherapy for hepatoblastoma. (Abstract #9534)
E. Hiya^{ma}, A. Kamimatsuse, N. Kamei, K. Watanabe, T. Hishiki, T. Tajiri, K. Ida, M. Yano, S. Kondo, F. Sasaki, Japanese Study Group for Pediatric Liver Tumor
- Brd. 41E** Phase II trial of pemetrexed in children with refractory solid tumors: A Children's Oncology Group study. (Abstract #9535)
A. B. Warwick, S. Malempati, M. D. Krailo, A. S. Melemed, P. C. Adamson, S. Blaney
- Brd. 41F** Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature b-NHL: A Children's Oncology Group report. (Abstract #9536)
M. S. Cairo, J. C. Lynch, L. Harrison, S. L. Perkins, B. Shiramizu, T. G. Gross, W. Sanger, S. Goldman
- Brd. 41G** A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin Disease (HD): A Children's Oncology Group (COG) study. (Abstract #9537)
T. M. Horton, R. A. Drachtman, L. Chen, T. M. Trippett, P. De Alarcon, A. R. Chen, R. P. Guillerman, K. McCarten, S. M. Hogan, C. L. Schwartz
- Brd. 41H** Predicting an optimal strategy for insulin-like growth factor 1 (IGF1) signaling interference in Ewing's sarcoma (ES). (Abstract #9538)
A. C. van de Luijngaarden, Y. M. Versleijen-Jonkers, M. H. Roeffen, U. E. Flucke, B. W. Schreuder, W. T. Graaf

- Brd. 42A** **A pilot study using carboplatin, vincristine, and temozolomide for children with progressive/symptomatic low-grade glioma: A Children's Oncology Group (COG) study. (Abstract #9539)**
M. M. Chintagumpala, A. Adesina, M. C. Morriss, T. Zhou, E. Holmes, C. C. Lau, A. J. Gajjar
- Brd. 42B** **Phase I study of single-agent perifosine for recurrent pediatric solid tumors. (Abstract #9540)**
O. J. Becher, T. M. Trippett, J. Kolesar, S. Gilheaney, Z. Jiang, Y. Khakoo, D. Lyden, C. Sima, E. C. Holland, I. J. Dunkel
- Brd. 42C** **Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma. (Abstract #9541)**
B. Geoerger, M. W. Kieran, S. Grupp, S. Blaney, D. Perek, J. Clancy, M. Krygowski, J. Boni, A. Berkenblit, S. L. Spunt
- Brd. 42D** **Effect of hypothalamic/pituitary radiation exposure in low doses on fertility in female childhood cancer survivor study (CCSS) participants. (Abstract #9542)**
D. M. Green, V. G. Nolan, T. Kawashima, M. Stovall, S. S. Donaldson, C. A. Sklar, L. L. Robison

Sunday, June 6, 2010

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Gastrointestinal (Colorectal) Cancer

Location: S Hall A2

Tracks(s): Gastrointestinal (Colorectal) Cancer

- Brd. 1A** **PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. (Abstract #3534)**
S. Kopetz, J. Desai, E. Chan, J. R. Hecht, P. J. O'Dwyer, R. J. Lee, K. B. Nolop, L. Saltz
- Brd. 1C** **Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. (Abstract #3536)**
C. H. Lieu, R. A. Wolff, C. Eng, M. J. Overman, L. Henry, R. Coulson, C. R. Garrett, J. L. Abbruzzese, G. E. Gallick, S. Kopetz
- Brd. 1D** **Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC). (Abstract #3537)**
M. B. Sawyer, S. Iqbal, H. Lenz, C. S. Rocha Lima, D. P. Rossignol, I. Krivelevich, J. Fan, A. B. El-Khoueiry
- Brd. 1E** **Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC). (Abstract #3538)**
N. C. Tebbutt, D. Kotasek, H. A. Burris III, L. S. Schwartzberg, H. Hurwitz, J. Stephenson, H. Adewoye, Y. Sun, Y. Ye, D. Goldstein
- Brd. 1F** **Phase II study of bevacizumab (B) plus oxaliplatin (Ox) plus capecitabine (C) followed by bevacizumab (B) plus erlotinib (E) as first-line treatment in metastatic colorectal cancer (mCRC). (Abstract #3539)**
A. Muñoz, C. Pericay, B. Llorente, V. Alonso, R. Dueñas, J. Roca, F. Rivera, E. Falco, I. Alvarez, A. Salud
- Brd. 1G** **Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC). (Abstract #3540)**
N. Moosmann, L. Fischer von Weikersthal, U. Vehling-Kaiser, M. Stauch, H. F. Dietzfelbinger, D. V. Oruzio, S. Klein, S. Stintzing, V. Heinemann
- Brd. 1H** **Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG). (Abstract #3541)**
D. G. Pectasides, I. Xanthakis, T. Makatsoris, E. Samantas, I. Varthalitis, G. Papaxoinis, P. Papakotoulas, E. Bournakis, C. Papandreou, G. Fountzilas
- Brd. 2A** **CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC). (Abstract #3542)**
N. Ziras, A. Polyzos, N. Xenidis, A. Kalykaki, N. E. Androulakis, P. Papakotoulas, N. K. Kentepozidis, P. Makrantonakis, S. Xynogalos, I. Sougklakos
- Brd. 2B** **FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCR): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO). (Abstract #3543)**
A. Falcone, F. Loupakis, S. Cupini, E. Cortesi, A. Buonadonna, G. Tomasello, M. Banzi, M. Ronzoni, A. Zaniboni, G. Masi
- Brd. 2C** **Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983). (Abstract #3544)**
H. Sorbye, M. Mauer, T. Gruenberger, B. Glimelius, G. J. Poston, P. M. Schlag, P. Rougier, J. N. Primrose, E. T. Walpole, B. Nordlinger

- Brd. 2D** **Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Resections and curative surgery in a phase II single arm, multicenter study (20060314). (Abstract #3545)**
Y. Hofheinz, L. Mineur, R. Greil, C. Kohne, H. Letocha, J. Thaler, E. Fernebro, E. Gamelin, L. DeCosta, M. Karthaus, 20060314 Study Group
- Brd. 2E** **Surgical cytoreduction in patients with colorectal peritoneal carcinomatosis treated with contemporary chemotherapy. (Abstract #3546)**
V. G. Gava, D. L. Reidy, P. Paty, L. Saltz, K. Y. Chung, M. R. Weiser, L. K. Temple, N. H. Segal, L. F. Moreira, G. Nash, Colorectal Service, Memorial Sloan-Kettering Cancer Center
- Brd. 2F** **Outcome of 123 patients (pts) with peritoneal carcinomatosis (PC)—Limited metastases from colorectal cancer (CRC) and appendiceal adenocarcinoma (ADC): The British Columbia Cancer Agency (BCCA) experience. (Abstract #3547)**
F. Aubin, S. Gill, C. Speers, H. F. Kennecke
- Brd. 2G** **Outcome of colorectal liver metastases vanishing under chemotherapy and finally missing after surgery. (Abstract #3548)**
S. Gaujoux, D. Goéré, P. Misitano, P. Burtin, F. Dumont, V. Boige, D. Malka, C. Dromain, M. Ducreux, D. Elias
- Brd. 2H** **Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II North Central Cancer Treatment Group study N054C. (Abstract #3549)**
A. Grothey, J. M. Lafky, B. W. Morlan, P. J. Stella, S. R. Dakhil, P. D. Steen, W. S. Loui, B. M. Bot, S. R. Alberts, J. T. Reynolds
- Brd. 3A** **FEB study: Efficacy treatment evaluation in metastatic colorectal cancer (mCRC) patients (pts) changing monoclonal antibody (MA) after progression with chemotherapy. (Abstract #3550)**
R. Grande, G. Cianci, I. Sperduti, D. Gemma, A. Gelibter, M. Giampaolo, L. Mentuccia, F. Narducci, E. Magnolfi, T. Gamucci
- Brd. 3B** **CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) plus cetuximab (Cmab) in unselected advanced colorectal cancer (ACC) patients. (Abstract #3551)**
C. Garufi, A. Torsello, C. Campanella, G. M. Ettore, G. Vennarecci, E. Melucci, M. Zeuli, I. Sperduti, A. Gelibter, F. Cognetti
- Brd. 3C** **Metronomic therapy irinotecan (IRI) capecitabine (CAP) plus bevacizumab (BEV) in treatment of advanced colorectal cancer (ACRC) in very elderly people. (Abstract #3552)**
I. U. Carreca, F. Bellomo, S. L. Burgio, G. Pernice, D. Piazza, L. Balducci
- Brd. 3D** **Phase II trial alternating mFOLFOX 6 and FOLFIRI (FIREFOX) regimens in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0701). (Abstract #3553)**
Y. Akagi, S. Tokunaga, Y. Emi, Y. Kakeji, T. Kusumoto, H. Baba, Y. Ogata, T. Tanaka, K. Shirouzu, Y. Maehara, Kyushu Study Group of Clinical Cancer (KSCC)
- Brd. 3E** **Analysis of prognostic factors for 60-day mortality: Evaluation of a randomized phase III trial investigating FUFIRI versus mIROX as first-line treatment of metastatic colorectal cancer (mCRC). (Abstract #3554)**
C. Giessen, A. Schalhorn, S. Stintzing, V. Heinemann
- Brd. 3F** **Capecitabine (C) and bevacizumab (B) for nonresectable metastatic colorectal cancer (mCRC) patients: Results from phase II AIO 0105 trial. (Abstract #3555)**
A. Kretzschmar, D. M. Behringer, T. Wolff, J. Zimmer, S. Hegewisch-Becker, E. Kettner, K. Pflüger, A. Kirsch, N. Ziegenhagen, D. Arnold

- Brd. 3G** Incidence and risk factors for biliary sclerosis following adjuvant hepatic arterial infusion with floxuridine after hepatectomy for metastatic colorectal cancer. (Abstract #3556)
K. Ito, H. Ito, N. E. Kemeny, M. Gonen, P. Allen, Y. Fong, R. P. DeMatteo, L. H. Blumgart, W. R. Jarnagin, M. I. D'Angelica
- Brd. 3H** A randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. (Abstract #3557)
N. E. Kemeny, W. R. Jarnagin, M. Capanu, Y. Fong, A. Gewirtz, R. P. DeMatteo, M. I. D'Angelica
- Brd. 4A** Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil (FU), leucovorin (LV), and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM) (CHOICE): A multicenter phase II study. (Abstract #3558)
D. Malka, E. Paris, C. Caramella, E. Boucher, R. Guimbaud, A. Celebic, T. De Baere, D. Elias, J. Pignon, M. Ducreux
- Brd. 4B** Unexpected increased biliary toxicity when systemic bevacizumab is added to hepatic arterial infusion. (Abstract #3559)
D. G. Power, M. Capanu, D. Patel, A. Gewirtz, W. R. Jarnagin, Y. Fong, M. I. D'Angelica, R. P. DeMatteo, N. E. Kemeny
- Brd. 4C** Feasibility of neoadjuvant transarterial chemoembolization (TACE) using irinotecan beads (DEBIRI) before hepatectomy (HPX) for easily resectable colorectal liver metastases (RCLM): A phase II study. (Abstract #3560)
G. J. Poston, E. O'Grady, H. Z. Malik, S. W. Fenwick, M. Terlizzo, C. Byrne, M. Rees, J. Figueras, R. Adam
- Brd. 4D** Premedication and incidence of infusion-related reactions in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan-based chemotherapy. (Abstract #3561)
H. Wilke, S. Siena, A. H. Loos, K. Berghoff, C. Kohne, E. Van Cutsem
- Brd. 4E** Use of germ-line polymorphisms in genes involved in the IGF pathway to predict efficacy of cetuximab independent of K-ras in mCRC patients (IMCL-0144). (Abstract #3562)
T. Winder, W. Zhang, D. Yang, Y. Ning, P. O. Bohanes, S. Hu-Lieskovan, D. J. Mauro, C. Langer, E. K. Rowinsky, H. Lenz
- Brd. 4F** Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in advanced rectal cancer. (Abstract #3563)
D. Vallbohmer, P. P. Grimminger, D. Yang, K. D. Danenberg, P. Danenberg, D. Arnold, J. H. Machiels, C. Roedel, V. Velenik, H. Lenz
- Brd. 4G** Early magnesium modifications as a surrogate markers of efficacy of cetuximab-based anticancer treatment in KRAS wild-type colorectal cancer patients. (Abstract #3564)
B. Vincenzi, D. Santini, S. Galluzzo, F. Loupakis, P. Correale, R. Addeo, S. Del Prete, A. Falcone, G. Francini, G. Tonini
- Brd. 4H** Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining. (Abstract #3565^)
M. Peeters, A. Cervantes-Ruiperez, A. Strickland, T. Ciuleanu, P. N. Mainwaring, V. I. Tzekova, A. Santoro, C. W. Johnson, A. Zhang, J. L. Gansert
- Brd. 5A** Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining. (Abstract #3566^)
S. Siena, J. Tabernero, D. Cunningham, P. Koralewski, P. Ruff, M. Rother, C. W. Johnson, A. Zhang, J. L. Gansert, J. Douillard

- Brd. 5B** **Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC). (Abstract #3567)**
A. Sood, D. McClain, R. Seetharam, M. Al-rahamneh, A. Kaubisch, L. Rajdev, K. Tanaka, J. Mariadason, S. Goel
- Brd. 5C** **Relationship between K-Ras mutational status and EGFR expression evaluated using Allred score in primary and metastatic colorectal cancer. (Abstract #3568)**
E. Melucci, S. Conti, M. G. Diodoro, A. Torsello, M. Zeuli, B. Casini, C. Ercolani, F. Cognetti, C. Garufi, M. Mottolese
- Brd. 5D** **Economic impact in the management of dermatologic toxicities (dTs) induced by the epidermal growth factor receptor inhibitor (EGFRI) cetuximab in colorectal cancer. (Abstract #3569)**
J. H. Borovicka, M. F. Mulcahy, C. Calahan, D. P. West, M. E. Lacouture
- Brd. 5E** **Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. (Abstract #3570)**
E. Van Cutsem, I. Lang, G. Folprecht, M. Nowacki, C. Barone, I. Shchepotin, J. Maurel, D. Cunningham, I. Celik, C. Kohne
- Brd. 5F** **Impact of the amount of tumor cells in tissue samples for detection of KRAS mutations in colorectal cancer. (Abstract #3571)**
J. Selves, D. Grand, R. Guimbaud, K. Gordien, S. Valmary, E. Delabesse, M. Danjoux, E. Tournier, S. Kirzin, P. Brousset
- Brd. 5G** **KRAS mutation testing in patients with metastatic colorectal carcinoma: An 18-month experience emphasizing the risk of false-negative results. (Abstract #3572)**
F. Bibeau, H. Frugier, E. Crapez, P. Lamy, M. Ychou, F. Boissière-Michot
- Brd. 5H** **Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy. (Abstract #3573)**
B. V. Jensen, J. V. Schou, H. H. Johannesen, I. J. Christensen, D. Nielsen, J. S. Johansen, E. V. Høgdall, O. Larsen, M. Yilmaz, P. Pfeiffer
- Brd. 6A** **Predictive role of carcinoembryonic antigen (CEA) for therapeutic efficacy of angiogenesis-targeting therapy in colorectal cancer: Novel clinical observation based upon recently discovered CEA biology. (Abstract #3574)**
K. H. Bramswig, G. W. Prager, A. Martel, G. Heinze, B. R. Binder, T. Brodowicz, G. Kornek, W. Scheithauer, C. Zielinski
- Brd. 6B** **Bevacizumab-induced changes in small arterial dilatation measured in vivo by dynamic retinal vessel analysis. (Abstract #3575)**
G. Folprecht, K. Trautmann, M. Reimann, R. Haase, F. Ziemssen, G. Ehninger, H. Reichmann, T. Ziemssen
- Brd. 6C** **Gene expression profiles to predict outcome following liver resection in patients with metastasis of colorectal cancer. (Abstract #3576)**
H. Ito, Q. Mo, A. V. Maker, Q. Li-Xuan, P. Allen, R. P. DeMatteo, Y. Fong, L. H. Blumgart, W. R. Jarnagin, M. I. D'Angelica
- Brd. 6D** **Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer. (Abstract #3577)**
B. Chibaudel, C. Tournigand, F. Bonnetain, T. Andre, G. Lledo, F. Maindault-Goebel, A. K. Larsen, C. Louvet, A. de Gramont
- Brd. 6E** **Selecting colorectal cancer (CRC) patients for therapy based on mutational analysis by next generation sequencing: Are we analyzing the appropriate tumor? (Abstract #3578)**
J. S. Vermaat, I. J. Nijman, F. L. Gerritse, M. Mokry, W. M. Roessingh, M. Koopman, P. J. van Diest, E. Cuppen, E. E. Voest

- Brd. 6F Association between deficient mismatch repair system and efficacy to irinotecan containing first-line chemotherapy in patients with sporadic metastatic colorectal cancer. (Abstract #3579)**
J. Kim, Y. Hong, J. Lee, M. Ryu, H. Chang, S. Jang, M. Kim, C. Yu, T. Kim
- Brd. 6G Detector-C: A blood-based IVD with high sensitivity and specificity for early detection of colorectal cancer. (Abstract #3580)**
A. Rosenthal, D. Nuernberg, M. Pross, J. Pertschy, P. Nartschik, T. Manger, B. Unger, W. Pommerien, H. Adams
- Brd. 6H Correlation between bevacizumab-related hypertension and response in mCRC patients. (Abstract #3581)**
A. De Stefano, L. Cannella, C. Carlomagno, A. Crispo, R. Bianco, R. Marciano, S. Pepe, S. De Placido
- Brd. 7A Personalized adjuvant chemotherapy for colorectal cancer based on an individual 50% inhibitory area under the concentration curve using collagen gel droplet embedded culture-drug sensitivity test. (Abstract #3582)**
T. Ochiai, K. Nishimura, T. Watanabe, M. Kitajima, T. Hashiguchi, A. Nakatani, A. Muraki, N. Sakuyama, S. Futagawa, I. Nagaoka
- Brd. 7B Genetic polymorphism associated with chronic neurotoxicity and recurrence in curatively-resected colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. (Abstract #3583)**
S. Lee, H. Won, E. Son, J. Lee, S. Park, J. Park, Y. Park, H. Lim, W. Kang
- Brd. 7C Are MGMT promoter methylation and EGFR mutations early markers of tumor progression in colorectal cancer? (Abstract #3584)**
T. Wenner, B. Metzger, L. Chambeau, G. Mahon, M. Pauly, J. Kaiser, G. J. Berchem, M. Dicato
- Brd. 7D Prospective study of paresthetic neurotoxicity from oxaliplatin-based regimens in the treatment of colorectal cancer. (Abstract #3585)**
X. S. Wang, D. R. Fogelman, C. Eng, M. Malekifar, R. J. Reynolds, N. A. Shah, T. R. Mendoza, K. Y. Glover, P. M. Dougherty, C. S. Cleeland
- Brd. 7E Prognostic values of micrnas in patients with Dukes' B and C colon cancer. (Abstract #3586)**
M. Karaayvaz, T. Pal, B. Song, C. Zhang, P. Geogakopoulos, S. Mehmood, S. Burke, K. Shroyer, J. Ju
- Brd. 7F Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting. (Abstract #3587)**
A. Koutras, A. Antonacopoulou, F. Fostira, E. C. Briasoulis, I. Sgouros, A. Koumariou, N. Xiros, C. Christodoulou, G. Fountzilas, H. Kalofonos
- Brd. 7G New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC). (Abstract #3588)**
E. Budinska, M. Delorenzi, W. De Rooock, B. Jacobs, S. Walker, C. Wilson, T. Davison, R. D. Kennedy, S. Tejpar
- Brd. 7H Analysis of EGFR pathway mediators in KRAS wild-type primary tumors is not representative of their status in related metastases. (Abstract #3589)**
P. Cejas, M. Lopez-Gomez, C. Aguayo, R. Madero, J. De Castro, C. Belda-Iniesta, J. Barriuso, E. Burgos, M. Gonzalez-Baron, J. Feliu
- Brd. 8A Association of GRP78 polymorphisms with response and TTP in patients with mCRC treated with FOLFOX/BV or XELOX/BV. (Abstract #3590)**
H. Lenz, W. Zhang, D. Yang, A. B. El-Khoueiry, Y. Ning, A. Pohl, P. O. Bohanes, K. D. Danenberg, T. Wang
- Brd. 8B Lessons from PETACC 2: No prognostic impact of KRAS/BRAF-status in stage III colon cancer treated with adjuvant 5-FU monotherapy. (Abstract #3591)**
D. E. Aust, M. P. Lutz, M. Mauer, I. Popov, G. B. Baretton, L. Bedenne, A. Carrato, C. Kohne

- Brd. 8C** Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers. (Abstract #3592)
B. Tran, S. Kopetz, J. Tie, P. Gibbs, Z. Jiang, C. H. Lieu, A. Agarwal, D. Maru, O. Sieber, J. Desai
- Brd. 8D** Number of lymph nodes examined and prognosis among pathologically node-negative patients after preoperative chemoradiation for rectal cancer. (Abstract #3593)
C. Tsai, C. H. Crane, J. M. Skibber, M. A. Rodriguez-Bigas, G. J. Chang, B. W. Feig, C. Eng, M. E. Delclos, S. Krishnan, P. Das
- Brd. 8E** Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study. (Abstract #3594)
E. Terrebbonne, D. Smith, Y. Becouarn, P. Michel, R. Guimbaud, D. Auby, A. sa Cunha, A. Ravaud, M. Rouyer, A. Fourrier-Réglat, ETNA Study Group
- Brd. 8F** Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS). (Abstract #3595)
T. S. Bekaii-Saab, J. C. Bendell, A. L. Cohn, H. Hurwitz, M. Kozloff, N. Roach, H. Tezcan, S. Feng, A. Sing, A. Grothey, on behalf of the ARIES Study Investigators
- Brd. 8G** Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). (Abstract #3596)
A. L. Cohn, T. Bekaii-Saab, J. C. Bendell, H. Hurwitz, M. Kozloff, N. Roach, H. Tezcan, S. Feng, A. Sing, A. Grothey, on behalf of the ARIES Study Investigators
- Brd. 8H** Molecular classes in CRC: Characterization of MSI by expression profiling in the translational study of the PETACC 3-EORTC 40993-SAKK 60-00 trial. (Abstract #3597)
M. Delorenzi, E. Budinska, V. Popovici, H. Estrella, A. Pavlicek, P. Yan, S. Weinrich, F. Bosman, S. Tejpar, A. Roth
- Brd. 9A** Impact of ethnicity and insurance on colorectal cancer outcomes. (Abstract #3598)
K. B. Young, J. D. Acoba
- Brd. 9B** Use of day 4 CEP and baseline CXCR4 plus CEC as predictive markers for bevacizumab in mCRC. (Abstract #3599)
S. Matsusaka, Y. Mishima, M. Suenaga, K. Takagi, E. Shinozaki, Y. Terui, N. Mizunuma, K. Hatake
- Brd. 9C** Use of a four gene panel of epigenetic markers to classify serrated colonic adenomas with CpG island methylator phenotype. (Abstract #3600)
J. Jenab-Wolcott, Y. Yao, W. Yan, S. Schulte, S. Harada, C. Brensinger, B. J. Giantonio, A. Rustgi, A. Sepulveda
- Brd. 9D** Prognostic factors for actual 5-year survivors after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal surface disease. (Abstract #3601)
P. Shen, G. Watson, J. H. Stewart IV, T. P. McCoy, E. A. Levine
- Brd. 9E** Global microRNA expression and survival in patients with metastatic colorectal cancer in third-line treatment with cetuximab and irinotecan. (Abstract #3602)
J. V. Schou, J. S. Johansen, B. V. Jensen, D. L. Nielsen, M. Kruhøffer
- Brd. 9F** Incidence of diagnosed VTE among elderly Americans in the year following stage III or IV colon cancer diagnosis. (Abstract #3603)
C. D. Mullins, K. A. Bikov, N. C. Onwudiwe, B. S. Seal, N. Hanna

Sunday, June 6, 2010

- Brd. 9G Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of over 6,000 patients in randomized phase II and III studies. (Abstract #3604)**
J. Cassidy, L. Saltz, E. Van Cutsem, E. E. Hedrick, S. Lasserre, F. Sirzen, U. P. Rohr, H. Hurwitz
- Brd. 9H Adjuvant chemotherapy for colorectal cancer in the over 75 age group: A 10-year experience. (Abstract #3605)**
R. M. Bambury, N. H. Coleman, M. M. Tharmabala, D. Gough, W. Grogan, O. S. Breathnach, Department of Medical Oncology
- Brd. 10A Predictors of lymph node count in colon adenocarcinoma. (Abstract #3606)**
K. L. Mathis, R. Pendlimari, E. Green, D. J. Sargent, H. Nelson
- Brd. 10B The number of lymph nodes is influenced by the MSI phenotype in resected colorectal cancers (CRC): A study in a large monocentric series. (Abstract #3607)**
J. Flejou, M. Svrcek, Y. Parc, O. Lascols, C. Colas, C. Louvet, E. Tiret, A. Duval, R. Hamelin
- Brd. 10C Clinicopathologic factors and outcomes associated with lymph node retrieval in resectable colon cancer. (Abstract #3608)**
S. Kanuri, W. Gonsalves, T. Tashi, I. Aldoss, A. R. Sama, I. Al-Howaidi, A. Ganti, P. Townley, S. Subbiah, P. T. Silberstein
- Brd. 10D Clinicopathologic significance of p53, hypoxia-inducible factor 1 alfa, and vascular endothelial growth factor expression in colorectal cancer. (Abstract #3609)**
H. Kwon, S. Kim, S. Oh, S. Lee, K. Kwon, J. H. Lee, H. Choi, K. Park, M. Roh, H. Kim
- Brd. 10E Mutation-based detection of molecular tumor margins in colorectal liver metastasis. (Abstract #3610)**
K. Schmidt, M. Holdhoff, F. Diehl, P. Angenendt, N. Agrawal, K. Judge, K. W. Kinzler, B. Vogelstein, M. A. Choti, L. A. Diaz
- Brd. 10F Safety analysis of FOLFOX4 treatment in advanced/recurrent or adjuvant colorectal cancer in Asian and Western patients. (Abstract #3611)**
K. Sugihara, A. Ohtsu, Y. Shimada, N. Mizunuma, P. Lee, A. De Gramont, R. M. Goldberg, M. L. Rothenberg, T. Andre, S. Brienza
- Brd. 10G Predictor-C: A tissue-based IVD predicting progression of disease in colorectal cancer UICC stages II or III. (Abstract #3612)**
H. Adams, B. Hinzmann, T. Mayr, I. Klaman, A. Rosenthal
- Brd. 10H Oxaliplatin- or irinotecan-based combination therapy versus 5-fluorouracil/leucovorin alone in the treatment of advanced colon cancer patients age 66 and older: An analysis using SEER-Medicare data. (Abstract #3613)**
F. S. Hsiao, C. D. Mullins, N. B. Pandya, E. Onukwugha, B. S. Seal, N. Hanna
- Brd. 11A Analysis of KRAS mutations in colorectal cancer (CRC) patients by gender in a Brazilian cohort of 3,346 patients. (Abstract #3614)**
C. G. Ferreira, I. Zalberg-Renault, F. M. Vieira, M. H. Bonamino, M. Zalis
- Brd. 11B Vitamin D levels and survival in colorectal cancer (CRC). (Abstract #3615)**
K. M. Wesa, G. Jacobs, D. Woo, A. Cronin, N. H. Segal, M. Coleton, L. Saltz, B. R. Cassileth
- Brd. 11F Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978–1995 versus 1996–2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS)—Findings from the ACCENT dataset. (Abstract #3616)**
T. Andre, Q. Shi, G. A. Yothers, B. M. Bot, D. G. Haller, E. Van Cutsem, J. Cassidy, J. Benedetti, M. O'Connell, D. J. Sargent
- Brd. 11G Genetic polymorphism and toxicity of adjuvant FOLFOX-4 chemotherapy in Korean colon cancer patients. (Abstract #3617)**
H. Chang, S. Han, S. Kim, K. Lee, T. Kim, Y. Park, S. Shin, D. Oh, S. Im

- Brd. 11H Reproductive history and risk of colorectal cancer in postmenopausal women. (Abstract #3618)**
A. Zervoudakis, A. Schatzkin, H. D. Strickler, Y. Park, A. Hollenbeck, M. J. Gunter
- Brd. 12A The effect of opposed versus unopposed hormone replacement therapy (HRT) on the risk of colorectal cancer (CRC). (Abstract #3619)**
K. Lin, W. Y. Cheung, J. Y. Lai, E. L. Giovannucci
- Brd. 12B Guideline adherence rates of chemotherapy treatment for colon cancer patients treated in U.S. community oncology practices. (Abstract #3620)**
Z. Wang, K. A. Bergstrom, I. Aksamit, L. Tuscher, T. Lam, B. S. Tom, C. G. Baker, K. B. Whitlock, Z. Ansari-Jaberi, M. Mayo
- Brd. 12F Presurgical diagnostic accuracy of five imaging procedures in chemotherapy-naive (group A) or chemotherapy-pretreated (group B) patients with colorectal liver metastases (Italian PROMETEO Study). (Abstract #3621)**
F. L. Rojas Llimpe, F. Di Fabio, G. Ercolani, C. Serra, P. Castellucci, S. Pini, V. Mutri, R. Golfieri, A. Martoni, C. Pinto
- Brd. 12G Dietary grape-derived resveratrol for colon cancer prevention. (Abstract #3622)**
M. Martinez, C. Hope, K. Planutis, M. Planutiene, A. Pontello, B. Duarte, C. G. Albers, R. F. Holcombe
- Brd. 12H Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer. (Abstract #3623)**
D. Villa, L. Hedden, S. Peacock, H. F. Kennecke
- Brd. 13A Association of survival outcomes with dose intensity of adjuvant therapy (AT) with capecitabine for colorectal cancer (CRC). (Abstract #3624)**
J. Ho, S. Gill, R. Woods, H. F. Kennecke
- Brd. 13B Characterize medical care during disease phases in metastatic colorectal cancer. (Abstract #3625)**
X. Song, B. Barber, Z. Zhao, C. Gregory, Z. Cao
- Brd. 13C Use of an electronic health record (iKnowMed), in conjunction with evidence-based pathways, for data capture and outcome measurement in colorectal cancer patients treated with first-line therapy in the US Oncology Network. (Abstract #3626)**
T. H. Cartwright, M. Clayton, J. S. Garey, K. A. Boehm
- Brd. 13D Spectrum of colon polyposis and colonic neoplasia in the PTEN hamartoma tumor syndrome (PHTS). (Abstract #3627)**
P. P. Stanich, S. Khambatta, S. R. Sweetser, R. L. Richardson, M. P. Goetz, M. M. Patnaik
- Brd. 13E Treatment patterns in patients with colorectal liver metastasis: A cohort study. (Abstract #3628)**
D. A. Anaya, P. A. Richardson, D. Albo, A. Artinyan, N. J. Petersen, S. S. Awad, D. H. Berger, J. N. Cormier
- Brd. 13F The awareness and knowledge levels of colorectal cancer (CRC) patients and their first-degree relatives (FDR) for CRC screening. (Abstract #3629)**
C. Arslan, S. Kilickap, D. Rama, S. Yalcin
- Brd. 13G To detect Lynch syndrome patients, which colorectal cancers should be tested for microsatellite instability? (Abstract #3630)**
B. M. Boman, K. Orio, N. J. Petrelli, M. Parker, C. Somerman, Z. Ali-Khan Catts
- Brd. 13H A novel, noninvasive, mRNA gene expression colon cancer screening methodology. (Abstract #3631)**
L. A. Boardman, Y. S. Chiu, O. Petruskane, L. Wiczorek, D. H. Moore, K. V. Ballman, S. N. Thibodeau, H. Nelson
- Brd. 14A Results of a German noninterventional study (NIS) of cetuximab-based therapy in pretreated patients (pts) with metastatic colorectal cancer (mCRC). (Abstract #3632)**
C. Jehn, K. Stenzel, L. Böning, H. Kröning, K. Possinger, D. Lueftner

Sunday, June 6, 2010

- Brd. 14B** Timing of failure of resected rectal cancer: What is the appropriate duration of postoperative imaging? (Abstract #3633)
K. Fischkoff, J. Juan, L. Saltz, E. Riedel, M. R. Weiser, G. Nash, L. K. Temple, P. Paty, W. D. Wong, J. G. Guillem
- Brd. 14C** Preoperative chemoradiotherapy (QRT) and total mesorectal excision (TME) by laparoscopy (LPS) in rectal cancer (RC): Long-term outcomes. (Abstract #3634)
E. Pineda, X. Garcia-Albeniz, S. Delgado, C. Conill, A. Gines, J. Ayuso, R. Gallego, M. Cuatrecasas, A. Lacy, J. Maurel
- Brd. 14D** A randomized phase II trial of preoperative chemoradiotherapy with or without cetuximab in locally advanced adenocarcinoma of the rectum. (Abstract #3635)
A. D. McCollum, D. M. Kocs, P. Chada, D. A. Richards, Y. Wang, K. A. Boehm, L. Asmar, L. Munoz
- Brd. 14E** Preoperative chemoradiation (CRT) with concurrent capecitabine and irinotecan in MRI-defined locally advanced rectal cancer: Relationship of histologic downstaging to long-term survival end points. (Abstract #3636)
S. W. Gollins, S. Myint, S. Susnerwala, M. Wise, B. J. Haylock, M. P. Saunders, R. Neupane, C. Topham, L. M. Samuel, E. L. Levine
- Brd. 14F** Chemotherapy induction followed by preoperative chemoradiation versus preoperative chemoradiation alone in locally advanced rectal cancer (LARC): A randomized controlled phase II study. (Abstract #3637)
R. Maréchal, B. Vos, M. Polus, T. Delaunoit, M. Peeters, P. Demetter, P. Van Houtte, A. Demols, J. Van de Stadt, J. Van Laethem
- Brd. 14G** Short-course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer: A phase II multicenter study of the Dutch Colorectal Cancer Group. (Abstract #3638)
T. H. van Dijk, K. Havenga, J. Beukema, G. L. Beets, H. Gelderblom, K. P. de Jong, H. J. Rutten, C. J. Van De Velde, T. Wiggers, G. Hospers
- Brd. 14H** Effect of preoperative radiotherapy on local recurrences in rectal cancer patients with *PIK3CA* mutation. (Abstract #3639)
Y. He, L. van 't Veer, M. Lopez Yurda, I. Mikolajewska-Hanclich, I. D. Nagtegaal, C. J. Van De Velde, C. A. Marijnen
- Brd. 15A** Association of intratumoral gene expression levels of thymidine phosphorylase (TP) and VEGF with clinical outcome in stage II/III rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III intergroup trial (SWOG 9304). (Abstract #3640)
R. D. Ladner, C. M. Ulrich, C. J. Rankin, K. D. Danenberg, P. V. Danenberg, S. R. Smalley, K. W. Makar, J. K. Benedetti, C. D. Blanke, H. Lenz
- Brd. 15B** Use of EGF a+61G and TS-5'UTR 2R/3R polymorphisms to predict complete pathologic response in locally advanced rectal cancer patients undergoing preoperative cetuximab-based chemoradiation followed by surgery. (Abstract #3641)
S. Hu-Lieskovan, D. Yang, P. P. Grimminger, D. Arnold, K. Dellas, J. H. Machiels, C. Roedel, V. Velenik, H. Lenz, D. Vallbohmer
- Brd. 15C** Predictors of site-specific recurrence following combined modality therapy for locally advanced rectal cancer. (Abstract #3642)
P. Ding, D. Liska, K. A. Goodman, L. Saltz, J. G. Guillem, P. Paty, L. K. Temple, G. M. Nash, W. D. Wong, M. R. Weiser
- Brd. 15D** Correlation of single nucleotide polymorphisms (SNPs) of hypoxia-related genes with pathologic complete response (pCR) following neoadjuvant chemoradiation (chemoXRT) for locally advanced rectal cancer. (Abstract #3643)
M. Tanaka, I. Bedrosian, G. J. Chang, Y. N. You, P. Das, D. Li, M. A. Rodriguez-Bigas, J. M. Skibber, J. L. Abbruzzese, C. Eng

- Brd. 15E** **Patterns of recurrence in rectal cancer treated with neoadjuvant chemoradiotherapy and TME. (Abstract #3644)**
D. Liska, P. Ding, K. A. Goodman, L. Saltz, J. G. Guillem, P. Paty, L. K. Temple, G. M. Nash, W. D. Wong, M. R. Weiser
- Brd. 15G** **Local excision after neoadjuvant chemoradiation for rectal cancer: Is it an acceptable treatment option? (Abstract #3646)**
B. Brenner, R. Brenner, O. Puirn, N. Peled, E. Idelevich, B. Nisenbaum, E. Fenig, A. Sulkes
- Brd. 15H** **Multimodal salvage therapy for locally recurrent and re-recurrent rectal cancer. (Abstract #3647)**
Y. You, E. A. Choi, J. M. Skibber, M. A. Rodriguez-Bigas, B. W. Feig, C. Eng, C. H. Crane, P. Das, G. J. Chang
- Brd. 16A** **Plasma levels of total RNA and hTERT mRNA as biomarkers of response in rectal cancer patients receiving preoperative chemoradiotherapy. (Abstract #3648)**
S. Pucciarelli, E. Rampazzo, M. Briarava, L. Serra, C. Bedin, S. Lonardi, C. Mescoli, M. Digito, A. De Rossi, D. Nitti
- Brd. 16B** **Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. (Abstract #3649)**
A. Cercek, M. R. Weiser, K. A. Goodman, D. L. Reidy, W. D. Wong, J. G. Guillem, L. K. Temple, D. Schrag, P. Paty, L. Saltz
- Brd. 16C** **KRAS mutation status and clinical outcome of preoperative chemoradiation (CRT) with or without cetuximab in locally advanced rectal cancer (LARC): A pooled analysis of two phase II trials. (Abstract #3650)**
S. Kim, E. Shim, H. Yeo, Y. Hong, D. Kim, T. Kim, J. Kim, S. Im, K. Jung, H. Chang
- Brd. 16D** **Quantitative assessment of tumor cell density in rectal cancer following three different preoperative therapies compared to surgery alone. (Abstract #3651)**
N. West, H. Grabsch, D. Treanor, D. Sebag-Montefiore, H. Thorpe, D. Jayne, H. Rutten, H. A. Swellengrebel, I. D. Nagtegaal, P. Quirke
- Brd. 16E** **Relationship of completion of planned treatment and timing of adjuvant chemotherapy to survival in patients with colorectal cancer (CRC). (Abstract #3652)**
S. Ahmed, I. Ahmad, T. Zhu, S. K. Yadav, F. M. Arnold, K. Haider, R. Alvi, A. Sami
- Brd. 16F** **EGFR, PTEN, and survivin expression in pre- and posttherapeutic specimens does not predict a clinical benefit from preoperative chemoradiation with cetuximab in patients (pts) with locally advanced rectal cancer (LARC). (Abstract #3653)**
K. Dellas, F. Roedel, D. Arnold, M. Kappler, M. Hipp, F. Bataille, D. Vordermark, C. Roedel, A. Hartmann
- Brd. 16G** **Evaluation of serum/plasma VEGF/e-selectin and 18F-FDG PET uptake after panitumumab infusion in locally advanced rectal cancer (LARC) patients treated with chemoradiation (CTR) (StarPan/STAR-02 phase II study). (Abstract #3654)**
S. Pini, F. Di Fabio, P. Di Tullio, E. Bucca, T. Latiano, E. Perrone, M. Gion, E. Maiello, A. Martoni, C. Pinto
- Brd. 16H** **Treatment of rectal carcinoid tumors and role of preoperative imaging. (Abstract #3655)**
T. Akasu, K. Sato, S. Yamamoto, T. Matsuda, Y. Saito
- Brd. 17A** **Do older Americans undergo stoma reversal following low anterior resection for rectal cancer? (Abstract #3656)**
C. M. Dodgion, B. A. Neville, S. R. Lipsitz, D. Schrag, C. C. Greenberg
- Brd. 17B** **Bowel dysfunction after sphincter-preserving surgery. (Abstract #3657)**
L. K. Temple, S. Patil, P. Paty, M. R. Weiser, G. Nash, J. G. Guillem, K. A. Goodman, W. D. Wong, D. Schrag

Sunday, June 6, 2010

- Brd. 17C** **The prognostic significance of tumor human papillomavirus status in patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. (Abstract #3658)**
H. Yhim, E. Song, N. Lee, J. Hwang, H. Shim, I. Chung, H. Park, M. Park, C. Yim

SUNDAY

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Gastrointestinal (Noncolorectal) Cancer

Location: S Hall A2

Tracks(s): Gastrointestinal (Noncolorectal) Cancer

- Brd. 18A** **Linifanib phase II trial in patients with advanced hepatocellular carcinoma (HCC). (Abstract #4038)**
H. Toh, P. Chen, B. I. Carr, J. J. Knox, S. Gill, J. Qian, Q. Qin, J. L. Ricker, D. M. Carlson, W. Yong
- Brd. 18B** **Phase III study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. (Abstract #4039)**
M. M. Javle, G. R. Varadhachary, R. T. Shroff, P. Bhosale, M. J. Overman, J. Weatherly, R. A. Wolff, J. L. Abbruzzese
- Brd. 18C** **Clinicopathologic characteristics of microsatellite instability (MSI) tumors in resected gastric cancer patients. (Abstract #4040)**
H. J. Cho, J. Kim, S. Im, M. Kim, S. Han, D. Oh, T. Kim, H. Yang, W. Kim, Y. Bang
- Brd. 18D** **Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle as second-line treatment for advanced or recurrent gastric cancer. (Abstract #4041)**
K. Chin, K. Kato, T. Yoshikawa, K. Yamaguchi, T. Esaki, Y. Tsuji, K. Sakai, M. Kimura, R. Ikeda, Y. Matsumura
- Brd. 18E** **Meta-analyses of randomized trials assessing the effect of neoadjuvant chemotherapy in locally advanced gastric cancer. (Abstract #4042)**
H. Li, F. Zhu, Y. Cao, L. Zhai, T. Lin
- Brd. 18F** **KRAS, BRAF mutations, and HER2 expression in patients operated for pancreatic adenocarcinomas. (Abstract #4043)**
N. A. Schultz, A. Roslind, M. Heeran, I. J. Christensen, E. V. Høgdall, T. Horn, M. Wøjdemann, E. Balslev, J. S. Johansen
- Brd. 18G** **Prospective analysis of clinical outcomes and prognostic factors in patients with neuroendocrine tumors (NETs). (Abstract #4044)**
M. Ter-Minassian, C. S. Fraumeni, S. M. Hooshmand, K. Asomaning, X. Lin, J. A. Chan, D. C. Christiani, M. Kulke
- Brd. 18H** **Comparative effectiveness of radioembolization and the standard of care for hepatocellular carcinoma: Is a randomized survival study feasible? (Abstract #4045)**
R. Salem, A. Riaz, R. Lewandowski, L. Kulik, M. Abecassis, M. F. Mulcahy
- Brd. 19A** **Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study. (Abstract #4046)**
A. O. Kaseb, J. Morris, M. Hassan, M. Iwasaki, L. Deaton, M. M. Javle, E. Garrett-Mayer, G. Onicescu, J. L. Abbruzzese, M. B. Thomas
- Brd. 19B** **Association of germline polymorphisms in genes involved in the CD44 pathway and clinical outcome in localized gastric adenocarcinoma (GA). (Abstract #4047)**
Y. Ning, T. Winder, D. G. Power, D. Yang, W. Zhang, P. O. Bohanes, G. Lurje, L. H. Tang, M. A. Shah, H. Lenz
- Brd. 19C** **(Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. (Abstract #4048)**
H. C. Chung, Y. Bang, E. Van Cutsem, Y. Kang, Y. Hamamoto, V. Moiseyenko, E. Gotovkin, A. Urspruch, P. Ducourneau

- Brd. 19D** **Setting the standard for advanced pancreatic ductal adenocarcinoma (A-PDAC) in 2010: Meta-regression and power analysis of phase III randomized clinical trials (RCT) evaluating gemcitabine (GEM) in combination with cisplatin (CIS), oxaliplatin (L-OHP), or capecitabine (CAP). (Abstract #4049)**
I. Sperduti, E. Bria, D. Giannarelli, M. Di Maio, A. Gelibter, V. Vaccaro, F. Cuppone, F. Cognetti, M. Milella
- Brd. 19E** **Final results of a phase II study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ). (Abstract #4050)**
Z. A. Wainberg, L. Lin, B. DiCarlo, K. M. Dao, R. Patel, D. J. Park, R. Elashoff, N. Ryba, J. R. Hecht
- Brd. 19F** **Efficacy and safety of sorafenib (Sor) in patients (Pts) with advanced hepatocellular carcinoma (HCC): Subgroup analyses of the SHARP trial by baseline (BL) transaminase (ALT/AST)/ α -fetoprotein (AFP) and bilirubin (bil) levels. (Abstract #4051[^])**
J. Raoul, M. Sherman, A. Nadel, G. Lentini, M. M. Moscovicci, D. Voliotis, G. Meinhardt, J. Bruix, J. M. Llovet
- Brd. 19G** **Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). (Abstract #4052)**
H. Takiuchi, H. Fukuda, N. Boku, Y. Shimada, J. Nasu, Y. Hamamoto, S. Hironaka, K. Yamaguchi, A. Takashima, A. Ohtsu, Japan Clinical Oncology Group
- Brd. 19H** **A multicenter randomized phase II (rPII)/III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303). (Abstract #4053)**
M. Shinoda, N. Ando, H. Kato, Y. Tsubosa, K. Minashi, G. Watanabe, K. Ikeda, T. Kawano, K. Nakamura, H. Fukuda
- Brd. 20A** **Association of germline polymorphism in the SPARC gene and tumor recurrence in patients with resected gastric cancer. (Abstract #4054)**
P. M. Wilson, T. Winder, D. G. Power, D. Yang, W. Zhang, Y. Ning, P. O. Bohanes, L. H. Tang, M. A. Shah, H. Lenz
- Brd. 20B** **Ten-year experience of percutaneous radiofrequency ablation for hepatocellular carcinoma. (Abstract #4055)**
S. Shiina, R. Tateishi, T. Goto, Y. Kondo, E. Goto, R. Masuzaki, H. Nakagawa, F. Kanai, H. Yoshida, K. Koike
- Brd. 20C** **An analysis of the effect of smoking status on erlotinib pharmacokinetics (PKs), toxicity, and ability to dose escalate in a phase II study of erlotinib in advanced pancreatic cancer (PC). (Abstract #4056)**
D. J. Renouf, P. A. Tang, E. X. Chen, R. Ho, L. Lourenco, L. Wang, M. J. Moore
- Brd. 20D** **Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. (Abstract #4057)**
T. Satoh, Y. Bang, J. Wang, J. Xu, H. C. Chung, K. Yeh, J. Chen, A. Mukaiyama, P. Yoshida, A. Ohtsu
- Brd. 20E** **A multicenter phase II trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. (Abstract #4058)**
T. Ioka, M. Ikeda, Y. Ito, N. Yonemoto, M. Nagase, K. Yamao, H. Miyakawa, K. Sato, T. Sato, T. Okusaka
- Brd. 20F** **Effect of hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survival: Preliminary analysis of phase II data. (Abstract #4059)**
J. M. Hardacre, M. F. Mulcahy, M. Talamonti, J. C. Obel, C. S. Rocha Lima, H. Safran, G. R. Rossi, L. Tennant, N. N. Vahanian, C. J. Link, NewLink Genetics

- Brd. 20G** **Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer. (Abstract #4060)**
V. Heinemann, M. P. Ebert, T. Pinter, P. Bevan, N. G. Neville, C. Mala
- Brd. 20H** **Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): Results from combined analysis of JCOG9205 and JCOG9912. (Abstract #4061)**
A. Takashima, N. Boku, K. Kato, J. Mizusawa, K. Nakamura, H. Fukuda, K. Shirao, Y. Shimada, A. Ohtsu
- Brd. 21A** **A single-institution (MSKCC) analysis of incidence and clinical outcomes in patients with thromboembolic events and exocrine pancreas cancer. (Abstract #4062)**
A. S. Epstein, C. Crosbie, S. Gardos, G. A. Soff, M. A. Shah, D. P. Kelsen, E. M. O'Reilly
- Brd. 21B** **Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy. (Abstract #4063)**
Y. Shao, Z. Lin, T. Chen, C. Hsu, Y. Shen, A. Cheng
- Brd. 21C** **E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus. (Abstract #4064)**
M. K. Gibson, P. J. Catalano, L. Kleinberg, C. A. Staley, E. Montgomery, W. Song, M. F. Mulcahy, L. P. Leichman, A. B. Benson
- Brd. 21D** **Prognostic significance of xCT gene single nucleotide polymorphisms (SNPs) in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (GEM) plus platinum analogues (PLAT). (Abstract #4065)**
T. J. Huang, D. Li, J. Weatherly, H. Tang, P. W. Gout, R. A. Wolff, J. L. Abbruzzese, M. M. Javle
- Brd. 21E** **Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: A randomized phase II trial. (Abstract #4066)**
S. Cascinu, R. Berardi, A. F. Sobrero, R. Labianca, P. Bidoli, S. Siena, D. Ferraris, S. Barni, R. Cengarle, M. Monteforte
- Brd. 21F** **Significance of pathologic response to preoperative therapy in pancreatic cancer. (Abstract #4067)**
Y. S. Chun, H. S. Cooper, J. C. Watson, J. P. Hoffman
- Brd. 21H** **Predictive value of restaging after induction concurrent chemoradiotherapy (CCRT) for locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastroesophageal junction (GEJ). (Abstract #4069)**
B. E. Phillips, D. J. Adelstein, T. W. Rice, L. A. Rybicki, C. P. Rodriguez, G. M. Videtic, J. P. Saxton, S. C. Murthy, D. P. Mason, D. I. Ives
- Brd. 22A** **Trastuzumab and capecitabine in patients with HER2-expressing metastatic pancreatic cancer: A multicenter phase II study of the German AIO Pancreatic Cancer Group (AIO PK-0204). (Abstract #4070)**
M. Geissler, R. Hofheinz, M. H. Moehler, M. Bitzer, S. H. Boeck, A. Reinacher-Schick, V. Heinemann, J. Harder
- Brd. 22B** **Is minimally invasive oesophagectomy for cancer decreasing pulmonary complications? Results from a case-control study. (Abstract #4071)**
N. Briez, G. Piessen, A. Claret, J. Triboulet, C. Mariette
- Brd. 22C** **Multicenter phase II study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma: The Asia-Pacific Hepatocellular Carcinoma Trials Group Protocol 05 (AHCC05). (Abstract #4072)**
P. K. Chow, D. Poon, K. M. Win, H. Singh, H. S. Han, A. Goh, S. Choo, R. H. Lo, S. B. Tan, K. C. Soo, Asia-Pacific Hepatocellular Carcinoma Trials Group
- Brd. 22D** **Phase II trials (P2T) in advanced pancreatic cancer (APC): Systematic review with focus on the design, entry criteria, and endpoints used. (Abstract #4073)**
A. Stathis, D. J. Renouf, M. J. Moore

- Brd. 22E** **Extended safety and efficacy data on triple combination therapy using S-1, cisplatin, and paclitaxel in patients with advanced gastric cancer in a multicenter phase II study. (Abstract #4074)**
H. Iwase, K. Ina, H. Goto, J. Haruta, T. Kumada, M. Shinoda, M. Sugihara, T. Tsuzuki, M. Shimada
- Brd. 22F** **Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: Safety and response results from a multicenter phase II trial. (Abstract #4075)**
L. E. Ferri, S. Ades, T. Alcindor, V. Marcus, M. Hickeson, G. Artho, M. R. Chasen, M. P. Thirlwell
- Brd. 22G** **A phase II randomized double blind multicenter trial of gemcitabine (Gem) plus imexon (IMX) versus Gem plus placebo (P) in patients with chemotherapy-naïve pancreatic adenocarcinoma (PC). (Abstract #4076)**
S. J. Cohen, M. M. Zalupski, P. Conkling, F. W. Nugent, W. Ma, M. Modiano, R. A. Pascual, F. Lee, L. Wong, E. Hersh
- Brd. 22H** **The impact of socioeconomic status upon specialist consultation, treatment, and outcomes for pancreatic adenocarcinoma. (Abstract #4077)**
J. E. Carroll, M. M. Murphy, J. K. Smith, J. P. Simons, S. Ng, Z. Zhou, J. F. Tseng
- Brd. 23A** **Registry of Gastric Cancer Treatment Evaluation (REGATE): Regional differences in surgical approaches. (Abstract #4078)**
M. Ter-Ovanesov, J. Kulig, F. Munasyrov, Y. Bang, S. Yalcin, A. Roth, J. R. Zalberg, E. B. Ecstein-Fraïssé, C. Wu
- Brd. 23B** **Comorbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC): Results from NCIC CTG PA.3-A phase III trial of erlotinib plus gemcitabine (E+G) versus gemcitabine (G) alone. (Abstract #4079)**
M. M. Vickers, E. D. Powell, T. R. Asmis, D. J. Jonker, C. J. O'Callaghan, D. Tu, W. Parulekar, M. J. Moore
- Brd. 23C** **Hereditary gastric cancer caused by germline CDH1 gene mutations in the Netherlands. (Abstract #4080)**
I. Kluijft, E. Siemerink, M. Ausems, M. Ligtenberg, D. de Jong, R. Sijmons, J. T. Plukker, R. van. Hillegersberg, A. Cats, N. Hoogerbrugge, The Dutch Working Group on Hereditary Gastric Cancer
- Brd. 23D** **Early toxicity of sunitinib as a potential predictive biomarker in advanced hepatocellular carcinoma (HCC) patients. (Abstract #4081)**
G. D. Duda, M. Ancukiewicz, J. W. Clark, R. A. Miksad, C. Fuchs, D. P. Ryan, R. K. Jain, A. X. Zhu
- Brd. 23E** **Registry of Gastric Cancer Treatment Evaluation (REGATE): Geographic analysis of baseline characteristics of 10,124 patients (pts). (Abstract #4082)**
J. R. Zalberg, K. M. Mohandas, Y. Kang, Y. Bang, M. Ter-Ovanesov, S. Ben Ahmed, C. Wu, A. Roth, E. B. Ecstein-Fraïssé, S. Yalcin
- Brd. 23F** **A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). (Abstract #4083)**
A. X. Zhu, R. S. Finn, M. F. Mulcahy, J. S. Gurtler, W. Sun, J. D. Schwartz, P. Rojas, A. Dontabaktuni, H. Youssoufian, K. E. Stuart
- Brd. 23G** **Prognostic significance of cell cycle regulating protein expressions in gastric carcinoma patients receiving adjuvant chemotherapy. (Abstract #4084)**
Y. Park, S. Jang, S. Lee, H. Park, M. Ryu, B. Ryoo, J. Yook, B. Kim, K. Kim, Y. Kang
- Brd. 23H** **Neoadjuvant paclitaxel poliglumex (PPX), cisplatin, and radiation (RT) for esophageal cancer. (Abstract #4085)**
T. Ng, J. Fontaine, M. Suntharalingam, T. Dipetrillo, M. N. Horiba, N. B. Oldenburg, K. Perez, W. Chen, F. Habr, H. Safran
- Brd. 24A** **Phase II trial of ixabepilone (IXA) plus cetuximab (C) as first-line therapy for advanced pancreatic carcinoma (PC). (Abstract #4086)**
C. S. Rocha Lima, E. H. Lin, G. P. Kim, J. K. Giguere, J. Marshall, M. Zalupski, C. N. Papageorgio, M. L. Auber, M. B. McHenry, P. A. Philip

- Brd. 24B** **Outcome of patients with recurrent hepatocellular carcinoma after liver transplantation. (Abstract #4087)**
A. Finkenstedt, I. W. Graziadei, H. Zoller, K. Nachbaur, W. Mark, W. Vogel
- Brd. 24C** **Relapse of hepatocellular carcinoma (HCC) after liver transplantation (LT): A single-center analysis on 139 patients in the sorafenib era. (Abstract #4088)**
T. E. Pfiffer, D. Seehofer, A. Nicolaou, R. Neuhaus, H. Riess, P. Neuhaus, R. Trappe
- Brd. 24D** **Survival of complete responder patients treated for esophageal cancer with chemoradiotherapy followed by surgery as compared to chemoradiotherapy alone: Case-control study. (Abstract #4089)**
M. Messager, G. Millet, N. Briez, G. Piessen, J. Triboulet, C. Mariette
- Brd. 24E** **Registry of Gastric Cancer Treatment Evaluation (REGATE): Staging and diagnosis of 10,124 patients (pts). (Abstract #4090)**
C. Wu, V. Soloviev, E. Semkina, M. Ter-Ovanesov, K. Govind Babu, A. Vila, S. Yalcin, A. Roth, E. B. Ecstein-Fraïssé, Y. Bang
- Brd. 24F** **FOLFOX6 as first-line treatment in metastatic gastric cancer: Preliminary results of a phase II trial. (Abstract #4091)**
A. Fontana, L. Losi, F. Bertolini, S. Zironi, R. Depenni, N. Malavasi, L. Scarabelli, G. Luppi, P. F. Conte
- Brd. 24G** **Outcome prediction in hepatocellular carcinoma (HCC): Comparison of alphafetoprotein (AFP) response and conventional radiologic criteria during sorafenib treatment. (Abstract #4092)**
N. Personeni, S. Bozzarelli, T. Pressiani, L. Rimassa, M. C. Tronconi, F. Sclafani, C. Carnaghi, L. Giordano, A. Santoro
- Brd. 24H** **Association of human epidermal growth factor receptor 2 (HER2) Ile655Val polymorphism (plrm) and gender-specific time to tumor recurrence (TTR) in patients (pts) with localized gastric adenocarcinoma (GA). (Abstract #4093)**
E. Y. Lin, P. O. Bohanes, D. Yang, G. Lurje, T. Winder, Y. Ning, E. Ho, L. H. Tang, M. A. Shah, H. Lenz
- Brd. 25A** **A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine. (Abstract #4094)**
J. Manzano, F. Rivera, M. Galan, M. Valladares, C. Pericay, M. J. Mendez, M. Safont, A. Irigoyen, A. Arrivi, J. Sastre
- Brd. 25B** **Association between smoking history and disease-free and overall survival in resected gastric cancer. (Abstract #4095)**
E. C. Smyth, V. E. Strong, M. Capanu, Y. Y. Janjigian, D. G. Coit, D. P. Kelsen, M. A. Shah
- Brd. 25F** **Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data. (Abstract #4096)**
R. S. Finn, J. Raoul, D. Manekas, C. Baudelet, I. B. Walters
- Brd. 25G** **A phase I dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma. (Abstract #4097)**
S. Choo, B. Chowbay, Q. Ng, C. Thng, H. Li, H. Huynh, D. Poon, M. Ang, S. Chang, H. Toh
- Brd. 25H** **Association between DNA repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. (Abstract #4098)**
P. Pacetti, E. Giovannetti, M. Reni, A. Mambrini, M. Ghidini, L. Gleon, N. Funel, S. Cereda, G. Peters, M. Cantore
- Brd. 26A** **Docetaxel, oxaliplatin, and capecitabine (TEX regimen) in patients with advanced or metastatic gastric or gastroesophageal cancer (GC): Results from a phase II trial of the German AIO Group. (Abstract #4099)**
D. Arnold, P. C. Thuss-Patience, A. Stein, W. Grothe, T. Seufferlein, A. Reinacher-Schick, M. Geissler, R. Hofheinz, M. H. Moehler, H. Schmoll

- Brd. 26B** Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC). (Abstract #4100)
N. I. Khushalani, G. Yang, W. Tan, J. Miecznikowski, D. Wang, R. V. Iyer, S. S. Yendamuri, C. E. Nwogu, H. R. Nava, M. M. Javle
- Brd. 26F** Role of IL-6 in cachexia progression in advanced pancreatic cancer. (Abstract #4101)
S. Mitsunaga, M. Ikeda, K. Nakachi, E. Suzuki, J. Furuse, M. Inagaki, Y. Uchitomi, S. Higashi, K. Terao, A. Ochiai
- Brd. 26G** Treatment of advanced or metastatic hepatocellular cancer (HCC): Interim analysis of a single-arm phase II study of bevacizumab and RAD001. (Abstract #4102)
G. Treiber, on behalf of the German HCC-RAD001/Bevacizumab Multicenter Study Group
- Brd. 26H** HER2 status of gastric and gastroesophageal cancer (GC) patients assessed by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and high-resolution array comparative genomic hybridization (aCGH). (Abstract #4103)
Y. Y. Janjigian, V. V. Barbashina, D. P. Kelsen, L. H. Tang, D. Ilson, L. J. Tafe, J. B. Hicks, M. A. Shah
- Brd. 27A** A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. (Abstract #4104)
P. L. Kunz, T. Kuo, J. M. Zahn, H. L. Kaiser, J. A. Norton, B. C. Visser, T. A. Longacre, J. M. Ford, R. R. Balise, G. A. Fisher
- Brd. 27B** Utility of post-treatment FDG-PET in predicting outcomes in anal cancer managed with chemoradiotherapy. (Abstract #4105)
A. G. Heriot, F. L. Day, E. Link, T. Leong, A. C. Lynch, M. Michael, R. Hicks, A. Hogg, S. Ngan
- Brd. 27C** Concurrent chemoradiotherapy with cetuximab plus twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma. (Abstract #4106)
C. Hsu, C. Lin, J. C. Cheng, C. Yen, J. Lee, H. Wang, K. Yeh, A. Cheng, Y. Lee
- Brd. 27D** Phase II study of cetuximab in combination with modified FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy (EFFI study). (Abstract #4107)
J. Li, X. Liu, B. Y. Wang, W. J. Guo, J. L. Yin, X. D. Zhu, J. Zhang, T. Liu
- Brd. 27E** A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer. (Abstract #4108)
A. A. Meluch, J. C. Bendell, J. D. Peyton, P. Rudolph, M. S. Rubin, C. D. Webb, F. A. Greco, J. R. Infante, H. A. Burris III, J. D. Hainsworth
- Brd. 27F** Overall survival and clinically deficient quality of life in patients with esophageal cancer or Barrett's esophagus: A Mayo Clinic Esophageal Adenocarcinoma and Barrett's Esophagus Registry Consortium study. (Abstract #4109)
R. C. Miller, P. J. Atherton, B. Kabat, M. B. Fredericksen, D. M. Geno, C. Deschamps, A. Jatoi, J. A. Sloan, Y. Romero
- Brd. 27G** Somatostatin analogue therapy and PROMIS health-related quality-of-life scores in patients with neuroendocrine tumors. (Abstract #4110)
M. Dong, J. L. Beaumont, Z. Liu, A. T. Phan, S. Choi, D. Cella, J. C. Yao
- Brd. 27H** Impact of a novel inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: A retrospective study of 398 Japanese patients. (Abstract #4111)
M. Ishizuka, K. Kubota, J. Kita, M. Shimoda, K. Rokkaku, M. Kato, T. Sawada

- Brd. 28A Intensity-modulated radiotherapy for esophageal cancer: Analysis of toxicity and outcomes. (Abstract #4112)**
N. Kurshan, D. Ilson, M. A. Shah, D. P. Kelsen, A. Y. Ho, Z. Zhang, Q. Mo, K. A. Goodman
- Brd. 28B Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms. (Abstract #4113)**
V. Vaccaro, J. B. Fleming, R. A. Wolff, D. B. Evans, E. P. Tamm, C. H. Crane, M. M. Javle, J. L. Abbruzzese, J. E. Lee, G. R. Varadhachary
- Brd. 28C Is diabetes mellitus (DM) associated with worse outcomes in pancreatic cancer (PC)? (Abstract #4114)**
O. O. Olowokure, M. S. Beg, S. Ali, A. Tandra, M. M. Safa, K. Havlin, S. A. Ahmad
- Brd. 28D Therapeutic effects of fractionated radioimmunotherapy (RAIT) with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC). (Abstract #4115)**
A. J. Ocean, M. J. Guarino, K. L. Pennington, B. H. O'Neil, C. S. Rocha Lima, T. S. Bekaii-Saab, S. A. Gulec, D. V. Gold, W. A. Wegener, D. M. Goldenberg
- Brd. 28E Docetaxel, cisplatin, and capecitabine (DCX) as perioperative chemotherapy in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4116)**
P. C. Thuss-Patience, M. Kneba, R. Hofheinz, D. Arnold, A. Florschütz, S. Daum, A. Kretzschmar, L. Mantovani-Löffler, D. Bichev, G. Schumacher
- Brd. 28F Association of diabetes with perineural invasion and overall survival in surgically resected patients with pancreatic cancer. (Abstract #4117)**
M. A. Shama, M. Tanaka, S. A. Curley, J. L. Abbruzzese, D. Li
- Brd. 28G Registry of Gastric Cancer Treatment Evaluation (REGATE): Variations in nonsurgical therapies. (Abstract #4118)**
S. Yalcin, M. Serralva, P. Arbeloa, W. Kang, Y. Bang, M. Gumus, C. Wu, A. Roth, E. B. Ecstein-Fraïssé, M. Ter-Ovanesov
- Brd. 28H Diagnostic value of Lens culinaris agglutinin isoform 3 fraction (AFP-L3%) and des-gamma-carboxy prothrombin (DCP) for the diagnosis of hepatocellular carcinoma in cirrhotic patients. (Abstract #4119)**
R. Romeo, A. Sangiovanni, M. Iavarone, S. Vavassori, C. Della Corte, M. Colombo
- Brd. 29A A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)-based therapy. (Abstract #4120)**
P. J. Hosein, G. d. Lopes Jr., C. M. Gomez, V. H. Pastorini, J. Macintyre, M. Easey, I. M. Reis, J. R. Merchan, P. Bejarano, C. S. Rocha Lima
- Brd. 29B *Helicobacter pylori* infection as an independent prognostic factor for locally advanced gastric cancer with curative resection. (Abstract #4121)**
S. Kang, J. Choi, M. Ahn, H. Lee, S. Han, Y. Cho, J. Han, J. Kim
- Brd. 29C Results of a phase II multicenter study of neoadjuvant S-1 and irinotecan in patients with locally advanced gastric cancer. (Abstract #4122)**
M. Terashima, Z. Saze, R. Hosotani, M. Takahashi, A. Takagane, O. Hachiya, K. Koeda, S. Matsui, W. Ohashi, M. Gotoh
- Brd. 30A Prognostic markers for response and overall survival in patients with esophageal adenocarcinoma treated with neoadjuvant therapy. (Abstract #4123)**
J. M. Leers, G. Lurje, D. Yang, A. Oezcelik, J. A. Hagen, S. R. DeMeester, T. R. DeMeester, H. Lenz
- Brd. 30B Early outcome of phase II study of preoperative chemotherapy (CX) with S-1 plus cisplatin for stage IV gastric cancer (StIV GC). (Abstract #4124)**
S. Satoh, H. Okabe, S. Teramukai, S. Hasegawa, N. Ozaki, S. Ueda, A. Tsuji, S. Sakabayashi, Y. Sakai

- Brd. 30C Cost-effectiveness of neoadjuvant (NeoAdj) versus adjuvant (Adj) therapies for resectable pancreatic cancer (PC). (Abstract #4125)**
R. T. Shroff, M. M. Javle, S. Krishnan, S. B. Cantor, J. E. Lee, J. B. Fleming, G. R. Varadhachary, J. L. Abbruzzese, R. A. Wolff, L. S. Elting
- Brd. 31A Association of elevated tissue factor (TF) with survival and thromboembolism (TE) in pancreaticobiliary cancers (PBC). (Abstract #4126)**
A. Bharthuar, A. A. Khorana, A. Hutson, J. Wang, N. Mackman, R. V. Iyer
- Brd. 31B Characterization and prognostic significance of circulating tumor cells in the peripheral blood of patients with metastatic pancreatic cancer. (Abstract #4127)**
B. P. Negin, N. J. Meropol, R. K. Alpaugh, K. Ruth, C. McAleer, T. Halbherr, C. Bingham, P. Fittipaldi, S. J. Cohen
- Brd. 31C Use of tumor arterial perfusion assessment and RECIST for prediction of survival and residual disease in hepatocellular carcinoma following intra-arterial infusion chemotherapy. (Abstract #4128)**
J. R. Daniels, M. A. Wallman, J. A. Donovan, A. B. El-Khoueiry, S. Iqbal, M. Hart, J. Pena
- Brd. 32A Analysis of D7S486 in primary gastric cancer and evaluation of TESTIN as a candidate tumor suppressor gene. (Abstract #4129)**
J. Xia, D. Weng, H. Ma, Y. Chen, W. Huang, K. Pan
- Brd. 32B Dynamic changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States. (Abstract #4130)**
P. Cen, F. Banki, L. Cheng, L. R. Kaiser, K. Khalil, X. L. Du, R. J. Amato
- Brd. 32C Identification of three potential biomarkers in early resectable hepatocellular carcinoma. (Abstract #4131)**
S. Ang, W. Wang, Y. Soe, C. Tan, W. Chow, A. K. Kwee, H. Toh
- Brd. 33A Clinical outcomes and survival in patients with hepatocellular carcinoma and HIV infection. (Abstract #4132)**
M. Berretta, E. Garlassi, P. Ventura, B. Cacopardo, A. Lleshi, S. Cocchi, G. Guaraldi, A. Pietrangelo, U. Tirelli
- Brd. 33B Analysis of biomarker expression (ki67, EGFR, HER2, ERK, NFkB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study. (Abstract #4133)**
C. Pinto, V. Mutri, F. Di Fabio, S. Giaquinta, C. Ceccarelli, F. L. Rojas Llimpe, P. Di Tullio, C. Barone, S. Siena, A. Martoni
- Brd. 33C A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naïve metastatic pancreatic cancer. (Abstract #4134)**
M. Aglietta, C. Barone, M. Muliello, C. Bagalà, D. Ferraro, K. D. Fly, B. Huang, F. Leone
- Brd. 34A Clinical outcome of local recurrence cases after endoscopic mucosal resection (EMR) for Japanese Classification stage 0 esophageal cancer. (Abstract #4135)**
T. Yoshii, S. Ohkawa
- Brd. 34B A phase I study, with expanded cohort, of biweekly fixed-dose rate gemcitabine (FDR GEM) plus capecitabine (CAP) in patients with advanced pancreatic (APC) and biliary carcinomas (ABC). (Abstract #4136)**
A. M. Espinoza, A. H. Ko, A. P. Venook, E. K. Bergsland, K. A. Jones, R. K. Kelley, W. M. Korn, E. Dito, A. Ong, M. A. Tempero
- Brd. 34C Final results from ARQ 197-114: A phase Ib safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC). (Abstract #4137)**
P. Zucali, A. Santoro, C. Rodriguez-Lope, M. Simonelli, L. H. Camacho, N. N. Senzer, L. Bolondi, M. Lamar, G. Abbadessa, B. E. Schwartz

- Brd. 35A** The utility of PET/CT in the treatment management of gastroesophageal cancer (GEC): Impact on staging and treatment decisions. (Abstract #4138)
W. Shan, C. K. Kollmannsberger, D. Wilson, A. Briede, C. D. Blanke, H. J. Lim
- Brd. 35B** Phase I study of sorafenib (S) with gemcitabine (G)-based radiotherapy (G-RT) in patients (pts) with locally advanced unresectable pancreatic adenocarcinoma (LAUPC). (Abstract #4139)
S. Anderson, H. R. Cardenes, F. Akisik, E. L. Johnston, R. Clark, S. M. Perkins, C. S. Johnson, P. J. Loehrer, B. P. Schneider, E. G. Chiorean
- Brd. 35C** Use of serum VEGF (SVEGF) levels to predict outcome of esophageal cancer (EC) patients undergoing preoperative chemoradiation (CRT). (Abstract #4140)
F. De Vita
- Brd. 35D** Chemoembolization with epirubicin drug-eluting beads (DEB-TACE) to treat early and intermediate hepatocellular carcinoma. (Abstract #4141)
A. Nicolini, A. Sangiovanni, M. Iavarone, L. Martinetti, M. A. Manini, S. Crespi, C. Della Corte, S. Vavassori, M. Colombo
- Brd. 35E** Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study. (Abstract #4142)
M. Dalla Chiesa, R. Poli, G. Tomasello, S. Lazzarelli, S. Buti, M. Brighenti, F. Negri, A. Curti, A. Auzzani, R. Passalacqua
- Brd. 35F** Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in patients with advanced pancreatic cancer. (Abstract #4143)
S. J. Lubner, W. R. Schelman, D. Mulkerin, K. D. Holen, S. Seo, N. K. LoConte
- Brd. 35G** Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy. (Abstract #4144)
T. S. Hong, H. K. Tsai, J. Coen, L. S. Blaszkiwsky, K. L. Hartshorn, E. L. Kwak, J. Willins, D. P. Ryan, L. A. Kachnic
- Brd. 35H** A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer. (Abstract #4145)
E. Suzuki, M. Ikeda, T. Okusaka, S. Nakamori, S. Ohkawa, T. Nagakawa, N. Boku, H. Yamagimoto, K. Sugimori, J. Furuse
- Brd. 36A** Upregulation of multidrug resistance-associated protein 4 in the early stage of vascular invasion of hepatocellular carcinoma. (Abstract #4146)
K. Higuchi, T. Terada, M. Fukudo, K. Ogasawara, T. Katsura, E. Hatano, I. Ikai, K. Inui
- Brd. 36B** A feasibility analysis from the patient preference randomized phase III clinical trial of second-line chemotherapy (SLC) in advanced gastric cancer (AGC) patients pretreated with both fluoropyrimidines and platinum. (Abstract #4147)
S. Park, S. Lee, J. Kang, I. Hwang, J. Lee, J. Park, Y. Park, H. Lim, W. Kang
- Brd. 36C** Prediction of prognosis in hepatocellular carcinoma based on a gene signature from highly tumorigenic liver cancer cells. (Abstract #4148)
X. Yang, J. Fan, Y. Xu, J. Zhou, B. Yu
- Brd. 36D** Phase I and II studies of intravenous Regin-G as monotherapy for stage IVb gemcitabine-resistant pancreatic cancer. (Abstract #4149)
H. Bruckner, S. P. Chawla, C. S. Chua, D. V. Quon, L. Fernandez, A. Saralou, M. Fisher, E. M. Gordon, F. L. Hall
- Brd. 36E** Phase II study of FOLFIRI chemotherapy as first-line treatment for elderly patients (pts) with advanced gastric cancer (AGC). (Abstract #4150)
Y. Becouarn, C. Bellera, R. Brunet, J. Legoux, L. Cany, J. Dauba, D. Smith, D. Auby, C. Mertens, M. Fonck

Sunday, June 6, 2010

- Brd. 36F Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in pts with cancer of unknown primary site (CUP). (Abstract #4151)**
G. R. Varadhachary, T. B. Edmonston, S. Karanth, H. R. Carlson, D. Lebanony, S. Rosenwald, R. Lenzi, Y. Spector, D. Cohen, M. N. Raber
- Brd. 36G Clinical outcomes in pancreatic adenocarcinoma (PAC) in breast cancer (BC) survivors. (Abstract #4152)**
M. A. Lowery, Z. K. Stadler, E. Ludwig Miller, D. R. D'Adamo, E. Salo-Mullen, P. Allen, R. C. Kurtz, D. P. Kelsen, E. M. O'Reilly
- Brd. 36H Phase II trial of gemcitabine (G), oxaliplatin (O), and erlotinib (T) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancers (BTC). (Abstract #4153)**
Y. Z. Patt, A. D. Baron, V. A. Parks, A. Small, M. Roach, S. Lee, F. Lee
- Brd. 37A Maruyama index (MI) and outcomes of gastric cancer resection. (Abstract #4154)**
J. C. Sachdev, M. Evangelist, W. S. Orr, J. Denbo, A. G. Khattak, M. Ul-Haq, A. Farooq, A. C. Thompson, A. Mahmoud, R. U. Osarogiagbon
- Brd. 37B A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients (pts) with gemcitabine-refractory advanced pancreatic adenocarcinoma (PC). (Abstract #4155)**
N. Starling, E. A. Hawkes, I. Chau, D. J. Watkins, J. Thomas, J. Webb, G. Brown, K. Thomas, J. R. Oates, D. Cunningham
- Brd. 37C Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric cancer undergoing a potentially curative resection. (Abstract #4156)**
S. Lorenzen, B. Panzram, R. Rosenberg, K. Becker, U. Schenk, H. Höfler, J. R. Siewert, K. Ott
- Brd. 37D Phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin (POF) in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. (Abstract #4157)**
R. Lin, N. Fan, L. Chen, J. Liu
- Brd. 37E Role of MT1-MMP and Kras in invasive pancreatic tumors with pronounced fibrosis. (Abstract #4158)**
S. B. Krantz, S. Dangi-Garimella, M. A. Shields, P. J. Grippo, D. J. Bentrem, H. G. Munshi
- Brd. 37F Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib. (Abstract #4159)**
H. Safran, K. Charpentier, G. Dubel, G. Soares, D. Berz, J. L. Shipley, K. E. Faricy-Anderson, A. M. Plette, K. Bishop, N. J. Espat
- Brd. 37G Analysis of four human PIGF isoforms and of VEGFR-1 in esophageal carcinoma. (Abstract #4160)**
A. Schultze, M. Bubenheim, E. Yekebas, A. Erbersdobler, U. Reichelt, J. R. Izbicki, K. Pantel, C. Bokemeyer, W. M. Fiedler, S. Loges, Otten, Jasmin; Riethdorf, Sabine
- Brd. 37H A phase I/II study of photodynamic therapy (PDT) using HPPH for the treatment of Barrett's and precancerous lesions of the esophagus. (Abstract #4161)**
H. R. Nava, S. S. Allamaneni, M. T. Cooper, T. Dougherty, G. E. Wilding, B. W. Henderson
- Brd. 38A Tumoral and angiogenesis factors in hepatocellular carcinoma (HCC) after drug eluting bead (DEB) transarterial chemoembolization (TACE) with doxorubicin. (Abstract #4162)**
A. B. Farris, R. Dhanasekaran, N. Dursun, I. Coban, E. B. McIntosh, V. Adsay, H. S. Kim
- Brd. 21G A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). (Abstract #4163)**
D. L. Reidy, E. Hollywood, M. Segal, L. Saltz

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Pediatric Oncology

Location: S Hall A2

Tracks(s): Pediatric Oncology

- Brd. 43A Phase I trial of oxaliplatin and doxorubicin in children and adolescents with recurrent solid tumors. (Abstract #9543)**
L. Mascarenhas, S. Armenian, J. L. Harrington, H. Mahmoud, R. Sposto, M. H. Malogolowkin
- Brd. 43B A phase I trial of continuous hyperthermic peritoneal perfusion using cisplatin in pediatric patients with carcinomatosis. (Abstract #9544)**
A. A. Hayes-Jordan, H. L. Green, P. M. Anderson, L. Xiao, K. Hunt, P. F. Mansfield
- Brd. 43C Pilot study of the novel chemotherapy regimen of topotecan, ifosfamide, and carboplatin (TIC) in children with refractory/recurrent solid tumors. (Abstract #9545)**
A. Lee, C. Handler, L. Harrison, W. V. Shen, L. Gates, R. J. Wells, J. E. Wolff, J. H. Garvin, D. Yamashiro, M. S. Cairo
- Brd. 43D Dose-finding study by continuous reassessment method (CRM) for topotecan (TT) in combination with ifosfamide (IF) as a second-line therapy for pediatric solid cancer: Preliminary report of phase I/II study. (Abstract #9546)**
H. Kawamoto, M. Saito, T. Kimura, A. Ogawa, Y. Ishida, T. Taga, H. Mugishima, A. Makimoto
- Brd. 43E An investigator-initiated registration-directed phase I/II clinical trial of irinotecan hydrochloride for refractory pediatric solid tumors. (Abstract #9547)**
A. Makimoto, H. Mugishima, T. Taga, Y. Ishida, Y. Nagatoshi, K. Ida, M. Kumagai, T. Kimura, Y. Ohashi, M. Kaneko
- Brd. 43F Simulations of cilengitide PK profiles in pediatric population by means of allometric scaling: Reliability and support to BSA-based dose adjustment strategy. (Abstract #9548)**
M. Zuehlsdorf, M. Campioni, U. Forssmann, A. Munafo, A. Kovar
- Brd. 43G Intensity-modulated radiation therapy for pediatric head and neck rhabdomyosarcoma: French preliminary results. (Abstract #9549)**
J. Leseur, V. Bernier, J. Habrand, A. Laprie, M. Mahe, S. Supiot, G. Truc, E. Le Prisé, L. Claude, C. Carrie
- Brd. 43H Sorafenib, gamma-secretase inhibitor, and bortezomib as potential therapeutic agents for hepatoblastoma. (Abstract #9550)**
P. C. Sanchez-Diaz, T. L. Chen, R. Meyers, M. H. Malogolowkin, J. Y. Hung, G. E. Tomlinson
- Brd. 44A Late side effects of neoadjuvant chemotherapy in patients treated for osteosarcoma and Ewing's sarcoma: An Italian Sarcoma Group study. (Abstract #9551)**
A. Longhi, C. Ferrari, A. Tamburini, M. Berta, F. Fagioli, G. Bacci, M. Mercuri, S. Ferrari
- Brd. 44B Feasibility of bevacizumab (NSC 704865, BB-IND# 7921) combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma (EWS): A Children's Oncology Group (COG) study. (Abstract #9552)**
P. Leavey, J. L. Glade Bender, L. Mascarenhas, L. Granowetter, M. Anderson, M. D. Krailo, R. G. Gorlick, N. Marina
- Brd. 44C Long-term results of expandable endoprosthesis replacement in children with malignant bone tumors. (Abstract #9553)**
W. Woźniak, I. Ługowska, A. Szymborska

- Brd. 44D Long-term neurocognitive outcomes in adult survivors of childhood medulloblastoma. (Abstract #9554)**
K. Edelstein, B. J. Spiegler, S. Fung, T. Panzarella, D. C. Hodgson, D. J. Mabbott, N. Laperrriere, U. Tabori, E. Bouffet, W. P. Mason
- Brd. 44E Premature deaths and severe morbidity in 192 long-term survivors of pediatric optic pathway tumors (OPT): A 50-year study. (Abstract #9555)**
E. De Carli, C. Kalifa, M. Raquin, J. Lemerle, J. Habrand, D. Couanet, C. Sainte-Rose, X. Rialland, D. Valteau-Couanet, J. Grill
- Brd. 44F Medulloblastoma histological variants as the most powerful prognostic indicator: A 10-year mono-institutional experience. (Abstract #9556)**
M. Massimino, L. Gandola, V. Biassoni, P. Collini, B. Pollo, F. Giangaspero
- Brd. 44H Improved collaboration and clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA program. (Abstract #9558)**
P. H. Shaw
- Brd. 45A Survival by race among children with extracranial solid malignancies. (Abstract #9559)**
K. Johnson, R. Aplenc, R. Bagatell
- Brd. 45B Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: A survey of ASCO oncologists. (Abstract #9560)**
M. Kigin, F. J. Hlubocky, K. Wroblewski, C. Daugherty, T. O. Henderson
- Brd. 45C Allogeneic stem cell transplantation from HLA identical donor in high-risk sarcoma (Abstract #9561)**
F. Fagioli
- Brd. 45D Reduced intensity conditioning regimen and allogeneic stem cell transplantation from related or unrelated HLA identical donor in high-risk neuroblastoma. (Abstract #9562)**
A. Prete
- Brd. 45E Tandem stem cell transplantation as consolidation therapy for high-risk neuroblastoma: The Children's Healthcare of Atlanta experience. (Abstract #9563)**
M. Qayed, K. Y. Chiang, A. E. Haight, B. A. George, R. Ricketts, A. Alazraki, A. Tahvildari, N. Esiashvili, H. M. Katzenstein
- Brd. 45F STAT3 as a molecular target in pediatric T-cell leukemia. (Abstract #9564)**
J. Ding, A. Batista, A. Turk, S. Rodriguez-Rodriguez, L. Wang, C. Mumaw, N. Carlesso, A. A. Cardoso
- Brd. 45G Activity of the heat shock protein 90 (HSP90) inhibitor, SNX-2112, in pediatric cancer cell lines. (Abstract #9565)**
D. C. Chinn, W. S. Holland, J. M. Yoon, T. Zwerdling, P. C. Mack
- Brd. 45H Effect of bortezomib on ER stress and killing of cisplatin-resistant U2OS osteosarcoma cell line. (Abstract #9566)**
W. Zhao, M. Callaghan, A. Fribley, Y. Ravindranath, Z. J. Wang
- Brd. 46A Effect of modulation of MET with the small molecule inhibitor PF-04217903 on osteosarcoma metastasis in vivo. (Abstract #9567)**
L. M. Niswander, L. M. Guenther, A. Mendoza, C. Khanna, J. G. Christensen, L. J. Helman, S. Kim
- Brd. 46B GD2 expression in tumorspheres from neuroblastoma cell lines and in tumor-initiating cells derived from patient samples. (Abstract #9568)**
A. M. Hammill, P. Wang, L. M. Hansford, D. Kaplan, T. P. Cripe
- Brd. 46C Effect of all-trans retinoic acid on proliferation of human rhabdomyosarcoma and remission in an in vivo mouse xenograft model. (Abstract #9569)**
R. H. Saab
- Brd. 46E Plasma fractionated total metanephrines for biochemical diagnosis of neuroblastoma. (Abstract #9571)**
L. Crosazzo Francini, E. Grouzmann, M. Faouzi, M. Beck Popovic

- Brd. 46F** **A prospective trial of prophylaxis and treatment (P+T) of acute tumor lysis syndrome (ATLS) with rasburicase (R) and nonalkaline hydration in children and adolescents (C+A) with intermediate- (Group B) and high-risk (Group C) mature B-NHL: A Children's Oncology Group report. (Abstract #9572)**
S. Goldman, J. C. Lynch, L. Harrison, M. S. Cairo
- Brd. 46G** **High-dose methotrexate in the treatment of acute lymphoblastic leukemia: Toxicity profile and comparison of tolerability between two dosage schedules. (Abstract #9573)**
A. R. Warriar, R. Rejiv, D. Biswajit, S. G. Ramanan, T. G. Sagar
- Brd. 46H** **T-cell lymphoblastic lymphoma in children and adolescents: The experience of the Israel Society of Pediatric Hematology Oncology. (Abstract #9574)**
M. W. Ben Arush, O. Beyar Katz, A. Ben Barak, G. Avrahami, R. Dvir, J. Kapelushnik, H. Kaplinsky, S. Vilik Revel, I. Yaniv, S. Linn
- Brd. 47A** **Risk-based outcome of childhood AML: Experience of National Guard Hospital, Jeddah, Saudi Arabia. (Abstract #9575)**
W. A. Jastaniah, T. M. Khattab, S. K. Felimban
- Brd. 47B** **High frequency of Gilbert's syndrome in ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL): Implications for etiology. (Abstract #9576)**
Y. Ravindranath, I. Brecht, J. Feldman, R. K. Severson, F. Nahhas, A. Nahar, G. Goyette
- Brd. 47C** ***Clostridium difficile* infection among children with cancer. (Abstract #9577)**
E. Tai, L. C. Richardson, J. Townsend, E. Howard, C. McDonald
- Brd. 47D** **Iterative anesthesia for radiation therapy in pediatric oncology: Safety of a procedure using propofol alone. (Abstract #9578)**
H. Sebban, L. Claude, C. Conter, V. Bachelot, P. Marec Bérard, P. Bachmann, A. Daunizeau, C. De La Fouchardiere, C. Carrie
- Brd. 47E** **Diagnosis of invasive fungal infections by RQ-PCR assay in pediatric acute leukemia induction. (Abstract #9579)**
S. Mandhaniya, S. Iqbal, S. K. Sharawat, I. Xess, S. Bakhshi
- Brd. 47F** **Clinical pharmacokinetics (PK) and safety of high-dose (HD) methotrexate (MTX) during induction therapy of pediatric patients younger than 3 years of age with primary brain tumors. (Abstract #9580)**
T. McKibbin, M. Tagen, J. C. Panetta, D. Ward, A. J. Gajjar, K. D. Wright, A. Broniscer, C. F. Stewart
- Brd. 47G** **Criteria defining the duration of chemoreduction with focal treatment in retinoblastoma: A retrospective analysis. (Abstract #9581)**
M. Beck Popovic, H. Abouzeid, M. Gaillard, M. Faouzi, A. Pica, A. Balmer, F. Munier

Sunday, June 6, 2010

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Sarcoma

Location: S Hall A2
Tracks(s): Sarcoma

- Brd. 48A** **Prognostic value of the most frequent mutations in GIST: Results of the French population-based prospective study MolecGIST. (Abstract #10034)**
J. Emile, S. Brahimi, J. Coindre, J. Blay, P. Aegerter, J. Scoazec, G. Viennet, O. Bouche, L. Doucet, A. Wacrenier
- Brd. 48B** **Combination of targeted therapy (imatinib) with immunotherapy (peginterferon α -2b) to overcome drug resistance and tumor stem cells in gastrointestinal stromal tumors (GIST). (Abstract #10035)**
L. L. Chen, X. Chen, L. G. Gouw, R. I. Andtbacka, K. A. Jones, J. H. Ward, R. Randall, J. C. Trent, S. Patel, R. S. Benjamin
- Brd. 48C** **Phase I/II study of TH-302 combined with doxorubicin in soft tissue sarcoma. (Abstract #10036)**
L. D. Cranmer, S. P. Chawla, D. A. Rushing, J. E. Butrynski, S. H. Okuno, D. Adkins, V. K. Langmuir, G. A. Lorente, S. Kroll, K. N. Ganjoo
- Brd. 48D** **Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study. (Abstract #10037)**
H. Gelderblom, J. Blay, B. M. Seddon, M. Leahy, I. L. Ray-Coquard, A. De brauwer, E. Veyt, S. D. Weitman, P. C. Hogendoorn, P. Hohenberger
- Brd. 48E** **Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. (Abstract #10038^A)**
S. Richter, D. Pink, P. Hohenberger, H. Schuette, P. G. Casali, A. Pustowka, P. Reichardt
- Brd. 48F** **Identification of oncogenic events in gastrointestinal stromal tumors (GISTs) by combined gene expression and copy number analysis. (Abstract #10039)**
M. Nannini, M. A. Pantaleo, A. Astolfi, A. Maleddu, M. C. Heinrich, C. L. Corless, M. di Battista, F. Catena, D. Santini, G. Biasco
- Brd. 48G** **Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts): An EORTC-STBSG study. (Abstract #10040)**
S. Sleijfer, M. M. Van Glabbeke, C. Lamers, H. Burger, J. Blay, A. I. Cesne, M. R. Scurr, A. N. Bartlett-Pandite, S. Marreaud, P. Hohenberger
- Brd. 48H** **Radiofrequency ablation of lung metastases arising from sarcoma. (Abstract #10041)**
J. Palussiere, A. Italiano, A. Avril, E. Descat, N. Bin Bui
- Brd. 49A** **Improvement in the survival for adult soft tissue sarcoma with adjuvant anthracycline chemotherapy combination: A meta-analysis and metaregression. (Abstract #10042)**
S. L. Afonso, L. A. Ramos, G. A. Viani, E. Stefano, V. Afonso
- Brd. 49B** **BRAF V600E mutations in benign and malignant peripheral nerve sheath tumors. (Abstract #10043)**
C. Serrano, S. Simonetti, J. Hernandez, C. Valverde, J. Carles, S. Bague, R. Orellana, R. Somoza, S. Ramon y Cajal, C. Romagosa
- Brd. 49C** **Use of a genome-wide single nucleotide polymorphism array-based chromosomal analysis to evaluate uniparental disomy (UPD) in gastrointestinal stromal tumors (GIST). (Abstract #10044)**
N. Lourenço, J. Emile, S. Brahimi, J. Bachet, F. Jardin, J. Tran van Nhieu, J. Coindre, C. Penna

- Brd. 49D Trends in survival for metastatic soft-tissue sarcoma: A French Sarcoma Group (GSF) database analysis. (Abstract #10045)**
A. Italiano, S. Mathoulin-Pelissier, P. Terrier, A. Le Cesne, S. Bonvalot, F. Collin, J. Michels, J. Blay, J. Coindre, N. Bin Bui, French Sarcoma Group GSF-GETO
- Brd. 49E Novel reconstruction using tumor-containing autologous bone grafts frozen in liquid nitrogen. (Abstract #10046)**
H. Tsuchiya, K. Hayashi, T. Shirai, H. Nishida, A. Takeuchi, S. Miwa, R. M. Hoffman
- Brd. 49F Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib (IM). (Abstract #10047)**
B. Nguyen, F. Grabellus, M. Hoiczky, G. Taeger, M. H. Schuler, S. Bauer
- Brd. 49G Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST. (Abstract #10048^)**
P. Hohenberger, S. Bauer, V. Gruenwald, J. T. Hartmann, E. Jaeger, O. G. Ottmann, C. Hosius, C. May, A. Pustowka, P. Reichardt
- Brd. 49H Targeting CHK1 pathway to induce cytotoxic response to histone deacetylase inhibitors and evaluating the synergistic effects of CHK1 and HDAC inhibitors in human soft tissue sarcoma cell lines and primary tumor xenografts. (Abstract #10049)**
D. R. Reed, W. Brazelle, J. Gemmer, S. Altiock
- Brd. 50A CSPG4 and B7-H3 as prognostic biomarkers in chordoma. (Abstract #10050)**
A. Schoenfeld, G. P. Nielsen, F. Hornicek, Z. Duan, S. Ferrone, J. H. Schwab
- Brd. 50B Outcome of patients (pts) with PDGFRA^{D842V} mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease. (Abstract #10051)**
P. Biron, P. A. Cassier, E. Fumagalli, A. Blesius, M. Debiec-Rychter, A. Adenis, J. Verweij, P. Hohenberger, J. Blay, P. G. Casali, EORTC Soft Tissue and Bone Sarcoma Group
- Brd. 50C Coexistence of gastrointestinal stromal tumor (GIST) with desmoid tumor (DT): Case series of 22 patients. (Abstract #10052)**
A. G. Dumont, L. Rink, M. Miettinen, H. Joensuu, J. R. Strosberg, A. Gronchi, C. L. Corless, A. J. Lazar, D. Lev, M. von Mehren
- Brd. 50D Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumor (GIST). (Abstract #10053)**
O. Oladeji, E. Wardelmann, U. Ronellenfitsch, D. Pink, P. Reichardt, P. Ströbel, P. Hohenberger
- Brd. 50E Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib. (Abstract #10054)**
D. Goldstein, C. Lee, Y. Hui, B. Shah, D. Yip, G. A. McArthur
- Brd. 50F Gastrointestinal stromal tumor (GIST) of the rectum and pararectal space: A French Sarcoma Group (FSG) retrospective review. (Abstract #10055)**
F. Duffaud, P. A. Cassier, A. Adenis, O. Bouche, M. Rios Sr., O. Collard, E. Bompas, S. Chabaud, J. Blay, A. Le Cesne
- Brd. 50G Surgery of residual disease of myxoid liposarcoma (MLS) patients responding to trabectedin. (Abstract #10056)**
R. Sanfilippo, F. Grosso, M. D'Incalci, P. Dileo, S. Pilotti, C. Morosi, M. Fiore, J. C. Tercero, A. Gronchi, P. G. Casali
- Brd. 50H Quality of randomized controlled trials reporting in the treatment of sarcomas. (Abstract #10057)**
M. Toulmonde, C. Bellera, S. Mathoulin-Pelissier, N. Bin Bui, A. Italiano

Sunday, June 6, 2010

- Brd. 51A Antiproliferative effect of mTOR inhibitor everolimus (EV) alone or in combination with multikinase inhibitor (MK-I) sorafenib (SOR) in preclinical models of osteosarcoma (OS). (Abstract #10058)**
Y. Pignochino, G. Grignani, M. Basiricò, G. Cavalloni, M. Motta, S. Bruno, S. Aliberti, M. Alberghini, P. Picci, M. Aglietta
- Brd. 51B Sunitinib (SU)-related hypertension in a randomized placebo (P)-controlled trial of GIST patients (pts). (Abstract #10059)**
M. Ewer, T. M. Suter, D. J. Lenihan, L. Niculescu, A. Breazna, R. J. Motzer, G. D. Demetri
- Brd. 51C A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor- α or - β ; (PDGFR- α /PDGFR- β): An Italian Sarcoma Group study. (Abstract #10060)**
G. Grignani, E. Palmerini, S. Stacchiotti, A. Boglione, V. Ferraresi, S. Frustaci, A. Comandone, P. G. Casali, S. Ferrari, M. Aglietta
- Brd. 51D Adjuvant imatinib therapy of 208 gastrointestinal stromal tumor (GIST) patients: Dose, duration, and risk assessment. (Abstract #10061)**
J. C. Trent, M. von Mehren, P. W. Pisters, E. Stealey, L. A. Sirulnik, C. D. Blanke
- Brd. 51E Quality of life (QoL) in osteosarcoma: First results of the presurgery treatment period of EURAMOS-1 (NCT00134030). (Abstract #10062)**
A. Wiener, R. Nagarajan, L. Hjorth, M. Jenney, P. De Vos, M. L. Bernstein, M. D. Krailo, M. R. Sydes, G. Calaminus, for the EURAMOS-1 Study Group
- Brd. 51F High-dose photon-beam radiation therapy in chordoma: A single-institution retrospective analysis. (Abstract #10063)**
C. Sangalli, S. Stacchiotti, A. Gronchi, P. G. Casali, E. Pignoli, P. Pittoni, E. Palassini, P. Olmi
- Brd. 51G Impact of imatinib plus best supportive care in imatinib- and sunitinib-exposed patients with refractory advanced gastrointestinal stromal tumor. (Abstract #10064)**
A. Sawaki, T. Kanda, Y. Komatsu, T. Nishida
- Brd. 51H Metronomic oral cyclophosphamide (CPM) and prednisolone in elderly patients (pts) with inoperable or metastatic soft tissue sarcoma (STS). (Abstract #10065)**
O. Mir, J. Domont, A. Cioffi, S. Bonvalot, B. Boulet, C. le Pechoux, G. Missenard, F. Rimareix, P. Terrier, A. Le Cesne
- Brd. 52A PAX3/7-FOXO1 fusions by fluorescent in situ hybridization (FISH) using an adult rhabdomyosarcoma tissue microarray. (Abstract #10066)**
S. N. Dumont, A. J. Lazar, J. A. Bridge, J. C. Trent
- Brd. 52B Cutaneous angiosarcoma of the head and neck. (Abstract #10067)**
P. K. Pandalai, J. L. Hornick, Q. Wang, J. A. Morgan, S. George, E. H. Baldini, P. M. Devlin, C. P. Raut
- Brd. 52C Quality of surgical margins and local recurrence in primary extremity soft tissue sarcoma (STS). (Abstract #10068)**
S. Bonvalot, A. Dunant, C. le Pechoux, P. Terrier, F. Rimareix, B. Boulet, L. Medjoub, A. Cioffi, J. Domont, A. Le Cesne
- Brd. 52D Immunohistochemical study and fluorescent in situ hybridization analysis of JAZF1 in 67 cases of endometrial stromal tumors collected in a tissue microarray. (Abstract #10069)**
J. Duclos, A. Valent, G. Malouf, F. Drusch, N. Auger, P. Vielh, G. Vassal, P. Duvillard, P. Pautier
- Brd. 52E Prognostic factors of KIT-negative GIST-like patients (KNGL): A Spanish Group for Sarcoma Research (GEIS) study. (Abstract #10070)**
J. Martin Broto, X. Garcia del Muro, J. Rubio, A. Gutierrez, J. Martinez-Trufero, I. Sevilla, N. Lainez, R. Andres, R. Ramos, J. A. Lopez-Guerrero

- Brd. 52F** **Absence of correlation between the molecular subtype of *COL1A1-PDGFB* fusion gene and the clinico-histopathological features of dermatofibrosarcoma protuberans: Analysis of 35 novel cases and review of 137 cases from the literature. (Abstract #10071)**
D. Giaccherio, G. Maire, P. Nuin, J. Coindre, J. P. Lacour, F. Pedeutour
- Brd. 52G** **Nonstandard dosing in gastrointestinal stromal tumors: A registry observation. (Abstract #10072)**
P. W. Pisters, M. von Mehren, E. Stealey, L. A. Sirulnik, J. C. Trent
- Brd. 52H** **Imaging-guided core needle biopsies (CNB) compared to surgical biopsies (SB) for soft tissue tumors: A cost-effectiveness analysis. (Abstract #10073)**
S. Taieb, Y. Robin, M. Morel, F. Watelle, L. Vanseymortier, N. Penel
- Brd. 53A** **First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histologic soft tissue sarcoma (STS) subtypes and as a prognostic factor for MPNST: An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) study. (Abstract #10074)**
J. R. Kroep, M. Ouali, H. Gelderblom, A. Le Cesne, T. J. Dekker, M. M. Van Glabbeke, P. Hohenberger, P. C. Hogendoorn
- Brd. 53B** **First report of outcomes with neoadjuvant chemoradiotherapy (NCR) using weekly intravenous (IV) cisplatin with radiation (NCWR) for treatment of stage II and III extremity soft tissue sarcoma (STS). (Abstract #10075)**
K. K. Curtis, J. B. Ashman, C. P. Beauchamp, M. D. Callister, M. W. Dopp, A. C. Dueck, L. L. Gunderson, T. R. Fitch
- Brd. 53F** **Antitumor activity of pemetrexed (Pem) in second-line advanced/metastatic osteosarcomas: A multicenter phase II study. (Abstract #10076)**
N. Bin Bui, G. Egerer, S. Ferrari, A. Comandone, A. Cioffi, H. Rassam, A. Michel, S. Ameryckx, S. Weitckus, F. Duffaud
- Brd. 53G** **Evaluation of quality of life in patients treated with resection and reconstruction of the upper or lower limb for bone sarcomas. (Abstract #10077)**
P. Ruggieri, M. Montalti, E. Pala, G. Guerra, T. Calabrò, A. Angelini, N. Fabbri, S. Ferrari, P. Picci, M. Mercuri
- Brd. 53H** **Prognostic significance of proliferation markers and telomerase activity in gastrointestinal stromal tumors. (Abstract #10078)**
A. Augustinakova, H. Brizova, I. Hilska, M. Kalinova, R. Kodet
- Brd. 54A** **Effect of adjuvant radiotherapy on survival in localized limb or trunk wall well-differentiated liposarcoma (WDLPS). (Abstract #10079)**
A. Duret, E. Stoeckle, S. Bonvalot, A. Italiano, S. Piperno-Neumann, G. Kantor, C. le Pechoux, L. Guillou, J. Coindre, J. Blay
- Brd. 54B** **Efficacy of neoadjuvant doxorubicin and ifosfamide (AI) in myxoid /round cell liposarcoma (MRCL): The M. D. Anderson Cancer Center experience (MDACC). (Abstract #10080)**
D. Katz, P. Boonsirikamchai, R. S. Benjamin, S. Patel, J. A. Ludwig, J. C. Trent, L. Xiao, V. Ravi, H. Choi, D. M. Araujo
- Brd. 54F** **Assessment of early response to imatinib 800 mg after 400 mg progression by 18 f-fluorodeoxyglucose positron emission tomography in patients with metastatic gastrointestinal stromal tumor. (Abstract #10081)**
A. Rodriguez Espindola, M. Chacon, M. Elela, E. Roca, G Mendez, S. Rojo, C. Puparelli, R Chacon
- Brd. 54G** **Effect of radiation therapy on survival of patients with surgically resected retroperitoneal sarcoma: A population-based matched pair study. (Abstract #10082)**
A. Choi, J. Barnholtz-Sloan, J. Kim
- Brd. 54H** **Sunitinib as the second-line therapy for advanced GISTs after failure of imatinib in Korean patients. (Abstract #10083)**
M. Ryu, D. Yoon, B. Ryoo, M. Beck, D. Choi, Y. Cho, J. Lee, H. Chang, T. Kim, Y. Kang

Sunday, June 6, 2010

- Brd. 55A** **Gastrointestinal stromal tumors (GISTs) and other cancers: Cambridge GIST Study Group experience. (Abstract #10084)**
V. R. Bulusu, N. Carroll, S. Pursglove, V. Save, R. Hardwick
- Brd. 55B** **Impact of subspecialty, clinical volume, and years of practice in selection of treatment sequencing in the management of localized extremity soft tissue sarcoma. (Abstract #10085)**
R. J. Canter, N. Wasif, R. M. Tamurian, S. Christensen, L. Do, S. R. Martinez, S. Chen, M. F. Brennan
- Brd. 55C** **Pattern of growth of retroperitoneal sarcoma: Do they push or infiltrate adjacent organs? Analysis of a single institution series. (Abstract #10086)**
C. E. Mussi, P. Bagnoli, M. Coladonato, A. Bertuzzi, S. Secondino, A. Santoro, P. Colombo, P. Navarra, E. Morengi, V. Quagliuolo
- Brd. 55D** **Neoadjuvant, adjuvant, and palliative treatment with imatinib in patients with gastrointestinal stromal tumors. (Abstract #10087)**
B. E. Nilsson, K. Sjolund, E. P. Nilsson, B. Wangberg, O. Nilsson, H. Ahlman
- Brd. 55E** **Long-term results of primary re-excision after unplanned resection of a soft tissue sarcoma of the extremities and trunk. (Abstract #10088)**
M. Peiper, A. Rehders, E. Boelke, W. Budach, C. Poremba, W. Knoefel
- Brd. 55F** **Effect of histone deacetylase inhibitor (HDACI) PCI-24781 on chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. (Abstract #10089)**
E. Choy, Y. Cao, F. Hornicek, K. B. Wood, J. H. Schwab, X. Liu, H. Mankin, Z. Duan
- Brd. 55G** **Evaluation of nilotinib (N) in advanced GIST previously treated with imatinib mesylate (IM) and sunitinib (S). (Abstract #10090)**
C. Cauchi, N. Somaiah, P. F. Engstrom, S. Litwin, M. Lopez, J. Lee, M. Davey, B. Bove, A. K. Godwin, M. von Mehren
- Brd. 55H** **Measurement of interstitial fluid pressure (IFP) and circulating biomarkers in soft tissue sarcoma (STS): An exploratory phase II clinical and correlative study of sorafenib (SOR) in patients with refractory STS (NCI Protocol 6948). (Abstract #10091)**
C. P. Raut, J. A. Morgan, R. H. Quek, Y. Boucher, G. D. Duda, J. Lahdenranta, M. Ancukiewicz, J. P. Eder, R. K. Jain, G. D. Demetri
- Brd. 56A** **The GOLD reGISTry: A global observational registry collecting longitudinal data on patients with advanced GIST—Second annual summary. (Abstract #10092)**
M. Chacon, P. Reichardt, J. Gu, T. Nishida, C. H. Barrios, J. Blay, A. Reichardt, M. E. Blackstein, P. G. Casali, Y. Kang
- Brd. 56B** **Extraskeletal osteosarcoma: Clinicopathologic features and results of multimodal management. (Abstract #10093)**
N. Fabbri, A. Tiwari, M. Umer, D. Vanel, M. Alberghini, P. Ruggieri, S. Ferrari, P. Picci, M. Mercuri
- Brd. 56C** **Analysis of prognostic factors of pediatric-type sarcomas in adult patients. (Abstract #10094)**
H. Ahn, J. Um, J. Lee, W. Kim, D. Lim, J. Park
- Brd. 56D** **Radiological tissue changes and pathological response in localized high-grade soft tissue sarcomas (STS) as predictors of outcome after neoadjuvant treatment with chemoradiotherapy (CRT). (Abstract #10095)**
A. Lopez-Pousa, S. Bague, J. Llauger, J. Majo, J. Isern, M. Quintana, M. Fernandez, L. Robert, N. Sala, I. Sullivan
- Brd. 56E** **Clear cell sarcoma (CCR): Clinical behavior and response to chemotherapy. (Abstract #10096)**
S. Stacchiotti, E. Palassini, T. Negri, M. Orsenigo, R. Bertulli, C. Morosi, S. Pilotti, M. Fiore, A. Gronchi, P. G. Casali

- Brd. 56F** **A national registry for the off-label use of targeted therapies in patients (pts) with malignant mesenchymal tumors: A retrospective study from the GSF-GETO. (Abstract #10097)**
J. Bay, A. Le Cesne, A. Cioffi, N. Penel, F. Duffaud, D. Cupissol, S. Piperno-Neumann, C. Cropet, L. Bouclier, I. Ray-Coquard
- Brd. 56G** **Systemic therapy in clear cell sarcoma. (Abstract #10098)**
A. Constantinidou, R. L. Jones, O. Al-Muderis, K. Thway, S. Ashley, M. R. Scurr, D. R. D'Adamo, M. Keohan, R. G. Maki, I. R. Judson

Sunday, June 6, 2010

4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM

Predictors of Response to Preoperative Therapy: Where Are We?

Location: N Hall B1

CME credit: 1.5

Track(s): Breast Cancer

William Fraser Symmans, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

Antonio C. Wolff, MD—Co-Chair

The Johns Hopkins University

Discussion

- 4:30 PM** Gabriel N. Hortobagyi, MD
University of Texas M. D. Anderson Cancer Center
Preoperative Therapy in Operable Breast Cancer: How, When, and Why?
- 4:45 PM** **Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: A multicenter, randomized phase II study (GEICAM/2006–03). (Abstract #500)**
E. Alba, L. Calvo, J. Albanell, J. De la Haba, J. Chacon, A. Arcusa Lanza, P. Sanchez Rovira, A. Plazaola, J. Lopez Garcia-Asenjo, A. Lluch, on behalf of GEICAM
- 5:00 PM** **Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials. (Abstract #501)**
G. Von Minckwitz, M. Untch, E. Nueesch, M. Kaufmann, S. Kuemmel, P. A. Fasching, W. Eiermann, J. U. Blohmer, S. Loibl, P. Jueni, GBG and AGO-Breast Study Group
- 5:15 PM** **Molecular and genomic predictors of response to single-agent doxorubicin (ADR) versus single-agent docetaxel (DOC) in primary breast cancer (PBC). (Abstract #502)**
M. Martin, A. Romero, J. Lopez Garcia-Asenjo, M. C. Cheang, B. Oliva, J. Garcia Saenz, X. He, T. Caldes, E. Diaz-Rubio, C. M. Perou
- 5:30 PM** **Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis. (Abstract #LBA503)**
H. R. Bonnefoi, J. Bogaerts, M. Piccart, L. Mauriac, P. Fumoleau, J. Jassem, V. Becette, D. A. Cameron, J. Bergh, R. Iggo, on behalf of the EORTC, SweBCG, SAKK, and ACCOG Investigators
- Discussion**
- 5:45 PM** Mitchell Dowsett, PhD (Abstracts #500–LBA503)
Royal Marsden Hospital

4:45 PM - 6:00 PM
SPECIAL SESSION

B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Location: S100a

CME credit: 1.25

Track(s): Special Session; Geriatric Oncology

Harvey Jay Cohen, MD

Duke University Medical Center

Geriatric Oncology: Where Have We Been? Where Are We Going?

Sunday, June 6, 2010

4:45 PM - 6:00 PM
EDUCATION SESSIONS

Aging, Frailty, and Medical Therapy for Colorectal Cancer: Who Should Be Treated and How?

Location: S404

CME credit: 1.25

Track(s): Gastrointestinal (Colorectal) Cancer; Geriatric Oncology

Richard M. Goldberg, MD—Chair

University of North Carolina

Elderly and/or Frail Patients with Colorectal Cancer: A Clinician's Approach

Martine Extermann, MD

H. Lee Moffitt Cancer Center & Research Institute

Age and Frailty: More Than Two Sides of the Same Coin?

Daniel J. Sargent, PhD

Mayo Clinic

Age, Frailty, and Chemotherapy: Data, More Data, and More Confusion

Myelodysplastic Syndromes and Elderly Acute Myeloid Leukemia

Location: E354a

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation

Guillermo Garcia-Manero, MD—Chair

University of Texas M. D. Anderson Cancer Center

Prognostic Models in MDS

David Steensma, MD

Dana-Farber Cancer Institute

Beyond Supportive Care in MDS: Growth Factors—Epigenetic Therapies, Immunomodulators, and Novel Chemotherapeutic Agents

Farhad Ravandi Kashani, MD

University of Texas M. D. Anderson Cancer Center

Acute Leukemia in the Elderly: Who Should Be Treated and How?

New Technology in Cancer Immune Therapy

Location: E353

CME credit: 1.25

Track(s): Tumor Biology; Developmental Therapeutics

Michel Sadelain, MD, PhD—Chair

Memorial Sloan-Kettering Cancer Center

Chimeric Immunoreceptor Engineered T-cells

Zelig Eshhar, PhD

Weizmann Institute of Science

T-cell Engineering for Adoptive Immunotherapy

Leisha A. Emens, MD, PhD

The Johns Hopkins University

Combinatorial Immunotherapy

Nonmelanoma Skin Cancers: New Insights, New Directions

Location: S406 (Vista Room)

CME credit: 1.25

Track(s): Melanoma/Skin Cancers

Paul Nghiem, MD, PhD—Chair

University of Washington

Merkel Cell Carcinoma: New Biologic Insights and Management Strategies

Juergen C. Becker, MD, PhD

University of Wuerzburg

Nonmelanoma Skin Cancer in the Immunosuppressed Patient

Jean Y. Tang, MD, PhD

Stanford University

Molecular Pathways In Basal Cell Carcinoma and Clinical Trials

Physical Activity in Cancer Populations: What's New?

Location: E354b

CME credit: 1.25

Track(s): Patient and Survivor Care; Breast Cancer; Gastrointestinal (Colorectal) Cancer

Jennifer A. Ligibel, MD—Chair

Dana-Farber Cancer Institute

Physical Activity and Cancer: Overview and Implications for Survivorship

Kerry S. Courneya, PhD

University of Alberta

Randomized Trials of Exercise in Cancer Patients: Health-related Fitness and Patient-reported Outcomes

Kathryn Schmitz, PhD, MPH

University of Pennsylvania

Exercise Testing and Prescription for Cancer Survivors: Guidelines from the American College of Sports Medicine

Stem Cells in Neuro-oncology

Location: S100b

CME credit: 1.25

Track(s): Central Nervous System Tumors; Tumor Biology

Richard Gilbertson, MD, PhD—Chair

St. Jude Children's Research Hospital

Stem Cells in Neuro-oncology: Overview

Charles D. Stiles, PhD

Dana-Farber Cancer Institute

Central Nervous System Stem Cells as Therapeutic Targets

Evan Snyder, MD, PhD

Burnham Institute for Medical Research

Using Stem Cells to Treat Brain Tumors

Sunday, June 6, 2010

The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers Affect Treatment Decisions?

Location: E Hall D1

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer; Cancer Genetics; Cancer Prevention/Epidemiology

Johanna C. Bendell, MD—Chair

Sarah Cannon Research Institute

Understanding the Evolution in Epidemiology of Esophagogastric Cancer

Jason L. Hornick, MD, PhD

Brigham and Women's Hospital

The Molecular Continuum of Barrett's Esophagus to Esophagogastric Cancer

Janusz Jankowski, PsyD

Digestive Diseases Center

Using the Newest Molecular Markers in Prognosis and Risk Stratification

SUNDAY

4:45 PM - 6:00 PM
MEET THE PROFESSOR SESSION

Cutaneous B-cell Lymphoma (M08)-TICKETED SESSION

Location: E451b

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders

Lynn D. Wilson, MD, MPH
Yale University

4:45 PM - 6:00 PM
CLINICAL PROBLEMS IN ONCOLOGY

Incidental Findings on Imaging in the Patient with Cancer: A Prudent Approach to Evaluation and Management (C10)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Health Services Research; Patient and Survivor Care

Scott Michael Gilbert, MD, MS—Chair
University of Florida

The Incidental Renal Mass: Evaluation and Management in the Cancer Patient

J. Stuart Wolf Jr., MD
University of Michigan

The Incidental Adrenal Mass: Evaluation and Management in the Cancer Patient

David E. Ost, MD

University of Texas M. D. Anderson Cancer Center

The Incidental Pulmonary Nodule: Evaluation and Management in the Cancer Patient

Monday, June 7, 2010

7:30 AM - 9:00 AM

HIGHLIGHTS OF THE DAY

Highlights of the Day II including Partners in Progress Award

Location: E Hall D1

CME credit: 1.5

Track(s): Special Session; General Oncology

Kim Allyson Margolin, MD—Co-Chair

Seattle Cancer Care Alliance

Douglas W. Blayney, MD—Co-Chair

University of Michigan

7:30 AM

Ellen V. Sigal, PhD—Partners in Progress Award Recipient

Friends of Cancer Research

7:40 AM

Nicholas J. Vogelzang, MD

Nevada Cancer Institute

Genitourinary (Prostate) Cancer

7:55 AM

Howard S. Hochster, MD

New York University

Gastrointestinal (Colorectal) Cancer

8:10 AM

Claire F. Verschraegen, MD

University of New Mexico

Gynecologic Cancer

8:25 AM

Jean-Luc Harousseau, MD

Rene Gauducheau Cancer Center

Myeloma

8:40 AM

Scott Michael Lippman, MD

University of Texas M. D. Anderson Cancer Center

Cancer Prevention/Epidemiology

MONDAY

**8:00 AM - 9:15 AM
SPECIAL SESSION**

Cancer Survivors: A Challenge to Health Care Systems Worldwide

Location: S100b

CME credit: 1.25

Track(s): Special Session; Health Services Research; International

Eliezer Robinson, MD—Chair

Israel Cancer Association

The Needs of Cancer Survivors

Douglas W. Blayney, MD

University of Michigan

ASCO's Efforts to Promote Survivorship Care

Eva Grunfeld, MD, PhD

University of Toronto

Follow-up and Other Health Care Needs of Cancer Survivors: How Are Different Health Care Systems Meeting the Challenge?

Sophie D. Fossa, MD

The Norwegian Radium Hospital

Life-threatening Long-term Effects after Cancer: Who Needs What Follow-up?

Lawrence N. Shulman, MD

Dana-Farber Cancer Institute

Challenges and Opportunities in Developing a Cancer Survivorship Program in the Context of Current Trends in Oncology Care

Monday, June 7, 2010

8:00 AM - 9:15 AM
EDUCATION SESSIONS

Biomarker-driven Treatment in Stage II Colon Cancer: When to Hold and When to Fold

Location: S100a

CME credit: 1.25

Track(s): Gastrointestinal (Colorectal) Cancer; Tumor Biology

Al Bowen Benson III, MD—Chair

Northwestern University

Overview of Adjuvant Clinical Trials in Stage II Colon Cancer: Results, Challenges, and Confusion

Sabine Tejpar, MD, PhD

UZ Gasthuisberg-Katholieke University Leuven

Prognostic and Predictive Molecular Biomarkers in Stage II Colon Cancer: Current Evidence and Future Perspective

Neal J. Meropol, MD

University Hospitals Case Medical Center

Biomarker-driven Treatment Decisions in Stage II Colon Cancer: Making Sense of What We Know

Controversies in Adjuvant Systemic Treatment of Early-stage Breast Cancer

Location: N Hall B1

CME credit: 1.25

Track(s): Breast Cancer

Anthony Howell, MD—Chair

Christie Hospital NHS Trust

Is It Ok Not to Give Chemotherapy in Node-positive Breast Cancer?

Harold J. Burstein, MD, PhD

Dana-Farber Cancer Institute

Tailoring Adjuvant Therapy for HER2-negative Breast Cancer

Ana M. Gonzalez-Angulo, MD, MSc

University of Texas M. D. Anderson Cancer Center

Small HER2-positive Tumors: When to Add Anti-HER2 Therapy?

Disparities in Cancer Care

Location: S404

CME credit: 1.25

Track(s): Health Services Research; Geriatric Oncology; International

Lisa A. Newman, MD, MPH—Chair

University of Michigan

Evolving U.S. Population Demographics and Implications for Disparities in Cancer Care

Beverly Moy, MD, MPH

Massachusetts General Hospital

Complex Etiologies and Strategies for Reducing Disparities in Cancer Care

Michael Silbermann, DMD, PhD

Middle East Cancer Consortium

Cancer Care in Different Contexts: Domestic and International Perspectives

Health Disparities in Lung Cancer: Race, Sex, and Genes

Location: E Hall D2

CME credit: 1.25

Track(s): Lung Cancer; Health Services Research; Tumor Biology

Alex A. Adjei, MD, PhD—Chair

Roswell Park Cancer Institute

Molecular Epidemiology of Lung Cancer: Ancestry Matters

Patrick C. Ma, MD, MSc

Case Western Reserve University

Molecular Genetic Variations between Human Populations

Nithya Ramnath, MD

University of Michigan

Impact of Gender on Incidence, Behavior, and Therapy of Lung Cancer

Impact of Health Literacy on Health Care, Decision Making, and Consent

Location: E353

CME credit: 1.25

Track(s): Patient and Survivor Care; Clinical Trials; Health Services Research

Terry C. Davis, PhD—Chair

Louisiana State University Medical Center

Impact of Limited Health Literacy: Assessing Literacy and Overcoming Barriers to Limited Literacy in Delivering Health Care

Cathy A. Coyne, PhD

West Virginia University

Overcoming Literacy Issues in Obtaining Informed Consent

Angela Fagerlin, PhD

University of Michigan

Decision Making in Breast and Prostate Cancer

Personalizing Therapeutic Approaches to Chronic Lymphocytic Leukemia

Location: E354a

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation

Susan Mary O'Brien, MD—Chair

University of Texas M. D. Anderson Cancer Center

Evolving Therapies for CLL

Sami N. Malek, MD

University of Michigan

Prognostic Markers in CLL: Do They Matter?

Clive Zent, MD

Mayo Clinic

CLL in the Elderly: How Should It Be Treated?

Monday, June 7, 2010

The Biology and Treatment of Wilms Tumor

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology; Tumor Biology

Jeffrey Dome, MD—Chair

Children's National Medical Center

Wilms Tumor: Unsettled Questions and Controversies

Nazneen Rahman, PhD, FRCP

The Royal Marsden Institute of Cancer Research

New Developments in Wilms Tumor Genetics

Elizabeth Perlman, MD

Northwestern University

Gene Expression Arrays: What Have They Taught Us about Wilms Tumor?

Toward Optimizing Outcomes in Early-stage Testicular Cancer: How Little or How Much Therapy?

Location: E354b

CME credit: 1.25

Track(s): Genitourinary Cancer; Patient and Survivor Care

Christian K. Kollmannsberger, MD—Chair

British Columbia Cancer Agency

Management Options for Early-stage Seminoma and Nonseminoma

David Peter Wood, MD

University of Michigan

Is RPLND Still Relevant?

George J. Bosl, MD

Memorial Sloan-Kettering Cancer Center

Toxicity and Survivorship in Testicular Cancer Survivors: Should It Modify What I Do?

Translocation-specific Sarcomas: Can Molecular Targets Translate to Therapeutics?

Location: S406 (Vista Room)

CME credit: 1.25

Track(s): Sarcoma; Pediatric Oncology

Lee J. Helman, MD—Chair

National Institutes of Health/National Cancer Institute

IGF1R Targeting of Translocation-associated Sarcomas

Marc Ladanyi, MD

Memorial Sloan-Kettering Cancer Center

Target Genes of Chimeric Transcription Factors in Pediatric Sarcomas: A Source of Potential Therapeutic Targets

Jeffrey Toretsky, MD

Georgetown University

Targeting Protein Products of Sarcoma-specific Translocations with Small Molecules

MONDAY

8:00 AM - 9:15 AM
MEET THE PROFESSOR SESSION

Contract Negotiation for Your First Job (M09)-TICKETED SESSION

Location: E451b

CME credit: 1.25

Track(s): Professional Development

Jamie H. Von Roenn, MD
Northwestern University

8:00 AM - 9:15 AM
CLINICAL PROBLEMS IN ONCOLOGY

The Spectrum of Therapeutic Dilemmas in Kidney Cancer: From Early- to Late-stage Disease (C11)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Genitourinary Cancer; Patient and Survivor Care

Steven Campbell, MD, PhD—Chair
Cleveland Clinic
Diagnosis and Management of the Renal Mass

Przemyslaw Twardowski, MD
City of Hope
Management of Non-clear Cell Histology

Tim Eisen, PhD, FRCP
University of Cambridge/Cancer Research UK
Optimal Management of Toxicities Related to Targeted Agents

Monday, June 7, 2010

8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM

Paths for Clinical Development of PI3K Inhibition

Location: E Arie Crown Theater

CME credit: 1.5

Track(s): Developmental Therapeutics

A. Dimitrios Colevas, MD—Co-Chair

Stanford University

Pasi A. Janne, MD, PhD—Co-Chair

Dana-Farber Cancer Institute

Discussion

8:00 AM Neal Rosen, MD, PhD
Memorial Sloan-Kettering Cancer Center

8:15 AM **A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. (Abstract #3003)**
J. Baselga, M. J. De Jonge, J. Rodon, H. A. Burris III, D. C. Birlle, S. S. De Buck, D. Demanse, Q. C. Ru, M. Goldbrunner, J. C. Bendell

8:30 AM **A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. (Abstract #3004)**
G. Edelman, C. Bedell, G. Shapiro, S. S. Pandya, E. L. Kwak, C. Scheffold, L. T. Nguyen, A. Laird, J. Baselga, J. Rodon

8:45 AM **First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. (Abstract #3005)**
H. Burris, J. Rodon, S. Sharma, R. S. Herbst, J. Tabernero, J. R. Infante, A. Silva, D. Demanse, W. Hackl, J. Baselga

Discussion

9:00 AM Carlos L. Arteaga, MD (Abstracts #3003–3005)
Vanderbilt University Medical Center
Next Steps in Clinical Development of PI3K Inhibitors?

**8:00 AM - 12:00 PM
POSTER DISCUSSION SESSION**

Melanoma/Skin Cancers

Display Time: 8:00 AM - 12:00 PM
 Display Location: S403
 Discussion Time: 11:00 AM - 12:00 PM
 Discussion Location: S406 (Vista Room)
CME credit: 1
 Track(s): Melanoma/Skin Cancers

Ravi K. Amaravadi, MD—Co-Chair

University of Pennsylvania

Gregory A. Daniels, MD, PhD—Co-Chair

University of California, San Diego Moores Cancer Center

Discussion

11:00 AM Julie R. Lange, MD (Abstracts #8513–8517)
 The Johns Hopkins University School of Medicine

Discussion

11:15 AM David F. McDermott, MD (Abstracts #8518–8522)
 Beth Israel Deaconess Medical Center

Discussion

11:30 AM Henry B. Koon, MD (Abstracts #8523–8526)
 Ireland Cancer Center/University Hospital

Discussion

11:45 AM Anna C. Pavlick, MD (Abstracts #8527–8532)
 New York University Cancer Institute

Brd. 1 **Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as an independent prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008. (Abstract #8513)**

J. A. Sosman, J. Moon, P. Liu, L. E. Flaherty, M. B. Atkins, K. A. Margolin, J. M. Kirkwood, V. K. Sondak

Brd. 2 **Early ultrasound criteria drive sensitivity for detection of sentinel node metastases in melanoma patients: A prospective study in 800 patients. (Abstract #8514)**

C. A. Voit, A. C. Van Akkooi, G. Schaefer-Hesterberg, A. Schoengen, W. Sterry, A. M. Eggermont

Brd. 3 **Report card for compliance with NCCN guidelines in the surgical management of cutaneous melanoma across the United States: Time for remedial classes? (Abstract #8515)**

N. Wasif, R. J. Gray, B. A. Pockaj

Brd. 4 **Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study. (Abstract #8516)**

M. B. Atkins, G. V. Long, C. L. Warneke, M. Carlino, E. R. DeRose, M. M. Johnson, P. T. Brown, M. Lee, R. Kefford, J. E. Gershenwald

Brd. 5 **Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008. (Abstract #8517)**

V. K. Sondak, R. Tuthill, J. Moon, J. A. Thompson, C. D. Lao, B. G. Redman, L. E. Flaherty

Brd. 6 **Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers. (Abstract #8518)**

L. Decoster, B. Neyns, I. Vande Broek, E. Anckaert, D. De Clerck, J. De Mey, F. Majois, J. Baurain, H. Denys, J. De Greve

Monday, June 7, 2010

- Brd. 7** **A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). (Abstract #8519[^])**
R. D. Carvajal, M. K. Wong, J. A. Thompson, M. S. Gordon, K. D. Lewis, A. C. Pavlick, J. D. Wolchok, F. E. Fox, J. D. Schwartz, A. Y. Bedikian
- Brd. 8** **Phase II trial of bevacizumab and high-dose interferon alpha-2b in metastatic melanoma. (Abstract #8520)**
V. P. Grignol, T. Olencki, C. Taylor, A. Kibler, C. Kefauver, L. Wei, M. J. Walker, H. X. Chen, K. L. Kendra, W. E. Carson III
- Brd. 9** **First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07). (Abstract #8521)**
R. Dummer, O. Michielin, B. Seifert, A. F. Ochsenbein, R. Cathomas, M. R. Schlaeppli, M. Simcock, S. Gillessen, S. M. Goldinger, R. von Moos, Swiss Group for Clinical Cancer Research (SAKK)
- Brd. 10** **Evaluation of circulating angiopoietin levels with prognosis and disease progression in metastatic malignant melanoma. (Abstract #8522)**
R. Mouawad, J. Spano, R. Conforti, S. Vignot, T. de La Motte Rouge, D. Khayat
- Brd. 11** **Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. (Abstract #8523)**
D. P. Lawrence, O. Hamid, D. F. McDermott, I. Puzanov, M. Sznol, J. Clark, T. Logan, F. S. Hodi, K. N. Heller, K. A. Margolin
- Brd. 12** **Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma. (Abstract #8524)**
A. A. Tarhini, S. J. Moschos, H. Tawbi, Y. Shuai, W. E. Gooding, C. Sander, J. M. Kirkwood
- Brd. 13** **Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. (Abstract #8525)**
O. Hamid, M. Sznol, A. C. Pavlick, H. M. Kluger, K. B. Kim, P. D. Boasberg, R. Simantov, T. A. Davis, E. Crowley, P. Hwu
- Brd. 14** **Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial. (Abstract #8526)**
A. Hauschild, R. Gutzmer, S. Ugurel, U. Trefzer, F. Egberts, J. Hassel, D. Schadendorf, C. Mauch, C. Garbe, M. Weichenthal
- Brd. 15** **A phase II study of imatinib for advanced melanoma patients with KIT aberrations. (Abstract #8527)**
J. Guo, L. Si, Y. Kong, X. W. Xu, K. T. Flaherty, C. L. Corless, Y. Y. Zhu, L. Li, H. F. Li
- Brd. 16** **Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM). (Abstract #8528)**
L. G. Feun, M. You, C. Wu, M. Wangpaichitr, M. T. Kuo, A. Marini, A. Jungbluth, N. Savaraj
- Brd. 17** **Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma. (Abstract #8529)**
G. A. McArthur, I. Puzanov, A. Ribas, P. B. Chapman, K. B. Kim, J. A. Sosman, R. J. Lee, K. B. Nolop, K. T. Flaherty, R. Hicks
- Brd. 18** **Phase II study of vorinostat in patients with advanced melanoma. (Abstract #8530)**
N. B. Haas, E. McWhirter, D. Hogg, L. P. Martin, R. Polintan, S. Litwin, L. Wang, R. K. Alpaugh, J. A. Zwiebel, A. M. Oza
- Brd. 19** **Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma. (Abstract #8531)**
W. Hwu, W. L. Akerley, J. Stephenson, M. K. Yu, B. A. Evans, G. Mather, E. A. Swabb, O. Hamid
- Brd. 20** **A phase I/II trial of DTIC and dasatinib in metastatic melanoma. (Abstract #8532)**
A. P. Algazi, J. S. Weber, S. Andrews, P. Urbas, E. Arimura, J. Hwang, V. K. Sondak, B. Bastian, A. Daud

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy

Location: S Hall A2

Tracks(s): Developmental Therapeutics

- Brd. 1A** **A phase I study of CD40 agonist monoclonal antibody (CP-870, 893) with gemcitabine in pancreatic cancer. (Abstract #2539)**
G. L. Beatty, E. G. Chiorean, D. A. Torigian, U. R. Teitelbaum, W. Sun, K. D. Fly, R. D. Huhn, R. H. Vonderheide, P. J. O'Dwyer
- Brd. 1B** **Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors. (Abstract #2540)**
D. S. Hong, B. S. Koetz, R. Kurzrock, N. N. Senzer, W. Hanekom, A. Naing, J. J. Wheler, J. Mink, M. Ren, J. J. Nemunaitis
- Brd. 1C** **A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. (Abstract #2541)**
D. D. Von Hoff, P. LoRusso, R. Tibes, G. Shapiro, G. J. Weiss, J. A. Ware, J. Fredrickson, K. E. Mazina, G. G. Levy, A. J. Wagner
- Brd. 1D** **Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with adjuvant HER2/neu-based peptide vaccines. (Abstract #2542)**
K. S. Clive, T. A. Summers, G. T. Clifton, R. Patil, J. Tyler, J. P. Holmes, E. A. Mittendorf, A. Stojadinovic, S. Ponniah, G. E. Peoples
- Brd. 1E** **PET imaging of [¹¹C]docetaxel uptake and tumor perfusion in lung cancer. (Abstract #2543)**
A. A. van der Veldt, M. Lubberink, E. F. Comans, H. N. Greuter, A. van Lingen, S. Rizvi, A. D. Windhorst, E. Smit, N. Hendrikse, A. A. Lammertsma
- Brd. 1F** **Effect of a novel recombinant alphaviral vector on tolerance to self-antigen in the setting of elevated regulatory T cells. (Abstract #2544)**
M. Morse, A. Hobeika, T. Osada, P. Berglund, S. Negri, D. Niedzwiecki, B. Hubby, B. K. Burnett, T. M. Clay, H. K. Lyerly
- Brd. 1G** **Phase I study of vorinostat for patients with advanced solid tumors and hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI #8057). (Abstract #2545)**
M. J. Egorin, S. Kummar, J. Sarantopoulos, S. Shibata, P. LoRusso, M. Yerk, Y. Lin, S. P. Ivy, C. P. Belani, S. S. Ramalingam
- Brd. 1H** **A phase I/II study of intravenous Regin-G and Regin-C for cancer immunotherapy: The GeneVieve protocol. (Abstract #2546)**
J. G. Ignacio, S. P. Chawla, R. E. Manalo, L. Baniqued, F. S. San Juan, A. Madamba, F. L. Hall, E. M. Gordon
- Brd. 2A** **Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors. (Abstract #2547)**
L. Q. Chow, S. A. Laurie, C. P. Belani, G. K. Dy, C. Fortin, D. Patricia, A. K. Gupta, J. Kopit, S. Zhang
- Brd. 2B** **Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors. (Abstract #2548)**
M. D. Forster, A. Patnaik, S. K. Sandhu, K. Papadopoulos, B. J. Tromp, C. Messiou, F. Balkwill, B. Berns, J. S. De Bono, A. W. Tolcher
- Brd. 2C** **New approach for assessment of potential ethnic differences in parallel phase I/II studies in the United States and Asia. (Abstract #2549)**
T. Doi, D. Oh, Y. Bang, S. Y. Rha, H. C. Chung, N. Sakamoto, K. Schlienger, D. A. Bergstrom, W. J. Grossman, A. Ohtsu

Monday, June 7, 2010

- Brd. 2D Overall survival (OS) analysis of a phase I trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). (Abstract #2550)**
R. A. Madan, M. Mohebtash, P. M. Arlen, M. Vergati, S. M. Steinberg, K. Y. Tsang, W. L. Dahut, J. Schlom, J. L. Gulley
- Brd. 2E The trifunctional antibody catumaxomab: Correlation between immunological response and clinical outcome—New analysis of a pivotal phase II/III study. (Abstract #2551)**
M. G. Ott, H. Lindhofer, R. G. Linke, M. Hennig, H. Martinius, A. Klein, D. Seimetz
- Brd. 2F A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors. (Abstract #2552)**
U. Banerji, L. van Doorn, D. Papadatos-Pastos, P. Debnam, M. Tall, M. Toal, L. Hooftman, J. Verweij, F. A. L. M. Eskens
- Brd. 2G Pharmacokinetics (PK) of PF-562271, a focal adhesion kinase (FAK) inhibitor, and its effect on CYP3A in patients with advanced nonhematologic malignancies. (Abstract #2553)**
H. Xu, D. Yin, K. J. Pierce, S. M. Shreeve, B. Duncan, A. Bello
- Brd. 2H Final results of a phase Ib trial of PR104, a pre-prodrug of the bioreductive prodrug PR104A, in combination with gemcitabine (G) or docetaxel (D) in patients with advanced solid tumors. (Abstract #2554)**
M. B. Jameson, M. J. McKeage, R. K. Ramanathan, J. Rajendran, Y. Gu, W. R. Wilson, T. J. Melink, N. S. Tchekmedyan
- Brd. 3A CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes. (Abstract #2555)**
A. Yang, R. F. Kendle, B. A. Ginsberg, R. Roman, A. I. Heine, E. Pogoriler, J. D. Yuan, J. D. Wolchok
- Brd. 3B ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases. (Abstract #2556)**
J. Sarantopoulos, N. Y. Gabrail, S. L. Moulder, A. J. Brenner, C. L. Smith, D. Bouchard, K. Elian, B. Lawrence, J. Castaigne, R. Kurzrock
- Brd. 3C Phase I and pharmacokinetic study of everolimus and capecitabine in patients with solid tumors. (Abstract #2557)**
J. Wilmink, M. J. Deenen, H. Klümpen, R. Sparidans, J. Beijnen, J. H. Schellens, D. Richel
- Brd. 3D A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential. (Abstract #2558)**
B. L. Lum, G. E. Morrison, I. Chang, K. Jorga, C. Hop, Y. Shin, V. Malhi, M. Xie, J. A. Low, R. A. Graham
- Brd. 3E NCCAM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors. (Abstract #2559)**
P. J. Mansky, D. B. Wallerstedt, T. Sannes, J. Stagl, L. Johnson, M. R. Blackman, J. L. Grem, S. M. Swain, B. P. Monahan
- Brd. 3F A phase I study of sonopiczumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors. (Abstract #2560)**
M. S. Gordon, R. Just, L. S. Rosen, A. Dorr
- Brd. 3G Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of aryl-hydrocarbon receptor-mediated aminoflavone prodrug AFP464 in advanced solid tumors. (Abstract #2561)**
C. Massard, C. A. Gomez-Roca, R. Bahleda, B. Nguyen, V. D'hondt, T. Besse-Hammer, A. Awada, J. Soria

- Brd. 3H** **A phase I safety and tolerability study of vorinostat (V) in combination with sorafenib (S) in patients with advanced solid tumors, with exploration of two tumor-type specific expanded cohorts at the recommended phase II dose (renal and non-small cell lung carcinoma). (Abstract #2562)**
A. Dasari, L. Gore, W. A. Messersmith, S. Diab, A. Jimeno, C. D. Weekes, K. D. Lewis, H. A. Drabkin, T. W. Flaig, D. R. Camidge
- Brd. 4A** **A phase I study of bortezomib (BTZ) and temozolomide (TMZ) in patients with advanced solid tumors. (Abstract #2563)**
J. Portnow, S. Koehler, M. C. Cristea, W. A. Chow, V. M. Chung, D. Lim, R. Morgan, S. Shibata, P. H. Frankel, T. W. Synold
- Brd. 4B** **Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle aspirates of solid tumors. (Abstract #2564)**
A. C. Fan, J. Dermody, C. Kong, N. Zhang, A. D. Colevas, D. W. Felsher
- Brd. 4C** **Effect of a novel II-key hybrid HER2/neu peptide (AE37) vaccine with GM-CSF as compared to GM-CSF alone on levels of regulatory T-cell (Treg) populations. (Abstract #2565)**
G. T. Clifton, K. S. Clive, R. Patil, J. P. Holmes, L. C. Benavides, J. D. Gates, J. Tyler, E. A. Mittendorf, S. Ponniah, G. E. Peoples
- Brd. 4D** **Pharmacology of high-dose methotrexate in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG #20 trial. (Abstract #2566)**
A. J. Ferreri, M. Joerger, A. D. Huitema, S. Krähenbühl, J. H. Schellens, T. Cerny, M. Reni, E. Zucca, F. Cavalli
- Brd. 4E** **Effect of TGF- β 1 expressed on tumor-derived exosomes on survival and function of regulatory T cells. (Abstract #2567)**
H. Onishi, J. Wada, H. Suzuki, A. Yamasaki, S. Nagai, T. Morisaki, M. Katano
- Brd. 4F** **Factors of interindividual hematopoietic toxicity of carboplatin. (Abstract #2568)**
E. Chatelut, A. Schmitt, N. Penel, M. Campone, R. Largillier, P. Soulié, M. Fabbro, N. Houede, J. Medioni, P. Bougnoux, Groupe de Pharmacologie Clinique en Oncologie
- Brd. 4G** **Effect of prophylactic administration of recombinant human thrombopoietin on chemotherapy-induced severe thrombocytopenia in patients with advanced non-small cell lung cancer: A prospective self-control clinic study. (Abstract #2569)**
S. Lu, Y. Xu
- Brd. 4H** **A phase I study of ARRY-520 in solid tumors. (Abstract #2570)**
P. H. Goncalves, E. A. Sausville, M. J. Edelman, N. B. Pandya, M. M. Houlehan, B. B. Freeman, H. M. Simmons, J. S. Stallings, A. M. Ptaszynski, P. LoRusso
- Brd. 5A** **A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD). (Abstract #2571)**
S. Shibata, J. Longmate, V. M. Chung, H. Lenz, S. Kummar, J. Sarantopoulos, M. L. Harrison, T. W. Synold, S. P. Ivy, E. M. Newman
- Brd. 5B** **Phase I, pharmacokinetic study of temsirolimus in combination with nelfinavir in patients with solid tumors. (Abstract #2572)**
W. Kromdijk, A. D. Huitema, M. E. Kemper, J. H. Schellens, D. Richel, H. Klumpen
- Brd. 5C** **Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer. (Abstract #2573^)**
W. M. Fiedler, B. Ritter, R. Seggewiss, C. Bokemeyer, P. Fettes, M. Klinger, E. Vieser, D. Ruettinger, S. Kaubitzsch, M. Wolf
- Brd. 5D** **Clinical outcome of first-line melanoma patients who continue tremelimumab in spite of early disease progression. (Abstract #2574)**
D. I. Healey, P. S. Carlson, B. Huang, M. A. Marshall

Monday, June 7, 2010

- Brd. 5E** Early disease progression in a phase I study of bortezomib (B), cetuximab (C), and intensity-modulated radiation therapy (IMRT) for squamous cell carcinoma of the head and neck (SCCHN). (Abstract #2575)
C. Van Waes, A. G. Duffy, N. L. Simone, M. K. Gibson, Y. Arai, S. F. Rudy, T. Cooley-Zgela, M. Nyati, J. J. Wright, A. Argiris
- Brd. 5F** Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer. (Abstract #2576)
G. J. Weiss, M. S. Gordon, L. S. Rosen, P. Savvides, B. J. Adams, D. Alvarez, L. Liu, Y. Xu, S. L. Gerson, B. R. Leigh
- Brd. 5G** Genetic polymorphisms of metabolizing enzymes and transporters correlate with pharmacokinetics (PK) and pharmacodynamics (PD) of amrubicin. (Abstract #2577)
Y. Makino, R. Ando, N. Yamamoto, H. Sato, H. Nokihara, I. Sekine, H. Kunitoh, F. Koizumi, T. Tamura, H. Yamamoto
- Brd. 5H** Identification of novel prostate cancer-associated antigens through antibody profiling of prostate cancer patients treated with CTLA-4 blockade. (Abstract #2578)
L. Fong, S. Kwek, V. Dao, R. Roy, Y. Hou, J. Simko, E. J. Small
- Brd. 6A** Clinical and immunological responses to a DNA fusion vaccine in patients with carcinoembryonic antigen-expressing tumors: A Cancer Research UK phase I/II study. (Abstract #2579)
C. H. Ottensmeier, A. Mander, K. McCann, L. Low, E. Hall, A. Bateman, S. Clive, D. A. Anthoney, F. K. Stevenson, A. O'Callaghan
- Brd. 6B** Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors. (Abstract #2580)
S. G. Eckhardt, G. Gallant, B. I. Sikic, D. R. Camidge, H. A. Burris III, H. A. Wakelee, W. A. Messersmith, S. F. Jones, A. D. Colevas, J. R. Infante
- Brd. 6C** Histopathologic and immunohistochemical findings of skin rash to HER1 and HER1/2 inhibitors during anticancer therapy. (Abstract #2581)
B. Nardone, V. G. Kakkamani, K. M. Nicholson, M. Newman, J. Guitart, P. Gerami, N. Talarico, A. Rademaker, D. P. West, M. E. Lacouture
- Brd. 6D** Eribulin mesylate pharmacokinetics in patients with hepatic impairment. (Abstract #2582)
P. Witteveen, S. Marchetti, M. Mergui-Roelvink, L. Reyderman, W. Copalu, J. Wanders, A. Jenner, G. Edwards, J. H. Schellens, E. E. Voest
- Brd. 6E** PI3KCA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. (Abstract #2583)
F. Janku, A. M. Tsimberidou, I. Garrido-Laguna, D. S. Hong, A. Naing, G. S. Falchook, J. J. Wheler, S. Fu, S. A. Piha-Paul, R. Kurzrock
- Brd. 6F** Pharmacokinetics (PK) of oxaliplatin (OX) after intraperitoneal (IP) and intravenous (IV) administration in patients with gynecological malignancies. (Abstract #2584)
A. J. Combest, K. K. Zorn, R. P. Edwards, S. K. Hanna, S. Habibi, M. Strange, B. Zamboni, T. C. Krivak, P. Sukumvanich, W. Zamboni
- Brd. 6G** Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma. (Abstract #2585)
L. Wang, B. C. Goh, T. W. Lwin, H. Lee, S. L. Chan, R. S. Lim, A. T. Chan, W. Yeo
- Brd. 6H** Impact of antidiabetic agents on the survival of subjects with colorectal cancer (CRC). (Abstract #2586)
T. C. Gray, E. Siegel, R. Govindarajan

- Brd. 7A** Correlation of immune responses with survival in a randomized phase II study investigating multi-peptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC). (Abstract #2587)
H. Singh, N. Hilf, R. Mendrzyk, D. Maurer, T. Weinschenk, A. Kirner, J. Frisch, C. Reinhardt, A. Stenzl, S. Walter
- Brd. 7B** Improving patient selection for oncology phase I trials: Predictors of 90-day mortality and overall survival. (Abstract #2588)
N. G. Chau, A. Florescu, K. K. Chan, L. Wang, E. X. Chen, A. M. Oza, L. L. Siu
- Brd. 7C** Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. (Abstract #2589)
U. Swami, D. P. Petrylak, H. Raftopoulos, D. E. Shuster, G. Wang, V. Kumar, G. Martinez, S. Goel, J. Aisner
- Brd. 7D** Phase I/II study of BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma. (Abstract #2590)
D. A. Reardon, Y. Fu, H. C. Thurm, on behalf of the Phase I Study Group
- Brd. 7E** A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies. (Abstract #2591)
E. E. Cohen, M. Sharma, L. A. Janisch, W. M. Stadler, S. P. Kang, G. F. Fleming, M. J. Ratain
- Brd. 7F** A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #2592)
A. Chatterjee, J. Biswas, A. K. Chatterjee, S. Bhattacharya, B. P. Mukhopadhyay, A. Chakraborty, S. Das, R. S. Bhakta
- Brd. 7G** Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: Response, survival, and prognostic factors. (Abstract #2593)
M. Gilabert, B. Esterni, F. Bertucci, P. Viens, A. Goncalves
- Brd. 7H** Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors. (Abstract #2594)
M. Zweifel, D. M. Patterson, A. R. Padhani, M. R. Middleton, P. Price, M. R. Stratford, P. Ross, S. Halford, Z. Goldberg, G. J. Rustin
- Brd. 8A** Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies. (Abstract #2595)
E. Bustinza-Linares, G. S. Falchook, S. Fu, A. Naing, D. S. Hong, W. Hu, S. L. Moulder, J. J. Wheler, A. Sood, R. Kurzrock
- Brd. 8B** Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. (Abstract #2596)
W. Tan, K. D. Wilner, Y. Bang, E. L. Kwak, R. G. Maki, D. R. Camidge, B. J. Solomon, S. I. Ou, R. Salgia, J. W. Clark
- Brd. 8C** Hyperglycemia, hypertriglyceridemia, and hypercholesterolemia in a phase I trial of the combination of an mTOR inhibitor and IGF-1 receptor inhibitor. (Abstract #2597)
N. Busaidy, R. Kurzrock, P. LoRusso, A. D. Owens, H. X. Chen, L. Doyle, J. Zhang, K. Lawhorn, C. Chandhasin, A. Naing
- Brd. 8D** Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). (Abstract #2598)
M. Kozloff, G. W. Sledge, F. M. Benedetti, A. Starr, J. A. Wallace, M. J. Stuart, D. Gruver, K. Miller
- Brd. 8E** A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors. (Abstract #2599)
L. R. Molife, M. D. Forster, M. Krebs, T. Pwint, M. R. Middleton, S. B. Kaye, P. McCormack, H. Swaisland, J. Carmichael, M. Ranson

Monday, June 7, 2010

- Brd. 8F** Evaluation of poxviruses targeting the tumor microenvironment for cancer therapy. (Abstract #2600)
D. Kim, S. Kim-Schulze, G. Deraffele, J. Schlom, H. Kaufman
- Brd. 8G** A comparison of the Cockcroft-Gault (CG) and the modification of diet in renal disease (MDRD) equations for estimating renal function and guiding dose adjustment of oncology-related drugs. (Abstract #2601)
J. A. Grillo, S. Abraham, A. Khandelwal, Q. Liu, B. Booth, N. A. Rahman
- Brd. 8H** A phase I study of prolonged infusion of triapine in combination with a fixed-dose rate of gemcitabine in patients with advanced solid tumors. (Abstract #2602)
A. Mortazavi, D. Deam, Y. Ling, E. J. Harper, M. A. Phelps, I. J. Espinoza-Delgado, J. P. Monk III, G. A. Otterson, M. R. Grever, T. Bekaii-Saab
- Brd. 9A** Phase I study of proteasome inhibitor bortezomib (B) concurrent with re-irradiation therapy (re-RT) for recurrent squamous cell carcinoma of the head and neck (SCCHN). (Abstract #2603)
J. C. Morris, D. E. Citrin, L. Nottingham, S. F. Rudy, N. Harold, T. Cooley-Zgela, D. Goldstein, J. J. Wright, B. A. Conley, C. Van Waes
- Brd. 9B** Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The M. D. Anderson Cancer Center experience. (Abstract #2604)
J. J. Wheler, A. M. Tsimberidou, S. Wen, A. Naing, D. S. Hong, G. S. Falchook, S. A. Piha-Paul, S. Fu, S. L. Moulder, R. Kurzrock, Toxicity Working Group
- Brd. 9C** A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas. (Abstract #2605)
S. Kumar, A. P. Chen, J. J. Ji, D. Allen, M. J. Egorin, D. R. Gandara, H. Lenz, R. Morgan, E. M. Newman, J. H. Doroshow
- Brd. 9D** Single-nucleotide polymorphisms (SNPs) of CYP19A1 and plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment. (Abstract #2606)
G. Lunardi, S. Lastraioli, P. Bruzzi, P. Pronzato, G. Bisagni, R. Ponzzone, M. Porpiglia, S. Russo, L. Del Mastro, M. Venturini, Gruppo Italiano Mammella (GIM)
- Brd. 9E** Phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): First-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent administered on days 1, 4, 8, and 11 of a 21-day cycle. (Abstract #2607)
M. J. De Jonge, S. Sleijfer, L. P. Martin, J. Marshall, J. F. Deeken, J. A. Konner, C. Aghajanian, BMS Phase I Clinical Research Team
- Brd. 9F** Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical results. (Abstract #2608)
B. D. Shah, J. Tao, L. Sokol, P. A. Chervenick, M. R. Tomblin, J. Pinilla-Ibarz, L. Moscinski, S. Antonia, E. M. Sotomayor, S. Dessureault
- Brd. 9G** Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. (Abstract #2609)
M. A. Marshall, A. Ribas, B. Huang
- Brd. 9H** Phase I trial of dasatinib (D) and lapatinib (L). (Abstract #2610)
C. Erlichman, M. E. Meneffee, D. W. Northfelt, R. Qin, J. M. Reid, M. Oursler, R. Marks, P. Haluska, J. R. Molina, K. Koch
- Brd. 10A** Trabectedin (AP 12009) in the treatment of patients with advanced tumors: Completion of dose-escalation and first efficacy data. (Abstract #2611)
H. Oettle, A. Hilbig, T. Seufferlein, T. Luger, R. M. Schmid, G. von Wichert, S. Schmaus, H. Heinrichs, K. Schlingensiepen
- Brd. 10B** Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors. (Abstract #2612)
M. von Mehren, C. Britten, K. Lear, D. R. Camidge, Z. A. Wainberg, P. C. Pieslor, M. Darif, S. Harris, K. Balogh, S. Leong

Brd. 10C **A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. (Abstract #2613)**

R. D. Baird, R. S. Kristeleit, D. Sarker, D. Olmos, S. K. Sandhu, Y. Yan, H. Koeppen, G. G. Levy, J. Jin, J. S. De Bono

Monday, June 7, 2010

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Developmental Therapeutics—Experimental Therapeutics

Location: S Hall A2

Tracks(s): Developmental Therapeutics

- Brd. 10D** Phase I study of PF-03446962, a fully human mab against ALK 1, a TGF β receptor involved in tumor angiogenesis. (Abstract #3034)
L. W. Goff, F. G. De Braud, R. B. Cohen, J. Berlin, C. Noberasco, H. Borghaei, E. Wang, D. Hu Lowe, W. J. Levin, C. Gallo-Stampino
- Brd. 10E** Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors. (Abstract #3035)
T. Shimizu, A. W. Tolcher, A. Patnaik, K. Papadopoulos, O. Christensen, T. Lin, G. R. Blumenschein Jr.
- Brd. 10F** French, multicentric, prospective study of dynamic contrast-enhanced ultrasound (DCE-US) for the evaluation of antiangiogenic treatments in 400 patients. (Abstract #3036)
N. Lassau, J. Lacroix, S. Taieb, R. Aziza, V. Vilgrain, M. Cuinet, A. Sarran, C. Labbe, A. Jean-Pierre, S. Koscielny
- Brd. 10G** Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer. (Abstract #3037[^])
M. B. Bass, M. T. Davis, L. Kivman, H. Khoo, K. Notari, G. R. Blumenschein Jr., J. R. Mackey, S. I. Sherman, Y. Hei, S. D. Patterson
- Brd. 10H** Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer. (Abstract #3038)
F. Robert, M. S. Gordon, L. S. Rosen, D. S. Mendelson, M. Mulay, B. J. Adams, D. Alvarez, C. P. Theuer, B. R. Leigh
- Brd. 11A** Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). (Abstract #3039)
H. Hurwitz, P. S. Douglas, J. P. Middleton, G. W. Sledge, D. H. Johnson, D. A. Reardon, D. Chen, O. Rosen
- Brd. 11B** Treatment of VHL patients with sunitinib: Clinical outcomes and translational studies. (Abstract #3040)
S. F. Marin, I. E. McCutcheon, D. S. Gombos, S. Waguespack, N. M. Tannir, S. Wen, D. W. Davis, L. A. Smith, G. Fuller, E. Jonasch
- Brd. 11F** Phase Ib study of PTC299, a novel oral inhibitor of tumor VEGF expression, in patients with advanced cancer. (Abstract #3041)
G. K. Schwartz, M. A. Dickson, L. A. Callahan, C. H. Darby, M. Llorente, Y. Cao, H. J. Dials, L. L. Miller, H. H. Miao
- Brd. 11G** Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. (Abstract #3042)
J. Gollob, J. R. Infante, G. Shapiro, P. LoRusso, B. J. Dezube, J. Heymach, J. Cehelsky, R. Falzone, A. Vaishnaw, H. A. Burris III
- Brd. 11H** Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors. (Abstract #3043)
E. G. Chiorean, D. Matei, A. Younger, J. M. Funke, M. J. Waddell, D. R. Jones, N. M. Hahn, S. M. Perkins, K. Sandrasegaran, C. Sweeney
- Brd. 12A** Proposal of a new population pharmacokinetics (PK) model of sorafenib and rationale for a three-daily schedule. (Abstract #3044)
P. Boudou-Rouquette, B. Blanchet, O. Mir, B. Billefont, S. Ropert, S. Barete, R. Coriat, N. Franck, M. Tod, F. Goldwasser

- Brd. 12B Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. (Abstract #3045)**
M. H. Langenberg, P. Witteveen, J. M. Roodhart, M. P. Lolkema, H. Verheul, M. Mergui-Roelvink, E. Brendel, J. Krätzschar, J. H. Schellens, E. E. Voest
- Brd. 12F A phase I study of sunitinib malate (S) and gemcitabine (G) in solid tumors. (Abstract #3046)**
S. S. Krishnamurthi, L. Rath, J. A. Bokar, A. Dowlati, P. Savvides, J. Gibbons, M. M. Cooney, N. J. Meropol, S. P. Ivy, J. M. Brell
- Brd. 12G Phase Ib clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors. (Abstract #3047)**
A. Fasolo, C. Sessa, J. A. Bauer, D. Hess, L. Viganò, G. Del Conte, G. Capri, D. Gibson, R. Ruiz-Soto, L. Gianni
- Brd. 12H Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC). (Abstract #3048)**
B. Suttle, H. A. Ball, M. Molimard, D. Rajagopalan, R. S. Swann, R. G. Amado, L. Pandite
- Brd. 13A Direct in vivo evaluation of tumor VEGFR in response to treatment with pazopanib: A novel molecular imaging study. (Abstract #3049)**
S. K. Sarkar, Z. Levashova, J. Pizzonia, M. V. Backer, J. M. Backer, F. G. Blankenberg
- Brd. 13B Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI. (Abstract #3050)**
R. Jeraj, G. Liu, U. Simoncic, M. Vanderhoek, S. Perlman, D. B. Alberti, M. R. Harrison, G. Wilding
- Brd. 13C Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at 3 tesla (T). (Abstract #3051)**
I. Desai, H. Van Laarhoven, T. Hambroek, E. Ter Voert, W. Van Der Graaf, D. Van Spronsen, J. O. Barentsz, A. Heerschap, C. Van Herpen
- Brd. 13D Predictive and mechanistic factors of tyrosine kinase inhibitor (TKI)-induced macrocytosis. (Abstract #3052)**
P. Hamberg, R. Dulfer, A. Oosten, M. M. von Lindern, I. A. Boere, L. van Doorn, E. V. Meerten, S. Sleijfer, J. Verweij, W. H. Kruit
- Brd. 13E Extended linifanib therapy in patients with advanced solid tumors in a phase I trial. (Abstract #3053)**
B. C. Goh, C. Wong, J. Qian, E. McKeegan, J. L. Ricker, D. M. Carlson, R. A. Soo
- Brd. 13F A first-in-human, phase I pharmacodynamic (PD) and pharmacokinetic (PK) study of BNC105P, a novel vascular disrupting agent (VDA) and inhibitor of cancer cell proliferation. (Abstract #3054)**
G. Chong, J. Desai, D. C. Bibby, G. Kremmidiotis, S. S. Wong, A. F. Leske, C. A. Matthews, M. A. Rosen, D. Rischin
- Brd. 13G Phase II trial of dose-escalated sorafenib in advanced solid tumors. (Abstract #3055)**
T. J. Semrad, C. Eddings, C. Pan, D. Lau, D. R. Gandara, L. Beckett, P. Lara Jr.
- Brd. 13H Association of VEGF feedback production in bevacizumab therapy with systemic response. (Abstract #3056)**
P. Starlinger, T. Maier, D. Schauer, C. Nemeth, L. Alidzanovic, B. Gruenberger, T. Gruenberger, C. Brostjan
- Brd. 14A A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results. (Abstract #3057)**
E. Angevin, C. Lin, A. U. Pande, J. A. Lopez, J. Gschwend, A. L. Harzstark, M. Shi, O. Anak, B. J. Escudier

Monday, June 7, 2010

- Brd. 14B** **A phase I dose-escalation study of IMGN388 in patients with solid tumors. (Abstract #3058)**
D. S. Thompson, A. Patnaik, J. C. Bendell, K. Papadopoulos, J. R. Infante, R. A. Mastico, D. Johnson, A. Qin, J. J. O'Leary, A. W. Tolcher
- Brd. 14C** **A phase I study of two different schedules of nab-paclitaxel (Nab-p) with ascending doses of vandetanib (V) in patients (pts) with advanced solid tumors. (Abstract #3059)**
A. B. El-Khoueiry, S. Iqbal, H. Lenz, L. Roman, B. J. Gitlitz, D. Yang, S. Cole, J. Shriki, C. Hughlett, A. Garcia
- Brd. 14D** **Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer. (Abstract #3060)**
D. J. Slamon, S. A. Hurvitz, S. Applebaum, J. A. Glaspy, M. K. Allison, B. A. DiCarlo, R. D. Courtney, S. T. Kim, S. Randolph, R. S. Finn
- Brd. 14E** **Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. (Abstract #3061)**
T. Gil, P. Schöffski, A. Awada, H. Dumez, S. Bartholomeus, J. Selleslach, M. Taton, H. Fritsch, P. Glomb, G. M. Munzert
- Brd. 14F** **Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase. (Abstract #3062)**
N. Brega, G. A. McArthur, C. Britten, S. G. Wong, E. Wang, K. D. Wilner, A. Blasina, G. K. Schwartz, J. Gallo, A. N. Tse
- Brd. 14G** **Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors. (Abstract #3063)**
R. Bahleda, A. Spreafico, J. Soria, C. Moldovan, C. Belli, F. Fiorentini, A. Scaburri, M. A. Pacciarini, B. Laffranchi, M. Reni
- Brd. 14H** **A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors. (Abstract #3064)**
A. Daud, G. M. Springett, D. S. Mendelson, P. N. Munster, J. W. Goldman, J. R. Strosberg, G. Kato, T. Nesheiwat, R. Isaacs, L. S. Rosen
- Brd. 15A** **Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration. (Abstract #3065)**
S. Cresta, C. Sessa, G. Del Conte, A. Locatelli, E. Gallerani, F. Fiorentini, A. Scaburri, M. A. Pacciarini, R. Alzani, L. Gianni
- Brd. 15B** **Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors. (Abstract #3066)**
P. J. Rosen, A. W. Tolcher, P. Lee, M. Smitley, M. Fuerst, R. Spinelli, S. Crippa, M. G. Jannuzzo, S. Comis, K. Papadopoulos
- Brd. 15C** **A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. (Abstract #3067)**
S. Leijen, J. H. Schellens, G. Shapiro, A. C. Pavlick, R. Tibes, T. Demuth, J. Viscusi, J. D. Cheng, Y. Xu, A. M. Oza
- Brd. 15D** **Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorothamine in relapsed/refractory Hodgkin lymphoma (HL). (Abstract #3068)**
C. Carlo-Stella, A. Guidetti, S. Viviani, V. Bonfante, A. Marchiano, B. Gatti, C. D'Urzo, M. A. Di Nicola, P. Corradini, A. M. Gianni
- Brd. 15E** **Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors. (Abstract #3069)**
G. Shapiro, E. L. Kwak, B. J. Dezube, D. P. Lawrence, J. M. Cleary, S. Lewis, M. Squires, V. Lock, J. F. Lyons, M. Yule

- Brd. 15F** **A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors. (Abstract #3070)**
C. Moldovan, J. Soria, P. LoRusso, T. Guthrie, C. Song, L. T. Nguyen, J. Martini, J. R. Infante, H. A. Burris III
- Brd. 15G** **First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies. (Abstract #3071)**
E. T. Rodler, J. R. Infante, L. L. Siu, D. C. Smith, D. Sullivan, G. Vlahovic, J. Gomez-Navarro, G. Liu, S. Blakemore, J. A. Thompson
- Brd. 15H** **Phase I dose-finding study of BN80927 as an intravenous infusion every 21 days in patients with advanced malignant solid tumors. (Abstract #3072)**
T. Lesimple, F. Bertheault-Cvitkovic, P. Delavault, G. Prevost, V. Fohanno
- Brd. 16A** **Emergence of oral targeted agents in early clinical development: Experience at M. D. Anderson Cancer Center (MDACC) Clinical and Translational Research Center (CTRC). (Abstract #3073)**
K. S. Culotta, R. Kurzrock, C. D. Stewart, V. Dorsey, D. Harleaux-Grant, M. Wyles, M. A. Kramer, Y. Zhang, T. L. Madden, D. D. Karp
- Brd. 16B** **Application of multinomial (MN) phase II designs in trials of targeted agents. (Abstract #3074)**
R. Jamal, R. A. Goodwin, D. Tu, W. Walsh, E. A. Eisenhauer
- Brd. 16C** **Novel strategy to identify drugs that delay relapse. (Abstract #3075)**
M. Hall, J. Evans, D. E. Kornbrot, M. Persic, S. Tahir, J. Morgan, C. Gourley, N. S. Stuart, S. M. Crawford, G. J. Rustin
- Brd. 16D** **Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1 α . (Abstract #3076)**
R. Tibes, G. S. Falchook, D. D. Von Hoff, G. J. Weiss, T. Iyengar, R. Kurzrock, L. Pestano, A. M. Lowe, R. S. Herbst
- Brd. 16E** **Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results. (Abstract #3077)**
S. J. Hotte, E. Y. Yu, H. W. Hirte, C. S. Higano, M. E. Gleave, K. N. Chi
- Brd. 16F** **A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. (Abstract #3078)**
A. M. Traynor, R. Kurzrock, H. H. Bailey, S. Attia, C. Scheffold, B. van Leeuwen, B. Wu, G. S. Falchook, S. L. Moulder, J. Wheler
- Brd. 16G** **A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma. (Abstract #3079)**
S. Dolly, A. J. Wagner, J. C. Bendell, Y. Yan, J. A. Ware, K. E. Mazina, S. N. Holden, M. K. Derynck, J. S. De Bono, H. A. Burris III
- Brd. 16H** **A phase I/II study of oncolytic reovirus plus carboplatin/paclitaxel in patients with advanced solid cancers with emphasis on squamous cell carcinoma of the head and neck (SCCHN). (Abstract #3080)**
E. M. Karapanagiotou, J. D. Chester, H. S. Pandha, G. M. Gill, M. C. Coffey, K. Mettinger, K. J. Harrington
- Brd. 17A** **Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study. (Abstract #3081)**
S. F. Jones, R. B. Cohen, J. C. Bendell, C. S. Denlinger, R. D. Harvey, S. Parasuraman, X. Chi, C. Scholz, T. Wyant, J. Kauh
- Brd. 17B** **A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle. (Abstract #3082)**
S. Sharma, E. A. Sausville, P. LoRusso, N. J. Vogelzang, W. E. Samlowski, J. Carter, K. Forman, S. Bever, R. A. Messmann

Monday, June 7, 2010

- Brd. 17C** **A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors. (Abstract #3083)**
J. M. Cleary, E. I. Heath, E. L. Kwak, B. J. Dezube, L. Gandhi, C. Zack, R. Bradley, V. M. Vukovic, G. Shapiro, P. LoRusso
- Brd. 17D** **Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II, open-label study. (Abstract #3084)**
R. Dreicer, D. B. Agus, G. R. MacVicar, J. Wang, D. MacLean, W. M. Stadler
- Brd. 17E** **A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. (Abstract #3085)**
P. L. Nghiemphu, A. M. Omuro, T. Cloughesy, I. K. Mellinghoff, A. D. Norden, L. T. Nguyen, K. Rajangam, P. Y. Wen
- Brd. 17F** **Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloroquine in combination with adjuvant temozolomide and radiation (ABTC 0603). (Abstract #3086)**
M. R. Rosenfeld, S. A. Grossman, S. Brem, T. Mikkelsen, D. Wang, S. Piao, L. E. Davis, P. J. O'Dwyer, R. K. Amaravadi
- Brd. 17G** **First-in-human study evaluating safety and pharmacokinetics of endoxifen, a potent estrogen-receptor antagonist for breast cancer. (Abstract #3087)**
A. Ahmad, S. Shahabuddin, S. Sheikh, P. Kale, M. K, R. C. Rane, I. Ahmad
- Brd. 17H** **A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer. (Abstract #3088)**
W. A. Harb, B. A. Conley, P. LoRusso, E. A. Sausville, E. I. Heath, S. R. Chandana, M. Hamm, J. Carter, W. J. Perez, R. A. Messmann
- Brd. 18A** **Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. (Abstract #3089)**
A. Jimeno, R. S. Herbst, G. S. Falchook, W. A. Messersmith, S. Hecker, S. Peterson, D. F. Hausman, R. Kurzrock, S. G. Eckhardt, D. S. Hong
- Brd. 18B** **Temsirolimus (TEM) in endometrial cancer: Predictors of response and progression. (Abstract #3090)**
R. A. Goodwin, R. Jamal, D. Tu, W. Walsh, J. Dancey, A. M. Oza, L. Elit, E. A. Eisenhauer
- Brd. 18C** **Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response. (Abstract #3091)**
A. S. Nallari, T. Karrison, G. L. Rosner, M. R. Levine, L. Sit, K. Wu, W. M. Stadler, M. J. Ratain, E. E. Cohen, M. L. Maitland
- Brd. 18D** **Gene expression analysis in human hair bulbs as a potential pharmacodynamic readout in the LDE225 clinical program. (Abstract #3092)**
K. Rose, D. Robinson, T. Sharp, S. Nicholas, A. Haider, L. Ostrom, A. Vattay, M. Dorsch, Y. Shou, J. C. Barrett
- Brd. 18E** **Sensitive detection of gamma-H2AX induction as a pharmacodynamic marker for profiling patients with cancer treated with topotecan. (Abstract #3093)**
D. W. Davis, D. Mittelman, G. Copper, Y. Zhang, S. Sukumaran, W. Yutzy, J. J. Ji
- Brd. 18F** **Characterization of proliferative rebound during drug holiday by FLT-PET imaging in patients treated with sunitinib (SU). (Abstract #3094)**
M. R. Harrison, R. Jeraj, M. Vanderhoek, U. Simoncic, S. Perlman, J. Kolesar, J. C. Eickhoff, D. B. Alberti, G. Wilding, G. Liu
- Brd. 18G** **Characterization of brivanib pharmacokinetics and exposure-response (E-R): Relationship of fatigue in patients with advanced and metastatic solid tumors. (Abstract #3095)**
X. Wang, S. Syed, E. Masson, I. B. Walters, A. Roy

- Brd. 18H Pharmacokinetic, pharmacodynamic, and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer. (Abstract #3096)**
A. Kubo, Y. Koh, T. Hori, S. Isa, J. Fukuoka, T. Kawaguchi, A. Masahiko, I. Okamoto, M. Kitaichi, M. Takada, PHAME Study Group
- Brd. 19A Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer. (Abstract #3097)**
V. Stearns, L. K. Jacobs, T. N. Tsangaris, Z. Cheng, S. Slater, M. J. Fackler, C. Chao, R. Bugarini, E. Gabrielson, N. E. Davidson
- Brd. 19B Pharmacogenetic factors predicting the need for a higher dose of imatinib. (Abstract #3098)**
H. Klumpen, K. Eechoute, M. S. Hertzberg, A. A. Schwarzer, D. Goldstein, T. P. Hughes, C. Liddle, R. Mathijssen, J. H. Schellens, H. Gurney
- Brd. 19C DPYD single nucleotide polymorphisms (SNPs) and haplotypes in patients (pts) with metastatic colorectal cancer and toxicity of capecitabine. (Abstract #3099)**
M. J. Deenen, J. Tol, A. M. Burylo, A. De Boer, A. Vincent, H. Guchelaar, J. H. Beijnen, C. J. Punt, J. H. Schellens, A. Cats
- Brd. 19D Relationship of *HLA-DQA1*0201* and lapatinib-induced hepatotoxicity in women with advanced breast cancer. (Abstract #3100)**
C. F. Spraggs, L. R. Budde, L. P. Briley, N. Bing, A. J. Preston, V. E. Mooser, L. R. Cardon, S. H. Stein
- Brd. 19E The contribution of *UGT1A* and *ABCB1* to irinotecan-induced toxicity: A prospective pharmacogenetic study of patients with metastatic colorectal cancer. (Abstract #3101)**
E. Levesque, A. Bélanger, F. Couture, D. J. Jonker, L. Villeneuve, M. Harvey, C. Guillemette
- Brd. 19F Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors. (Abstract #3102)**
S. P. Chawla, J. Taberner, H. L. Kindler, E. G. Chiorean, P. LoRusso, M. Hsu, V. Haddad, B. A. Bach, J. Baselga
- Brd. 19G Phase I study of AV-412, a novel, irreversible EGFR inhibitor, administered intermittently in patients with advanced solid tumors. (Abstract #3103)**
K. Kelly, J. J. Hwang, G. Shapiro, S. Mani, M. M. Cotreau, M. Credi, M. Al-Adhami, P. Bhargava
- Brd. 19H Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. (Abstract #3104)**
J. Desai, B. J. Solomon, I. D. Davis, L. R. Lipton, R. Hicks, A. M. Scott, J. Park, P. L. Clemens, T. A. Gestone, F. G. Finckenstein
- Brd. 20A A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma. (Abstract #3105)**
D. C. Smith, C. Britten, E. B. Garon, G. Vlahovic, R. Chugh, M. A. Lee, B. Cancilla, D. O. Clary, S. C. Robertson, H. Hurwitz
- Brd. 20B Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265–101). (Abstract #3106)**
M. A. Drouin, C. K. Kollmannsberger, H. E. Uronis, R. E. Martell, J. Wang, M. Dubay, I. Dupont, J. M. Besterman, H. Hurwitz, G. Shapiro
- Brd. 20C Evaluation of serum protein mass spectrometry technology to identify NSCLC patients with tumor response to gefitinib. (Abstract #3107)**
Y. Pei, S. Wei, B. Yao, X. Ma, Y. Yang, L. Yuan, Q. Li, P. Ji, S. Hu, L. Ji
- Brd. 20D A phase I study of oral administration of MGCD265 in patients with advanced malignancies (study 265–102). (Abstract #3108)**
E. I. Heath, P. LoRusso, R. Kurzrock, G. S. Falchook, C. R. Maroun, M. A. Drouin, M. Juretic, R. E. Martell, J. M. Besterman, J. J. Wheler

Monday, June 7, 2010

TRIALS IN PROGRESS POSTER SESSION

Trials in Progress Poster Session

Location: S Hall A2

The Trials in Progress Poster Session is a new Annual Meeting session designed to facilitate awareness of open, ongoing clinical trials. This session will encourage discussions of new clinical research and the exchange of ideas on clinical trial design. There will be no presentation of trial results. Abstracts being presented during the poster session are listed below.

Breast Cancer—Local-Regional and Adjuvant Therapy

- Brd. 20E** Neoadjuvant bevacizumab with weekly nanoparticle albumin bound nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer. (Abstract #TPS100)
J. C. Sachdev, L. E. Kronish, S. West, L. Schwartzberg, M. Jahanzeb
- Brd. 20F** Feasibility of an exercise program for aromatase inhibitor-related arthralgia (AIRA) in breast cancer survivors. (Abstract #TPS101)
J. Katz, D. C. Savior, P. Gilman
- Brd. 20G** A randomized phase II trial evaluating the performance of genomic expression profiles to direct the use of preoperative chemotherapy for early-stage breast cancer. (Abstract #TPS102)
P. K. Marcom, W. Barry, M. B. Datto, J. Geradts, J. A. Olson, J. Marks, G. H. Lyman, A. Potti, G. S. Ginsburg, J. R. Nevins
- Brd. 20H** TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer. (Abstract #TPS103)
E. L. Mayer, J. A. Ligibel, H. J. Burstein, K. Miller, L. A. Carey, H. S. Rugo, N. Ryabin, R. S. Gelman, E. P. Winer, A. C. Wolff
- Brd. 21A** ICE II: An investigational randomized phase II study on epirubicin (E) plus cyclophosphamide (C) (or CMF) versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly nonfrail patients with an increased risk for relapse of a primary carcinoma of the breast. (Abstract #TPS104) G. Von Minckwitz
- Brd. 21B** A multicenter, randomized phase II study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (JBCRG-10 study). (Abstract #TPS105)
N. Masuda, M. Toi, T. Ueno, K. Aogi, H. Iwata, S. Ohno, K. Kuroi, N. Sato, S. Nakamura
- Brd. 21C** WSG PLAN B trial: Evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAL-1. (Abstract #TPS106^)
O. Gluz, C. Liedtke, S. Markmann, S. Henschel, M. R. Clemens, M. Salem, C. Thomssen, H. Kreipe, N. Harbeck, U. Nitz, on behalf of PlanB Investigators/West German Study Group
- Brd. 21D** A phase II clinical trial of four cycles of doxorubicin and cyclophosphamide followed by weekly paclitaxel given concurrently with pazopanib as neoadjuvant therapy followed by postoperative pazopanib for women with locally advanced breast cancer (LABC): A phase II trial of the NSABP foundation research group (FB-6/VEG110264). (Abstract #TPS107)
P. Rastogi, M. E. Buyse, A. R. Tan, S. A. Jacobs, S. M. Swain, C. E. Geyer, N. Wolmark

- Brd. 21E** **A randomized, pharmacologic intervention study evaluating the effect of the angiotensin II-receptor blocker candesartan versus placebo to prevent trastuzumab-associated cardiotoxicity in women with early breast cancer. (Abstract #TPS108)**
R. Altena, A. H. Boekhout, on behalf of the Candy Study Co-Investigators
- Brd. 21F** **Lapatinib and trastuzumab: Molecular effects and efficacy, separately and combined in breast cancer. (Abstract #TPS109)**
F. A. Holmes, V. A. Espina, L. A. Liotta, Y. M. Nagarwala, J. C. Chang, J. O'Shaughnessy
- Brd. 21G** **Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. (Abstract #TPS110)**
W. M. Sikov, C. M. Perou, M. Golshan, D. Collyar, D. A. Berry, O. M. Hahn, B. Singh, C. Hudis, E. P. Winer, Cancer and Leukemia Group B, North American Intergroup
- Brd. 21H** **A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and nab-paclitaxel (CP) with or without vorinostat as preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer (TBCRC008). (Abstract #TPS111)**
R. M. Connolly, S. Jeter, J. Zorzi, Z. Zhang, D. K. Armstrong, J. H. Fetting, A. C. Wolff, M. P. Goetz, A. M. Storniolo, V. Stearns
- Brd. 22A** **SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with previously untreated primary breast cancer (BC). (Abstract #TPS112)**
S. Loibl, German Breast Group
- Brd. 22B** **MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. (Abstract #TPS113)**
M. S. Block, S. Markovic, D. W. Northfelt, P. Mukherjee, B. A. Pockaj, W. K. Nevala, J. N. Ingle, E. A. Perez, V. Suman, S. J. Gendler
- Brd. 22C** **Sentinel-node biopsy before or after neoadjuvant systemic treatment: The German SENTINA trial. (Abstract #TPS114)**
T. Kühn, I. Bauerfeind, T. N. Fehm, B. Fleige, G. Helms, C. Liedtke, M. Mai, G. Von Minckwitz, A. Staebler, M. Untch
- Brd. 22D** **A new resource to accelerate translational breast cancer research: The Love/Avon Army of Women. (Abstract #TPS115)**
S. M. Love
- Brd. 22E** **LAPATAX: A randomized phase II trial of FEC-docetaxel combined with lapatinib and/or trastuzumab as neoadjuvant therapy of HER2-positive breast cancer—EORTC 10054 trial. (Abstract #TPS116)**
D. A. Cameron, S. Marreaud, K. Zaman, A. Bodmer, J. Pierga, E. Brain, C. Veyret, J. M. Bartlett, J. Bogaerts, H. R. Bonnefoi
- Brd. 22F** **Phase I/II study evaluating the maximum tolerated dose, pharmacokinetics, safety, and efficacy of approved hyperthermia and lyso-thermosensitive liposomal doxorubicin in patients with breast cancer recurrence at the chest wall. (Abstract #TPS117)**
N. Borys, F. Muggia, W. Simonich, S. A. Lewis
- Brd. 22G** **A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1–4, N1–2, M0) at initial diagnosis: ACOSOG Z1071. (Abstract #TPS118)**
K. Hunt, H. T. Le-Petross, V. Suman, B. G. Haffty, A. M. Leitch, D. Ollila, D. R. Byrd, T. A. Buchholz, W. F. Symmans, J. C. Boughey
- Brd. 22H** **A phase II neoadjuvant study of cisplatin/paclitaxel with or without RAD001 in patients with triple-negative (TN) locally advanced breast cancer (BC). (Abstract #TPS119)**
I. A. Mayer, I. M. Meszoely, M. Sanders, Y. Shyr, V. G. Abramson, J. A. Means-Powell, A. B. Chakravarthy, C. L. Arteaga, J. A. Pieterpol

Breast Cancer—Metastatic

- Brd. 23A** **A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment—GLICO-0801. (Abstract #TPS120)**
H. L. Gomez, S. P. Neciosup, Y. Neron do Nascimento, G. Ismael, C. H. Barrios
- Brd. 23B** **Suppression of bone turnover following treatment with zoledronic acid in patients with metastatic breast cancer: Duration of effect—The SuBDuE study. (Abstract #TPS121)**
C. E. Simmons, E. Amir, E. Lee, S. Hogeveen, R. A. Dent, P. J. Goodwin, M. Clemons
- Brd. 23C** **Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in *FGFR1*-amplified and nonamplified HER2-negative metastatic breast cancer. (Abstract #TPS122)**
F. Andre, J. Baselga, M. J. Ellis, S. A. Hurvitz, H. S. Rugo, N. C. Turner, E. Argonza-Aviles, S. Lake, M. M. Shi, O. Anak
- Brd. 23D** **Multicentric, open-label, single-arm phase II study with oral lapatinib in combination with oral capecitabine plus intrathecally administered liposomal cytarabine for the treatment of meningeal metastases (NM) in HER2-positive breast cancer patients. (Abstract #TPS123)**
J. Bischoff
- Brd. 23E** **Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC). (Abstract #TPS124)**
P. G. Morris, J. C. Chang, A. Abbruzzi, S. Patil, S. Modi, A. D. Seidman, N. T. Sklarin, L. Norton, C. Hudis, M. N. Fornier
- Brd. 23F** **Clinical relevance of HER2 expression/activation, as measured in circulating tumor cells by a multiplexed immunoassay, in women with HER2-negative (by FISH) metastatic breast cancer (MBC). (Abstract #TPS125)**
J. D. Hainsworth, D. A. Yardley, H. A. Burris
- Brd. 23G** **Metronomic chemotherapy with cyclophosphamide and celecoxib in breast cancer patients progressing after standard chemotherapy: Phase I/II trial. (Abstract #TPS126)**
V. R. Rozados, A. Rossa, C. M. Alasino, H. A. Perroud, F. N. Queralt, S. M. Pezzotto, O. G. Scharovsky
- Brd. 23H** **Randomized phase II study of metronomic chemotherapy (MC) plus aromatase inhibitor (AI) versus MC alone in postmenopausal hormone receptor-positive, metastatic breast cancer (MBC), with correlative circulating endothelial cell (CEC), circulating endothelial progenitor cell (CEP), VEGF, and VEGFR levels. (Abstract #TPS127)**
N. Wong, K. Hui, F. Sun, Y. Yap, R. C. Ng, J. W. Chia, L. Ngo, S. Lo
- Brd. 24A** **A double-blind, randomized, placebo-controlled phase II study of the steroidal aromatase inhibitor exemestane with and without the isoform selective histone deacetylase inhibitor (HDACi) entinostat in metastatic breast cancer (MBC). (Abstract #TPS128)**
D. A. Yardley, R. Ismail-Khan, J. F. Eakle, K. Miller, D. Paul, V. F. Borges, T. L. Helsten, J. F. Kroener, B. Melichar, K. H. Tkaczuk
- Brd. 24B** **N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer. (Abstract #TPS129)**
P. Haluska, M. M. Reinholz, A. C. Dueck, H. M. Linden, W. L. Lingle, A. M. Bernath, M. C. Arbushites, H. Youssoufian, H. X. Chen, E. A. Perez
- Brd. 24C** **Gene signature-based patient selection for dasatinib therapy in metastatic breast cancer (MBC). (Abstract #TPS130)**
L. Pusztai, S. L. Moulder, J. K. Litton, V. Valero, N. T. Ueno, P. H. Morrow, K. Dotter, D. Mattair, L. C. Strauss, W. F. Symmans

- Brd. 24D** Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC). (Abstract #TPS131)
L. J. Goldstein, S. M. Stemmer, B. Schmalfeldt, N. Gottschalk, F. Cardoso, H. Dushkin, C. Mala, N. Uebler, P. Bevan, N. Harbeck
- Brd. 24E** TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). (Abstract #TPS132)
N. U. Lin, I. A. Mayer, T. J. Hobday, C. I. Falkson, E. C. Dees, R. Nanda, I. E. Krop, M. F. Rimawi, A. C. Wolff, E. P. Winer, on behalf of the Translational Breast Cancer Research Consortium (TBCRC)
- Brd. 24F** Three parallel randomized phase II trials of dasatinib plus hormone therapy (HT) in advanced ER+ breast cancer (ER+ ABC). (Abstract #TPS133)
L. C. Strauss, J. O'Shaughnessy, J. Jackson, D. Paul, G. L. Wright, A. Rybicki, A. Goldhirsch
- Brd. 24G** A phase II comparative study of metformin plus first-line chemotherapy (CT) versus CT alone in HER2-negative, insulin-resistant (IR), nondiabetic metastatic breast cancer (MBC). (Abstract #TPS134)
A. Gennari, O. Nanni, P. Bruzzi, A. De Censi, U. Pfeffer, R. Zamarchi, M. Maglie, L. Gianni, D. Amadori
- Brd. 24H** A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC). (Abstract #TPS135)
W. Janni, J. V. Álvarez, C. A. Papadimitriou, B. Karaszewska, W. Wiest, M. L. Lim, A. Das-Gupta
- Brd. 25A** A randomized multicenter phase II trial of capecitabine versus S-1 as first-line treatment in unresectable or recurrent breast cancer patients. (Abstract #TPS136)
D. Yamamoto, S. Iwase, H. Odagiri, Y. Kuroda, K. Akazawa, K. Kitamura, T. Kawaguchi, C. Yamamoto, Y. Nagumo, N. Sakata
- Brd. 25B** Comparison of zoledronic acid retention in bone of multiple myeloma and breast cancer patients: Consequences for efficacy? (Abstract #TPS137)
K. Søre, J. Delaisse, E. H. Jakobsen, H. B. Jørgensen, T. Plesner
- Brd. 25F** Evaluation of toll-like receptor (TLR)-7 agonist imiquimod applied topically to breast cancer chest wall recurrences or skin metastases. (Abstract #TPS138)
S. Adams, Z. Dewan, T. Meng, J. D. Goldberg, A. Tiersten, N. Bhardwaj, S. Formenti, S. Demaria
- Cancer Prevention/Epidemiology**
- Brd. 25G** Utilization of 5HTT-gene polymorphism as a prognostic indicator in cancer. (Abstract #TPS139)
N. M. Awad, M. Farouk, H. Elshafei, S. Ghobashy, M. Elbordiny, A. A. Elsaid, A. Omar
- Brd. 25H** Fish oil, green tea, and prostate cancer prevention. (Abstract #TPS140)
J. Shannon, S. Lieberman, C. Maxcy, P. Thuillier, L. Peters, M. Garzotto
- Brd. 26A** A randomized trial of atorvastatin versus placebo in women at high risk for breast cancer. (Abstract #TPS141)
M. E. Wood, F. Kingsley, J. A. Ellerton, J. N. Atkins, S. S. Grubbs, H. B. Muss, J. E. Garber
- Brd. 26B** Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer. (Abstract #TPS142)
K. D. Crew, P. Brown, H. Greenlee, T. B. Bevers, B. Arun, C. Hudis, H. L. McArthur, L. Vornik, T. L. Cornelison, D. L. Hershman, Phase I/II Chemoprevention Trials Consortium
- Brd. 26F** Sulforaphane supplementation in women newly diagnosed with DCIS: A biomarker study. (Abstract #TPS143)
J. Shannon, E. Ho, A. Naik, M. Troxell, A. Cox, C. Maxcy, J. T. Vetto

Monday, June 7, 2010

Central Nervous System Tumors

- Brd. 26G** **Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine (PCB), vincristine (VINC), and cytarabine (Ara-C) for primary CNS lymphoma (PCNSL) in elderly patients. (Abstract #TPS144)**
A. M. Omuro, L. Taillandier, O. L. Chinot, H. Ghesquieres, C. Soussain, V. Delwail, S. Choquet, M. Tanguy, T. Lamy, K. Hoang-Xuan
- Brd. 26H** **Phase II trial of chemotherapy with temozolomide in combination with topotecan for central nervous system (CNS) metastases of solid tumors. (Abstract #TPS145)**
P. Z. New, J. Jac
- Brd. 27A** **Phase I study of bendamustine and fractionated stereotactic radiotherapy (FSRT) in patients with one to three brain metastases from solid malignancies. (Abstract #TPS146)**
J. C. Grecula, M. Ammirati, K. L. Kendra, M. Phelps, R. Cavaliere, B. McCracken-Bussa, J. Radawski, L. Wei, E. Mrozek, N. A. Mayr
- Brd. 27B** **A pilot study of fosbretabulin with bevacizumab in recurrent high-grade gliomas. (Abstract #TPS147)**
R. Altaha, M. Almubarak, M. D. Newton, A. Torres-Trejo, G. Marano, G. Hobbs, L. Gibson, W. P. Petros, S. C. Remick
- Brd. 27C** **Phase II trial of sunitinib as maintenance therapy after stereotactic radiosurgery in patients with one to three newly diagnosed brain metastases. (Abstract #TPS148)**
D. Peereboom, C. Brewer, J. H. Suh, S. T. Chao, B. I. Rini, M. Parsons, P. Elson, G. Barnett
- Brd. 27E** **A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma. (Abstract #TPS150)**
P. Chinnaiyan, S. Chowdhary, S. Brem, M. Yu, R. Murtagh, A. Rojiani, Y. Tsai, E. Pan
- Brd. 27F** **Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: Protocol of a multicenter, randomized, open-label, controlled phase II study. (Abstract #TPS151)**
L. B. Nabors, K. Fink, D. A. Reardon, G. J. Lesser, J. Trusheim, S. N. Raval, C. Hicking, M. Picard, T. Mikkelsen
- Brd. 27G** **Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). (Abstract #TPS152)**
R. Stupp, M. J. Van Den Bent, S. C. Erridge, D. A. Reardon, Y. Hong, H. Wheeler, M. Hegi, J. R. Perry, M. Picard, M. Weller
- Brd. 27H** **An academic prospective single-arm phase II clinical trial for evaluation of advanced functional neuroimaging and molecular markers during bevacizumab/irinotecan therapy for recurrent malignant glioma. (Abstract #TPS153)**
M. Hutterer, M. Nowosielski, T. Gotwald, D. Putzer, D. Waitz, H. Maier, A. Muigg, H. Kostron, G. Stockhammer
- Brd. 28A** **Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma. (Abstract #TPS154)**
M. Weller, G. Tabatabai, G. Reifenberger, U. Herrlinger, J. Pichler, O. Schnell, W. Wick, DIRECTOR Trial Group

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy

- Brd. 28B** **Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS). (Abstract #TPS155)**
K. Pietzner, R. G. Linke, M. Jäger, H. Lindhofer, H. Friccius-Quecke, F. Chen, E. I. Braicu, G. Oskay-Özcelik, J. Sehouli

- Brd. 28C** **Catumaxomab observational study to investigate efficacy and safety profile in clinical practice. (Abstract #TPS156)**
V. Kunzmann, R. G. Linke, P. Ruf, H. Lindhofer, M. Hennig, M. M. Essing
- Brd. 28D** **Phase I trial of CCL21 gene modified dendritic cells in non-small cell lung cancer. (Abstract #TPS157)**
J. M. Lee, E. B. Garon, F. Baratelli, D. Schaeue, P. S. Pak, W. D. Wallace, R. Suh, F. Abtin, G. Zeng, S. M. Dubinett
- Brd. 28E** **New approaches in dendritic cell vaccination design and efficacy tests for patients with advanced ovarian cancer: Prospects for a phase I clinical study. (Abstract #TPS158)**
M. Imhof
- Brd. 28F** **An intersubject dose-escalation study of tisetaxel administered orally once every 3 weeks and once weekly for 3 consecutive weeks in patients with advanced or metastatic solid tumors. (Abstract #TPS159)**
M. Beeram, S. C. Novick, A. Qureshi, A. Patnaik, K. Papadopoulos, A. W. Tolcher
- Brd. 28G** **Dose-escalation phase I study of NKTR-105, a novel pegylated form of docetaxel. (Abstract #TPS160)**
E. Calvo, U. Hoch, D. J. Maslyar, A. W. Tolcher
- Brd. 28H** **Treating HIV+ patients for non-AIDS-defining cancers (NADCs) in the era of targeted chemotherapy: An AIDS malignancy consortium study of sunitinib in patients on ART. (Abstract #TPS161)**
J. F. Deeken, R. T. Mitsuyasu, R. F. Little, S. P. Ivy, R. F. Ambinder, M. A. Rudek, J. Y. Lee, P. C. Moore, K. Mosby, B. J. Dezube
- Brd. 29A** **Use of a human ribonuclease variant, QBI-139, for the treatment of cancer. (Abstract #TPS162)**
L. E. Strong, J. A. Kink, B. Mei, M. N. Shahan, R. T. Raines
- Brd. 29B** **Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors. (Abstract #TPS163)**
G. Kim, C. M. Annunziata, G. A. Sarosy, L. M. Minasian, S. A. Prindiville, J. Zujewski, L. Otten, J. Squires, N. D. Houston, E. C. Kohn
- Brd. 29C** **A multicenter, open-label phase Ib/II study to assess the safety and clinical activity of intravenous combretastatin A1 diphosphate (OXI4503) as monotherapy in subjects with primary or secondary hepatic tumor burden. (Abstract #TPS164)**
P. N. Mainwaring, J. Lickliter, M. P. Brown, M. Millward, D. J. Chaplin, Z. Goldberg
- Brd. 30A** **Attempt to improve the safety of development studies with a new design for phase I combination trials of targeted therapies: The PARASOL trial. (Abstract #TPS165)**
S. Negrier, D. Pérol, J. Soria, S. Chabaud, S. Metzger, B. Escudier
- Brd. 30B** **Phase I trial of everolimus and gemcitabine for patients with solid tumors refractory to standard therapy and for a cohort of patients with cholangiocarcinoma/gallbladder cancer. (Abstract #TPS166)**
B. A. Costello, Y. Qi, M. J. Borad, G. P. Kim, D. W. Northfelt, C. Erlichman, S. R. Alberts
- Brd. 30C** **Selective inhibition of proliferating endothelial cells: A phase I study of the novel organoarsenical compound GSAO in patients with advanced solid tumors. (Abstract #TPS167)**
G. Kumaran, M. R. Middleton, Y. K. Zee, L. McGuigan, A. R. Clamp, P. J. Hogg, A. Jackson, G. J. Parker, A. L. Harris, G. C. Jayson
- Brd. 31A** **Targeting fanconi anemia (FA) repair pathway deficiency for treatment with PARP inhibitors. (Abstract #TPS168)**
W. Zhao, W. Duan, M. E. Leon, A. P. Chen, G. Sofletea, J. Thurmond, B. Ramaswamy, D. O'Malley, T. S. Bekaii-Saab, M. A. Villalona-Calero

Monday, June 7, 2010

- Brd. 31B** A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers. (Abstract #TPS169)
C. S. Denlinger, M. Beeram, A. W. Tolcher, L. J. Goldstein, W. J. Slichenmyer, J. Murray, C. McDonagh, K. Andreas, V. M. Moyo
- Brd. 31C** SORAVE trial: Phase I sorafenib and everolimus in solid tumors. (Abstract #TPS170)
L. Nogova, M. Scheffler, I. Papachristou, C. Mattonet, R. Kraiss, I. Katay, P. Mallmann, U. Fuhr, M. Dietlein, J. Wolf
- Brd. 32A** A randomized, open-label phase IIb study of maintenance therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission. (Abstract #TPS171)
H. J. Gray, A. A. Secord, M. L. Anderson, G. DelPriore, N. E. Tchabo, J. S. Berek
- Brd. 32B** Multiple tumor associated peptide vaccination as consolidation treatment in women affected by breast and ovarian cancer. (Abstract #TPS172)
M. Nuti, F. Bellati, C. Napoletano, V. Visconti, M. Antonilli, H. Rahimi, S. Pauselli, A. Rughetti, L. Frati, P. Benedetti Panici
- Brd. 32C** A phase II study of personalized selection of peptide vaccines combined with conventional chemo- or endocrine therapy for refractory breast cancer. (Abstract #TPS173)
U. Toh, H. Otsuka, N. Iwakuma, K. Shirouzu, E. Ogo, H. Yamana, K. Itoh, M. Tanaka, T. Fujii
- Brd. 33A** A phase I study of NY-ESO-1 overlapping peptides with or without incomplete Freund's adjuvant and poly-ICLCL vaccination of ovarian cancer patients in second or third clinical remission. (Abstract #TPS174)
C. S. Magid Diefenbach, P. Sabbatini, M. L. Hensley, J. A. Konner, W. P. Tew, G. Ritter, A. Jungbluth, L. S. Pan, L. J. Old, S. Gnjjatic
- Brd. 33B** Endogenous heat-shock protein vaccines for metastatic melanoma. (Abstract #TPS175)
J. M. Heun, W. K. Nevala, M. R. Callstrom, T. D. Atwell, M. A. Farrell, E. Galanis, L. Erickson, V. Suman, W. J. Charboneau, S. Markovic

Developmental Therapeutics—Experimental Therapeutics

- Brd. 33C** Investigation of pathways regulating early antiangiogenic response to bevacizumab given prior to neoadjuvant breast cancer chemotherapy. (Abstract #TPS176)
S. Mehta, S. P. Li, N. P. Hughes, R. F. Adams, A. R. Padhani, F. M. Buffa, C. A. Wright, L. A. McRae, A. Makris, A. L. Harris
- Brd. 34A** A phase I study of cediranib plus whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer. (Abstract #TPS177)
A. F. Eichler, H. A. Shih, L. V. Sequist, P. Y. Wen, R. K. Jain, A. G. Sorensen, T. Batchelor
- Brd. 34B** Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). (Abstract #TPS178^)
R. Lencioni, J. Zou, M. Leberre, G. Meinhardt, D. Voliotis, J. Bruix, J. M. Llovet
- Brd. 34C** Phase I study of ACE-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma. (Abstract #TPS179)
N. G. Borgstein, S. Sharma, J. C. Bendell, M. S. Gordon, H. Hurwitz, N. Solban, D. Mitchell, S. Pearsall, C. H. Condon, M. L. Sherman
- Brd. 35A** A phase Ib study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously in combination with bevacizumab with or without weekly paclitaxel in patients with advanced solid tumors. (Abstract #TPS180)
A. Patnaik, C. D. Weekes, P. Hegde, Y. Xin, R. Yu, H. Xiang, R. K. Brachmann, P. LoRusso

- Brd. 35B** **Combination of vorinostat with whole-brain radiotherapy in the treatment of brain metastases. (Abstract #TPS181)**
Y. R. Lawrence, R. M. Pfeffer, M. Werner-Wasik, H. Choy, A. Dicker
- Brd. 35C** **Correlation between FLT-PET and Ki-67 change in breast cancer during neoadjuvant chemotherapy (Abstract #TPS182)**
S. C. Blackman, R. A. Raikar, R. Fox, L. George, R. Iannone, D. A. Bergstrom, P. D. Mozley
- Brd. 35D** **APR-246, a new class anticancer compound in phase I/IIa clinical trials. (Abstract #TPS183)**
C. Liljebriis, N. Mohell, E. Olaisson, T. Uhlin, K. G. Wiman, S. Lehmann
- Brd. 35E** **Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia after MDS: A phase I/II study. (Abstract #TPS184)**
S. Wroblewski, W. Shi, P. Mudd Jr., M. Aivado
- Brd. 35F** **An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BeICaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary. (Abstract #TPS185)**
G. Daugaard, K. Fizazi, G. Huebner, D. Braumann, J. R. Rubinsak, D. Allouache, G. I. Rodriguez, M. Stahl, L. Fuglsang, J. D. Hainsworth
- Brd. 35G** **A randomized, double-blind, placebo-controlled study to assess siltuximab (CNTO 328, an anti-IL-6) in patients with multicentric Castleman's disease. (Abstract #TPS186)**
J. Vermeulen, M. Qi, J. B. Herring, J. Flisak, H. M. Prince, J. Rossi, M. J. Cornfeld, F. Van Rhee
- Brd. 35H** **A phase II study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme (GBM). (Abstract #TPS187)**
L. Trani, S. M. Alam, S. M. Rudman, L. R. Molife, G. W. Middleton, D. Propper, P. Stopfer, M. M. Uttenreuther-Fischer, G. Wallenstein, J. F. Spicer
- Brd. 36A** **An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumors. (Abstract #TPS188)**
M. S. Gordon, G. Edelman, M. D. Galsky, D. C. Smith, P. Schoffski, K. Houggy, Y. Lee, F. Schimmoller, X. Shen, R. Kurzrock
- Gastrointestinal (Colorectal) Cancer**
- Brd. 36B** **PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS. (Abstract #TPS189)**
L. S. Schwartzberg, V. J. Wagner
- Brd. 36C** **Phase II study to determine surgical conversion rate in patients receiving neoadjuvant mFOLFOX7 plus cetuximab for unresectable wild-type KRAS colorectal cancer with metastases confined to liver. (Abstract #TPS190)**
S. A. Jacobs, C. J. Allegra, L. D. Wagman, D. A. Geller, M. J. O'Connell, M. E. Buyse, N. Wolmark
- Brd. 36D** **A multicenter phase II clinical study evaluating the deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (CRT). (Abstract #TPS191)**
I. Y. Chong, G. Brown, R. J. Heald, K. Thomas, I. Chau, A. Wotherspoon, D. M. Tait
- Brd. 36E** **FOxTROT: Randomized phase II study of neoadjuvant chemotherapy with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer. (Abstract #TPS192)**
R. G. Gray, D. Morton, G. Brown, D. R. Ferry, L. Magill, P. Quirke, M. T. Seymour, B. Warren, on behalf of the FOxTROT Collaborative Group

Monday, June 7, 2010

- Brd. 36G Phase I/II personalized therapy trial for metastatic colorectal cancer using functional pathway mapping: Stratification to imatinib therapy. (Abstract #TPS194)**
M. Pierobon, S. Banks, A. Silvestri, G. Gambarà, J. Wiedemann, L. A. Liotta, E. Petricoin III, K. H. Edmiston, A. I. Spira
- Brd. 36H SPIRITT: A multicenter, open-label, randomized, phase II clinical trial evaluating safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with metastatic colorectal cancer (mCRC) with wild-type KRAS tumors. (Abstract #TPS195)**
A. L. Cohn, K. Krishnan, J. R. Hecht
- Brd. 37A Induction chemotherapy with or without chemoradiation in intermediate-risk rectal cancer patients defined by magnetic resonance imaging (MRI): A GEMCAD study. (Abstract #TPS196)**
C. Fernandez-Martos, M. Safont, J. Feliu, C. Pericay, M. Gallen, R. Vera, J. Maurel, J. Aparicio, M. P. Escudero, G. Brown, GEMCAD
- Brd. 37B Yttrium microspheres with cetuximab plus irinotecan for patients with advanced colorectal cancer metastases to liver. (Abstract #TPS197)**
R. Murthy, A. Mahvash, R. Avritscher, W. Erwin, B. Chasen, C. Eng
- Brd. 37C Optimal control of liver metastases with intravenous cetuximab and hepatic artery infusion of three-drug chemotherapy in patients with liver-only metastases from colorectal cancer: A European multicenter phase II trial. (Abstract #TPS198)**
F. Levi, M. Bouchahda, M. Ducreux, A. Karaboué, C. N. Focan, P. Rougier, P. Innominato, D. Smith, S. Awad, R. Adam
- Brd. 37D The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint. (Abstract #TPS199)**
R. Salazar, J. Marshall, L. Stork-Sloots, I. Simon, M. Lutke Holzik, J. Taberner, J. J. Van Der Hoeven, F. Bibeau, R. Rosenberg

Gastrointestinal (Noncolorectal) Cancer

- Brd. 37E Perioperative chemotherapy plus bevacizumab with early salvage therapy based on PET response in patients with locally advanced resectable gastric/GEJ cancer. (Abstract #TPS200)**
E. C. Smyth, H. Schöder, D. G. Coit, V. E. Strong, M. F. Brennan, Y. Y. Janjigian, M. Capanu, L. H. Tang, D. P. Kelsen, M. A. Shah
- Brd. 37F Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers. (Abstract #TPS201)**
N. I. Khushalani, G. J. Fetterly, R. V. Iyer, A. Litwin, W. Brady, M. M. Javle
- Brd. 37H Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma. (Abstract #TPS203)**
J. Li, J. S. Kortmanky, M. Saif, N. A. Fischbach, L. Ravage-Mass, K. Elligers, C. Hahn, M. K. Cohenuram, J. Lacy
- Brd. 38A A phase II trial of combined treatment of endoscopic mucosal resection (EMR) and chemoradiotherapy (CRT) for clinical stage I esophageal squamous cell carcinoma (ESCC): Japan Clinical Oncology Group study JCOG0508. (Abstract #TPS204)**
T. Tsuchida, M. Muto, K. Minashi, H. Ono, Y. Morita, R. Ishihara, I. Toshiro, H. Kawai, N. Boku, H. Fukuda
- Brd. 38B Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071). (Abstract #TPS205)**
A. Roth, M. H. Moehler, M. Mauer, A. Schad, M. Karrasch, M. Praet, M. L. Lim, A. Das-Gupta, M. P. Lutz
- Brd. 38C Phase II study of irinotecan plus panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma (EAC). (Abstract #TPS206)**
A. Atasoy, H. Yoon, A. M. Egloff, R. L. Ferris, A. H. Zaidi, B. Hough, A. A. Forastiere, B. A. Jobe, K. S. Nason, M. K. Gibson

- Brd. 38D** Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence. (Abstract #TPS207)
F. Bi, Q. Li, C. Zhou, J. Yu, X. Cai, M. Qiu, J. Liu, C. Yi, D. Luo, F. Xu, The Western Cooperative Gastrointestinal Oncology Group of China
- Brd. 38E** DRAFT: RAMSETE trial of everolimus (RAD001) in the treatment of silent (nonfunctioning) advanced neuroendocrine tumors. (Abstract #TPS208)
B. Wiedenmann, S. Caglio, L. Decroix, C. May, K. E. Oberg
- Brd. 38F** A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060). (Abstract #TPS209)
M. A. Shah, E. C. Smyth, S. Shibata, W. Yong, L. H. Tang, Y. Y. Janjigian, D. P. Kelsen, G. K. Schwartz
- Brd. 38G** Gefitinib in the adjuvant treatment of hepatocellular carcinoma: A pilot study by the Singapore hepatocellular carcinoma consortium. (Abstract #TPS210)
G. Lopes, C. K. Ho, K. H. Liau, A. Chung, P. Cheow, A. Y. Chang, Singapore Hepatocellular Carcinoma Consortium
- Brd. 38H** Phase I trial of sorafenib in high-risk hepatocellular carcinoma (HCC) patients after liver transplantation (LT). (Abstract #TPS211)
A. B. Siegel, S. X. Hsu, K. D. Becker, S. Anderson, S. Clark-Garvey, R. Hidalgo, D. Tsushima, I. Matushansky, J. Emond, R. S. Brown Jr.
- Brd. 39A** A phase I trial of escalating doses of the anti-IGF-1R monoclonal antibody (mAb) cixutumumab (IMC-A12) and sorafenib for treatment of advanced hepatocellular carcinoma (HCC). (Abstract #TPS212)
R. O'Donnell, A. B. El-Khoueiry, H. Lenz, D. R. Gandara
- Brd. 39B** A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC). (Abstract #TPS213)
R. K. Kelley, H. S. Nimeiri, M. T. Vergo, E. K. Bergsland, A. H. Ko, P. N. Munster, A. Reinert, M. F. Mulcahy, A. B. Benson, A. P. Venook
- Brd. 39F** Panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study. (Abstract #TPS214)
W. Sun, K. Mykulowycz, U. R. Teitelbaum, N. Damjanov, D. G. Haller, B. J. Giantonio, M. Carberry, P. J. O'Dwyer
- Brd. 39G** ARQ 197-215: A randomized, placebo-controlled phase II clinical trial evaluating the c-Met inhibitor, ARQ 197, in patients (pts) with hepatocellular carcinoma (HCC). (Abstract #TPS215)
I. Borbath, A. Santoro, J. Van Laethem, B. Daniele, L. Cicalese, S. Zeuzem, P. Buggish, L. Bolondi, J. R. Strosberg, G. Abbadessa
- Brd. 39H** Dose-escalating study of yttrium 90 microspheres with capecitabine for intrahepatic cholangiocarcinoma or metastatic disease to the liver. (Abstract #TPS216)
R. M. Hickey, M. F. Mulcahy, R. Lewandowski, R. Salem
- Brd. 40A** Combined biological treatment and chemotherapy for patients with inoperable cholangiocarcinoma. (Abstract #TPS217)
L. H. Jensen, U. N. Lassen, J. Lindebjerg, T. Hansen, A. K. Jakobsen
- Brd. 40B** ABC-03: A randomized, phase II/III study of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine for patients with advanced biliary tract cancers. (Abstract #TPS218)
J. W. Valle, J. A. Bridgewater, M. Roughton, C. Dive, S. Hughes, H. S. Wasan
- Brd. 40F** The antiproliferative effect of pasireotide LAR alone and in combination with everolimus (RAD001) in patients with progressive medullary thyroid cancer (MTC): A single-center, open-label, phase II, proof-of-concept study. (Abstract #TPS219)
A. Faggiano, A. Colao

Monday, June 7, 2010

- Brd. 40G Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma. (Abstract #TPS220)**
L. B. Anthony, P. J. Loehrer, S. Leong, M. H. Shah, H. Safran, N. N. Senzer, N. J. Zojwalla, H. Youssoufian
- Brd. 40H A multicenter randomized phase II study of UFT/leucovorin and radiotherapy (RT) with or without cetuximab following induction gemcitabine plus capecitabine (GEM-CAP) in locally advanced pancreatic cancer (LAPC). (Abstract #TPS221)**
I. Y. Chong, A. F. Okines, D. M. Tait, M. Hawkins, D. Cunningham, C. Saffery, K. Thomas, I. Chau
- Brd. 41A A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. (Abstract #TPS222)**
S. Mukherjee, C. Hurt, G. Griffiths, T. Crosby, J. Staffurth, S. Bridges, J. A. Bridgewater, A. McDonald, S. Falk, T. S. Maughan, scaloptmg
- Brd. 41B SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer. (Abstract #TPS223)**
P. A. Philip, B. H. Goldman, R. K. Ramanathan, H. Lenz, A. M. Lowy, R. P. Whitehead, S. Iqbal, V. M. Chung, J. K. Benedetti, C. D. Blanke
- Brd. 41C APRICoT-P: A phase II randomized placebo controlled study of apricoxib, a potent COX-2 inhibitor in combination with erlotinib and gemcitabine in pancreatic cancer patients. (Abstract #TPS224)**
G. P. Keogh, R. M. Langdon, P. J. Stella, R. Manges, C. H. Chay, E. Looper, S. L. Zaknoen
- Brd. 41D CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24 h) in combination with lapatinib as a second-line therapy in pancreatic cancer after gemcitabine failure: A phase I/II trial. (Abstract #TPS225)**
J. Stieler, U. Pelzer, M. Sinn, B. Dörken, H. Oettle, H. Riess
- Brd. 41E A randomized, placebo-controlled, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer with activating ras mutations. (Abstract #TPS226)**
S. H. Whiting, P. Muscarella, A. Rosemurgy, W. E. Fisher, D. A. Richards, F. E. Harrell Jr., J. Ferraro, S. Speyer, A. Cohn

Genitourinary Cancer

- Brd. 41F Novel early stopping rule uses early progression rather than lack of response as rapid assessment for futility. (Abstract #TPS227)**
Y. Wong, S. Litwin, D. J. Vaughn, E. R. Plimack, S. M. Cohen, H. Tuttle, G. R. Hudes
- Brd. 41G A randomized phase II study of a novel antigen-presenting cell-targeted hCG- β vaccine (the CDX-1307 regimen) in muscle-invasive bladder cancer. (Abstract #TPS228)**
D. A. Bradley, M. Morse, T. Keler, J. A. Green, T. A. Davis, B. A. Inman
- Brd. 41H Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. (Abstract #TPS229)**
M. I. Milowsky, A. Trout, A. M. Regazzi, I. Garcia-Grossman, A. Flaherty, S. Tickoo, H. Al-Ahmadie, D. F. Bajorin
- Brd. 42A Pilot study of external hyperthermia and intravesical mitomycin-C to treat recurrent bladder cancer after failed standard therapy. (Abstract #TPS230)**
Z. Vujaskovic, O. I. Craciunescu, P. Stauffer, M. Carroll, L. Lan, M. Dewhirst, B. A. Inman

- Brd. 42B** A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma. (Abstract #TPS231)
S. S. Sridhar, C. M. Canil, S. D. Mukherjee, E. Winquist, C. Elser, A. Eisen, A. Chung, Y. Ko
- Brd. 42C** First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC). (Abstract #TPS232)
J. J. Knox, A. C. Kay, E. Schiff, N. Hollaender, N. Rouyrre, A. Ravaud, R. J. Motzer
- Brd. 42D** Open-label phase II trial of everolimus monotherapy in patients with recurrent metastatic and/or unresectable renal cell carcinoma (RCC). (Abstract #TPS233)
B. Tannir, S. Hardikar
- Brd. 42E** Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinoma. (Abstract #TPS234)
S. Caglio, K. Slimane, C. May, B. Escudier
- Brd. 42F** Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC). (Abstract #TPS235)
E. Jonasch, A. Bair, Y. Chen, B. I. Rini
- Brd. 42G** Treatment of refractory metastatic renal cell carcinoma (RCC) with bevacizumab and RAD001. (Abstract #TPS236)
L. C. Harshman, A. McMillan, S. Srinivas
- Brd. 42H** A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC). (Abstract #TPS237)
B. J. Escudier, D. Cella, J. E. Gschwend, T. Powles, C. N. Sternberg, R. Hodge, M. Lau, M. Neary, F. Mehmud, T. Eisen
- Brd. 43A** Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as first-line therapy in patients with metastatic clear cell renal cell carcinoma. (Abstract #TPS238)
A. Ravaud, E. Bajetta, A. C. Kay, D. Pelov, N. Hollaender, N. Rouyrre, J. A. Thompson
- Brd. 43B** Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab. (Abstract #TPS239)
A. S. Alva, N. Agarwal, A. O. Siefker-Radtke, B. J. Roth, D. C. Smith, S. Daignault, S. Srinivas, D. A. Bradley, M. Hussain
- Brd. 43C** A phase II trial of docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced and metastatic carcinoma of the penis (CRUK/09/001). (Abstract #TPS240)
A. K. Bahl, S. Nicholson, J. Barber, E. Hall
- Brd. 43D** A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC). (Abstract #TPS241)
R. Z. Szmulewitz, E. M. Posadas, B. Manchen, W. M. Stadler
- Brd. 43E** Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer (CRPC). (Abstract #TPS242)
D. E. Rathkopf, D. C. Danila, J. J. Chudow, M. J. Morris, S. F. Slovin, S. Fine, J. J. Fox, S. M. Larson, N. Rosen, H. I. Scher
- Brd. 43F** Phase I/II study of sorafenib concurrent with androgen deprivation and radiotherapy in treatment of intermediate- and high-risk localized prostate cancer. (Abstract #TPS243)
S. Talwar, S. M. Cohen, N. A. Romas, R. D. Ennis

Monday, June 7, 2010

- Brd. 43G Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients. (Abstract #TPS244)**
G. Gibney, A. Elfikey, C. J. Hoimes, A. Burns, E. Rowen, J. A. McDonough, R. Lampert, C. Gross, W. K. Kelly
- Brd. 43H First-in-human phase I trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer. (Abstract #TPS245)**
P. Kantoff, D. P. Petrylak, M. Pomerantz, R. J. Israel, W. C. Olson, T. Ramakrishna, S. Morris
- Brd. 44A A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC). (Abstract #TPS246)**
U. Emmenegger, S. S. Sridhar, C. M. Booth, R. Kerbel, S. R. Berry, Y. Ko
- Brd. 44B Phase I dose-escalation study of docetaxel/prednisone and fractionated ¹⁷⁷Lu-J591 for metastatic castrate-resistant prostate cancer (metCRPC). (Abstract #TPS247)**
H. Beltran, S. Vallabhajosula, W. K. Kelly, Y. E. Whang, J. Osborne, K. Petrillo, S. J. Goldsmith, N. H. Bander, D. M. Nanus, S. T. Tagawa
- Brd. 44C A randomized phase II trial of ¹⁷⁷Iu radiolabeled monoclonal antibody J591 (¹⁷⁷Lu-J591) and ketoconazole in patients (pts) with high-risk castrate biochemically relapsed prostate cancer (PC) after local therapy. (Abstract #TPS248)**
S. T. Tagawa, J. Osborne, P. J. Christos, S. Vallabhajosula, K. Petrillo, K. Nadeau, L. Tyrell, H. Beltran, S. J. Goldsmith, D. M. Nanus
- Brd. 44D Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study. (Abstract #TPS249)**
A. J. Armstrong, G. Kemeny, J. D. Turnbull, C. Chao, C. Winters, Y. A. Fesko, D. A. Bradley, S. Halabi, D. J. George, M. Garcia-Blanco
- Brd. 44E Phase I/II study of preoperative intensity-modulated radiation therapy (IMRT) and docetaxel for high-risk prostate cancer: A platform for radiosensitizer development. (Abstract #TPS250)**
M. Garzotto, A. Hung, T. M. Beer, P. E. Farris
- Brd. 44F Neoadjuvant IMC-A12 and combined androgen deprivation with prostatectomy for high-risk prostate cancer: A phase II trial. (Abstract #TPS251)**
J. P. Dean, S. R. Plymate, B. L. Dalkin, W. J. Ellis, D. W. Lin, J. L. Wright, J. M. Corman, L. D. True, P. H. Lange, R. B. Montgomery

Gynecologic Cancer

- Brd. 44G Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer. (Abstract #TPS252)**
I. Zigelboim, J. D. Wright, M. A. Powell, A. S. Case, E. L. Eisenhauer, D. E. Cohn, F. A. Valea, A. A. Secord, L. T. Lippmann, J. S. Rader
- Brd. 44H Phase I/II trial of reovirus serotype 3–Dearing strain in patients with recurrent ovarian cancer. (Abstract #TPS253)**
D. E. Cohn, G. Nuovo, M. C. Coffey, D. O'Malley, M. A. Villalona-Calero, M. R. Grever, D. Deam, J. A. Zwiebel, M. A. Phelps
- Brd. 45A Panitumumab and pegylated liposomal doxorubicin to platinum-resistant epithelial ovarian cancer with KRAS wild type: An ongoing, nonrandomized, multicenter, phase II trial. (Abstract #TPS254)**
K. D. Steffensen, M. Waldstrøm, B. Lund, K. Bergfeldt, N. Keldsen, C. Marth, I. B. Vergote, A. K. Jakobsen

- Brd. 45B** A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer. (Abstract #TPS255)
L. Elit, J. A. Konner, D. K. Armstrong, M. Buck, A. Dean, N. J. Finkler, A. Hulstine, C. Schweizer, M. Phillips, S. Weil
- Brd. 45C** Randomized phase II trial of pegylated liposomal doxorubicin (PLD) with or without anti-platelet-derived growth factor receptor-alpha (PDGFR-alpha) monoclonal antibody IMC-3G3 in platinum-refractory/resistant advanced ovarian cancer. (Abstract #TPS256)
W. P. McGuire, G. D. Shah, N. Loizos, H. Youssoufian, E. K. Rowinsky, M. E. Gore
- Brd. 45D** A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer. (Abstract #TPS257)
J. D. Hainsworth, T. M. Numnum, G. G. Rao
- Brd. 45E** Phase II study of clinical activity of pegaspargase in women with relapsed or refractory epithelial ovarian, fallopian tube, and/or primary peritoneal cancer. (Abstract #TPS258)
G. Kim, J. Squires, M. Yu, A. Walker, N. D. Houston, L. Otten, E. C. Kohn
- Brd. 45F** A phase II trial of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503). (Abstract #TPS259)
K. Matsumoto, N. Katsumata, I. Saito, I. Konishi, T. Kamura, Japan Clinical Oncology Group
- Brd. 45G** Enrolling a rare patient population: Establishing proof of concept for FP-1039, an FGF "trap," in endometrial cancer patients with the S252W FGFR2 mutation. (Abstract #TPS260)
H. N. Keer, T. C. Harding, W. M. Kavanaugh
- Brd. 45H** A prospective study to evaluate the efficacy of curcumin in the management of advanced carcinoma cervix. (Abstract #TPS261)
S. K. Jain, N. Singh, D. Sharma, G. K. Rath, P. K. Julka, P. Heera, B. Ayan, S. Sen, S. Thulkar, S. Duttagupta
- Head and Neck Cancer**
- Brd. 46A** A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN). (Abstract #TPS262)
R. L. Ferris, A. P. Kotsakis, D. E. Heron, S. Kim, U. Duvvuri, G. J. Kubicek, J. R. Grandis, J. T. Johnson, A. Argiris
- Brd. 46B** Phase II trial of everolimus with sorafenib for patients with differentiated thyroid cancer (DTC) who progress on sorafenib alone. (Abstract #TPS263)
M. S. Brose, A. B. Troxel, R. Mamtani
- Brd. 46C** Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN). (Abstract #TPS264)
A. P. Kotsakis, D. E. Heron, G. J. Kubicek, R. L. Ferris, S. Kim, M. K. Gibson, U. Duvvuri, J. R. Grandis, J. T. Johnson, A. Argiris
- Brd. 46D** Docetaxel, cisplatin (TP), and radiation with or without cetuximab in advanced larynx carcinoma (DeLOS II trial). (Abstract #TPS265^)
A. Dietz, M. Flentje, R. Hagen, R. D. Kortmann, G. Hildebrand, F. Hoppe, I. Schwienhorst, U. Keilholz
- Brd. 46E** A phase I/II study of erlotinib in combination with chemoradiation in patients with surgically resected locally advanced squamous head and neck cancer (HNSCC). (Abstract #TPS266)
F. Arias de la Vega, I. Herruzo, M. de las Heras, A. de la Torre, V. Arrazubi, J. Contreras, J. Garcia Saenz, J. Romero, J. Serrano, F. A. Calvo, Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)

Monday, June 7, 2010

Brd. 46F **VortigERN: Variation of radiotherapy target volume definition, dose to organs at risk (OAR), and clinical target volumes using anatomic (CT) versus combined anatomic and molecular imaging (PET-CT): Intensity-modulated radiotherapy delivered using a tomotherapy hi art machine. (Abstract #TPS267)**

S. Chatterjee, J. Frew, J. B. Wilsdon, H. M. McCallum, J. H. Mott, P. Stevenson, W. Dobrowsky, R. J. Maxwell, C. G. Kelly

Brd. 46G **Correlative analyses between EGFR pathways and stroma-tumor profiles in head and neck cancer patients (HNSCC) on postoperative radiotherapy plus cisplatin (PORTc) plus or minus gefitinib (GORTEC-GETTEC CARISSA trial): Implications for sensitivity to gefitinib. (Abstract #TPS268)**

J. Thariat, D. Grall, M. Etienne-Grimaldi, F. Penault-Llorca, M. Francoual, G. A. Milano, D. De Raucourt, P. Garaud, R. Bensadoun, E. van-Obberghen Schilling

Brd. 46H **Rexinoid therapy for poorly differentiated thyroid cancer: A pilot clinical phase II trial and correlation to retinoid and peroxisome proliferator-activated receptor gamma receptors expression. (Abstract #TPS269)**

L. P. De Oliveira, B. Haugen, M. Kane, A. Jimeno, J. Klopffer

Brd. 47A **Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: An ongoing pilot, randomized, sham-controlled trial. (Abstract #TPS270)**

W. Lu, J. H. Lorch, T. A. Balboni, D. J. Sher, L. A. Goguen, C. M. Norris Jr., R. B. Tishler, M. R. Posner, D. S. Rosenthal, R. I. Haddad

Brd. 47B **Phase II trial of doxorubicin (D) and bortezomib (B) in patients with incurable adenoid cystic carcinoma of the head and neck. (Abstract #TPS271)**

A. P. Kotsakis, W. E. Gooding, A. Argiris

Health Services Research

Brd. 47C **A pilot study comparing a patient-centered symptom-reporting follow-up program to standard care in patients who have completed the acute phase of treatment for early breast cancer. (Abstract #TPS272)**

M. E. Melisko, E. Mihalis, M. Ernest, H. S. Rugo, J. W. Park, M. M. Moasser, P. N. Munster, L. Esserman

Brd. 47D **Telephone-based health coaching for cognitive, affective, and quality-of-life improvement in patient-caregiver cancer survivorship: A mixed-methods educational intervention. (Abstract #TPS273)**

D. R. Close

Brd. 47E **Validation study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). (Abstract #TPS274)**

A. C. Dueck, T. R. Mendoza, B. B. Reeve, J. A. Sloan, C. S. Cleeland, J. Hay, Y. Li, A. M. O'Mara, A. Denicoff, E. M. Basch

Leukemia, Myelodysplasia, and Transplantation

Brd. 47F **CPX-351: A randomized phase IIb study first-relapse patients younger than age 65. (Abstract #TPS275)**

J. E. Kolitz, J. E. Cortes, K. Paulsen, A. C. Louie

Brd. 47G **A phase Ib study of oral panobinostat (LBH589) in combination with cytarabine (ARA-C) and mitoxantrone (MT) as salvage therapy for refractory or relapsed acute myeloid leukemia (AML). (Abstract #TPS276)**

J. Krauter, O. G. Ottmann, R. F. Schlenk, M. Schaich, D. Bouscary, H. Dombret, F. Lüdicke, H. J. Weber, I. J. Winiger

Brd. 47H **The OPAL study: A phase II study to evaluate the efficacy, safety, and tolerability of tosedostat (CHR-2797) in elderly subjects with treatment refractory or relapsed acute myeloid leukemia. (Abstract #TPS277)**

J. E. Cortes, E. J. Feldman, K. W. Yee, M. J. Toal, A. Richardson, A. Charman, N. Flores, The OPAL Investigators

- Brd. 48A** A phase IIa pharmacokinetic and efficacy study of amonafide (AS1413) in combination with cytarabine in patients with acute myeloid leukemia. (Abstract #TPS278)
A. S. Lundberg, S. L. Allen, AS1413–101 Investigator Group
- Brd. 48B** A multicenter dose-finding randomized controlled phase IIb study of the aptamer AS1411 in patients with primary refractory or relapsed AML. (Abstract #TPS279)
R. K. Stuart, A. Wei, I. D. Lewis, E. Estey, F. Erlandsson, G. J. Schiller
- Brd. 48C** An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients. (Abstract #TPS280)
D. A. Pollyea, H. E. Kohrt, R. Rajwanshi, L. Gallegos, C. Berube, S. E. Coutre, J. R. Gotlib, M. Liedtke, B. S. Mitchell, B. C. Medeiros
- Brd. 48D** Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph+) leukemias resistant or intolerant to imatinib. (Abstract #TPS281)
J. A. Rosenberg, D. Derreumaux, L. Gore, P. Kearns, A. Baruchel, T. Barrett, M. Zwaan
- Brd. 48E** A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). (Abstract #TPS282)
O. G. Ottmann, P. Fenaux, M. Lübbert, D. J. DeAngelo, G. Garcia-Manero, K. N. Bhalla, M. A. Sekeres, F. Lüdicke, H. J. Weber, I. J. Winiger
- Brd. 48F** A phase II trial of oral panobinostat (LBH589), a novel deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis. (Abstract #TPS283)
D. J. DeAngelo, A. Tefferi, R. A. Mesa, C. S. Paley, M. Wadleigh, D. Snyder, M. S. Ondovik, J. Rine, K. N. Bhalla

Lung Cancer—Local Regional and Adjuvant Therapy

- Brd. 48G** Induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer. (Abstract #TPS284)
W. Zhong, X. Yang, R. Liao, Q. Nie, X. Zhang, J. Su, Q. Zhou, C. Xu, J. Yang, Y. Wu
- Brd. 48H** A multi-institutional feasibility study of induction pemetrexed (Pem) plus cisplatin (Cis) followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation (RT) for malignant pleural mesothelioma (MPM): Japan Mesothelioma Research Center (JMRC) 001001 trial. (Abstract #TPS285)
F. Tanaka, S. Hasegawa, T. Yamanaka, M. Okada, T. Soejima, N. Kamikonya, K. Yokoi, K. Fukuoka, T. Nakano, JMRC (Japan Mesothelioma Research Center)
- Brd. 49A** A dose-escalation study of vorinostat in combination with radiotherapy for patients with non-small cell lung cancer. (Abstract #TPS286)
R. H. Decker, S. N. Gettinger, L. D. Wilson
- Brd. 49B** Trial of poor performance status patients (ToPPS): A randomized phase II trial of pemetrexed versus pemetrexed/bevacizumab versus pemetrexed/carboplatin/bevacizumab in patients with stage IIIb/IV non-small cell lung cancer and ECOG performance status 2. (Abstract #TPS287)
D. R. Spigel, R. Lilienbaum, J. D. Hainsworth
- Brd. 49C** Stereotactic radiosurgery for stage I NSCLC in medically inoperable patients: A prospective multicenter phase II study. (Abstract #TPS288)
A. Pennathur, R. I. Whyte, A. Zajac, D. G. Brachman, W. E. Gooding, N. A. Christie, H. C. Urschel, B. W. Loo, D. E. Heron, J. D. Luketich, and the Multicenter Stereotactic Radiosurgery Investigators for the Treatment of Lung Cancer

Monday, June 7, 2010

Brd. 49D Peripheral non-small cell lung cancer treated in stereotactic conditions: A prospective medico-economic French study. (Abstract #TPS289)
L. Claude, B. Prevost, P. Boisselier, F. Gassa, C. Carrie, S. Dussart

Lung Cancer—Metastatic

Brd. 49E Randomized, open-label study of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) of nonsquamous histology. (Abstract #TPS290)
R. Zinner, S. Saxman, G. Peng, W. F. Ortuzar

Brd. 49F Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies. (Abstract #TPS291)

E. M. Bertino, G. A. Otterson, M. A. Villalona-Calero, S. P. Nana-Sinkam, A. M. Ghany, K. R. Donthireddy, N. F. Abdel Karim, S. Cantrell, G. S. Phillips

Brd. 49G Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors. (Abstract #TPS292)

E. T. Lam, G. A. Otterson, K. R. Donthireddy, J. Thurmond, E. Hade, M. C. Coffey, M. A. Villalona-Calero

Brd. 49H Thymidylate synthetase (TS) immunohistochemistry (IHC): Feasibility in a routine clinical setting for patients receiving treatment with pemetrexed for advanced nonsquamous NSCLC. (Abstract #TPS293)

K. M. Kerr, D. A. Fennell, R. N. Shah, M. Kumar, G. Skales, V. A. Potter, S. Moore, P. Maxwell, M. Das, M. Nicolson

Brd. 50A Phase II trial evaluating addition of fulvestrant to erlotinib in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who are stable on erlotinib and exhibit immunohistochemical (IHC) or PCR positivity for estrogen or progesterone receptor (PR). (Abstract #TPS294)

L. Bazhenova, R. Quintana, R. H. Hastings, K. Messer

Brd. 50B Randomized phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC). (Abstract #TPS295)

E. B. Garon, S. M. Dubinett, W. Hosmer, K. L. Reckamp, F. F. Kabbinavar, L. Goodglick, D. C. Marquez-Garban, L. P. Stabile, J. Siegfried, R. J. Pietras

Brd. 50C Randomized phase II study of human anti-platelet-derived growth factor receptor alpha (PDGFR α) monoclonal antibody (IMC-3G3) with paclitaxel/carboplatin (P/C) or P/C alone in first-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC). (Abstract #TPS296)

D. E. Gerber, R. A. Brekken, T. Hoang, H. Youssoufian, E. K. Rowinsky, N. Loizos, G. D. Shah

Lymphoma and Plasma Cell Disorders

Brd. 50D A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas. (Abstract #TPS297)
H. Tilly, F. Morschhauser, G. A. Salles, O. Casasnovas, P. Feugier, T. J. Molina, C. Haioun, B. Coiffier, Groupe d'Etudes des Lymphomes de l'Adulte (GELA)

Brd. 50E ENGAGE-501: Phase II study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory Hodgkin's lymphoma (HL). (Abstract #TPS298)

A. Younes, P. J. Rosen, F. J. Hernandez-Ilizaliturri, G. Bociek, Y. L. Kasamon, A. Copeland, G. T. Lee

Brd. 50F An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL). (Abstract #TPS299)

P. B. Johnston, L. T. Lewis, J. W. Rogerio

- Brd. 50G** A pilot study of sorafenib examining biomarkers in refractory or relapsed T-cell lymphoma patients. (Abstract #TPS300)
F. Lansigan, M. Komarovskaya, S. Seropian, D. Cooper, F. M. Foss
- Brd. 50H** Targeting the epigenome: A phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab in relapsed B-cell malignancies. (Abstract #TPS301)
S. E. Spurgeon, C. Y. Okada, J. Huang, J. Phillips, E. E. Epner
- Brd. 51A** A phase II trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic lymphoma. (Abstract #TPS302)
C. Rudin, R. J. Johnson, B. Pottinger, P. Smith, O. A. Adedayo
- Brd. 51B** A randomized, open-label, multicenter phase II study of bortezomib with fludarabine in comparison to rituximab with fludarabine in follicular lymphoma subjects previously treated with rituximab. (Abstract #TPS303)
P. Theocharous, O. Shpilberg, Y. A. Elsayed
- Brd. 51C** RCHOPB: Feasibility study of RCHOP plus bevacizumab (B) in patients (pts) with diffuse large B-cell lymphoma (DLBCL). (Abstract #TPS304)
E. A. Hawkes, I. Chau, K. Thomas, J. R. Oates, J. Webb, C. Costello, P. W. Johnson, D. Cunningham
- Brd. 51D** Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. (Abstract #TPS305)
J. R. Westin, F. Chu, M. Foglietta, R. Rotem-Yehudar, S. S. Neelapu
- Brd. 51E** A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma. (Abstract #TPS306)
L. D. Kaplan, S. Jung, J. L. Johnson, C. A. Linker, J. C. Byrd, W. Stock, E. D. Hsi, B. D. Cheson
- Brd. 51F** Phase II multisite study to evaluate efficacy and safety of single weekly administration of bortezomib (BZ) and dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts). (Abstract #TPS307)
N. C. Munshi, S. Lee, G. D. Roodman, C. Behler, S. Kambhampati, M. G. Rose, M. T. Brophy, A. Houranieh, D. Esseltine, A. Lichtenstein
- Brd. 51G** PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM). (Abstract #TPS308)
M. Alsina, S. Lonial, D. M. Weber, S. E. Coutre, B. P. Kang, T. Glynos, G. Warsi, S. M. Snodgrass, P. G. Richardson

Melanoma/Skin Cancers

- Brd. 51H** A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in metastatic melanoma. (Abstract #TPS309)
J. M. Mehnert, J. H. Lee, J. Shirk, D. Bhavsar, O. Anosike, J. L. Chan, W. Shih, S. Chen, J. S. Goydos
- Brd. 52A** Treatment of melanoma with wild-type p53 (wtp53) and detectable S100B using pentamidine: A phase II trial with correlative biomarker endpoints. (Abstract #TPS310)
J. M. Mehnert, P. F. Hausner, M. Tan, D. Weber, E. A. Sausville
- Brd. 52B** Low-dose temozolomide modulation of peripheral blood regulatory T cells before dendritic cell-based vaccination in metastatic melanoma: Phase I/II study. (Abstract #TPS311)
L. Ridolfi, L. Fiammenghi, M. Petrini, A. Granato, V. Ancarani, E. Pancisi, M. Guidoboni, A. Riccobon, P. A. Ascierto, R. Ridolfi
- Brd. 52C** A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607). (Abstract #TPS312)
K. Kalinsky, S. J. Lee, D. P. Lawrence, J. M. Kirkwood

Monday, June 7, 2010

- Brd. 52D** LPS-activated dendritic cell vaccine in combination with immunomodulatory dose of cytoxin in patients with stage IV melanoma: Phase I/IIa clinical trial. (Abstract #TPS313)
A. K. Palucka, H. Ueno, J. W. Fay, J. Banchereau
- Brd. 52E** An open-label, multicenter, phase III trial of nab-paclitaxel (NP) versus dacarbazine (DTIC) in previously untreated patients (PTs) with metastatic malignant melanoma (MMM). (Abstract #TPS314)
E. Hersh, M. Millward, I. Elias, J. Iglesias

Patient and Survivor Care

- Brd. 52F** Randomized phase II study of gabapentin alone versus gabapentin plus tramadol for the management of oxaliplatin-induced peripheral neuropathy. (Abstract #TPS315)
H. Shim, J. Yoon, J. Hwang, W. Bae, S. Cho, I. Chung
- Brd. 52G** Evaluation of a Web-based cognitive rehabilitation program for cancer survivors with self-reported cognitive impairment. (Abstract #TPS316)
V. J. Bray, H. M. Dhillon, J. L. Vardy
- Brd. 52H** ICORG 07-11: A phase II trial evaluating the efficacy of a radiobiological based re-irradiation strategy for patients with malignant spinal cord compression. (Abstract #TPS317)
P. G. Thirion, A. Clayton-Lea, M. Parker, J. Coffey, J. G. Armstrong, D. Hollywood, All Ireland Co-operative Oncology Research Group (ICORG)
- Brd. 53A** The effect of dexamethasone on symptom burden in patients with advanced cancer. (Abstract #TPS318)
S. Yennurajalingam, J. L. Palmer, J. M. Reuben, E. Bruera
- Brd. 53B** A randomized placebo-controlled trial of melatonin for poor appetite in advanced cancer patients. (Abstract #TPS319)
E. Del Fabbro, S. Dalal, R. Dev, E. Bruera
- Brd. 53F** A randomized, controlled trial of parenteral hydration in patients with advanced cancer. (Abstract #TPS320)
E. Bruera, K. O. Anderson, J. L. Palmer, M. Z. Cohen, B. Coldman, L. E. Roberts, W. L. Shen, M. B. Lake
- Brd. 53G** A randomized, double-blind, controlled trial of methylphenidate for fatigue in patients with advanced cancer. (Abstract #TPS321)
E. Bruera, V. Valero, W. Breitbart, Y. Guo, J. L. Palmer, M. Z. Cohen, C. Scott, M. B. Lake
- Brd. 53H** Phase II randomized study of compound Chinese herbal extract LC09 for external treatment of hand-foot syndrome induced by anticancer therapy. (Abstract #TPS322)
L. Jia
- Brd. 54A** Feasibility of a comprehensive lifestyle modification program during and for one year after completing cancer treatment in breast and prostate cancer patients in a large urban health center. (Abstract #TPS323)
E. M. Walker, D. Kerrigan, S. Keteyian, S. Brown, R. Filipiak, N. Martinez, J. K. Ehrman
- Brd. 54B** A randomized comparison of oral methadone as a "first-switch" opioid versus opioid switching between sustained-release morphine and oxycodone for oncology outpatients with pain management problems. (Abstract #TPS324)
A. F. Elsayem, K. T. Bain, J. L. Palmer, J. Bearden, M. Fisch
- Brd. 54F** Design of an ongoing randomized study on the long-term safety and efficacy of darbepoetin alfa (DA) administered 500 mcg every three weeks (Q3W) to non-small cell lung cancer (NSCLC) patients (pts) with anemia concomitant with chemotherapy (ACC). (Abstract #TPS325)
P. Gascon, D. H. Henry, A. Fleishman, J. E. Borenstein

- Brd. 54G** **A phase III randomized, double-blind, placebo-controlled study of pegfilgrastim in first-line colorectal cancer patients receiving bevacizumab and either FOLFOX or FOLFIRI. (Abstract #TPS326)**
 T. Pinter, J. Decaestecker, L. Choi, M. Mo, S. Whittaker, T. A. Rado, L. B. Holt

Pediatric Oncology

- Brd. 54H** **A phase I study of clofarabine and liposomal daunorubicin in childhood and adolescent acute myeloid leukemia. (Abstract #TPS327)**
 N. J. Graham, P. J. Johnson, M. Cummins, R. Keenan, B. Gibson, I. Hawley, P. Kearns
- Brd. 55A** **Randomized phase II study of two cross-over sequences comprising vinorelbine/cyclophosphamide and temozolomide/etoposide in outpatient setting for relapsed or refractory solid tumors in children and young adults. (Abstract #TPS328)**
 M. Saito, H. Kawamoto, A. Ogawa, A. Makimoto
- Brd. 55B** **A phase I trial of TPI-287 as a single agent and its combination with temozolomide in relapsed neuroblastoma or medulloblastoma. (Abstract #TPS329)**
 G. L. Saulnier Sholler, G. Bergendahl, S. Lenox, P. E. Zage, W. Roberts, J. M. Kravaka, D. Eslin, J. Kaplan, T. Higgins, W. Ferguson
- Brd. 55C** **A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). (Abstract #TPS330)**
 J. C. Chisholm, M. Casanova, B. Georger, J. H. Merks, G. Massimini, N. Moore, I. A. Rooney, L. Viviers, O. Oberlin

Sarcoma

- Brd. 55D** **Viscum album fermentatum Pini versus oral etoposide as adjuvant treatment in osteosarcoma patients after second relapse. (Abstract #TPS331)**
 A. Longhi, S. Ferrari, E. Mariani
- Brd. 55E** **Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST). (Abstract #TPS332^)**
 P. G. Casali, H. Joensuu, J. Martin Broto, X. Garcia del Muro, J. Blay, C. May, A. Pustowka, P. Reichardt
- Brd. 55F** **Phase I and II trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with soft tissue sarcoma of the extremity. (Abstract #TPS333)**
 A. Olusanya, R. M. Tamurian, S. Christensen, D. Borys, A. M. Chen, W. Mak, M. Buonocore, P. Mack, W. Monsky, R. J. Canter
- Brd. 55G** **An open-label, dose-ranging study to assess the safety, efficacy, and pharmacokinetics of eltrombopag in treating thrombocytopenia in patients with advanced sarcomas receiving doxorubicin and ifosfamide. (Abstract #TPS334)**
 S. P. Chawla, A. P. Staddon, C. Messam, A. M. Graham, Y. M. Mostafa Kamel
- Brd. 55H** **Sorafenib (S) with preoperative chemoradiotherapy for extremity soft tissue sarcomas (STS) and evaluation by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). (Abstract #TPS335)**
 K. S. Perlewitz, W. Huang, J. B. Hayden, Z. B. Adler, A. Hung, A. Mansoor, M. L. Holtorf, S. L. Hemmingson, W. J. Woodward, C. W. Ryan

Tumor Biology

- Brd. 56A** **Phase 0 microdose trial to identify chemoresistance in lung and bladder cancer. (Abstract #TPS336)**
 P. T. Henderson, M. He, S. Wang, R. de Vere White, P. Lara Jr., D. R. Gandara, P. C. Mack, M. P. Dutia, K. Turteltaub, C. Pan

Monday, June 7, 2010

- Brd. 56B** **Randomized, placebo-controlled, phase II trial of EGFR and COX-2 inhibition in advanced non-small cell lung cancer. (Abstract #TPS337)**
K. L. Reckamp, M. Koczywas, M. C. Cristea, J. Dowell, B. Gardner, G. Milne, S. Fouladi Rad, R. A. Figlin, R. Elashoff, S. M. Dubinett
- Brd. 56C** **MESH: Phase II trial of methotrexate as a synthetic lethal therapy for metastatic MSH2-deficient colorectal and other tumors. (Abstract #TPS338)**
M. Hewish, C. Saffery, Y. Barbachano, A. Wotherspoon, G. Brown, S. A. Martin, C. J. Lord, I. Chau, A. Ashworth, D. Cunningham
- Brd. 56D** **Phase Ib trial of lapatinib oxaliplatin and capecitabine in early HER2-overexpressing esophagogastric cancer. (Abstract #TPS339)**
H. Ford, D. Hochhauser, A. Paterson, L. Lovat, M. Jobanputra, R. C. Fitzgerald
- Brd. 56E** **Molecular prognostic and predictive markers in gynecologic cancers: The translational 1 (T-1) study of the Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) Group. (Abstract #TPS340)**
A. Mosconi, L. Crino, V. Ludovini, G. Scambia, G. Ferrandina, E. Breda, R. Sabbatini, C. Caserta, V. De Angelis, S. Pignata
- Brd. 56F** **DCIS neoadjuvant therapy: Targeting the autophagy pathway in malignant precursor cells. (Abstract #TPS341)**
V. A. Espina, R. I. Gallagher, B. D. Mariani, S. Banks, J. Wiedemann, E. Petricoin III, L. Pastore, J. Johal, L. A. Liotta, K. H. Edmiston
- Brd. 56G** **Circulating tumor cell capture and analysis in a multicenter SWOG-coordinated prostate cancer trial. (Abstract #TPS342)**
A. Goldkorn, T. Xu, B. Lu, A. Williams, L. M. Fink, C. M. Tangen, P. Twardowski, Y. Tai, D. I. Quinn, R. Cote, Southwest Oncology Group (SWOG) Genitourinary Committee
- Brd. 56H** **Autophagy as a therapeutic target in cancer treatment. (Abstract #TPS343)**
V. Karantza, R. A. Moss, J. M. Mehnert, M. N. Stein, E. Poplin, B. Saraiya, J. Aisner, A. R. Tan, E. White, R. S. DiPaola

**8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION**

Genitourinary (Prostate) Cancer

Display Time: 8:00 AM - 12:00 PM

Display Location: E450a

Discussion Time: 12:00 PM - 1:00 PM

Discussion Location: E Hall D2

CME credit: 1

Track(s): Genitourinary Cancer

Andrea Lynne Harzstark, MD—Co-Chair

University of California, San Francisco

Daniel W. Lin, MD—Co-Chair

University of Washington

Discussion

12:00 PM Johann Sebastian De Bono, MD, PhD (Abstracts #4544–4549)
Drug Development Unit, The Royal Marsden NHS Foundation Trust and
The Institute of Cancer Research
Biomarkers of Response in Prostate Cancer

Discussion

12:15 PM Robert Dreicer, MD (Abstracts #4550–4552)
Cleveland Clinic Taussig Cancer Institute
Can Immunotherapy Be Personalized?

Discussion

12:25 PM Celestia S. Higano, MD (Abstracts #4553–4557)
University of Washington
Novel Therapies and Response Predictors for CRPC

Discussion

12:40 PM Matthew Raymond Smith, MD, PhD (Abstracts #4558–4560)
Massachusetts General Hospital
The Impact of ADT on Bone and Brain

Discussion

12:50 PM Joel B. Nelson, MD (Abstracts #4561–4565)
University of Pittsburgh
Risk Identification, Chemoprevention, Surveillance, and Neoadjuvant Therapy in Early Prostate Cancer

Brd. 1 **A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating tumor cell analysis. (Abstract #4544)**

N. Mitsiades, Y. Antipin, B. Reva, N. Schultz, D. C. Danila, C. C. Sung, A. Anand, C. Sander, H. I. Scher

Brd. 2 **Bone scan “flare” in patients receiving abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. (Abstract #4545)**

S. K. Shah, C. J. Ryan, C. Kilian, A. Hubbell, T. S. Kheoh, C. M. Haqq, A. Molina, E. J. Small

Brd. 3 **Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. (Abstract #4546)**

A. Anand, H. I. Scher, T. M. Beer, C. S. Higano, D. C. Danila, M. Taplin, E. Efsthathiou, M. Hirmand, C. L. Sawyers, G. Heller, Prostate Cancer Clinical Trials Consortium

Monday, June 7, 2010

- Brd. 4** Use of “intracrine androgen signaling signature” to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC). (Abstract #4547)
E. Efstathiou, S. Tu, A. Aparicio, A. Hoang, S. Wen, P. Troncoso, L. A. Smith, N. Chieffo, A. Molina, C. Logothetis
- Brd. 5** Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity. (Abstract #4548)
T. M. Beer, B. L. Rademacher, H. Geng, J. Pittsenbarger, M. Garzotto, P. Nelson, C. S. Higano, D. Z. Qian
- Brd. 6** The effect of changes in PSA kinetics on metastasis-free survival (MFS) in patients with PSA-recurrent prostate cancer (PC) treated with nonhormonal agents: Combined analysis of three randomized trials. (Abstract #4549)
E. S. Antonarakis, J. Lin, D. Keizman, M. A. Carducci, M. A. Eisenberger
- Brd. 7** Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer. (Abstract #4550)
C. S. Higano, E. J. Small, P. F. Schellhammer, P. Kantoff, C. H. Redfern, J. J. Nemunaitis, C. Nabhan, Y. Xu, J. B. Whitmore, M. W. Frohlich
- Brd. 8** Persistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studies. (Abstract #4551)
D. P. Petrylak, N. A. Dawson, T. Gardner, L. Klotz, B. D. Curti, R. C. Flanigan, M. N. Fishman, Y. Xu, J. B. Whitmore, M. W. Frohlich
- Brd. 9** Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer. (Abstract #4552)
F. P. Stewart, C. P. dela Rosa, N. A. Sheikh, D. G. McNeel, M. W. Frohlich, D. L. Urdal, N. M. Provost
- Brd. 10** Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC). (Abstract #4553)
P. L. De Souza, B. Mellado, C. Pfister, M. Rosenthal, D. E. Castellano, D. Weber, S. Ferrara, N. Shaik, E. Tan, S. G. Patterson
- Brd. 11** Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts). (Abstract #4554)
D. Keizman, V. J. Sinibaldi, M. A. Carducci, S. R. Denmeade, C. G. Drake, R. Pili, E. S. Antonarakis, S. Hudock, M. Zahurak, M. A. Eisenberger
- Brd. 12** Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy. (Abstract #4555)
M. T. Fleming, M. A. Kolodziej, S. Awasthi, T. E. Hutson, D. Martincic, G. Sonpavde, Y. Wang, K. A. Boehm, L. Asmar, T. M. Beer
- Brd. 13** ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). (Abstract #4556)
M. N. Stein, Y. Chen, G. R. Hudes, M. A. Carducci, W. Tan, R. S. DiPaola
- Brd. 14** Association between genetic polymorphisms in *SLCO1B3* gene and response to ketoconazole (K) in men with castration-resistant prostate cancer (CRPC). (Abstract #4557)
M. Taplin, M. Nakabayashi, L. Werner, M. Yang, W. Xie, T. Sun, M. Pomerantz, M. Freedman, G. M. Lee, P. Kantoff
- Brd. 15** Dynamics of bone mineral density during intermittent androgen deprivation for men with biochemical recurrence of prostate cancer. (Abstract #4558)
E. Y. Yu, K. Kuo, R. Gulati, P. Y. Jiang, C. S. Higano

- Brd. 16** **Fractures and post-fracture mortality in elderly prostate cancer (PC) patients receiving androgen deprivation therapy (ADT) in the United States. (Abstract #4559)**
K. Cetin, J. Beebe-Dimmer, K. A. Schwartz, C. Yee, H. Morgenstern, V. B. Shahinian, J. F. Acquavella
- Brd. 17** **The effect of ADT on objective cognitive performance and self-reported cognitive function in men with prostate cancer. (Abstract #4560)**
S. Marzouk, S. Duff Canning, G. Naglie, G. A. Tomlinson, M. Leach, F. Hussain, I. Tannock, S. M. Alibhai
- Brd. 18** **The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study. (Abstract #4561)**
D. G. Bostwick, D. J. Tindall, C. A. Pettaway, T. L. Tammela, C. Teloken, T. H. Wilson, R. S. Castro
- Brd. 19** **Effect of inflammation on prostate cancer incidence and dutasteride efficacy in the Reduction by Dutasteride of Cancer Events (REDUCE) study. (Abstract #4562)**
O. W. Brawley, G. L. Andriole, C. Teloken, M. C. Somerville, R. P. Gagnier
- Brd. 20** **Positive biopsy (bx) rates for prostate cancer (PCA) based on prostate specific antigen (PSA) grouping in a large cancer screening trial: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). (Abstract #4563)**
D. Reding, C. McCarty, T. Riley, T. Hickey, W. G. Hocking
- Brd. 21** **Cancer genetics-guided discovery of serum biomarker signatures for prostate cancer. (Abstract #4564)**
S. Gillessen, I. Cima, R. Schiess, P. Wild, M. Kälin, P. Schueffler, J. M. Buhmann, H. Moch, R. Aebbersold, W. Krek
- Brd. 22** **Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer. (Abstract #4565)**
E. Crawford, S. S. Sutton, J. W. Moul, C. A. Pettaway, J. W. Hardin, S. A. Poston, E. J. Kruep

Monday, June 7, 2010

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Lung Cancer—Metastatic

Display Time: 8:00 AM - 12:00 PM

Display Location: E450b

Discussion Time: 12:00 PM - 1:00 PM

Discussion Location: E Hall D1

CME credit: 1

Track(s): Lung Cancer

Shirish M. Gadgeel, MD—Co-Chair

Karmanos Cancer Institute/Wayne State University

Taofeek Kunle Owonikoko, MD—Co-Chair

Winship Cancer Institute of Emory University

Discussion

12:00 PM Michael J. Kelley, MD (Abstracts #7512–7517)

Duke University Medical Center

Biomarkers

Discussion

12:15 PM Karen L. Reckamp, MD, MS (Abstracts #7518–7524)

City of Hope

New Approaches in EGFR Targeted Therapy

Discussion

12:30 PM Silvia Novello, MD, PhD (Abstracts #7525–7529)

University of Turin

Antiangiogenic Agents

Discussion

12:45 PM Suresh S. Ramalingam, MD (Abstracts #7530–7535)

Winship Cancer Institute of Emory University

New Agents

Brd. 1 **Use of ERCC1 expression levels in circulating tumor cells to predict response to platinum-based chemotherapy in patients with non-small cell lung cancer. (Abstract #7512)**

A. C. Hoffmann, T. Gauler, A. Parr, W. E. Eberhardt, M. H. Schuler

Brd. 2 **Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy. (Abstract #7513)**

D. R. Gandara, P. P. Grimminger, P. C. Mack, P. V. Danenberg, P. Lara Jr., K. D. Danenberg

Brd. 3 **Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies. (Abstract #7514)**

R. Rosell, M. A. Molina, C. Costa, M. Taron, J. Bertran-Alamillo, C. Mayo, S. Benlloch, T. Moran, F. Cardenal, R. Porta

Brd. 5 **Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC. (Abstract #7516)**

B. E. Johnson, A. J. Ryan, J. Heymach, C. Stephens, S. J. Kennedy, P. B. Langmuir, R. S. Herbst

Brd. 6 **Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC). (Abstract #7517)**

L. V. Sequist, R. B. Natale, N. N. Senzer, R. Martins, R. Lilienbaum, J. E. Gray, D. R. Borger, G. Paez, D. S. Grayzel, S. N. Gettinger

MONDAY

- Brd. 7** **A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). (Abstract #7518)**
 R. M. Gaafar, V. Surmont, G. Scagliotti, R. Van Klaveren, D. Papamichael, J. Welch, B. Hasan, V. Torri, J. P. Van Meerbeek
- Brd. 8** **Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. (Abstract #7519)**
 L. Vamvakas, S. Agelaki, N. K. Kentepozidis, A. Karampeazis, A. G. Pallis, C. Christophyllakis, A. P. Kotsakis, I. Boukovinas, D. Mavroudis, V. Georgoulas
- Brd. 9** **Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI). (Abstract #7520)**
 G. R. Oxnard, G. J. Riely, M. H. Arcila, M. G. Kris, W. Pao, M. Ladanyi, V. A. Miller
- Brd. 10** **A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). (Abstract #7521^)**
 C. Yang, J. Shih, W. Su, T. Hsia, C. Tsai, S. I. Ou, R. Calvo, X. J. Cong, M. Shahidi, V. A. Miller
- Brd. 11** **Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504). (Abstract #7522)**
 S. S. Ramalingam, J. Lee, C. P. Belani, S. C. Aisner, J. Kolesar, C. W. Howe, M. R. Velasco, J. H. Schiller
- Brd. 12** **Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT). (Abstract #LBA7523)**
 M. J. Boyer, F. H. Blackhall, K. Park, C. H. Barrios, M. J. Krzakowski, I. Taylor, J. Q. Liang, L. J. Denis, J. P. O'Connell, S. S. Ramalingam
- Brd. 13** **Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7524)**
 N. B. Leigh, J. Soria, J. Bennouna, N. Blais, A. M. Traynor, V. Papadimitrakopoulou, J. Klimovsky, A. Jappe, V. Jehl, B. E. Johnson
- Brd. 14** **Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). (Abstract #7525)**
 J. Lee, V. Hirsh, K. Park, S. Qin, C. R. Blajman, R. Perng, L. Emerson, P. B. Langmuir, C. Manegold
- Brd. 15** **Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). (Abstract #7526)**
 F. F. Kabbinavar, V. A. Miller, B. E. Johnson, P. G. O'Connor, C. Soh, ATLAS Investigators
- Brd. 16** **A multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical effects of paclitaxel-carboplatin (TC) alone or with endostatin for advanced non-small cell lung cancer (NSCLC). (Abstract #7527)**
 B. Han, Q. Xiu, Y. Luo, C. Bai, S. Guo, W. Liu, Z. Zhuang, Y. Zhang, J. Zhou, X. Jin
- Brd. 17** **Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract #7528)**
 G. R. Blumenschein, F. F. Kabbinavar, H. Menon, T. Mok, J. Stephenson, J. T. Beck, K. Lakshmaiah, K. Kracht, R. S. Sikorski, L. S. Schwartzberg

Monday, June 7, 2010

- Brd. 19** **Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605). (Abstract #7530)**
H. Yoshioka, I. Okamoto, S. Morita, M. Ando, K. Takeda, T. Seto, N. Yamamoto, S. Nakamura, M. Fukuoka, K. Nakagawa, West Japan Oncology Group (WJOG)
- Brd. 20** **Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). (Abstract #7531)**
T. J. Lynch, I. N. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, R. T. Chacko, M. Sebastian, J. Siegel, J. Cuillerot, M. Reck
- Brd. 22** **Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC). (Abstract #7533)**
P. Lara, J. Longmate, A. Argiris, B. J. Gitlitz, P. C. Mack, D. H. Lau, M. Koczywas, N. B. Leighl, D. R. Gandara
- Brd. 23** **A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small cell lung cancer (NSCLC). (Abstract #7534)**
F. H. Blackhall, Z. Márk, P. Zatloukal, B. Szima, I. Albert, E. Juhász, X. Yang, D. Smethurst, Y. Hei, J. Soria
- Brd. 24** **Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC). (Abstract #7535)**
C. S. Karapetis, P. R. Clingan, N. B. Leighl, B. Durbin-Johnson, V. O'Neill, D. R. Spigel

9:30 AM - 10:45 AM
EDUCATION SESSION

Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer

Location: S406 (Vista Room)

CME credit: 1.25

Track(s): Genitourinary Cancer; Geriatric Oncology; Patient and Survivor Care

David I. Quinn, PhD, FRACP, MBBS—Chair

University of Southern California

Review of Standard and Emerging Therapies for Localized and Advanced Urothelial Cancer

Jonathan E. Rosenberg, MD

Dana-Farber Cancer Institute

Personalizing Therapy for Urothelial Cancer: Clinical and Molecular Biomarkers

Ralph deVere White, PhD

University of California, Davis

How to Overcome Barriers to the Adoption of Neoadjuvant Therapy for Locally Advanced Urothelial Cancer

Monday, June 7, 2010

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Breast Cancer—Local-Regional and Adjuvant Therapy

Location: N Hall B1

CME credit: 3

Track(s): Breast Cancer

Seema Ahsan Khan, MD, FACS, MPH—Co-Chair

Northwestern Memorial Hospital

Rita Nanda, MD—Co-Chair

The University of Chicago

- 9:30 AM ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. (Abstract #CRA504)**
R. Cote, A. E. Giuliano, D. Hawes, K. V. Ballman, P. W. Whitworth, P. W. Blumencranz, D. S. Reintgen, M. Morrow, A. M. Leitch, K. Hunt
- 9:45 AM Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. (Abstract #LBA505)**
D. N. Krag, S. J. Anderson, T. B. Julian, A. Brown, S. P. Harlow, J. P. Costantino, T. Ashikaga, D. Weaver, E. P. Mamounas, N. Wolmark
- 10:00 AM ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1–2 N0 M0 breast cancer who have a positive sentinel node. (Abstract #CRA506)**
A. E. Giuliano, L. M. McCall, P. D. Beitsch, P. W. Whitworth, M. Morrow, P. W. Blumencranz, A. M. Leitch, S. Saha, K. Hunt, K. V. Ballman
- 10:15 AM Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. (Abstract #507)**
K. S. Hughes, L. A. Schnaper, C. Cirrincione, D. A. Berry, B. McCormick, H. B. Muss, B. Shank, C. Hudis, E. P. Winer, B. L. Smith, CALGB, ECOG, RTOG

Discussion

- 10:30 AM** William C. Wood, MD (Abstracts #CRA504–507)
Emory University
- 10:45 AM Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor (PAM50) for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial. (Abstract #508)**
S. K. Chia, K. Ung, V. H. Bramwell, D. Tu, C. M. Perou, M. J. Ellis, P. S. Bernard, T. Vickery, L. E. Shepherd, T. O. Nielsen
- 11:00 AM Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. (Abstract #509)**
G. Tang, J. Cuzick, C. Wale, J. P. Costantino, M. Crager, S. Shak, N. Wolmark, M. Dowsett, J. F. Forbes
- 11:15 AM Pharmacogenetics of tamoxifen in relation to disease-free survival in a Dutch cohort of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. (Abstract #510)**
V. O. Dezentje, R. H. Van Schaik, J. M. Vletter - Bogaartz, J. A. Wessels, E. T. Hille, C. Seynaeve, C. J. Van De Velde, J. W. Nortier, H. Gelderblom, H. Guchelaar

Discussion

11:30 AM Angelo Di Leo, MD, PhD (Abstracts #508–510)
Sandro Pitigliani Medical Oncology Unit

11:45 AM **Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer. (Abstract #511)**
K. S. Albain, W. E. Barlow, S. Shak, G. N. Hortobagyi, D. F. Hayes, for The Breast Cancer Intergroup of North America

12:00 PM **Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial. (Abstract #512)**
G. Pfeiler, R. Königsberg, C. F. Singer, M. Seifert, P. C. Dubsy, H. Samonigg, V. Bjelic-Radusic, R. Greil, C. Marth, M. Gnant

Discussion

12:15 PM Pamela Jean Goodwin, MD (Abstracts #511–512)
Mount Sinai Hospital

Monday, June 7, 2010

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Health Services Research

Location: S404

CME credit: 3

Track(s): Health Services Research

Elena B. Elkin, PhD—Co-Chair

Memorial Sloan-Kettering Cancer Center

Sarah T. Hawley, MD, PhD—Co-Chair

University of Michigan Health Systems

9:30 AM Changes over time in quality of psychosocial care: Results from the Quality Oncology Practice Initiative (QOPI). (Abstract #6000)

P. B. Jacobsen, P. Kadlubeck

9:45 AM Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone—A study of NCI-CTEP-sponsored clinical trials. (Abstract #6001)

S. K. Cheng, M. S. Dietrich, S. Finnigan, D. M. Dilts

10:00 AM Assessment of performance measures for patients with the myelodysplastic syndrome (MDS) in the United States. (Abstract #6002)

G. A. Abel, B. A. Neville, J. C. Weeks, R. M. Stone

Discussion

10:15 AM Steven J. Katz, MD (Abstracts #6000–6002)

University of Michigan

Implementing Performance Measures to Improve Patient Care

10:30 AM Comparison of SEER registry data to patient self-report. (Abstract #6003)

R. Jagsi, P. Abrahamse, J. J. Graff, S. T. Hawley, S. J. Katz

10:45 AM State-wide application of breast and colon cancer quality measures (QMs) using linked claims and registry data. (Abstract #6004)

S. B. Edge, K. Mallin, B. E. Palis, A. Stewart, L. N. Newcomer, D. E. Walczak, J. Singer, J. Barron, W. J. Blumenthal, B. L. Warther

11:00 AM Comorbidity severity and long-term mortality in men with early-stage prostate cancer. (Abstract #6005)

T. J. Daskivich, N. Sadetsky, S. H. Kaplan, S. Greenfield, M. S. Litwin

11:15 AM Development of a performance status prediction model for use in administrative data analyses. (Abstract #6006)

A. J. Davidoff, I. H. Zuckerman, N. B. Pandya, F. Hendrick, X. Ke, A. Hurria, S. M. Lichtman, A. Hussain, M. J. Edelman

Discussion

11:30 AM To be determined

11:45 AM Adoption of CT-based simulation and outcomes following radiation for stage III non-small cell lung cancer. (Abstract #6007)

A. B. Chen, B. A. Neville, D. Schrag

12:00 PM Factors influencing the uptake of the human papillomavirus (HPV) vaccine to prevent cervical cancer (CC). (Abstract #6008)

J. Y. Lai, A. V. Tinker, W. Y. Cheung

Discussion

12:15 PM Joseph Lipscomb, PhD (Abstract #6008)

Emory University

Diffusion of Therapeutic and Preventive Innovations

MONDAY

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Leukemia, Myelodysplasia, and Transplantation

Location: E354b

CME credit: 3

Track(s): Leukemia, Myelodysplasia, and Transplantation

Jessica K. Altman, MD—Co-Chair

Northwestern University

William G. Blum, MD—Co-Chair

The Ohio State University

- 9:30 AM** **Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study. (Abstract #LBA6500)**
H. Kantarjian, N. P. Shah, A. Hochhaus, J. E. Cortes, S. Shah, M. Ayala, B. Moiraghi, M. Bradley-Garelik, C. Zhu, M. Baccarani
- 9:45 AM** **Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year. (Abstract #6501)**
R. A. Larson, P. D. le Coutre, J. Reiffers, T. P. Hughes, G. Saglio, P. Edrich, A. Hoenekopp, N. J. Gallagher, H. Kantarjian, A. Hochhaus
- 10:00 AM** **Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM). (Abstract #6502)**
J. E. Cortes, H. Kantarjian, T. Brümmendorf, H. J. Khoury, D. Kim, A. Turkina, A. Volkert, J. Wang, S. Arkin, C. Gambacorti-Passerini

Discussion

- 10:15 AM** Michael J. Mauro, MD (Abstracts #LBA6500–6502)
 Oregon Health and Science University
Chronic Phase CML: Beyond Imatinib?
- 10:30 AM** **Time-dependent decision analysis: Stable disease in azacitidine (AZA) treated patients (pts) with higher-risk MDS. (Abstract #6503)**
S. Gore, P. Fenaux, V. Santini, J. M. Bennett, L. R. Silverman, J. F. Seymour, E. Hellstrom-Lindberg, A. S. Swern, C. L. Beach, A. F. List
- 10:45 AM** **A randomized study of two dose levels of intravenous (IV) clofarabine (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS). (Abstract #6504)**
E. Jabbour, H. Kantarjian, G. Garcia-Manero, F. Ravandi Kashani, G. Borthakur, Z. Estrov, V. Gandhi, A. Byrd, M. Kwari, S. Faderl
- 11:00 AM** **Improvement of leukemia-free survival (LFS) and reduction of relapse incidence by allogeneic stem cell transplantation (SCT) in elderly patients (pts) with AML irrespective of the FLT3-ITD and npm status except npm+/flt3(ITD)-. (Abstract #6505)**
D. Niederwieser, F. Schueler, U. Hegenbart, G. Maschmeyer, T. Fischer, C. Junghanss, H. Wolf, H. G. Sayer, U. Kreibich, G. Doelken, East German Study Group Hematology and Oncology OSHO

Discussion

- 11:15 AM** Jeffrey E. Lancet, MD (Abstracts #6503–6505)
 H. Lee Moffitt Cancer Center & Research Institute
High-risk MDS and AML in Elderly Patients: Are We Making Progress?
- 11:30 AM** **Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). (Abstract #6506)**
D. A. Thomas, S. M. O'Brien, S. Faderl, F. Ravandi Kashani, W. G. Wierda, M. Andreeff, R. S. Garris, R. E. Champlin, J. E. Cortes, H. Kantarjian

Monday, June 7, 2010

11:45 AM Phase II study of vincristine sulfate liposomes injection in adult patients with refractory or relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). (Abstract #6507)

S. M. O'Brien, W. Aulitzky, D. Ben Yehuda, J. Lister, G. J. Schiller, K. Seiter, S. E. Smith, W. Stock, J. A. Silverman, H. Kantarjian

Discussion

12:00 PM To be determined

12:15 PM A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. (Abstract #6508)

X. Badoux, W. G. Wierda, S. M. O'Brien, S. Faderl, Z. Estrov, K. A. Yarrow, M. J. Keating, A. Ferrajoli

MONDAY

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Pediatric Oncology II

Location: S504

CME credit: 3

Track(s): Pediatric Oncology

Gregory T. Armstrong, MD, MSCE—Co-Chair

St. Jude Children's Research Hospital

Tara O. Henderson, MD, MPH—Co-Chair

The University of Chicago

- 9:30 AM Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: A Children's Oncology Group study. (Abstract #9512)**
J. G. Blanco, C. Sun, W. Landier, L. Chen, K. C. Oeffinger, M. M. Hudson, J. P. Neglia, A. K. Ritchey, M. V. Relling, S. Bhatia
- 9:45 AM Late cardiac status in long-term survivors of childhood high-risk ALL 8 years after continuous or bolus infusion of doxorubicin: The DFCI Childhood ALL 91-01 randomized trial. (Abstract #9513)**
S. E. Lipshultz, S. R. Lipsitz, T. L. Miller, D. S. Neuberg, S. E. Dahlberg, S. D. Colan, L. B. Silverman, L. L. Cushman, J. M. Henkel, S. E. Sallan, The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium
- 10:00 AM Chronic medical conditions, health status, and health care practices at 25 years in 5-year survivors of Wilms tumor: A report from the Childhood Cancer Survivor study. (Abstract #9514)**
A. M. Termuhlen, J. M. Tersak, Y. Yasui, Q. Liu, M. Stovall, M. Deutsch, C. A. Sklar, K. C. Oeffinger, L. L. Robison, D. M. Green
- Discussion**
- 10:15 AM** Melissa M. Hudson, MD (Abstracts #9512–9514)
 St. Jude Children's Research Hospital
Cardiac Status in Survivors of Pediatric Cancer
- 10:30 AM Childhood cancer: Do females experience more acute toxicities than males? A Report from the Children's Oncology Group (Abstract #9515)**
K. A. Meeske, L. Ji, A. Butturini, D. R. Freyer, P. S. Gaynon, K. Ruccione, R. Sposto, N. L. Seibel, S. E. Siegel
- 10:45 AM MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study. (Abstract #9516)**
G. A. Yanik, M. T. Parisi, A. Naranjo, K. K. Matthay, W. B. London, P. W. McGrady, S. G. Kreissman, B. L. Shulkin
- 11:00 AM Racial and ethnic disparities in disease presentation and survival among children with neuroblastoma (NBL): A Children's Oncology Group (COG) study. (Abstract #9517)**
S. L. Cohn, S. Bhatia, W. B. London, P. W. Mcgrady, C. Crotty, C. Sun, T. O. Henderson
- 11:15 AM Clinical and biological features predictive of survival after relapse of neuroblastoma: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database. (Abstract #9518)**
W. B. London, K. K. Matthay, P. F. Ambros, T. Monclair, A. D. Pearson, S. L. Cohn, V. Castel

Discussion

- 11:30 AM** Andrew Pearson, MD, FRCP (Abstracts #9515–9518)
 The Institute of Cancer Research
Prognostic Variables in Neuroblastoma

Monday, June 7, 2010

11:45 AM Multiple subsequent neoplasms in the Childhood Cancer Survivor Study (CCSS) cohort. (Abstract #9519)

G. T. Armstrong, W. Liu, S. Hammond, S. Bhatia, J. P. Neglia, M. Stovall, W. Leisenring, Y. Yasui, D. Srivatava, L. L. Robison

12:00 PM Gastrointestinal malignancies as a subsequent malignant neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #9520)

T. O. Henderson, J. Whitton, W. Leisenring, J. P. Neglia, A. T. Meadows, K. C. Oeffinger, L. Diller, G. T. Armstrong, L. L. Robison, P. C. Nathan

Discussion

12:15 PM Flora E. Van Leeuwen, PhD (Abstracts #9519–9520)
The Netherlands Cancer Institute

MONDAY

9:45 AM - 11:00 AM
SPECIAL SESSION

ASCO—American Cancer Society Award and Lecture

Location: S100b

CME credit: 1.25

Track(s): Special Session

Joseph V. Simone, MD

University of Florida Shands Cancer Center

Promoting Excellence in Cancer Care

Monday, June 7, 2010

9:45 AM - 11:00 AM
EDUCATION SESSIONS

Family Members and Caretakers: Helping the Family and Helping the Family Help the Patient

Location: E353

CME credit: 1.25

Track(s): Patient and Survivor Care; Ethics; Professional Development

Francis J. Keefe, PhD—Chair

Duke University Medical Center

Partner-based Interventions to Enhance Coping and Pain Management and to Reduce Distress in Individuals with Cancer

Barbara Given, PhD, RN, FAAN

Michigan State University

Family and Caregiver Needs over the Course of the Cancer

Wendy Demark-Wahnefried, MD

University of Texas M. D. Anderson Cancer Center

Capitalizing on the Mother-Daughter Bond to Promote Primary and Tertiary Prevention

Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction?

Location: E Hall D2

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer; Clinical Trials; Head and Neck Cancer

Peter C. Enzinger, MD—Chair

Dana-Farber Cancer Institute

(Neo)adjuvant Chemotherapy in the Management of Localized Esophagogastric Carcinoma

Mohan Suntharalingam, MD

University of Maryland Medical Center

Neoadjuvant Chemoradiation in the Management of Localized Esophagogastric Carcinoma

Cliff P. Connery, MD

Beth Israel Cancer Center

Implications for Surgery Following Chemotherapy or Chemoradiation

Seminal Advances in Lung Cancer Research 2010: Translational and Clinical

Location: E Hall D1

CME credit: 1.25

Track(s): Lung Cancer

Jeffrey Crawford, MD—Chair

Duke University Medical Center

Perspectives on Recent Advances in Lung Cancer

Ravi Salgia, MD, PhD

The University of Chicago

Translational Advances in Lung Cancer

Ramaswamy Govindan, MD

Washington University School of Medicine

Clinical Advances in Lung Cancer

MONDAY

9:45 AM - 11:00 AM
MEET THE PROFESSOR SESSION

Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor (M10)-TICKETED SESSION

Location: E451b

CME credit: 1.25

Track(s): Professional Development; Clinical Trials; Developmental Therapeutics

Evanthia Galanis, MD

Mayo Clinic

9:45 AM - 11:00 AM
CLINICAL PROBLEMS IN ONCOLOGY

Treatment of Barrett's Esophagus to Prevent Esophageal Cancer (C12)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Cancer Prevention/Epidemiology; Gastrointestinal (Noncolorectal) Cancer

Brian J. Reid, MD, PhD—Chair

Fred Hutchinson Cancer Research Center

Risk Stratification, Chemoprevention, and Early Detection in Barrett's Esophagus

Hiran C. Fernando, MD, MBBS

Boston University School of Medicine

Esophageal Resection for High-grade Dysplasia and Superficial Cancer

Kenneth K. Wang, MD

Mayo Clinic

Multimodality Approaches for Endoscopic Ablation of Barrett's Esophagus

Monday, June 7, 2010

9:45 AM - 11:15 AM
CLINICAL SCIENCE SYMPOSIUM

Novel Therapies and Approaches for Management of Gynecologic Cancers

Location: E Arie Crown Theater

CME credit: 1.5

Track(s): Gynecologic Cancer

Robert L. Coleman, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

Ronald J. Buckanovich, MD—Co-Chair

University of Michigan

9:45 AM Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. (Abstract #5000)

B. Y. Karlan, A. M. Oza, V. L. Hansen, G. E. Richardson, D. M. Provencher, P. Ghatage, M. Tassoudji, D. E. Stepan, D. M. Weinreich, I. B. Vergote

Discussion

10:00 AM George Coukos, MD, PhD (Abstract #5000)

University of Pennsylvania, Perelman Center for Advanced Medicine

Anti-angiogenic Options in Ovarian Cancer

10:15 AM Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. (Abstract #5001)

A. J. White, R. L. Coleman, D. K. Armstrong, D. Glenn, A. Bicher, D. A. Richards, A. Schneeweiss, L. J. Old, C. Schweizer, S. Weil

Discussion

10:30 AM Alan Hilary Calvert, MD (Abstract #5001)

Cancer Research Unit

Targeting the Folate Receptor in Ovarian Cancer

10:45 AM Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer. (Abstract #5002)

H. W. Hirte, W. P. McGuire III, R. P. Edwards, A. Husain, P. Hoskins, J. E. Michels, U. Matulonis, C. Sexton, J. A. Fox, G. Michelson

Discussion

11:00 AM Hani Gabra, PhD, FRCP (Abstract #5002)

Imperial College, London

Mechanisms of Resistance in Ovarian Cancer

MONDAY

9:45 AM - 11:15 AM
CLINICAL SCIENCE SYMPOSIUM

Promising Targeted Therapies for Head and Neck Cancer

Location: E354a

CME credit: 1.5

Track(s): Head and Neck Cancer

Bonnie S. Glisson, MD—Chair

University of Texas M. D. Anderson Cancer Center

9:45 AM Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008–02. (Abstract #5500)

S. Schmitz, M. Kaminsky-Forrett, S. Henry, S. Zanetta, L. Geoffrois, E. Bompas, A. Moxhon, J. Guigay, J. H. Machiels

Discussion

10:00 AM Bonnie S. Glisson, MD (Abstract #5500)
University of Texas M. D. Anderson Cancer Center

10:15 AM BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study. (Abstract #5501)

T. Y. Seiwert, P. M. Clement, D. Cupissol, J. Del Campo, H. de Mont-Serrat, H. C. Thurm, A. S. Blackman, E. E. Cohen

Discussion

10:30 AM Lisa F. Licitra, MD (Abstract #5501)
Istituto Nazionale Tumori

10:45 AM Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. (Abstract #5502)

R. Kurzrock, E. E. Cohen, S. I. Sherman, D. G. Pfister, R. B. Cohen, D. Ball, D. S. Hong, C. S. Ng, R. Salgia, M. J. Ratain

Discussion

11:00 AM Manisha H. Shah, MD (Abstract #5502)
The Ohio State University

Monday, June 7, 2010

**9:45 AM - 11:30 AM
EDUCATION SESSION**

Improving the Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the National Cancer Institute's Clinical Trials and Translational Research Advisory Committee

Location: S100a

CME credit: 1.75

Track(s): Clinical Trials; Health Services Research; Special Session

James H. Doroshow, MD—Chair

National Cancer Institute

Streamlining the Extramural Clinical Trials System

David M. Dilts, PhD, MBA

Oregon Health & Science University

Obstacles to Clinical Trial Development and Implementation

John Mendelsohn, MD

University of Texas M. D. Anderson Cancer Center

Recommendations by the IOM on Reinvigorating Cooperative Group Clinical Trials

Richard L. Schilsky, MD

The University of Chicago

The Role of Cooperative Groups in Comparative Effectiveness Research

**11:30 AM - 12:45 PM
SPECIAL SESSION**

The Hospital/Physician Relationship: Tensions Arising

Location: E354a

CME credit: 1.25

Track(s): Practice Management and Information Technology; Special Session

Barbara L. McAneny, MD—Chair

New Mexico Oncology Hematology Consultants, Ltd.

Where We Have Been, Where We Are: The Life of a Practice and the Pros and Cons of Intersecting with the Hospital

Michael L. Blau, JD

Foley & Lardner LLP

Options for Practice and for Hospitals: How to Balance For-profit and Nonprofit Entities?

Lowell E. Schnipper, MD

Beth Israel Deaconess Medical Center

Why We Must Cooperate: An Integrated Health Care Delivery Model Is Important—Cost and Quality and Survival

Hoangmai Pham, MD, MPH

The Johns Hopkins University

The Future Drives Us Together: New Payment Schemes—Where Episode of Care Leaves Oncology? Can You Survive outside of the Institution?

11:30 AM - 12:45 PM
EDUCATION SESSIONS

Addressing the Cost of Cancer Care with Patients: Practice-based Strategies for Communicating the “New Bad News”

Location: E353

CME credit: 1.25

Track(s): Professional Development; Health Services Research; Practice Management and Information Technology

Lidia Schapira, MD—Chair

Massachusetts General Hospital

Communication about Cost of Cancer Care

Deborah Schrag, MD

Dana-Farber Cancer Institute

Communicating the Costs and Benefits of Medical Interventions

Anthony Back, MD

Seattle Cancer Care Alliance

Inside the Patient-Physician Encounter: Communication and Value

Are We Asking Too Much? The Challenges of Mandatory Research Biopsies within Clinical Trials

Location: S100b

CME credit: 1.25

Track(s): Ethics; Clinical Trials; Developmental Therapeutics

Jeffrey M. Peppercorn, MD, MPH—Chair

Duke University Medical Center

The Ethical Framework: Can We Pursue Mandatory Research Biopsy under Select Circumstances?

Eric P. Winer, MD

Dana-Farber Cancer Institute

What Can We Learn? The Scientific Justification for Consideration of Mandatory Research Biopsy within Some Clinical Trials

Michael Katz

Eastern Cooperative Oncology Group, Patient Advisory Board

Are We Asking Too Much? Ethical Concerns over Mandatory Research Biopsy: Concerns over Coercion

Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer

Location: E Arie Crown Theater

CME credit: 1.25

Track(s): Genitourinary Cancer; General Oncology; Geriatric Oncology; Patient and Survivor Care

Michael J. Morris, MD—Chair

Memorial Sloan-Kettering Cancer Center

Phase III Trial Results and the Impact on Standard of Care and Trial Design

Kim N. Chi, MD

British Columbia Cancer Agency

Second-line Treatment after Docetaxel

Evan Y. Yu, MD

University of Washington

Bone-directed Therapy for Prostate Cancer: Present Standards and Potential New Options

Monday, June 7, 2010

**11:30 AM - 12:45 PM
CLINICAL PROBLEMS IN ONCOLOGY**

**Management of Less Common Head and Neck Cancers (C16)-TICKETED
SESSION**

Location: E451a

CME credit: 1.25

Track(s): Head and Neck Cancer; Melanoma/Skin Cancers

David J. Adelstein, MD—Chair

Cleveland Clinic Taussig Cancer Institute

Salivary Gland Cancer

Quynh-thu Le, MD

Stanford University

Nasopharyngeal Carcinoma

Carol Rossier Bradford, MD

University of Michigan

Cutaneous Melanoma of the Head and Neck

**12:00 PM - 1:00 PM
SPECIAL SESSION**

**ASCO Annual Business Meeting including ASCO Statesman Awards
(ASCO Members Only)**

Location: Hyatt McCormick Place Regency Ballroom

Track(s): Special Session

MONDAY

**1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION**

Sarcoma

Location: S406 (Vista Room)
CME credit: 3
Track(s): Sarcoma

Mark Agulnik, MD—Co-Chair
Northwestern University

Richard Riedel, MD—Co-Chair
Duke University Medical Center

- 1:00 PM Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study. (Abstract #10000)**
A. S. Pappo, S. Patel, J. Crowley, D. K. Reinke, A. P. Staddon, K. Kuenkele, S. P. Chawla, R. S. Benjamin, L. J. Helman, L. H. Baker, Sarcoma Alliance for Research through Collaboration
- 1:15 PM AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results. (Abstract #10001)**
W. D. Tap, G. D. Demetri, P. Barnette, J. Desai, P. Kavan, R. Tozer, G. R. Friberg, H. Deng, I. McCaffery, A. W. Tolcher
- 1:30 PM Combination mTOR+IGF-1R inhibition: Phase I trial of everolimus and CP-751,871 in patients (pts) with advanced sarcomas and other solid tumors. (Abstract #10002)**
R. H. Quek, J. A. Morgan, G. Shapiro, J. E. Butrynski, Q. Wang, T. Huftalen, N. Jederlinic, A. J. Wagner, G. D. Demetri, S. George

Discussion

- 1:45 PM** To be determined
- 2:00 PM Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: Three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: A phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS). (Abstract #10003)**
A. Gronchi, S. Frustaci, M. Mercuri, J. Martin Broto, A. Lopez-Pousa, L. Mariani, P. Verderio, V. Quagliuolo, P. G. Casali, P. Picci
- 2:15 PM A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). (Abstract #10004)**
C. F. Verschraegen, S. P. Chawla, M. M. Mita, C. W. Ryan, L. Blakely, V. L. Keedy, A. Santoro, J. Y. Buck, R. G. Maki, J. J. Lewis, PICASSO Study Investigators
- 2:30 PM Identification of selective inhibitors of dedifferentiated liposarcoma cells by high-throughput screening (HTS). (Abstract #10005)**
C. V. Angeles, B. Laxa, D. Shum, P. DeCarolis, R. Gobble, E. Brill, S. Ugras, R. O'Connor, H. Djaballah, S. Singer

Monday, June 7, 2010

Discussion

2:45 PM Andrew J. Wagner, MD, PhD (Abstracts #10003–10005)
Dana-Farber Cancer Institute

3:00 PM **Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. (Abstract #10006)**
C. L. Corless, K. V. Ballman, C. Antonescu, C. D. Blanke, M. E. Blackstein, G. D. Demetri, M. von Mehren, R. G. Maki, P. W. Pisters, R. P. DeMatteo, American College of Surgeons Oncology Group

3:15 PM **In vitro activity of novel KIT/PDGFR α switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors. (Abstract #10007)**
M. C. Heinrich, S. Wise, M. Hood, B. Smith, M. Kaufman, W. Lu, Y. Wang, D. Griffith, D. Flynn, J. A. Fletcher

3:30 PM **Succinate dehydrogenase in KIT/PDGFR α wild-type gastrointestinal stromal tumors. (Abstract #10008)**
K. A. Janeway, S. Kim, M. Lodish, V. Nose, P. Dahia, P. Rustin, G. D. Demetri, J. A. Fletcher, L. J. Helman, C. A. Stratakis, Consortium for Pediatric and Wildtype GIST Research (CPGR)

Discussion

3:45 PM Robert D. Marsh, MD (Abstracts #10006–10008)
Kellogg Cancer Center, Northshore University Health System

MONDAY

1:00 PM - 5:00 PM
GENERAL POSTER SESSION

Genitourinary Cancer

Location: S Hall A2

Tracks(s): Genitourinary Cancer

- Brd. 1A** **The impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The M. D. Anderson Cancer Center experience. (Abstract #4566)**
S. P. Lynch, T. T. Vu, A. M. Kamat, H. B. Grossman, R. E. Millikan, C. P. Dinney, A. O. Siefker-Radtke
- Brd. 1B** **Impact of dose density of adjuvant chemotherapy for locally advanced urothelial cancer. (Abstract #4567)**
T. B. Dorff, J. Cai, G. Miranda, E. C. Skinner, A. Schuckman, S. G. Groshen, D. I. Quinn
- Brd. 1C** **Concentration-depth profiles of mitomycin-C in the human bladder wall after passive diffusion, thermochemotherapy, and electromotive drug administration. (Abstract #4568)**
G. Leprini, R. Massoud, S. Dolci, P. Navarra, C. Verri, F. Torelli, F. Angelini, S. M. Di Stasi
- Brd. 1D** **Paclitaxel-gemcitabine (P-G) for patients (pts) with advanced urothelial cancer (UC) age > 70 years (yrs): SWOG 0028. (Abstract #4569)**
D. Raghavan, C. M. Tangen, C. Moinpour, C. Gotay, K. S. Albain, S. Louie, H. Lenz, D. I. Quinn, M. Hussain, I. Thompson, Southwest Oncology Group
- Brd. 1E** **The impact of a bladder cancer diagnosis on smoking behavior: An opportunity to improve care. (Abstract #4570)**
J. C. Bassett, J. L. Gore, A. C. Chi, L. Kwan, K. Chamie, C. Saigal
- Brd. 1F** **Evaluation of African American ethnicity and socioeconomic status as prognostic factors for overall survival in bladder cancer. (Abstract #4571)**
F. Jiang, A. Ziogas, J. A. Zell, S. I. Ou
- Brd. 1G** **Gene expression profile of advanced squamous and transitional cell carcinoma of the bladder. (Abstract #4572)**
H. M. Khaled, F. Abu-Taleb, A. Zekri, R. Haggag
- Brd. 1H** **Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC). (Abstract #4573)**
M. D. Galsky, G. Sonpavde, B. A. Hellerstedt, S. A. McKenney, T. E. Hutson, M. A. Rauch, Y. Wang, K. A. Boehm, L. Asmar
- Brd. 2A** **Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). (Abstract #4574)**
S. Krege, H. Rexer, F. vom Dorp, P. Albers, P. De Geeter, T. Klotz, AUO
- Brd. 2B** **Validation of a trimodalitity treatment and selective organ preservation for bladder cancer: Influence of clinical different parameters on the 15-year long-term outcome. (Abstract #4575)**
F. Krause, O. Ott, L. Haeberle, B. Wullich
- Brd. 2C** **Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy. (Abstract #4576)**
G. Sonpavde, M. M. Khan, S. P. Lerner, R. S. Svatek, E. C. Skinner, P. I. Karakiewicz, W. Kassouf, C. P. Dinney, Y. Fradet, S. F. Shariat
- Brd. 2D** **Comparison of HER2 amplification in primary tumors and lymph node metastases of urinary bladder cancer. (Abstract #4577)**
A. Fleischmann, R. Seiler, D. Rotzer, G. N. Thalmann
- Brd. 2E** **Influence of age and socioeconomic status (SES) on testicular cancer (TC) specific mortality: A population-based study of 27,948 patients. (Abstract #4578)**
S. D. Fossa, L. B. Travis, L. Chen, M. Cvancarova

Monday, June 7, 2010

- Brd. 2F** **Clinical relevance of germ cell cancer cells detected by real time PCR in apheresis products of poor risk patients undergoing high dose chemotherapy. (Abstract #4579)**
A. Burchert, L. Sytik, A. Lorch, J. T. Hartmann, C. Bokemeyer, O. Rick, J. Beyer, T. D. Kim, A. Neubauer
- Brd. 2G** **Management of testicular neoplasms in France and compliance with national guidelines. (Abstract #4580)**
S. Culine, S. Hoppe, C. Hennequin, M. Saves, N. Mottet, FRANCIM network
- Brd. 2H** **$2\text{-}^{18}\text{F}$ fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residuals: A retrospective validation of the SEMPET trial. (Abstract #4581)**
M. Bachner, P. Zucali, A. Horwich, K. Oechsle, Y. Lorient, A. Flechon, C. K. Kollmannsberger, J. R. Germa-Lluch, J. Oldenburg, M. De Santis
- Brd. 3A** **Sunitinib in patients with multiply relapsed or cisplatin-refractory germ cell cancer: A CUOG/GTCSG cooperative phase II study. (Abstract #4582)**
C. K. Kollmannsberger, K. Oechsle, T. Cheng, F. Mayer, P. Czaykowski, E. Winquist, L. Wood, M. Fenner, K. N. Chi, C. Bokemeyer
- Brd. 3B** **Progression-free survival (PFS) as a new endpoint for designing phase II trials in patients with refractory germ cell tumors (GCT). (Abstract #4583)**
D. R. Feldman, S. Patil, M. J. Trinos, M. Carouso, M. S. Ginsberg, J. Sheinfeld, D. F. Bajorin, G. J. Bosl, R. J. Motzer
- Brd. 3C** **Impact of delayed orchiectomy (OE) on overall survival (OS) in patients (pts) with metastatic germ cell tumors (mGCT). (Abstract #4584)**
M. Fedyanin, A. Tryakin, D. Kanagavel, E. Burova, T. Zakharova, I. Fainstein, U. Sergeev, I. Pokataev, A. Garin, S. Tjulandin
- Brd. 3D** **Long term outcome in patients with cisplatin-refractory or multiply relapsed germ cell tumors following treatment with gemcitabine and oxaliplatin +/- paclitaxel. (Abstract #4585)**
K. Oechsle, C. K. Kollmannsberger, F. Honecker, F. Mayer, C. F. Waller, I. Böhlke, C. Bokemeyer
- Brd. 3E** **Residual tumor resection in patients with germ cell tumors (GCT): Use of IGCCCG risk group and tumor volume to predict additional vascular procedures. (Abstract #4586)**
C. Winter, C. Bingoel, R. Witthuhn, P. De Geeter, P. Albers
- Brd. 3F** **Paclitaxel plus BEP (T-BEP) regimen as induction chemotherapy (CT) in nonseminomatous germ cell tumors (NSGCT) patients with poor prognosis: A phase II study. (Abstract #4587)**
A. Tryakin, M. Fedyanin, U. Sergeev, I. Pokataev, B. Ahmedov, T. Zakharova, A. Mitin, I. Fainstein, A. Garin, S. Tjulandin
- Brd. 3G** **A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. (Abstract #4588)**
A. Amin, A. Dudek, T. Logan, R. S. Lance, J. M. Holzbeierlein, W. L. Williams, R. Jain, T. G. Chew, C. A. Nicolette, R. A. Figlin, AGS-003-006 Study Group
- Brd. 3H** **Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC). (Abstract #4589)**
G. Procopio, E. Verzoni, S. Bracarda, S. Ricci, C. Sacco, L. Ridolfi, C. Porta, R. Miceli, N. Zilembo, E. Bajetta, on behalf of ITMO Study Group
- Brd. 4A** **A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC). (Abstract #4590)**
J. E. Rosenberg, H. A. Drabkin, P. Lara Jr., A. L. Harzstark, R. A. Figlin, G. W. Smith, F. Erlandsson, D. A. Laber

- Brd. 4B** **Interleukin-2 (IL-2)-based immunotherapy for the treatment of metastatic renal cell carcinoma (mRCC): An analysis of 422 consecutive patients treated between 1999 and 2008. (Abstract #4591)**
 F. Donskov, H. K. Jensen, A. N. Jeppesen, K. Fode, H. Schmidt, M. Agerbaek, L. Broendum, H. von der Maase
- Brd. 4C** **Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma (mRCC) receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone. (Abstract #4592)**
 P. Karakiewicz, M. Sun, V. Sneller, B. Escudier
- Brd. 4D** **Use of the UCLA Integrated Staging System (UISS) to predict survival after sunitinib treatment for patients with metastatic renal cell carcinoma. (Abstract #4593)**
 F. Pouliot, C. Anterasian, T. Klatte, D. Finley, B. Shuch, F. F. Kabbinar, N. Zomorodian, A. S. Belldegrun, A. J. Pantuck
- Brd. 4E** **TWIST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon- α (IFN- α). (Abstract #4594)**
 S. Patil, R. A. Figlin, T. E. Hutson, D. Michaelson, S. Negrier, S. T. Kim, X. Huang, R. J. Motzer
- Brd. 4F** **Overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: Two analyses from the RECORD-1 trial. (Abstract #4595)**
 P. Korhonen, E. Malangone, S. Sherman, R. Casciano, R. J. Motzer, J. Baladi, T. Haas, E. Zuber, A. C. Kay, D. E. Lebwolh
- Brd. 4G** **Patient preferences for targeted agents in renal cell carcinoma (RCC): A benefit-risk conjoint study. (Abstract #4596)**
 A. B. Hauber, A. F. Mohamed, F. R. Johnson, M. Neary
- Brd. 4H** **Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon- α (IFN- α): Analysis of the pivotal randomized trial. (Abstract #4597)**
 J. Wilkerson, W. D. Stein, S. T. Kim, X. Huang, R. J. Motzer, A. T. Fojo, S. E. Bates
- Brd. 5A** **Epidemiological trends in renal cell carcinoma (RCC) in the cytokine (CYT) and targeted therapy (TT) eras: A registry analysis of 28,252 patients (pts). (Abstract #4598)**
 D. W. Shek, M. Brown, C. Pan, P. Lara Jr.
- Brd. 5B** **Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT). (Abstract #4599)**
 P. Bhargava, B. Esteves, M. Al-Adhami, D. Nosov, O. N. Lipatov, A. A. Lyulko, A. A. Anischenko, R. T. Chacko, D. Doval, W. J. Slichenmyer
- Brd. 5C** **Complete remission with TKI in renal cell carcinomas: Experience in 65 patients of the French Kidney Cancer Group. (Abstract #4600)**
 L. Albiges, S. Oudard, S. Negrier, A. Caty, G. Gravis, F. Joly, B. Duclos, L. Geoffrois, F. Rolland, B. Escudier
- Brd. 5D** **A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib. (Abstract #4601)**
 N. A. Ilias-Khan, A. Y. Khakoo, N. M. Tannir
- Brd. 5E** **Risk of congestive heart failure with VEGF-targeted therapy: A systematic review and meta-analysis of clinical trials. (Abstract #4602)**
 F. A. Schutz, Y. Je, G. R. Azzi, T. K. Choueiri
- Brd. 5F** **The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. (Abstract #4603)**
 T. Powles, I. Kayani, C. U. Blank, S. Chowdhury, S. Horenblas, N. Sarwar, P. D. Nathan, E. Boleti, J. B. Haanen, A. Bex

Monday, June 7, 2010

- Brd. 5G Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. (Abstract #4604)**
E. R. Plimack, E. Jonasch, B. N. Bekele, W. Qiao, C. S. Ng, N. M. Tannir
- Brd. 5H Sorafenib (SOR) safety profile in more than 4,600 patients (pts) with renal cell carcinoma (RCC): Assessment at 3-month (mo) intervals using an integrated database of eight company-sponsored studies. (Abstract #4605)**
M. E. Gore, J. Beck, J. J. Knox, T. Eisen, C. Szczylik, S. Negrier, T. E. Hutson, A. Brueckner, J. Kalmus, B. Escudier
- Brd. 6A Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. (Abstract #4606)**
Z. Dubauskas Lim, T. K. Choueiri, M. S. Hirsch, E. Jonasch, U. N. Vaishampayan, P. Tamboli, P. G. Corn, D. Y. Heng, N. M. Tannir
- Brd. 6B Presurgical bevacizumab and sunitinib induced changes in primary clear cell renal tumor tissue. (Abstract #4607)**
A. Bex, E. Jonasch, F. Vyth-Dreese, C. de Hoog, T. Dellelijn, A. W. Griffioen
- Brd. 6C Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #4608)**
S. Osanto, T. E. Hutson, E. Calvo, B. J. Escudier, S. Oudard, C. Porta, S. Bracarda, V. Grunwald, A. Ravaud, R. J. Motzer
- Brd. 6D Bevacizumab (BEV) and the risk of arterial thromboembolic events (ATE) in patients with renal cell carcinoma and other cancers: A large comprehensive meta-analysis of more than 13,000 patients. (Abstract #4609)**
G. R. Azzi, F. A. Schutz, Y. Je, T. K. Choueiri
- Brd. 6E Long-term responders to sunitinib therapy for metastatic renal cell carcinoma (mRCC). (Abstract #4610)**
A. M. Molina, X. Jia, M. S. Ginsberg, S. Velasco, D. R. Feldman, S. Patil, R. J. Motzer
- Brd. 6F An indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients. (Abstract #4611)**
R. Casciano, E. Malangone, S. Sherman, J. Baladi, A. C. Kay, D. Kim, C. A. Garay, N. Hollaender, J. Wang
- Brd. 6G Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. (Abstract #4612)**
G. H. Mickisch, B. Schwander, B. J. Escudier, J. Bellmunt, J. P. Maroto, C. Porta, S. Walzer, M. Nuijten
- Brd. 6H Outcome of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). (Abstract #4613)**
S. L. Richey, S. H. Culp, E. Jonasch, P. G. Corn, L. C. Pagliaro, S. F. Matin, C. G. Wood, N. M. Tannir
- Brd. 7A Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal cell carcinoma (RCC) treated for 12 to 42 months (mos). (Abstract #4614)**
T. E. Hutson, G. Procopio, B. Escudier, S. Negrier, J. J. Knox, U. Keilholz, C. Szczylik, A. Brueckner, J. Kalmus, C. Bokemeyer
- Brd. 7B Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG). (Abstract #4615)**
R. Passalacqua, S. Buti, M. Brighenti, L. Rivoltini, C. Castelli, C. Camisaschi, C. Simonelli, G. Lo Re, R. Mattioli, S. Lazzarelli
- Brd. 7C Risk of primary progressive disease with tyrosine kinase inhibitors sorafenib and sunitinib in patients with renal cell carcinoma: A meta-analysis. (Abstract #4616)**
X. Su, V. Ranpura, S. Wu

- Brd. 7D** **Effect of GSK-3 inhibition in vitro and in vivo on antitumor effect of sorafenib in renal cell carcinoma (RCC). (Abstract #4617)**
H. Kawazoe, V. Bilim, K. Yuuki, S. Naito, A. Muto, Y. Tomita
- Brd. 7E** **Detection of circulating tumor cells in patients with renal cell carcinoma compared with a control group. (Abstract #4618)**
T. Gutsch, O. Pachernegg, K. Lackner, G. C. Hutterer, R. Stauber, K. Pummer, R. Zigeuner
- Brd. 7F** **Correlation of regulatory T-cell levels and overall survival in metastatic renal cancer patients treated with sunitinib-based therapy. (Abstract #4619)**
E. Tartour, O. Adotevi, H. Pere, B. Beuselinck, J. Ayllon, J. Medioni, S. Oudard
- Brd. 7G** **The effect of sunitinib on immune parameters and haemopoetic stem cell markers in patients with untreated clear cell renal cancer. (Abstract #4620)**
S. Chowdhury, T. S. O'Brien, N. Sarwar, J. Shamash, S. McGrath, S. Agrawal, L. Lim, S. M. Rudman, P. G. Harper, T. Powles
- Brd. 7H** **Fibroblast growth factor pathway in renal cell carcinoma. (Abstract #4621)**
I. Tsimafeyeu, L. Demidov, H. Ta, E. Stepanova, N. Wynn
- Brd. 8A** **Expression of enhancer of zeste homolog 2 in renal cell carcinoma and relationship to downregulation of micro RNA-101. (Abstract #4622)**
T. Sakurai, V. Bilim, K. Yuuki, M. Tsukigi, A. V. Ougolkov, Y. Tomita
- Brd. 8B** **Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice. (Abstract #4623)**
N. M. Agostino, V. M. Chinchilli, A. M. Koszyk-Szewczyk, R. Gingrich, J. M. Sivik, J. J. Drabick
- Brd. 8C** **Renal cell carcinoma in octogenarians: Comprehensive analysis using the SEER database. (Abstract #4624)**
N. J. Hellenthal, M. H. Hayn, H. L. Kim, W. Underwood III, T. Schwaab
- Brd. 8D** **Single-fraction radiosurgery for treatment of spinal and cerebral metastases from renal cell carcinoma under systemic tyrosine kinase inhibition. (Abstract #4625)**
M. D. Staehler, N. Haseke, P. Nuhn, C. Nordhaus, C. G. Stief, B. Wowra, A. Muacevic
- Brd. 8E** **Metastatic renal cell carcinoma (mRCC): Relationship between initial non-renal RECIST-target metastases hypoxia, change after 1 month of sunitinib, and therapeutic response: An ¹⁸F-MISO PET-CT study. (Abstract #4626)**
F. Hugonnet, L. Fournier, S. Oudard, Hypoxia in Renal Cancer (HYRC) Multicentric Group
- Brd. 8F** **Pro-BNP for detection of sunitinib-induced cardiac toxicity in patients with renal cell carcinoma. (Abstract #4627)**
M. Schmidinger, M. Bojic, U. Vogl, W. Lamm, C. Zielinski
- Brd. 8G** **Serum thrombospondin-1 (TSP-1), vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), and basic-fibroblast growth factor (b-FGF) as predictive factors for sorafenib plus interferon-alfa-2a (IFN) in metastatic renal cell carcinoma (MRCC): Biologic results from the randomized phase II RAPSODY trial. (Abstract #4628)**
S. Bracarda, V. Ludovini, C. Porta, C. Boni, A. Santoro, D. Gasparro, E. Cortesi, V. De Angelis, M. Sisani, L. Crinò, GOIRC Group
- Brd. 8H** **Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib. (Abstract #4629)**
J. J. Kim, S. A. Vaziri, P. Elson, B. I. Rini, A. Patel, N. S. Basappa, M. Ganapathi, R. Ganapathi

Monday, June 7, 2010

- Brd. 9A Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC). (Abstract #4630)**
A. J. Bullock, L. Zhang, A. M. O'Neill, A. Percy, V. Sukhatme, J. W. Mier, M. B. Atkins, R. S. Bhatt
- Brd. 9B Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC). (Abstract #4631)**
A. J. Armstrong, D. J. George, S. Halabi
- Brd. 9C A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902. (Abstract #4632)**
H. M. Sandler, D. Hunt, A. O. Sartor, L. G. Gomella, A. Hartford, K. L. Zeitzer, R. Rajan, K. Kerlin, J. M. Michalski, S. A. Rosenthal
- Brd. 9D Treatment of intermediate- or high-risk prostate cancer by dose escalation with high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B): Early results of a prospective comparative trial. (Abstract #4633)**
B. Guix, J. Bartrina, J. Tello, L. Quinzaños, J. Sole, T. Lacorte, J. Fernandez, I. Guix, G. Galdon, M. Espino
- Brd. 9E Phase I/II trial of combined hormonal therapy and hypofractionated accelerated radiotherapy with concomitant intensity-modulated boost for high-risk prostate cancer: Toxicity analysis. (Abstract #4634)**
H. Quon, D. A. Loblaw, G. Morton, E. Szumacher, C. Danjoux, R. Choo, G. Thomas, A. Kiss, A. Deabreu, P. Cheung
- Brd. 9F Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy. (Abstract #4635)**
D. C. Danila, A. Anand, C. C. Sung, M. Leversha, D. E. Rathkopf, M. J. Morris, S. F. Slovin, A. Molina, M. Fleisher, H. I. Scher
- Brd. 9G A sensitive exosome-based biosignature for the diagnosis of prostate cancer. (Abstract #4636)**
C. Kuslich, T. L. Pawlowski, T. Deng, T. Tinder, J. Kim, J. Kimbrough, D. Spetzler
- Brd. 9H Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial. (Abstract #4637)**
G. R. Pond, G. Sonpavde, W. R. Berry, R. De Wit, A. J. Armstrong, M. A. Eisenberger, I. Tannock
- Brd. 10A Fluorodeoxyglucose (FDG) PET as an outcome measure for metastatic prostate cancer. (Abstract #4638)**
M. J. Morris, J. J. Fox, E. R. Dennis, K. Tse, E. Flatts, G. Heller, X. Jia, H. Schöder, S. M. Larson, H. I. Scher
- Brd. 10B Association of genetic polymorphisms in ERCC1 gene with PSA response to carboplatin chemotherapy in men with metastatic castration-resistant prostate cancer (CRPC). (Abstract #4639)**
M. Nakabayashi, W. K. Oh, L. Werner, W. Xie, M. M. Regan, T. J. McKearn, P. Kantoff, M. Pomerantz
- Brd. 10C Serum-free circulating DNA as a biomarker of prostate cancer diagnosis. (Abstract #4640)**
E. Gordian, K. Ramachandran, I. M. Reis, M. Manoharan, M. S. Soloway, R. Singal
- Brd. 10D Correlation between serum PSA and testosterone (T) kinetics in patients (pts) with biochemically relapsed prostate cancer (BRPC) (M0), after local treatment (tx), treated with intermittent androgen deprivation (IAD). (Abstract #4641)**
V. J. Sinibaldi, D. Keizman, M. A. Carducci, S. R. Denmeade, P. Huang, M. A. Eisenberger

- Brd. 10F** **Effect of tissue ischemia on prostatic androgen levels. (Abstract #4643)**
M. C. Risk, E. A. Mostaghel, B. Marck, A. M. Matsumoto, P. Nelson,
 R. B. Montgomery, D. W. Lin
- Brd. 10G** **Prognostic value of metastasis pattern for morbidity in prostate cancer measured by quantitative bone scintigraphy. (Abstract #4644)**
M. Hoejgaard, B. Zerahn, K. Avogdilan, B. Kristensen, K. J. Mikines
- Brd. 10H** **Performance of expressed prostatic secretion assays in prediction of surgical pathology outcomes in patients undergoing radical prostatectomy. (Abstract #4645)**
C. M. Whelan, J. P. Clark, T. G. Wilson, D. Y. Josephson, M. H. Kawachi,
 L. E. Crocitto, D. D. Smith, S. S. Smith
- Brd. 11A** **Correlation of epigenetic silencing of *SOCS3* with a subset of prostate cancer with aggressive behavior. (Abstract #4646)**
F. Pierconti, M. Martini, T. Cenci, F. Pinto, P. Bassi, L. Larocca
- Brd. 11B** **Prostate cancer metastasis, the noncanonical Wnt pathway, and the transcription factor PITX2. (Abstract #4647)**
I. Vela, C. Morrissey, E. Corey, R. Vessella, S. Chen, G. Strutton, C. Nelson,
 J. Clements, D. Nicol, E. M. Gardiner
- Brd. 11F** **PCA3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy. (Abstract #4648)**
K. Okihara, A. Ochiai, Z. Fros, T. Miki
- Brd. 11G** **Neuroendocrine carcinoma in conjunction with Gleason score 8-10 prostate cancer: Clinical implications for patients treated with radiotherapy. (Abstract #4649)**
D. J. Krauss, M. Amin, S. Hayek, H. Ye, L. L. Kestin, F. Vicini, A. Martinez
- Brd. 11H** **Molecular markers that predict for recurrence in men with margin-positive localized prostate cancer. (Abstract #4650)**
P. Yip, J. Kench, K. Rasiyah, R. Benito, C. Lee, S. Henshall, R. Sutherland,
 L. Horvath
- Brd. 12A** **Use of a pretreatment systems pathology model to predict the likelihood of disease progression in patients treated with primary radiotherapy. (Abstract #4651)**
M. J. Donovan, F. Khan, G. Fernandez, V. Bayer-Zubek, P. C. Albertsen
- Brd. 12B** **Expression of EGFR and HER2/neu and absence of activating mutations in patients with castration-resistant prostate cancer. (Abstract #4652)**
C. H. Ohlmann, E. Markert, M. Stöckle, H. Dienes, U. Engelmann, A. Heidenreich
- Brd. 12F** **Natural history of castration-resistant nonmetastatic prostate cancer: Secondary analyses of a multicenter randomized controlled trial. (Abstract #4653)**
M. R. Smith, R. J. Cook, J. B. Nelson
- Brd. 12G** **Prostate cancer in men under the age of 50: A comparison of race and outcomes. (Abstract #4654)**
P. M. Parker, K. R. Rice, Y. Chen, D. G. McLeod, S. A. Brassell
- Brd. 12H** **Who receives chemotherapy: An analysis of stage IV prostate cancer (PCa) patients in SEER-Medicare. (Abstract #4655)**
M. Grabner, E. Onukwugha, C. D. Mullins, B. S. Seal, A. Hussain
- Brd. 13A** **A population-based study of cardiovascular (CV) mortality among patients with prostate cancer (PCa) treated with radical external beam radiation therapy (EBRT) with and without adjuvant androgen deprivation therapy (ADT) at a provincial cancer agency. (Abstract #4656)**
J. O. Kim, M. Vaid, S. Tyldesley, R. Woods, T. Pickles
- Brd. 13B** **A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned. (Abstract #4657)**
J. L. Gulley, W. D. Stein, J. Schlom, R. A. Madan, W. L. Dahut, W. D. Figg,
 Y. M. Ning, D. Price, S. E. Bates, A. T. Fojo

Monday, June 7, 2010

- Brd. 13C** Patterns of use of docetaxel in stage IV prostate cancer (PCa) patients in SEER-Medicare. (Abstract #4658)
E. Onukwugha, M. Grabner, C. D. Mullins, B. S. Seal, A. Hussain
- Brd. 13D** Characteristics of men with abnormal prostate-specific antigen (PSA) who had a biopsy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). (Abstract #4659)
W. G. Hocking, C. McCarty, T. Riley, T. Hickey, J. K. Burmester, D. Reding
- Brd. 13E** Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostate cancer (CPRC). (Abstract #4660)
G. C. Buckle, L. Werner, W. K. Oh, G. Bublely, J. H. Hayes, D. Weckstein, A. Elfiky, D. M. Sims, P. Kantoff, M. Taplin
- Brd. 13F** A phase II study of oral phenoxodiol in castrate and noncastrate prostate cancer patients with associated cytokine changes. (Abstract #4661)
G. Gibney, A. Elfiky, S. Bussom, C. J. Hoimes, A. Burns, J. A. McDonough, E. Rowen, Y. C. Cheng, W. K. Kelly
- Brd. 13G** A phase II study of preoperative figitumumab (F) in patients (pts) with localized prostate cancer (PCa). (Abstract #4662)
K. N. Chi, M. E. Gleave, L. Fazli, S. L. Goldenberg, A. So, C. K. Kollmannsberger, N. Murray, A. Tinker, A. Gualberto, M. N. Pollak
- Brd. 13H** Modulation of candidate therapy targets in regionally advanced prostate cancer by androgen ablation and docetaxel. (Abstract #4663)
V. Tzelepi, E. Efstathiou, P. Troncoso, C. A. Pettaway, A. Hoang, C. Logothetis, L. C. Pagliaro
- Brd. 14A** Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety. (Abstract #4664)
D. L. Trump, H. Payne, K. Miller, J. S. De Bono, J. Stephenson, H. A. Burris III, F. E. Nathan, M. Taboada, T. Morris, A. Hübner
- Brd. 14B** Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) levels in patients with castration-resistant progressive prostate cancer (CRPC). (Abstract #4665)
F. Dayyani, G. E. Gallick, J. T. Thompson, G. C. Trudel, C. Logothetis, J. C. Araujo
- Brd. 14C** Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07). (Abstract #4666)
R. Cathomas, C. Rothermundt, R. von Moos, D. C. Betticher, R. C. Winterhalder, C. Droege, D. Siciliano, D. R. Berthold, M. Pless, S. Gillissen
- Brd. 14D** Phase I trial of fractionated-dose ¹⁷⁷lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). (Abstract #4667)
S. T. Tagawa, S. Vallabhajosula, J. Osborne, S. J. Goldsmith, K. Petrillo, L. Tyrell, G. S. Dhillon, H. Beltran, N. H. Bander, D. M. Nanus
- Brd. 14E** Phase II trial of lapatinib in patients in stage D0 prostate cancer (E5803): Effect of Kras and EGFR status on clinical outcome. (Abstract #4668)
Y. Chen, J. Kolesar, W. Huang, R. S. DiPaola, M. Pins, M. A. Carducci, M. N. Stein, G. Bublely, G. Wilding, G. Liu
- Brd. 14F** Phase I dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC). (Abstract #4669)
M. A. Carducci, M. A. Eisenberger, S. R. Denmeade, S. F. Slovin, A. Jakobovits, M. Vincent, H. I. Scher, M. J. Morris
- Brd. 14G** The effect of inhibition of the insulin-like growth factor receptor with nordihydroguaiaretic acid on PSA progression: Results of a phase II study. (Abstract #4670)
T. W. Friedlander, V. K. Weinberg, C. Formaker, J. Mi, A. M. Lin, A. L. Harzstark, L. Fong, E. J. Small, C. J. Ryan

- Brd. 14H Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred). (Abstract #4671)**
C. J. Ryan, M. R. Smith, C. Logothetis, K. Koepfgen, M. Taplin, A. L. Harzstark, P. Kantoff, T. S. Kheoh, A. Molina, E. J. Small
- Brd. 15A Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC). (Abstract #4672)**
D. Bianchini.
- Brd. 15B Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment. (Abstract #4673)**
N. D. Shore, J. W. Moul, E. Crawford, T. Olesen, B. Persson
- Brd. 15C HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial. (Abstract #4674)**
R. B. Montgomery, M. J. Morris, C. J. Ryan, D. R. Stickney, J. M. Frincke, C. L. Reading, J. Sarantopoulos, H. I. Scher
- Brd. 15D Association of ADT for older men with biochemical recurrence of prostate cancer with obese frailty and falls: A case-control study. (Abstract #4675)**
W. Dale, K. A. Bylow, J. Hemmerich, S. G. Mohile, S. Sajid, W. M. Stadler
- Brd. 15E Effect of toremifene on fracture risk in men younger than age 80 on androgen-deprivation therapy. (Abstract #4676)**
M. K. Brawer, M. R. Smith, S. B. Malkowicz, M. L. Hancock, R. A. Morton, M. S. Steiner
- Brd. 15F Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) +/- strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747. (Abstract #4677)**
E. Porfiri, S. I. Collins, D. Barton, L. Billingham, D. McLaren, G. G. Nixon, J. M. Russell, C. Parker, J. Wylie, N. D. James, Trapeze Phase II
- Brd. 15G Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials. (Abstract #4678)**
S. Nilsson, C. Parker, I. Haugen, A. Lokna, A. Aksnes, B. Bolstad, G. O'Bryan-Tear, O. S. Bruland
- Brd. 15H Analysis of the cost-effectiveness of zoledronic acid for the prevention of skeletal-related events in patients with prostate cancer and bone metastases: A comparison across four European countries. (Abstract #4679)**
M. Botteman, F. Logman, S. Kaura
- Brd. 16A Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone. (Abstract #4680)**
J. A. Carrasquillo, J. A. O' Donoghue, N. Pandit-Taskar, D. E. Rathkopf, A. Aksnes, C. L. Viner, C. T. Hong, S. M. Larson, H. I. Scher, M. J. Morris
- Brd. 16B Safety results of a phase III trial evaluating ADT+ docetaxel versus ADT alone in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403). (Abstract #4681)**
I. Latorzeff, B. Esterni, M. Habibian, G. Delplanque, C. Theodore, M. Baciuchka, J. Dauba, B. Laguerre, I. Krakowski, G. Gravis
- Brd. 16C Carboplatin plus weekly docetaxel as second-line chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (CRPC). (Abstract #4682)**
C. W. Reuter, V. Gruenwald, P. Ivanyi, M. A. Morgan, M. Fenner, A. Ganser

Monday, June 7, 2010

- Brd. 16D Phase II trial of non pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: A translational study. (Abstract #4683)**
M. Montanari, F. Fabbri, L. Frassinetti, E. Rondini, R. Mattioli, S. Luzi Fedeli, D. Turci, S. Carloni, D. Amadori, G. Cruciani
- Brd. 16E Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium. (Abstract #4684)**
E. J. Small, T. M. Beer, V. K. Weinberg, C. S. Higano, L. T. Nordquist, J. E. Rosenberg, J. J. Alumkal, E. Y. Yu, J. Sun, A. M. Lin
- Brd. 16F Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy +/- docetaxel: An analysis of final safety results. (Abstract #4685)**
S. Oudard, I. Latorzeff, P. Beuzebec, A. Caty, E. Sevin, R. Delva, F. Rolland, L. Mourey, F. Priou, S. Culine
- Brd. 16G Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study. (Abstract #4686)**
S. Niraula, I. Tannock, G. R. Pond, R. De Wit, M. A. Eisenberger, A. M. Joshua
- Brd. 16H Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer. (Abstract #4687)**
D. R. Shepard, A. Weil, J. A. Garcia, R. Dreicer, D. Raghavan
- Brd. 17A A phase I study of combined docetaxel and repeated high activity rhenium-186-HEDP in castration resistant prostate cancer metastatic to bone (the TAXIUM trial). (Abstract #4688)**
J. M. van Dodewaard-de Jong, H. Bloemendal, J. M. de Klerk, B. P. van Bezooijen, M. J. de Haas, R. H. Wilson, J. M. O'Sullivan
- Brd. 17B Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4689)**
A. L. Harzstark, L. Fong, V. K. Weinberg, C. J. Ryan, A. M. Lin, J. Sun, E. J. Small
- Brd. 17C Correcting overall survival (OS) effect for the impact of cross-over via rank preserving structural failure time (RPSFT) model: Case of mRCC RECORD-1 trial of everolimus (EVE). (Abstract #4690)**
E. Zuber, P. Korhonen, M. Branson, N. Hollaender, T. Katiskalahti, D. E. Lebwohl, T. Haas

1:00 PM - 5:00 PM
GENERAL POSTER SESSION

Health Services Research

Location: S Hall A2

Tracks(s): Health Services Research

- Brd. 18A** **Effect of computerized physician order entry (CPOE) on chemotherapy prescribing error. (Abstract #6034)**
 R. Stein, S. Cheesman, D. Blake, N. Saini, T. Cave, G. Pang, B. Bagnall, J. Bradley
- Brd. 18B** **RCT of community-based patient assistance to improve breast cancer care. (Abstract #6035)**
 N. Bickell, R. Franco, K. Fei, H. Leventhal
- Brd. 18C** **Evaluating psychosocial and belief differences in a diverse racial and socioeconomic cancer population. (Abstract #6036)**
 B. N. Polite, D. M. Smith, M. Ray, F. J. Hlubocky, O. I. Olopade, C. Daugherty, S. J. Gehlert
- Brd. 18D** **Cost-effectiveness of lapatinib plus capecitabine (LAP+C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ+C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the U.K. National Health Service (NHS) perspective. (Abstract #6037)**
 O. Sofrygin, T. E. Delea, P. Tappenden, J. Karnon, D. Browning, M. Amonkar, K. Lykopoulos, D. A. Cameron
- Brd. 18E** **Impact of medicaid-enrollment status/timing on stage at diagnosis among male cancer patients. (Abstract #6038)**
 K. S. Virgo, A. Pavluck, A. Y. Chen, N. M. Marlow, H. Kirby, C. Finney, E. M. Ward
- Brd. 18F** **Use of a 21-gene reverse transcriptase-polymerase chain reaction (RT-PCR) assay to guide therapy in 14 Michigan Breast Oncology Quality Initiative (MiBOQI) sites. (Abstract #6039)**
 S. M. Silver, H. Y. Ali, D. W. Blayney, J. Caughran, J. G. Herman, J. E. Pettinga, D. Share, A. Mehringer, A. Hayes, J. L. Vandergrift
- Brd. 18G** **Barriers to treatment in patients with locally advanced breast cancer. (Abstract #6040)**
 L. Bourdeanu, T. H. Luu, J. E. Mortimer, A. Hurria, C. T. Chung, D. D. Smith, N. Baker, S. Swain-Cabrales, S. Helton, G. Somlo
- Brd. 18H** **Physician's perspectives and racial disparity in the surgical treatment of early lung cancer. (Abstract #6041)**
 P. R. Walker, S. Cykert
- Brd. 19A** **Cost-effectiveness of adding information about common risk alleles to current decision models for breast cancer chemoprevention. (Abstract #6042)**
 T. Dinh, L. Green, P. Alperin, D. Hinds, B. Walser
- Brd. 19B** **Initial use of newer agents for advanced non-small cell lung cancer: Evidence from the National Cancer Institute Patterns of Care study. (Abstract #6043)**
 B. L. Goulart, S. D. Ramsey
- Brd. 19C** **Analysis of the cause of discordance between two radiologists on the assessment of radiographic response and progression for subjects enrolled in breast cancer clinical trials employing blinded independent central review. (Abstract #6044)**
 K. Borradaile, R. Ford, J. M. O'Neal, K. Byrne

Monday, June 7, 2010

- Brd. 19D** **Communication of the essential elements of informed consent (IC) for research: A RIAS analysis of phase I clinical trial encounters. (Abstract #6045)**
C. Daugherty, F. J. Hlubocky, N. E. Kass, D. Roter, S. Larson, J. Sugarman, K. Wroblewski, M. J. Ratain
- Brd. 19E** **The impact of routine pathology review on treatment for node-negative breast cancer. (Abstract #6046)**
H. F. Kennecke, C. Speers, K. A. Gelmon, I. Olivotto, M. Hayes
- Brd. 19F** **Characterization of prostate cancer treatment information quality obtained through Yahoo, Google, and Bing search engines. (Abstract #6047)**
D. Landau, J. Hajdenberg
- Brd. 19G** **Costs of absenteeism and short-term disability associated with breast cancer to U.S. employers. (Abstract #6048)**
S. D. Sullivan, A. Z. Fu, M. Jhaveri, N. P. Christiansen
- Brd. 19H** **Changes in chemotherapy uptake and wait times in early-stage non-small cell lung cancer (NSCLC). (Abstract #6049)**
S. L. Gray, J. Bu, N. Saint-Jacques, D. Rayson, T. Younis
- Brd. 20A** **Global variations in reimbursement of new cancer therapeutics: Improving access through risk-sharing agreements. (Abstract #6050)**
P. K. Cheema, S. Gavura, B. Godman, L. Yeung, M. E. Trudeau
- Brd. 20B** **Medical oncologists and quality of life of women treated for breast cancer. (Abstract #6051)**
C. R. Friese, T. M. Pini, P. Abrahamse, S. T. Hawley, S. J. Katz
- Brd. 20C** **Equipoise lost: Ethics, costs, and the regulation of cancer clinical research. (Abstract #6052)**
D. J. Stewart, R. Kurzrock, S. Whitney
- Brd. 20D** **Practice standardization in the staging and treatment of colon cancer at Intermountain Healthcare. (Abstract #6053)**
J. R. Whisenant, T. Belnap, B. D. Rowley, K. Alleman, K. G. Rowe, C. Jones, W. T. Sause
- Brd. 20E** **Impact of cancer on the quality of life and health status of patients and their family members. (Abstract #6054)**
Y. T. Shih, I. Pan
- Brd. 20F** **Health care cost of breast cancer: A claims data analysis. (Abstract #6055)**
A. Z. Fu, M. Jhaveri, S. D. Sullivan, N. P. Christiansen
- Brd. 20G** **Comparison of the Veterans Affairs Oncology Registry and the SEER Cancer Registry among patients with lung cancer. (Abstract #6056)**
S. B. Zeliadt, N. K. Sekaran, C. G. Slatore, D. H. Au, D. Y. Wu, J. Crawford, G. H. Lyman, D. C. Dale
- Brd. 20H** **Unmet psychosocial needs among cancer patients at the National Cancer Centre Singapore (NCCS). (Abstract #6057)**
R. C. Ng, H. Verkooijen, L. L. Ooi, W. Koh
- Brd. 21A** **Accuracy of cancer information on the Internet: A comparison of a Wiki with a professionally maintained database. (Abstract #6058)**
M. S. Rajagopalan, V. Khanna, M. Stott, Y. Leiter, T. N. Showalter, A. Dicker, Y. R. Lawrence
- Brd. 21B** **Quality of published studies supporting off-label and accelerated approval oncology indications. (Abstract #6059)**
K. R. Carson, Y. Chia, J. Sekhar, R. R. Coeytaux, J. L. Wheeler, C. L. Bennett, A. P. Abernethy
- Brd. 21C** **Effects of ethnicity on genotype-phenotype correlations in individuals with a BRCA1 or BRCA2 mutation. (Abstract #6060)**
M. Jackson, A. Brandt, A. Gutierrez-Barrera, F. Meric-Bernstam, J. K. Litton, K. H. Lu, G. N. Hortobagyi, B. Arun

- Brd. 21D** **The impact of breast care nurses on early-stage breast cancer patients' perception of quality of care: The results of a multilevel regression analysis. (Abstract #6061)**
C. Kowalski, S. Diener, P. Steffen, R. Wuerstlein, N. Harbeck, H. Pfaff
- Brd. 21E** **Consenting factors in clinical cancer research: Observations from a cancer center tissue repository. (Abstract #6062)**
D. E. Gerber, D. W. Rasco, C. S. Skinner, J. Dowell, J. Yan, J. R. Sayne, Y. Xie
- Brd. 21F** **Changing rates of organ-preservation therapy over time for head and neck cancer: A SEER-Medicare analysis. (Abstract #6063)**
D. J. Sher, B. A. Neville, R. B. Tishler, D. Schrag
- Brd. 21G** **Social, biological, and tumor characteristics of 139 African American (AA) women with newly diagnosed breast cancer in Chicago. (Abstract #6064)**
S. J. Gehlert, B. N. Polite, T. A. Grushko, T. Cipriano, S. Charoenthammaraksa, Z. Franklin, S. D. Conzen, M. McClintock, O. I. Olopade
- Brd. 21H** **FDA accelerated approval of anticancer agents. (Abstract #6065)**
Y. M. Ning, J. R. Johnson, A. T. Farrell, V. E. Maher, R. L. Justice, R. Pazdur
- Brd. 22A** **Protocol performance metrics and resource utilization of phase II investigator-initiated trials. (Abstract #6066)**
H. Durivage, K. D. Bridges, J. Sauers, M. Wellons, L. Baker
- Brd. 22B** **Factors influencing use of genetic tests in clinical practice among U.S. oncologists. (Abstract #6067)**
J. M. Peppercorn, E. P. Hamilton, L. Beskow, I. Lipkus, P. K. Marcom, G. H. Lyman
- Brd. 22C** **Treatment delays in non-small cell lung cancer (NSCLC) and their prognostic implications. (Abstract #6068)**
R. Diaconescu, C. Lafond, L. Choiniere, C. Sirois, B. Laliberte, M. Doyon, R. Whittom
- Brd. 22D** **Nature and outcome of clinical trials conducted by the Eastern Cooperative Group (ECOG) from 1977 to 2006. (Abstract #6069)**
R. S. Go, C. M. Meyer, M. A. Mathiason, A. E. Emmel, K. A. Frisby, L. A. Meyer, J. E. Schroeder, D. L. Sieber, K. L. Crampton, S. R. Pingali
- Brd. 22E** **Factors contributing to delays in breast cancer management. (Abstract #6070)**
E. Barlow, S. Verma, F. Kanji, S. Hopkins, L. Paquet
- Brd. 22F** **Impact of Medicare's July 2007 erythropoiesis-stimulating agent (ESA) national coverage determination (NCD) on transfusion use in chemotherapy-treated cancer patients. (Abstract #6071)**
T. Arneson, S. Li, D. T. Gilbertson, S. C. Dunning, K. R. Bridges, J. F. Acquavella
- Brd. 22G** **Influence of patient beliefs and patient knowledge on adherence to hormone treatment for breast cancer. (Abstract #6072)**
K. P. Joseph, R. Franco, K. Fei, N. Bickell
- Brd. 22H** **Understanding premature discontinuation of aromatase inhibitor (AI) therapy in postmenopausal breast cancer survivors. (Abstract #6073)**
C. T. Stricker, S. C. Palmer, A. DeMichele, J. Mao
- Brd. 23A** **Predictors of BRCA-positive parents' disclosure of cancer risk and risk reduction options to offspring. (Abstract #6074)**
L. J. Patrick-Miller, B. Egleston, O. I. Olopade, M. B. Daly, C. Daugherty, C. B. Sands, H. Schmidheiser, C. Gulden, K. Pawlowski, A. R. Bradbury
- Brd. 23B** **The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel. (Abstract #6075)**
S. Klang, N. Liebermann, S. Rizel, N. Ben-Baruch, S. Merling, L. Soussan-Gutman, R. Bugarini, C. Chao, S. Shak
- Brd. 23C** **Follow-up of abnormal Pap smear results: A population-based study. (Abstract #6076)**
R. Kupets, L. F. Paszat

Monday, June 7, 2010

- Brd. 23D NCI Cancer Trials Support Unit at year 10. (Abstract #6077)**
S. E. Riordan, M. F. Hering, J. R. Hopkins, R. Lambersky, D. M. Marinucci,
K. E. Martier, M. M. Mooney, A. Nelson, R. Rajaram, J. S. Abrams
- Brd. 23E Retrospective health care claims database analysis of direct medical costs of newly diagnosed patients (pts) with hepatocellular carcinoma (HCC) in the United States. (Abstract #6078)**
A. S. Poklepovic, A. Sanyal, E. Moyneur, S. Meyers, V. Barghout
- Brd. 23F Using administrative data to describe adherence to colon cancer follow-up testing in Manitoba, Canada. (Abstract #6079)**
J. J. Sisler, B. Seo, A. Katz, E. Shu
- Brd. 23G Information technology (IT) and chemotherapy (CT) prescribing errors. (Abstract #6080)**
M. Aita, O. Belvedere, F. De Pauli, L. Deroma, L. Gurrieri, J. Menis, V. Merlo,
F. Puglisi, L. Zanier, G. Fasola
- Brd. 23H Strategies to increase access to quality genetic testing services: Case study of BRCA1/2 testing. (Abstract #6081)**
B. Kim, T. G. Bentley, S. S. Olmsted, S. Wooding, E. Eiseman, M. T. Scheuner
- Brd. 24A Synergy made simple: What does it mean and how valid are claims for synergy between antitumor agents? (Abstract #6082)**
A. Ocana, C. Yeung, I. Tannock
- Brd. 24B Treatment patterns by oncologists and urologists for castration-resistant prostate cancer (CRPC). (Abstract #6083)**
B. Alemayehu, N. M. Engel-Nitz, F. E. Nathan
- Brd. 24C Analysis of cancer clinical trials in the United States with comparison of National Institute of Health (NIH) and pharmaceutical industry (PHARMA)-sponsored studies. (Abstract #6084)**
K. R. Oettel, N. R. Ruther, M. A. Mathiason, J. K. Keller, J. E. Schroeder, R. S. Go
- Brd. 24D Rural-urban disparity in cancer screening among elder Medicare beneficiaries: Does rurality matter? (Abstract #6085)**
L. Fan, S. G. Mohile, K. Noyes
- Brd. 24E Small world networks and treatment discovery process in cancer. (Abstract #6086)**
A. Tsalatsanis, I. Hozo, B. Djulbegovic
- Brd. 24F Baseline MUGA scans for patients with early-stage breast cancer receiving adjuvant chemotherapy. (Abstract #6087)**
A. S. Jeyakumar, J. Dipenta, S. L. Snow, D. Rayson, K. Thompson, C. Theriault,
T. Younis
- Brd. 24G Neutropenic risk, use of colony-stimulating factors, and impact on the relative dose intensity of administered chemotherapy. (Abstract #6088)**
W. B. Webb, Y. Wu, H. Head, S. Singh, G. H. Lyman
- Brd. 24H A prospective evaluation of the patients' knowledge about their chemotherapy treatment (CT) before the first course. (Abstract #6089)**
N. Kohen, E. L. Morgenfeld, C. Garcia Gerardi, M. Nacul, C. Coronel Lezcano,
E. Rivarola, E. Gil Deza, N. Gercovich, F. G. Gercovich
- Brd. 25A Dose reductions and delays in patients (pts) with renal cell carcinoma (RCC) treated with sorafenib (SR) or sunitinib (SU): Retrospective analysis of two large U.S. health care claims databases. (Abstract #6090)**
S. M. Keefe, E. Moyneur, S. Meyers, V. Barghout, K. T. Flaherty
- Brd. 25B Pattern of aromatase inhibitor use in males. (Abstract #6091)**
M. Subar, C. J. Kuntz, S. Lust
- Brd. 25F Concomitant medication (CM) use in phase I and II cancer clinical trials (CCT): Effects on trial eligibility and potential interactions with study medications. (Abstract #6092)**
M. Benjamin, K. K. Curtis, R. Tibes, R. K. Ramanathan, D. D. Von Hoff, K. Wright,
G. S. Jameson, M. J. Borad

- Brd. 25G Evaluation of multidisciplinary (MultiD) care in thoracic oncology. (Abstract #6093)**
G. L. Phelps, O. O. Bankole, S. Sarwar, J. J. McFarlane, R. U. Osarogiagbon
- Brd. 25H The role of NCI-sponsored research in ASCO Clinical Cancer Advances 2005–2008. (Abstract #6094)**
B. Zuckerman, J. Corrigan
- Brd. 26A Adherence to cardiovascular (CV) medications after myocardial infarction (MI) in cancer survivors (CS). (Abstract #6095)**
S. Setoguchi, M. L. McBride, R. Levin, W. Y. Cheung
- Brd. 26B Quality and consistency in breast cancer clinical guidelines internationally: Are we globally consistent? (Abstract #6096)**
C. E. Simmons, S. Hogeveen, J. Nichols, S. Trudeau-Tavara, M. Quan
- Brd. 26F The relationship between service quality measures and patient willingness to recommend at a national oncology provider network: The Cancer Treatment Centers of America experience. (Abstract #6097)**
D. Gupta, M. Rodeghier, J. F. Grutsch, A. Roberts, C. G. Lis
- Brd. 26G Patients' views on delayed diagnosis in cancer. (Abstract #6098)**
T. H. Gallagher, S. Greene, D. Roblin, J. Calvi, K. Horner, C. Prouty, C. Firreno, C. Lemay, C. Lo, K. Mazor
- Brd. 26H Optimal chemotherapy utilization rate in cancer care: Setting an evidence-based benchmark for quality improvement. (Abstract #6099)**
W. L. Ng, S. Jacob, G. Delaney, M. Barton
- Brd. 27A Patients' willingness to be informed on cancer clinical trials. (Abstract #6100)**
I. Pauporte, E. Manach, M. Duperray, N. Thammavong, N. Bachouche, A. Hommais
- Brd. 27B Utility of routine cardiac ejection fraction (EF) measurement prior to anthracycline-based chemotherapy (ABC) in patients with diffuse large b-cell lymphoma (DLBCL). (Abstract #6101)**
A. L. Conrad, V. L. McHugh, J. D. Gundrum, R. S. Go
- Brd. 27C Treatment strategies for low-risk febrile neutropenia in adult cancer patients: A cost-utility analysis. (Abstract #6102)**
O. Teuffel, E. Amir, L. Sung, S. M. Alibhai
- Brd. 27D What are physician and patient factors important for proper follow-up of high-grade Pap smear abnormalities? (Abstract #6103)**
L. F. Paszat, R. Kupets
- Brd. 27E The shortage of medical oncologists and low chemotherapy utilization in Australia. (Abstract #6104)**
B. Koczwara, M. Barton, P. L. Blinman, S. Crossing, P. S. Grimison, E. T. Walpole, N. Wong, K. Francis
- Brd. 27F Nomogram to predict risk of 30-day mortality for patients with disseminated malignancy undergoing surgical intervention. (Abstract #6105)**
W. H. Tseng, N. H. Willits, S. L. Chen, S. R. Martinez, F. J. Meyers, R. J. Bold, J. E. Goodnight, R. J. Canter
- Brd. 27G Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network. (Abstract #6106)**
M. A. Neubauer, J. L. Espirito, M. Clayton, D. A. Patt, US Oncology Pathways Task Force
- Brd. 27H Association of black race and outcomes in patients with nonmetastatic triple-negative breast cancer (TNBC): Results from a U.S. local oncology practice. (Abstract #6107)**
B. A. Feinberg, L. Chen, L. Zhao, J. W. Gilmore, S. Haislip, M. N. Saleh, S. D. Sullivan, N. P. Christiansen

Monday, June 7, 2010

- Brd. 28A Calibration of quality-adjusted life years (QALYs) for oncology clinical trials (OCT). (Abstract #6108)**
J. A. Sloan, P. J. Novotny, D. J. Sargent, P. A. Decker, R. Marks, H. Nelson
- Brd. 28B Relationship between neuroendocrine tumor-related symptoms and PROMIS health-related quality-of-life scores. (Abstract #6109)**
J. L. Beaumont, Z. Liu, S. Choi, J. C. Yao, A. T. Phan, D. Cella
- Brd. 28C The value of concurrent symptoms in predicting clinical outcomes in lung cancer survivors. (Abstract #6110)**
A. L. Cheville, P. J. Novotny, J. A. Sloan, J. R. Basford, J. A. Wampfler, Y. I. Garces, A. Jatoi, P. Yang
- Brd. 28D Prospective change in 25-OH vitamin D levels over long-term follow-up and health outcomes in breast cancer survivors. (Abstract #6111)**
S. K. Taylor, M. Ennis, N. S. Hood, M. Graham, K. I. Pritchard, P. J. Goodwin
- Brd. 28E Estimating minimally important differences (MID) for the worst pain rating of the brief pain inventory (BPI)-short form (SF). (Abstract #6112)**
S. D. Mathias, R. D. Crosby, Y. Qian, K. Chung
- Brd. 28F The long-term impact of surgical complications after resection of stage I non-small cell lung cancer: A population-based survival analysis. (Abstract #6113)**
N. M. Rueth, H. M. Parsons, S. S. Groth, E. B. Habermann, B. A. Virnig, T. M. Tuttle, R. S. Andrade, M. Maddaus, J. D'Cunha
- Brd. 28G Cancer recurrence and survival in patients with early-stage triple-negative breast cancer in a U.S. local oncology practice. (Abstract #6114)**
L. Zhao, B. S. Seal, B. A. Feinberg, J. W. Gilmore, S. Haislip, S. D. Sullivan, N. P. Christiansen
- Brd. 28H Evaluation of the state of health of patients with localized prostate cancer (cT1-cT2) compared to the normal population. (Abstract #6115)**
M. J. Mathers, S. Roth, M. Gerken, M. Klinkhammer-Schalke, F. Hofstädter, A. Heidenreich, T. Klotz
- Brd. 29A Publication bias in randomized controlled trials (RCTs) of colorectal cancer presented at ASCO Annual Meetings. (Abstract #6116)**
A. I. Leal, W. F. Barra, D. F. Saragiotto, E. D. Saad, P. M. Hoff
- Brd. 29B The role of acculturation in end-of-life outcomes for Latino advanced cancer patients. (Abstract #6117)**
E. T. Loggers, E. Soto, S. Desanto-Madeya, A. A. Wright, H. Stieglitz, M. E. Paulk, H. G. Prigerson
- Brd. 29C Neuroendocrine tumor disease state and PROMIS health-related quality of life scores. (Abstract #6118)**
D. Cella, J. L. Beaumont, Z. Liu, A. T. Phan, S. Choi, J. C. Yao
- Brd. 30A Racial disparities in stage II prostate cancer outcomes in the Veterans Affairs hospital system. (Abstract #6119)**
D. Crockett, W. Gonsalves, T. Tashi, I. Aldoss, A. R. Sama, I. Al-Howaidi, X. Fang, P. Townley, S. Subbiah, P. T. Silberstein
- Brd. 30B A prospective paired survey of oncologist and patient attitudes toward therapeutic cancer clinical trial (CT) enrollment in a diverse academic health center patient population. (Abstract #6120)**
M. Ray, D. M. Smith, O. I. Olopade, B. N. Polite
- Brd. 30C Impact of response shift in longitudinal postoperative quality of life (QoL) analysis among breast cancer (BC) patients: A randomized multicenter cohort study. (Abstract #6121)**
F. Bonnetain, T. Conroy, M. Velten, D. Jolly, M. Mercier, S. Causeret, J. Cuisenier, O. Graesslin, M. Gauthier, F. Guillemin, Plateforme de Recherche Clinique Qualite de Vie et Cancer
- Brd. 31A Adequacy of data provision and analysis in oncology phase III trials over the past 5 years. (Abstract #6122)**
H. K. Gan, B. You, G. R. Pond, E. X. Chen

- Brd. 31B The National Lung Cancer Audit in the United Kingdom: Results after 4 years. (Abstract #6123)**
P. Beckett, I. Woolhouse, R. Stanley, M. D. Peake
- Brd. 31C Education level as prognostic factor of patients (pts) with advanced non-small cell lung cancer (NSCLC) enrolled in clinical trials. (Abstract #6124)**
M. Di Maio, A. Morabito, S. Barbera, V. Gebbia, B. Daniele, A. Ceribelli, F. Carrozza, A. Rossi, S. Signoriello, C. Gridelli
- Brd. 32A Relationship between survival and lymph node assessment from a population-based study of colorectal cancer patients. (Abstract #6125)**
R. Urquhart, J. Bu, G. A. Porter, R. Dewar, R. Moineddin, E. Grunfeld
- Brd. 32B Comparison between the causes of rejection to participate (RP) and screening failures (SF) in oncology clinical trials (OCT). (Abstract #6126)**
L. E. Fein, A. Romera, M. C. Micherl, M. I. Diaz, R. A. Sala
- Brd. 32C Outcomes from placebo/best supportive care-controlled trials (PBSCT) in the era of molecular targeted therapy: A meta-analysis. (Abstract #6127)**
M. C. Miranda, A. B. Fede, N. Magalhaes, N. Fraile, V. Ayres, M. B. Santos, S. Gonzaga, K. Brunetti, A. Del Giglio, R. Riechelmann
- Brd. 33A Is the informed consent (IC) to treatment truly “informed”? The use of a comprehension check tool (CCT). (Abstract #6128)**
R. Biamonte, S. Turano, C. Mastroianni, V. Liguori, R. De Simone, S. Conforti, G. Gadaleta-Caldarola, A. Piattelli, M. Iuvaro, S. Palazzo
- Brd. 33B Assuring continuous quality improvement using outcomes data: A potential role for cancer registries. (Abstract #6129)**
R. O. Dillman, S. E. McClure
- Brd. 33C Evaluation of hormone receptor and benefit from adjuvant chemotherapy in breast cancer patients with intermediate- and high-risk disease. (Abstract #6130)**
C. Kurzeder, A. Woeckel, T. Kuehn, E. Schlicht, M. Blettner, R. E. Felberbaum, M. Wischnewsky, R. Kreienberg
- Brd. 34A Second-line pancreatic cancer therapy: Patterns of care and survival. (Abstract #6131)**
S. N. Hoang, J. R. Hoverman, B. Turnwald, US Oncology Pathways Task Force
- Brd. 34B Effect of race and comorbidities on patterns of bevacizumab toxicity: A single-institution experience. (Abstract #6132)**
M. Raza, S. Raza, Z. Latif, J. C. Sachdev
- Brd. 34C Symptom burden in chronic myeloid leukemia (CML). (Abstract #6133)**
L. A. Williams, P. Ault, C. S. Cleeland, R. J. Reynolds, N. A. Shah, P. K. Shah, J. E. Cortes
- Brd. 35A Correlation of 5-year survival and cure in NSCLC: An analysis of delayed cancer deaths in long-term survivors of NSCLC. (Abstract #6134)**
M. O. Hubbard, P. Fu, J. L. Worthington, A. Dowlati, P. A. Linden
- Brd. 35B Impact of neoadjuvant chemotherapy on breast reconstruction. (Abstract #6135)**
Y. Hu, C. M. Weeks, H. In, C. M. Dodgion, M. Golshan, Y. S. Chun, M. J. Hassett, X. Gu, S. R. Lipsitz, C. C. Greenberg
- Brd. 35C Can patient-reported kidney cancer-specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma? (Abstract #6136)**
P. C. Trask, A. G. Bushmakin, J. C. Cappelleri, J. C. Tarazi, B. Rosbrook, P. W. Bycott, S. Kim, W. M. Stadler, B. I. Rini
- Brd. 35D Impact of comorbidities on clinical and economic outcomes among patients with advanced non-small cell lung cancer (NSCLC) receiving care in the community-based outpatient setting. (Abstract #6137)**
J. R. Hoverman, S. K. Gruschkus, C. E. Muehlenbein, M. T. Forsyth, C. Chen, A. H. Lawson, G. Pohl

Monday, June 7, 2010

- Brd. 35E Capturing breast cancer patients' experience beyond disease progression: Implementation of a patient-reported outcome (PRO) substudy in the VIRGO Metastatic Breast Cancer Observational Cohort study. (Abstract #6138)**
P. A. Kaufman, N. A. Dreyer, M. Mayer, J. A. Sloan, C. Chung, A. Sing, Y. Yim, E. Yu, S. D. Mathias, C. S. Cleeland
- Brd. 35F Retrospective application of Nottingham Prognostic Index (NPI) and Adjuvant! Online tool in newly diagnosed patients with early breast cancer in mid-western Ireland. (Abstract #6139)**
K. I. Quiltyne, B. Woulfe, R. K. Gupta
- Brd. 35G Cost and outcome of vascular resections during pancreaticoduodenectomy. (Abstract #6140)**
G. Bullock, M. J. Ott, T. Belnap, J. R. Whisenant
- Brd. 35H Technologic advancements and error rates in radiation therapy (RT) delivery. (Abstract #6141)**
D. N. Margalit, K. Heckman, Y. Chen, P. J. Catalano, T. Vivencio, K. Nissen, P. Mauch, A. K. Ng
- Brd. 36A Impact of CPOE on workflow and direct patient care time in an inpatient hematology/oncology service. (Abstract #6142)**
D. A. Hanauer, K. Zheng, S. W. Choi, R. Beasley, J. Schumacher, M. Duck, D. W. Blayney
- Brd. 36B Novel uses of coded data in clinical trials. (Abstract #6143)**
A. Daunton, D. Liu, S. I. Collins, A. Pope, D. Barton, D. Ray, N. D. James
- Brd. 36C Factors influencing the career decisions of United States hematology oncology fellows training at NCI- and NCCN-designated cancer centers. (Abstract #6144)**
L. Horn, E. Koehler, Y. Shyr, J. Gilbert, D. H. Johnson
- Brd. 36D Continuity of care for cancer patients at the end of life (EoL). (Abstract #6145)**
R. Bascioni, B. Esperide, D. Iacopini, F. Basirat, F. Rastelli, L. Acito, R. Bionni, L. Giustini, F. Giorgi
- Brd. 36E Care delivery barriers to personalized medicine in breast cancer. (Abstract #6146)**
J. C. Schink, C. B. Weldon, J. R. Trosman, A. B. Benson, A. I. Löffler, W. J. Gradishar
- Brd. 36F Hepatitis B screening prior to chemotherapy: A survey of practitioners' knowledge, beliefs, and screening practices. (Abstract #6147)**
R. Lee, C. M. Bell, L. K. Hicks
- Brd. 36G The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB). (Abstract #6148)**
M. L. Katz, L. Archer, J. M. Peppercorn, S. Kereakoglow, D. Collyar, H. J. Burstein, R. L. Schilsky, A. H. Partridge
- Brd. 36H Prescribing and safety issues of oral molecular therapies and chemotherapies in Australian haematology oncology practice. (Abstract #6149)**
M. J. Dooley, M. A. Larizza, S. G. Poole, C. Carrington
- Brd. 37A Comparison of hospital costs versus DRG reimbursement for treatment of febrile neutropenia during adjuvant CTX for primary breast cancer. (Abstract #6150)**
S. C. Mayer, A. Ihbe-Heffinger, B. Paessens, U. R. Schwarz-Boeger, J. Ettl, S. Paepke, R. Bernard, N. Harbeck, M. Kiechle, V. R. Jacobs
- Brd. 37B Development and testing of multiple versions of a radiation oncology treatment planning workflow application in the era of HIPAA. (Abstract #6151)**
J. B. Fiveash, J. Howerton, M. Hyatt, K. Sinclair, O. L. Burnett, R. A. Popple, B. Graham

- Brd. 37C** Evaluating clinical trials: What exactly do medical oncologists know and use? (Abstract #6152)
K. R. Hoffman
- Brd. 37D** Quantitative aspects of failure mode and effects analysis (FMEA) scoring in a prospective safety study of a large academic radiation oncology department. (Abstract #6153)
S. A. Terezakis, L. Myers, R. Bell, A. Souranis, D. Y. Song, R. C. Zellars, T. L. DeWeese, E. C. Ford
- Brd. 37E** The 2008 National Comprehensive Cancer Network (NCCN) Research Benchmarking Survey (RBS): Clinical trials (CTs) operations in the academic center. (Abstract #6154)
S. L. Sherman, M. B. Waldinger, E. M. Lepisto, J. M. Hinkel, K. A. Minogue, D. E. Paul
- Brd. 37F** Toxicity symptom reporting by patients and clinicians during phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403). (Abstract #6155)
G. Gravis, K. Fizazi, B. Esterni, C. Protiere, M. Habibian, M. Soulie, I. Latorzeff, F. Priou, F. Joly, S. Oudard
- Brd. 37G** ERCC, TS, RRM1, EGFR, and KRAS biomarker integration into a community-based medical oncology practice. (Abstract #6156)
S. K. Reddy
- Brd. 37H** Fellowship characteristics associated with fellows' interest in pursuing clinical research: A National Comprehensive Cancer Network (NCCN) survey. (Abstract #6157)
J. M. Hinkel, J. L. Vandergrift, E. M. Lepisto, K. A. Minogue, F. M. Stewart
- Brd. 38A** Physicians' nonverbal behaviors: Oncology patients perspective. (Abstract #6158)
H. V. Naina, S. Harris

Monday, June 7, 2010

1:00 PM - 5:00 PM
GENERAL POSTER SESSION

Patient and Survivor Care

Location: S Hall A2

Tracks(s): Patient and Survivor Care

- Brd. 39A Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial. (Abstract #9042)**
S. Vadhan-Raj, D. H. Henry, R. von Moos, V. Hungria, F. Goldwasser, G. Scagliotti, J. Wang, S. Jun, R. D. Dansey, H. Yeh
- Brd. 39B Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): Results from a randomized phase III clinical trial. (Abstract #9043)**
R. von Moos, D. Patrick, L. Fallowfield, C. S. Cleeland, D. H. Henry, Y. Qian, R. D. Dansey, K. Chung
- Brd. 39F Contraception after breast cancer: Results of a survey among French gynecologists. (Abstract #9044)**
H. Hocini, A. Hamy, A. Gorins, D. Serfaty, H. Abuellellah, B. Tournant, F. Perret, S. Bonfils, M. Espie, GERM
- Brd. 39G Treatment with antidepressant and anti-anxiety medications after breast cancer diagnosis in a large HMO. (Abstract #9045)**
V. P. Quinn, C. C. Avila, J. E. Schottinger, A. H. Fisher, R. Haque
- Brd. 39H Development of a functional assessment of chronic illness therapy questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors: FACT-EGFRI. (Abstract #9046)**
L. I. Wagner, S. E. Rosenbaum, M. Gandhi, K. Webster, M. S. Aneja, D. Cella, J. Brieva, M. E. Lacouture
- Brd. 40A Influence of fatigue after breast cancer adjuvant therapy on health care utilization and perceived needs. (Abstract #9047)**
K. Webber, D. Goldstein, B. K. Bennett, F. M. Boyle, P. L. De Souza, N. Wilcken, M. Friedlander, A. R. Lloyd
- Brd. 40B Satisfaction with physician-patient discussions on fertility and sexual health among young women with cancer. (Abstract #9048)**
M. M. Scanlon, A. H. Blaes, M. A. Geller, N. S. Majhail, T. C. Haddad
- Brd. 40F Utility of pre-chemotherapy echocardiographical assessment of cardiac abnormalities. (Abstract #9049)**
N. V. Karanth, A. Roy, M. Joseph, C. Depasquale, C. S. Karapetis, B. Koczvara
- Brd. 40G Evaluation of pandemic H1N1(2009) influenza vaccine in adults with solid tumor malignancies on active systemic treatment. (Abstract #9050)**
J. D. McGee, A. M. Oza, L. M. Tinker, J. Gubbay, K. MacAlpine, L. Shi, D. Villa, J. Kuruvilla, L. Wang, H. Mackay
- Brd. 40H Patient-reported side effects from molecularly targeted therapies in renal cell carcinoma (RCC). (Abstract #9051)**
V. J. Seery, B. M. McGree, M. Lee, D. F. McDermott, D. C. Cho
- Brd. 41A Impact of the change in service name from “palliative” to “supportive” care on patient referral at a comprehensive cancer center. (Abstract #9052)**
S. Dalal, S. L. Palla, R. Chacko, L. Nguyen, N. A. Fadul, Z. Li, E. Bruera
- Brd. 41B Pathophysiological role of hormones and cytokines in cancer cachexia. (Abstract #9053)**
H. Park, H. Kim, J. Kwon, J. Yun, S. Lee, S. Bae, C. Kim, N. Lee, D. Hong
- Brd. 41C The cancer survivor survey: Using Web-based technology to assess cancer survivor challenges. (Abstract #9054)**
E. M. Smith, K. Skalla, T. Onega, K. Anton, S. Gallagher, J. Rhoda, W. DiSalvo, A. Dietrich

- Brd. 41D** **Vanderbilt Head and Neck Symptom Survey Version 2.0 (VHSS 2.0): A tool for the study of long-term oral health consequences of therapy for head and neck cancer (HNC). (Abstract #9055)**
E. Cooperstein, J. B. Epstein, B. A. Murphy, M. S. Dietrich, J. Gilbert
- Brd. 41E** **Visual analog scale (VAS) and time trade-off (TTO) preferences for side effects (SE) of chemoradiation (chemoXRT): A comparison of patients (pts) and caregivers (CG). (Abstract #9056)**
D. C. Bodurka, A. Jhingran, L. M. Ramondetta, P. J. Eifel, C. H. Crane, A. T. Phan, D. Urbauer, M. M. Frumovitz, L. S. Elting, C. C. Sun
- Brd. 41F** **Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: Analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs). (Abstract #9057)**
R. J. Gralla, B. L. Rapoport, K. Jordan, J. C. Street, A. Carides
- Brd. 41G** **The impact of bone health on endocrine treatment strategy in older adults with early-stage, hormone receptor–positive breast cancer. (Abstract #9058)**
S. K. Pal, A. Hurria, L. Wong, A. Naeim
- Brd. 41H** **Expectations of benefit and symptom burdens among advanced cancer patients (ACP) and spousal caregivers during the course of phase I trials. (Abstract #9059)**
F. J. Hlubocky, T. G. Sher, K. Wroblewski, E. Luzar, M. J. Ratain, C. Daugherty
- Brd. 42A** **Refinement of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) via cognitive interviewing. (Abstract #9060)**
J. Hay, T. M. Atkinson, T. R. Mendoza, B. B. Reeve, G. Willis, J. J. Gagne, A. P. Abernethy, C. S. Cleeland, D. Schrag, E. M. Basch
- Brd. 42B** **Predicting cisplatin-induced ototoxicity in testicular germ cell cancer. (Abstract #9061)**
J. G. Monzon, L. Brunham, C. K. Kollmannsberger, N. Murray, A. J. Attwell, C. Ross, T. Wong, B. Carleton, M. Hayden, K. A. Gelmon
- Brd. 42C** **Timing of palliative care referral and symptom burden in phase I cancer patients: A retrospective cohort study. (Abstract #9062)**
H. A. Parsons, D. Hui, L. Nguyen, S. L. Palla, J. Liu, S. Yennurajalingam, R. Kurzrock, E. Bruera
- Brd. 42D** **Evaluation of axillary node dissection on measures of upper-extremity disability and overall quality of life after breast cancer surgery. (Abstract #9063)**
S. A. McLaughlin, A. S. Parker, N. N. Diehl, M. Arnold, J. H. Nguyen, E. A. Perez
- Brd. 42E** **Mini-Cog: A brief screening tool for cognitive impairment in older cancer patients. (Abstract #9064)**
M. S. Thein, I. S. Browner, C. Klein, M. Binner, G. R. Shapiro
- Brd. 42F** **Changes in symptoms and inpatient mortality among advanced cancer patients admitted to a palliative care unit in a comprehensive cancer center. (Abstract #9065)**
M. Mori, H. A. Parsons, M. De la Cruz, A. F. Elsayem, S. L. Palla, J. Liu, Z. Li, J. L. Palmer, E. Bruera, N. A. Fadul
- Brd. 42G** **Retrospective mortality comparisons of cancer patients with sepsis syndromes. (Abstract #9066)**
D. Joyce, V. Holly, R. Dukes, E. Trueblood
- Brd. 42H** **Cancer care on a continuum: Maintaining fertility after diagnosis and treatment. (Abstract #9067)**
J. M. Knopman, J. A. Grifo, P. A. Labella, N. Noyes
- Brd. 43A** **Use of thermal sensation as a biomarker of response to palliative radiotherapy for cancer-induced bone pain. (Abstract #9068)**
A. C. Scott, B. J. Laird, H. I. Wan, S. M. Fleetwood-Walker, R. Mitchell, G. D. Murray, L. A. Colvin, M. T. Fallon

Monday, June 7, 2010

- Brd. 43B** An evaluation of health literacy (HL) in a consecutive sample of patients (pts) with cancer (ca) of the head and neck (H+N) region. (Abstract #9069)
K. Koay, P. Schofield, K. Gough, R. Buchbinder, D. Rischin, J. Corry, M. Jefford
- Brd. 43C** Innovative quality initiative measurement using Web-based drug dispensing technology with interactive physician queries to evaluate bisphosphonate use across community oncology practices nationwide. (Abstract #9070)
C. G. Baker, G. Grabavoy, I. Aksamit, H. J. McKenzie, K. A. Bergstrom
- Brd. 43D** The associations between spirituality (S), religiosity (R), and spiritual pain (SP) in advanced cancer patients (AdCa). (Abstract #9071)
M. O. Delgado-Guay, D. Hui, H. A. Parsons, M. De la Cruz, K. B. Govan, L. Arciniega, S. Thorney, J. L. Palmer, E. Bruera
- Brd. 43E** The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash with cetuximab in cancer patients: A meta-analysis. (Abstract #9072)
Y. Balagula, S. Wu, X. Su, S. W. Dusza, M. E. Lacouture
- Brd. 43F** Use of unnecessary medications by terminally ill cancer patients. (Abstract #9073)
R. Riechelmann, A. B. Fede, M. C. Miranda, D. V. Antonangelo, H. L. Schaffhausser, L. Trevizan, B. Hamermesz, C. Zimmermann, A. Del Giglio
- Brd. 43G** Polypharmacy in elderly cancer patients. (Abstract #9074)
T. L. Jorgensen, J. Hallas, J. Herrstedt
- Brd. 43H** The association between clinical, sociodemographic, and logistic-administrative factors and adherence to completing health-related quality-of-life questionnaires. (Abstract #9075)
J. Vercauteren, J. Maringwa, C. Coens, C. Quinten, C. Gotay, J. Ringash, M. King, D. Osoba, H. Flechtner, A. Bottomley, on behalf of the EORTC
- Brd. 44A** Evaluation of variants of the rs1934951 locus of *CYP2C8* and bisphosphonate-related osteonecrosis of the jaw in castrate-resistant prostate cancer (CRPC) patients. (Abstract #9076)
P. G. Kluetz, B. C. English, C. E. Baum, T. M. Sissung, D. Adelberg, W. L. Dahut, D. K. Price, W. D. Figg
- Brd. 44B** An exploratory analysis of transfusion risk when initiating darbepoetin alfa (DA) therapy at baseline hemoglobin (Hb) < 9 g/dl vs 9 to < 10 g/dl versus ≥10 g/dl in patients (pts) with chemotherapy-induced anemia (CIA). (Abstract #9077)
J. R. Canon, J. F. Vansteenkiste, M. Hedenus, P. Gascon, C. Bokemeyer, H. Ludwig, J. B. Vermorken, J. C. Legg, K. R. Bridges, B. Pujol
- Brd. 44C** Interpretation of do-not-resuscitate (DNR) orders among oncology health care professionals and the potential for these orders to influence care for medical issues unrelated to resuscitation. (Abstract #9078)
C. R. Lund, R. Samant
- Brd. 44D** How accurate is clinician reporting of chemotherapy side effects? A prospective study comparing clinician with patient-reported symptoms. (Abstract #9079)
S. Ghosh, M. Van Hemelrijck, C. D. Holdridge, J. F. Gibson, P. J. Ross, J. Mansi, R. Lal, P. A. Ellis, P. G. Harper, S. Chowdhury
- Brd. 44E** The effect of palliative care consultations on the end-of-life care in the Veteran's cancer population. (Abstract #9080)
W. Gonsalves, T. Tashi, I. Aldoss, M. Kalaiah, N. Didwaniya, S. Stenoien, C. Eberle, A. Ganti, S. Subbiah, P. T. Silberstein
- Brd. 44F** Validation of first speech-specific questionnaire for English-speaking head and neck cancer (HNC) patients. (Abstract #9081)
R. Kazi, R. C. Dwivedi, S. St. Rose, J. W. Roe, C. Nutting, P. H. Rhys-Evans, K. J. Harrington
- Brd. 44G** Differences in lung cancer clinical trial accrual between a public and university medical oncology clinic. (Abstract #9082)
S. j. Vara, D. E. Gerber, A. Avila, J. Bolluyt, J. Yan, Y. Xie, J. H. Schiller

- Brd. 44H Barriers to symptom management in oncology. (Abstract #9083)**
B. R. Ferrell, M. Koczywas, T. Borneman, B. F. Piper, G. Uman
- Brd. 45A Uridine triacetate: An orally administered, life-saving antidote for 5-FU overdose. (Abstract #9084)**
M. K. Bamat, R. Tremmel, J. D. O'Neil, R. von Borstel
- Brd. 45B Differences between old (70–80 years) and very old (80+ years) cancer patients: Results from the IN-GHO registry. (Abstract #9085)**
F. Honecker, U. Wedding, K. Rettig, S. Huschens, C. Bokemeyer, on behalf of the IN-GHO Advisory Board
- Brd. 45C Depression and EGFR mutation status in stage IV non-small cell lung cancer. (Abstract #9086)**
W. F. Pirl, J. Greer, H. Bemis, R. S. Heist, E. Gallagher, L. V. Sequist, J. A. Engelman, L. Traeger, I. T. Lennes, J. S. Temel
- Brd. 45D Polypharmacy and functional status in older patients with breast, colon, and lung cancers. (Abstract #9087)**
G. K. Prithviraj, R. Bagai, S. M. Koroukian, N. A. Berger, C. Owusu
- Brd. 45E Reactivation of chronic hepatitis B virus in cancer patients receiving immunosuppression: The case for screening. (Abstract #9088)**
R. B. Mendelsohn, S. Nagula, Y. Taur, M. Kamboj, K. Sepkowitz, A. D. Zelenetz, E. Ludwig
- Brd. 45F Osteopenia in survivors of childhood cancer. (Abstract #9089)**
R. Nagarajan, S. R. Rose, M. M. Rutter, J. Correll, D. Kent, M. Kim, B. Schnell, K. C. Burns
- Brd. 45G Breast cancer survivors perception of family physician (FP) or specialist as principal provider of routine follow-up care. (Abstract #9090)**
E. Grunfeld, M. N. Levine, J. Julian, A. Folkes, G. R. Pond, E. Maunsell, FUP2 Trial Investigators
- Brd. 45H The use of complementary and alternative medicine in patients seen in phase I clinical trials program. (Abstract #9091)**
S. Stephen, A. Naing, D. S. Hong, S. Fu, J. J. Wheler, S. L. Moulder, G. S. Falchhook, A. M. Tsimberidou, S. A. Piha-Paul, R. Kurzrock
- Brd. 46A Late toxicity and quality of life in oral cavity and oropharyngeal cancer survivors treated with chemoradiotherapy. (Abstract #9092)**
M. Oliveira, A. Luís, E. Carvalho, S. Esteves, I. Sargento, M. Ferreira, A. Moreira, J. Oliveira
- Brd. 46B What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development. (Abstract #9093)**
H. Raftopoulos, R. J. Gralla, P. J. Hollen, B. J. Davis, J. A. Petersen, J. L. Horigan
- Brd. 46C Long-term safety, tolerability, and acceptability of fentanyl pectin nasal spray in the treatment of breakthrough cancer pain. (Abstract #9094[^])**
A. W. Burton, N. Y. Gabrail, L. Radbruch, D. Taylor, E. Reyes, R. Portenoy, Fentanyl Nasal Spray Study 045 Investigators Group
- Brd. 46D Randomized trial of combined treatment versus usual care plus antidepressant in depressed oncologic patients: One-year follow-up. (Abstract #9095)**
A. Palao Tarrero, C. Bayón Perez, G. Torres Sancho, A. Hospital Moreno, B. Castelo Fernandez, J. Barriuso, B. Rodriguez Vega
- Brd. 46E The prognostic role of quality-of-life assessment in lung cancer. (Abstract #9096)**
D. P. Braun, D. Gupta, J. F. Grutsch, E. D. Staren
- Brd. 46F Predictors of high symptom severity in caregivers of underserved minority cancer patients. (Abstract #9097)**
G. R. Palos, T. R. Mendoza, K. E. Liao, A. Garcia-Gonzalez, K. Hahn, L. A. Nazario, G. R. Lynch, K. O. Anderson, X. S. Wang, C. S. Cleeland

Monday, June 7, 2010

- Brd. 46G Correlates and mediators of worry about breast cancer recurrence. (Abstract #9098)**
N. K. Janz, S. T. Hawley, M. S. Mujahid, J. Graff, A. S. Hamilton, S. J. Katz
- Brd. 46H Role of yoga in modulating fatigue, sleep disturbances, salivary cortisol, and immune measures in breast cancer survivors: A randomized controlled trial. (Abstract #9099)**
R. M. Raghavendra, B. S. Ajaikumar, H. S. Vadiraja, S. Patil, R. B. Diwakar, P. Sashidhara, R. Nagarathna
- Brd. 47A A randomized trial of weekly high-dose calcitriol and weight-bearing exercise for cancer treatment-induced bone loss (CTIBL) and bone metabolism in ER+ breast cancer (BC) patients. (Abstract #9100)**
L. J. Peppone, R. N. Rosier, K. M. Mustian, M. N. Ling, A. Huston, O. Palesh, J. Q. Purnell, M. C. Janelins, L. Sprod, G. R. Morrow
- Brd. 47B Longitudinal prospective assessment of sleep disturbance in breast cancer. (Abstract #9101)**
S. D. Sanford, L. I. Wagner, J. L. Beaumont, Z. Butt, J. J. Sweet, D. Cella
- Brd. 47C Clinician perceptions of care difficulty and quality of life for lung cancer patients: Results from the ECOG SOAPP study (E2Z02). (Abstract #9102)**
H. A. Hamann, J. Lee, J. H. Schiller, L. Horn, C. S. Cleeland, J. Manola, L. I. Wagner, V. T. Chang, M. Fisch
- Brd. 47D The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy. (Abstract #9103)**
J. R. Westin, F. B. Hagemeister, M. A. Thompson, V. D. Cataldo, B. B. Toth, P. Sanjorjo, S. Bourgeois, C. Jimenez, W. A. Murphy, L. W. Kwak, M. D. Anderson
Department of Lymphoma/Myeloma
- Brd. 47E Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. (Abstract #9104)**
D. R. Pachman, D. L. Barton, P. E. Carns, P. J. Novotny, S. L. Wolf, B. Linqvist, S. Kohli, D. R. Smith, C. L. Loprinzi
- Brd. 47F Geriatric assessment in 347 elderly cancer patients: Study of geriatric factors modifying the cancer treatment plan. (Abstract #9105)**
P. Caillet, E. Pailaud, J. Vouriot, M. Berle, N. Reinald, S. Bastuji-Garin, S. Culine
- Brd. 47G How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): A systematic review of recent randomized trials. (Abstract #9106)**
B. E. Kiely, Y. Soon, M. H. Tattersall, M. Stockler
- Brd. 47H Assessing the clinical significance of real-time quality of life (QOL) data in cancer patients treated with radiation therapy. (Abstract #9107)**
M. Y. Halyard, A. Tan, M. D. Callister, J. B. Ashman, S. A. Vora, W. Wong, S. E. Schild, P. J. Atherton, J. A. Sloan
- Brd. 48A Pilot trial of decision aids for patients with advanced breast, lung, colorectal, or prostate cancer. (Abstract #9108)**
L. A. Dow, T. J. Smith, E. A. Virago, R. K. Matsuyama, J. L. Khatchersian, L. J. Lyckholm
- Brd. 48B National survey of U.S. oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by cancer patients. (Abstract #9109)**
R. T. Lee, L. Cohen, O. I. Olopade, F. C. Curlin
- Brd. 48C Patient surveillance following curative-intent treatment for breast carcinoma: Current practice patterns. (Abstract #9110)**
J. A. Margenthaler, E. Allam, L. Chen, K. S. Virgo, U. Kulkarni, A. Patel, F. E. Johnson
- Brd. 48D Perspectives on the financial burden of cancer care: Concurrent surveys of patients (Pts), caregivers (CGs), and oncology social workers (OSWs). (Abstract #9111)**
M. Eichholz, J. Pevar, T. Bernthal

- Brd. 48E** **Cancer treatment impact on cognitive functioning and quality of life in lung cancer survivors. (Abstract #9112)**
S. Kohli, P. J. Novotny, J. A. Sloan, J. C. Buckner, P. D. Brown, P. Yang
- Brd. 48F** **A phase II clinical study of interleukin-11 mutein to treat patients with chemotherapy-induced thrombocytopenia. (Abstract #9113)**
Y. Jung, S. Ho, S. Yu, S. Wu, Y. Zhang, L. Xu, Y. Dai, Y. Teng, S. Ma, S. Song
- Brd. 48G** **Can the short screening test Vulnerable Elders Survey 13 (VES-13) substitute for the time-consuming comprehensive geriatric assessment (CGA) to identify vulnerable/frail elderly breast cancer patients? (Abstract #9114)**
S. Monfardini, U. Basso, P. Fiduccia, A. Brunello, Z. Baretta, C. Soldà, E. Lamberti, F. Bozza, A. Jirillo, C. Falci
- Brd. 48H** **A real-world evaluation of the effectiveness of dalteparin in the prevention of recurrent venous thromboembolism compared to warfarin in patients with cancer. (Abstract #9115)**
W. R. Simons, Y. Choe, A. Powers, C. McQueen
- Brd. 49A** **A report on the development and validation of first-ever perceptual speech evaluation tool for head and neck cancer (HNC) patients. (Abstract #9116)**
R. C. Dwivedi, S. St. Rose, C. Nutting, P. H. Rhys-Evans, K. J. Harrington, R. Kazi
- Brd. 49B** **Adolescent and young adult use of Internet-based cancer survivorship care plans. (Abstract #9117)**
C. E. Hill-Kayser, C. Vachani, M. K. Hampshire, L. A. Jacobs, J. M. Metz
- Brd. 49C** **Predictors of employment (empl) outcomes in outpatients (pts) with common solid tumors: A secondary analysis from E2Z02 (ECOG's SOAPP study). (Abstract #9118)**
A. Tevaarwerk, J. Lee, M. C. Sesto, K. A. Buhr, C. S. Cleeland, J. Manola, L. I. Wagner, V. T. Chang, M. Fisch
- Brd. 49D** **Enrollment of and toxicity in patients 70 years and older on CTEP/NCI-sponsored, single-agent phase I studies from 1980 to 2005. (Abstract #9119)**
S. L. Chow, Y. Lin, N. K. LoConte, R. B. Royds, T. G. Nekrassova, S. P. Ivy, J. Mauer, G. Wilding, R. Stoller, M. J. Egorin
- Brd. 49E** **A prospective evaluation of symptom change over 4 weeks for outpatients with common solid tumors: Results from E2Z02 (the SOAPP study). (Abstract #9120)**
M. Fisch, J. Lee, V. T. Chang, L. I. Wagner, D. Cella, L. M. Minasian, W. J. McCaskill-Stevens, M. Weiss, M. Smith, C. S. Cleeland
- Brd. 49F** **Prechemotherapy hepatitis B virus (HBV) screening in medical oncology patients: A national survey. (Abstract #9121)**
F. L. Day, E. Link, K. Thursky, D. Rischin
- Brd. 49G** **Pregnancy and survival after primary breast carcinoma in young women: A meta-analysis of healthy mother effect studies. (Abstract #9122)**
D. Mauri, A. Valachis, L. Tsali, K. Tsalis, N. P. Polyzos, L. L. Pesce
- Brd. 49H** **Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403). (Abstract #9123)**
F. Joly, G. Gravis, S. Oudard, M. Soulie, B. Esterni, C. Protiere, M. Habibian, I. Latorzeff, F. Priou, K. Fizazi
- Brd. 50A** **Out-of-pocket (OOP) spending burden for Medicare beneficiaries with cancer. (Abstract #9124)**
X. Ke, F. Hendrick, T. Shaffer, A. J. Davidoff
- Brd. 50B** **Development of the lymphedema symptoms intensity and distress survey arm. (Abstract #9125)**
S. H. Ridner, M. S. Dietrich
- Brd. 50D** **Chemotherapy-induced nausea and vomiting-associated hospital and ER visits in real-world practice: Palonosetron versus other 5-HT₃-RA anti-emetic regimens. (Abstract #9127)**
H. T. Hatoum, S. Lin, D. Buchner, D. Cox

Monday, June 7, 2010

- Brd. 50E** The development and implementation of an institution-based communication skills training program for oncologists. (Abstract #9128)
P. A. Bialer, T. Gilewski, D. Kissane, T. Levin, M. N. Dickler, B. J. Park, C. Bylund
- Brd. 50F** Treatment of chemotherapy-induced peripheral neuropathy (CIPN) with topical menthol: A phase I study. (Abstract #9129)
D. J. Storey, L. A. Colvin, A. C. Scott, D. Boyle, L. Green, A. P. Jones, M. T. Fallon
- Brd. 50G** Activation of the MAP-kinase pathway in the skin of patients treated with sorafenib: Clinical and molecular characterization of skin tumors associated with the multikinase inhibitor sorafenib. (Abstract #9130)
C. Mateus, J. Arnault, G. Tomasic, E. Hollville, L. Lacroix, J. Wechsler, B. J. Escudier, A. Eychene, J. Soria, C. Robert
- Brd. 50H** Quality of life (QOL) and cognitive performance among irradiated brain cancer patients. (Abstract #9131)
M. J. Naughton, L. D. Case, C. A. Meyers, M. E. Loghin, E. G. Shaw, T. J. Saphner, B. G. Sleckman, J. K. Giguere, G. J. Lesser, S. R. Rapp
- Brd. 51A** The impact of pharmacotherapy on depression and quality of life in patients undergoing a bone marrow transplant (BMT). (Abstract #9132)
P. B. Mumby, C. Garcia, R. Trivedi-Purohit, R. Gourvitz, K. Rychlik, T. Rodriguez, S. E. Smith, A. A. Toor, M. Rao, P. J. Stiff, BMT Program
- Brd. 51B** Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer. (Abstract #9133)
D. H. Henry, R. von Moos, V. Hungria, L. Costa, P. J. Woll, G. Scagliotti, J. Wang, S. Jun, R. D. Dansey, H. Yeh
- Brd. 51C** Prevalence of memory problems that limit daily functioning in adult cancer patients: A national representative sample of the U.S. population. (Abstract #9134)
P. Jean-Pierre, P. Winters, T. Ahles, M. Antoni, D. Armstrong, F. Penedo, S. E. Lipschultz, T. L. Miller, G. R. Morrow, K. Fiscella
- Brd. 51D** Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1. (Abstract #9135)
B. Reeves, S. R. Dakhil, J. A. Sloan, A. Kamal, S. L. Wolf, K. N. Burger, N. LeLindqwister, G. S. Soori, A. J. Jaslowski, C. L. Loprinzi
- Brd. 51E** Effect of bevacizumab on the risk of chemotherapy-associated anemia in cancer patients: A meta-analysis. (Abstract #9136)
A. F. Sher, S. Wu
- Brd. 51F** Prevalence of lymphedema and upper-limb impairments after axillary lymph node dissection or sentinel lymph node dissection in breast cancer: A two-year follow-up study. (Abstract #9137)
A. Sagen, R. Kåresen, M. J. Hjermstad, M. Risberg, Oslo University Hospital
- Brd. 51G** Effect of timing of information on exercise behavior during cancer treatment: A URCC CCOP protocol. (Abstract #9138)
L. Sprod, L. J. Peppone, O. Palesh, M. C. Janelins, C. E. Heckler, L. K. Colman, J. J. Kirshner, P. W. Bushnow, G. R. Morrow, K. M. Mustian
- Brd. 51H** Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB. (Abstract #9139)
A. R. Moraska, P. J. Atherton, D. W. Szydlo, D. L. Barton, P. J. Stella, K. M. Rowland, P. L. Schaefer, J. E. Krook, J. Bearden, C. L. Loprinzi
- Brd. 52A** Testosterone levels and quality of life (QoL) in male patients with hormone-independent cancers (HIC). (Abstract #9140)
S. B. Fleishman, H. Khan, M. J. Guarino, M. Suhail, R. A. Strebel, P. Homel, V. Rosenwald, T. Mirzoyev, T. F. Wozniak, K. Suppiah
- Brd. 52B** Overall survival in randomized controlled trials of chemotherapy (CT) with or without GCSF support: A systematic review. (Abstract #9141)
G. H. Lyman, D. C. Dale, E. Culakova, M. S. Poniewierski, D. A. Wolff, N. M. Kuderer, J. Crawford

- Brd. 52C Disparities in receipt of supportive/palliative care services among women with breast cancer. (Abstract #9142)**
M. T. Halpern, D. J. Holden, A. Larsen
- Brd. 52D Post-traumatic stress in patients with acute leukemia. (Abstract #9143)**
C. Zimmermann, C. Lo, A. Rydall, A. Chan, J. Andrews, M. Minden, A. Schimmer, J. Brandwein, G. Rodin
- Brd. 52E Potential plasma biomarkers predicting radiation dermatitis in breast cancer patients. (Abstract #9144)**
J. L. Ryan, A. P. Pentland, C. E. Heckler, G. R. Morrow
- Brd. 52F The impact of symptom clusters on survival in patients with advanced cancer. (Abstract #9145)**
A. Aktas, L. A. Rybicki, D. Walsh
- Brd. 52G Use of health-related quality of life and clinical data as prognostic tools for survival prediction in a subgroup of metastatic cancer patients. (Abstract #9146)**
C. Quinten, F. Martinelli, J. Vercauteren, E. Greimel, B. B. Reeve, M. J. Taphoorn, C. S. Cleeland, J. Weis, J. Schmucker-Von Koch, A. Bottomley, on behalf of the EORTC
- Brd. 52H Effect of GTx-024, a selective androgen receptor modulator (SARM), on stair climb performance and quality of life (QOL) in patients with cancer cachexia. (Abstract #9147)**
M. S. Steiner, K. G. Barnette, M. L. Hancock, S. T. Dodson, D. Rodriguez, R. A. Morton
- Brd. 53A Effect of gabapentin on anxiety among 306 breast cancer patients: A URCC CCOP study. (Abstract #9148)**
O. Palesh, J. E. Lavigne, K. M. Mustian, L. J. Peppone, C. E. Heckler, M. C. Janelsins, J. Mathews, J. Q. Purnell, L. Sprod, G. R. Morrow
- Brd. 53B Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib. (Abstract #9149)**
C. M. Walko, R. E. Aubert, N. M. La-Beck, G. Hawk, V. Herrera, H. Kourlas, R. S. Epstein, H. L. McLeod
- Brd. 54A Randomized phase II trial of carboplatin (C) and gemcitabine (G) with or without dexamethasone (Dex) in patients (pts) with stage IV non-small cell lung cancer (NSCLC). (Abstract #9150)**
J. J. Rinehart, S. M. Arnold, G. H. Kloecker, A. Lim, M. A. Zaydan, S. Slone, J. Croley, E. Kvale
- Brd. 54B Effect of oral magnesium on hot flashes in breast cancer survivors. (Abstract #9151)**
H. Park, T. J. Smith, G. L. Parker, P. Dodson, C. Boardman, M. M. Morris
- Brd. 55A PROCHE: A program to monitor side effects among patients treated in a medical oncology outpatient unit. (Abstract #9152)**
F. Scotte, M. Berhoune, S. Marsan, H. Aboudagga, A. Morel, J. Fouque, C. Nedelec, J. Stevens, B. Bonan, S. Oudard
- Brd. 55B Cardioprotective effect of telmisartan in cancer patients treated with telmisartan. (Abstract #9153)**
M. Dessì, C. Madeddu, R. Serpe, E. Massa, C. Cadeddu, A. Piras, G. Mercurio, G. Mantovani
- Brd. 55C Venothromboembolism (VTE) in patients (pts) with acute myelogenous leukemia (AML). (Abstract #9154)**
N. V. Luong, M. Kroll, S. Faderl, D. Yang, A. Zalpour, K. T. Nguyen, D. Verma, G. Borthakur, H. Kantarjian, K. D. Vu
- Brd. 55D Pharmacokinetic study of pegylated liposomal doxorubicin (PLD) in patients over 70: Association with increasing age and cutaneous toxicity. (Abstract #9155)**
A. Bononi, M. Gusella, I. Modena, C. Bolzonella, C. Barile, G. Crepaldi, D. Menon, L. Stievano, S. Toso, F. Pasini

Monday, June 7, 2010

- Brd. 55E Functional disability and aromatase inhibitor-associated arthralgia in breast cancer survivors. (Abstract #9156)**
C. F. Friedman, D. Bruner, S. Xie, K. Desai, C. T. Stricker, A. DeMichele, J. Mao
- Brd. 55F Bone mineral density in childhood cancer survivors (CCS). (Abstract #9157)**
A. C. Dietz, L. Polgreen, A. Petryk, W. Leisenring, P. Goodman, D. A. Mulrooney, L. Steffen, A. Kelly, K. S. Baker, J. Steinberger
- Brd. 55G Venous thrombosis associated with central venous catheter in cancer patients with surgical chest port (S) or venography-guided arm port insertion (R): A randomized controlled study. (Abstract #9158)**
P. Marcy, E. Chamorey, A. Figl, M. Frenay, F. Peyrade, R. Largillier, J. Machiavello, J. Ferrero, E. Francois, J. Thariat
- Brd. 55H Coping strategies in young women with breast cancer. (Abstract #9159)**
K. J. Ruddy, S. Gelber, R. M. Tamimi, L. Schapira, S. E. Come, M. E. Meyer, E. P. Winer, A. H. Partridge
- Brd. 56A A practical program for measuring the quality of ambulatory oncology care in the United States: The Quality Oncology Practice Initiative. (Abstract #9160)**
M. N. Neuss, K. K. McNiff, P. Kadlubek, J. O. Jacobson, J. V. Simone
- Brd. 56B Chemotherapy-associated cardiotoxicity: Timeline of left ventricular function recovery on standard heart failure regimen. (Abstract #9161)**
J. K. Steiner, V. L. Beggs, G. N. Schwartz, A. T. Kono
- Brd. 56C Biochemical correlates of fatigue in patients at a comprehensive cancer center. (Abstract #9162)**
A. A. Bharne, P. Mills, W. Bardwell, M. White, K. Messer, L. Bazhenova
- Brd. 56D Supplemental oxygen for relief of dyspnea in hospice patients. (Abstract #9163)**
L. A. Joque, J. S. Kaur, R. A. Vierkant
- Brd. 56E Focus on the assessment of physical activity level of patients with cancer cachexia enrolled in a randomized phase III clinical trial. (Abstract #9164)**
G. Mantovani, A. Macciò, C. Madeddu, M. Dessì, R. Serpe, G. Antoni, E. Massa, G. Astara, F. Panzone
- Brd. 56F An analysis of prognostic factors of comprehensive geriatric assessment (CGA) and development of a clinical scoring system in elderly Asian cancer patients. (Abstract #9165)**
R. Kanesvaran, H. Li, K. Koo, D. Poon
- Brd. 56G Use of a pharmacist/nurse model for the delivery of supportive care in adult oncology clinics at the University of North Carolina Hospital. (Abstract #9166)**
S. A. Bernard, J. Valgus, S. Jarr, M. Rice, R. Schwartz

1:15 PM - 2:30 PM
SPECIAL SESSION

ASCO/European Cancer Organisation Joint Session: Personalized Medicine in Locally Advanced Non-small Cell Lung Cancer

Location: E Arie Crown Theater

CME credit: 1.25

Track(s): Special Session; Lung Cancer

Michael Baumann, MD—Co-Chair

University Hospital Carl Gustav Carus, TU Dresden

Introduction: The Need for Personalized Medicine in Locally Advanced NSCLC

Douglas W. Blayney, MD—Co-Chair

University of Michigan

Summary: The Future of Personalized Medicine

David Paul Carbone, MD, PhD

Vanderbilt University Medical Center

Tumor Biology and Its Impact on Decision Making (Assay Technology)

Michael Brada, MD

Institute of Cancer Research and Royal Marsden NHS Trust

Multidisciplinary Localized Therapy: Innovative Developments in Multidisciplinary Treatments of NSCLC

Jean-Charles Soria, MD, PhD

Gustave Roussy Institute

Systemic Therapy: What Lies Ahead?

Monday, June 7, 2010

**1:15 PM - 2:30 PM
EDUCATION SESSIONS**

Combined Modalities in Pancreatic Cancer: Should Recent Trials Change Our Practice?

Location: N Hall B1

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer; Developmental Therapeutics

David Linehan, MD—Chair

Washington University School of Medicine

Surgical Approach in Resectable and Borderline Resectable Pancreatic Cancer

Gauri R. Varadhachary, MD

University of Texas M. D. Anderson Cancer Center

The Role of Neoadjuvant versus Adjuvant Chemotherapy in Pancreatic Cancer: What Does the Data Tell Us?

Theodore Steven Lawrence, MD, PhD

University of Michigan

Role of Radiation in Locally Advanced Pancreatic Cancer

Complications of Myeloma and Myeloma Therapies

Location: E354a

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders; Patient and Survivor Care

Todd M. Zimmerman, MD—Chair

The University of Chicago

Prophylaxis of Venous Thromboembolic Disease Associated with Immunomodulatory Agents

Paul Gerard Guy Richardson, MD

Dana-Farber Cancer Institute

Prevention and Management of Treatment-induced Peripheral Neuropathy

G. David Roodman, MD, PhD

University of Pittsburgh

Myeloma Bone Disease: What's New?

Controversies in the Management of Metastatic Breast Cancer

Location: E Hall D1

CME credit: 1.25

Track(s): Breast Cancer; Professional Development

Cliff Hudis, MD—Chair

Memorial Sloan-Kettering Cancer Center

Integration and Sequence of Systemic Options: How to Translate Clinical Trial Results into Routine Practice?

Jonas Bergh, MD, PhD

Karolinska University Hospital

Biological Evolution of Breast Cancer: Should a Metastasis Be Rebiopsed?

Michael J. Hassett, MD, MPH

Dana-Farber Cancer Institute

Should Cost Be a Consideration in the Management of Metastatic Breast Cancer?

Defining Professionalism in Oncology: Current Dilemmas and the Future of the Workforce

Location: E353

CME credit: 1.25

Track(s): Professional Development; Ethics

Timothy Jerome Moynihan, MD—Chair

Mayo Clinic

Can We Teach Professionalism?

Robert Martensen, MD, PhD

National Institutes of Health

Medical Professionalism in Historical Perspective

David H. Johnson, MD

Vanderbilt Ingram Cancer Center

Professionalism and the Oncologist: How Professionalism Impacts Practice

Exploiting the Endocrine Axis in Prostate Cancer Therapy: Current Status and Future Directions

Location: E Hall D2

CME credit: 1.25

Track(s): Genitourinary Cancer; Geriatric Oncology; Patient and Survivor Care

William K. Oh, MD—Chair

Mount Sinai School of Medicine

Exploiting the Endocrine Axis in Prostate Cancer: What Are the New Targets?

Mary-Ellen Taplin, MD

Dana-Farber Cancer Institute

Recent Advances in Endocrine Therapy for Prostate Cancer: New Agents, New Options

Peter Nelson, MD

Fred Hutchinson Cancer Research Center

Where Is Endocrine Therapy Going in the Next Five Years?

Immunoconjugates as Cancer Therapeutics

Location: S100b

CME credit: 1.25

Track(s): Developmental Therapeutics; Lymphoma and Plasma Cell Disorders; Tumor Biology

Andrew Antony Raubitschek, MD—Chair

City of Hope

The History and Evolution of Immunoconjugate Treatment as Anticancer Therapy

Raffit Hassan, MD

National Cancer Institute

The Present State of Trials Using Immunoconjugates Targeting Solid Tumors and New Strategies Emerging from the Lab

Paul A. Hamlin, MD

Memorial Sloan-Kettering Cancer Center

The Present State of Trials Using Immunoconjugates Targeting Lymphoma and Heme Malignancies and New Strategies Emerging from the Lab

Monday, June 7, 2010

NCI Community Cancer Centers Program (NCCCP): A New Paradigm for Clinical Trials in the Community Setting

Location: S404

CME credit: 1.25

Track(s): Clinical Trials; Practice Management and Information Technology; Professional Developmental

Mark Krasna, MD—Chair

St. Joseph Medical Center

Multidisciplinary Cancer Care as the Paradigm for Prospective Case Management and Clinical Trial Accrual in the Community Setting

John E. Niederhuber, MD

National Cancer Institute

The Vision of the NCCCP and Its Potential Impact on Community Cancer Care in the Future

Nicholas J. Petrelli, MD

Helen F. Graham Cancer Center

Disparities and Community Outreach in the NCCCP

Response-based Therapy: A Personalized Approach to Pediatric Hodgkin Lymphoma

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology; Lymphoma and Plasma Cell Disorders

Cindy L. Schwartz, MD—Chair

Brown Medical School

Optimizing Chemotherapy: Response and Biology

Louis S. Constine, MD

James P. Wilmot Cancer Center

RT or not RT: That Is the Question!

Stephan Voss, MD, PhD

Children's Hospital Boston

Functional Imaging and Hodgkin Lymphoma

The Biology of Leukemia and Myeloproliferative Disorders: Implications for Treatment

Location: E354b

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation

Olatoyosi Odenike, MD—Chair

University of Chicago

Epigenetic and Other Rational Therapeutic Approaches in MPD

Catrina Jamieson, MD, PhD

University of California, San Diego

JAK 2 and Related Mutations in Myeloid Neoplasms: Biology and Therapeutic Implications

Guido Marcucci, MD

The Ohio State University Medical Center

MicroRNA in AML and CLL: What Does It Mean?

1:15 PM - 2:30 PM
CLINICAL PROBLEMS IN ONCOLOGY

Nonglial and Heritable Central Nervous System Tumors (C14)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Central Nervous System Tumors

Marc C. Chamberlain, MD—Chair

University of Washington

Adult Meningioma: The Evolving Role for Oncologists

Patrick Y. Wen, MD

Dana-Farber Cancer Institute

Neurofibromatosis Type 2

Michael Prados, MD

University of California, San Francisco

Adult Medulloblastoma

Monday, June 7, 2010

1:15 PM - 2:45 PM
CLINICAL SCIENCE SYMPOSIUM

Unraveling the Cancer Genome: Clinical Implications of Next-generation Technologies

Location: S100a

CME credit: 1.5

Track(s): Tumor Biology

Anil Potti, MD—Chair

Duke University Medical Center

- 1:15 PM** **Massive parallel sequencing of an African-American basal-like breast cancer: Comparison of primary tumor, metastasis, and xenograft. (Abstract #10500)**
E. Mardis, L. Ding, S. Li, D. E. Larson, K. Chen, J. Wallis, J. Hoog, K. Deshryver, R. Wilson, M. J. Ellis
- 1:30 PM** **Characterization of the microRNAome in a patient with acute myeloid leukemia. (Abstract #10501)**
G. Ramsingh, D. Koboldt, V. Magrini, M. Trissal, S. Koul, L. Chang, R. Nagarajan, T. J. Ley, E. Mardis, D. C. Link

Discussion

- 1:45 PM** Samuel Aparicio, BM, BCh, PhD, MRCPATH (Abstracts #10500–10501)
British Columbia Cancer Agency
- 2:00 PM** **Detection of phosphoinositide-3-kinase, catalytic, and alpha polypeptide (PIK3CA) mutations in matched tissue and plasma samples from patients with metastatic breast cancer. (Abstract #10502)**
P. Angenendt, K. David, H. Juhl, F. Diehl
- 2:15 PM** **Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry. (Abstract #10503)**
C. Beadling, M. C. Heinrich, K. Schuff, B. J. Druker, C. L. Corless

Discussion

- 2:30 PM** Matthew James Ellis, PhD, MB, BCh (Abstracts #10502–10503)
Siteman Cancer Center, Washington University

MONDAY

**2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION**

Breast Cancer—Local-Regional and Adjuvant Therapy

Display Time: 2:00 PM - 6:00 PM

Display Location: S403

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: N Hall B1

CME credit: 1

Track(s): Breast Cancer

Stephen K. L. Chia, MD—Co-Chair

British Columbia Cancer Agency

Lisa Yee, MD—Co-Chair

The Ohio State University

Discussion

5:00 PM Seema Ahsan Khan, MD, FACS, MPH (Abstracts #LBA513–LBA517)
Northwestern Memorial Hospital

Discussion

5:15 PM Antonio C. Wolff, MD (Abstracts #518–522)
The Johns Hopkins University

Discussion

5:30 PM Claudine Isaacs, MD (Abstracts #523–528)
Lombardi Comprehensive Cancer Center

Discussion

5:45 PM Carlos Caldas, MD (Abstracts #530–535)
Cambridge University

Brd. 1 ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. (Abstract #LBA513)

M. J. Ellis, G. Babiera, G. W. Unzeitig, P. K. Marcom, J. M. Guenther, K. Deshryver, D. C. Allred, V. Suman, K. Hunt, J. A. Olson

Brd. 2 Impact of multifocal/multicentric versus unifocal breast cancer on local recurrence. (Abstract #514)

R. Woods, K. A. Gelmon, S. Tyldesley, H. F. Kennecke, C. Speers, R. Yerushalmi

Brd. 3 Determination of clear margin in breast-conserving surgery: Is 1 mm needed? (Abstract #515)

J. Geffrelot, F. Toudic Emily, C. Levy, C. Blanc Fournier, C. Segura, O. Switers, D. Allouache, C. Delcambre, S. Martin, T. Delozier

Brd. 5 Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: First report of a randomized controlled trial at 10-years maximum follow-up. (Abstract #LBA517)

M. Baum, D. J. Joseph, J. S. Tobias, F. K. Wenz, M. R. Keshtgar, M. Alvarado, M. Bulsara, W. Eiermann, N. R. Williams, J. S. Vaidya, on behalf of the TARGIT Trialists' Group

Brd. 6 Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. (Abstract #518)

M. F. Press, G. Sauter, M. E. Buyse, L. Bernstein, W. Eiermann, T. Pienkowski, M. Martin, N. J. Robert, J. Crown, D. J. Slamon

Brd. 7 Final results of a meta-analysis testing HER2 and topoisomerase II α genes as predictors of incremental benefit from anthracyclines in breast cancer. (Abstract #519)

A. Di Leo, C. Desmedt, J. M. Bartlett, B. Ejlersen, K. I. Pritchard, C. J. Poole, D. Larsimont, M. Tanner, F. Piette, M. E. Buyse

Monday, June 7, 2010

- Brd. 8 Use of meta-analysis of gene expression profiling studies to identify biologically relevant pathways associated with aggressive breast cancer (BC) in young women. (Abstract #520)**
P. Bedard, R. Salgado, S. K. Singhal, V. Durbecq, M. Ignatiadis, B. Haibe-Kains, M. Piccart, C. Sotiriou, S. Loi
- Brd. 9 Clinically relevant gene signatures in triple-negative and basal-like breast cancer. (Abstract #521)**
A. Rody, T. Karn, C. Liedtke, E. Ruckhäberle, L. Hanker, L. Pusztai, V. Mueller, M. Schmidt, U. Holtrich, M. Kaufmann
- Brd. 10 Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy. (Abstract #522)**
S. Loi, B. Haibe-Kains, D. N. Brown, J. Metallo, L. X. Huan, C. Desmedt, L. Pusztai, M. Piccart, F. J. Esteva, C. Sotiriou
- Brd. 11 First results from the Patient's Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer (EBC). (Abstract #523)**
N. Harbeck, P. Hadji, C. Jackisch, M. Landthaler, V. Heilmann, B. Baier, M. Blettner, H. Lück, A. Rexrodt von Fircks, R. Kreienberg
- Brd. 12 Early discontinuation of tamoxifen and aromatase inhibitors (AIs) by postmenopausal women with early-stage breast cancer. (Abstract #524)**
J. A. Charlson, T. Hedin, R. Sparapani, C. Guo, A. Nattinger
- Brd. 14 Genetic variation in CYP19A1 and interleukin-6 and aromatase inhibitor-associated arthralgia in breast cancer survivors. (Abstract #526)**
J. Mao, I. Su, R. Feng, K. Desai, M. Horn, D. Chan, A. DeMichele
- Brd. 15 Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. (Abstract #527)**
K. Ribi, J. Aldridge, K. Phillips, Z. Sun, A. M. Thompson, V. J. Harvey, B. Thürlimann, F. Cardoso, A. S. Coates, J. Bernhard
- Brd. 16 Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. (Abstract #528)**
L. Del Mastro, L. Boni, A. Michelotti, T. Gamucci, N. Olmeo, M. Giordano, S. Gori, O. Garrone, C. Bighin, M. Venturini, GIM group
- Brd. 18 Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). (Abstract #530)**
G. G. Steger, R. Greil, R. Jakesz, A. Lang, B. Mlineritsch, M. Rudas, C. Marth, H. Stoeger, C. F. Singer, M. Gnant, Austrian Breast and Colorectal Cancer Study Group (ABCSG)
- Brd. 19 Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC). (Abstract #531)**
H. Joensuu, P. Kellokumpu-Lehtinen, R. Huovinen, A. Jukkola-Vuorinen, M. Tanner, R. Kokko, J. Ahlgren, P. Bono, P. Auvinen, H. Lindman
- Brd. 21 Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. (Abstract #533)**
M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, S. Poestlberger, P. C. Dubsy, R. Jakesz, C. F. Singer, H. Eidtmann, R. Greil

- Brd. 22** Two years of tamoxifen followed by 3 years of anastrozole versus 5 years of tamoxifen alone in postmenopausal women with hormone-responsive early breast cancer: Efficacy results from 3,714 patients from the Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 8. (Abstract #534)
P. C. Dubsy, R. Jakesz, R. Greil, D. Heck, H. Stoeger, W. Kwasny, C. Menzel, C. F. Singer, M. Medl, M. Gnant, Austrian Breast and Colorectal Cancer Study Group
- Brd. 23** Phase III study of sequential treatment with epirubicin/cyclophosphamide followed by docetaxel compared to FEC₁₂₀ in the adjuvant treatment of breast cancer patients: The German ADEBAR study. (Abstract #535)
W. Janni, N. Harbeck, H. L. Sommer, B. K. Rack, D. Augustin, W. Simon, A. Wischnik, K. Anneke, K. Friese, M. Kiechle, AGO-Study Group

Monday, June 7, 2010

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Cancer Prevention/Epidemiology

Display Time: 2:00 PM - 6:00 PM

Display Location: E450b

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: E451b

CME credit: 1

Track(s): Cancer Prevention/Epidemiology

Kala Visvanathan, MD, MHS—Co-Chair

The Johns Hopkins University

Marie Wood, MD—Co-Chair

University of Vermont

Discussion

5:00 PM Judy Ellen Garber, MD, MPH (Abstracts #1509–1514)
Dana-Farber Cancer Institute

Discussion

5:15 PM Barnett S. Kramer, MD, MPH (Abstracts #1515–1520)
National Institutes of Health

Discussion

5:30 PM Dean Brenner, MD (Abstracts #1521–1524)
University of Michigan Medical Center

Discussion

5:45 PM To be determined

Brd. 1 **Impact of early detection strategies on cancer mortality in germline *TP53* mutation carriers in Li-Fraumeni syndrome. (Abstract #1509)**

A. Villani, U. Tabori, J. D. Schiffman, A. Shlien, H. Druker, A. Novokmet, J. L. Finlay, D. Malkin

Brd. 2 **PTEN hamartoma tumor syndrome (PHTS): Clinical characteristics, onco-phenotype, and molecular analysis. (Abstract #1510)**

M. M. Patnaik, S. Khambatta, S. I. Robinson, R. L. Richardson, M. P. Goetz

Brd. 3 **Prevalence of *BRCA1* mutations among 284 women with triple-negative breast cancer. (Abstract #1511)**

F. Fostira, M. Tsitlaidou, H. Gogas, M. Pertesi, D. Yannoukakos, E. Bournakis, V. Karavassilis, P. Skarlos, I. Konstantopoulou, G. Fountzilias

Brd. 4 **Primary fallopian tube lesions in *BRCA* mutation carriers undergoing risk-reducing surgery. (Abstract #1512)**

F. Dao, G. Han, K. J. Park, G. J. Gardner, N. D. Kauff, R. R. Barakat, R. A. Soslow, D. A. Levine, Memorial Sloan-Kettering Cancer Center

Brd. 5 **Noncancer endpoints in *BRCA1/2* carriers after risk-reducing salpingo-oophorectomy. (Abstract #1513)**

J. Cohen, L. Chiel, J. Stopfer, J. Powers, S. M. Domchek

Brd. 6 **Characterization of new Ashkenazi Jewish founder mutations in *MSH6* causing Lynch syndrome. (Abstract #1514)**

L. Raskin, F. Schwenter, M. Freytsis, M. Tischkowitz, D. A. Levine, S. Narod, S. Gallinger, G. Rennert, W. Foulkes, S. B. Gruber

Brd. 7 **What size of tumors should we detect as early-stage lung cancers in CT screening? Stage-size relationship in long-term repeated screening over 15 years. (Abstract #1515)**

N. Seki, K. Eguchi, M. Kaneko, H. Ohmatsu, R. Kakinuma, E. Matsui, M. Kusumoto, T. Tsuchida, H. Nishiyama, N. Moriyama

- Brd. 8 Assessment of overdiagnosis in CT screening for lung cancer. (Abstract #1516)**
 G. Veronesi, M. Bellomi, P. Maisonneuve, G. Pelosi, M. Casiraghi, C. Rampinelli, L. Spaggiari
- Brd. 9 Prospective evaluation of whole-body cancer screening with multiple modalities including FDG-PET: Results from annual screening for 5 years in 1,197 healthy volunteers. (Abstract #1517)**
 S. Nishizawa, H. Kodama, Y. Maeda, H. Okada, S. Kojima, S. Teramukai, M. Fukushima
- Brd. 10 Optically guided surgical approach and the outcome of early-stage oral cancers. (Abstract #1518)**
 C. F. Poh, J. S. Durham, D. Anderson, K. W. Berean, C. E. MacAulay, L. Zhang, M. P. Rosin
- Brd. 12 Effect of screening on the detection of good and poor prognosis breast cancers. (Abstract #1520)**
 Y. Shieh, L. Esserman, E. J. Rutgers, M. Knauer, V. Retel, S. Mook, A. Glas, S. C. Linn, F. E. van Leeuwen, L. van't Veer
- Brd. 13 Phase II randomized placebo-controlled double-blind chemoprevention trial of fruit/vegetable concentrates on intermediate biomarkers in head/neck cancer. (Abstract #1521)**
 E. G. Shaw, L. D. Case, J. D. Browne, J. Gilbert, J. Metzner-Sidurski, E. Franzmann, B. Frizzell, C. Schneider, V. Thomas, J. J. Hu
- Brd. 14 Effect of successful weight loss program on biomarkers for breast cancer in postmenopausal high-risk women. (Abstract #1522)**
 C. J. Fabian, J. R. Klemp, B. F. Kimler, S. Aversman, T. A. Phillips, C. M. Zalles, D. Sullivan, B. Smith, J. Donnelly, H. Yeh
- Brd. 15 Role of dietary polyamines in a phase III clinical trial of DFMO and sulindac for prevention of metachronous colorectal adenomas. (Abstract #1523)**
 K. P. Raj, J. A. Zell, C. L. Rock, C. E. McLaren, C. Zoumas-Morse, E. W. Gerner, F. L. Meyskens
- Brd. 16 Cigarette smoking, fitness, and obesity as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention Trial (BCPT). (Abstract #1524)**
 S. R. Land, N. Christian, W. M. Cronin, D. Wickerham, J. P. Costantino, P. A. Ganz
- Brd. 17 Race and colon cancer: Unanswered questions. (Abstract #1525)**
 R. Sehgal, C. C. Larck, Y. Dementieva, M. R. Tria Tirona, P. Edwards, W. M. McHayleh, B. C. Lembersky
- Brd. 18 Investigation of ethnic differences in the prevalence of chromosomal number aberrations of luminal and triple-negative breast cancers associated with risk of recurrence. (Abstract #1526)**
 A. M. Brewster, P. Thompson, K. Do, A. Sahin, L. Zhang, J. L. Murray, S. Tsachavidis, G. B. Mills, M. Bondy
- Brd. 19 Celecoxib and aromatase activity in breast cancer: Results from a prospective randomized preoperative trial. (Abstract #1527)**
 E. R. Port, K. Subbaramaiah, E. Brogi, M. Sampson, K. Panageas, A. Dannenberg, C. Hudis
- Brd. 20 Evaluation of the potential clinical utility of risk models incorporating genomic risk information. (Abstract #1528)**
 E. A. Comen, L. Balistreri, T. Kirchoff, M. Gaudet, A. V. Dutra-Clarke, K. Offit, M. E. Robson
- Brd. 21 Integration of specific copy number imbalances and prediction models of early-stage breast cancer recurrence. (Abstract #1529)**
 P. Thompson, K. Do, A. M. Brewster, J. Shim, J. L. Murray, S. Tsachavidis, A. Sahin, G. B. Mills, M. Bondy

Monday, June 7, 2010

- Brd. 22** **Nicotinic acetylcholine receptor polymorphism, smoking history, and tobacco-related cancer in the general population. (Abstract #1530)**
D. Kaur-Knudsen, S. E. Bojesen, A. Tybjerg-Hansen, B. G. Nordestgaard
- Brd. 23** **Evaluation of C-reactive protein and YKL-40 as risk factors for incident cancer and early death after a diagnosis of cancer. (Abstract #1531)**
K. H. Allin, S. E. Bojesen, J. S. Johansen, B. G. Nordestgaard
- Brd. 24** **Neurocognitive outcomes in adult survivors of childhood Hodgkin lymphoma. (Abstract #1532)**
N. Jain, K. R. Krull, D. K. Srivastava, E. B. Morris, M. Metzger, K. Helton, L. L. Robison, M. M. Hudson

MONDAY

**2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION**

Leukemia, Myelodysplasia, and Transplantation

Display Time: 2:00 PM - 6:00 PM

Display Location: E450a

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: E354a

CME credit: 1

Track(s): Leukemia, Myelodysplasia, and Transplantation

Lucy A. Godley, MD, PhD—Co-Chair

The University of Chicago

Rami S. Komrokji, MD—Co-Chair

H. Lee Moffitt Cancer Center & Research Institute

Discussion

5:00 PM Mier Wetzler, MD (Abstracts #6509–6514)
Roswell Park Cancer Institute
Optimizing TKI Therapy in Advanced CML

Discussion

5:15 PM John C. Byrd, MD (Abstracts #6515–6523)
The Ohio State University
Advances in the Therapy of Chronic Lymphoid Leukemias

Discussion

5:30 PM Harry Paul Erba, MD, PhD (Abstracts #6524–6528)
University of Michigan Health Systems
Novel Therapeutic Strategies in MDS and AML

Discussion

5:45 PM Jane Liesveld, MD (Abstracts #6529–6532)
University of Rochester
Can Management of High-risk AML Be Optimized?

- Brd. 1** **Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200. (Abstract #6509)**
C. Gambacorti-Passerini, J. E. Cortes, H. J. Khoury, M. Baccarani, H. Kantarjian, M. Chandy, N. Besson, J. Wang, S. Arkin, T. Brümmendorf
- Brd. 2** **Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. (Abstract #6510)**
F. J. Giles, H. Kantarjian, P. D. le Coutre, M. Baccarani, R. E. Blakesley, N. J. Gallagher, K. Gillis, R. A. Larson, O. G. Ottmann
- Brd. 3** **Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies. (Abstract #6511)**
M. Talpaz, J. E. Cortes, M. W. Deininger, N. P. Shah, I. W. Flinn, M. J. Mauro, T. O'Hare, V. Rivera, H. Kantarjian, F. G. Haluska
- Brd. 4** **Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily. (Abstract #6512)**
N. P. Shah, J. E. Cortes, C. A. Schiffer, P. le Coutre, E. Bahceci, A. Lambert, G. Saglio
- Brd. 5** **Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib. (Abstract #6513)**
S. Branford, G. Martinelli, G. Saglio, D. Kim, Y. Shou, J. Reynolds, R. C. Woodman, H. Kantarjian, A. Hochhaus, J. P. Radich

Monday, June 7, 2010

- Brd. 6 Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML). (Abstract #6514)**
H. J. Khoury, D. Kim, A. Zaritskey, J. Apperley, N. Besson, A. Volkert, J. Wang, S. Arkin, J. E. Cortes
- Brd. 7 Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years. (Abstract #6515)**
G. Rosti, F. Castagnetti, F. Palandri, A. Poerio, S. Soverini, M. Breccia, F. Pane, G. Martinelli, M. Baccarani, G. Saglio
- Brd. 8 Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. (Abstract #6516)**
A. Hochhaus, G. Saglio, H. Kantarjian, A. Haque, Y. Shou, R. C. Woodman, T. P. Hughes, J. P. Radich, G. Martinelli, D. Kim
- Brd. 9 Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV. (Abstract #6517)**
R. Hehlmann, M. Lauseker, S. Jung-Munkwitz, J. E. Schubert, C. Haferlach, S. W. Krause, A. Gratwohl, J. Hasford, A. Hochhaus, S. Saussele, the German CML Study Group
- Brd. 10 Relationship between dasatinib exposure and long-term clinical outcomes in chronic-phase chronic myeloid leukemia (CML-CP) patients. (Abstract #6518)**
A. Roy, N. P. Shah, P. le Coutre, X. Wang, C. A. Schiffer, G. Saglio, A. Lambert, A. Damokosh, E. Bahceci, J. E. Cortes
- Brd. 11 Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL). (Abstract #6519)**
S. A. Parikh, W. G. Wierda, X. Badoux, S. M. O'Brien, A. Ferrajoli, S. Faderl, J. A. Burger, S. Lerner, H. Kantarjian, M. J. Keating
- Brd. 12 Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL). (Abstract #6520^)**
W. G. Wierda, T. J. Kipps, J. Dürig, L. Griskevicius, S. Stilgenbauer, J. Mayer, M. Gorczyca, M. Andersen, T. Nielsen, C. A. Russell
- Brd. 13 Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). (Abstract #6521)**
A. M. Tsimberidou, W. G. Wierda, X. Badoux, S. Wen, W. Plunkett, S. M. O'Brien, T. J. Kipps, J. A. Jones, H. Kantarjian, M. J. Keating
- Brd. 14 Phase II trial of daily, oral green tea extract in patients with asymptomatic, Rai stage 0-II chronic lymphocytic leukemia (CLL). (Abstract #6522)**
T. D. Shanafelt, T. Call, C. S. Zent, B. LaPlant, J. F. Leis, D. Bowen, M. Roos, D. F. Jelinek, C. Erlichman, N. E. Kay
- Brd. 15 Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia. (Abstract #6523)**
R. J. Kreitman, M. S. Tallman, S. E. Coutre, T. Robak, W. H. Wilson, M. Stetler-Stevenson, P. Noel, D. J. FitzGerald, J. T. McDevitt, I. Pastan
- Brd. 16 Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL). (Abstract #6524)**
C. E. Vigil, H. Kantarjian, D. A. Thomas, S. M. O'Brien, F. Ravandi Kashani, C. A. Koller, J. A. Burger, R. S. Garris, M. D. Baccus, S. Faderl

- Brd. 17** **Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules. (Abstract #6525)**
R. K. Stuart, F. Ravandi Kashani, L. D. Cripe, M. B. Maris, M. A. Cooper, S. R. Dakhil, R. M. Stone, F. Turturro, J. A. Fox, G. Michelson
- Brd. 18** **Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. (Abstract #6526)**
G. J. Roboz, J. E. Lancet, L. D. Cripe, F. Ravandi Kashani, A. F. List, J. A. Fox, G. Michelson, J. E. Karp
- Brd. 19** **Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR). (Abstract #6527)**
F. Ravandi Kashani, J. Jorgensen, S. Faderl, J. Issa, J. Autry, G. Garcia-Manero, G. Borthakur, X. Huang, J. E. Cortes, H. Kantarjian
- Brd. 20** **A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. (Abstract #6528)**
G. Garcia-Manero, S. M. Luger, P. Venugopal, L. J. Maness, M. Wetzler, J. K. Altman, D. Claxton, S. A. Strickland, J. H. Chiao, H. Kantarjian
- Brd. 21** **Evaluation of efficacy and mortality in elderly patients (pts) (70 years [yrs] or older) with acute myeloid leukemia (AML) treated with intensive chemotherapy (IC). (Abstract #6529)**
T. M. Kadia, F. Ravandi Kashani, S. M. O'Brien, J. E. Cortes, E. Jabbour, G. Borthakur, S. Faderl, S. Pierce, M. Brandt, H. Kantarjian
- Brd. 22** **Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML patients. (Abstract #6530)**
C. Gardin, R. Itzykson, S. Thépot, C. Recher, A. Marfaing, O. Beyne-Rauzy, S. Bohrer, F. Dreyfus, P. Fenaux, H. Dombret, for the GFM and ALFA Groups
- Brd. 23** **Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies. (Abstract #6531)**
M. R. Baer, S. L. George, B. L. Sanford, R. M. Stone, G. Marcucci, R. J. Mayer, R. A. Larson
- Brd. 24** **Treatment of acute myeloid leukemia (AML) in first remission (CR1) with unrelated donor (UD) allogeneic hematopoietic cell transplantation (HCT). (Abstract #6532)**
Q. Bashir, B. Andersson, L. De Padua Silva, G. Rondon, A. Chiattonne, C. Hosing, M. Fernandez-Vina, S. Giralt, R. E. Champlin, M. J. De Lima

Monday, June 7, 2010

**3:00 PM - 4:15 PM
EDUCATION SESSIONS**

Acute Leukemia: Integration of Novel Diagnostic and Therapeutic Measures

Location: E354a

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation

Richard F. Schlenk, MD—Chair

University of Ulm

Molecular/Cytogenetic Prognostication in AML and Its Impact on Treatment

Ivana Gojo, MD

University of Maryland

Upfront and Salvage Therapy in AML: What's New?

Anjali S. Advani, MD

Cleveland Clinic

An Update on Treatment of Adult ALL

Caring for the Child with Brain Cancer

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology; Central Nervous System Tumors; Health Services Research

Stewart Goldman, MD—Chair

Children's Memorial Hospital

Relapsed Pediatric Central Nervous System Tumors in 2010: Strategies and New Agents

Amar J. Gajjar, MD

St. Jude Children's Research Hospital

High-dose Chemotherapy for Malignant Brain Tumors: What Have We Learned in the Past Two Decades and What Does the Future Hold for This Therapy?

Thomas E. Merchant, DO, PhD

St. Jude Children's Research Hospital

Understanding Late Effects of Irradiation and Measures to Reduce Dose to Normal Tissue

Integrated Considerations in the Management of the Patient with Advanced Ovarian Cancer

Location: E Arie Crown Theater

CME credit: 1.25

Track(s): Gynecologic Cancer

Elise C. Kohn, MD—Chair

National Cancer Institute

The Promise and Toxicity of Novel Targeted Therapies in Ovarian Cancer: Hope or Hype?

Andreas Du Bois, MD, PhD

HSK, Dr. Horst Schmidt Klinik

Balancing Biologic Behavior with Surgical Therapy

Michael Friedlander, MD, PhD

The University of New South Wales

Does Palliative Chemotherapy Palliate? Assessment of Symptom Benefit in Recurrent Ovarian Cancer

Maintenance Chemotherapy for Non-small Cell Lung Cancer: Effectiveness and Cost-effectiveness

Location: S404

CME credit: 1.25

Track(s): Lung Cancer; General Oncology

Tom Stinchcombe, MD—Chair

University of North Carolina

Maintenance Therapy for Advanced NSCLC Is Not Standard of Care

Tracey L. Evans, MD

University of Pennsylvania

Maintenance Therapy for Advanced NSCLC Is Standard of Care

Scott Ramsey, MD, PhD

Fred Hutchinson Cancer Research Center

Cost Effectiveness in Lung Cancer Trials and Treatment

Navigating Conflicts of Interest in Medicine and Research: Proper Interactions with Industry in a Time of Increasing Scrutiny

Location: S100b

CME credit: 1.25

Track(s): Ethics

Richard M. Goldberg, MD—Chair

University of North Carolina

Conflicts of Interest: The Physician's and ASCO's Viewpoints

Bernard Lo, MD

University of California, San Francisco

Conflicts of Interest in Medicine: An Ethicist's View of the Changing Landscape

Stephen M. Weiner, JD

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C.

Conflicts of Interest: The Public Policy, the Science, and the Professional Standards

Physician Burnout: How to Survive and Stay Happy in Oncology

Location: E353

CME credit: 1.25

Track(s): Professional Development

Tait D. Shanafelt, MD—Chair

Mayo Clinic

Physician Burnout: What Is It? What Are the Consequences, and How Do We Recognize It in Ourselves or Our Colleagues?

Charles M. Balch, MD, FACS

The Johns Hopkins University

Recognizing Risk Factors for Physician Burnout and Developing Strategies to Intervene

Amanda Kracen, MS

Virginia Commonwealth University

Prevention of Physician Burnout

Monday, June 7, 2010

3:00 PM - 4:15 PM

CLINICAL PROBLEMS IN ONCOLOGY

Neuro-oncology for Medical Oncologists (C15)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Central Nervous System Tumors

Lisa Marie DeAngelis, MD—Chair

Memorial Sloan-Kettering Cancer Center

Neurology Perspective

Roger Stupp, MD

University of Lausanne Hospital

Medical Oncology Perspective

MONDAY

3:00 PM - 4:30 PM
CLINICAL SCIENCE SYMPOSIUM

Circulating Tumor Cells in Breast Cancer: Where Are We?

Location: N Hall B1

CME credit: 1.5

Track(s): Breast Cancer

Suzanne D. Conzen, MD—Co-Chair

The University of Chicago

Minetta C. Liu, MD—Co-Chair

Georgetown University Hospital

Discussion

- 3:00 PM** John W. Park, MD
 University of California, San Francisco
- 3:15 PM** **Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. (Abstract #1000)**
 A. Giordano, M. Giuliano, L. Hsu, B. C. Handy, N. T. Ueno, E. Andreopoulou, R. H. Alvarez, V. Valero, G. N. Hortobagyi, M. Cristofanilli
- 3:30 PM** **Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study. (Abstract #1001)**
 A. Bardia, P. Huang, Z. Zhang, L. Sokoll, J. N. Ingle, L. A. Carey, N. U. Lin, R. Nanda, K. Visvanathan, A. C. Wolff, on behalf of the Translational Breast Cancer Research Consortium (TBCRC)
- 3:45 PM** **Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results. (Abstract #1002)**
 S. Greenberg, J. W. Park, M. E. Melisko, A. Goga, M. M. Moasser, M. Anderson, J. H. Scott, L. A. Petrillo, D. H. Moore, H. S. Rugo
- 4:00 PM** **Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict increased risk for relapse: The SUCCESS trial. (Abstract #1003)**
 B. K. Rack, C. Schindlbeck, U. Andergassen, A. Schneeweiss, T. Zwingers, W. Lichtenegger, M. Beckmann, H. L. Sommer, K. Pantel, W. Janni, for the SUCCESS Study Group

Discussion

- 4:15 PM** Lyndsay Harris, MD (Abstracts #1000–1003)
 Yale University

Monday, June 7, 2010

3:00 PM - 5:30 PM
ORAL ABSTRACT SESSION

Lung Cancer—Metastatic

Location: E Hall D2

CME credit: 2.5

Track(s): Lung Cancer

Nithya Ramnath, MD—Co-Chair

University of Michigan

Lecia Sequist, MD—Co-Chair

Massachusetts General Hospital

3:00 PM **Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. (Abstract #7503)**
P. A. Janne, X. F. Wang, M. A. Socinski, J. Crawford, M. Capelletti, M. J. Edelman, M. A. Villalona-Calero, R. A. Kratzke, E. E. Vokes, V. A. Miller

3:15 PM **TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. (Abstract #7504)**
S. Lee, R. Rudd, I. Khan, S. Upadhyay, C. R. Lewanski, S. Falk, G. Skailles, R. Partridge, Y. Ngai, C. Boshoff

Discussion

3:30 PM Fadlo Raja Khuri, MD (Abstracts #7503–7505)
Winship Cancer Institute at Emory University
EGFR Inhibitors: Are We Done Yet?

3:45 PM **Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7506)**
C. P. Belani, D. M. Waterhouse, H. Ghazal, S. S. Ramalingam, R. Bordoni, R. Greenberg, R. M. Levine, J. M. Waples, Y. Jiang, G. Reznikoff

4:00 PM **Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. (Abstract #7507)**
M. Perol, C. Chouaid, B. J. Milleron, R. Gervais, F. Barlesi, V. Westeel, J. Crequit, H. Lena, A. Vergnenegre, D. Pérol

4:15 PM **International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial. (Abstract #7508)**
C. Gridelli, F. Ciardiello, R. Feld, C. A. Butts, V. Gebbia, G. Genestreti, A. G. Favaretto, R. Wierzbicki, C. Gallo, F. Perrone, on behalf of the TORCH Investigators

Discussion

4:30 PM Gregory Peter Kalemkerian, MD (Abstracts #7506–7508)
University of Michigan
Maintenance Therapy: Are We There Yet?

4:45 PM **Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial. (Abstract #7509)**
J. S. Temel, J. Greer, E. Gallagher, S. Admane, W. F. Pirl, V. Jackson, C. Dahlin, A. Muzikansky, J. Jacobsen, T. J. Lynch

5:00 PM **Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). (Abstract #LBA7511)**
M. A. Socinski, I. N. Bondarenko, N. A. Karaseva, A. Makhson, I. Vynnichenko, I. Okamoto, J. K. Hon, V. Hirsch, P. Bhar, J. Iglesias

Discussion

5:15 PM Raffit Hassan, MD (Abstract #7509–LBA7511)
National Cancer Institute
Optimizing Care in Advanced Lung Cancer

Monday, June 7, 2010

3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Gastrointestinal (Noncolorectal) Cancer

Location: E Hall D1

CME credit: 3

Track(s): Gastrointestinal (Noncolorectal) Cancer

Theodore S. Hong, MD—Co-Chair

Massachusetts General Hospital

Alexandria T. Phan, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

3:00 PM Effect of preoperative concurrent survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. (Abstract #4004)

A. V. Gaast, P. van Hagen, M. Hulshof, D. Richel, M. I. van Berge Henegouwen, G. A. Nieuwenhuijzen, J. T. Plukker, J. J. Bonenkamp, E. W. Steyerberg, H. W. Tilanus, CROSS study group

3:15 PM Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901. (Abstract #4005)

C. Mariette, J. F. Seitz, E. Maillard, F. Mornex, P. a. Thomas, J. Raoul, V. Boige, D. Pezet, C. Genet, L. Bedenne, Federation Francaise de Cancerologie Digestive

3:30 PM CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. (Abstract #4006)

P. C. Enzinger, B. Burtness, D. Hollis, D. Niedzwiecki, D. Ilson, A. B. Benson, R. J. Mayer, R. M. Goldberg

3:45 PM AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). (Abstract #LBA4007)

Y. Kang, A. Ohtsu, E. Van Cutsem, S. Y. Rha, A. Sawaki, S. Park, H. Lim, J. Wu, B. Langer, M. A. Shah

Discussion

4:00 PM Charles Fuchs, MD (Abstracts #4004–LBA4007)
Dana-Farber Cancer Institute

4:15 PM Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. (Abstract #4008)

S. Qin, Y. Bai, S. Ye, J. Fan, H. Lim, J. Y. Cho, S. Thongprasert, Y. Chao, K. Rau, Y. Sun

4:30 PM Effect of IFN therapy and amino acid substitutions in the hepatitis C virus (HCV) core region on hepatocarcinogenesis in HCV-related cirrhotic patients. (Abstract #4009)

M. Hirakawa, K. Ikeda, N. Akuta, Y. Kawamura, T. Hosaka, M. Kobayashi, F. Suzuki, Y. Suzuki, Y. Arase, H. Kumada

Discussion

4:45 PM Timothy Pawlik, MD, MPH (Abstracts #4008–4009)
The Johns Hopkins University

5:00 PM Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. (Abstract #4010)

T. Conroy, F. Desseigne, M. Ychou, M. Ducreux, O. Bouche, R. Guimbaud, Y. Becouarn, C. Montoto-Grillot, S. Gourgou-Bourgade, A. Adenis, FNCLCC-FFCD PRODIGE Group

- 5:15 PM** **Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #LBA4011)**
S. H. Boeck, U. Vehling-Kaiser, D. Waldschmidt, E. Kettner, A. Märten, C. Winkelmann, S. Klein, G. Kojouharoff, A. Jung, V. Heinemann
- 5:30 PM** **CapRI: Final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon- α -2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC). (Abstract #LBA4012)**
A. Marten, J. Schmidt, J. Debus, S. Harig, K. Lindel, J. Klein, D. K. Bartsch, L. Capussotti, C. Zülke, M. Buchler

Discussion

- 5:45 PM** Margaret A. Tempero, MD (Abstracts #4010–LBA4012)
University of California, San Francisco

Monday, June 7, 2010

3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Head and Neck Cancer

Location: E354b

CME credit: 3

Track(s): Head and Neck Cancer

Søren M. Bentzen, MD—Co-Chair

University of Wisconsin

A. Dimitrios Colevas, MD—Co-Chair

Stanford University

3:00 PM Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). (Abstract #5503)

S. A. Wells, B. G. Robinson, R. F. Gagel, H. Dralle, J. A. Fagin, M. Santoro, E. Baudin, J. R. Vasselli, J. Read, M. Schlumberger

3:15 PM Phase II trial of sunitinib in medullary thyroid cancer (MTC). (Abstract #5504)

J. A. De Souza, N. Busaidy, A. Zimrin, T. Y. Seiwert, V. M. Villaflor, K. B. Poluru, P. L. Reddy, J. Nam, E. E. Vokes, E. E. Cohen

3:30 PM Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5505)

K. J. Harrington, A. Berrier, M. Robinson, E. Remenar, M. Housset, F. Hurtado de Mendoza, N. Compton, M. Lau, P. Legenne, R. Kumar

3:45 PM An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE). (Abstract #LBA5506)

J. H. Machiels, S. Subramanian, A. Ruzsa, G. Repassy, I. Lifrenko, A. Flygare, P. Sorensen, E. Ehrnrooth, O. Baadsgaard, P. M. Clement

Discussion

4:00 PM A. Dimitrios Colevas, MD (Abstracts #5503–LBA5506)
Stanford University

4:15 PM A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome. (Abstract #5507)

K. Ang, Q. Zhang, R. H. Wheeler, D. I. Rosenthal, F. Nguyen-Tan, H. Kim, C. Lu, R. S. Axelrod, C. I. Silverman, R. S. Weber

4:30 PM Postoperative accelerated radiotherapy (POPART) versus conventional postoperative radiotherapy (CPORT) in squamous cell head and neck cancer: A multicenter prospective randomized study of the Dutch Head and Neck Cooperative Study Group. (Abstract #5508)

J. A. Langendijk, J. H. Kaanders, P. Doornaert, F. R. Burlage, P. L. van den Ende, S. B. Oei, R. B. Keus, S. Nuyts, C. R. Leemans, C. H. Terhaard, Dutch Head and Neck Cancer Research Group

Discussion

4:45 PM Søren M. Bentzen, MD (Abstracts #5507–5508)
University of Wisconsin

5:00 PM Prognostic significance of interleukin-8 (IL-8) and hepatocyte growth factor (HGF) in patients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on a phase III trial. (Abstract #5509)

D. Rischin, R. Fisher, K. Oliner, R. J. Young, H. Cao, G. A. McArthur, L. J. Peters, B. O'Sullivan, Q. Le

5:15 PM **Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003. (Abstract #5510)**
M. L. Gillison, Q. Zhang, K. Ang, K. K. Fu, M. E. Hammond, R. Jordan, A. Trotti, S. Spencer, M. Rotman, C. H. Chung

5:30 PM **PTEN as prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck. (Abstract #5519)**
M. P. Snietura, M. Jaworska, J. Mlynarczyk-Liszka, W. Piglowski, G. Wozniak, D. Lange, R. Suwinski

Discussion

5:45 PM Ezra E. W. Cohen, MD, FRCPC (Abstracts #5509, 5510, 5519)
The University of Chicago

Monday, June 7, 2010

3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Tumor Biology

Location: S100a

CME credit: 3

Track(s): Tumor Biology

Robert Arthur Kratzke, MD—Co-Chair

University of Minnesota

Jorge Reis-Filho, MD, PhD—Co-Chair

Breakthrough Breast Cancer Research Centre

- 3:00 PM Use of gene expression signatures to identify origin of primary and therapeutic strategies for patients with advanced solid tumors. (Abstract #10504)**
S. D. Hsu, M. K. Kim, A. Foye, A. Silvestri, H. K. Lyerly, M. Morse, E. Petricoin III, P. G. Febbo
- 3:15 PM Comparative analysis of the chromosomal origins of circulating nucleic acids in breast and prostate cancer. (Abstract #10505)**
E. Schütz, J. Beck, W. M. Mitchell, H. B. Urnovitz
- 3:30 PM Use of integrated genomic analysis to evaluate BRCA-associated protein 1 (BAP1) as a mutated gene in malignant pleural mesothelioma (MPM). (Abstract #10506)**
M. J. Bott, M. Brevet, B. S. Taylor, S. Shimizu, T. Ito, Q. Zhou, A. Olshen, M. F. Zakowski, V. W. Rusch, M. Ladanyi
- 3:45 PM Characterizing the clinical relevance of epithelial-mesenchymal transition (EMT) in human tumors. (Abstract #10507)**
K. A. Higgins, K. S. Walters, A. Potti

Discussion

- 4:00 PM** David N. Hayes, MD (Abstracts #10504–10507)
University of North Carolina
- 4:15 PM Pre-existence of invasive cells in breast ductal carcinoma in situ. (Abstract #10508)**
V. A. Espina, R. I. Gallagher, B. D. Mariani, K. Tran, C. Mueller, S. Banks, L. Pastore, K. H. Edmiston, L. A. Liotta
- 4:30 PM Relationship of breast cancer stem cells (CSCs) and chronic O₂/glucose deprivation (C-OGD). (Abstract #10509)**
M. Quintela-Fandino, E. Arpaia, R. Cairns, H. Blaser, M. W. Tusche, R. Colomer, A. Rufini, A. Wakeham, T. W. Mak

Discussion

- 4:45 PM** Sridhar Ramaswamy, MD (Abstracts #10508–10509)
Massachusetts General Hospital
- 5:00 PM Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers. (Abstract #10510)**
T. A. Grushko, C. Nwachukwu, S. Charoenthammaraksa, D. Huo, A. Khramtsov, H. Mashek, C. Zhang, J. Xu, C. M. Perou, O. I. Olopade
- 5:15 PM PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. (Abstract #10511)**
S. Loibl, B. Mueller, G. Von Minckwitz, J. U. Blohmer, A. d. Bois, J. B. Huober, F. Fend, J. Budczies, C. Denkert
- 5:30 PM Protein signal pathway mapping of human breast cancer from I-SPY: Correlations with response and genomic subtyping. (Abstract #10512)**
J. D. Wulfkühle, M. E. Lenburg, M. Pierobon, J. Illi, J. Zhu, A. DeMichele, V. A. Espina, L. A. Liotta, L. Esserman, E. Petricoin III, I-SPY Investigators

Discussion

- 5:45 PM** James M. Ford, MD (Abstracts #10510–10512)
Stanford University Medical Center

4:45 PM - 6:00 PM
SPECIAL SESSION

From the Cancer Genome to Patients with Cancer: The Next Generation of Innovation—An ASCO/American Association for Cancer Research Joint Session

Location: S404

CME credit: 1.25

Track(s): Special Session; Cancer Genetics

Douglas W. Blayney, MD—Co-Chair

University of Michigan

Welcome and Introduction

Tyler Jacks, PhD—Co-Chair

Massachusetts Institute of Technology Center for Cancer Research

Conclusion

Stephen B. Gruber, MD, PhD

University of Michigan

Next-generation Sequencing and Clinical Applications

Jeffrey M. Trent, PhD

TGen/VARI

System Medicine in Cancer Therapeutics

A. John Iafrate, MD, PhD

Massachusetts General Hospital

Challenges in Clinical Tumor Genotyping Applications

Monday, June 7, 2010

4:45 PM - 6:00 PM
EDUCATION SESSIONS

Biology and Treatment of Breast Cancer in Survivors of Pediatric Cancer

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology; Breast Cancer

Tara O. Henderson, MD, MPH—Chair

The University of Chicago

Overview of Breast Cancer Incidence in Pediatric Cancer Survivors with a Focus on Education and Screening

Gail E. Tomlinson, MD, PhD

University of Texas Health Science Center at San Antonio

Update on the Genetics of Pediatric Survivors Who Develop Breast Cancer and Tumor Biology

Melanie R. Palomares, MD

City of Hope National Medical Center

Use of Tamoxifen in Hodgkin's Patients for the Prevention of Breast Cancer

Decision-making Capacity: When Should Oncologists Honor Refusals of Treatment by Individuals with Diminished Capacity?

Location: S100b

CME credit: 1.25

Track(s): Ethics; Geriatric Oncology; Pediatric Oncology

Rebecca D. Pentz, PhD—Chair

Winship Cancer Institute at Emory University

Cancer Patients with Diminished Capacity: Ethical Dilemmas and Strategies for Resolving Them

Scott Y. Kim, MD, PhD

University of Michigan

Overview of Criteria for and Methods of Determining Capacity

Steven Joffe, MD, MPH

Dana-Farber Cancer Institute

Lessons from Pediatrics

Oral Chemotherapy: A Hard Pill to Swallow

Location: S406 (Vista Room)

CME credit: 1.25

Track(s): Developmental Therapeutics; Health Services Research; Patient and Survivor Care

Merrill J. Egorin, MD—Chair

University of Pittsburgh Cancer Institute

General Issues Relevant to Oral Chemotherapy and Patient Health Care Literacy

Jan Hendrik Beumer, PhD, PharmD

University of Pittsburgh

Drug-Drug and Food-Drug Interactions Relevant to Oral Chemotherapy Agents

Ann H. Partridge, MD

Dana-Farber Cancer Institute

Adherence and Persistence (Or Lack Thereof) with Oral Agents: The Scope of the Problem—What the Data Say

MONDAY

4:45 PM - 6:00 PM
CLINICAL PROBLEMS IN ONCOLOGY

Advances in Hereditary Pancreatic Cancer (C13)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Cancer Genetics; Gastrointestinal (Noncolorectal) Cancer

Teresa Brentnall, MD—Chair

University of Washington

Pancreatic Cancer Screening

Ralph Hruban, MD

The Johns Hopkins University

Genetics of Hereditary Pancreatic Cancer

Sean J. Mulvihill, MD

University of Utah

Surgical Management and Hereditary Pancreatic Cancer

6:30 PM - 9:00 PM
SPECIAL SESSION

Answers to Cancer: Annual Meeting Public Forum

Location: Sheraton Chicago Hotel & Towers, Chicago Ballroom 10

CME credit: 0

Track(s): Special Session

Tuesday, June 8, 2010

**7:30 AM - 9:00 AM
HIGHLIGHTS OF THE DAY**

Highlights of the Day III

Location: E Hall D1

CME credit: 1.5

Track(s): Special Session; General Oncology

Kathy Miller, MD—Chair

Indiana University

7:30 AM

Kathy Miller, MD

Indiana University

Breast Cancer—Local-Regional and Adjuvant Therapy

7:45 AM

Charles M. Rudin, MD, PhD

The Johns Hopkins University

Lung Cancer—Metastatic

8:00 AM

Gary K. Schwartz, MD

Memorial Sloan-Kettering Cancer Center

Sarcoma

8:15 AM

Charles D. Blanke, MD

University of British Columbia/British Columbia Cancer Agency

Gastrointestinal (Noncolorectal) Cancer

8:30 AM

Everett E. Vokes, MD

The University of Chicago

Head and Neck Cancer

8:45 AM

To be determined

Leukemia, Myelodysplasia, and Transplantation

TUESDAY

8:00 AM - 9:15 AM
EDUCATION SESSIONS

Building Bridges for Successful Breast Cancer Survivorship Care

Location: E354a

CME credit: 1.25

Track(s): Breast Cancer; Geriatric Oncology; Patient and Survivor Care

Claire Frances Snyder, PhD—Chair

The Johns Hopkins University School of Medicine

Coordination of Care in Breast Cancer Survivors: An Overview

Sharon Hermes Giordano, MD

University of Texas M. D. Anderson Cancer Center

Impact of Comorbid Conditions on Breast Cancer Survivorship

Larissa Nekhlyudov, MD, MPH

Harvard Medical School

Information and Training Needs of Primary Care Providers to Promote Quality Care for Breast Cancer Survivors

Eva Grunfeld, MD, D.Phil

University of Toronto

Communication Strategies, Models, and Tools for Partnerships between Primary Care and Oncology Care to Provide Quality Breast Cancer Survivorship Care

Comparative Effectiveness Research in Oncology: Opportunities and Challenges

Location: S404

CME credit: 1.25

Track(s): Health Services Research; Patient and Survivor Care

Neal J. Meropol, MD—Chair

University Hospitals Case Medical Center

Comparative Effectiveness Research to Address Uncertainties in Oncology Practice

Gary H. Lyman, MD, MPH

Duke Comprehensive Cancer Center

Comparative Effectiveness Research: What Is It and Why Is It Important?

Jerome Seidenfeld, PhD

American Society of Clinical Oncology

Methods of Comparative Effectiveness Research in Oncology

Developing Drugs in Special Populations: Organ Dysfunction Studies

Location: E354b

CME credit: 1.25

Track(s): Developmental Therapeutics; Clinical Trials; Gastrointestinal (Noncolorectal) Cancer

Daniel Mulkerin, MD—Chair

University of Wisconsin

Renal Dysfunction Studies

Ghassan K. Abou-Alfa, MD

Memorial Sloan-Kettering Cancer Center

Liver Dysfunction Studies

Shiew-Mei Huang, PhD

U.S. Food and Drug Administration

Regulatory Considerations for Organ Dysfunction Studies

Tuesday, June 8, 2010

Early-stage Non-small Cell Lung Cancer: Staging and Primary Treatment

Location: E353

CME credit: 1.25

Track(s): Lung Cancer; General Oncology

Harvey I. Pass, MD—Chair

New York University School of Medicine

Lobectomies for Small or Noninvasive Lung Cancers: Going, Going, Gone?

Scott Shofer, MD, PhD

Duke University Medical Center

Nonsurgical Staging of the Mediastinum

Andrea Bezzak, MD

Princess Margaret Hospital

Outcome of Early-stage NSCLC Treated with SBRT

Localized Prostate Cancer: Reducing Mortality and Burden of Therapy

Location: E Arie Crown Theater

CME credit: 1.25

Track(s): Genitourinary Cancer; Geriatric Oncology; Health Services Research

Andrew J. Stephenson, MD—Chair

Cleveland Clinic

Everything You Need to Know about Prostate Cancer Screening

David C. Miller, MD

University of Michigan

Elevated PSA: Biopsy or Chemoprevention?

Laurence Klotz, MD, FRCSC

Stony Brook University Cancer Center

What Is "Active Surveillance" and What Is Its Role in Management Today?

Omics: Toward Personalizing Care

Location: S100a

CME credit: 1.25

Track(s): Tumor Biology

Dimitrios Spentzos, MD—Chair

Beth Israel Deaconess Medical Center

From High-throughput Transcriptomics to Personalized Cancer Care

Kate Nathanson, MD, FACP

University of Pennsylvania

The Genomics and Genetics of Melanoma

Gordon B. Mills, MD

University of Texas M. D. Anderson Cancer Center

Proteomics Pathway Analysis for Tumor Classification and Therapy (Focus on Breast and Ovary)

TUESDAY

Selection of Endpoints in Clinical Trials: From Bench to Trials to Practice

Location: S100b

CME credit: 1.25

Track(s): Clinical Trials; Developmental Therapeutics

Christopher M. Booth, MD—Chair

Queen's University

Translating Clinical Trial Results into Societal Benefit: The Role of Population-based Outcome Studies

Carlos Cordon-Cardo, MD, PhD

Columbia University

Use of Molecular Markers as Surrogate Endpoints in Clinical Trials

Mary W. Redman, PhD

Fred Hutchinson Cancer Research Center

Design of Clinical Trials to Achieve Meaningful Results

Tuesday, June 8, 2010

8:00 AM - 9:15 AM

CLINICAL PROBLEMS IN ONCOLOGY

Debates in Adjuvant Therapy: Chemotherapy versus Observation for Node-negative Non-small Cell Lung Cancer and Radiotherapy versus Observation for Node-positive Non-small Cell Lung Cancer (C17)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Lung Cancer

Heather A. Wakelee, MD—Chair

Stanford University

Neoadjuvant versus Adjuvant Chemotherapy for Early-stage Non-small Cell Lung Cancer: Does Pre versus Post Really Matter?

Katherine Pisters, MD

University of Texas M. D. Anderson Cancer Center

Is There a Role for Adjuvant Chemotherapy for Node-negative Non-small Cell Lung Cancer?

Christopher Ryan Kelsey, MD

Duke University Medical Center

When Should One Consider Adjuvant Radiotherapy for Resected Non-small Cell Lung Cancer?

TUESDAY

**8:00 AM - 12:00 PM
POSTER DISCUSSION SESSION**

Gastrointestinal (Colorectal) Cancer

Display Time: 8:00 AM - 12:00 PM

Display Location: S403

Discussion Time: 11:00 AM - 12:00 PM

Discussion Location: S406 (Vista Room)

CME credit: 1

Track(s): Gastrointestinal (Colorectal) Cancer

Richard Herrmann, MD—Co-Chair

University Hospital

John S. Kauh, MD—Co-Chair

Winship Cancer Institute at Emory University

Discussion

11:00 AM Bruce D. Minsky, MD (Abstracts #3509–3512)
The University of Chicago

Discussion

11:15 AM Patrick Johnston, MD, PhD (Abstracts #3513–3519)
Queen's University Belfast

Discussion

11:30 AM To be determined

Discussion

11:45 AM Wells A. Messersmith, MD (Abstracts #3525–3535)
University of Colorado

Brd. 1 **A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS). (Abstract #3509)**

S. Ngan, R. Fisher, D. Goldstein, M. Solomon, B. Burmeister, S. P. Ackland, D. J. Joseph, B. McClure, S. McLachlan, J. Mackay, TROG, AGITG, CSSANZ, RACS

Brd. 2 **Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) of uT2uN0 rectal cancer (RC) treated by local excision (LE): Results of the ACOSOG Z6041 trial. (Abstract #3510)**

J. Garcia-Aguilar, Q. Shi, C. R. Thomas Jr., E. Chan, P. Cataldo, J. Marcet, D. Medich, A. Pigazzi, S. Oommen, M. Posner, ACOSOG

Brd. 3 **Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. (Abstract #3511)**

D. Schrag, M. R. Weiser, K. A. Goodman, M. Gonen, A. Cercek, D. L. Reidy, L. K. Temple, W. D. Wong, P. Paty, L. Saltz

Brd. 4 **Identification of localized rectal cancer (RC) patients (pts) who may not require preoperative (preop) chemoradiation (CRT). (Abstract #3512)**

D. Roda, M. Frasson, E. Garcia-Granero, S. Roselló, B. Flor, E. Rodríguez, P. Esclapez, S. Campos, S. García-Botello, A. Cervantes-Ruiperez

Brd. 5 **Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. (Abstract #3513)**

R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, M. Snel, I. Simon, K. Janssen, H. Friess

Brd. 6 **Genome-wide association study for germline prognostic markers in colorectal cancer. (Abstract #3514)**

A. Walthers, E. Domingo, D. Mesher, E. Johnstone, T. Orntoft, P. Sasieni, M. Dunlop, S. Tejpar, D. J. Kerr, I. Tomlinson, Victor Trial Steering Group and Petacc TR Steering Group

- Brd. 7 Metachronous colorectal cancer in mismatch repair gene mutation carriers: The advantage of more extensive surgery. (Abstract #3515)**
S. Parry, A. Win, F. Macrae, B. Parry, N. M. Lindor, S. Gallinger, J. L. Hopper, M. A. Jenkins, Colon Cancer Family Registry
- Brd. 8 Use of a combination of prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy. (Abstract #3516)**
K. L. Pogue-Geile, G. A. Yothers, P. Gavin, D. Fumagalli, C. Kim, L. H. Colangelo, C. E. Geyer, M. J. O'Connell, N. Wolmark, S. Paik
- Brd. 9 Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. (Abstract #3517)**
G. Hutchins, K. Southward, K. Handley, L. Magill, C. Beaumont, S. Richman, M. T. Seymour, D. J. Kerr, R. G. Gray, P. Quirke, for the QUASAR Collaborative Group
- Brd. 10 Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC). (Abstract #3518)**
G. P. Kim, S. Marsoni, G. Monges, C. J. Allegra, S. N. Thibodeau, S. R. Hamilton, B. Kabat, G. A. Yothers, S. Gallinger, D. J. Sargent
- Brd. 11 DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials. (Abstract #3519)**
F. Sinicrope, N. R. Foster, D. J. Sargent, S. Gallinger, P. Benatti, S. Marsoni, G. Monges, R. Labianca, M. J. O'Connell, C. J. Allegra
- Brd. 12 Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials. (Abstract #3520)**
C. D. Blanke, B. M. Bot, D. M. Thomas, A. Bleyer, C. Kohne, M. T. Seymour, A. De Gramont, R. M. Goldberg, D. J. Sargent, LIVESTRONG Young Adult Alliance (LSYAA)
- Brd. 13 Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS). (Abstract #3521)**
D. G. Haller, J. Cassidy, J. Taberero, J. A. Maroun, F. G. De Braud, T. J. Price, E. Van Cutsem, M. Hill, F. Gilberg, H. Schmoll
- Brd. 14 FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial. (Abstract #3522)**
C. Tournigand, T. Andre, J. Bachet, L. Teixeira, C. Boni, P. R. Clingan, T. Hickish, J. Taberero, A. De Gramont, for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators and GERCOR
- Brd. 15 Benefits and adverse events (AEs) in younger (Y) (age <50) versus older patients (pts) receiving adjuvant chemotherapy (AT) for colon cancer (CC): Findings from the 33,574 pt ACCENT dataset. (Abstract #3523)**
D. J. Sargent, G. A. Yothers, E. Green, C. D. Blanke, M. J. O'Connell, R. Labianca, A. Bleyer, A. De Gramont, D. M. Thomas, A joint project of the LIVESTRONG Young Adult Alliance and the ACCENT Collaborative Group
- Brd. 16 Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors. (Abstract #3524)**
L. Teixeira, T. Hickish, C. Tournigand, J. Bachet, A. Bonetti, F. Rivera, C. Boni, J. Taberero, T. Andre, A. De Gramont, for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators and GERCOR

- Brd. 17 Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial. (Abstract #3525)**
R. Adams, R. H. Wilson, M. T. Seymour, A. M. Meade, A. Madi, J. Cassidy, D. Fisher, S. Kenny, R. S. Kaplan, T. S. Maughan, COIN Trial Investigators
- Brd. 18 A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10. (Abstract #3527)**
L. E. McCahill, G. A. Yothers, S. Sharif, N. J. Petrelli, S. Lopa, M. J. O'Connell, N. Wolmark
- Brd. 19 Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). (Abstract #3528^)**
J. Douillard, J. Cassidy, J. Jassem, F. Rivera, I. Kocáková, W. Rogowski, J. R. Canon, E. P. Yanez, F. Xu, J. L. Gansert
- Brd. 20 Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). (Abstract #3529^)**
T. J. Price, A. F. Sobrero, G. Wilson, E. Van Cutsem, B. Aleknaviciene, A. Zaniboni, J. T. Hartmann, Y. Tian, J. L. Gansert, M. Peeters
- Brd. 21 Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC). (Abstract #3530)**
J. C. Bendell, L. L. Hart, I. Firdaus, I. Gore, R. C. Hermann, H. M. Mackey, R. A. Graham, K. Zerivitz, J. A. Low, J. Berlin
- Brd. 22 Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC). (Abstract #3531)**
D. A. Richards, J. J. Nemunaitis, S. J. Vukelja, C. T. Hagenstad, L. T. Campos, J. P. Letzer, R. C. Hermann, P. Sportelli, L. R. Gardner, J. C. Bendell
- Brd. 23 A randomized phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results. (Abstract #3532)**
J. R. Hecht, T. Yoshino, E. P. Mitchell, M. S. Dees III, A. M. Countouriotis, E. C. Maneval, A. Kretschmar
- Brd. 24 DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer. (Abstract #3533)**
A. J. Weickhardt, T. J. Price, N. Pavlakis, E. Skrinos, A. Dobrovic, R. Salemi, A. M. Scott, J. Mariadason, G. Chong, N. C. Tebbutt
- Brd. 25 Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC). (Abstract #3535)**
I. Altomare, K. B. Russell, H. E. Uronis, M. Morse, S. D. Hsu, Y. Zafar, J. C. Bendell, A. Starodub, W. Honeycutt, H. Hurwitz

Tuesday, June 8, 2010

8:00 AM - 12:00 PM
POSTER DISCUSSION SESSION

Patient and Survivor Care

Display Time: 8:00 AM - 12:00 PM
Display Location: E450a
Discussion Time: 11:00 AM - 12:00 PM
Discussion Location: E353
CME credit: 1
Track(s): Patient and Survivor Care

Amy Pickar Abernethy, MD—Co-Chair

Duke University Medical Center

Janet Lee Abraham, MD—Co-Chair

Dana-Farber Cancer Institute

Discussion

11:00 AM Michael Fisch, MD, MPH (Abstracts #9017–9022)
University of Texas M. D. Anderson Cancer Center

Discussion

11:15 AM Vered Stearns, MD (Abstracts #9023–9028)
The Johns Hopkins University

Discussion

11:30 AM Charles L. Loprinzi, MD (Abstracts #9029–9034)
Mayo Clinic

Discussion

11:45 AM Frederick J. Meyers, MD (Abstracts #9035–9041)
University of California, Davis

Brd. 1 **Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5. (Abstract #9017)**

S. L. Wolf, R. Qin, S. P. Menon, K. M. Rowland, J. W. Kugler, P. J. Flynn, D. Christian, D. Satele, J. L. Berenberg, C. L. Loprinzi

Brd. 2 **Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993). (Abstract #9018)**

P. J. Atherton, K. N. Burger, C. L. Loprinzi, R. C. Miller, A. Jatoi, J. A. Sloan

Brd. 3 **CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. (Abstract #9019)**

G. Deplanque, J. Chavaillon, A. Vergnenegre, L. Falchero, G. Fraboulet, R. Gervais, B. Taviot, P. J. Souquet, C. Robert, O. Chosidow

Brd. 4 **Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial. (Abstract #9020)**

R. M. Navari, S. E. Gray, A. C. Kerr

Brd. 5 **Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting. (Abstract #9021[^])**

S. M. Grunberg, D. T. Chua, A. Maru, S. DeVandry, J. A. Boice, J. Hardwick, A. Taylor, A. Carides, F. Roila, J. Herrstedt, PN017 Study Group

Brd. 6 **To be determined**

Brd. 7 **A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors. (Abstract #9023)**

L. Bordeleau, O. Jugovic, M. Ennis, K. I. Pritchard, D. Warr, R. Haq, C. L. Loprinzi, P. J. Goodwin

Brd. 8 **A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA. (Abstract #9024)**

C. L. Loprinzi, E. P. Balcueva, H. Liu, L. A. Kottschade, P. J. Stella, M. D. Carlson, D. F. Moore Jr., R. Zon, R. Levitt, J. A. Sloan

- Brd. 9** **Phase II study of gonadotropin-releasing hormone analogue for ovarian function preservation in hematopoietic stem cell transplantation patients. (Abstract #9025)**
Y. Cheng, M. Takagi, A. Milbourne, R. E. Champlin, N. T. Ueno
- Brd. 10** **Value of early referral to improve fertility preservation outcomes in women with breast cancer. (Abstract #9026)**
K. Oktay, S. Lee, S. Ozkavukcu, E. Heytens, R. M. Alappat
- Brd. 11** **Impact of 12 months of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC): A matched cohort study. (Abstract #9027)**
S. M. Alibhai, S. Marzouk, G. Naglie, I. Tannock, G. A. Tomlinson, N. Timilshina, D. Stewart, N. Fleshner, P. R. Warde, S. Duff Canning
- Brd. 12** **The incidence of potential medication interactions including herbs and supplements among breast and prostate cancer patients during and after systemic anticancer therapy. (Abstract #9028)**
N. Kwon, R. T. Lee, M. Ray, R. Z. Szmulewitz, J. H. Von Roenn, W. M. Stadler, F. C. Curlin
- Brd. 13** **Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare) for chemotherapy-induced peripheral neuropathy. (Abstract #9029)**
T. J. Smith, P. J. Coyne, P. Dodson, G. L. Parker, V. Ramakrishnan
- Brd. 14** **Signs and symptoms of peripheral neuropathy in adult survivors of childhood acute lymphoblastic leukemia (ALL): Associations with physical performance and chemotherapy doses. (Abstract #9030)**
K. K. Ness, M. M. Hudson, C. Pui, D. M. Green, R. Karlage, L. L. Robison, E. B. Morris
- Brd. 15** **Comparison of in-dwelling catheters and talc pleurodesis in the management of malignant pleural effusions. (Abstract #9031)**
T. L. Demmy, L. Gu, J. E. Burkhalter, E. M. Toloza, T. A. D'Amico, S. Sutherland, X. F. Wang, L. Archer, L. J. Veit, L. Kohman, for the Cancer and Leukemia Group B
- Brd. 16** **Use of postoperative venous thromboembolism to predict disease-specific survival in cancer patients. (Abstract #9032)**
R. A. Auer, A. S. Scheer, J. I. McSparron, A. R. Schulman, S. Tuorto, M. Gonen, J. Gonsalves, Y. Fong
- Brd. 17** **Comparison of venous thromboemboli (VTE) incidence in cancer patients who are on statin therapy versus those not on statin therapy. (Abstract #9033)**
T. A. Giever, K. M. Adwan, Y. Cheng, E. L. Atallah
- Brd. 18** **Screening for cardiac dysfunction and cardiovascular risk factors in childhood cancer survivors using the Children's Oncology Group (COG) Long-term Follow-up (LTFU) Guidelines. (Abstract #9034)**
S. Armenian, W. Landier, C. Sun, J. Lee, M. Zomorodi, L. Francisco, K. Wilson, S. Bhatia
- Brd. 19** **Quality of life and symptoms in long-term survivors (LTS) of colorectal cancer (CRC): Results from NSABP protocol LTS-01. (Abstract #9035)**
H. Kunitake, P. Zheng, G. A. Yothers, S. R. Land, L. Petersen, L. Fehrenbacher, J. K. Giguere, D. L. Wickerham, C. Y. Ko, P. A. Ganz
- Brd. 20** **Quality-of-life results of an EORTC phase III randomized trial of adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases of solid tumors. (Abstract #9036)**
R. Soffietti, R. P. Mueller, M. U. Abacioglu, S. Villa, F. Fauchon, B. Baumert, L. Fariselli, G. Tridello, M. Kocher, A. Bottomley
- Brd. 21** **Cancer outcomes at end of life in Michigan. (Abstract #9037)**
M. Darwish-Yassine, S. Affholter, J. Towns, J. W. Finn

Tuesday, June 8, 2010

- Brd. 22 Predictors of patient misunderstanding of the goals of care at initiation of chemotherapy. (Abstract #9038)**
I. T. Lennes, J. S. Temel, C. Hoedt, P. J. Saylor, T. M. Ortiz, S. Admane, E. B. Lamont
- Brd. 23 Hope, optimism, and survival in a randomized trial of first-line chemotherapy for patients with metastatic colorectal cancer. (Abstract #9039)**
P. Schofield, M. Stockler, D. Zannino, N. Wong, D. Ransom, E. Moylan, R. J. Simes, T. J. Price, N. C. Tebbutt, M. Jefford, Australasian Gastrointestinal Trials Group (AGITG)
- Brd. 24 Patient-reported outcomes for determining prognostic groups in veterans with advanced cancer. (Abstract #9040)**
V. T. Chang, C. B. Scott, H. Yan, M. L. Gonzalez, J. Einhorn, B. Zhou, J. Cogswell, B. Crump, M. McPherson, B. Kasimis
- Brd. 25 Symptom burden in cancer survivors 1 year after diagnosis: A report from the American Cancer Society's studies of cancer survivors. (Abstract #9041)**
Q. Shi, T. Smith, J. D. Michonski, K. Stein, C. Kaw, C. S. Cleeland

TUESDAY

**8:00 AM - 12:00 PM
POSTER DISCUSSION SESSION**

Sarcoma

Display Time: 8:00 AM - 12:00 PM
 Display Location: S103
 Discussion Time: 11:00 AM - 12:00 PM
 Discussion Location: S100a
CME credit: 1
 Track(s): Sarcoma

Mark Agulnik, MD—Co-Chair
 Northwestern University
Anette Duensing, MD—Co-Chair
 University of Pittsburgh School of Medicine

Discussion

11:00 AM Ian Robert Judson, MD (Abstracts #10009–10014)
 Cancer Research UK

Discussion

11:15 AM Margaret von Mehren, MD (Abstracts #10015–10020)
 Fox Chase Cancer Center

Discussion

11:30 AM Rashmi Chugh, MD (Abstracts #10021–10026)
 University of Michigan

Discussion

11:45 AM James E. Butrynski, MD (Abstracts #10027–10033)
 Dana-Farber Cancer Institute

- Brd. 1** **Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma. (Abstract #10009)**
S. Schuetz, K. Wathen, E. Choy, B. L. Samuels, K. N. Ganjoo, A. P. Staddon, M. von Mehren, W. A. Chow, J. C. Trent, L. H. Baker
- Brd. 2** **Advanced phase I/II evaluation of tumor-targeted gene delivery: Intravenous retrovector encoding mutant anticyclin G1 as stand-alone therapy for chemotherapy-resistant bone and soft tissue sarcoma. (Abstract #10010)**
 K. N. Ganjoo, S. P. Chawla, V. S. Chua, L. Fernandez, D. V. Quon, A. Saralou, F. L. Hall, E. M. Gordon
- Brd. 3** **Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis. (Abstract #10011)**
V. Ravi, W. Wang, D. M. Araujo, J. A. Ludwig, R. J. Luke, V. O. Lewis, J. C. Trent, R. S. Benjamin, S. Patel
- Brd. 4** **Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). (Abstract #10012)**
 P. A. Cassier, S. Stacchiotti, H. Gelderblom, D. M. Thomas, W. Van Der Graaf, B. M. Seddon, D. Julien, A. J. Wagner, J. Blay
- Brd. 5** **Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF). (Abstract #10013)**
 M. M. Gounder, C. Antonescu, M. R. Hameed, D. R. D'Adamo, M. Keohan, S. Singer, M. F. Brennan, L. S. Ahn, R. G. Maki
- Brd. 6** **Sunitinib malate (SM) in alveolar soft part sarcoma (ASPS). (Abstract #10014)**
 E. Palassini, S. Stacchiotti, T. Negri, S. Brich, A. Marrari, C. Morosi, F. Crippa, A. Gronchi, S. Pilotti, P. G. Casali
- Brd. 7** **Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan. (Abstract #10015)**
 T. Nishida, A. Sawaki, T. Doi, Y. Yamada, Y. Komatsu, T. Kanda, Y. Kakeji, Y. Onozawa, M. Yamasaki, A. Ohtsu

Tuesday, June 8, 2010

- Brd. 8** **Nilotinib for patients with advanced GIST who failed imatinib and sunitinib: Negative effect of prior major gastrectomy on exposure to nilotinib. (Abstract #10016)**
K. Kim, M. Ryu, C. Yoo, B. Ryoo, D. Choi, H. Chang, J. Lee, T. Kim, M. Beck, Y. Kang
- Brd. 9** **Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. (Abstract #10017^)**
P. Reichardt, J. Blay, H. Gelderblom, M. Schlemmer, G. D. Demetri, N. Bin Bui, G. A. McArthur, S. Yazji, Y. Hsu, P. Rutkowski
- Brd. 10** **Validation of Joensuu risk criteria for primary resectable gastrointestinal stromal tumors. (Abstract #10018)**
P. Rutkowski, E. Bylina, A. Wozniak, Z. Nowecki, C. Osuch, M. Matlok, W. Michej, A. Pienkowski, H. Joensuu, W. Ruka
- Brd. 11** **Correlation of the topography of KIT exon 11 mutation with primary GIST location and predictive value for PFS in patients with advanced GIST: Results from the BFR14 randomized phase III trial of the French Sarcoma Group. (Abstract #10019)**
J. Blay, N. Bin Bui, P. A. Cassier, F. Duffaud, A. Adenis, F. Bertucci, J. Dhomont, J. Emile, P. Bringuier, A. Le Cesne, French Sarcoma Group-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO)
- Brd. 12** **Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib. (Abstract #10020)**
G. Floris, R. Sciot, A. Wozniak, C. Deroose, P. Vermaelen, B. Dewaele, M. Debiec-Rychter, P. Schoffski
- Brd. 13** **Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005. (Abstract #10021)**
M. L. Hensley, K. Wathen, R. G. Maki, D. M. Araujo, G. Sutton, D. A. Priebat, S. George, L. H. Baker
- Brd. 14** **Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large extremity soft tissue sarcomas. (Abstract #10022)**
J. T. Mullen, W. Kobayashi, D. C. Harmon, E. Choy, F. Hornicek, M. C. Gebhardt, D. S. Springfield, A. E. Rosenberg, I. J. Spiro, T. F. DeLaney
- Brd. 15** **A phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas. (Abstract #10023)**
S. S. Yoon, Y. Chen, D. Karl, E. Choy, D. C. Harmon, A. Kambadakone, D. Sahani, D. G. Duda, R. K. Jain, T. F. DeLaney
- Brd. 16** **Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study. (Abstract #10024)**
X. Garcia del Muro, A. Lopez-Pousa, J. Martin Broto, R. Cubedo, L. Jimenez Colomo, O. Gallego, M. Provencio-Pulla
- Brd. 17** **Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy. (Abstract #10025)**
A. Bertuzzi, E. M. Stroppa, S. Secondino, P. Pedrazzoli, P. Zucali, V. Quagliuolo, A. Comandone, U. Basso, H. J. Soto Parra, A. Santoro
- Brd. 18** **A stratified phase II trial investigating sorafenib (SORA) in patients (pts) with metastatic or locally advanced angiosarcoma (AS). (Abstract #10026)**
N. Penej, I. Ray-Coquard, A. Cioffi, E. Bompas, C. Chevreau, A. Italiano, J. Bay, N. Isambert, S. Clisant, J. Blay, French Sarcoma Group-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO)

- Brd. 19** **Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study. (Abstract #10027)**
B. L. Samuels, W. D. Tap, S. Patel, M. von Mehren, J. T. Hamm, P. E. Kaiser, S. Schuetze, J. Li, E. Bayever, G. D. Demetri
- Brd. 20** **Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose. (Abstract #10028)**
I. R. Judson, J. Blay, S. P. Chawla, J. A. Radford, A. Le Cesne, J. Verweij, M. von Mehren, J. Pontes, E. Bayever, G. D. Demetri
- Brd. 21** **Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr). (Abstract #10029)**
G. D. Demetri, J. Blay, P. Schoffski, R. G. Maki, A. J. Yovine, I. R. Judson, P. G. Casali, J. Gomez, E. Bayever, A. Le Cesne
- Brd. 22** **Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A retrospective analysis of 39 patients (pts) from three European institutions. (Abstract #10030)**
P. Dileo, R. Sanfilippo, F. Grosso, E. Fumagalli, J. Blay, J. Domont, A. Le Cesne, J. C. Tercero, P. G. Casali
- Brd. 23** **Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052). (Abstract #10031)**
P. Schoffski, I. L. Ray-Coquard, A. Cioffi, N. Bin Bui, S. Bauer, J. T. Hartmann, R. Sciot, J. Wanders, D. Druyts, P. Hohenberger, European Organization for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG)
- Brd. 24** **Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment—A French Sarcoma Group study. (Abstract #10032)**
I. L. Ray-Coquard, N. Bin Bui, A. Adenis, M. Rios Sr., F. Bertucci, S. Chabaud, D. Pérol, J. Blay, A. Le Cesne, Groupe Sarcome Francais-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO)
- Brd. 25** **Time to onset of progression after imatinib interruption and outcome of patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. (Abstract #10033)**
A. Le Cesne, I. Ray-Coquard, N. Bin Bui, A. Adenis, M. Rios Sr., F. Duffaud, F. Bertucci, S. Chabaud, J. Emile, J. Blay

Tuesday, June 8, 2010

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Lung Cancer—Local-Regional and Adjuvant Therapy

Display Time: 8:00 AM - 12:00 PM

Display Location: E450b

Discussion Time: 12:00 PM - 1:00 PM

Discussion Location: E354b

CME credit: 1

Track(s): Lung Cancer

Joseph Kamel Salama, MD—Co-Chair

The University of Chicago

Corey J. Langer, MD—Co-Chair

University of Pennsylvania

Discussion

12:00 PM John Heymach, MD, PhD (Abstracts #7008–7013)
University of Texas M. D. Anderson Cancer Center
Biomarkers in Early-stage Non-small Cell Lung Cancer: Has the Future Arrived?

Discussion

12:15 PM Jeffrey Bogart, MD (Abstracts #7014–7016)
SUNY Upstate Medical University
New Directions for Radiotherapy in Non-small Cell Lung Cancer

Discussion

12:30 PM William Roy Smythe, MD (Abstracts #7017–7020)
Texas A&M University
Surgical Perspective on Systemic Therapy for NSCLC and Mesothelioma

Discussion

12:45 PM Jessica S. Donington, MD (Abstracts #7021–7026)
New York University School of Medicine
Alternate Approaches to Advanced, Resectable Non-small Cell Lung Cancer

Brd. 1 **Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. (Abstract #7008)**

M. Capelletti, X. F. Wang, L. Gu, S. L. Graziano, R. A. Kratzke, G. M. Strauss, M. Maddaus, M. R. Green, E. E. Vokes, P. A. Janne

Brd. 2 **Initial results of LC-MAP: An institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma. (Abstract #7009)**

M. G. Kris, C. Y. Lau, D. Ang, E. Brzostowski, G. J. Riely, V. W. Rusch, S. Jhanwar, A. Lash, M. F. Zakowski, M. Ladanyi

Brd. 3 **Association of genetic variations in DNA-methyltransferases, histone-methyltransferases, and methylated DNA-binding proteins with recurrence and survival in early-stage non-small cell lung cancer treated with surgery alone or surgery and chemotherapy. (Abstract #7010)**

K. W. Wagner, Y. Ye, J. Lin, A. A. Vaporciyan, J. A. Roth, M. R. Spitz, X. Wu

Brd. 4 **Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. (Abstract #7011)**

S. P. D'Angelo, Y. Y. Janjigian, M. G. Kris, W. Pao, G. J. Riely, J. Marks, C. Sima, J. Dycoco, B. J. Park, C. G. Azzoli

Brd. 5 **Clinical relevance of insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression. (Abstract #7012)**

Y. Bellil, A. M. Burke, I. S. Chan, W. Mostertz, A. Potti

Brd. 6 **KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424. (Abstract #7013)**

P. C. Mack, M. W. Redman, K. Chansky, S. Matsumoto, W. S. Holland, P. Lara Jr., C. B. Ambrosone, D. R. Gandara

- Brd. 7 Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer (NSCLC). (Abstract #7014)**
 L. E. Coate, C. Massey, A. J. Hope, A. Pierre, A. Bezzak, N. B. Leighl, G. E. Darling, A. Sun, S. Keshavjee, F. A. Shepherd
- Brd. 8 A multinational pooled analysis of 434 cases of stage I non-small cell lung cancer (NSCLC) treated with volumetrically image-guided (VIGRT) stereotactic lung radiotherapy (SBRT): Results from the Elekta Collaborative Lung Research Group. (Abstract #7015)**
 I. S. Grills, A. J. Hope, M. Guckenberger, L. L. Kestin, M. Werner-Wasik, D. Yan, J. Sonke, J. Bissonnette, Y. Xiao, J. Belderbos
- Brd. 9 Thoracic radiation therapy in locally advanced NSCLC patients (pts) with EGFR mutations. (Abstract #7016)**
 R. H. Mak, E. Doran, A. Muzikansky, J. Kang, N. C. Choi, H. Willers, D. M. Jackman, L. V. Sequist
- Brd. 10 Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project. (Abstract #7017)**
 C. Zornosa, R. Mamet, M. E. Reid, D. S. Ettinger, G. A. Otterson, M. S. Rabin, J. Hayman, J. C. Niland, K. Pisters, NCCN Oncology Outcomes Database Non-small Cell Lung Cancer Disease-specific Executive Committee
- Brd. 11 Adoption of adjuvant chemotherapy for non-small cell lung cancer: A population-based outcomes study. (Abstract #7018)**
 C. M. Booth, F. A. Shepherd, Y. Peng, G. E. Darling, G. Li, W. Kong, W. J. Mackillop
- Brd. 12 A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIa non-small cell lung cancer (NSCLC): An interim preliminary result. (Abstract #7019)**
 H. Jie, Z. Xiangru, B. Han, Y. Liu, Q. Wang, S. Xu, Y. Sheng, Q. Li, S. Wu, C. Chen
- Brd. 13 IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. (Abstract #7020)**
 G. Zalcman, J. Margery, A. Scherpereel, P. Astoul, I. Monnet, B. J. Milleron, L. M. Paule, M. André, D. Moro-Sibilot, J. Mazieres, on behalf of IFCT
- Brd. 14 Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030). (Abstract #7021)**
 J. J. Fibla, S. D. Cassivi, P. A. Decker, M. S. Allen, G. E. Darling, R. J. Landreneau, R. J. McKenna Jr., D. R. Jones, R. I. Incelet, J. B. Putnam, ACOSOG Z0030 Study Group
- Brd. 15 The impact of stage migration on survival after resection in the UICC 7 TNM classification of lung cancer. (Abstract #7022)**
 J. P. Van Meerbeeck, K. Chansky, P. Goldstraw, IASLC Staging Committee
- Brd. 16 Prognostic significance of the number of tumor (+) N2 nodes in N2 stage IIIa non-small cell lung cancer after curative resection. (Abstract #7023)**
 C. Yoo, S. Yoon, D. Lee, C. Suh, J. Lee, S. Park, D. Kim, Y. Kim, W. Kim, S. Kim
- Brd. 17 RTOG 0229: A phase II trial of neoadjuvant therapy with concurrent chemotherapy and high-dose radiotherapy (XRT) followed by resection and consolidative therapy for LA-NSCLC. (Abstract #7024)**
 M. Suntharalingam, R. Paulus, M. J. Edelman, M. Krasna, W. Burrows, E. Gore, S. Yom, H. Choy

Tuesday, June 8, 2010

- Brd. 18** **Seven-year follow-up of preoperative chemoradiotherapy in superior sulcus tumor: Report of a Japan Clinical Oncology Group Trial (JCOG9806). (Abstract #7025)**
M. Tsuboi, H. Kunitoh, T. Shibata, H. Asamura, Y. Ichinose, N. Katakami, K. Nagai, T. Mitsudomi, A. Matsumura, N. Saijo, Lung Cancer Surgical Study Group of Japan Clinical Oncology Group (JCOG)
- Brd. 19** **Treatment for superior sulcus tumors (SST): Effect of surgery first followed by adjunct concurrent chemoradiotherapy on survival for patients with marginally resectable SST. (Abstract #7026)**
R. Komaki, X. Wei, P. Allen, J. A. Roth, S. Swisher, D. C. Rice, G. L. Walsh, F. V. Fossella, J. J. Erasmus, J. D. Cox

TUESDAY

**9:00 AM - 12:00 PM
SPECIAL SESSION**

Advancing Pain and Palliative Care Globally for Patients with Cancer

Location: S504

CME credit: 3

Track(s): Special Session; International; Patient and Survivor Care

Jamie H. Von Roenn, MD—Chair

Northwestern University

David Hill, PhD

International Union Against Cancer

Global Access to Cancer Pain Initiative

Joe B. Harford, PhD

National Cancer Institute/National Institutes of Health

International Activities in Cancer and Palliative Care

James F. Cleary, MD

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center

International Drug Policy and Cancer Pain Control

Frank Douglas Ferris, MD

Institute for Palliative Medicine at San Diego Hospice

International Education Activities in Palliative Care

Eduardo Bruera, MD

University of Texas M. D. Anderson Cancer Center

Panel: Palliative Care and Cancer in the Future

Kathleen M. Foley, MD

Memorial Sloan-Kettering Cancer Center

Panel: Palliative Care and Cancer in the Future

Aziza T. Shad, MD

Georgetown University

Panel: Palliative Care and Cancer in the Future

Tuesday, June 8, 2010

**9:30 AM - 10:45 AM
EDUCATION SESSIONS**

Closing the Loop: Evidence, Guidelines, Reporting, and Quality

Location: S100a

CME credit: 1.25

Track(s): Health Services Research; Patient and Survivor Care

Sandra L. Wong, MD, MS—Chair

University of Michigan Health Systems

Barriers to Quality Improvement Initiatives

Craig Earle, MD

Sunnybrook Health Science Center

Quality Reporting, Measurement, and Feedback

Gary H. Lyman, MD, MPH

Duke Comprehensive Cancer Center

Distilling Research and Evidence into Opportunities for Quality Improvement

Supportive Care for Patients with Non-small Cell Lung Cancer

Location: E353

CME credit: 1.25

Track(s): Lung Cancer; Central Nervous System Tumors; General Oncology; Patient and Survivor Care

Minesh P. Mehta, MD—Chair

University of Wisconsin

Management of Brain Metastases in Lung Cancer Patients

David J. Feller-Kopman, MD

The Johns Hopkins University

Management of Dyspnea and Pleural Effusion in Patients with Lung Cancer

Vera Hirsh, MD

McGill University Health Centre

Ancillary Therapy for Bone Metastases in the Age of Bisphosphonates

T
U
E
S
D
A
Y

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Breast Cancer—Metastatic

Location: E Hall D1

CME credit: 3

Track(s): Breast Cancer

Herve R. Bonnefoi, MD—Co-Chair

Bergonié Institute, Bordeaux University

Elizabeth Claire Dees, MD—Co-Chair

University of North Carolina Lineberger Comprehensive Cancer Center

9:30 AM A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. (Abstract #CRA1004^)

C. Twelves, D. Loesch, J. L. Blum, L. T. Vahdat, K. Petrakova, P. J. Chollet, C. E. Akerele, S. Seegobin, J. Wanders, J. Cortes, on behalf of the Study 305 Investigators

Discussion

9:45 AM Harold J. Burstein, MD, PhD (Abstract #CRA1004^)
 Dana-Farber Cancer Institute

10:00 AM Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). (Abstract #LBA1010)

J. Bergh, R. Greil, N. Voytko, A. Makhson, J. Cortes, A. Lortholary, X. Huang, C. Giorgetti, K. A. Kern, M. Lichinitser

10:15 AM Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). (Abstract #LBA1011)

J. Crown, V. Dieras, E. Staroslawska, D. A. Yardley, N. Davidson, T. D. Bachelot, V. R. Tassell, X. Huang, K. A. Kern, G. Romieu

Discussion

10:30 AM Kimberly L. Blackwell, MD (Abstracts #LBA1010–LBA1011)
 Duke University Medical Center

10:45 AM A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). (Abstract #1005)

J. O'Shaughnessy, D. Miles, R. J. Gray, V. Dieras, E. A. Perez, R. Zon, J. Cortes, X. Zhou, S. Phan, K. Miller

11:00 AM Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). (Abstract #1006)

A. F. Schott, D. Lew, W. E. Barlow, K. S. Albain, H. K. Chew, J. L. Wade, K. S. Lanier, H. M. Linden, G. N. Hortobagyi, R. B. Livingston

Discussion

11:15 AM Hope S. Rugo, MD (Abstracts #1005–1006)
 University of California, San Francisco

11:30 AM Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. (Abstract #1007)

E. Amir, M. Clemons, O. C. Freedman, N. Miller, R. E. Coleman, C. Purdie, L. Jordan, P. Quinlan, A. M. Thompson

11:45 AM Should liver metastases of breast cancer be biopsied to improve treatment choice? (Abstract #CRA1008)

M. A. Locatelli, G. Curigliano, L. Fumagalli, V. Bagnardi, G. Aurilio, P. Della Vigna, L. Monfardini, S. Giudici, G. Viale, A. Goldhirsch

Tuesday, June 8, 2010

12:00 PM **Discordance in hormone receptor status in breast cancer during tumor progression. (Abstract #1009)**
E. Karlsson, L. S. Lindström, U. Wilking, L. Skoog, U. Johansson, J. Bergh

Discussion

12:15 PM Andrea L. Richardson, MD, PhD (Abstracts #1007–1009)
Brigham and Women's Hospital

TUESDAY

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy

Location: E354a

CME credit: 3

Track(s): Developmental Therapeutics

Tyler J. Curiel, MD—Chair

University of Texas Health Science Center at San Antonio

9:30 AM Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. (Abstract #2506)

M. Sznol, J. D. Powderly, D. C. Smith, J. R. Brahmer, C. G. Drake, D. F. McDermott, D. P. Lawrence, J. D. Wolchok, S. L. Topalian, I. Lowy

9:45 AM A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4. (Abstract #2507)

P. W. Johnson, N. M. Steven, F. Chowdhury, J. Dobbyn, E. Hall, M. Ashton-Key, E. Hodges, C. H. Ottensmeier, A. Williams, M. Glennie

10:00 AM Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC). (Abstract #2508)

A. J. Rech, R. Mick, A. Recio, A. DeMichele, C. K. Tweed, K. R. Fox, S. M. Domchek, R. H. Vonderheide

Discussion

10:15 AM Tyler J. Curiel, MD (Abstracts #2506–2508)
University of Texas Health Science Center at San Antonio

10:30 AM Cell therapy with EBV-specific cytotoxic T-lymphocytes for patients with nasopharyngeal carcinoma. (Abstract #2509)

P. Comolli, S. Secondino, L. F. Licitra, R. Schiavo, I. Schiavetto, A. Gurrado, L. Locati, P. Pedrazzoli, F. Locatelli, S. Siena

10:45 AM Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematologic malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: A phase II study. (Abstract #2510)

S. Slavin

11:00 AM Vaccination with DC/RCC fusions following cytoreductive nephrectomy. (Abstract #2511)

D. Avigan, J. Rosenblatt, B. Vasir, M. B. Atkins, D. F. McDermott, P. Somaiya, H. Mills, D. Fitzgerald, D. Dombagoda, D. W. Kufe

Discussion

11:15 AM To be determined

11:30 AM A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. (Abstract #2512)

G. S. Falchook, J. J. Wheeler, A. Naing, D. S. Hong, S. L. Moulder, S. A. Piha-Paul, C. S. Ng, E. Jackson, R. Kurzrock

11:45 AM First-line chemoimmunotherapy in metastatic breast carcinoma: Effect of a combination of paclitaxel and LAG-3-ig (IMP321), a novel MHC class II agonist, on T-cell responses and antitumor activity. (Abstract #2513)

M. Gutierrez, C. Brignone, F. Mefti, F. Triebel

12:00 PM Pharmacodynamic response in phase I combination study of ABT-888 and topotecan in adults with refractory solid tumors and lymphomas. (Abstract #2514)

J. J. Ji, S. Kummar, A. P. Chen, Y. Zhang, R. Putvtana, R. J. Kinders, L. Rubinstein, R. E. Parchment, J. E. Tomaszewski, J. H. Doroshow

Discussion

12:15 PM Mark J. Ratain, MD (Abstracts #2512–2514)
The University of Chicago

Tuesday, June 8, 2010

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Genitourinary (Testes, Kidney, and Bladder) Cancer

Location: E Arie Crown Theater

CME credit: 3

Track(s): Genitourinary Cancer

Deborah Ann Bradley, MD—Co-Chair

Duke University Medical Center

Hyung Lae Kim, MD—Co-Chair

Roswell Park Cancer Institute

9:30 AM A randomized phase III study comparing standard-dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): An intergroup study of EORTC, GTCSSG, and Grupo Germinal (EORTC 30974). (Abstract #4512)
G. Daugaard, I. A. Skoneczna, N. Aass, R. De Wit, M. De Santis, H. Dumez, S. Marreaud, L. Collette, C. Bokemeyer, H. Schmoll

9:45 AM Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. (Abstract #4513)
A. Lorch, C. Mollevi, A. Kramar, L. H. Einhorn, A. Necchi, C. Massard, U. DeGiorgi, A. Flechon, K. A. Margolin, J. Beyer, for the International Prognostic Factors Study Group

Discussion

10:00 AM Derek Raghavan, MD, PhD (Abstracts #4512–4513)
Cleveland Clinic
Treatment Intensity and Outcome in Germ Cell Tumors

10:15 AM The high-dose aldesleukin (HD IL-2) SELECT trial in patients with metastatic renal cell carcinoma (mRCC). (Abstract #4514)
D. F. McDermott, M. S. Ghebremichael, S. Signoretti, K. A. Margolin, J. Clark, J. A. Sosman, J. P. Dutcher, T. Logan, R. A. Figlin, M. B. Atkins, Cytokine Working Group

10:30 AM A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS). (Abstract #4530)
U. B. Dandamudi, M. S. Ghebremichael, J. A. Sosman, M. M. Regan, M. B. Atkins, J. Clark, J. P. Dutcher, B. D. Curti, U. N. Vaishampayan, M. S. Ernstoff, Cytokine Working Group

10:45 AM Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. (Abstract #4516)
B. J. Escudier, S. Negrier, G. Gravis, C. Chevreau, R. Delva, J. Bay, L. Geoffrois, E. Legouffe, E. Blanc, C. Ferlay

Discussion

11:00 AM Dror Michaelson, MD, PhD (Abstracts #4514, 4530, and 4516)
Massachusetts General Hospital
Metastatic Renal Cell Carcinoma: Which Way Forward?

11:15 AM Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004). (Abstract #4517)
N. D. James, S. A. Hussain, E. Hall, P. Jenkins, J. Tremlett, C. Rawlings, C. Hendron, R. Lewis, S. Rogers, R. A. Huddart, on behalf of the BC2001 Investigators

- 11:30 AM** **Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. (Abstract #LBA4518)**
L. G. Paz-Ares, E. Solsona, E. Esteban, A. Saez, J. Gonzalez-Larriba, A. Anton, M. Hevia, F. de la Rosa, V. Guillem, J. Bellmut
- 11:45 AM** **Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986. (Abstract #LBA4519)**
M. De Santis, J. Bellmunt, G. Mead, J. M. Kerst, M. G. Leahy, G. Daugaard, T. Gil, J. P. Maroto, S. Marreaud, R. Sylvester

Discussion

- 12:00 PM** Cora N. Sternberg, MD (Abstracts #4517–LBA4519)
San Camillo Forlanini Hospital
Is Systemic Therapy Impacting Progress in Urothelial Cancer?

Tuesday, June 8, 2010

**9:45 AM - 11:00 AM
SPECIAL SESSION**

**Imaging Informatics and Optimizing Imaging in Cancer Diagnosis: An
ASCO/Radiological Society of North America Joint Session**

Location: S404

CME credit: 1.25

Track(s): Special Session; Practice Management and Information Technology

Richard Baron, MD, FACP—Co-Chair

The University of Chicago

Douglas W. Blayney, MD—Co-Chair

University of Michigan

Paul Chang, MD, FSIIM

The University of Chicago

Imaging Informatics and How It Can Help Improve Quality of Care in Patients with Cancer

David M. Panicek, MD, FACP

Memorial Sloan-Kettering Cancer Center

Oncologic Imaging: Which Exam to Order and How to Integrate the Results?

TUESDAY

9:45 AM - 11:00 AM
EDUCATION SESSIONS

Angiogenesis: Where Do We Go from Here?

Location: S100b

CME credit: 1.25

Track(s): Tumor Biology

Lee M. Ellis, MD, FACS—Chair

University of Texas M. D. Anderson Cancer Center

Targeting Tumor Angiogenesis: What Have Learned So Far?

George Coukos, MD

University of Pennsylvania Perelman Center for Advanced Medicine

Genomic Approaches for Vascular Target Identification in Solid Tumors

Robert S. Kerbel, PhD

Sunnybrook Health Sciences Centre

Contrasting Effects of VEGF Pathway-targeting Antibodies and TKIs on Microscopic versus Advanced Metastatic Disease

Even Patients with Liver Dysfunction Can Get Chemotherapy!

Location: E354b

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer; Developmental Therapeutics; Patient and Survivor Care

Melanie B. Thomas, MD—Chair

Hollings Cancer Center/Medical University of South Carolina

Management of Dosing and Side Effects of Specific Chemotherapeutic Agents

Lewis R. Roberts, PhD, MBChB

Mayo Clinic

Understanding Assessment of Liver Function and Viral Hepatitis for the Medical Oncologist

Timothy W. Synold, PharmD

City of Hope

Understanding the Importance of Hepatic Function and Dysfunction in Metabolism of Anticancer Agents Delivering Chemotherapy to the Patient with Liver Dysfunction

Tuesday, June 8, 2010

9:45 AM - 11:00 AM

CLINICAL PROBLEMS IN ONCOLOGY

**The Best Treatment for Hepatic Metastases: What Is the Evidence? (C18)-
TICKETED SESSION**

Location: E451a

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer; Gastrointestinal (Colorectal) Cancer; Patient and Survivor Care

Christopher Willett, MD—Chair

Duke University Medical Center

The Incorporation of Conventional and Stereotactic Body Radiation Therapy into the Treatment of Hepatic Metastases

Heinz-Josef Lenz, MD

University of Southern California

Review of the Data Supporting Chemotherapy and Molecular Targeted Therapy in Management of Hepatic Metastases

Bryan M. Clary, MD

Duke University Medical Center

Evidence for Patient Benefit Using Surgical and/or Ablation for Hepatic Metastases

11:30 AM - 12:45 PM

EDUCATION SESSION

Management of the Elderly Patient with Cancer

Location: S100b

CME credit: 1.25

Track(s): Health Services Research; General Oncology; Geriatric Oncology; Patient and Survivor Care

Elizabeth B. Lamont, MD, MS—Chair

Harvard Medical School

Generalizability of Clinical Trials to the Elderly Patient

Cary P. Gross, MD

Yale University

Under-representation of Elderly Patients in Clinical Trials and Implications for Comparative Effectiveness Research

Arti Hurria, MD

City of Hope National Medical Center

Assessing Elderly Patients for Therapy

T
U
E
S
D
A
Y

11:30 AM - 12:45 PM
CLINICAL PROBLEMS IN ONCOLOGY

Hepatocellular Carcinoma: Is This Patient a Transplant, Resection, or Chemoembolization Candidate? (C19)-TICKETED SESSION

Location: E451a

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer

Lynt Johnson, MD, MBA—Chair

Lombardi Comprehensive Cancer Center

The Role of Liver Transplantation in Management of Hepatocellular Carcinoma

Riad Salem, MD, MBA

Northwestern University

The Role of Intrahepatic Interventions in Hepatocellular Carcinoma

Timothy Pawlik, MD, MPH

The Johns Hopkins University

The Role of Hepatic Resection in Management of Patients with Hepatocellular Carcinoma